,drug_name,pubmed_id,title,authors,mesh_terms,paper_url
0,ciprofloxacin,3292209,"Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.","['Campoli-Richards DM', 'Monk JP', 'Price A', 'Benfield P', 'Todd PA', 'Ward A']","['Animals', 'Bacteria/drug effects', 'Bacterial Infections/*drug therapy', 'Ciprofloxacin/pharmacokinetics/*pharmacology/therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/3292209/
1,ciprofloxacin,2667104,Tolerance of intravenous ciprofloxacin.,"['Thorsteinsson SB', 'Rahm V', 'Bergan T']","['Ciprofloxacin/*administration & dosage/adverse effects', 'Drug Tolerance', 'Evaluation Studies as Topic', 'Humans', 'Infusions, Intravenous']",https://pubmed.ncbi.nlm.nih.gov/2667104/
2,ciprofloxacin,3281368,Ciprofloxacin in management of urinary tract infection.,"['Tolkoff-Rubin NE', 'Rubin RH']","['Bacterial Infections/*drug therapy', 'Ciprofloxacin/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Male', 'Microbial Sensitivity Tests', 'Prostatitis/drug therapy', 'Urinary Tract Infections/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3281368/
3,ciprofloxacin,21075583,Ciprofloxacin-induced torsade de pointes.,"['Ibrahim M', 'Omar B']","['Aged', 'Anti-Infective Agents/*adverse effects/therapeutic use', 'Ciprofloxacin/*adverse effects/therapeutic use', 'Electrocardiography', 'Heart/drug effects/physiopathology', 'Humans', 'Male', 'Torsades de Pointes/*chemically induced/physiopathology', 'Treatment Outcome', 'Urinary Tract Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21075583/
4,ciprofloxacin,19534690,Efficacy of fluoroquinolones against pathogenic oral bacteria.,"['Nunez Otero V', 'Limeres Posse J', 'Carmona IT', 'Diz Dios P']","['Aza Compounds/chemistry/pharmacokinetics/pharmacology/*therapeutic use', 'Bacteria/drug effects', 'Bacterial Infections/*drug therapy', 'Ciprofloxacin/chemistry/pharmacokinetics/pharmacology/*therapeutic use', 'Fluoroquinolones/chemistry/pharmacokinetics/pharmacology/*therapeutic use', 'Humans', '*Levofloxacin', 'Mouth Diseases/*drug therapy', 'Moxifloxacin', 'Ofloxacin/chemistry/pharmacokinetics/pharmacology/*therapeutic use', '*Oral Medicine', 'Quinolines/chemistry/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19534690/
5,ciprofloxacin,15243351,"[Pharmacokinetics and dose adaptation of ofloxacine, pefloxacine and ciprofloxacine during haemodialysis and continuous ambulatory peritoneal dialysis].","['Daniel JP', 'Moulin B', 'Christmann D']","['Anti-Infective Agents/*administration & dosage/*pharmacokinetics', 'Ciprofloxacin/*administration & dosage/*pharmacokinetics', 'Fluoroquinolones/*administration & dosage/*pharmacokinetics', 'Humans', 'Kidney Failure, Chronic/*metabolism', 'Ofloxacin/*administration & dosage/*pharmacokinetics', '*Peritoneal Dialysis, Continuous Ambulatory', '*Renal Dialysis', 'Pefloxacin']",https://pubmed.ncbi.nlm.nih.gov/15243351/
6,ciprofloxacin,38970065,"An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus an aminoglycoside + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial-an update to the published protocol.","['Randremanana RV', 'Raberahona M', 'de Dieu Randria MJ', 'Bourner J', 'Zadonirina G', 'Razananaivo H', 'Mayouya-Gamana T', 'Mangahasimbola R', 'Pesonel E', 'Gillesen A', 'Rajerison M', 'Andrianaivoarimanana V', 'Edwards T', 'Horby P', 'Olliaro P']","['*Ciprofloxacin/adverse effects/administration & dosage/therapeutic use', 'Treatment Outcome', 'Humans', '*Anti-Bacterial Agents/adverse effects/administration & dosage/therapeutic use', 'Plague/drug therapy', 'Randomized Controlled Trials as Topic', 'Equivalence Trials as Topic', 'Drug Therapy, Combination', 'Animals', 'Aminoglycosides/adverse effects/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38970065/
7,ciprofloxacin,12869605,Fluoroquinolone therapy and Achilles tendon rupture.,"['Vanek D', 'Saxena A', 'Boggs JM']","['Achilles Tendon/*drug effects', 'Adult', 'Aged', 'Anti-Infective Agents/*adverse effects/therapeutic use', 'Ciprofloxacin/*adverse effects/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Muscular Diseases/chemically induced', 'Risk Factors', 'Rupture', 'Tendon Injuries/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/12869605/
8,ciprofloxacin,25680964,[DRESS syndrome induced by ciprofloxacine].,"['Sahnoun R', 'El Aidli S', 'Zaiem A', 'Lakhoua G', 'Kastalli S', 'Daghfous R']","['Anti-Bacterial Agents/*adverse effects', 'Ciprofloxacin/*adverse effects', 'Drug Hypersensitivity Syndrome/*etiology', 'Female', 'Humans', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/25680964/
9,ciprofloxacin,29637871,Community Acquired Pseudomonas Aeruginosa Pneumonia in a Young Athlete Man: A Case Report and Literature Review.,"['Rahdar HA', 'Kazemian H', 'Bimanand L', 'Shahraki-Zahedani S', 'Feyisa SG', 'Taki E', 'Havaei SA', 'Karami-Zarandi M']","['Adult', '*Athletes', 'Ciprofloxacin/administration & dosage/therapeutic use', 'Community-Acquired Infections/complications/*diagnosis/drug therapy/microbiology', 'Cross Infection/complications/diagnosis/drug therapy/microbiology', 'Fatal Outcome', 'Female', 'Humans', 'Male', 'Middle Aged', 'Pneumonia/complications/*diagnosis/drug therapy/microbiology', 'Pseudomonas Infections/complications/*diagnosis/drug therapy/microbiology', 'Pseudomonas aeruginosa/drug effects/*pathogenicity', 'Risk Factors', 'Smoking/adverse effects', 'Thoracic Injuries/complications', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/29637871/
10,ciprofloxacin,2924060,Ciprofloxacin.,"['Smyth EG', 'Pallet AP']","['Ciprofloxacin/pharmacokinetics/pharmacology/*therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/2924060/
11,ciprofloxacin,22645722,Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin.,['Serisier DJ'],"['Administration, Inhalation', 'Animals', 'Anti-Bacterial Agents/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Bronchiectasis/drug therapy', 'Ciprofloxacin/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Cystic Fibrosis/*drug therapy', 'Humans', 'Liposomes/administration & dosage', 'Nebulizers and Vaporizers', 'Pseudomonas Infections/drug therapy', 'Pulmonary Disease, Chronic Obstructive/drug therapy', 'Respiratory Tract Infections/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22645722/
12,ciprofloxacin,18979434,[Fluorquinolone associated tendon rupture].,"['Ratz Bravo A', 'Stoll R', 'Burr P', 'Haschke M']","['Achilles Tendon/*drug effects/injuries', 'Adult', 'Adverse Drug Reaction Reporting Systems', 'Aged', 'Aged, 80 and over', 'Anti-Bacterial Agents/*adverse effects/therapeutic use', 'Athletic Injuries/*chemically induced', 'Chlamydia Infections/drug therapy', 'Ciprofloxacin/adverse effects/therapeutic use', 'Female', 'Fluoroquinolones/*adverse effects/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Ofloxacin/adverse effects/therapeutic use', 'Risk Factors', 'Rupture, Spontaneous', 'Soccer/*injuries', 'Switzerland', 'Tendon Injuries/*chemically induced', 'Urethritis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18979434/
13,ciprofloxacin,31556841,Evolving Antibiotic Resistance of Aeromonas Species in Finger Replantation.,"['Mokhtar K', 'Culnan DM', 'Lineaweaver WC']","['Aeromonas/*drug effects', 'Anti-Bacterial Agents/*pharmacology/therapeutic use', 'Cefepime/pharmacology/therapeutic use', 'Ciprofloxacin/pharmacology/therapeutic use', 'Drug Resistance, Microbial/*drug effects', 'Humans', 'Leeching/adverse effects/*methods', 'Microbial Sensitivity Tests', 'Replantation/adverse effects/*methods']",https://pubmed.ncbi.nlm.nih.gov/31556841/
14,ciprofloxacin,23256815,Medicinal potential of ciprofloxacin and its derivatives.,"['Castro W', 'Navarro M', 'Biot C']","['Acquired Immunodeficiency Syndrome/drug therapy', 'Anti-Bacterial Agents/pharmacology/*therapeutic use', 'Ciprofloxacin/analogs & derivatives/pharmacology/*therapeutic use', 'Humans', 'Malaria, Falciparum/drug therapy', 'Microbial Sensitivity Tests', 'Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/23256815/
15,ciprofloxacin,22186073,[Efficacy and future of the aerosoltherapy in the treatment of cystic fibrosis patients infected by Pseudomonas aeruginosa].,"['Rognon A', 'Curti C', 'Montana M', 'Terme T', 'Rathelot P', 'Vanelle P']","['Administration, Inhalation', 'Aerosols', 'Amikacin/administration & dosage/adverse effects/therapeutic use', 'Anti-Infective Agents/*administration & dosage/adverse effects/*therapeutic use', 'Ciprofloxacin/administration & dosage/therapeutic use', 'Colistin/administration & dosage/adverse effects/therapeutic use', 'Cystic Fibrosis/*complications', 'Drug Therapy, Combination', 'Fluoroquinolones/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Pseudomonas Infections/*drug therapy/*etiology/microbiology', 'Pseudomonas aeruginosa/drug effects', 'Tobramycin/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22186073/
16,ciprofloxacin,26164023,Ciprofloxacin as a Trigger for Bullous Pemphigoid: The Second Case in the Literature.,"['Cozzani E', 'Chinazzo C', 'Burlando M', 'Romagnoli M', 'Parodi A']","['Administration, Oral', 'Aged, 80 and over', 'Anti-Bacterial Agents/administration & dosage/adverse effects', 'Ciprofloxacin/administration & dosage/*adverse effects', 'Drug Eruptions/*etiology/pathology', 'Female', 'Humans', 'Pemphigoid, Bullous/*chemically induced/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/26164023/
17,ciprofloxacin,25189336,Bilateral Achilles Tendon Ruptures Associated With Ciprofloxacin Use in the Setting of Minimal Change Disease: Case Report and Review of the Literature.,"['Kawtharani F', 'Masrouha KZ', 'Afeiche N']","['Achilles Tendon/diagnostic imaging/*drug effects/pathology', 'Aged', 'Anti-Bacterial Agents/*adverse effects/therapeutic use', 'Ciprofloxacin/*adverse effects/therapeutic use', 'Cross Infection/drug therapy', 'Glucocorticoids/administration & dosage', 'Humans', 'Magnetic Resonance Imaging', 'Male', 'Nephrosis, Lipoid/complications/*drug therapy', 'Pneumonia/drug therapy', 'Rupture', 'Tendon Injuries/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/25189336/
18,ciprofloxacin,1504404,Ciprofloxacin-induced psychosis.,['Reeves RR'],"['Ciprofloxacin/administration & dosage/*adverse effects', 'Humans', 'Male', 'Middle Aged', 'Psychoses, Substance-Induced/drug therapy/*etiology', 'Thiothixene/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1504404/
19,ciprofloxacin,2055655,"MICs of ciprofloxacin and trimethoprim for Escherichia coli: influence of pH, inoculum size and various body fluids.","['Aagaard J', 'Gasser T', 'Rhodes P', 'Madsen PO']","['Animals', 'Body Fluids/chemistry/drug effects/microbiology', 'Chronic Disease', 'Ciprofloxacin/administration & dosage/pharmacology/*therapeutic use', 'Dogs', 'Dose-Response Relationship, Drug', 'Escherichia coli Infections/*drug therapy/microbiology/urine', 'Humans', 'Hydrogen-Ion Concentration', 'Male', 'Prostatitis/*drug therapy/microbiology/urine', 'Trimethoprim/administration & dosage/pharmacology/*therapeutic use', 'Urine/microbiology']",https://pubmed.ncbi.nlm.nih.gov/2055655/
20,doxazosin,36196467,Role of alpha1-blockers in the current management of hypertension.,"['Li H', 'Xu TY', 'Li Y', 'Chia YC', 'Buranakitjaroen P', 'Cheng HM', 'Van Huynh M', 'Sogunuru GP', 'Tay JC', 'Wang TD', 'Kario K', 'Wang JG']","['Adrenergic alpha-Antagonists/therapeutic use', 'Aged', 'Aldosterone', 'Antihypertensive Agents/pharmacology/therapeutic use', 'Diuretics/therapeutic use', 'Doxazosin/therapeutic use', 'Humans', '*Hypertension/drug therapy', 'Renin']",https://pubmed.ncbi.nlm.nih.gov/36196467/
21,doxazosin,31714582,Efficacy of alpha-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial.,"['Buitenwerf E', 'Osinga TE', 'Timmers HJLM', 'Lenders JWM', 'Feelders RA', 'Eekhoff EMW', 'Haak HR', 'Corssmit EPM', 'Bisschop PHLT', 'Valk GD', 'Veldman RG', 'Dullaart RPF', 'Links TP', 'Voogd MF', 'Wietasch GJKG', 'Kerstens MN']","['Adrenal Gland Neoplasms/*surgery', 'Adrenergic alpha-Antagonists/administration & dosage/*therapeutic use', 'Blood Pressure/*drug effects', 'Doxazosin/administration & dosage/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Phenoxybenzamine/administration & dosage/therapeutic use', 'Pheochromocytoma/*surgery', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31714582/
22,doxazosin,38379309,Safety and Feasibility of Opening Tamsulosin Capsules for Enteral Feeding Tube Administration.,"['Fazio V', 'Altshuler J', 'Song YB']","['Humans', '*Tamsulosin/administration & dosage', 'Retrospective Studies', 'Male', '*Enteral Nutrition/methods', 'Female', '*Capsules', 'Middle Aged', 'Aged', '*Feasibility Studies', 'Adrenergic alpha-1 Receptor Antagonists/administration & dosage', 'Doxazosin/administration & dosage', 'Adult', 'Hypotension/prevention & control/chemically induced', 'Aged, 80 and over']",https://pubmed.ncbi.nlm.nih.gov/38379309/
23,doxazosin,34456560,Doxazosin Attenuates Liver Fibrosis by Inhibiting Autophagy in Hepatic Stellate Cells via Activation of the PI3K/Akt/mTOR Signaling Pathway.,"['Xiu AY', 'Ding Q', 'Li Z', 'Zhang CQ']","['Adrenergic alpha-1 Receptor Antagonists/administration & dosage/*pharmacology', 'Animals', 'Apoptosis/drug effects', 'Autophagy/drug effects', 'Carbon Tetrachloride', 'Cell Line', 'Cell Proliferation/drug effects', 'Disease Models, Animal', 'Dose-Response Relationship, Drug', 'Doxazosin/administration & dosage/*pharmacology', 'Hepatic Stellate Cells/*drug effects/metabolism', 'Humans', 'Liver Cirrhosis/*drug therapy', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Phosphatidylinositol 3-Kinase/metabolism', 'Proto-Oncogene Proteins c-akt/metabolism', 'Signal Transduction/drug effects', 'TOR Serine-Threonine Kinases/metabolism']",https://pubmed.ncbi.nlm.nih.gov/34456560/
24,doxazosin,14681504,"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.","['McConnell JD', 'Roehrborn CG', 'Bautista OM', 'Andriole GL Jr', 'Dixon CM', 'Kusek JW', 'Lepor H', 'McVary KT', 'Nyberg LM Jr', 'Clarke HS', 'Crawford ED', 'Diokno A', 'Foley JP', 'Foster HE', 'Jacobs SC', 'Kaplan SA', 'Kreder KJ', 'Lieber MM', 'Lucia MS', 'Miller GJ', 'Menon M', 'Milam DF', 'Ramsdell JW', 'Schenkman NS', 'Slawin KM', 'Smith JA']","['*5-alpha Reductase Inhibitors', 'Adrenergic alpha-Antagonists/adverse effects/*therapeutic use', 'Analysis of Variance', 'Disease Progression', 'Double-Blind Method', 'Doxazosin/adverse effects/*therapeutic use', 'Drug Therapy, Combination', 'Enzyme Inhibitors/adverse effects/*therapeutic use', 'Finasteride/adverse effects/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Prostatic Hyperplasia/classification/*drug therapy/surgery', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/14681504/
25,doxazosin,17563267,Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia.,"['Bhardwa J', 'Goldstraw M', 'Tzortzis S', 'Kirby R']","['5-alpha Reductase Inhibitors', 'Adrenergic alpha-Antagonists/administration & dosage/*therapeutic use', 'Aged', 'Doxazosin/administration & dosage/*therapeutic use', 'Drug Therapy, Combination', 'Enzyme Inhibitors/administration & dosage/*therapeutic use', 'Finasteride/administration & dosage/*therapeutic use', 'Humans', 'Male', 'Prostatic Hyperplasia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17563267/
26,doxazosin,9021791,"Measures of Proscar, Hytrin, and Cardura side effects.",['Frankel S'],"['Adrenergic alpha-Antagonists/adverse effects', 'Doxazosin/*adverse effects', 'Finasteride/*adverse effects', 'Humans', 'Male', 'Prazosin/adverse effects/*analogs & derivatives', 'Prostatic Hyperplasia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9021791/
27,doxazosin,16469026,Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health.,"['Kaplan SA', 'DE Rose AF', 'Kirby RS', ""O'leary MP"", 'McVary KT']","['Adrenergic alpha-Antagonists/*administration & dosage', 'Adult', 'Aged', 'Aged, 80 and over', 'Delayed-Action Preparations/administration & dosage', 'Doxazosin/*administration & dosage', 'Erectile Dysfunction/*drug therapy', 'Humans', 'Hypertension/*drug therapy', 'Libido/drug effects', 'Male', 'Middle Aged', 'Patient Satisfaction', 'Prostatic Hyperplasia/*drug therapy', 'Quality of Life', 'Treatment Outcome', 'Vasodilation/drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/16469026/
28,doxazosin,39160179,Change in prostate tissue gene expression following finasteride or doxazosin administration in the medical therapy for prostatic symptoms (MTOPS) study.,"['Choi HY', 'Torkko KC', 'Lucia MS', 'Mozhui K', 'Choi WY', 'Clark PE', 'Fowke JH']","['*Prostate/metabolism', 'Gene Expression Regulation/drug effects', '*Finasteride/pharmacology/therapeutic use', '*Doxazosin/pharmacology/therapeutic use', 'Urological Agents/pharmacology/therapeutic use', 'Drug Resistance', '*Prostatic Diseases/drug therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/39160179/
29,doxazosin,38206436,The combination of doxazosin and metyrosine as a preoperative treatment for pheochromocytomas and paragangliomas.,"['Ohmachi Y', 'Yamamoto M', 'Inaba Y', 'Makino S', 'Urai S', 'Matsumoto R', 'Bando H', 'Kanie K', 'Tsujimoto Y', 'Motomura Y', 'Sasaki Y', 'Oi-Yo Y', 'Yamamoto N', 'Suzuki M', 'Takahashi M', 'Iguchi G', 'Kanzawa M', 'Furukawa J', 'Shigemura K', 'Mizobuchi S', 'Ogawa W', 'Fukuoka H']","['Humans', '*Doxazosin/therapeutic use/administration & dosage', 'Female', 'Male', '*Pheochromocytoma/surgery/drug therapy', 'Middle Aged', '*Adrenal Gland Neoplasms/surgery/drug therapy', 'Retrospective Studies', '*Paraganglioma/drug therapy/surgery', 'Adult', 'Aged', '*alpha-Methyltyrosine/therapeutic use/administration & dosage/pharmacology', '*Adrenergic alpha-1 Receptor Antagonists/therapeutic use/administration & dosage', 'Drug Therapy, Combination', 'Preoperative Care/methods', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38206436/
30,doxazosin,19110560,Assessment of therapeutic drug efficiency.,"['Pokrovskii VM', 'Kompaniets OG']","['Adrenergic alpha-Antagonists/therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Blood Pressure/*drug effects', 'Calcium Channel Blockers/therapeutic use', 'Doxazosin/therapeutic use', 'Heart Rate/*drug effects', 'Humans', 'Nifedipine/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/19110560/
31,doxazosin,12230262,Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia.,"['Pool JL', 'Kirby RS']","['Adrenergic alpha-Antagonists/pharmacokinetics/*therapeutic use', 'Aged', 'Aged, 80 and over', 'Blood-Brain Barrier', 'Doxazosin/pharmacokinetics/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Prostatic Hyperplasia/*drug therapy', 'Quinazolines/pharmacokinetics/*therapeutic use', 'Receptors, Adrenergic, alpha-1/*classification/metabolism']",https://pubmed.ncbi.nlm.nih.gov/12230262/
32,doxazosin,33566468,Otorhinolaryngological adverse effects of urological drugs.,"['Maia NPD', 'Lopes KC', 'Gananca FF']","['Adrenergic alpha-Antagonists', 'Doxazosin', 'Humans', 'Male', '*Pharmaceutical Preparations', 'Prazosin', '*Prostatic Hyperplasia', 'Tadalafil', 'Tamsulosin']",https://pubmed.ncbi.nlm.nih.gov/33566468/
33,doxazosin,10750258,The role of alpha 1-blockers in combination therapy for hypertension.,['Zusman RM'],"['Adrenergic alpha-Antagonists/*therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Blood Pressure/drug effects', 'Diabetes Mellitus, Type 2/drug therapy', 'Doxazosin/therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hyperlipidemias/drug therapy', 'Hypertension/*drug therapy', 'Male', 'Prazosin/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10750258/
34,doxazosin,9609620,Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.,"['Beduschi MC', 'Beduschi R', 'Oesterling JE']","['Adrenergic alpha-Antagonists/*therapeutic use', 'Clinical Trials as Topic', 'Doxazosin/therapeutic use', 'Humans', 'Male', 'Prazosin/analogs & derivatives/therapeutic use', 'Prostatic Hyperplasia/*drug therapy', 'Sulfonamides/therapeutic use', 'Tamsulosin']",https://pubmed.ncbi.nlm.nih.gov/9609620/
35,doxazosin,11750252,"Terazosin, doxazosin, and prazosin: current clinical experience.","['Akduman B', 'Crawford ED']","['Adrenergic alpha-Antagonists/adverse effects/pharmacokinetics/*therapeutic use', 'Adult', 'Aged', 'Doxazosin/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Prazosin/adverse effects/*analogs & derivatives/pharmacokinetics/*therapeutic use', 'Prostatic Hyperplasia/complications/*drug therapy', 'Randomized Controlled Trials as Topic', 'Receptors, Adrenergic, alpha/classification']",https://pubmed.ncbi.nlm.nih.gov/11750252/
36,doxazosin,36883885,A Double-Blind Randomized Controlled Trial of Doxazosin for Co-Occurring PTSD and Alcohol Use Disorder in Veterans.,"['Back SE', 'Flanagan JC', 'Mintz J', 'Brady KT', 'Jones J', 'Jarnecke AM', 'Joseph JE', 'Shirley DW', 'Malcolm RJ', 'Hamner M', 'Litz BT', 'Niles BL', 'Young-McCaughan S', 'Keane TM', 'Peterson AL']","['Humans', '*Veterans', '*Stress Disorders, Post-Traumatic/complications/diagnosis/drug therapy', 'Doxazosin/therapeutic use', '*Alcoholism/diagnosis/drug therapy/epidemiology', 'Treatment Outcome', 'Adrenergic alpha-1 Receptor Antagonists/adverse effects', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/36883885/
37,doxazosin,1353110,The cardiovascular effects of alpha-receptor blocking agents.,['Leren P'],"['Adrenergic alpha-Antagonists/*therapeutic use', 'Animals', 'Antihypertensive Agents/*therapeutic use', 'Cardiomegaly/drug therapy', 'Cardiovascular System/*drug effects', 'Cost-Benefit Analysis', 'Doxazosin', 'Humans', 'Hypertension/*drug therapy', 'Lipids/blood', 'Prazosin/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1353110/
38,doxazosin,12296615,"The effect of doxazosin on sexual function in patients with benign prostatic hyperplasia, hypertension, or both.",['Flack JM'],"['Adrenergic alpha-Antagonists/*adverse effects', 'Aged', 'Doxazosin/*adverse effects', 'Erectile Dysfunction/*chemically induced', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Prostatic Hyperplasia/*drug therapy', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/12296615/
39,doxazosin,31177904,Management of Insomnia and Anxiety in Myasthenia Gravis.,"['Jordan H', 'Ortiz N']","['Adult', 'Antihypertensive Agents/*administration & dosage', 'Anxiety/*psychology', 'Depression/psychology', 'Doxazosin/*administration & dosage', 'Female', 'Humans', 'Myasthenia Gravis/*complications', 'Sleep Initiation and Maintenance Disorders/complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31177904/
40,atenolol,17686376,The vasodilatory beta-blockers.,"['Pedersen ME', 'Cockcroft JR']","['Adrenergic beta-Antagonists/adverse effects/*pharmacology/*therapeutic use', 'Antihypertensive Agents/pharmacology/therapeutic use', 'Antioxidants/pharmacology/therapeutic use', 'Atenolol/pharmacology/therapeutic use', 'Benzopyrans/pharmacology/therapeutic use', 'Blood Pressure/drug effects', 'Carbazoles/pharmacology/therapeutic use', 'Cardiac Output/drug effects', 'Cardiovascular Diseases/physiopathology/prevention & control', 'Carvedilol', 'Endothelium, Vascular/*drug effects', 'Ethanolamines/pharmacology/therapeutic use', 'Hemodynamics/*drug effects', 'Humans', 'Labetalol/pharmacology/therapeutic use', 'Nebivolol', 'Propanolamines/pharmacology/therapeutic use', 'Vascular Resistance/drug effects', 'Vasodilation/*drug effects', 'Ventricular Function, Left/drug effects']",https://pubmed.ncbi.nlm.nih.gov/17686376/
41,atenolol,18404602,Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension.,"['Gojanovic B', 'Feihl F', 'Liaudet L', 'Waeber B']","['Adult', 'Aged', 'Angiotensin II/antagonists & inhibitors', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use', 'Atenolol/administration & dosage', 'Calcium Channel Blockers/adverse effects/*therapeutic use', 'Drug Combinations', 'Drug Therapy, Combination', 'Enzyme Inhibitors/adverse effects/therapeutic use', 'Humans', 'Hypertension/*drug therapy', 'Indoles/administration & dosage', 'Middle Aged', 'Randomized Controlled Trials as Topic', 'Renin-Angiotensin System/*drug effects', 'Sympathetic Nervous System/drug effects', 'Verapamil/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/18404602/
42,atenolol,2871805,Use of beta adrenoceptor blockade during and after acute myocardial infarction.,['Sleight P'],"['Adrenergic beta-Antagonists/*therapeutic use', 'Arrhythmias, Cardiac/drug therapy', 'Atenolol/administration & dosage/therapeutic use', 'Cardiotonic Agents/therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Fibrinolytic Agents/administration & dosage', 'Heart Rupture/prevention & control', 'Humans', 'Injections, Intravenous', 'Male', 'Metoprolol/administration & dosage/therapeutic use', 'Myocardial Infarction/*drug therapy/mortality/prevention & control', 'Random Allocation', 'Retrospective Studies', 'Risk', 'Streptokinase/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/2871805/
43,atenolol,2508047,New antiarrhythmic agents in pediatrics.,"['Case CL', 'Trippel DL', 'Gillette PC']","['Action Potentials/drug effects', 'Amiodarone/pharmacology', 'Anilides/pharmacology', 'Anti-Arrhythmia Agents/administration & dosage/pharmacokinetics/*pharmacology', 'Atenolol/pharmacology', 'Child', 'Child, Preschool', 'Encainide', 'Flecainide/pharmacology', 'Heart Conduction System/drug effects', 'Humans', 'Infant', '*Pediatrics']",https://pubmed.ncbi.nlm.nih.gov/2508047/
44,atenolol,15616067,Atenolol administration via a nasogastric tube after abdominal surgery: an unreliable route.,"['Gosgnach M', 'Aymard G', 'Huraux C', 'Fleron MH', 'Coriat P', 'Diquet B']","['Abdomen/*surgery', 'Adrenergic beta-Antagonists/*administration & dosage/pharmacokinetics', 'Area Under Curve', 'Atenolol/*administration & dosage/pharmacokinetics', 'Biological Availability', 'Half-Life', 'Heart Rate/drug effects', 'Humans', '*Intubation, Gastrointestinal']",https://pubmed.ncbi.nlm.nih.gov/15616067/
45,atenolol,3288468,"Efficacy and tolerability of atenolol, nifedipine and their combination in the management of hypertension.","['Stanley NN', 'Thirkettle JL', 'Varma MP', 'Larkin H', 'Heath ID']","['Adult', 'Aged', 'Atenolol/administration & dosage/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Creatinine/blood', 'Double-Blind Method', 'Drug Therapy, Combination', 'Drug Tolerance', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Nifedipine/administration & dosage/adverse effects/*therapeutic use', 'Potassium/blood', 'Random Allocation', 'Uric Acid/blood']",https://pubmed.ncbi.nlm.nih.gov/3288468/
46,atenolol,22149523,Carvedilol: a third-generation beta-blocker should be a first-choice beta-blocker.,"['DiNicolantonio JJ', 'Hackam DG']","['Adrenergic beta-Antagonists/adverse effects/pharmacokinetics/*therapeutic use', 'Animals', 'Antihypertensive Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Atenolol/adverse effects/pharmacokinetics/therapeutic use', 'Biomarkers/blood', 'Carbazoles/adverse effects/pharmacokinetics/*therapeutic use', 'Carvedilol', 'Humans', 'Hypertension/blood/*drug therapy/metabolism/physiopathology', 'Metoprolol/adverse effects/pharmacokinetics/therapeutic use', 'Myocardial Infarction/etiology/prevention & control', 'Propanolamines/adverse effects/pharmacokinetics/*therapeutic use', 'Secondary Prevention', 'Sympathetic Nervous System/drug effects', 'Vasodilator Agents/adverse effects/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22149523/
47,atenolol,3049118,"The efficacy and tolerability of atenolol, nifedipine, and their combination in the management of hypertension.","['Stanley NN', 'Thirkettle JL', 'Varma MP', 'Larkin H', 'Heath ID']","['Adult', 'Aged', 'Atenolol/administration & dosage/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Combinations', 'Drug Therapy, Combination', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Nifedipine/administration & dosage/adverse effects/*therapeutic use', 'Patient Compliance', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/3049118/
48,atenolol,9850301,Irbesartan treatment in hypertension.,['Brown MJ'],"['Angiotensin-Converting Enzyme Inhibitors/adverse effects', 'Antihypertensive Agents/pharmacokinetics/*therapeutic use', 'Atenolol/therapeutic use', 'Biphenyl Compounds/pharmacokinetics/*therapeutic use', 'Enalapril/therapeutic use', 'Humans', 'Hypertension/complications/*drug therapy', 'Irbesartan', 'Losartan/therapeutic use', 'Renin-Angiotensin System/drug effects', 'Tetrazoles/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9850301/
49,atenolol,1897264,A comparison of Chinese traditional and Western medical approaches for the treatment of mild hypertension.,"['Wong ND', 'Ming S', 'Zhou HY', 'Black HR']","['Aged', 'Atenolol/adverse effects/therapeutic use', 'Blood Pressure/drug effects', 'China', 'Diastole', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hydrochlorothiazide/adverse effects/*therapeutic use', 'Hypertension/*drug therapy', 'Male', '*Medicine, Chinese Traditional', 'Middle Aged', 'Multivariate Analysis', 'Systole', 'United States']",https://pubmed.ncbi.nlm.nih.gov/1897264/
50,atenolol,4044884,Treatment of social phobia with atenolol.,"['Gorman JM', 'Liebowitz MR', 'Fyer AJ', 'Campeas R', 'Klein DF']","['Adult', 'Atenolol/adverse effects/*therapeutic use', 'Autonomic Nervous System/physiopathology', 'Female', 'Humans', 'Male', 'Middle Aged', 'Phobic Disorders/*drug therapy/physiopathology', 'Social Behavior']",https://pubmed.ncbi.nlm.nih.gov/4044884/
51,atenolol,9631898,Septal panniculitis induced by atenolol--a case report.,"['Fragasso G', 'Ciboddo G', 'Pagnotta P', 'Chierchia SL']","['Adrenergic beta-Antagonists/*adverse effects/therapeutic use', 'Aged', 'Angina, Unstable/drug therapy', 'Atenolol/*adverse effects/therapeutic use', 'Female', 'Humans', 'Panniculitis/*chemically induced', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/9631898/
52,atenolol,1590224,Safety of combined intravenous beta-adrenergic blockade (atenolol or metoprolol) and thrombolytic therapy in acute myocardial infarction.,"['Green BK', 'Gordon GD', 'Horak AR', 'Millar RN', 'Commerford PJ']","['Administration, Oral', 'Adult', 'Aspirin/therapeutic use', 'Atenolol/*administration & dosage/adverse effects', 'Combined Modality Therapy', 'Female', 'Humans', 'Infusions, Intravenous', 'Male', 'Metoprolol/*administration & dosage/adverse effects', 'Middle Aged', 'Myocardial Infarction/*drug therapy/mortality/pathology', 'Recurrence', '*Thrombolytic Therapy']",https://pubmed.ncbi.nlm.nih.gov/1590224/
53,atenolol,2872875,Long-acting beta-adrenergic antagonists as preparation for surgery in thyrotoxicosis.,"['Gerst PH', 'Fildes J', 'Baylor P', 'Zonszein J']","['Adrenergic beta-Antagonists/*therapeutic use', 'Adult', 'Atenolol/administration & dosage/therapeutic use', 'Drug Administration Schedule', 'Female', 'Graves Disease/*surgery', 'Humans', 'Middle Aged', 'Nadolol', '*Premedication', 'Propanolamines/administration & dosage/therapeutic use', 'Pulse/drug effects', '*Thyroidectomy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2872875/
54,atenolol,1671244,How much drug in the tablet?,['Herxheimer A'],"['Aged', 'Atenolol/administration & dosage', 'Biological Availability', '*Chemistry, Pharmaceutical', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Humans', 'Mathematics', 'Middle Aged', 'Pharmacokinetics', 'Product Surveillance, Postmarketing/*standards', 'Tablets/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/1671244/
55,atenolol,28601540,Atrial Fibrillation in Anaphylaxis.,"['Rojas-Perez-Ezquerra P', 'Noguerado-Mellado B', 'Morales-Cabeza C', 'Zambrano Ibarra G', 'Datino Romaniega T']","['Actinidia/adverse effects/immunology', 'Administration, Intravenous', 'Adult', 'Aged, 80 and over', 'Anaphylaxis/*complications/drug therapy/etiology', 'Animals', 'Anisakis/immunology/parasitology', 'Anti-Arrhythmia Agents/administration & dosage/immunology/therapeutic use', 'Anti-Inflammatory Agents/administration & dosage/therapeutic use', 'Arachis/adverse effects/immunology', 'Atenolol/*administration & dosage/immunology/therapeutic use', 'Atrial Fibrillation/drug therapy/*etiology', 'Bronchodilator Agents/administration & dosage/therapeutic use', 'Chlorpheniramine/*administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Epinephrine/administration & dosage/*therapeutic use', 'Food Hypersensitivity/*complications/diagnosis/drug therapy/etiology', 'Gadiformes/immunology/parasitology', 'Histamine H1 Antagonists/administration & dosage/therapeutic use', 'Humans', 'Hypodermoclysis', 'Male', 'Methylprednisolone/administration & dosage/*therapeutic use', 'Urticaria/*complications/etiology/immunology']",https://pubmed.ncbi.nlm.nih.gov/28601540/
56,atenolol,15581720,[Perioperative administration of betablockers: a practice survey].,"['Danton N', 'Viale JP', 'Gueugniaud PY', 'Lehot JJ', 'Piriou V']","['Adrenergic beta-Antagonists/adverse effects/*therapeutic use', 'Anesthesiology/*trends', 'Atenolol/adverse effects/therapeutic use', 'Attitude of Health Personnel', 'Data Collection', 'France', 'Humans', '*Perioperative Care', 'Surveys and Questionnaires']",https://pubmed.ncbi.nlm.nih.gov/15581720/
57,atenolol,9504355,Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial.,"['Van Nueten L', 'Taylor FR', 'Robertson JI']","['Adolescent', 'Adrenergic beta-Antagonists/*therapeutic use', 'Adult', 'Aged', 'Atenolol/adverse effects/*therapeutic use', 'Benzopyrans/adverse effects/*therapeutic use', 'Double-Blind Method', 'Ethanolamines/adverse effects/*therapeutic use', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Nebivolol']",https://pubmed.ncbi.nlm.nih.gov/9504355/
58,atenolol,8004839,Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension.,"['Ram CV', 'Ames RP', 'Applegate WB', 'Burris JF', 'Davidov ME', 'Mroczek WJ']","['Adolescent', 'Adult', 'Aged', 'Amlodipine/administration & dosage/adverse effects/*therapeutic use', 'Atenolol/administration & dosage/adverse effects/therapeutic use', 'Blood Pressure/drug effects', 'Cholesterol/blood', 'Cholesterol, HDL/blood', 'Cholesterol, LDL/blood', 'Cholesterol, VLDL/blood', 'Double-Blind Method', 'Drug Combinations', 'Electrocardiography/drug effects', 'Female', 'Humans', 'Hydrochlorothiazide/administration & dosage/adverse effects/*therapeutic use', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Pulse/drug effects', 'Safety', 'Single-Blind Method', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/8004839/
59,atenolol,8491252,Dose proportional absorption of 25-150 mg atenolol.,"['Wakelkamp M', 'Alvan G', 'Paintaud G', 'Hedman A']","['Administration, Oral', 'Adult', 'Atenolol/administration & dosage/*pharmacokinetics', 'Biological Availability', 'Female', 'Humans', '*Intestinal Absorption', 'Male']",https://pubmed.ncbi.nlm.nih.gov/8491252/
60,famotidine,25750443,Urticaria pigmentosa-like disease in a dog.,"['Pariser MS', 'Gram DW']","['Animals', 'Anti-Allergic Agents/administration & dosage/therapeutic use', 'Anti-Ulcer Agents/administration & dosage/therapeutic use', 'Cetirizine/administration & dosage/therapeutic use', 'Diphenhydramine/administration & dosage/therapeutic use', 'Dog Diseases/diagnosis/*pathology', 'Dogs', 'Famotidine/administration & dosage/therapeutic use', 'Male', 'Urticaria Pigmentosa/diagnosis/drug therapy/pathology/*veterinary']",https://pubmed.ncbi.nlm.nih.gov/25750443/
61,famotidine,28153970,A Rare Case of Famotidine-Induced Delirium in a Peritoneal Dialysis Patient.,"['Chan GC', 'Lee KM', 'Kwan LP', 'Mok MM', 'Ma MK', 'Yap DY', 'Tang SC']","['Acute Disease', 'Delirium/*chemically induced/physiopathology', 'Dyspepsia/diagnosis/*drug therapy', 'Famotidine/*adverse effects/therapeutic use', 'Follow-Up Studies', 'Humans', 'Kidney Failure, Chronic/diagnosis/*therapy', 'Male', 'Middle Aged', 'Peritoneal Dialysis/*adverse effects/methods', 'Risk Assessment', 'Treatment Outcome', 'Withholding Treatment']",https://pubmed.ncbi.nlm.nih.gov/28153970/
62,famotidine,32912894,"Angioedema, ACE inhibitor and COVID-19.","['Grewal E', 'Sutarjono B', 'Mohammed I']","['Angioedema/*chemically induced/*complications/drug therapy', 'Angiotensin-Converting Enzyme Inhibitors/*adverse effects', 'Anti-Allergic Agents/therapeutic use', 'Benzazepines/*adverse effects', '*Betacoronavirus', 'COVID-19', 'Coronavirus Infections/*complications', 'Diagnosis, Differential', 'Diphenhydramine/therapeutic use', 'Famotidine/therapeutic use', 'Histamine H2 Antagonists/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Pandemics', 'Pneumonia, Viral/*complications', 'SARS-CoV-2', 'Tranexamic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32912894/
63,famotidine,24267478,The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.,"['Tuskey A', 'Peura D']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Anti-Ulcer Agents/therapeutic use', 'Drug Therapy, Combination', 'Famotidine/therapeutic use', 'Gastrointestinal Diseases/chemically induced/*drug therapy/prevention & control', 'Histamine H2 Antagonists/*therapeutic use', 'Humans', 'Ibuprofen/adverse effects/therapeutic use', 'Intestinal Mucosa/*drug effects/pathology', 'Stomach Ulcer/chemically induced/drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/24267478/
64,famotidine,37722599,Oral famotidine reduces the plasma level of soluble P-selectin in children with sickle cell disease.,"['Allali S', 'Marquant F', 'Rignault-Bricard R', 'Taylor M', 'Brice J', 'de Montalembert M', 'Maciel TT', 'Elie C', 'Hermine O']","['Child', 'Humans', '*Famotidine/therapeutic use', 'P-Selectin/metabolism', 'Histamine', 'Prospective Studies', '*Anemia, Sickle Cell']",https://pubmed.ncbi.nlm.nih.gov/37722599/
65,famotidine,7914403,Intestinal clearance of H2-antagonists.,"['Hui YF', 'Kolars J', 'Hu Z', 'Fleisher D']","[""4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid/administration & dosage"", 'Animals', 'Cimetidine/analogs & derivatives/analysis/pharmacokinetics', 'Famotidine/pharmacokinetics', 'Histamine H2 Antagonists/*pharmacokinetics', 'Humans', 'Intestinal Mucosa/*metabolism', 'Jejunum/*metabolism', 'Methionine/administration & dosage', 'Perfusion', 'Rats']",https://pubmed.ncbi.nlm.nih.gov/7914403/
66,famotidine,24532249,WITHDRAWN: Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood.,"['Huertas-Ceballos AA', 'Logan S', 'Bennett C', 'Macarthur C', 'Martin AE']","['Abdominal Pain/*drug therapy', 'Adolescent', 'Analgesics, Non-Narcotic/*therapeutic use', 'Child', 'Child, Preschool', 'Famotidine/therapeutic use', 'Humans', 'Irritable Bowel Syndrome/*drug therapy', 'Mentha piperita', 'Pizotyline/therapeutic use', 'Plant Oils/therapeutic use', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/24532249/
67,famotidine,10410190,Famotidine in the management of schizophrenia.,['Martinez MC'],"['Clinical Trials as Topic', 'Famotidine/*therapeutic use', 'Histamine H2 Antagonists/*therapeutic use', 'Humans', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/10410190/
68,famotidine,28867258,Risk factors for suboptimal drug concentration of posaconazole oral suspension in patients with hematologic malignancy.,"['Kim EJ', 'Yu KS', 'Na SH', 'Nam EY', 'Oh HS', 'Kim M', 'Yoon SH', 'Lee JO', 'Koh Y', 'Song KH', 'Choe PG', 'Cho JY', 'Song SH', 'Kim ES', 'Kim HB', 'Bang SM', 'Kim NJ', 'Oh MD', 'Kim I', 'Park WB']","['Administration, Oral', 'Adult', 'Aged', 'Antifungal Agents/*pharmacokinetics', 'Famotidine/therapeutic use', 'Female', 'Hematologic Neoplasms/*drug therapy', 'Histamine H2 Antagonists/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Mycoses/prevention & control', '*Pre-Exposure Prophylaxis', 'Prospective Studies', 'Risk Factors', 'Triazoles/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/28867258/
69,famotidine,11967601,H(2) antagonist-induced thrombocytopenia: is this a real phenomenon?,"['Wade EE', 'Rebuck JA', 'Healey MA', 'Rogers FB']","['Cimetidine/adverse effects', 'Critical Care', 'Famotidine/adverse effects', 'Histamine H2 Antagonists/*adverse effects/therapeutic use', 'Humans', 'Peptic Ulcer/*prevention & control', 'Ranitidine/adverse effects', 'Risk Factors', 'Thrombocytopenia/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/11967601/
70,famotidine,33135390,Effect of gastric acid-reducing agents on the pharmacokinetics and efficacy of lemborexant.,"['Landry I', 'Aluri J', 'Hall N', 'Kumar D', 'Dayal S', 'Moline M', 'Reyderman L']","['Adult', 'Double-Blind Method', 'Drug Interactions/physiology', 'Famotidine/administration & dosage/*pharmacokinetics', 'Female', 'Gastric Acid/*metabolism', 'Histamine H2 Antagonists/administration & dosage/*pharmacokinetics', 'Humans', 'Male', 'Orexin Receptor Antagonists/administration & dosage/*pharmacokinetics', 'Pyridines/administration & dosage/*pharmacokinetics', 'Pyrimidines/administration & dosage/*pharmacokinetics', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33135390/
71,famotidine,25318791,Iron-deficiency anemia caused by a proton pump inhibitor.,"['Hashimoto R', 'Matsuda T', 'Chonan A']","['Anemia, Iron-Deficiency/*chemically induced', 'Famotidine/therapeutic use', 'Gastroesophageal Reflux/drug therapy', 'Humans', 'Male', 'Middle Aged', 'Proton Pump Inhibitors/*adverse effects/therapeutic use', 'Rabeprazole/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/25318791/
72,famotidine,24550598,Stevens-Johnson syndrome following use of metronidazole in a dental patient.,"['Mazumdar G', 'Shome K']","['*Dental Health Services', 'Dibenzoxepins/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Erythromycin/administration & dosage/therapeutic use', 'Famotidine/administration & dosage/therapeutic use', 'Humans', 'Lichen Planus, Oral/drug therapy', 'Male', 'Methylprednisolone/administration & dosage/therapeutic use', 'Metronidazole/administration & dosage/*adverse effects', 'Middle Aged', 'Olopatadine Hydrochloride', 'Stevens-Johnson Syndrome/drug therapy/*etiology', 'Triamcinolone/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/24550598/
73,famotidine,7976805,Effects of the H2-antagonists famotidine and nizatidine and the cytoprotectant misoprostol on human colonic and rat peritoneal mast cells.,"['Shah PM', 'Boulos PB', 'Springall R', 'Vashisht R', 'Pearce FL']","['Animals', 'Colon/cytology', 'Famotidine/*pharmacology', 'Histamine H2 Antagonists/*pharmacology', 'Humans', 'In Vitro Techniques', 'Mast Cells/*drug effects', 'Misoprostol/*pharmacology', 'Nizatidine/*pharmacology', 'Peritoneal Cavity/cytology', 'Rats']",https://pubmed.ncbi.nlm.nih.gov/7976805/
74,famotidine,2979247,Dose--response effect of famotidine on patterns of gastro-oesophageal reflux.,"['Orr WC', 'Robinson MG', 'Humphries TJ', 'Antonello J', 'Cagliola A']","['Adult', 'Aged', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Famotidine/administration & dosage/*therapeutic use', 'Gastric Acidity Determination', 'Gastroesophageal Reflux/*drug therapy/physiopathology', 'Humans', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/2979247/
75,famotidine,22419335,Histamine H2-receptor antagonists for urticaria.,"['Fedorowicz Z', 'van Zuuren EJ', 'Hu N']","['Cimetidine/adverse effects/therapeutic use', 'Diphenhydramine/adverse effects/therapeutic use', 'Drug Therapy, Combination/methods', 'Famotidine/adverse effects/therapeutic use', 'Histamine H1 Antagonists', 'Histamine H2 Antagonists/adverse effects/*therapeutic use', 'Humans', 'Randomized Controlled Trials as Topic', 'Ranitidine/adverse effects/therapeutic use', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22419335/
76,famotidine,34609001,The association between famotidine and in-hospital mortality of patients with COVID-19.,"['Kuno T', 'So M', 'Takahashi M', 'Egorova NN']","['Famotidine/therapeutic use', 'Hospital Mortality', 'Humans', 'Retrospective Studies', 'SARS-CoV-2', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/34609001/
77,famotidine,11027567,Ghrelin stimulates gastric acid secretion and motility in rats.,"['Masuda Y', 'Tanaka T', 'Inomata N', 'Ohnuma N', 'Tanaka S', 'Itoh Z', 'Hosoda H', 'Kojima M', 'Kangawa K']","['Animals', 'Atropine/pharmacology', 'Dose-Response Relationship, Drug', 'Famotidine/pharmacology', 'Gastric Acid/*metabolism', 'Gastric Mucosa/metabolism', 'Ghrelin', 'Histamine/pharmacology', 'Histamine H2 Antagonists/pharmacology', 'Male', '*Peptide Hormones', 'Peptides/administration & dosage/antagonists & inhibitors/*pharmacology', 'Peristalsis/*drug effects', 'Rats', 'Rats, Sprague-Dawley', 'Stomach/*drug effects/innervation/physiology', 'Vagotomy']",https://pubmed.ncbi.nlm.nih.gov/11027567/
78,famotidine,1625532,The clinical use of histamine-2 receptor antagonists.,"['Michocki RJ', 'Richardson JP']","['Cimetidine/administration & dosage/*therapeutic use', 'Drug Evaluation', 'Famotidine/administration & dosage/*therapeutic use', 'Gastroesophageal Reflux/*drug therapy', 'Humans', 'Nizatidine/administration & dosage/*therapeutic use', 'Peptic Ulcer/*drug therapy', 'Ranitidine/administration & dosage/*therapeutic use', 'Recurrence', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/1625532/
79,Amethopterin,30243154,Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review.,"['Wang W', 'Zhou H', 'Liu L']","['Animals', 'Antirheumatic Agents/*adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Gastrointestinal Diseases/chemically induced', 'Humans', 'Methotrexate/*adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Neoplasms/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/30243154/
80,Amethopterin,39433528,Methotrexate-Induced Epidermal Necrosis.,"['Loesch AJ', 'Jin A', 'Huang S', 'Motaparthi K', 'Lee JB', 'Hsu S']","['Humans', '*Methotrexate/adverse effects/therapeutic use/administration & dosage', 'Female', 'Aged', '*Necrosis/chemically induced', '*Psoriasis/drug therapy/chemically induced/pathology', 'Dermatologic Agents/adverse effects/therapeutic use', 'Epidermis/pathology', 'Drug Eruptions/etiology/pathology/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/39433528/
81,Amethopterin,7011005,Intrathecal methotrexate-induced neurotoxicities.,"['Nelson RW', 'Frank JT']","['Humans', 'Injections', 'Injections, Spinal', 'Lumbosacral Region', 'Methotrexate/administration & dosage/*adverse effects/cerebrospinal fluid', 'Nervous System Diseases/*chemically induced/prevention & control', 'Risk']",https://pubmed.ncbi.nlm.nih.gov/7011005/
82,Amethopterin,29975207,Folate Supplementation for Methotrexate Therapy in Patients With Rheumatoid Arthritis: A Systematic Review.,"['Liu L', 'Liu S', 'Wang C', 'Guan W', 'Zhang Y', 'Hu W', 'Zhang L', 'He Y', 'Lu J', 'Li T', 'Liu X', 'Xuan Y', 'Wang P']","['Antirheumatic Agents/administration & dosage/adverse effects/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Folic Acid/*therapeutic use', 'Humans', 'Leucovorin/*therapeutic use', 'Methotrexate/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29975207/
83,Amethopterin,27993660,Much more than you expected: The non-DHFR-mediated effects of methotrexate.,"['Sramek M', 'Neradil J', 'Veselska R']","['Animals', 'Folic Acid/*metabolism', 'Folic Acid Antagonists/pharmacology/therapeutic use', 'Humans', 'Methotrexate/*pharmacology/*therapeutic use', 'Signal Transduction/*drug effects', 'Tetrahydrofolate Dehydrogenase/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/27993660/
84,Amethopterin,32066146,Adverse Effects of Low-Dose Methotrexate: A Randomized Trial.,"['Solomon DH', 'Glynn RJ', 'Karlson EW', 'Lu F', 'Corrigan C', 'Colls J', 'Xu C', 'MacFadyen J', 'Barbhaiya M', 'Berliner N', 'Dellaripa PF', 'Everett BM', 'Pradhan AD', 'Hammond SP', 'Murray M', 'Rao DA', 'Ritter SY', 'Rutherford A', 'Sparks JA', 'Stratton J', 'Suh DH', 'Tedeschi SK', 'Vanni KMM', 'Paynter NP', 'Ridker PM']","['Aged', 'Antirheumatic Agents/*administration & dosage/*adverse effects', 'Cardiovascular Diseases/*drug therapy', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Methotrexate/*administration & dosage/*adverse effects', 'Middle Aged', 'Placebos', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/32066146/
85,Amethopterin,3913771,Drug interactions with methotrexate.,"['Evans WE', 'Christensen ML']","['Absorption', 'Anti-Bacterial Agents/pharmacology', 'Arthritis, Rheumatoid/drug therapy', 'Aspirin/pharmacology', 'Biological Transport/drug effects', 'Cell Membrane/metabolism', 'Cisplatin/pharmacology', 'Dose-Response Relationship, Drug', '*Drug Interactions', 'Folic Acid/pharmacology', 'Humans', 'Kidney Tubules/drug effects/metabolism', 'Methotrexate/administration & dosage/adverse effects/*metabolism/therapeutic use', 'Probenecid/pharmacology', 'Protein Binding/drug effects', 'Salicylates/pharmacology', 'Serum Albumin/metabolism', 'Sulfamethoxazole/pharmacology', 'Sulfonamides/pharmacology', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/3913771/
86,Amethopterin,39392455,Methotrexate polyglutamates.,"['Yang Z', 'Mo J', 'Li W', 'Zhao Z', 'Mei S']","['*Methotrexate/analogs & derivatives/adverse effects/administration & dosage/pharmacology/pharmacokinetics', 'Humans', '*Polyglutamic Acid/analogs & derivatives/pharmacology', 'Animals', 'Antirheumatic Agents/adverse effects/administration & dosage/pharmacology/pharmacokinetics', 'Precision Medicine']",https://pubmed.ncbi.nlm.nih.gov/39392455/
87,Amethopterin,31276602,Optimising low-dose methotrexate for rheumatoid arthritis-A review.,"['Lucas CJ', 'Dimmitt SB', 'Martin JH']","['Administration, Oral', 'Antirheumatic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Arthritis, Rheumatoid/*drug therapy', 'Dose-Response Relationship, Drug', 'Humans', 'Methotrexate/*administration & dosage/adverse effects/pharmacokinetics', 'Polyglutamic Acid/metabolism', ""Practice Patterns, Physicians'""]",https://pubmed.ncbi.nlm.nih.gov/31276602/
88,Amethopterin,1918470,The pharmacology of methotrexate.,['Olsen EA'],"['Bone Marrow/drug effects', 'Central Nervous System/drug effects', 'Digestive System/drug effects', 'Drug Therapy, Combination', 'Humans', 'Kidney/drug effects', 'Leucovorin/administration & dosage/metabolism/pharmacology', 'Lung/drug effects', 'Methotrexate/administration & dosage/adverse effects/pharmacokinetics/*pharmacology', 'Skin/drug effects']",https://pubmed.ncbi.nlm.nih.gov/1918470/
89,Amethopterin,21044430,Methotrexate bioavailability.,"['van Roon EN', 'van de Laar MA']","['Antirheumatic Agents/administration & dosage/adverse effects/*pharmacokinetics', 'Biological Availability', 'Drug Administration Routes', 'Drug Administration Schedule', 'Drug Dosage Calculations', 'Drug Interactions', 'Humans', 'Intestinal Absorption', 'Methotrexate/administration & dosage/adverse effects/analogs & derivatives/*pharmacokinetics', 'Polyglutamic Acid/analogs & derivatives/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/21044430/
90,Amethopterin,300460,High-dose methotrexate therapy.,"['Bell R', 'Sullivan JR', 'Moon WJ', 'Hurley TH']","['Adult', 'Carcinoma, Squamous Cell/drug therapy', 'Drug Therapy, Combination', 'Head and Neck Neoplasms/drug therapy', 'Humans', 'Leucovorin/therapeutic use', 'Lymphoma/drug therapy', 'Methotrexate/*administration & dosage/adverse effects/therapeutic use', 'Neoplasms/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/300460/
91,Amethopterin,26349496,Microemulsions for Colorectal Cancer Treatments. General Considerations and Formulation of Methotrexate.,"['Flores SE', 'Rial-Hermida MI', 'Ramirez JC', 'Pazos A', 'Concheiro A', 'Alvarez-Lorenzo C', 'Peralta RD']","['Animals', 'Antimetabolites, Antineoplastic/*administration & dosage/chemistry/pharmacology/therapeutic use', 'Chemistry, Pharmaceutical/methods', 'Colon/drug effects/pathology', 'Colorectal Neoplasms/*drug therapy/pathology', 'Drug Delivery Systems/methods', 'Emulsions/adverse effects/*chemistry', 'Humans', 'Methotrexate/*administration & dosage/chemistry/pharmacology/therapeutic use', 'Oils, Volatile/adverse effects/*chemistry', 'Pharmaceutical Vehicles/adverse effects/*chemistry', 'Surface-Active Agents/adverse effects/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/26349496/
92,Amethopterin,9544409,Methotrexate therapy.,['Schep GN'],"['Antimetabolites, Antineoplastic/*therapeutic use', 'Antirheumatic Agents/*therapeutic use', 'Dermatologic Agents/*therapeutic use', 'Folic Acid Antagonists/*therapeutic use', 'Humans', 'Immunosuppressive Agents/*therapeutic use', 'Methotrexate/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9544409/
93,Amethopterin,39356310,"A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment.","['Bielack SS', 'Soussain C', 'Fox CP', 'Houillier C', 'Murciano T', 'Osborne W', 'Zinzani PL', 'Rizzari C', 'Schwartz S']","['Humans', '*Methotrexate/therapeutic use/administration & dosage/adverse effects', '*gamma-Glutamyl Hydrolase/therapeutic use', '*Leucovorin/administration & dosage/therapeutic use', 'Antimetabolites, Antineoplastic/adverse effects/therapeutic use/administration & dosage', 'Consensus', 'Europe', 'Neoplasms/drug therapy', 'Recombinant Proteins/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/39356310/
94,Amethopterin,25340735,Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers.,"['Lima A', 'Sousa H', 'Monteiro J', 'Azevedo R', 'Medeiros R', 'Seabra V']","['ATP-Binding Cassette Transporters/*genetics', 'Dose-Response Relationship, Drug', 'Drug-Related Side Effects and Adverse Reactions/genetics', 'Humans', 'Membrane Transport Proteins/*genetics', 'Methotrexate/*administration & dosage/adverse effects/pharmacokinetics', '*Pharmacogenetics', 'Polymorphism, Single Nucleotide']",https://pubmed.ncbi.nlm.nih.gov/25340735/
95,Amethopterin,2679014,Methotrexate in the treatment of rheumatoid arthritis.,"['Korn S', 'Dehoratius RJ']","['Arthritis, Rheumatoid/*drug therapy', 'Humans', 'Methotrexate/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2679014/
96,Amethopterin,12222556,Methotrexate-induced toxic leukoencephalopathy.,"['Gowan GM', 'Herrington JD', 'Simonetta AB']","['Aged', 'Antimetabolites, Antineoplastic/administration & dosage/*adverse effects/therapeutic use', 'Dementia, Vascular/*chemically induced', 'Fatal Outcome', 'Female', 'Humans', 'Injections, Intraventricular', 'Leukemia, Lymphocytic, Chronic, B-Cell/complications/drug therapy/radiotherapy', 'Magnetic Resonance Imaging', 'Methotrexate/administration & dosage/*adverse effects/therapeutic use', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/12222556/
97,Amethopterin,9608316,Disease-modifying antirheumatic drugs.,"['Li E', 'Brooks P', 'Conaghan PG']","['Antimalarials/adverse effects/therapeutic use', 'Antirheumatic Agents/administration & dosage/adverse effects/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Drug Therapy, Combination', 'Humans', 'Liver/drug effects', 'Lung/drug effects', 'Methotrexate/adverse effects/therapeutic use', 'Organogold Compounds', 'Penicillamine/adverse effects/therapeutic use', 'Sulfasalazine/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9608316/
98,Amethopterin,17377896,Medical therapy for ectopic pregnancy.,['Lipscomb GH'],"['Abortifacient Agents, Nonsteroidal/administration & dosage/adverse effects/*therapeutic use', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Methotrexate/administration & dosage/adverse effects/*therapeutic use', 'Pregnancy', 'Pregnancy, Ectopic/*drug therapy/surgery']",https://pubmed.ncbi.nlm.nih.gov/17377896/
99,thalidomide,15172781,Thalidomide.,"['Franks ME', 'Macpherson GR', 'Figg WD']","['Clinical Trials as Topic', 'Gastrointestinal Diseases/drug therapy', 'HIV Infections/complications', 'Humans', 'Neoplasms/drug therapy', 'Rheumatic Diseases/drug therapy', 'Skin Diseases/drug therapy', 'Thalidomide/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15172781/
100,thalidomide,37913505,Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia.,"['Chen H', 'Wu S', 'Tang M', 'Zhao R', 'Zhang Q', 'Dai Z', 'Gao Y', 'Yang S', 'Li Z', 'Du Y', 'Yang A', 'Zhong L', 'Lu L', 'Xu L', 'Shen X', 'Liu S', 'Zhong J', 'Li X', 'Lu H', 'Xiong H', 'Shen Y', 'Chen H', 'Gong S', 'Xue H', 'Ge Z']","['Humans', '*Angiodysplasia/complications/drug therapy', 'China', 'Double-Blind Method', '*Gastrointestinal Hemorrhage/drug therapy/etiology', '*Thalidomide/administration & dosage/adverse effects/therapeutic use', 'Treatment Outcome', '*Intestinal Diseases/complications/drug therapy', 'Recurrence', '*Intestine, Small/blood supply', 'Administration, Oral', '*Hematologic Agents/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37913505/
101,thalidomide,26927826,[Lenalidomide nephrotoxicity].,"['Kheder El-Fekih R', 'Izzedine H']","['Graft vs Host Disease/chemically induced/immunology', 'Humans', 'Immunologic Factors/administration & dosage/*adverse effects/pharmacokinetics', 'Kidney/*drug effects/pathology', 'Kidney Tubules/drug effects/pathology', 'Lenalidomide', 'Necrosis/chemically induced', 'Nephritis, Interstitial/chemically induced', 'Prevalence', '*Renal Insufficiency/epidemiology/metabolism', 'Thalidomide/administration & dosage/adverse effects/*analogs & derivatives/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/26927826/
102,thalidomide,25843431,Lenalidomide in multiple myeloma.,"['Kim Y', 'Schmidt-Wolf IG']","['Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Combined Modality Therapy', 'Dexamethasone/administration & dosage', 'Disease-Free Survival', 'Humans', 'Immunologic Factors/adverse effects/*therapeutic use', 'Lenalidomide', 'Multiple Myeloma/*drug therapy/pathology', 'Stem Cell Transplantation/methods', 'Survival Rate', 'Thalidomide/administration & dosage/analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/25843431/
103,thalidomide,32545946,Apremilast for psoriasis treatment.,"['Carrascosa JM', 'Del-Alcazar E']","['Administration, Oral', 'Humans', 'Phosphodiesterase 4 Inhibitors/*administration & dosage/adverse effects/pharmacology', 'Psoriasis/*drug therapy/pathology', 'Quality of Life', 'Severity of Illness Index', 'Thalidomide/administration & dosage/adverse effects/*analogs & derivatives/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/32545946/
104,thalidomide,11155589,Thalidomide.,"['Radomsky CL', 'Levine N']","['Dermatologic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Immunosuppressive Agents/adverse effects/pharmacokinetics/therapeutic use', 'Practice Guidelines as Topic', 'Skin Diseases/*drug therapy', 'Thalidomide/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11155589/
105,thalidomide,28338672,Posttransplant maintenance therapy in multiple myeloma: the changing landscape.,"['Sengsayadeth S', 'Malard F', 'Savani BN', 'Garderet L', 'Mohty M']","['Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Bortezomib/administration & dosage/adverse effects/therapeutic use', 'Hematopoietic Stem Cell Transplantation', 'Humans', 'Immunologic Factors/administration & dosage/adverse effects/therapeutic use', 'Lenalidomide', 'Maintenance Chemotherapy', 'Molecular Targeted Therapy', 'Multiple Myeloma/*drug therapy/mortality/pathology', 'Postoperative Care', 'Thalidomide/administration & dosage/adverse effects/analogs & derivatives/therapeutic use', 'Transplantation, Autologous', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28338672/
106,thalidomide,38441805,Aponermin: First Approval.,['Dhillon S'],"['Humans', '*Multiple Myeloma/drug therapy', '*Thalidomide/analogs & derivatives/pharmacology/therapeutic use', '*Drug Approval', '*Dexamethasone/pharmacology/therapeutic use/administration & dosage', '*TNF-Related Apoptosis-Inducing Ligand/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/pharmacology/therapeutic use', 'China', 'Antineoplastic Agents/pharmacology/therapeutic use', 'Apoptosis/drug effects']",https://pubmed.ncbi.nlm.nih.gov/38441805/
107,thalidomide,29290125,Management of Common Side Effects of Apremilast.,"['Langley A', 'Beecker J']","['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects/therapeutic use', 'Diarrhea', '*Drug-Related Side Effects and Adverse Reactions/diagnosis/therapy', 'Headache', 'Humans', 'Nasopharyngitis', 'Nausea', 'Psoriasis/*drug therapy', 'Thalidomide/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29290125/
108,thalidomide,21327565,New immunomodulatory drugs in myeloma.,['Lacy MQ'],"['Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Dexamethasone/administration & dosage', 'Humans', 'Immunologic Factors/adverse effects/therapeutic use', 'Lenalidomide', 'Multiple Myeloma/*drug therapy/pathology', 'Neutropenia/chemically induced', 'Thalidomide/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21327565/
109,thalidomide,28958290,Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.,"['Talati C', 'Sallman D', 'List A']","['Chromosome Deletion', 'Chromosomes, Human, Pair 5/*genetics', 'Humans', 'Immunologic Factors/administration & dosage/pharmacology/*therapeutic use', 'Lenalidomide', 'Myelodysplastic Syndromes/*drug therapy/pathology', 'Thalidomide/administration & dosage/*analogs & derivatives/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28958290/
110,thalidomide,24998775,Cutaneous adverse reactions to lenalidomide.,"['Imbesi S', 'Allegra A', 'Calapai G', 'Musolino C', 'Gangemi S']","['Amyloidosis/complications/*drug therapy', 'Animals', 'Drug Eruptions/etiology/*prevention & control', 'Humans', 'Lenalidomide', 'Multiple Myeloma/complications/*drug therapy', 'Myelodysplastic Syndromes/complications/*drug therapy', 'Skin/*drug effects/pathology', 'Thalidomide/adverse effects/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24998775/
111,thalidomide,27654579,Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.,"['Ball B', 'Zeidan A', 'Gore SD', 'Prebet T']","['Antineoplastic Agents, Immunological/administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'DNA Methylation/*drug effects', 'Histone Deacetylase Inhibitors/administration & dosage', 'Humans', 'Lenalidomide', 'Molecular Targeted Therapy', 'Myelodysplastic Syndromes/*drug therapy/*genetics/pathology', 'Protein Kinase Inhibitors/administration & dosage', 'Thalidomide/administration & dosage/analogs & derivatives', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27654579/
112,thalidomide,25432812,Lucio's leprosy: a clinical and therapeutic challenge.,"['Jurado F', 'Rodriguez O', 'Novales J', 'Navarrete G', 'Rodriguez M']","['Biopsy, Needle', 'Disease Progression', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Humans', 'Immunohistochemistry', 'Leprostatic Agents/*administration & dosage', 'Leprosy, Lepromatous/complications/*drug therapy/*pathology', 'Male', 'Mycobacterium leprae/*drug effects', 'Risk Assessment', 'Severity of Illness Index', 'Skin Physiological Phenomena/*drug effects', 'Skin Ulcer/drug therapy/etiology/*pathology', 'Thalidomide/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25432812/
113,thalidomide,16433584,Thalidomide in multiple myeloma.,['Garcia-Sanz R'],"['Humans', 'Multiple Myeloma/*drug therapy/metabolism/mortality', 'Survival Analysis', 'Thalidomide/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16433584/
114,thalidomide,16305990,Immunomodulatory drugs.,"['Crane E', 'List A']","['Humans', 'Immunosuppressive Agents/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Interleukin-12/physiology', 'Lenalidomide', 'Lymphoma, B-Cell, Marginal Zone/drug therapy', 'Multiple Myeloma/*drug therapy', 'Myelodysplastic Syndromes/*drug therapy', 'Neovascularization, Pathologic', 'T-Lymphocytes/drug effects/physiology', 'Thalidomide/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16305990/
115,thalidomide,20510766,Innovative uses of thalidomide.,"['Chen M', 'Doherty SD', 'Hsu S']","['Contraindications', 'Female', 'Humans', 'Leprostatic Agents/adverse effects/pharmacology/*therapeutic use', 'Male', '*Off-Label Use', 'Skin Diseases/*drug therapy', 'Thalidomide/adverse effects/pharmacology/*therapeutic use', '*Therapies, Investigational']",https://pubmed.ncbi.nlm.nih.gov/20510766/
116,thalidomide,23680477,Novel agents for chronic lymphocytic leukemia.,"['Wu M', 'Akinleye A', 'Zhu X']","['Antibodies, Monoclonal/administration & dosage/adverse effects/therapeutic use', 'Antibodies, Monoclonal, Humanized', 'Antineoplastic Agents/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Bendamustine Hydrochloride', 'Humans', 'Lenalidomide', 'Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy', 'Nitrogen Mustard Compounds/administration & dosage/adverse effects/therapeutic use', 'Thalidomide/administration & dosage/adverse effects/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23680477/
117,thalidomide,21434945,"A review of the history, properties, and use of the immunomodulatory compound lenalidomide.","['Zeldis JB', 'Knight R', 'Hussein M', 'Chopra R', 'Muller G']","['Drug Discovery/history/trends', 'History, 20th Century', 'History, 21st Century', 'Humans', 'Immunologic Factors/adverse effects/chemical synthesis/*pharmacology/*therapeutic use', 'Lenalidomide', 'Models, Biological', 'Neoplasms/drug therapy/immunology', 'Thalidomide/adverse effects/*analogs & derivatives/chemical synthesis/pharmacology/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21434945/
118,thalidomide,27521311,Is Maintenance Therapy for Everyone?,"['Nooka AK', 'Lonial S']","['Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Clinical Decision-Making', 'Disease Management', 'Humans', 'Lenalidomide', 'Maintenance Chemotherapy', 'Molecular Targeted Therapy', 'Mortality', 'Multiple Myeloma/diagnosis/*drug therapy/mortality', 'Proportional Hazards Models', 'Thalidomide/administration & dosage/adverse effects/analogs & derivatives/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27521311/
119,aspirin,32580960,Aspirin in Primary Prevention of Cardiovascular Events.,"['Soodi D', 'VanWormer JJ', 'Rezkalla SH']","['Aspirin/*therapeutic use', 'Cardiovascular Diseases', 'Humans', '*Primary Prevention', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/32580960/
120,aspirin,17107286,Prasugrel.,"['Tantry US', 'Bliden KP', 'Gurbel PA']","['Adenosine Diphosphate/antagonists & inhibitors/pharmacology', 'Animals', 'Aspirin/administration & dosage/therapeutic use', 'Clinical Trials, Phase I as Topic', 'Clinical Trials, Phase III as Topic', 'Clopidogrel', 'Collagen/antagonists & inhibitors/pharmacology', 'Coronary Disease/drug therapy', 'Drug Evaluation, Preclinical', 'Drug Resistance', 'Drug Synergism', 'Drug Therapy, Combination', '*Drugs, Investigational/administration & dosage/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Humans', '*Piperazines/administration & dosage/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Platelet Activation/drug effects', 'Platelet Aggregation/drug effects', '*Platelet Aggregation Inhibitors/administration & dosage/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Prasugrel Hydrochloride', 'Prodrugs/pharmacokinetics/therapeutic use', '*Purinergic P2 Receptor Antagonists', 'Pyridines/administration & dosage/therapeutic use', 'Rats', 'Receptors, Purinergic P2Y12', '*Thiophenes/administration & dosage/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Ticlopidine/analogs & derivatives/chemistry/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17107286/
121,aspirin,38704715,[Not Available].,"['Andersen MF', 'Rode L', 'Christiansen ILR', 'Tabor A', 'Ekelund CK']","['Humans', '*Pre-Eclampsia/prevention & control', 'Pregnancy', '*Aspirin/administration & dosage/adverse effects/therapeutic use', 'Female', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38704715/
122,aspirin,31669590,Aspirin and its pleiotropic application.,"['Hybiak J', 'Broniarek I', 'Kiryczynski G', 'Los LD', 'Rosik J', 'Machaj F', 'Slawinski H', 'Jankowska K', 'Urasinska E']","['Animals', 'Aspirin/*pharmacology/therapeutic use', 'Female', 'Humans', 'Mental Disorders/drug therapy', 'Neoplasms/drug therapy/prevention & control', 'Platelet Aggregation Inhibitors/pharmacology/therapeutic use', 'Pre-Eclampsia/prevention & control', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/31669590/
123,aspirin,34824680,Aspirin in the Modern Era of Cardiovascular Disease Prevention.,"['Murphy E', 'Curneen JMG', 'McEvoy JW']","['Aspirin/adverse effects', '*Cardiovascular Diseases/epidemiology/prevention & control', 'Humans', '*Myocardial Infarction', '*Percutaneous Coronary Intervention', 'Platelet Aggregation Inhibitors/adverse effects', 'Purinergic P2Y Receptor Antagonists']",https://pubmed.ncbi.nlm.nih.gov/34824680/
124,aspirin,38839268,Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease.,['Patrono C'],"['Humans', '*Aspirin/administration & dosage', '*Platelet Aggregation Inhibitors/administration & dosage', '*Atherosclerosis/prevention & control', 'Cardiovascular Diseases/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/38839268/
125,aspirin,17523700,Aspirin and Reye syndrome: a review of the evidence.,['Schror K'],"['Aspirin/administration & dosage/*adverse effects/pharmacokinetics/pharmacology', 'Child', 'Energy Metabolism', 'Humans', 'Liver/drug effects/metabolism', '*Reye Syndrome/chemically induced/epidemiology/etiology']",https://pubmed.ncbi.nlm.nih.gov/17523700/
126,aspirin,12638472,[Antiaggregation: aspirin].,"['Eichenberger A', 'Pontiggia L', 'Beer JH']","['Administration, Oral', 'Adult', 'Age Factors', 'Aged', 'Anticoagulants/administration & dosage/therapeutic use', 'Aspirin/administration & dosage/adverse effects/*therapeutic use', 'Cardiovascular Diseases/prevention & control', 'Diabetes Complications', 'Diabetes Mellitus/drug therapy', 'Drug Interactions', 'Drug Therapy, Combination', 'Female', 'Fibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use', 'Hemorrhage/chemically induced', 'Humans', 'Male', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/*therapeutic use', 'Primary Prevention', 'Randomized Controlled Trials as Topic', 'Risk Factors', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/12638472/
127,aspirin,1199984,Aspirin hepatitis.,"['Zucker P', 'Daum F', 'Cohen MI']","['Adolescent', 'Anemia, Sickle Cell/complications', 'Arthritis, Juvenile/complications/*drug therapy', 'Aspartate Aminotransferases/blood', 'Aspirin/administration & dosage/*adverse effects/therapeutic use', 'Chemical and Drug Induced Liver Injury/*etiology', 'Child', 'Female', 'Humans', 'Lupus Erythematosus, Systemic/*drug therapy', 'Male', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/1199984/
128,aspirin,31300475,Are Platelets the Primary Target of Aspirin's Remarkable Anticancer Activity?,"['Lichtenberger LM', 'Vijayan KV']","['Aspirin/*pharmacology', 'Blood Platelets/*drug effects/pathology', 'Cyclooxygenase Inhibitors/pharmacology', 'Humans', 'Neoplasms/*blood/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/31300475/
129,aspirin,22372726,Acetylsalicylic acid/esomeprazole fixed-dose combination.,"['Burness CB', 'Scott LJ']","['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Anti-Ulcer Agents/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Aspirin/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Capsules', 'Cardiovascular Diseases/prevention & control', 'Drug Combinations', 'Esomeprazole/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Humans', 'Peptic Ulcer/prevention & control', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Prodrugs/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Proton Pump Inhibitors/administration & dosage/adverse effects/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22372726/
130,aspirin,20338720,[Prevention of preeclampsia].,"['Deruelle P', 'Girard JM', 'Coutty N', 'Subtil D']","['Adolescent', 'Adult', 'Anticoagulants/therapeutic use', 'Antioxidants/therapeutic use', 'Aspirin/administration & dosage/therapeutic use', 'Calcium Compounds/therapeutic use', 'Diuretics/adverse effects/therapeutic use', 'Female', 'Heparin, Low-Molecular-Weight/therapeutic use', 'Humans', 'Male', 'Malnutrition/complications', 'Nitric Oxide Donors/adverse effects/therapeutic use', 'Platelet Aggregation Inhibitors/administration & dosage/therapeutic use', 'Pre-Eclampsia/*prevention & control', 'Pregnancy', 'Risk', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/20338720/
131,aspirin,26369684,Prevention of Upper Gastrointestinal Ulcer and Complications in Low-Dose Aspirin Users.,['Sugano K'],"['Aspirin/administration & dosage/*adverse effects', 'Dose-Response Relationship, Drug', 'Gastrointestinal Hemorrhage/*chemically induced/prevention & control', 'Humans', 'Peptic Ulcer/*chemically induced/prevention & control', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects', 'Practice Guidelines as Topic', 'Proton Pump Inhibitors/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26369684/
132,aspirin,30665790,[Aspirin and preeclampsia].,"['Atallah A', 'Lecarpentier E', 'Goffinet F', 'Gaucherand P', 'Doret-Dion M', 'Tsatsaris V']","['Aspirin/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Chronobiology Phenomena', 'Contraindications, Drug', 'Cyclooxygenase Inhibitors/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Drug Utilization', 'Early Diagnosis', 'Female', 'Fetal Diseases/chemically induced', 'France/epidemiology', 'Humans', 'Mass Screening', 'Meta-Analysis as Topic', 'Placenta/metabolism', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Pre-Eclampsia/diagnosis/epidemiology/*prevention & control', 'Pregnancy', 'Pregnancy Complications/chemically induced', 'Pregnancy Trimester, First', 'Primary Prevention', 'Prostaglandin Antagonists/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Risk Factors', 'Secondary Prevention']",https://pubmed.ncbi.nlm.nih.gov/30665790/
133,aspirin,25577431,[Managing antithrombotic therapy in vitreoretinal surgery].,"['Gallice M', 'Rouberol F', 'Albaladejo P', 'Brillat Zaratzian E', 'Palombi K', 'Aptel F', 'Romanet JP', 'Chiquet C']","['Anesthesia, Local', 'Anticoagulants/administration & dosage/adverse effects/classification/pharmacokinetics/*therapeutic use', 'Aspirin/administration & dosage/adverse effects/therapeutic use', 'Blood Coagulation/drug effects/physiology', 'Eye Diseases/surgery', 'Fibrinolytic Agents/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Hemorrhage/chemically induced/*prevention & control', 'Humans', 'International Normalized Ratio', 'Intraoperative Complications/prevention & control', 'Models, Biological', '*Ophthalmologic Surgical Procedures', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/therapeutic use', 'Postoperative Complications/prevention & control', 'Purinergic P2Y Receptor Antagonists/administration & dosage/adverse effects/therapeutic use', 'Retinal Diseases/complications/surgery', 'Risk Assessment', 'Thromboembolism/*prevention & control', 'Thrombophilia/complications/drug therapy', 'Vitreous Body/surgery']",https://pubmed.ncbi.nlm.nih.gov/25577431/
134,aspirin,6344620,Aspirin in the treatment of juvenile arthritis.,['Baum J'],"['Arthritis, Juvenile/*drug therapy', 'Aspirin/administration & dosage/adverse effects/*therapeutic use', 'Chemical and Drug Induced Liver Injury', 'Child', 'Clinical Trials as Topic', 'Humans', 'Liver Diseases/enzymology', 'Protein Binding', 'Salicylates/administration & dosage/blood', 'Serum Albumin/metabolism']",https://pubmed.ncbi.nlm.nih.gov/6344620/
135,aspirin,22591976,"Aspirin: a history, a love story.",['Wick JY'],"['Analgesics/*history', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*history/therapeutic use', 'Aspirin/adverse effects/*history/therapeutic use', 'Benzyl Alcohols/chemistry', 'Cardiovascular Diseases/prevention & control', 'Drug Hypersensitivity', 'Drug Resistance', 'Glucosides/chemistry', 'History, 18th Century', 'History, 19th Century', 'History, 20th Century', 'Humans', 'Neoplasms/prevention & control', 'Salix/chemistry', 'Sex Characteristics']",https://pubmed.ncbi.nlm.nih.gov/22591976/
136,aspirin,28342880,[For a targeted use of aspirin].,"['Madar H', 'Brun S', 'Coatleven F', 'Nithart A', 'Lecoq C', 'Gleyze M', 'Merlot B', 'Sentilhes L']","['Abnormalities, Drug-Induced/etiology', 'Antiphospholipid Syndrome/complications/drug therapy', 'Aspirin/*adverse effects/*therapeutic use', 'Female', 'Humans', 'Pre-Eclampsia/drug therapy', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/*drug therapy', 'Premature Birth/prevention & control', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/28342880/
137,aspirin,24558899,[Aspirin: once or twice a day?].,"['Fontana P', 'Casini A', 'Boehlen F', 'Reny JL']","['Aspirin/*administration & dosage/metabolism', 'Blood Platelets/drug effects/physiology', 'Drug Administration Schedule', 'Hemostasis/drug effects', 'Humans', 'Individuality']",https://pubmed.ncbi.nlm.nih.gov/24558899/
138,aspirin,26747390,The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.,"['Tamargo J', 'Castellano JM', 'Fuster V']","['Aspirin/*administration & dosage/adverse effects/therapeutic use', 'Atorvastatin/*administration & dosage/adverse effects/therapeutic use', 'Cardiovascular Agents/*administration & dosage/adverse effects/therapeutic use', 'Cardiovascular Diseases/drug therapy/economics/*prevention & control', 'Drug Combinations', 'Humans', 'Ramipril/*administration & dosage/adverse effects/therapeutic use', 'Secondary Prevention/*methods']",https://pubmed.ncbi.nlm.nih.gov/26747390/
139,Ultram,26218943,"Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review.","['Beakley BD', 'Kaye AM', 'Kaye AD']","['Analgesics, Opioid/*adverse effects', 'Animals', 'Drug Interactions', 'Humans', 'Risk Factors', 'Serotonin Syndrome/*chemically induced/*diagnosis/epidemiology', 'Selective Serotonin Reuptake Inhibitors/adverse effects', 'Tramadol/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/26218943/
140,Ultram,15509185,Clinical pharmacology of tramadol.,"['Grond S', 'Sablotzki A']","['Acute Disease', 'Analgesics, Opioid/adverse effects/*pharmacokinetics/*pharmacology', 'Animals', 'Chronic Disease', 'Clinical Trials as Topic', 'Humans', 'Models, Biological', 'Pain/drug therapy', 'Tramadol/adverse effects/*pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/15509185/
141,Ultram,12749738,Tramadol/paracetamol.,"['McClellan K', 'Scott LJ']","['Acetaminophen/administration & dosage/adverse effects/*therapeutic use', 'Acute Disease', 'Administration, Oral', 'Analgesics/administration & dosage/adverse effects/*therapeutic use', 'Biological Availability', 'Chronic Disease', 'Clinical Trials as Topic', 'Drug Administration Schedule', 'Drug Combinations', 'Humans', 'Pain/*drug therapy', 'Tramadol/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12749738/
142,Ultram,9771272,Remifentanil and tramadol.,['Duthie DJ'],"['Analgesics, Opioid/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Piperidines/pharmacokinetics/*pharmacology', 'Remifentanil', 'Tramadol/adverse effects/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/9771272/
143,Ultram,27861439,"Trends in Tramadol: Pharmacology, Metabolism, and Misuse.","['Miotto K', 'Cho AK', 'Khalil MA', 'Blanco K', 'Sasaki JD', 'Rawson R']","['Acute Pain/*drug therapy', 'Analgesics, Opioid/administration & dosage/adverse effects/*pharmacokinetics', 'Animals', 'Chronic Pain/*drug therapy', 'Cytochrome P-450 CYP3A/genetics/metabolism', 'Cytochrome P-450 Enzyme System/genetics/metabolism', 'Drug Compounding', 'Drug Interactions', 'Genotype', 'Humans', 'Opioid-Related Disorders/*epidemiology', 'Pharmacogenetics', 'Pharmacogenomic Variants', 'Phenotype', 'Polymorphism, Genetic', '*Prescription Drug Misuse', 'Risk Factors', 'Tramadol/administration & dosage/adverse effects/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/27861439/
144,Ultram,15771942,Tramadol-associated pericarditis.,"['Krantz MJ', 'Garcia JA', 'Mehler PS']","['Aged', 'Aged, 80 and over', 'Analgesics, Opioid/*adverse effects', 'Humans', 'Male', 'Pericarditis/*chemically induced/diagnosis', 'Tramadol/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/15771942/
145,Ultram,29752906,Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures.,"['Hassamal S', 'Miotto K', 'Dale W', 'Danovitch I']","['Analgesics, Opioid/*adverse effects', 'Anticonvulsants/therapeutic use', 'Humans', 'Risk Factors', 'Seizures/*chemically induced', 'Serotonin Syndrome/*chemically induced/complications/diagnosis/drug therapy', 'Tramadol/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/29752906/
146,Ultram,30594783,An overview of tramadol and its usage in pain management and future perspective.,"['Subedi M', 'Bajaj S', 'Kumar MS', 'Yc M']","['Analgesics, Opioid/*pharmacokinetics/*therapeutic use', 'Animals', 'Chronic Pain/*drug therapy/metabolism/psychology', 'Drug Interactions', 'Forecasting', 'Humans', 'Pain Management/*methods/psychology', 'Tramadol/*pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30594783/
147,Ultram,16451094,Tramadol sustained-release capsules.,['Keating GM'],"['Analgesics, Opioid/*administration & dosage/adverse effects/pharmacokinetics', 'Capsules', 'Delayed-Action Preparations', 'Humans', 'Pain/*drug therapy/metabolism', 'Tramadol/*administration & dosage/adverse effects/pharmacokinetics', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16451094/
148,Ultram,30892453,Opioids in the immune system: from experimental studies to clinical practice.,"['Moyano J', 'Aguirre L']","['Adaptive Immunity/drug effects', 'Analgesics, Opioid/administration & dosage/*pharmacology', 'Fentanyl/administration & dosage/pharmacology', 'Humans', 'Immune System/*drug effects', 'Morphine/administration & dosage/pharmacology', 'Perioperative Period', 'Remifentanil/administration & dosage/pharmacology', 'Tramadol/administration & dosage/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30892453/
149,Ultram,34196947,"Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients.","['Roulet L', 'Rollason V', 'Desmeules J', 'Piguet V']","['Analgesics, Opioid/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Cytochrome P-450 CYP2D6/genetics', 'Dose-Response Relationship, Drug', 'Humans', 'Liver Failure/metabolism', 'Pain/drug therapy/physiopathology', 'Renal Insufficiency/metabolism', 'Tapentadol/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Tramadol/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34196947/
150,Ultram,32295441,The effect of tramadol on blood glucose concentrations: a systematic review.,"['Nakhaee S', 'Brent J', 'Hoyte C', 'Farrokhfall K', 'Shirazi FM', 'Askari M', 'Mehrpour O']","['Analgesics, Opioid/administration & dosage/*adverse effects', 'Animals', 'Blood Glucose/analysis/*drug effects', 'Humans', 'Hyperglycemia/chemically induced', 'Hypoglycemia/chemically induced', 'Tramadol/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32295441/
151,Ultram,25776506,"Tramadol hydrochloride: pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems.","['Vazzana M', 'Andreani T', 'Fangueiro J', 'Faggio C', 'Silva C', 'Santini A', 'Garcia ML', 'Silva AM', 'Souto EB']","['Analgesics, Opioid/administration & dosage/adverse effects/pharmacokinetics', 'Animals', 'Chemistry, Pharmaceutical/methods', 'Dizziness/chemically induced/metabolism', 'Drug Delivery Systems/*trends', 'Humans', 'Pharmaceutical Preparations/*administration & dosage/*metabolism', 'Tramadol/*administration & dosage/adverse effects/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/25776506/
152,Ultram,7517822,Tramadol for the management of acute pain.,['Lehmann KA'],"['Administration, Oral', 'Adult', 'Child', 'Clinical Trials as Topic', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Pain/*drug therapy', 'Pain, Postoperative/drug therapy', 'Self Administration', 'Tramadol/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7517822/
153,Ultram,26749092,Current Pharmacological Management of Premature Ejaculation: A Systematic Review and Meta-analysis.,"['Castiglione F', 'Albersen M', 'Hedlund P', 'Gratzke C', 'Salonia A', 'Giuliano F']","['Administration, Cutaneous', 'Analgesics, Opioid/pharmacology/*therapeutic use', 'Anesthetics, Local/administration & dosage/pharmacology/*therapeutic use', 'Benzylamines/therapeutic use', 'Humans', 'Male', 'Naphthalenes/therapeutic use', 'Phosphodiesterase 5 Inhibitors/pharmacology/*therapeutic use', 'Premature Ejaculation/*drug therapy/physiopathology', 'Reaction Time/drug effects', 'Selective Serotonin Reuptake Inhibitors/pharmacology/*therapeutic use', 'Tramadol/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26749092/
154,Ultram,33181582,Tramadol Treatment for Chemotherapy-induced Mucositis Pain in Children.,"['Yaffe Ornstein M', 'Stocki D', 'Levin D', 'Dvir R', 'Manisterski M', 'Berger-Achituv S', 'Rosenfeld Keidar H', 'Peled Y', 'Hazan S', 'Rosenberg T', 'Oppenheimer N', 'Elhasid R']","['Analgesics, Opioid', '*Antineoplastic Agents/therapeutic use', 'Child', 'Humans', '*Mucositis/chemically induced/drug therapy', 'Pain/chemically induced/drug therapy', 'Retrospective Studies', '*Tramadol/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33181582/
155,Ultram,31637686,Mania induced by tramadol-venlafaxine combination.,"['Hefzi N', 'Grekin J', 'Ahmed A']","['Analgesics, Opioid', '*Bipolar Disorder/chemically induced', '*Depressive Disorder, Major/drug therapy', 'Humans', 'Male', 'Middle Aged', 'Selective Serotonin Reuptake Inhibitors/adverse effects', '*Tramadol/adverse effects/therapeutic use', '*Venlafaxine Hydrochloride/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31637686/
156,Ultram,15461118,Tramadol (Ultram) concentrations in death investigation and impaired driving cases and their significance.,"['Clarkson JE', 'Lacy JM', 'Fligner CL', 'Thiersch N', 'Howard J', 'Harruff RC', 'Logan BK']","['Analgesics, Opioid/*blood/pharmacology/poisoning', '*Automobile Driving', '*Cause of Death', 'Central Nervous System Depressants/poisoning', 'Drug Interactions', 'Forensic Medicine', 'Humans', 'Muscle Relaxants, Central/poisoning', 'Reference Values', 'Tramadol/*blood/pharmacology/poisoning']",https://pubmed.ncbi.nlm.nih.gov/15461118/
157,Ultram,10969362,Tramadol--present and future.,['Shipton EA'],"['*Analgesics, Opioid/adverse effects/metabolism/pharmacokinetics/therapeutic use', 'Biological Availability', 'Chemistry, Pharmaceutical', 'Gastrointestinal Transit/drug effects', 'Humans', 'Pain/*drug therapy', '*Tramadol/adverse effects/metabolism/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10969362/
158,dicyclomine,31515515,Nausea and vomiting of pregnancy and hyperemesis gravidarum.,"['Fejzo MS', 'Trovik J', 'Grooten IJ', 'Sridharan K', 'Roseboom TJ', 'Vikanes A', 'Painter RC', 'Mullin PM']","['Antiemetics/therapeutic use', 'Dicyclomine/therapeutic use', 'Doxylamine/therapeutic use', 'Drug Combinations', 'Female', 'Growth Differentiation Factor 15/analysis', 'Humans', 'Hyperemesis Gravidarum/*diagnosis/epidemiology', 'Mass Screening/methods', 'Nausea/etiology', 'Pregnancy', 'Pyridoxine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31515515/
159,dicyclomine,29941700,Infantile Colic: An Update.,"['Sarasu JM', 'Narang M', 'Shah D']","['Behavior Therapy/methods', 'Colic/*diagnosis/etiology/therapy', 'Counseling/methods', 'Crying', 'Diet Therapy/methods', 'Humans', 'Infant', 'Infant, Newborn', 'Parasympatholytics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29941700/
160,dicyclomine,15160628,Infantile colic.,['Kanabar D'],"['Antifoaming Agents/therapeutic use', 'Anxiety/etiology', '*Colic/diagnosis/therapy', 'Controlled Clinical Trials as Topic', 'Crying', 'Dicyclomine/therapeutic use', 'Evidence-Based Medicine', 'Humans', '*Infant Welfare', 'Infant, Newborn', '*Lactose Intolerance/diagnosis/drug therapy', 'Parent-Child Relations', 'Simethicone/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15160628/
161,dicyclomine,30306546,Dietary modifications for infantile colic.,"['Gordon M', 'Biagioli E', 'Sorrenti M', 'Lingua C', 'Moja L', 'Banks SS', 'Ceratto S', 'Savino F']","['Allergens', 'Colic/*diet therapy', 'Crying', 'Diet Therapy/methods', 'Female', 'Humans', 'Infant', '*Infant Formula', 'Lactase/administration & dosage', 'Male', 'Randomized Controlled Trials as Topic', 'Soybean Proteins/administration & dosage', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/30306546/
162,dicyclomine,26447441,Infantile Colic: Recognition and Treatment.,"['Johnson JD', 'Cocker K', 'Chang E']","['Colic/*diagnosis/*diet therapy/*drug therapy', 'Education, Medical, Continuing', 'Female', 'Gastrointestinal Agents/*therapeutic use', 'Humans', 'Infant', 'Infant, Newborn', 'Male', 'Pediatrics/*standards', '*Practice Guidelines as Topic', 'Probiotics/*therapeutic use', 'United States']",https://pubmed.ncbi.nlm.nih.gov/26447441/
163,dicyclomine,27038970,The Link Between Infantile Colic and Migraine.,"['Qubty W', 'Gelfand AA']","['Colic/complications/diagnosis/*drug therapy', 'Dicyclomine/*therapeutic use', '*Diet Therapy', 'Humans', 'Migraine Disorders/complications/diagnosis/*drug therapy', 'Proton Pump Inhibitors/*therapeutic use', 'Simethicone/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27038970/
164,dicyclomine,3777291,Drugs and stillbirth.,"['Porter JB', 'Hunter-Mitchell J', 'Jick H', 'Walker AM']","['Abnormalities, Drug-Induced', 'Adult', 'Anti-Bacterial Agents/*adverse effects', 'Contraceptives, Oral/*adverse effects', 'Dicyclomine', 'Doxylamine/*adverse effects', 'Drug Combinations/adverse effects', 'Female', 'Fetal Death/*chemically induced', 'Health Surveys', 'Humans', 'Pregnancy', 'Pyridines/*adverse effects', 'Pyridoxine/*adverse effects', 'Spermatocidal Agents/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/3777291/
165,dicyclomine,33993133,Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options.,"['Brenner DM', 'Lacy BE']","['Abdominal Pain/*drug therapy', 'Chronic Pain/*drug therapy', 'Humans', 'North America', 'Parasympatholytics/*supply & distribution/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33993133/
166,dicyclomine,24548499,A new pharmacologic treatment for nausea and vomiting of pregnancy.,['Fantasia HC'],"['Abnormalities, Drug-Induced/prevention & control', 'Antiemetics/administration & dosage/adverse effects/*therapeutic use', 'Delayed-Action Preparations', 'Dicyclomine/administration & dosage/adverse effects/*therapeutic use', 'Doxylamine/administration & dosage/adverse effects/*therapeutic use', 'Drug Administration Schedule', 'Drug Combinations', 'Drug Information Services', 'Female', 'Humans', 'Hyperemesis Gravidarum/*drug therapy/etiology', 'Morning Sickness/*drug therapy/etiology', 'Obstetric Nursing/standards', 'Pregnancy', 'Pyridoxine/administration & dosage/adverse effects/*therapeutic use', 'Therapeutic Equivalency']",https://pubmed.ncbi.nlm.nih.gov/24548499/
167,dicyclomine,6384676,Effects of drugs and chemicals on the fetus and newborn (1).,"['Hill LM', 'Kleinberg F']","['Abnormalities, Drug-Induced/*etiology', 'Animals', 'Antiemetics/adverse effects', 'Behavior/drug effects', 'Caffeine/adverse effects', 'Dicyclomine', 'Doxylamine/adverse effects', 'Drug Combinations/adverse effects', 'Embryo, Mammalian/drug effects', 'Female', 'Ferrous Compounds/adverse effects', 'Fetus/*drug effects', 'Humans', 'Infant, Newborn', 'Male', 'Maternal-Fetal Exchange', 'Nervous System/drug effects', 'Nonprescription Drugs/adverse effects', 'Oocytes/drug effects', 'Pregnancy', 'Prenatal Exposure Delayed Effects', 'Pyridoxine/adverse effects', 'Reproduction/drug effects', 'Spermatozoa/drug effects', 'Vitamins/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/6384676/
168,dicyclomine,14994923,[Hyperemesis gravidarum--etiology and treatment].,"['Imperato F', 'Canova I', 'Basili R', 'Iuele T', 'Mossa B']","['Adrenal Cortex Hormones/administration & dosage/adverse effects/therapeutic use', 'Antiemetics/administration & dosage/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Dicyclomine', 'Doxylamine/administration & dosage/therapeutic use', 'Drug Combinations', 'Enteral Nutrition', 'Female', 'Histamine Antagonists/administration & dosage/therapeutic use', 'Humans', '*Hyperemesis Gravidarum/complications/drug therapy/etiology/psychology/therapy', 'Odds Ratio', 'Parenteral Nutrition', 'Placebos', 'Pregnancy', 'Pyridoxine/administration & dosage/therapeutic use', 'Risk Factors', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/14994923/
169,dicyclomine,16822454,Clinical inquiries. What is the best treatment for infants with colic?,"['Crotteau CA', 'Wright ST', 'Eglash A']","['Breast Feeding', 'Colic/diet therapy/drug therapy/*therapy', 'Food Hypersensitivity/complications', 'Humans', 'Infant', '*Infant Formula']",https://pubmed.ncbi.nlm.nih.gov/16822454/
170,dicyclomine,22436257,Epidemiological evidence in forensic pharmacovigilance.,"['Persaud N', 'Healy D']","['Abnormalities, Drug-Induced/epidemiology', 'Antiemetics/adverse effects/toxicity', 'Breast Implantation/adverse effects/statistics & numerical data', '*Causality', 'Connective Tissue Diseases/epidemiology', 'Dicyclomine/adverse effects/toxicity', 'Doxylamine/adverse effects/toxicity', 'Drug Combinations', 'Female', 'Forensic Sciences/*legislation & jurisprudence/organization & administration', 'Humans', 'Pharmacoepidemiology/*legislation & jurisprudence/organization & administration', 'Pharmacology/legislation & jurisprudence/methods', '*Pharmacovigilance', 'Pregnancy', 'Pyridoxine/adverse effects/toxicity']",https://pubmed.ncbi.nlm.nih.gov/22436257/
171,dicyclomine,24798673,Should doxylamine-pyridoxine be used for nausea and vomiting of pregnancy?,"['Persaud N', 'Chin J', 'Walker M']","['Abnormalities, Drug-Induced', 'Antiemetics/*therapeutic use', 'Dicyclomine/*therapeutic use', 'Doxylamine/*therapeutic use', 'Drug Combinations', 'Female', 'Humans', 'Morning Sickness/*drug therapy', 'Neoplasms/chemically induced', 'Practice Guidelines as Topic', 'Pregnancy', 'Pyloric Stenosis/chemically induced', 'Pyridoxine/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/24798673/
172,dicyclomine,38262412,Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer.,"['Wang J', 'Wei J', 'Pu T', 'Zeng A', 'Karthikeyan V', 'Bechtold B', 'Vo K', 'Chen J', 'Lin TP', 'Chang AP', 'Corey E', 'Puhr M', 'Klocker H', 'Culig Z', 'Bland T', 'Wu BJ']","['Male', 'Humans', 'Docetaxel/pharmacology/therapeutic use', '*Receptor, Muscarinic M1/genetics', '*Prostatic Neoplasms, Castration-Resistant/drug therapy/genetics/metabolism', 'Cell Line, Tumor', 'Cholinergic Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38262412/
173,dicyclomine,3927122,"The creation of therapeutic orphans--or, what have we learnt from the Debendox fiasco?","['Sheffield LJ', 'Batagol R']","['Abnormalities, Drug-Induced/*etiology', 'Animals', 'Antiemetics/*adverse effects', 'Australia', 'Clinical Trials as Topic', 'Cyclohexanecarboxylic Acids/*adverse effects', 'Dicyclomine/*adverse effects', 'Doxylamine/*adverse effects', 'Drug Combinations/adverse effects', 'Female', 'Haplorhini', 'Humans', 'Infant, Newborn', 'Macaca fascicularis', 'Pregnancy', 'Pyridines/*adverse effects', 'Pyridoxine/*adverse effects', 'Rabbits', 'Random Allocation', 'Rats', 'Risk', '*Teratogens', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/3927122/
174,dicyclomine,8486081,Preliminary note: dangerous use of anticholinergic drugs in Brazil.,['Carlini EA'],"['Adolescent', 'Adult', 'Brazil/epidemiology', 'Child', 'Cross-Sectional Studies', '*Developing Countries', 'Humans', 'Incidence', 'Parasympatholytics/*adverse effects', 'Substance-Related Disorders/epidemiology/*etiology']",https://pubmed.ncbi.nlm.nih.gov/8486081/
175,dicyclomine,32737240,Protection Versus Progress: The Challenge of Research on Cannabis Use During Pregnancy.,"['MacDuffie KE', 'Kleinhans NM', 'Stout K', 'Wilfond BS']","['Antiemetics/adverse effects', 'Dicyclomine/therapeutic use', 'Doxylamine/therapeutic use', 'Drug Approval', 'Drug Combinations', '*Ethics, Research', 'Female', 'Humans', 'Medical Marijuana/adverse effects/*therapeutic use', 'Morning Sickness/*therapy', 'Ondansetron/therapeutic use', 'Pediatrics/*ethics', 'Pregnancy', '*Pregnant People', 'Pyridoxine/therapeutic use', '*Research Subjects', 'Teratogens', 'Thalidomide/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32737240/
176,dicyclomine,329860,Treatment of pregnancy sickness.,['Wheatley D'],"['Clinical Trials as Topic', 'Cyclohexanecarboxylic Acids/*therapeutic use', 'Dicyclomine/*therapeutic use', 'Double-Blind Method', 'Doxylamine/therapeutic use', 'Female', 'Humans', 'Nausea/*drug therapy', 'Placebos', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Pregnancy Trimester, First', 'Pyridoxine/*therapeutic use', 'Vomiting/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/329860/
177,dicyclomine,2772850,Bendectin and human congenital malformations.,"['Shiono PH', 'Klebanoff MA']","['Abnormalities, Drug-Induced/*etiology', 'Central Nervous System/abnormalities', 'Dicyclomine', 'Digestive System Abnormalities', 'Doxylamine/*adverse effects', 'Drug Combinations/adverse effects', 'Female', 'Head/abnormalities', 'Heart Defects, Congenital/chemically induced', 'Humans', 'Lung/abnormalities', 'Pregnancy', 'Pregnancy Trimester, First', 'Prospective Studies', 'Pyridines/*adverse effects', 'Pyridoxine/*adverse effects', 'Urogenital Abnormalities', 'Vomiting']",https://pubmed.ncbi.nlm.nih.gov/2772850/
178,Solgol,1353872,[Beta-blockers and migraine].,"['Massiou H', 'Bousser MG']","['Adrenergic beta-Antagonists/pharmacology/therapeutic use', 'Atenolol/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Dilatation, Pathologic/drug therapy', 'Evoked Potentials, Visual/drug effects', 'Humans', 'Metoprolol/pharmacology/*therapeutic use', 'Migraine Disorders/*drug therapy', 'Nadolol/pharmacology/therapeutic use', 'Platelet Aggregation/drug effects', 'Propranolol/pharmacology/*therapeutic use', 'Receptors, Serotonin/drug effects', 'Timolol/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1353872/
179,Solgol,28685702,A Focus on Pharmacological Management of Catecholaminergic Polymorphic Ventricular Tachycardia.,"['Claudio B', 'Alice M', 'Daniel S']","['Adrenergic beta-Antagonists/*therapeutic use', 'Anti-Arrhythmia Agents/*therapeutic use', 'Calcium Channel Blockers/*therapeutic use', 'Death, Sudden, Cardiac/etiology', 'Defibrillators, Implantable', 'Electrocardiography', 'Humans', 'Sodium Channel Blockers/*therapeutic use', 'Tachycardia, Ventricular/complications/diagnosis/*drug therapy/physiopathology', 'Polymorphic Catecholaminergic Ventricular Tachycardia']",https://pubmed.ncbi.nlm.nih.gov/28685702/
180,Solgol,34747977,Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial.,"['Pope E', 'Lara-Corrales I', 'Sibbald C', 'Liy-Wong C', 'Kanigsberg N', 'Drolet B', 'Ma J']","['Administration, Oral', 'Adrenergic beta-Antagonists/adverse effects/pharmacology/standards', 'Double-Blind Method', 'Equivalence Trials as Topic', 'Female', 'Hemangioma, Capillary/*drug therapy/physiopathology', 'Humans', 'Infant', 'Male', 'Nadolol/adverse effects/pharmacology/*standards', 'Neoplastic Syndromes, Hereditary/*drug therapy/physiopathology', 'Ontario', 'Propranolol/adverse effects/pharmacology/*standards', 'Prospective Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34747977/
181,Solgol,6407348,New antiarrhythmic drugs.,"['Scheinman MM', 'Hess DS']","['Amiodarone/therapeutic use', 'Angina Pectoris/drug therapy', 'Anti-Arrhythmia Agents/pharmacology/*therapeutic use', 'Blood Circulation', 'Bradycardia/chemically induced', 'Diltiazem/therapeutic use', 'Half-Life', 'Humans', 'Hypertension/drug therapy', 'Lidocaine/analogs & derivatives/therapeutic use', 'Metoprolol/therapeutic use', 'Nadolol', 'Nifedipine/therapeutic use', 'Propanolamines/therapeutic use', 'Propranolol/therapeutic use', 'Tocainide', 'Verapamil/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6407348/
182,Solgol,30372514,"Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.","['Zacharias AP', 'Jeyaraj R', 'Hobolth L', 'Bendtsen F', 'Gluud LL', 'Morgan MY']","['Adrenergic beta-Antagonists/adverse effects/*therapeutic use', 'Adult', 'Carvedilol/adverse effects/*therapeutic use', 'Esophageal and Gastric Varices/complications/*drug therapy/mortality', 'Gastrointestinal Hemorrhage/mortality/*prevention & control', 'Humans', 'Liver Cirrhosis/complications/*drug therapy/mortality', 'Nadolol/adverse effects/*therapeutic use', 'Primary Prevention', 'Propranolol/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Secondary Prevention']",https://pubmed.ncbi.nlm.nih.gov/30372514/
183,Solgol,11153162,Beta blockers and lactation: an update.,"['Shannon ME', 'Malecha SE', 'Cha AJ']","['Adrenergic beta-Antagonists/*adverse effects/*pharmacokinetics', 'Adult', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Infant', 'Milk, Human/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/11153162/
184,Solgol,35353122,Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With beta-Blockers.,"['Mazzanti A', 'Kukavica D', 'Trancuccio A', 'Memmi M', 'Bloise R', 'Gambelli P', 'Marino M', 'Ortiz-Genga M', 'Morini M', 'Monteforte N', 'Giordano U', 'Keegan R', 'Tomasi L', 'Anastasakis A', 'Davis AM', 'Shimizu W', 'Blom NA', 'Santiago DJ', 'Napolitano C', 'Monserrat L', 'Priori SG']","['Adolescent', 'Adrenergic beta-Antagonists/therapeutic use', 'Adult', 'Child', 'Cohort Studies', 'Electrocardiography', 'Female', 'Humans', 'Male', '*Nadolol/therapeutic use', 'Prospective Studies', 'Ryanodine Receptor Calcium Release Channel/genetics', 'Syncope', '*Tachycardia, Ventricular/diagnosis', 'Young Adult', 'Polymorphic Catecholaminergic Ventricular Tachycardia']",https://pubmed.ncbi.nlm.nih.gov/35353122/
185,Solgol,6145385,Antiadrenergic antihypertensive drugs: their effect on renal function.,"['Bernstein KN', ""O'Connor DT""]","['Administration, Oral', 'Adrenergic alpha-Agonists/pharmacology', 'Adrenergic alpha-Antagonists/pharmacology', 'Adrenergic beta-Antagonists/administration & dosage/pharmacology', 'Animals', 'Antihypertensive Agents/*pharmacology', 'Hemodynamics/drug effects', 'Humans', 'Injections', 'Kallikreins/physiology', 'Kidney/*drug effects', 'Plasma Volume/drug effects', 'Renal Circulation/drug effects', 'Renin/physiology', 'Renin-Angiotensin System/drug effects', 'Sympatholytics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6145385/
186,Solgol,26436966,Beta blocker treatment for infantile hemangiomas.,"['Rouhana HF', 'Fruge JH', 'Massengale WT']","['Administration, Oral', 'Adrenergic beta-Antagonists/*therapeutic use', 'Atenolol/therapeutic use', 'Child', 'Child, Preschool', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Follow-Up Studies', 'Hemangioma, Capillary/diagnosis/*drug therapy', 'Humans', 'Infant', 'Male', 'Nadolol/therapeutic use', 'Propranolol/*therapeutic use', 'Skin Neoplasms/diagnosis/*drug therapy', 'Timolol/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26436966/
187,Solgol,19882938,[Beta blockers in migraine prophylaxis].,['Shimizu T'],"['Adrenergic beta-Antagonists/*administration & dosage/pharmacokinetics/pharmacology', 'Drug Administration Schedule', 'Humans', 'Metoprolol/administration & dosage/pharmacokinetics/pharmacology', 'Migraine Disorders/*prevention & control', 'Nadolol/administration & dosage/pharmacokinetics/pharmacology', '*Premedication', 'Propranolol/*administration & dosage/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/19882938/
188,Solgol,30660822,Interaction of herbal products with prescribed medications: A systematic review and meta-analysis.,"['Awortwe C', 'Bruckmueller H', 'Cascorbi I']","['Animals', 'Biological Transport/drug effects', 'Cytochrome P-450 Enzyme System/metabolism', 'Echinacea/chemistry', '*Herb-Drug Interactions', 'Humans', 'Hypericum/chemistry', 'Hypnotics and Sedatives/metabolism/pharmacokinetics', 'Midazolam/metabolism/pharmacokinetics', 'Oximes/metabolism/pharmacokinetics', 'Plant Preparations/chemistry/*pharmacology', 'Tea/chemistry']",https://pubmed.ncbi.nlm.nih.gov/30660822/
189,Solgol,33010357,beta-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.,"['Zhou H', 'Sim JJ', 'Shi J', 'Shaw SF', 'Lee MS', 'Neyer JR', 'Kovesdy CP', 'Kalantar-Zadeh K', 'Jacobsen SJ']","['Adrenergic beta-Antagonists/metabolism/*therapeutic use', 'Aged', 'Aged, 80 and over', 'Atenolol/metabolism/therapeutic use', 'Bisoprolol/metabolism/therapeutic use', 'Carvedilol/metabolism/therapeutic use', 'Cause of Death', 'Cohort Studies', 'Female', 'Heart Failure/complications/*drug therapy', 'Hospitalization/*statistics & numerical data', 'Humans', 'Kidney Failure, Chronic/complications/*therapy', 'Labetalol/metabolism/therapeutic use', 'Logistic Models', 'Male', 'Metoprolol/metabolism/therapeutic use', 'Middle Aged', '*Mortality', 'Nadolol/metabolism/therapeutic use', 'Proportional Hazards Models', 'Propranolol/metabolism/therapeutic use', 'Protective Factors', '*Renal Dialysis', 'Retrospective Studies', 'Risk', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/33010357/
190,Solgol,6124267,Nadolol in thyrotoxicosis.,"['Peden NR', 'Isles TE', 'Stevenson IH', 'Crooks J']","['Adrenergic beta-Antagonists/*therapeutic use', 'Adult', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hyperthyroidism/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Nadolol', 'Peak Expiratory Flow Rate', 'Physical Exertion', 'Propanolamines/*therapeutic use', 'Thyroid Hormones/blood', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6124267/
191,Solgol,27798055,Exercise-induced syncope in a 22-year-old man.,"['Yeo C', 'Tan VH', 'Wong KC']","['Action Potentials', 'Anti-Arrhythmia Agents/therapeutic use', 'DNA Mutational Analysis', 'Electrocardiography', '*Exercise', 'Exercise Test', 'Genetic Predisposition to Disease', 'Heart Conduction System/drug effects/*physiopathology', '*Heart Rate/drug effects', 'Humans', 'Male', '*Mutation, Missense', 'Nadolol/therapeutic use', 'Phenotype', 'Ryanodine Receptor Calcium Release Channel/*genetics', 'Syncope/*etiology', 'Tachycardia, Ventricular/diagnosis/drug therapy/*genetics/physiopathology', 'Time Factors', 'Young Adult', 'Polymorphic Catecholaminergic Ventricular Tachycardia']",https://pubmed.ncbi.nlm.nih.gov/27798055/
192,Solgol,2883876,Clinical significance of beta 1-selectivity and intrinsic sympathomimetic activity in a beta-adrenergic blocking drug.,['Frishman WH'],"['Adrenergic beta-Agonists/pharmacology', 'Adrenergic beta-Antagonists/*metabolism/therapeutic use', 'Antihypertensive Agents/therapeutic use', 'Chemical Phenomena', 'Chemistry', 'Glucose/metabolism', 'Humans', 'Lipids/blood', 'Lipoproteins/blood', 'Lung/drug effects', 'Receptors, Adrenergic, beta/*classification/metabolism', 'Sympathomimetics/*therapeutic use', 'Vascular Resistance/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2883876/
193,Solgol,8310973,Usefulness of amlodipine for angina pectoris.,['Taylor SH'],"['Amlodipine/administration & dosage/*therapeutic use', 'Angina Pectoris/*drug therapy/etiology/physiopathology', 'Angina Pectoris, Variant/drug therapy', 'Cardiac Output', 'Clinical Trials as Topic', 'Diltiazem/administration & dosage', 'Double-Blind Method', 'Drug Administration Schedule', 'Electrocardiography', 'Exercise', 'Humans', 'Male', 'Myocardial Ischemia/physiopathology', 'Nadolol/administration & dosage', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/8310973/
194,Solgol,6348587,Nadolol in essential tremor.,['Koller WC'],"['Clinical Trials as Topic', 'Double-Blind Method', 'Humans', 'Male', 'Middle Aged', 'Nadolol', 'Placebos', 'Propanolamines/*administration & dosage/therapeutic use', 'Propranolol/therapeutic use', 'Tremor/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6348587/
195,Solgol,12499857,Central beta-adrenergic modulation of cognitive flexibility.,"['Beversdorf DQ', 'White DM', 'Chever DC', 'Hughes JD', 'Bornstein RA']","['Adrenergic beta-Agonists/administration & dosage', 'Adrenergic beta-Antagonists/administration & dosage', 'Adult', 'Cognition/drug effects/*physiology', 'Ephedrine/administration & dosage', 'Female', 'Humans', 'Male', 'Nadolol/administration & dosage', 'Norepinephrine/physiology', 'Problem Solving/drug effects', 'Propranolol/administration & dosage', 'Receptors, Adrenergic, beta/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/12499857/
196,Solgol,6125096,Therapeutic trials of pindolol in hypertension: comparison and combination with other drugs.,['Fanchamps A'],"['Adrenergic beta-Antagonists/therapeutic use', 'Adult', 'Aged', 'Antihypertensive Agents/*therapeutic use', 'Clinical Trials as Topic', 'Diuretics/therapeutic use', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Pindolol/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6125096/
197,Solgol,32662682,beta-blocker therapy for infantile hemangioma.,"['Koh SP', 'Leadbitter P', 'Smithers F', 'Tan ST']","['Adrenergic beta-Antagonists/*administration & dosage/adverse effects/pharmacology', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage/adverse effects/pharmacology', 'Animals', 'Hemangioma/*drug therapy/pathology', 'Humans', 'Infant', 'Propranolol/administration & dosage/adverse effects/pharmacology', 'Renin-Angiotensin System/drug effects', 'Skin Neoplasms/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/32662682/
198,Salbutamol,36430683,Salbutamol in the Management of Asthma: A Review.,"['Marques L', 'Vale N']","['Humans', 'Albuterol/therapeutic use', '*Asthma/drug therapy', 'Bronchi', '*Drug-Related Side Effects and Adverse Reactions', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/36430683/
199,Salbutamol,11253864,Single-isomer beta-agonists.,['Handley DA'],"['Administration, Inhalation', 'Adrenergic beta-Agonists/chemistry/*pharmacology', 'Albuterol/adverse effects/chemistry/pharmacology', 'Asthma/*drug therapy', 'Bronchi/drug effects', 'Bronchodilator Agents/chemistry/*pharmacology', 'Ethanolamines/adverse effects/chemistry/pharmacology', 'Formoterol Fumarate', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/11253864/
200,Salbutamol,11802253,Levalbuterol hydrochloride.,"['Slattery D', 'Wong SW', 'Colin AA']","['Adrenergic beta-Agonists/adverse effects/chemistry/pharmacology/*therapeutic use', 'Albuterol/adverse effects/chemistry/pharmacology/*therapeutic use', 'Asthma/*drug therapy', 'Bronchial Provocation Tests', 'Bronchodilator Agents/adverse effects/chemistry/pharmacology/*therapeutic use', 'Eosinophils/drug effects', 'Humans', 'Mucociliary Clearance/drug effects', 'Receptors, Adrenergic, beta-2/*metabolism', 'Research', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/11802253/
201,Salbutamol,12493336,The long and short of beta2-agonists.,['Lotvall J'],"['Administration, Inhalation', '*Adrenergic beta-2 Receptor Agonists', 'Adrenergic beta-Agonists/*administration & dosage/therapeutic use', 'Albuterol/adverse effects/*analogs & derivatives/pharmacology/therapeutic use', 'Animals', 'Anti-Inflammatory Agents/administration & dosage/therapeutic use', 'Asthma/*drug therapy', 'Bronchodilator Agents/*administration & dosage/therapeutic use', 'Budesonide/adverse effects/pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Ethanolamines/adverse effects/pharmacology/therapeutic use', 'Formoterol Fumarate', 'Humans', 'Salmeterol Xinafoate']",https://pubmed.ncbi.nlm.nih.gov/12493336/
202,Salbutamol,7875287,Salmeterol-induced vertigo.,"['Lopez-Guillen A', 'Marques L', 'Lopez-Llorente MT', 'Pastor E', 'Figueras A']","['Administration, Inhalation', 'Aged', 'Albuterol/adverse effects/*analogs & derivatives/therapeutic use', 'Asthma/*drug therapy', 'Bronchodilator Agents/*adverse effects/therapeutic use', 'Female', 'Humans', 'Salmeterol Xinafoate', 'Vertigo/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/7875287/
203,Salbutamol,9877002,Pharmacokinetic and pharmacodynamic aspects of salmeterol therapy.,"['Buchwald A', 'Hochhaus G']","['Adrenergic beta-Agonists/*pharmacokinetics/*pharmacology/therapeutic use', 'Albuterol/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Asthma/drug therapy', 'Bronchodilator Agents/*pharmacokinetics/*pharmacology/therapeutic use', 'Humans', 'Salmeterol Xinafoate']",https://pubmed.ncbi.nlm.nih.gov/9877002/
204,Salbutamol,17547854,Levalbuterol for asthma: a better treatment?,['Kelly HW'],"['Albuterol/adverse effects/*therapeutic use', 'Animals', 'Asthma/*drug therapy', 'Bronchial Hyperreactivity/chemically induced', 'Bronchodilator Agents/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Disease Models, Animal', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/17547854/
205,Salbutamol,12562558,Single-isomer levalbuterol: a review of the acute data.,['Nowak R'],"['Acute Disease', 'Albuterol/economics/pharmacokinetics/*pharmacology', 'Asthma/*drug therapy', 'Bronchodilator Agents/economics/pharmacokinetics/*pharmacology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/12562558/
206,Salbutamol,26742192,Usefulness Of Glucocorticoids In The Management Of Foreign Body Aspiration.,"['Pagan Rivera BL', 'Anselmi FJ', 'Torres Mdel M', 'Segarra A', 'Rivera JR']","['Acetaminophen/administration & dosage/therapeutic use', 'Analgesics/therapeutic use', 'Anti-Bacterial Agents/therapeutic use', 'Anti-Inflammatory Agents/administration & dosage/*therapeutic use', 'Azithromycin/administration & dosage/therapeutic use', 'Bronchodilator Agents/administration & dosage/therapeutic use', 'Ceftriaxone/administration & dosage/therapeutic use', 'Cough/etiology', 'Drug Therapy, Combination', 'Dyspnea/etiology', 'Fluoroquinolones/administration & dosage/therapeutic use', 'Foreign Bodies/diagnostic imaging/*drug therapy', 'Humans', 'Levalbuterol/administration & dosage/therapeutic use', 'Male', 'Methylprednisolone/administration & dosage/*therapeutic use', 'Moxifloxacin', 'Play and Playthings', 'Pneumonia, Aspiration/*drug therapy/etiology', 'Ranitidine/administration & dosage/therapeutic use', 'Tomography, X-Ray Computed', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/26742192/
207,Salbutamol,36865421,Loeffler's Syndrome and Multifocal Cutaneous Larva Migrans: Case report of an uncommon occurrence and review of the literature.,"['Sil A', 'Bhanja DB', 'Chandra A', 'Biswas SK']","['Male', 'Humans', 'Adult', '*Larva Migrans/diagnosis/drug therapy', 'Skin', 'Albendazole/therapeutic use', 'India', 'Levalbuterol']",https://pubmed.ncbi.nlm.nih.gov/36865421/
208,Salbutamol,10452792,Clinical experience with levalbuterol.,['Nelson HS'],"['Adrenergic beta-Agonists/administration & dosage/adverse effects/chemistry/*therapeutic use', 'Adult', 'Albuterol/administration & dosage/adverse effects/chemistry/*therapeutic use', 'Asthma/*drug therapy', 'Bronchodilator Agents/administration & dosage/adverse effects/chemistry/*therapeutic use', 'Child', 'Clinical Trials as Topic', 'Female', 'Humans', 'Male', 'Respiratory Hypersensitivity/drug therapy', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/10452792/
209,Salbutamol,1897692,Cyclosporin for steroid-dependent asthma.,"['Szczeklik A', 'Nizankowska E', 'Dworski R', 'Domagala B', 'Pinis G']","['Adult', 'Albuterol/administration & dosage/therapeutic use', 'Aminophylline/administration & dosage/therapeutic use', 'Asthma/*drug therapy', 'Beclomethasone/administration & dosage/therapeutic use', 'Cyclosporins/administration & dosage/blood/*therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Peak Expiratory Flow Rate/drug effects', 'Prednisone/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1897692/
210,Salbutamol,39213627,beta-Adrenergic Agonist-Induced Lactic Acidosis: A Case Report.,['Blush RR 3rd'],"['Humans', '*Acidosis, Lactic/chemically induced', '*Adrenergic beta-Agonists/adverse effects', '*Albuterol/adverse effects/therapeutic use/administration & dosage', 'Asthma/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/39213627/
211,Salbutamol,12810191,Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?,"['Tennant RC', 'Erin EM', 'Barnes PJ', 'Hansel TT']","['*Adrenergic beta-2 Receptor Agonists', 'Adrenergic beta-Agonists/administration & dosage/therapeutic use', 'Albuterol/administration & dosage/*analogs & derivatives/pharmacology/therapeutic use', 'Anti-Inflammatory Agents/administration & dosage/pharmacology/therapeutic use', 'Bronchodilator Agents/administration & dosage/pharmacology/*therapeutic use', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Ethanolamines/administration & dosage/pharmacology/therapeutic use', 'Exercise Tolerance/drug effects', 'Formoterol Fumarate', 'Humans', 'Mucus/metabolism', 'Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology', 'Quality of Life', 'Randomized Controlled Trials as Topic', 'Salmeterol Xinafoate', 'Scopolamine Derivatives/administration & dosage/pharmacology/*therapeutic use', 'Tiotropium Bromide']",https://pubmed.ncbi.nlm.nih.gov/12810191/
212,Salbutamol,19671384,Levalbuterol versus albuterol.,"['Ameredes BT', 'Calhoun WJ']","['Administration, Inhalation', 'Adrenergic beta-Agonists/administration & dosage/chemistry/*therapeutic use', 'Albuterol/administration & dosage/chemistry/*therapeutic use', 'Animals', 'Asthma/*drug therapy/immunology', 'Clinical Trials as Topic', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/19671384/
213,Salbutamol,8322251,Prolonged hypoxaemia after nebulised salbutamol.,"['Connett G', 'Lenney W']","['Acute Disease', 'Albuterol/administration & dosage/*adverse effects', 'Asthma/drug therapy', 'Child', 'Child, Preschool', 'Humans', 'Hypoxia/*chemically induced', 'Infant', 'Nebulizers and Vaporizers']",https://pubmed.ncbi.nlm.nih.gov/8322251/
214,Salbutamol,889727,The effect of intravenous and oral salbutamol on fetus and mother in premature labour.,"['Dawson AM', 'Davies HJ']","['Administration, Oral', 'Adolescent', 'Adult', 'Albuterol/administration & dosage/*therapeutic use', 'Blood Pressure/drug effects', 'Depression, Chemical', 'Female', 'Fetal Heart/drug effects', 'Fetus/drug effects', 'Heart Rate/drug effects', 'Humans', 'Injections, Intravenous', 'Obstetric Labor, Premature/*drug therapy', 'Pregnancy', 'Uterine Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/889727/
215,Salbutamol,7780253,"Acute asthma, salbutamol and hyperglycaemia.","['Dawson KP', 'Penna AC', 'Manglick P']","['Acute Disease', 'Age Factors', 'Albuterol/administration & dosage/*adverse effects/blood', 'Asthma/*drug therapy', 'Blood Glucose/analysis', 'Child', 'Child, Preschool', 'Chromatography, High Pressure Liquid', 'Fluorometry', 'Humans', 'Hyperglycemia/*chemically induced', 'Nebulizers and Vaporizers', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/7780253/
216,Salbutamol,32051218,Rebound of Involuted Infantile Hemangioma After Administration of Salbutamol.,"['Knopfel N', 'Oesch V', 'Theiler M', 'Szello P', 'Weibel L']","['Adrenergic beta-2 Receptor Agonists/administration & dosage/*adverse effects', 'Albuterol/administration & dosage/*adverse effects', 'Bronchitis/drug therapy', 'Child, Preschool', 'Female', 'Hemangioma/drug therapy/*pathology', 'Humans', 'Infusions, Intravenous', 'Neoplasm Recurrence, Local/*chemically induced', 'Propranolol/therapeutic use', 'Skin Neoplasms/drug therapy/*pathology', 'Vasodilator Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32051218/
217,Salbutamol,10678290,Levalbuterol nebulizer solution: is it worth five times the cost of albuterol?,"['Asmus MJ', 'Hendeles L']","['Administration, Inhalation', 'Adrenergic beta-Agonists/administration & dosage/*economics/*therapeutic use', 'Albuterol/administration & dosage/*economics/*therapeutic use', 'Anti-Asthmatic Agents/administration & dosage/*economics/*therapeutic use', 'Asthma/*drug therapy/*economics', 'Humans', 'Nebulizers and Vaporizers', 'Pharmaceutical Solutions', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/10678290/
218,nisoldipine,25283255,Treatment for calcium channel blocker poisoning: a systematic review.,"['St-Onge M', 'Dube PA', 'Gosselin S', 'Guimont C', 'Godwin J', 'Archambault PM', 'Chauny JM', 'Frenette AJ', 'Darveau M', 'Le Sage N', 'Poitras J', 'Provencher J', 'Juurlink DN', 'Blais R']","['Animals', 'Calcium Channel Blockers/blood/*poisoning', 'Disease Models, Animal', 'Dose-Response Relationship, Drug', 'Drug Overdose/mortality/*therapy', 'Guidelines as Topic', 'Hospitalization', 'Humans', 'Insulin/therapeutic use', 'Length of Stay', 'Observational Studies as Topic', 'Treatment Outcome', 'Vasoconstrictor Agents/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/25283255/
219,nisoldipine,3154705,Calcium channel antagonists. Part V: Second-generation agents.,['Opie LH'],"['Animals', 'Calcium Channel Blockers/*pharmacology/therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/3154705/
220,nisoldipine,8429113,Nisoldipine: a new dihydropyridine calcium-channel blocker.,"['Mitchell J', 'Frishman W', 'Heiman M']","['Angina Pectoris/drug therapy/physiopathology', 'Cardiovascular Diseases/*drug therapy/physiopathology', 'Heart Rate/drug effects', 'Hemodynamics/drug effects', 'Humans', 'Hypertension/drug therapy/physiopathology', 'Nisoldipine/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8429113/
221,nisoldipine,8370362,Nisoldipine in severe ischaemic left ventricular dysfunction.,"['Pouleur H', 'Rousseau MF']","['Coronary Circulation/drug effects/physiology', 'Diastole/drug effects/physiology', 'Hemodynamics/drug effects/physiology', 'Humans', 'Myocardial Ischemia/*drug therapy/physiopathology', 'Nisoldipine/adverse effects/*therapeutic use', 'Ventricular Function, Left/*drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/8370362/
222,nisoldipine,33944777,Permeant fluorescent probes visualize the activation of SARM1 and uncover an anti-neurodegenerative drug candidate.,"['Li WH', 'Huang K', 'Cai Y', 'Wang QW', 'Zhu WJ', 'Hou YN', 'Wang S', 'Cao S', 'Zhao ZY', 'Xie XJ', 'Du Y', 'Lee CS', 'Lee HC', 'Zhang H', 'Zhao YJ']","['Animals', 'Armadillo Domain Proteins/antagonists & inhibitors/*chemistry/genetics/*metabolism', 'Cryoelectron Microscopy', 'Cytoskeletal Proteins/antagonists & inhibitors/*chemistry/genetics/*metabolism', 'Dihydropyridines/therapeutic use', 'Drug Evaluation, Preclinical/*methods', '*Fluorescent Dyes', 'HEK293 Cells', 'Humans', 'Mice', 'Mice, Inbred C57BL', 'Neurons/physiology', 'Neuroprotection/*drug effects', 'Pharmaceutical Preparations']",https://pubmed.ncbi.nlm.nih.gov/33944777/
223,nisoldipine,2457808,Calcium channels in thrombin-activated human platelet membrane.,"['Zschauer A', 'van Breemen C', 'Buhler FR', 'Nelson MT']","['Barium/blood', 'Blood Platelets/drug effects/*physiology', 'Calcium/*blood', 'Calcium Channel Blockers', 'Cations, Divalent', 'Cell Membrane/drug effects/physiology', 'Electric Conductivity', 'Humans', 'Ion Channels/drug effects/*physiology', 'Lipid Bilayers/metabolism', 'Membrane Potentials', 'Nickel/pharmacology', 'Nifedipine/analogs & derivatives/pharmacology', 'Nisoldipine', 'Sodium/blood', 'Thrombin/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/2457808/
224,nisoldipine,9129871,Nisoldipine coat-core. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of ischaemic heart disease.,"['Langtry HD', 'Spencer CM']","['Calcium Channel Blockers/pharmacokinetics/pharmacology/*therapeutic use', 'Delayed-Action Preparations', 'Drug Interactions', 'Food-Drug Interactions', 'Humans', 'Myocardial Ischemia/*drug therapy/metabolism', 'Nisoldipine/pharmacokinetics/pharmacology/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/9129871/
225,nisoldipine,2429539,Antihypertensive mechanism of action and binding sites of nitrendipine.,['Triggle DJ'],"['Animals', 'Blood Pressure/*drug effects', 'Calcium/metabolism', 'Calcium Channel Blockers/pharmacology', 'Calcium Channels', 'Heart/drug effects', 'Humans', 'Ion Channels/drug effects', 'Muscle, Smooth, Vascular/drug effects', 'Neurons/metabolism', 'Nitrendipine/metabolism/*pharmacology', 'Organ Specificity', 'Radioligand Assay', 'Receptors, Nicotinic', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/2429539/
226,nisoldipine,3154674,The pharmacology of nisoldipine.,['Knorr A'],"['Animals', 'Humans', 'Nisoldipine/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/3154674/
227,nisoldipine,8483021,Vascular effects of lacidipine: a review of animal and human data.,"['Mancia G', 'Ferrari AU', 'Giannattasio C', 'Trazzi S']","['Animals', 'Antihypertensive Agents/*pharmacology', 'Calcium Channel Blockers/*pharmacology', 'Dihydropyridines/*pharmacology', 'Hemodynamics/*drug effects', 'Humans', 'Hypertension/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/8483021/
228,nisoldipine,18176062,"Relationship between lipophilicities of 1,4-dihydropyridine derivatives and pharmacokinetic interaction strengths with grapefruit juice.","['Uesawa Y', 'Mohri K']","['Antihypertensive Agents/chemistry/*pharmacokinetics', 'Calcium Channel Blockers/chemistry/*pharmacokinetics', 'Chemical Phenomena', 'Chemistry, Physical', '*Citrus paradisi', 'Dihydropyridines/chemistry/*pharmacokinetics', '*Food-Drug Interactions', 'Humans', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/18176062/
229,nisoldipine,12578880,Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes.,"['Mehler PS', 'Coll JR', 'Estacio R', 'Esler A', 'Schrier RW', 'Hiatt WR']","['Antihypertensive Agents/*therapeutic use', 'Blood Pressure/drug effects', 'Cardiovascular Diseases/*prevention & control', 'Cohort Studies', 'Comorbidity', 'Death, Sudden, Cardiac/prevention & control', 'Diabetes Mellitus, Type 2/*complications', 'Enalapril/therapeutic use', 'Female', 'Follow-Up Studies', 'Humans', 'Hypertension/complications/*drug therapy', 'Male', 'Middle Aged', 'Myocardial Infarction/prevention & control', 'Nisoldipine/therapeutic use', 'Odds Ratio', 'Peripheral Vascular Diseases/*complications', 'Risk Assessment', 'Stroke/prevention & control', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12578880/
230,nisoldipine,2994701,Effects of verapamil and nisoldipine on human platelets: in vivo and in vitro studies.,"['Jones CR', 'Pasanisi F', 'Elliott HL', 'Reid JL']","['Adult', 'Blood Platelets/*drug effects/metabolism', 'Calcium Channel Blockers/*pharmacology', 'Humans', 'In Vitro Techniques', 'Male', 'Nifedipine/*analogs & derivatives/pharmacology', 'Nisoldipine', 'Platelet Aggregation/drug effects', 'Receptors, Adrenergic, alpha/metabolism', 'Verapamil/*pharmacology', 'Yohimbine/metabolism']",https://pubmed.ncbi.nlm.nih.gov/2994701/
231,nisoldipine,31013922,Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review.,"['Kim S', 'Yu YM', 'Kwon J', 'Yoo H', 'Jung SH', 'Lee E']","['Calcium Channel Blockers/*adverse effects', 'Chylous Ascites/*chemically induced', 'Humans', '*Peritoneal Dialysis', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/31013922/
232,nisoldipine,17433928,Risk and predictability of drug interactions in the elderly.,"['Levy RH', 'Collins C']","['Aged', '*Aging', 'Anticonvulsants/adverse effects', 'Antidepressive Agents/adverse effects', 'Antipsychotic Agents/adverse effects', 'Cardiovascular Agents/adverse effects', 'Dementia/drug therapy', '*Drug Interactions', 'Humans', 'Risk Assessment']",https://pubmed.ncbi.nlm.nih.gov/17433928/
233,nisoldipine,32259277,Drug treatments in patients with cardiac diseases and epilepsy.,"['Zaccara G', 'Lattanzi S', 'Cincotta M', 'Russo E']","['Animals', 'Anticonvulsants/*therapeutic use', 'Cardiovascular Agents/*therapeutic use', 'Drug Interactions', 'Epilepsy/*complications/*drug therapy', 'Heart Diseases/*complications/*drug therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/32259277/
234,nisoldipine,9126676,Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease.,['Fodor JG'],"['Aging/pathology', 'Angina Pectoris/drug therapy', 'Antihypertensive Agents/administration & dosage/pharmacology/*therapeutic use', 'Blood Pressure/drug effects', 'Calcium Channel Blockers/administration & dosage/pharmacology/*therapeutic use', 'Delayed-Action Preparations', 'Humans', 'Hypertension/*drug therapy', 'Myocardial Contraction/drug effects', 'Myocardial Infarction/drug therapy', 'Myocardial Ischemia/*drug therapy', 'Nisoldipine/administration & dosage/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9126676/
235,nisoldipine,9862440,Sulfonylureas blockade of neural and cardiac HERG channels.,"['Rosati B', 'Rocchetti M', 'Zaza A', 'Wanke E']","['Action Potentials/drug effects', 'Animals', '*Cation Transport Proteins', 'Chromans/pharmacology', '*DNA-Binding Proteins', 'Dose-Response Relationship, Drug', 'ERG1 Potassium Channel', 'Ether-A-Go-Go Potassium Channels', 'Glyburide/*pharmacology', 'Guinea Pigs', 'Humans', 'Inhibitory Concentration 50', 'Mice', 'Myocardium/cytology/*metabolism', 'Neuroblastoma', 'Neurons/drug effects/*metabolism', 'Nisoldipine/pharmacology', 'Piperidines/pharmacology', '*Potassium Channel Blockers', 'Potassium Channels/metabolism', '*Potassium Channels, Voltage-Gated', 'Pyridines/pharmacology', 'Rats', 'Sulfonamides/pharmacology', 'Sulfonylurea Compounds/*pharmacology', '*Trans-Activators', 'Transcriptional Regulator ERG', 'Tumor Cells, Cultured']",https://pubmed.ncbi.nlm.nih.gov/9862440/
236,nisoldipine,2731403,"Single- and multiple-dose nisoldipine kinetics and effects in the young, the middle-aged, and the elderly.","['van Harten J', 'Burggraaf J', 'Ligthart GJ', 'van Brummelen P', 'Breimer DD']","['Administration, Oral', 'Adult', 'Aged', 'Aged, 80 and over', 'Aging/*metabolism/physiology', 'Blood Pressure/drug effects', 'Dose-Response Relationship, Drug', 'Female', 'Half-Life', 'Heart Rate/drug effects', 'Humans', 'Male', 'Middle Aged', 'Nifedipine/administration & dosage/*analogs & derivatives/pharmacokinetics/pharmacology', 'Nisoldipine', 'Norepinephrine/blood', 'Vasodilator Agents/administration & dosage/*pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/2731403/
237,nisoldipine,12825828,"1,4-Dihydropyridines as calcium channel ligands and privileged structures.",['Triggle DJ'],"['Animals', 'Calcium Channel Blockers/*chemistry/*pharmacokinetics', 'Calcium Channels/*drug effects/metabolism', 'Cardiovascular System/drug effects/*metabolism', 'Cell Membrane/*drug effects/metabolism', 'Dihydropyridines/*chemistry', 'Humans', 'Ligands', 'Molecular Conformation', 'Molecular Structure', 'Receptors, Cell Surface/drug effects/metabolism']",https://pubmed.ncbi.nlm.nih.gov/12825828/
238,tizanidine,32563380,New directions in the treatment of opioid withdrawal.,"['Srivastava AB', 'Mariani JJ', 'Levin FR']","['Adrenergic alpha-2 Receptor Agonists/administration & dosage/adverse effects', 'Analgesics, Opioid/administration & dosage/adverse effects', 'Drug Administration Schedule', 'Humans', 'Narcotic Antagonists/administration & dosage/adverse effects', 'Opiate Substitution Treatment/*methods', 'Opioid-Related Disorders/*drug therapy', 'Substance Withdrawal Syndrome/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32563380/
239,tizanidine,38394496,"Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment.","['Haki M', 'Al-Biati HA', 'Al-Tameemi ZS', 'Ali IS', 'Al-Hussaniy HA']","['Humans', '*Multiple Sclerosis/epidemiology/etiology/therapy', 'Treatment Outcome', 'Chronic Disease', 'Muscle Spasticity/etiology']",https://pubmed.ncbi.nlm.nih.gov/38394496/
240,tizanidine,22976059,"Spasticity: pathophysiology, evaluation and management.","['Kheder A', 'Nair KP']","['Humans', '*Motor Neuron Disease/diagnosis/physiopathology/therapy', '*Quadriplegia/diagnosis/physiopathology/therapy']",https://pubmed.ncbi.nlm.nih.gov/22976059/
241,tizanidine,18225966,Skeletal muscle relaxants.,"['See S', 'Ginzburg R']","['Drug Interactions', 'Humans', 'Muscle Relaxants, Central/adverse effects/classification/*therapeutic use', 'Musculoskeletal Diseases/drug therapy', 'Nervous System Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18225966/
242,tizanidine,37059468,Therapies in Stiff-Person Syndrome: Advances and Future Prospects Based on Disease Pathophysiology.,['Dalakas MC'],"['Child', 'Humans', 'Female', 'Aged', '*Stiff-Person Syndrome/therapy/drug therapy', 'Autoantibodies', 'Autoimmunity', 'Baclofen/therapeutic use', 'Spasm']",https://pubmed.ncbi.nlm.nih.gov/37059468/
243,tizanidine,18711953,Choosing a skeletal muscle relaxant.,"['See S', 'Ginzburg R']","['Back Pain/drug therapy', 'Fibromyalgia/drug therapy', 'Humans', 'Neck Pain/drug therapy', 'Neuromuscular Agents/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18711953/
244,tizanidine,15276195,Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.,"['Chou R', 'Peterson K', 'Helfand M']","['Clinical Trials as Topic', 'Comorbidity', 'Evidence-Based Medicine/methods', 'Humans', 'Motor Neuron Disease/classification/*drug therapy/*epidemiology', 'Muscle Spasticity/classification/*drug therapy/*epidemiology', 'Musculoskeletal Diseases/classification/drug therapy/epidemiology', 'Neuromuscular Agents/*therapeutic use', 'Peripheral Nervous System Diseases/classification/*drug therapy/*epidemiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15276195/
245,tizanidine,29165784,Interventions for managing skeletal muscle spasticity following traumatic brain injury.,"['Synnot A', 'Chau M', 'Pitt V', ""O'Connor D"", 'Gruen RL', 'Wasiak J', 'Clavisi O', 'Pattuwage L', 'Phillips K']","['Baclofen/therapeutic use', 'Botulinum Toxins, Type A/therapeutic use', 'Brain Injuries, Traumatic/*complications', 'Casts, Surgical', 'Electric Stimulation Therapy', 'Head-Down Tilt', 'Humans', 'Muscle Relaxants, Central/therapeutic use', 'Muscle Spasticity/etiology/*therapy', 'Neuromuscular Agents/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/29165784/
246,tizanidine,25347760,Dystonia.,"['Snaith A', 'Wade D']","['Analgesics/therapeutic use', 'Anticonvulsants/therapeutic use', 'Dystonia/drug therapy/surgery/*therapy', 'Humans', 'Physical Therapy Modalities', 'Speech Therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25347760/
247,tizanidine,35754070,Pharmacotherapy for Spine-Related Pain in Older Adults.,"['Fu JL', 'Perloff MD']","['Acetaminophen/therapeutic use', 'Aged', 'Analgesics, Opioid/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', '*Neuralgia/drug therapy', 'Pregabalin/adverse effects', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35754070/
248,tizanidine,39298168,Long-Term Use of Muscle Relaxant Medications for Chronic Pain: A Systematic Review.,"['Oldfield BJ', 'Gleeson B', 'Morford KL', 'Adams Z', 'Funaro MC', 'Becker WC', 'Merlin JS']","['Humans', '*Chronic Pain/drug therapy', 'Muscle Relaxants, Central/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39298168/
249,tizanidine,38870050,An update on pharmacotherapy for trigeminal neuralgia.,"['Pergolizzi JV Jr', 'LeQuang JA', 'El-Tallawy SN', 'Wagner M', 'Ahmed RS', 'Varrassi G']","['*Trigeminal Neuralgia/drug therapy', 'Humans', '*Anticonvulsants/therapeutic use', '*Carbamazepine/therapeutic use', 'Oxcarbazepine/therapeutic use', 'Migraine Disorders/drug therapy', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/38870050/
250,tizanidine,36948512,Comparative effectiveness and safety of analgesic medicines for adults with acute non-specific low back pain: systematic review and network meta-analysis.,"['Wewege MA', 'Bagg MK', 'Jones MD', 'Ferraro MC', 'Cashin AG', 'Rizzo RR', 'Leake HB', 'Hagstrom AD', 'Sharma S', 'McLachlan AJ', 'Maher CG', 'Day R', 'Wand BM', ""O'Connell NE"", 'Nikolakopolou A', 'Schabrun S', 'Gustin SM', 'McAuley JH']","['Humans', 'Adult', 'Female', 'Male', 'Acetaminophen/adverse effects', '*Low Back Pain/drug therapy', '*Tramadol/therapeutic use', 'Network Meta-Analysis', 'Analgesics/adverse effects', '*Acute Pain/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/36948512/
251,tizanidine,19445753,Trigeminal neuralgia.,"['Zakrzewska JM', 'Linskey ME']","['Humans', 'Ophthalmic Solutions/therapeutic use', '*Pain/surgery', 'Pain Measurement', 'Phenytoin/therapeutic use', 'Radiosurgery', 'Trigeminal Ganglion', '*Trigeminal Neuralgia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19445753/
252,tizanidine,20927006,Managing spasticity with drugs.,"['Simon O', 'Yelnik AP']","['Administration, Oral', 'Baclofen/adverse effects/*therapeutic use', 'Botulinum Toxins, Type A/adverse effects/*therapeutic use', 'Clonidine/adverse effects/*analogs & derivatives/therapeutic use', 'Humans', 'Injections, Spinal', 'Muscle Relaxants, Central/adverse effects/*therapeutic use', 'Muscle Spasticity/*drug therapy', 'Neuromuscular Agents/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20927006/
253,tizanidine,35020700,Management of Xylazine Withdrawal in a Hospitalized Patient: A Case Report.,"['Ehrman-Dupre R', 'Kaigh C', 'Salzman M', 'Haroz R', 'Peterson LK', 'Schmidt R']","['Adrenergic Agonists/therapeutic use', 'Analgesics, Opioid/therapeutic use', 'Animals', '*Buprenorphine/therapeutic use', 'Clonidine', '*Dexmedetomidine/therapeutic use', 'Female', 'Gabapentin/therapeutic use', 'Humans', '*Opioid-Related Disorders/drug therapy', 'Phenobarbital/therapeutic use', '*Substance Withdrawal Syndrome/drug therapy', 'Xylazine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35020700/
254,tizanidine,16272661,Pharmacologic interventions for reducing spasticity in cerebral palsy.,"['Patel DR', 'Soyode O']","['Administration, Oral', 'Adrenergic alpha-Agonists/administration & dosage/*therapeutic use', 'Age Factors', 'Anti-Infective Agents, Local/administration & dosage/therapeutic use', 'Baclofen/administration & dosage/adverse effects/*therapeutic use', 'Botulinum Toxins/administration & dosage/*therapeutic use', 'Cerebral Palsy/*drug therapy/physiopathology', 'Child', 'Child, Preschool', 'Clonidine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Dantrolene/administration & dosage/adverse effects/*therapeutic use', '*Diazepam/administration & dosage/adverse effects/therapeutic use', 'Ethanol/administration & dosage/therapeutic use', 'Humans', 'Infant', 'Injections, Intramuscular', 'Injections, Spinal', 'Muscle Relaxants, Central/administration & dosage/adverse effects/*therapeutic use', 'Muscle Spasticity/*drug therapy/physiopathology', 'Neuromuscular Agents/administration & dosage/therapeutic use', 'Phenol/administration & dosage/therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/16272661/
255,tizanidine,7970008,Pharmacokinetics and pharmacodynamics of tizanidine.,"['Roberts RC', 'Part NJ', 'Pokorny R', 'Muir C', 'Leslie GC', 'Emre M']","['Clonidine/administration & dosage/*analogs & derivatives/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Humans', 'Muscle Relaxants, Central/*administration & dosage/*pharmacokinetics', 'Muscle Spasticity/blood/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/7970008/
256,tizanidine,38421578,Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis.,"['Shkodina AD', 'Bardhan M', 'Chopra H', 'Anyagwa OE', 'Pinchuk VA', 'Hryn KV', 'Kryvchun AM', 'Boiko DI', 'Suresh V', 'Verma A', 'Delva MY']","['Humans', '*Multiple Sclerosis/therapy/drug therapy', '*Trigeminal Neuralgia/complications/drug therapy', '*Acceptance and Commitment Therapy', '*Neuralgia/drug therapy/etiology', 'Antidepressive Agents/therapeutic use', 'Anticonvulsants/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38421578/
257,tizanidine,39348794,Comparative effect of oral drugs in improving spasticity of different etiology: a network meta-analysis.,"['Otero-Luis I', 'Martinez-Rodrigo A', 'Cavero-Redondo I', 'Moreno-Herraiz N', 'Lopez-Lopez S', 'Saz-Lara A']","['Humans', '*Muscle Spasticity/drug therapy/etiology', '*Baclofen/administration & dosage/therapeutic use', '*Network Meta-Analysis as Topic', '*Diazepam/therapeutic use/administration & dosage', '*Muscle Relaxants, Central/therapeutic use/administration & dosage', 'Administration, Oral', 'Quality of Life', 'Propiophenones']",https://pubmed.ncbi.nlm.nih.gov/39348794/
258,glyburide,9739505,Repaglinide.,"['Balfour JA', 'Faulds D']","['Animals', 'Carbamates/administration & dosage/pharmacokinetics/*therapeutic use', 'Diabetes Mellitus, Experimental/drug therapy', 'Diabetes Mellitus, Type 2/*drug therapy', 'Glyburide/therapeutic use', 'Humans', 'Hypoglycemic Agents/administration & dosage/pharmacokinetics/*therapeutic use', 'Islets of Langerhans/drug effects', 'Piperidines/administration & dosage/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/9739505/
259,glyburide,32654523,Glibenclamide as a neuroprotective antidementia drug.,"['Zubov A', 'Muruzheva Z', 'Tikhomirova M', 'Karpenko M']","['Humans', '*Alzheimer Disease/drug therapy', '*Diabetes Mellitus/drug therapy', 'Glyburide/pharmacology/therapeutic use', 'Hypoglycemic Agents/adverse effects', '*Neuroprotective Agents/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32654523/
260,glyburide,19366943,Use of hypoglycemic drugs during lactation.,"['Glatstein MM', 'Djokanovic N', 'Garcia-Bournissen F', 'Finkelstein Y', 'Koren G']","['Administration, Oral', 'Breast Feeding', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug-Related Side Effects and Adverse Reactions', 'Female', 'Glipizide/administration & dosage/adverse effects', 'Glyburide/administration & dosage/adverse effects', 'Humans', 'Hypoglycemic Agents/*administration & dosage/adverse effects', 'Infant, Newborn', 'Lactation/*drug effects', 'Maternal Welfare', 'Milk, Human/drug effects', 'Pregnancy', 'Pregnancy in Diabetics/drug therapy', 'Risk Assessment', 'Sulfonylurea Compounds/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/19366943/
261,glyburide,19640341,The use of oral antidiabetic medications in gestational diabetes mellitus.,"['Paglia MJ', 'Coustan DR']","['Administration, Oral', 'Diabetes, Gestational/*drug therapy', 'Female', 'Glyburide/administration & dosage/therapeutic use', 'Humans', 'Hypoglycemic Agents/*administration & dosage/*therapeutic use', 'Metformin/administration & dosage/therapeutic use', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/19640341/
262,glyburide,28665392,[Glibenclamide as a promising agent for prevention and treatment of cerebral edema].,"['Tsarenko SV', ""Dzyadz'ko AM"", 'Rybalko SS']","['Animals', 'Brain Edema/*drug therapy/prevention & control', 'Clinical Trials as Topic', 'Drug Evaluation, Preclinical', 'Glyburide/administration & dosage/*therapeutic use', 'Humans', 'Intracranial Pressure/drug effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28665392/
263,glyburide,38191184,"Safety and efficacy of glibenclamide on cerebral oedema following aneurysmal subarachnoid haemorrhage: a randomised, double-blind, placebo-controlled clinical trial.","['Feng X', 'Zhang T', 'Wang N', 'Qu X', 'Qi M', 'Zhao H', 'Zhang H', 'Xu Y']","['Humans', '*Glyburide/adverse effects/administration & dosage/therapeutic use', 'Male', 'Middle Aged', '*Subarachnoid Hemorrhage/drug therapy/diagnosis/complications', 'Double-Blind Method', 'Female', '*TRPM Cation Channels', '*Brain Edema/drug therapy/etiology/prevention & control/diagnostic imaging/diagnosis', '*Sulfonylurea Receptors/genetics', 'Treatment Outcome', 'Time Factors', 'Aged', 'Adult', 'Neuroprotective Agents/adverse effects/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38191184/
264,glyburide,11390165,Glyburide and fetal safety; transplacental pharmacokinetic considerations.,['Koren G'],"['Adult', 'Female', 'Fetal Diseases/chemically induced', 'Fetus/drug effects/*metabolism', 'Glyburide/adverse effects/*pharmacokinetics', 'Humans', 'Hypoglycemic Agents/adverse effects/*pharmacokinetics', 'Ions', '*Maternal-Fetal Exchange', 'Molecular Weight', 'Placenta/drug effects/*metabolism', 'Pregnancy', 'Pregnancy Outcome', 'Protein Binding', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/11390165/
265,glyburide,31805373,Found in translation: The rationale behind the early development of glibenclamide in large hemispheric infarction.,"['Jacobson SM', 'MacAllister TW', 'Geliebter DM']","['Animals', '*Brain Edema/drug therapy/etiology', '*Cerebral Infarction/complications/drug therapy', 'Disease Models, Animal', 'Glyburide/*pharmacology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/31805373/
266,glyburide,3923454,"Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use.",['Lebovitz HE'],"['Animals', 'Blood Glucose/metabolism', 'Chemical Phenomena', 'Chemistry', 'Clinical Trials as Topic', 'Diabetes Mellitus, Type 2/*drug therapy', 'Dogs', 'Glipizide/metabolism/pharmacology/*therapeutic use', 'Glyburide/metabolism/pharmacology', 'Half-Life', 'Humans', 'Insulin/metabolism', 'Insulin Secretion', 'Kinetics', 'Liver/metabolism', 'Mice', 'Pancreas/drug effects', 'Rats', 'Serum Albumin/metabolism', 'Sulfonylurea Compounds/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3923454/
267,glyburide,109337,Radioimmunoassay of glibenclamide.,"['Kawashima K', 'Kuzuya T', 'Matsuda A']","['Animals', 'Diabetes Mellitus/blood/drug therapy', 'Dogs', 'Glyburide/*blood/therapeutic use', 'Humans', 'Radioimmunoassay/methods']",https://pubmed.ncbi.nlm.nih.gov/109337/
268,glyburide,9533980,Is there a concentration-effect relationship for sulphonylureas?,"['Melander A', 'Donnelly R', 'Rydberg T']","['Diabetes Mellitus, Type 2/*drug therapy', 'Dose-Response Relationship, Drug', 'Glyburide/administration & dosage/pharmacokinetics', 'Humans', 'Hypoglycemic Agents/*administration & dosage/pharmacokinetics', 'Sulfonylurea Compounds/*administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/9533980/
269,glyburide,8864641,Cardiovascular effects of sulphonylurea derivatives.,"['Smits P', 'Bijlstra PJ', 'Russel FG', 'Lutterman JA', 'Thien T']","['Adenosine Triphosphate/*physiology', 'Animals', 'Cardiovascular System/*drug effects', 'Diabetes Mellitus, Type 2/*drug therapy', 'Glyburide/therapeutic use', 'Humans', 'Hypoglycemic Agents/*therapeutic use', 'Potassium Channels/*drug effects', 'Sulfonylurea Compounds/*therapeutic use', 'Tolbutamide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8864641/
270,glyburide,3082015,Oral sulfonylureas for the treatment of type II diabetes: an update.,"['Shank WA Jr', 'Morrison AD']","['Administration, Oral', 'Chlorpropamide/adverse effects', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Hypersensitivity/etiology', 'Glipizide/administration & dosage/metabolism/therapeutic use', 'Glyburide/administration & dosage/metabolism/therapeutic use', 'Humans', 'Insulin Resistance', 'Kinetics', 'Liver/metabolism', 'Nausea/chemically induced', 'Patient Education as Topic', 'Sulfonylurea Compounds/administration & dosage/metabolism/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3082015/
271,glyburide,27582151,Non-insulin pharmacological therapy in pregnancy.,['Bajaj S'],"['Diabetes, Gestational/*drug therapy', 'Female', 'Glyburide/therapeutic use', 'Humans', 'Hypoglycemic Agents/*therapeutic use', 'Insulin', 'Metformin/therapeutic use', 'Pregnancy', 'Pregnancy Outcome', '*Pregnancy in Diabetics']",https://pubmed.ncbi.nlm.nih.gov/27582151/
272,glyburide,9069698,Drug interaction: rifampicin and glibenclamide.,"['Surekha V', 'Peter JV', 'Jeyaseelan L', 'Cherian AM']","['Adult', 'Aged', 'Antibiotics, Antitubercular/administration & dosage/*pharmacology', 'Blood Glucose/drug effects', 'Diabetes Mellitus, Type 2/blood/drug therapy', 'Drug Interactions', 'Female', 'Glyburide/administration & dosage/*pharmacology', 'Humans', 'Hypoglycemic Agents/administration & dosage/*pharmacology', 'Male', 'Middle Aged', 'Rifampin/administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/9069698/
273,glyburide,3925246,Sulfonylureas in the treatment of diabetes mellitus--1985.,['Gerich JE'],"['Blood Glucose/metabolism', 'Body Weight', 'Diabetes Mellitus, Type 1/therapy', 'Diabetes Mellitus, Type 2/diet therapy/*drug therapy', 'Drug Therapy, Combination', 'Glipizide/pharmacology', 'Glyburide/pharmacology', 'Humans', 'Hypoglycemia/etiology', 'Insulin/metabolism/therapeutic use', 'Pancreas/metabolism', 'Sulfonylurea Compounds/administration & dosage/adverse effects/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3925246/
274,glyburide,19082520,Sulphonylureas and cancer: a case-control study.,"['Monami M', 'Lamanna C', 'Balzi D', 'Marchionni N', 'Mannucci E']","['Aged', 'Case-Control Studies', 'Diabetes Mellitus, Type 2/complications/*drug therapy', 'Female', 'Follow-Up Studies', 'Gliclazide/therapeutic use', 'Glyburide/adverse effects/therapeutic use', 'Humans', 'Hypoglycemic Agents/*adverse effects/therapeutic use', 'Male', 'Metformin/therapeutic use', 'Middle Aged', 'Neoplasms/epidemiology/*etiology', 'Risk Factors', 'Sulfonylurea Compounds/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19082520/
275,glyburide,28847172,The care of pregestational and gestational diabetes and drug metabolism considerations.,"['Hedrington MS', 'Davis SN']","['Animals', 'Blood Glucose/drug effects', 'Diabetes, Gestational/*drug therapy', 'Female', 'Glyburide/administration & dosage/adverse effects/pharmacokinetics', 'Humans', 'Hypoglycemia/chemically induced', 'Hypoglycemic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Insulin/administration & dosage/adverse effects/pharmacokinetics', 'Metformin/administration & dosage/adverse effects/pharmacokinetics', 'Pregnancy', 'Pregnancy in Diabetics/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/28847172/
276,glyburide,19791828,Saxagliptin.,"['Dhillon S', 'Weber J']","['Blood Glucose/analysis/drug effects', 'Diabetes Mellitus, Type 2/chemically induced/*drug therapy', 'Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use', 'Drug Therapy, Combination', 'Glucagon-Like Peptide 1/*therapeutic use', 'Glyburide/pharmacology/therapeutic use', 'Humans', 'Metformin/pharmacology/therapeutic use', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/19791828/
277,glyburide,1907291,Determination of glibenclamide and its two major metabolites in human serum and urine by column liquid chromatography.,"['Rydberg T', 'Wahlin-Boll E', 'Melander A']","['Adult', 'Chromatography, High Pressure Liquid/*methods/statistics & numerical data', 'Glyburide/analogs & derivatives/*blood/pharmacokinetics/urine', 'Half-Life', 'Humans', 'Male', 'Microchemistry']",https://pubmed.ncbi.nlm.nih.gov/1907291/
278,fluconazole,10830059,Fluconazole.,"['Agrawal PB', 'Narang A', 'Kumar P']","['Antifungal Agents/adverse effects/*therapeutic use', 'Candidiasis/*drug therapy/mortality', 'Child', 'Child, Preschool', 'Fluconazole/adverse effects/*therapeutic use', 'Humans', 'Infant', 'Infant, Newborn', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10830059/
279,fluconazole,21498839,Candida urinary tract infections--treatment.,"['Fisher JF', 'Sobel JD', 'Kauffman CA', 'Newman CA']","['Algorithms', 'Amphotericin B/administration & dosage/therapeutic use', 'Antifungal Agents/administration & dosage/*therapeutic use', 'Azoles/therapeutic use', 'Candida/*drug effects/growth & development/pathogenicity', 'Candidiasis/microbiology/*therapy/urine', 'Candidiasis, Invasive/*diagnosis/microbiology', 'Causality', 'Echinocandins/therapeutic use', 'Fluconazole/administration & dosage/therapeutic use', 'Flucytosine/adverse effects/therapeutic use', 'Humans', 'Urinary Tract Infections/microbiology/*therapy']",https://pubmed.ncbi.nlm.nih.gov/21498839/
280,fluconazole,31287594,Cutaneous candidiasis - an evidence-based review of topical and systemic treatments to inform clinical practice.,"['Taudorf EH', 'Jemec GBE', 'Hay RJ', 'Saunte DML']","['Administration, Oral', 'Administration, Topical', 'Antifungal Agents/administration & dosage/*therapeutic use', 'Candidiasis, Cutaneous/*drug therapy', 'Clotrimazole/administration & dosage/*therapeutic use', 'Drug Therapy, Combination', 'Evidence-Based Medicine', 'Fluconazole/administration & dosage/*therapeutic use', 'Humans', 'Ketoconazole/therapeutic use', 'Miconazole/administration & dosage/*therapeutic use', 'Nystatin/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31287594/
281,fluconazole,36688321,Off-label treatments as potential accelerators in the search for the ideal antifungal treatment of cryptococcosis.,"['Alves V', 'Araujo GR', 'Frases S']","['Animals', 'Humans', 'Antifungal Agents/adverse effects', 'Off-Label Use', 'Fluconazole/pharmacology/therapeutic use', '*Cryptococcosis/drug therapy/microbiology', 'Amphotericin B/pharmacology', '*Cryptococcus neoformans']",https://pubmed.ncbi.nlm.nih.gov/36688321/
282,fluconazole,8118162,Fluconazole: pharmacokinetics and indications.,['Montero-Gei F'],"['Animals', 'Fluconazole/metabolism/*pharmacokinetics/*therapeutic use', 'Humans', 'Mycoses/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/8118162/
283,fluconazole,26759844,Fluconazole use during breastfeeding.,"['Kaplan YC', 'Koren G', 'Ito S', 'Bozzo P']","['Antifungal Agents/*administration & dosage/adverse effects', 'Breast Diseases/drug therapy', '*Breast Feeding', 'Candidiasis/*drug therapy', 'Female', 'Fluconazole/*administration & dosage/adverse effects', 'Humans', 'Infant', 'Nipples/*microbiology']",https://pubmed.ncbi.nlm.nih.gov/26759844/
284,fluconazole,12956199,The use of oral antifungal agents to treat onychomycosis.,"['Gupta AK', 'Ryder JE']","['Administration, Oral', 'Antifungal Agents/administration & dosage/*therapeutic use', 'Drug Interactions', 'Fluconazole/administration & dosage/adverse effects/therapeutic use', 'Griseofulvin/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Itraconazole/administration & dosage/adverse effects/therapeutic use', 'Ketoconazole/administration & dosage/adverse effects/therapeutic use', 'Naphthalenes/administration & dosage/adverse effects/therapeutic use', 'Onychomycosis/diagnosis/*drug therapy/microbiology/pathology', 'Terbinafine']",https://pubmed.ncbi.nlm.nih.gov/12956199/
285,fluconazole,10423506,[Antifungal drugs for pediatric use].,['Nishimoto K'],"['Adult', '*Antifungal Agents/administration & dosage/adverse effects', 'Child', 'Fluconazole/administration & dosage/adverse effects', 'Humans', 'Infant', 'Infant, Newborn', 'Itraconazole/administration & dosage/adverse effects', 'Naphthalenes/administration & dosage/adverse effects', 'Terbinafine']",https://pubmed.ncbi.nlm.nih.gov/10423506/
286,fluconazole,29896619,Oral Fluconazole in Pregnancy and Risk of Stillbirth and Neonatal Death.,"['Pasternak B', 'Wintzell V', 'Furu K', 'Engeland A', 'Neovius M', 'Stephansson O']","['Administration, Oral', 'Antifungal Agents/administration & dosage/*adverse effects', 'Cohort Studies', 'Female', 'Fluconazole/administration & dosage/*adverse effects', 'Humans', 'Infant, Newborn', 'Perinatal Death/*etiology', 'Pregnancy', 'Pregnancy Complications, Infectious/drug therapy', 'Propensity Score', 'Regression Analysis', 'Stillbirth/*epidemiology']",https://pubmed.ncbi.nlm.nih.gov/29896619/
287,fluconazole,38392866,Antifungal Resistance in Cryptococcal Infections.,"['Melhem MSC', 'Leite Junior DP', 'Takahashi JPF', 'Macioni MB', 'Oliveira L', 'de Araujo LS', 'Fava WS', 'Bonfietti LX', 'Paniago AMM', 'Venturini J', 'Espinel-Ingroff A']","['*Antifungal Agents/therapeutic use/pharmacology', 'Humans', '*Drug Resistance, Fungal', '*Cryptococcosis/drug therapy', '*Cryptococcus neoformans/drug effects/genetics', '*Microbial Sensitivity Tests', 'Cryptococcus gattii/drug effects/genetics', 'Fluconazole/therapeutic use/pharmacology', 'Virulence']",https://pubmed.ncbi.nlm.nih.gov/38392866/
288,fluconazole,26938747,Fluconazole-Induced Type 1 Kounis Syndrome.,['Singh Mahal H'],"['Acute Coronary Syndrome/*chemically induced', 'Adult', 'Angina Pectoris/*chemically induced', 'Antifungal Agents/*adverse effects/therapeutic use', 'Drug Hypersensitivity/etiology', 'Eczema/drug therapy', 'Female', 'Fluconazole/*adverse effects/therapeutic use', 'Humans', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/26938747/
289,fluconazole,20463252,Traditional and emerging antifungal therapies.,"['Arnold TM', 'Dotson E', 'Sarosi GA', 'Hage CA']","['Amphotericin B/administration & dosage/adverse effects', 'Anidulafungin', 'Antifungal Agents/administration & dosage/adverse effects/classification/*pharmacology/*therapeutic use', 'Caspofungin', 'Drug Therapy, Combination', 'Echinocandins/administration & dosage/pharmacology', 'Fluconazole/therapeutic use', 'Humans', 'Itraconazole/therapeutic use', 'Lipopeptides/administration & dosage', 'Micafungin', 'Pyrimidines/adverse effects', 'Triazoles/adverse effects/pharmacokinetics/therapeutic use', 'Voriconazole']",https://pubmed.ncbi.nlm.nih.gov/20463252/
290,fluconazole,25263725,Toxic epidermal necrolysis in a neonate receiving fluconazole.,"['Islam S', 'Singer M', 'Kulhanjian JA']","['Disease Progression', 'Fatal Outcome', 'Female', 'Fluconazole/administration & dosage/*adverse effects', 'Humans', 'Infant, Newborn', '*Infant, Premature', 'Infant, Premature, Diseases/diagnosis/*drug therapy', 'Intensive Care Units, Neonatal', 'Liver Diseases/diagnosis/drug therapy', 'Multiple Organ Failure', 'Rare Diseases', 'Severity of Illness Index', 'Stevens-Johnson Syndrome/*etiology/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/25263725/
291,fluconazole,2191444,Prophylaxis of candidiasis in cancer patients.,"['Bodey GP', 'Samonis G', 'Rolston K']","['Adolescent', 'Adult', 'Aged', 'Candidiasis, Oral/*prevention & control', 'Double-Blind Method', 'Female', 'Fluconazole/adverse effects/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/*complications', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/2191444/
292,fluconazole,11218451,Antimycotic agents in oral candidosis: an overview: 2. Treatment of oral candidosis.,"['Ellepola AN', 'Samaranayake LP']","['Amphotericin B/administration & dosage/therapeutic use', 'Antifungal Agents/administration & dosage/adverse effects/classification/*therapeutic use', 'Candida/drug effects/growth & development/pathogenicity', 'Candidiasis, Oral/*drug therapy', 'Clotrimazole/administration & dosage/therapeutic use', 'Drug Interactions', 'Drug Resistance, Microbial', 'Fluconazole/administration & dosage/therapeutic use', 'Humans', 'Itraconazole/administration & dosage/therapeutic use', 'Ketoconazole/administration & dosage/therapeutic use', 'Miconazole/administration & dosage/therapeutic use', 'Nystatin/administration & dosage/therapeutic use', 'Virulence/drug effects']",https://pubmed.ncbi.nlm.nih.gov/11218451/
293,fluconazole,19519193,Fabrication and design of transdermal fluconazole spray.,"['Gohel MC', 'Nagori SA']","['Administration, Cutaneous', 'Adult', 'Animals', 'Antifungal Agents/*administration & dosage/pharmacokinetics/pharmacology/*therapeutic use', 'Camphor/administration & dosage/chemistry', 'Candida albicans/drug effects', 'Cellulose/administration & dosage/analogs & derivatives/chemistry', 'Drug Delivery Systems/*instrumentation/methods', 'Drug Stability', 'Equipment Design', 'Fluconazole/*administration & dosage/pharmacokinetics/pharmacology/*therapeutic use', 'Humans', 'Menthol/administration & dosage/chemistry', 'Middle Aged', 'Polyethylene Glycols/administration & dosage/chemistry', 'Rats', 'Skin Absorption', 'Tinea/*drug therapy/pathology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/19519193/
294,fluconazole,15055139,[New therapeutical options for pulmonary fungal infections in non-neutropenic ICU-patients].,['Hohl R'],"['Amphotericin B/administration & dosage/pharmacology/therapeutic use', 'Antifungal Agents/*pharmacology/*therapeutic use', 'Caspofungin', 'Echinocandins', 'Fluconazole/administration & dosage/pharmacology/therapeutic use', 'Fungi/drug effects', 'Humans', '*Intensive Care Units', 'Lipopeptides', 'Lung Diseases, Fungal/*drug therapy/epidemiology/microbiology/pathology', 'Neutropenia/*complications', 'Peptides/administration & dosage/pharmacology/therapeutic use', '*Peptides, Cyclic', 'Pyrimidines/administration & dosage/pharmacology/therapeutic use', 'Risk Factors', 'Triazoles/administration & dosage/pharmacology/therapeutic use', 'Voriconazole']",https://pubmed.ncbi.nlm.nih.gov/15055139/
295,fluconazole,27333619,[CANDIDIASIS GASTROINTESTINAL TRACT].,"['Kozlova IV', 'Lekareva LI', 'Bykova AP', 'Myalina JN', 'Ostrovskaja LJ']","['Antifungal Agents/administration & dosage/*therapeutic use', 'Candida/genetics/*isolation & purification/pathogenicity', 'Candidiasis/*drug therapy/microbiology', 'Diagnosis, Differential', 'Drug Resistance, Fungal', 'Fluconazole/administration & dosage/*therapeutic use', 'Gastrointestinal Tract/drug effects/*microbiology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/27333619/
296,fluconazole,23112430,Fixed drug eruption to fluconazole: a case report and review of literature.,"['Pai VV', 'Bhandari P', 'Kikkeri NN', 'Athanikar SB', 'Sori T']","['Adult', 'Antifungal Agents/*adverse effects', 'Drug Eruptions/*diagnosis/drug therapy', 'Fluconazole/*adverse effects', 'Humans', 'Male', 'Steroids/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/23112430/
297,fluconazole,1897559,Fluconazole: a new triazole antifungal agent.,['Morrow JD'],"['Animals', '*Antifungal Agents', 'Candidiasis/drug therapy', 'Costs and Cost Analysis', 'Cryptococcosis/drug therapy', 'Fluconazole/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Meningitis/drug therapy', 'Mycoses/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1897559/
298,amantadine,34678171,Amantadine in the treatment of Parkinson's disease and other movement disorders.,"['Rascol O', 'Fabbri M', 'Poewe W']","['Amantadine/pharmacology/therapeutic use', 'Antiparkinson Agents/adverse effects', '*Dyskinesia, Drug-Induced/drug therapy', 'Humans', 'Levodopa/adverse effects', '*Parkinson Disease/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34678171/
299,amantadine,37419676,Amantadine toxicity causing visual hallucinations.,"['Barbara JM', 'Pace A']","['Female', 'Humans', '*Antiparkinson Agents/adverse effects', 'Levodopa/therapeutic use', 'Amantadine/adverse effects', 'Hallucinations/chemically induced/drug therapy', '*Multiple Sclerosis/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37419676/
300,amantadine,33242419,"Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.","['Nourbakhsh B', 'Revirajan N', 'Morris B', 'Cordano C', 'Creasman J', 'Manguinao M', 'Krysko K', 'Rutatangwa A', 'Auvray C', 'Aljarallah S', 'Jin C', 'Mowry E', 'McCulloch C', 'Waubant E']","['Adult', 'Amantadine/administration & dosage/adverse effects/*pharmacology', 'Central Nervous System Stimulants/administration & dosage/adverse effects/*pharmacology', 'Cross-Over Studies', 'Double-Blind Method', 'Drug Administration Schedule', '*Drug-Related Side Effects and Adverse Reactions', 'Fatigue/*drug therapy/*etiology', 'Female', 'Humans', 'Male', 'Methylphenidate/administration & dosage/adverse effects/*pharmacology', 'Middle Aged', 'Modafinil/administration & dosage/adverse effects/*pharmacology', 'Multiple Sclerosis/*complications', '*Outcome Assessment, Health Care', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/33242419/
301,amantadine,4568331,Augmenting the action of levodopa.,"['Rao SK', 'Vakil SD', 'Calne DB', 'Hilson A']","['Amantadine/therapeutic use', 'Antacids/therapeutic use', 'Apomorphine/adverse effects', 'Carboxy-Lyases/antagonists & inhibitors', 'Catechol O-Methyltransferase Inhibitors', 'Dihydroxyphenylalanine/administration & dosage/adverse effects/*therapeutic use', 'Dopamine beta-Hydroxylase/antagonists & inhibitors', 'Drug Synergism', 'Humans', 'Methyldopa/therapeutic use', 'Monoamine Oxidase Inhibitors/therapeutic use', 'Parasympatholytics/therapeutic use', 'Parkinson Disease/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/4568331/
302,amantadine,770132,Treatment of parkinsonism.,['Selby G'],"['Amantadine/adverse effects/therapeutic use', 'Aromatic Amino Acid Decarboxylase Inhibitors', 'Drug Therapy, Combination', 'Humans', 'Levodopa/therapeutic use', 'Parasympatholytics/therapeutic use', 'Parkinson Disease/diagnosis/*drug therapy/etiology/metabolism/pathology/surgery']",https://pubmed.ncbi.nlm.nih.gov/770132/
303,amantadine,36100228,Pharmacologic Therapies to Promote Recovery of Consciousness.,"['Barra ME', 'Edlow BL', 'Brophy GM']","['Adult', 'Amantadine/therapeutic use', '*Consciousness', '*Consciousness Disorders/drug therapy', 'Humans', 'Recovery of Function']",https://pubmed.ncbi.nlm.nih.gov/36100228/
304,amantadine,22375973,Placebo-controlled trial of amantadine for severe traumatic brain injury.,"['Giacino JT', 'Whyte J', 'Bagiella E', 'Kalmar K', 'Childs N', 'Khademi A', 'Eifert B', 'Long D', 'Katz DI', 'Cho S', 'Yablon SA', 'Luther M', 'Hammond FM', 'Nordenbo A', 'Novak P', 'Mercer W', 'Maurer-Karattup P', 'Sherer M']","['Adult', 'Amantadine/adverse effects/*therapeutic use', 'Brain Injuries/complications/*drug therapy', 'Coma, Post-Head Injury/*drug therapy', 'Disability Evaluation', 'Dopamine Agents/adverse effects/*therapeutic use', 'Female', 'Glasgow Coma Scale', 'Humans', 'Male', 'Persistent Vegetative State/drug therapy/etiology', 'Recovery of Function']",https://pubmed.ncbi.nlm.nih.gov/22375973/
305,amantadine,10412704,['Fatigue' in multiple sclerosis].,"['Zimmermann C', 'Hohlfeld R']","['Amantadine/therapeutic use', 'Aminopyridines/therapeutic use', 'Disease Progression', 'Fatigue/*drug therapy/*etiology', 'Female', 'Humans', 'Male', 'Multiple Sclerosis/*complications/drug therapy', 'Pemoline/adverse effects/therapeutic use', 'Potassium Channel Blockers', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/10412704/
306,amantadine,12768511,[Memantine].,['Molinuevo JL'],"['Aged', 'Alzheimer Disease/*drug therapy', 'Antiparkinson Agents/*therapeutic use', 'Brain/*drug effects', 'Glutamic Acid/metabolism', 'Humans', 'Memantine/adverse effects/*pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12768511/
307,amantadine,10680275,Antiviral agents for treating influenza.,"['Long JK', 'Mossad SB', 'Goldman MP']","['Acetamides/therapeutic use', 'Amantadine/therapeutic use', 'Antiviral Agents/administration & dosage/adverse effects/*therapeutic use', 'Drug Administration Schedule', 'Guanidines', 'Humans', 'Influenza A virus/isolation & purification', 'Influenza B virus/isolation & purification', 'Influenza Vaccines/therapeutic use', 'Influenza, Human/*drug therapy/prevention & control/virology', 'Oseltamivir', 'Pyrans', 'Rimantadine/therapeutic use', 'Sialic Acids/therapeutic use', 'Zanamivir']",https://pubmed.ncbi.nlm.nih.gov/10680275/
308,amantadine,926844,Antiviral agents.,['Hermans PE'],"['Amantadine/pharmacology/therapeutic use', 'Antiviral Agents/*pharmacology', 'Humans', 'Idoxuridine/therapeutic use', 'Influenza, Human/drug therapy', 'Methisazone/pharmacology', 'Ribavirin/pharmacology', 'Vidarabine/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/926844/
309,amantadine,16905701,"Treating viral hepatitis C: efficacy, side effects, and complications.","['Manns MP', 'Wedemeyer H', 'Cornberg M']","['Amantadine/therapeutic use', 'Antiviral Agents/adverse effects/*therapeutic use', 'Hepatitis C, Chronic/*drug therapy', 'Humans', 'Interferon-alpha/adverse effects/therapeutic use', 'Ribavirin/adverse effects/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16905701/
310,amantadine,23229767,Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU.,"['Lyseng-Williamson KA', 'McKeage K']","['Alzheimer Disease/*drug therapy', 'Cost-Benefit Analysis', 'Drug Administration Schedule', 'European Union', 'Humans', 'Memantine/*administration & dosage/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23229767/
311,amantadine,6435991,Anti-parkinsonian drugs today.,['Quinn NP'],"['Amantadine/adverse effects/therapeutic use', 'Amphetamines/therapeutic use', 'Antiparkinson Agents/*therapeutic use', 'Brain Chemistry', 'Catechol O-Methyltransferase Inhibitors', 'Dopamine beta-Hydroxylase/antagonists & inhibitors', 'Droxidopa/therapeutic use', 'Humans', 'Kinetics', 'Levodopa/adverse effects/therapeutic use', 'Mental Disorders/etiology', 'Parasympatholytics/adverse effects/therapeutic use', 'Parkinson Disease/complications/metabolism', 'Selegiline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6435991/
312,amantadine,16133722,The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review.,"['Kraemer M', 'Linden D', 'Berlit P']","['Adolescent', 'Adult', 'Amantadine/adverse effects/therapeutic use', 'Autoantibodies/analysis', 'Cerebrovascular Disorders/diagnosis/pathology', 'Diagnosis, Differential', 'Female', 'Humans', 'Male', 'Middle Aged', 'Migraine Disorders/complications', 'Nervous System Diseases/*diagnosis/drug therapy/*etiology/pathology', 'Phospholipids/immunology', 'Prognosis', '*Review Literature as Topic', 'Skin Diseases, Vascular/*diagnosis/pathology', 'Syndrome', 'Vascular Diseases/complications/etiology']",https://pubmed.ncbi.nlm.nih.gov/16133722/
313,amantadine,2873715,The neuroleptic malignant syndrome: agent and host interaction.,"['Shalev A', 'Munitz H']","['Adolescent', 'Adult', 'Aftercare', 'Aged', 'Akathisia, Drug-Induced', 'Amantadine/therapeutic use', 'Antiparkinson Agents/therapeutic use', 'Antipsychotic Agents/administration & dosage/*adverse effects', 'Benzodiazepines/therapeutic use', 'Bromocriptine/therapeutic use', 'Carbidopa/therapeutic use', 'Child', 'Child, Preschool', 'Dantrolene/therapeutic use', 'Dose-Response Relationship, Drug', 'Electroconvulsive Therapy', 'Female', 'Haloperidol/adverse effects', 'Humans', 'Leukocytosis/chemically induced', 'Male', 'Middle Aged', 'Neuroleptic Malignant Syndrome/drug therapy/*etiology']",https://pubmed.ncbi.nlm.nih.gov/2873715/
314,amantadine,14521495,Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer's disease?,['Doggrell S'],"['Alzheimer Disease/*drug therapy/metabolism', 'Clinical Trials as Topic', 'Humans', 'Memantine/administration & dosage/adverse effects/*therapeutic use', 'Receptors, N-Methyl-D-Aspartate/*antagonists & inhibitors', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/14521495/
315,amantadine,33604795,Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2.,"['Cortes-Borra A', 'Aranda-Abreu GE']","['Amantadine/*therapeutic use', 'Antiviral Agents/*therapeutic use', 'Humans', 'SARS-CoV-2/*drug effects', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/33604795/
316,amantadine,9565792,[Amantadine-induced livedo reticularis].,"['Loffler H', 'Habermann B', 'Effendy I']","['Adult', 'Amantadine/*adverse effects/therapeutic use', 'Drug Eruptions/*diagnosis', 'Female', 'Humans', 'Lymphedema/chemically induced/diagnosis', 'Parkinson Disease/*drug therapy', 'Skin Diseases, Vascular/*chemically induced/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/9565792/
317,amantadine,24343538,[Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?].,"['Pagonabarraga J', 'Kulisevsky J']","['Amantadine/administration & dosage/adverse effects/therapeutic use', 'Antiparkinson Agents/administration & dosage/adverse effects/classification/*therapeutic use', 'Cardiovascular Diseases/chemically induced', 'Catechol O-Methyltransferase', 'Catechol O-Methyltransferase Inhibitors', 'Clinical Trials as Topic', 'Dopamine Agonists/administration & dosage/adverse effects/classification/*therapeutic use', 'Drug Interactions', 'Drug Therapy, Combination', 'Enzyme Inhibitors/administration & dosage/adverse effects/therapeutic use', 'Food-Drug Interactions', 'Humans', 'Indans/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Indoles/therapeutic use', 'Levodopa/administration & dosage/therapeutic use', 'Mental Disorders/chemically induced/prevention & control', 'Monoamine Oxidase Inhibitors/administration & dosage/pharmacology/therapeutic use', 'Multicenter Studies as Topic', 'Parkinson Disease/*drug therapy', 'Serotonin Syndrome/etiology/prevention & control', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24343538/
318,Solifenacin,29043374,[Overactive bladder-which treatment when?].,['Pannek J'],"['Behavior Therapy', 'Botulinum Toxins, Type A/therapeutic use', 'Diagnosis, Differential', 'Electric Stimulation Therapy', 'Female', 'Gabapentin/therapeutic use', 'Humans', 'Injections, Intramuscular', 'Lumbosacral Plexus/drug effects', 'Male', 'Muscarinic Antagonists/therapeutic use', 'Patient Preference', 'Physical Therapy Modalities', 'Solifenacin Succinate/therapeutic use', 'Tadalafil/therapeutic use', 'Urinary Bladder/drug effects', 'Urinary Bladder, Overactive/diagnosis/etiology/*therapy']",https://pubmed.ncbi.nlm.nih.gov/29043374/
319,Solifenacin,28394529,[Comprehensive pharmacologic management of overactive bladder].,"['Krivoborodov GG', 'Tur EI']","['Acetanilides/therapeutic use', 'Adrenergic beta-3 Receptor Agonists/therapeutic use', 'Drug Combinations', 'Humans', 'Muscarinic Antagonists/therapeutic use', 'Randomized Controlled Trials as Topic', 'Solifenacin Succinate/therapeutic use', 'Sulfonamides/therapeutic use', 'Tamsulosin', 'Thiazoles/therapeutic use', 'Urinary Bladder, Neurogenic/drug therapy/etiology', 'Urinary Bladder, Overactive/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/28394529/
320,Solifenacin,37506033,Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis.,"['He W', 'Huang G', 'Cui W', 'Tian Y', 'Sun Q', 'Zhao X', 'Zhao Y', 'Li D', 'Liu X']","['Humans', '*Urinary Bladder, Overactive/drug therapy', 'Solifenacin Succinate/adverse effects', 'Tolterodine Tartrate/therapeutic use', 'Network Meta-Analysis', 'Double-Blind Method', 'Constipation/drug therapy', '*Xerostomia/drug therapy', 'Treatment Outcome', 'Muscarinic Antagonists/adverse effects', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37506033/
321,Solifenacin,32432436,Conservative management of urinary incontinence following robot-assisted radical prostatectomy.,"['Marchioni M', 'Primiceri G', 'Castellan P', 'Schips L', 'Mantica G', 'Chapple C', 'Papalia R', 'Porpiglia F', 'Scarpa RM', 'Esperto F']","['*Conservative Treatment', 'Humans', 'Male', 'Postoperative Complications/*therapy', 'Prostatectomy/*adverse effects', 'Prostatic Neoplasms/complications/surgery', 'Robotic Surgical Procedures/*adverse effects', 'Urinary Incontinence/*etiology/*therapy']",https://pubmed.ncbi.nlm.nih.gov/32432436/
322,Solifenacin,31066800,Overactive bladder - pharmacological treatment.,"['Sacomani CAR', 'Almeida FG', 'Silvinato A', 'Bernardo WM']","['Acetanilides/*administration & dosage', 'Adrenergic beta-3 Receptor Agonists/*administration & dosage', 'Antidepressive Agents/administration & dosage', 'Benzilates/administration & dosage', 'Benzofurans/administration & dosage', 'Brazil', 'Clinical Decision-Making', 'Drug Therapy, Combination', 'Humans', 'Mandelic Acids/administration & dosage', 'Muscarinic Antagonists/*administration & dosage', 'Nortropanes/administration & dosage', 'Pyrrolidines/administration & dosage', 'Solifenacin Succinate/administration & dosage', 'Thiazoles/*administration & dosage', 'Tolterodine Tartrate/administration & dosage', 'Urinary Bladder, Overactive/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31066800/
323,Solifenacin,25741549,[Current pharmacotherapy of overactive bladder in neurological patients].,"['Shvarts PG', 'Vinarov AZ', 'Kadykov AS', 'Borodulina IV', 'Popov SV', 'Kravchenko MA']","['Humans', 'Muscarinic Antagonists/*therapeutic use', 'Quinuclidines/therapeutic use', 'Solifenacin Succinate', 'Tetrahydroisoquinolines/therapeutic use', 'Urinary Bladder, Overactive/*drug therapy/etiology/physiopathology', 'Urination', 'Urological Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25741549/
324,Solifenacin,21607875,Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.,"['Pagoria D', ""O'Connor RC"", 'Guralnick ML']","['Aged', 'Cognition Disorders/*chemically induced', 'Humans', 'Muscarinic Antagonists/*adverse effects/therapeutic use', 'Receptors, Muscarinic/drug effects', 'Urinary Bladder, Overactive/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21607875/
325,Solifenacin,16908335,Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.,"['Brubaker L', 'Chapple C', 'Coyne KS', 'Kopp Z']","['Benzhydryl Compounds/therapeutic use', 'Clinical Trials as Topic', 'Cresols/therapeutic use', 'Health Status', 'Humans', 'Mandelic Acids/therapeutic use', 'Muscarinic Antagonists/therapeutic use', 'Patient Compliance', 'Patient Satisfaction', 'Phenylpropanolamine/therapeutic use', '*Quality of Life', 'Quinuclidines/therapeutic use', 'Solifenacin Succinate', 'Tetrahydroisoquinolines/therapeutic use', 'Tolterodine Tartrate', 'Treatment Outcome', 'Urinary Bladder, Neurogenic/drug therapy/physiopathology/psychology/*therapy', 'Urinary Incontinence, Stress/therapy']",https://pubmed.ncbi.nlm.nih.gov/16908335/
326,Solifenacin,15461562,The emerging role of solifenacin in the treatment of overactive bladder.,"['Robinson D', 'Cardozo L']","['Clinical Trials as Topic', 'Humans', 'Muscarinic Antagonists/adverse effects/pharmacology/therapeutic use', 'Quinuclidines/adverse effects/pharmacology/*therapeutic use', 'Solifenacin Succinate', 'Tetrahydroisoquinolines/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome', 'Urinary Incontinence/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15461562/
327,Solifenacin,19388996,Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome.,"['Chapple CR', 'Rosenberg MT', 'Brenes FJ']","['Benzofurans/administration & dosage', 'Drug Administration Schedule', 'Humans', 'Mandelic Acids/administration & dosage', 'Multicenter Studies as Topic', 'Muscarinic Antagonists/*administration & dosage', '*Patient Satisfaction', 'Pyrrolidines/administration & dosage', 'Quinuclidines/administration & dosage', 'Randomized Controlled Trials as Topic', 'Solifenacin Succinate', 'Tetrahydroisoquinolines/administration & dosage', 'Urinary Bladder, Overactive/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/19388996/
328,Solifenacin,15963212,Darifenacin in the treatment of overactive bladder.,"['Parsons M', 'Robinson D', 'Cardozo L']","['Absorption', 'Benzofurans/adverse effects/metabolism/*therapeutic use', 'Central Nervous System Diseases/chemically induced', 'Drug Interactions', 'Drug Tolerance', 'Heart Rate/drug effects', 'Humans', 'Muscarinic Antagonists/adverse effects/metabolism/*therapeutic use', 'Pyrrolidines/adverse effects/metabolism/*therapeutic use', 'Receptors, Muscarinic/metabolism', 'Treatment Outcome', 'Urinary Bladder Diseases/*drug therapy', 'Urination Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15963212/
329,Solifenacin,36336627,Safety and tolerability of solifenacin in children and adolescents with overactive bladder- a systematic review.,"['Raman G', 'Tunnicliffe D', 'Lai E', 'Bennett T', 'Caldwell P']","['Child', 'Adolescent', 'Humans', 'Solifenacin Succinate/adverse effects', '*Urinary Bladder, Overactive/drug therapy', 'Treatment Outcome', 'Cholinergic Antagonists/adverse effects', '*Xerostomia/chemically induced/drug therapy', 'Constipation', 'Muscarinic Antagonists/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/36336627/
330,Solifenacin,30306278,Management of Overactive Bladder Symptoms After Radical Prostatectomy.,"['Peyronnet B', 'Brucker BM']","['Botulinum Toxins, Type A/therapeutic use', 'Humans', 'Male', 'Muscarinic Antagonists/*therapeutic use', 'Neuromuscular Agents/*therapeutic use', 'Postoperative Complications/physiopathology/*therapy', 'Prostate', '*Prostatectomy', 'Solifenacin Succinate/therapeutic use', 'Tolterodine Tartrate/therapeutic use', 'Urethral Stricture/surgery', 'Urinary Bladder Neck Obstruction/physiopathology/surgery', 'Urinary Bladder, Overactive/physiopathology/*therapy', 'Urinary Incontinence, Stress/physiopathology/therapy']",https://pubmed.ncbi.nlm.nih.gov/30306278/
331,Solifenacin,16503831,The emergence of new drugs for overactive bladder.,"['McCrery RJ', 'Smith PP', 'Appell RA']","['Acetylcholine/metabolism', 'Amines/pharmacology/therapeutic use', 'Animals', 'Anticonvulsants/pharmacology/*therapeutic use', 'Benzhydryl Compounds/pharmacology/therapeutic use', 'Cresols/pharmacology/therapeutic use', 'Cyclohexanecarboxylic Acids/pharmacology/therapeutic use', 'Drug Evaluation, Preclinical', 'Gabapentin', 'Humans', 'Mandelic Acids/pharmacology/therapeutic use', 'Muscarinic Antagonists/pharmacology/*therapeutic use', 'Muscle, Smooth/*drug effects/innervation/metabolism', 'Phenylpropanolamine/pharmacology/therapeutic use', 'Product Surveillance, Postmarketing', 'Quinuclidines/pharmacology/therapeutic use', 'Randomized Controlled Trials as Topic', 'Receptor, Muscarinic M3/antagonists & inhibitors/metabolism', 'Solifenacin Succinate', 'Tetrahydroisoquinolines/pharmacology/therapeutic use', 'Tolterodine Tartrate', 'Urinary Bladder/drug effects/innervation/metabolism', 'Urinary Incontinence/*drug therapy', 'gamma-Aminobutyric Acid/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16503831/
332,Solifenacin,30350884,Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.,"['Wang J', 'Zhou Z', 'Cui Y', 'Li Y', 'Yuan H', 'Gao Z', 'Zhu Z', 'Wu J']","['Acetanilides/adverse effects/*therapeutic use', 'Humans', 'Randomized Controlled Trials as Topic', 'Solifenacin Succinate/adverse effects/*therapeutic use', 'Thiazoles/adverse effects/*therapeutic use', 'Urinary Bladder, Overactive/*drug therapy', 'Urological Agents/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30350884/
333,Solifenacin,16483863,Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.,"['Staskin DR', 'MacDiarmid SA']","['Benzhydryl Compounds/therapeutic use', 'Benzilates', 'Benzofurans/therapeutic use', 'Cholinergic Antagonists/*therapeutic use', 'Cresols/therapeutic use', 'Humans', 'Mandelic Acids/therapeutic use', 'Nortropanes/therapeutic use', 'Phenylpropanolamine/therapeutic use', 'Pyrrolidines/therapeutic use', 'Quinuclidines/therapeutic use', 'Solifenacin Succinate', 'Tetrahydroisoquinolines/therapeutic use', 'Tolterodine Tartrate', 'Urinary Incontinence/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16483863/
334,Solifenacin,21069103,Gateways to clinical trials.,"['Tomillero A', 'Moral MA']","['*Clinical Trials as Topic', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/21069103/
335,Solifenacin,34493055,History and current trends in the treatment of idiopathic overactive bladder.,"['Habes Dominik', 'Lesko Daniel', 'Stepan Martin', 'Spacek Jiri', 'Kestranek Jan']","['Benzhydryl Compounds', 'Humans', 'Muscarinic Antagonists/therapeutic use', 'Quality of Life', 'Solifenacin Succinate', 'Treatment Outcome', '*Urinary Bladder, Overactive/therapy']",https://pubmed.ncbi.nlm.nih.gov/34493055/
336,Solifenacin,39353751,Toxic Epidermal Necrolysis Observed in a Patient With the HLA-B*1502 Treated With Levofloxacin.,"['Wang X', 'Cheng G', 'Liang X', 'Yang J', 'Deng A', 'Chen D', 'Liu C', 'Gao Y', 'Li J']","['Humans', '*Stevens-Johnson Syndrome/genetics/etiology/drug therapy', 'Female', '*Levofloxacin/adverse effects', 'Aged', 'Anti-Bacterial Agents/adverse effects/administration & dosage', 'HLA-B15 Antigen/genetics', 'Cystitis/genetics/chemically induced/drug therapy', 'Mutation', 'Alleles']",https://pubmed.ncbi.nlm.nih.gov/39353751/
337,Solifenacin,17011384,Solifenacin.,['Kreder KJ'],"['Clinical Trials as Topic', 'Humans', 'Muscarinic Antagonists/*therapeutic use', 'Quinuclidines/*therapeutic use', 'Solifenacin Succinate', 'Tetrahydroisoquinolines/*therapeutic use', 'Urinary Bladder, Overactive/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17011384/
338,rofecoxib,11566042,COX-1 and COX-2 inhibitors.,['Hawkey CJ'],"['Celecoxib', 'Cyclooxygenase 1', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/*adverse effects/pharmacology', 'Humans', 'Isoenzymes/*antagonists & inhibitors/metabolism', 'Lactones/*adverse effects/pharmacology', 'Membrane Proteins', 'Peptic Ulcer/chemically induced', 'Prostaglandin-Endoperoxide Synthases/metabolism', 'Pyrazoles', 'Sulfonamides/*adverse effects/pharmacology', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/11566042/
339,rofecoxib,15270001,[Etoricoxib (Arcoxia)].,"['Leclercq P', 'Malaise MG']","['Administration, Oral', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*therapeutic use', 'Arthritis, Gouty/*drug therapy', 'Arthritis, Rheumatoid/*drug therapy', 'Cyclooxygenase 2', 'Etoricoxib', 'Humans', 'Isoenzymes/antagonists & inhibitors', 'Membrane Proteins', 'Osteoarthritis/*drug therapy', 'Prostaglandin-Endoperoxide Synthases', 'Pyridines/administration & dosage/adverse effects/*therapeutic use', 'Sulfones/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15270001/
340,rofecoxib,10892637,Cyclooxygenase-2 enzyme inhibitors: place in therapy.,"['Noble SL', 'King DS', 'Olutade JI']","['Analgesics, Non-Narcotic/adverse effects/economics/pharmacokinetics/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/economics/pharmacokinetics/*therapeutic use', 'Arthritis/drug therapy', 'Bleeding Time', 'Blood Platelets/drug effects', 'Celecoxib', 'Cyclooxygenase Inhibitors/adverse effects/economics/pharmacokinetics/*therapeutic use', 'Drug Interactions', 'Duodenal Ulcer/chemically induced', 'Humans', 'Lactones/therapeutic use', 'Pyrazoles', 'Risk Factors', 'Sulfonamides/therapeutic use', 'Sulfones', 'United States']",https://pubmed.ncbi.nlm.nih.gov/10892637/
341,rofecoxib,10493277,Rofecoxib.,"['Scott LJ', 'Lamb HM']","['Analgesics/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Cyclooxygenase Inhibitors/pharmacokinetics/pharmacology/*therapeutic use', 'Drug Interactions', 'Dysmenorrhea/drug therapy', 'Enzyme Inhibitors/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Humans', 'Lactones/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Osteoarthritis/drug therapy', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/10493277/
342,rofecoxib,24393558,"Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications.","['Harirforoosh S', 'Asghar W', 'Jamali F']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacology/therapeutic use', 'Cardiovascular System/drug effects', 'Gastrointestinal Tract/drug effects', 'Humans', 'Kidney/drug effects']",https://pubmed.ncbi.nlm.nih.gov/24393558/
343,rofecoxib,35585779,Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials.,"['Stiller CO', 'Hjemdahl P']","['Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Celecoxib', 'Cyclooxygenase 2', '*Cyclooxygenase 2 Inhibitors/adverse effects', '*Diclofenac/adverse effects', 'Etoricoxib', 'Fibrinolytic Agents/therapeutic use', 'Humans', 'Ibuprofen/adverse effects', 'Lactones', 'Naproxen', 'Prostaglandins', 'Prostaglandins I', 'Sulfones', 'Thromboxanes']",https://pubmed.ncbi.nlm.nih.gov/35585779/
344,rofecoxib,32251635,Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: A review.,"['Arora M', 'Choudhary S', 'Singh PK', 'Sapra B', 'Silakari O']","['Cardiotoxicity/*etiology/physiopathology/prevention & control', 'Celecoxib/administration & dosage/adverse effects', 'Cyclooxygenase 2 Inhibitors/administration & dosage/*adverse effects/chemistry', 'Drug Labeling', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/32251635/
345,rofecoxib,17003914,COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.,"['Marwali MR', 'Mehta JL']","['Animals', 'Blood Platelets/*drug effects/metabolism', 'Cardiovascular Diseases/*chemically induced/metabolism', 'Celecoxib', 'Cyclooxygenase 2/metabolism', 'Cyclooxygenase 2 Inhibitors/*adverse effects', 'Diclofenac/adverse effects/analogs & derivatives', 'Drug Labeling', 'Endothelium, Vascular/*drug effects/metabolism', 'Epoprostenol/metabolism', 'Humans', 'Lactones/adverse effects', 'Platelet Aggregation', 'Product Surveillance, Postmarketing', 'Pyrazoles/adverse effects', 'Randomized Controlled Trials as Topic', 'Risk Assessment', 'Sulfonamides/adverse effects', 'Sulfones/adverse effects', 'Thromboxane A2/metabolism']",https://pubmed.ncbi.nlm.nih.gov/17003914/
346,rofecoxib,25956433,Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs.,"['Anwar A', 'Anwar IJ', 'Delafontaine P']","['Adult', 'Aged', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Cardiovascular Diseases/enzymology/*etiology/physiopathology', 'Case-Control Studies', 'Cyclooxygenase 1/drug effects/*metabolism', 'Cyclooxygenase 2/drug effects/*metabolism', 'Female', 'Follow-Up Studies', 'Homeostasis/drug effects', 'Humans', 'Lactones/adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Naproxen/adverse effects/therapeutic use', 'Prevalence', 'Randomized Controlled Trials as Topic', 'Risk Assessment', 'Sulfones/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25956433/
347,rofecoxib,24290093,Pioglitazone--do we really need it to manage type 2 diabetes?,"['Sinha B', 'Ghosal S']","['Diabetes Mellitus, Type 2/*drug therapy', 'Drug Administration Schedule', 'Female', 'Fractures, Bone/chemically induced', 'Humans', 'Hypoglycemic Agents/administration & dosage/*adverse effects', 'Male', 'Patient Safety', 'Pioglitazone', 'Risk Assessment', 'Thiazolidinediones/administration & dosage/*adverse effects', 'Treatment Outcome', 'Urinary Bladder Neoplasms/chemically induced', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/24290093/
348,rofecoxib,11087881,Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.,"['Bombardier C', 'Laine L', 'Reicin A', 'Shapiro D', 'Burgos-Vargas R', 'Davis B', 'Day R', 'Ferraz MB', 'Hawkey CJ', 'Hochberg MC', 'Kvien TK', 'Schnitzer TJ']","['Adult', 'Arthritis, Rheumatoid/*drug therapy/mortality', 'Cardiovascular Diseases/mortality', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/*therapeutic use', 'Duodenal Obstruction/chemically induced', 'Female', 'Gastric Outlet Obstruction/chemically induced', 'Gastrointestinal Diseases/*chemically induced', 'Gastrointestinal Hemorrhage/chemically induced', 'Humans', 'Isoenzymes/*antagonists & inhibitors', 'Lactones/*adverse effects/therapeutic use', 'Male', 'Membrane Proteins', 'Middle Aged', 'Naproxen/*adverse effects/therapeutic use', 'Peptic Ulcer/chemically induced', 'Proportional Hazards Models', 'Prostaglandin-Endoperoxide Synthases', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/11087881/
349,rofecoxib,11173045,Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors.,"['Buttgereit F', 'Burmester GR', 'Simon LS']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Anti-Ulcer Agents/therapeutic use', 'Celecoxib', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/*adverse effects', 'Gastric Mucosa/drug effects', 'Gastrointestinal Diseases/*chemically induced/epidemiology/prevention & control', 'Humans', 'Incidence', 'Isoenzymes/*antagonists & inhibitors', 'Lactones/*adverse effects', 'Membrane Proteins', 'Patient Selection', 'Practice Guidelines as Topic', 'Prostaglandin-Endoperoxide Synthases', 'Pyrazoles', 'Sulfonamides/*adverse effects', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/11173045/
350,rofecoxib,14519044,Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity.,"['West PM', 'Fernandez C']","['Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use', 'Aspirin/administration & dosage/*adverse effects', 'Asthma/*chemically induced/drug therapy/*prevention & control', 'Celecoxib', 'Cyclooxygenase 2', 'Drug Hypersensitivity/complications/*etiology', 'Humans', 'Isoenzymes/*antagonists & inhibitors', 'Lactones/administration & dosage/pharmacokinetics/therapeutic use', 'Membrane Proteins', 'Meta-Analysis as Topic', 'Prostaglandin-Endoperoxide Synthases', 'Pyrazoles', 'Sulfonamides/administration & dosage/pharmacokinetics/therapeutic use', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/14519044/
351,rofecoxib,11249495,Rofecoxib.,"['Hillson JL', 'Furst DE']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Arthritis/drug therapy', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Drug Approval', 'Humans', 'Isoenzymes/*drug effects', 'Lactones/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Membrane Proteins', 'Pain/drug therapy', 'Prostaglandin-Endoperoxide Synthases/*drug effects', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/11249495/
352,rofecoxib,18663451,4 years after withdrawal of rofecoxib: where do we stand today?,"['Jaksch W', 'Dejaco C', 'Schirmer M']","['Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Cardiovascular Diseases/*chemically induced', 'Contraindications', 'Cyclooxygenase 2 Inhibitors/*adverse effects', 'Drug Approval', 'Drug Therapy, Combination', '*Drug and Narcotic Control', 'Europe', 'Gastrointestinal Hemorrhage/*chemically induced', 'Humans', 'Lactones/*adverse effects', 'Proton Pump Inhibitors/therapeutic use', 'Rheumatic Diseases/drug therapy', 'Risk', 'Sulfones/*adverse effects', 'United States']",https://pubmed.ncbi.nlm.nih.gov/18663451/
353,rofecoxib,11550988,Nephrotoxicity of selective COX-2 inhibitors.,"['Woywodt A', 'Schwarz A', 'Mengel M', 'Haller H', 'Zeidler H', 'Kohler L']","['Acute Kidney Injury/*chemically induced/therapy', 'Adult', 'Arthritis, Psoriatic/diagnosis/*drug therapy', 'Cyclooxygenase Inhibitors/*adverse effects/therapeutic use', 'Follow-Up Studies', 'Humans', 'Kidney/*drug effects', 'Kidney Function Tests', 'Kidney Transplantation', 'Lactones/*adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Osteoarthritis/diagnosis/*drug therapy', 'Renal Dialysis/methods', 'Risk Assessment', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/11550988/
354,rofecoxib,11953329,Cyclooxygenase inhibition: between the devil and the deep blue sea.,['Hawkey CJ'],"['Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Arthritis/drug therapy', 'Celecoxib', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/*adverse effects', 'Gastroscopy', 'Humans', 'Isoenzymes/*antagonists & inhibitors', 'Kidney/drug effects', 'Lactones/adverse effects', 'Meloxicam', 'Membrane Proteins', 'Myocardial Infarction/chemically induced', 'Prostaglandin-Endoperoxide Synthases', 'Proton Pump Inhibitors', 'Pyrazoles', 'Randomized Controlled Trials as Topic', 'Stomach Ulcer/*chemically induced', 'Sulfonamides/adverse effects', 'Sulfones', 'Thiazines/adverse effects', 'Thiazoles/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11953329/
355,rofecoxib,18457612,The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis.,"['Scanzello CR', 'Moskowitz NK', 'Gibofsky A']","['Administration, Topical', 'Analgesics/*administration & dosage', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Dietary Supplements', 'Humans', 'Inflammation/drug therapy/physiopathology', 'Joints/drug effects/innervation/physiopathology', 'Osteoarthritis/*drug therapy/physiopathology', 'Pain/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18457612/
356,rofecoxib,16184084,Essay: the political logic of regulatory error.,"['Carpenter D', 'Ting MM']","['Drug Approval/legislation & jurisprudence/*methods/statistics & numerical data', 'Humans', 'Lactones/adverse effects/therapeutic use', '*Logic', 'Observer Variation', '*Politics', 'Research Design/*statistics & numerical data', 'Sulfones/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16184084/
357,rofecoxib,11478054,Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.,"['Wildy KS', 'Wasko MC']","['Adjuvants, Immunologic/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use', 'Antibodies, Monoclonal/therapeutic use', 'Antirheumatic Agents/therapeutic use', 'Arthritis, Rheumatoid/*drug therapy/physiopathology', 'Celecoxib', 'Cyclooxygenase Inhibitors/therapeutic use', 'Digestive System/drug effects', 'Etanercept', 'Glucocorticoids/therapeutic use', 'Humans', 'Hydroxychloroquine/therapeutic use', 'Immunoglobulin G/therapeutic use', 'Infliximab', 'Isoxazoles/therapeutic use', 'Lactones/therapeutic use', 'Leflunomide', 'Methotrexate/therapeutic use', 'Osteoarthritis/*drug therapy', 'Pyrazoles', 'Receptors, Tumor Necrosis Factor/therapeutic use', 'Sulfasalazine/therapeutic use', 'Sulfonamides/therapeutic use', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/11478054/
358,clomipramine,15336236,Pharmacotherapy for cataplexy.,"['Houghton WC', 'Scammell TE', 'Thorpy M']","['Antidepressive Agents/adverse effects/*therapeutic use', 'Cataplexy/*drug therapy', 'Central Nervous System Stimulants/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Clomipramine/adverse effects/*therapeutic use', 'Cyclohexanols/adverse effects/*therapeutic use', 'Humans', 'Long-Term Care', 'Sodium Oxybate/adverse effects/*therapeutic use', 'Treatment Outcome', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/15336236/
359,clomipramine,10446735,Mirtazapine: clinical overview.,['Gorman JM'],"['Adrenergic alpha-Antagonists/*therapeutic use', 'Aged', 'Antidepressive Agents, Tricyclic/pharmacology/*therapeutic use', 'Clomipramine/pharmacology/therapeutic use', 'Controlled Clinical Trials as Topic', 'Cyclohexanols/pharmacology/therapeutic use', 'Depressive Disorder/*drug therapy', 'Humans', 'Meta-Analysis as Topic', 'Mianserin/*analogs & derivatives/pharmacology/therapeutic use', 'Middle Aged', 'Mirtazapine', 'Placebos', 'Receptors, Serotonin/drug effects', 'Selective Serotonin Reuptake Inhibitors/pharmacology/therapeutic use', 'Treatment Outcome', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/10446735/
360,clomipramine,36103361,Psychotropic medication in pregnancy and lactation and early development of exposed children.,"['Leutritz AL', 'van Braam L', 'Preis K', 'Gehrmann A', 'Scherf-Clavel M', 'Fiedler K', 'Unterecker S', 'Kittel-Schneider S']","['Pregnancy', 'Female', 'Infant, Newborn', 'Child', 'Humans', '*Sertraline/therapeutic use', 'Clomipramine/therapeutic use', 'Quetiapine Fumarate/therapeutic use', 'Psychotropic Drugs/adverse effects', 'Lactation', '*Pregnancy Complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36103361/
361,clomipramine,2875011,Successful treatment of obsessive-compulsive disorders.,['Murray JB'],"['Anti-Anxiety Agents/therapeutic use', 'Antidepressive Agents/therapeutic use', 'Behavior Therapy/methods', 'Clomipramine/adverse effects/therapeutic use', 'Depressive Disorder/complications', 'Electroencephalography', 'Follow-Up Studies', 'Humans', 'Neurotransmitter Agents/physiology', 'Obsessive-Compulsive Disorder/etiology/psychology/*therapy', 'Psychological Theory', 'Psychotherapy', 'Repression, Psychology']",https://pubmed.ncbi.nlm.nih.gov/2875011/
362,clomipramine,3779595,Tricyclic antidepressant agranulocytosis.,"['Gravenor DS', 'Leclerc JR', 'Blake G']","['Agranulocytosis/*chemically induced', 'Clomipramine/*adverse effects', 'Female', 'Humans', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/3779595/
363,clomipramine,18087649,Premature ejaculation: current and future treatments.,"['Gurkan L', 'Oommen M', 'Hellstrom WJ']","['Anesthetics, Local', 'Behavior Therapy', 'Clomipramine/therapeutic use', '*Ejaculation', 'Humans', 'Lidocaine/administration & dosage', 'Male', 'Prilocaine/administration & dosage', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Sexual Dysfunction, Physiological/psychology/*therapy']",https://pubmed.ncbi.nlm.nih.gov/18087649/
364,clomipramine,9184625,Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions.,"['Goodman WK', 'Ward H', 'Kablinger A', 'Murphy T']","['Adolescent', 'Child', 'Clinical Trials as Topic', 'Clomipramine/pharmacology/therapeutic use', 'Compulsive Behavior/drug therapy', 'Disruptive, Impulse Control, and Conduct Disorders/drug therapy', 'Drug Administration Schedule', 'Drug Interactions', 'Fluvoxamine/administration & dosage/pharmacology/*therapeutic use', 'Humans', 'Obsessive Behavior/drug therapy', 'Obsessive-Compulsive Disorder/*drug therapy/prevention & control/psychology', 'Recurrence', 'Selective Serotonin Reuptake Inhibitors/administration & dosage/pharmacology/therapeutic use', 'Somatoform Disorders/drug therapy', 'Tourette Syndrome/drug therapy/prevention & control/psychology']",https://pubmed.ncbi.nlm.nih.gov/9184625/
365,clomipramine,7795952,Clomipramine and obsessive-compulsive disorder.,"['Scahill L', 'Lynch KA']","['Adolescent', 'Child', 'Clomipramine/pharmacology/*therapeutic use', 'Humans', 'Obsessive-Compulsive Disorder/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/7795952/
366,clomipramine,6174553,The psychopharmacological treatment of obsessive-compulsive disorder: a review.,"['Insel TR', 'Murphy DL']","['Anti-Anxiety Agents/therapeutic use', 'Antipsychotic Agents/therapeutic use', 'Clinical Trials as Topic', 'Clomipramine/adverse effects/therapeutic use', 'Double-Blind Method', 'Humans', 'Hydroxyindoleacetic Acid/cerebrospinal fluid', 'Nortriptyline/therapeutic use', 'Obsessive-Compulsive Disorder/diagnosis/*drug therapy', 'Psychiatric Status Rating Scales']",https://pubmed.ncbi.nlm.nih.gov/6174553/
367,clomipramine,1806635,Obsessive-compulsive disorder.,['George MS'],"['Clomipramine/adverse effects/therapeutic use', 'Fluoxetine/adverse effects/therapeutic use', 'Fluvoxamine/adverse effects/*therapeutic use', 'Humans', 'Obsessive-Compulsive Disorder/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/1806635/
368,clomipramine,39557288,[Translated article] Trichotillomania Treatment Update.,"['Nina Dominguez L', 'Imbernon-Moya A', 'Saceda-Corralo D', 'Vano-Galvan S']","['*Trichotillomania/therapy/drug therapy', 'Humans', '*Cognitive Behavioral Therapy', 'Acetylcysteine/therapeutic use', 'Combined Modality Therapy', 'Naltrexone/therapeutic use', 'Clomipramine/therapeutic use', 'Memantine/therapeutic use', 'Fluoxetine/therapeutic use', 'Olanzapine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39557288/
369,clomipramine,6355073,Combined use of tricyclic antidepressants and monoamine oxidase inhibitors.,['Lader M'],"['Adult', 'Antidepressive Agents, Tricyclic/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Clomipramine/adverse effects/therapeutic use', 'Depressive Disorder/*drug therapy/psychology', 'Drug Therapy, Combination', 'Female', 'Fever/chemically induced', 'Humans', 'Male', 'Monoamine Oxidase Inhibitors/adverse effects/*therapeutic use', 'Psychiatric Status Rating Scales', 'Tranylcypromine/adverse effects/therapeutic use', 'Trimipramine/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6355073/
370,clomipramine,23477795,Aquagenic pruritus induced by clomipramine.,"['Mendlowicz MV', 'Lima JL', 'Fontenelle LF']","['Antidepressive Agents, Tricyclic/*adverse effects/therapeutic use', 'Clomipramine/*adverse effects/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Panic Disorder/drug therapy', 'Pruritus/*chemically induced', 'Skin/drug effects', 'Water/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/23477795/
371,clomipramine,170899,Treatment of Cataplexy with Clomipramine.,['Shapiro WR'],"['Adult', 'Cataplexy/*drug therapy', 'Clomipramine/adverse effects/*therapeutic use', 'Dibenzazepines/*therapeutic use', 'Drug Evaluation', 'Female', 'Humans', 'Male', 'Middle Aged', 'Sleep, REM/drug effects']",https://pubmed.ncbi.nlm.nih.gov/170899/
372,clomipramine,18940380,Air swallowing as a tic.,"['Weil RS', 'Cavanna AE', 'Willoughby JM', 'Robertson MM']","['Aerophagy/chemically induced/diagnostic imaging/*etiology', 'Antidepressive Agents, Tricyclic/adverse effects/therapeutic use', 'Clomipramine/adverse effects/therapeutic use', 'Depression/drug therapy', 'Diagnosis, Differential', 'Gastric Dilatation/diagnostic imaging/*etiology', 'Humans', 'Male', 'Radiography', 'Tourette Syndrome/*complications/diagnosis/diagnostic imaging', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/18940380/
373,clomipramine,2960711,Drug treatment of obsessive-compulsive disorder.,"['Zohar J', 'Insel TR']","['Clomipramine/therapeutic use', 'Depressive Disorder/drug therapy', 'Humans', 'Obsessive-Compulsive Disorder/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2960711/
374,clomipramine,3887445,Clomipramine and imipramine in obsessive-compulsive disorder.,"['Volavka J', 'Neziroglu F', 'Yaryura-Tobias JA']","['Adult', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Clomipramine/adverse effects/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Imipramine/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Obsessive-Compulsive Disorder/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3887445/
375,clomipramine,27756961,Melasma: A rare adverse effect of clomipramine.,['Kar SK'],"['Adult', 'Antidepressive Agents, Tricyclic/administration & dosage/*adverse effects/therapeutic use', 'Clomipramine/administration & dosage/*adverse effects/therapeutic use', 'Humans', 'Male', 'Melanosis/*chemically induced/diagnosis', 'Obsessive-Compulsive Disorder/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27756961/
376,clomipramine,2775959,Hyponatraemia and clomipramine therapy.,"['Pledger DR', 'Mathew H']","['Clomipramine/*adverse effects', 'Depression/drug therapy', 'Female', 'Humans', 'Hyponatremia/*chemically induced', 'Inappropriate ADH Syndrome/*chemically induced', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/2775959/
377,clomipramine,2197816,Clomipramine: a tricyclic antidepressant effective in obsessive compulsive disorder.,"['Kelly MW', 'Myers CW']","['Clomipramine/*therapeutic use', 'Humans', 'Obsessive-Compulsive Disorder/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/2197816/
378,nicotinate,25828829,Ethionamide-induced Pellagra.,"['Gupta Y', 'Shah I']","['Adolescent', 'Antitubercular Agents/administration & dosage/*adverse effects/therapeutic use', 'Diagnosis, Differential', 'Ethionamide/*adverse effects', 'Female', 'Humans', 'Niacin/therapeutic use', 'Pellagra/*chemically induced/diagnosis/*drug therapy', 'Treatment Outcome', 'Tuberculosis, Pulmonary/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/25828829/
379,nicotinate,38051244,A Second Look at Niacin.,['Epstein H'],"['Humans', '*Niacin/therapeutic use/physiology', 'Niacinamide/therapeutic use', 'Skin', '*Skin Diseases', '*COVID-19']",https://pubmed.ncbi.nlm.nih.gov/38051244/
380,nicotinate,29477227,Niacin.,"['Kirkland JB', 'Meyer-Ficca ML']","['Aging/drug effects', 'Humans', 'Neoplasms', 'Niacin/*administration & dosage/metabolism/*pharmacology', 'Pellagra/*prevention & control', 'Risk Factors', 'Vitamins/administration & dosage/metabolism/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/29477227/
381,nicotinate,24854407,"HDL-targeted therapies: progress, failures and future.","['Kingwell BA', 'Chapman MJ', 'Kontush A', 'Miller NE']","['Animals', 'Apolipoprotein A-I/agonists/genetics/metabolism', 'Cardiovascular Diseases/blood/metabolism/*prevention & control', 'Cholesterol Ester Transfer Proteins/antagonists & inhibitors/metabolism', '*Clinical Trials as Topic', 'Drugs, Investigational/adverse effects/metabolism/*therapeutic use', 'Humans', 'Hypolipidemic Agents/adverse effects/metabolism/*therapeutic use', 'Lipoproteins, HDL/*agonists/blood/metabolism/therapeutic use', '*Models, Biological', '*Molecular Targeted Therapy/adverse effects', 'Niacin/adverse effects/metabolism/therapeutic use', 'Phosphatidylcholine-Sterol O-Acyltransferase/adverse effects/genetics/metabolism/therapeutic use', 'Recombinant Proteins/adverse effects/metabolism/therapeutic use', 'Up-Regulation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/24854407/
382,nicotinate,21418500,Future of GPR109A agonists in the treatment of dyslipidaemia.,"['Wanders D', 'Judd RL']","['Adipocytes/drug effects', 'Cardiovascular Diseases/*drug therapy', 'Dyslipidemias/*drug therapy', 'Hepatocytes/drug effects', 'Humans', 'Niacin/*pharmacology', 'Nicotinic Agonists/*pharmacology', 'Receptors, G-Protein-Coupled/*agonists/*therapeutic use', 'Receptors, Nicotinic/*drug effects/physiology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21418500/
383,nicotinate,30813414,Niacin in the Central Nervous System: An Update of Biological Aspects and Clinical Applications.,"['Gasperi V', 'Sibilano M', 'Savini I', 'Catani MV']","['Animals', 'Central Nervous System/*metabolism', '*Clinical Trials as Topic', 'Humans', 'Nervous System Diseases/drug therapy/metabolism', 'Niacin/chemistry/deficiency/*metabolism/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30813414/
384,nicotinate,22116693,Niacin: vitamin and antidyslipidemic drug.,"['Jacobson EL', 'Kim H', 'Kim M', 'Jacobson MK']","['Animals', 'Clinical Trials as Topic', 'Dyslipidemias/drug therapy', 'Humans', 'Hypolipidemic Agents/*therapeutic use', 'Lipid Metabolism/drug effects', 'Lipids/blood', 'Niacin/deficiency/*metabolism/*therapeutic use', 'Pellagra/blood/drug therapy/etiology', 'Vitamins/*metabolism/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22116693/
385,nicotinate,31617441,Activation of HCAR2 by niacin: benefits beyond lipid lowering.,['Tuteja S'],"['Cholesterol, HDL/genetics', 'Coronary Disease/*drug therapy/genetics/pathology', 'Genotype', 'Humans', 'Hypolipidemic Agents/adverse effects/*therapeutic use', 'Lipids/antagonists & inhibitors/genetics', 'Niacin/adverse effects/*pharmacology', 'Polymorphism, Single Nucleotide', 'Receptors, G-Protein-Coupled/*genetics']",https://pubmed.ncbi.nlm.nih.gov/31617441/
386,nicotinate,22138132,Niacin requirements for genomic stability.,['Kirkland JB'],"['Animals', 'DNA Damage/*drug effects', 'DNA Repair/drug effects', 'Dietary Supplements', '*Genomic Instability', 'Humans', 'Models, Animal', 'Neoplasms/epidemiology', 'Niacin/administration & dosage/deficiency/*pharmacology', 'Skin/drug effects']",https://pubmed.ncbi.nlm.nih.gov/22138132/
387,nicotinate,22133050,Safety and tolerability of extended-release niacin with laropiprant.,"['Yadav R', 'Kwok S', 'Ammori BJ', 'Issa B', 'Soran H']","['Animals', 'Delayed-Action Preparations', 'Drug Combinations', 'Dyslipidemias/drug therapy', 'Flushing/chemically induced/prevention & control', 'Humans', 'Hypolipidemic Agents/administration & dosage/*adverse effects/therapeutic use', 'Indoles/administration & dosage/*pharmacology', 'Niacin/administration & dosage/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22133050/
388,nicotinate,27749252,Pleiotropic effects of niacin: Current possibilities for its clinical use.,"['Zeman M', 'Vecka M', 'Perlik F', 'Stankova B', 'Hromadka R', 'Tvrzicka E', 'Sirc J', 'Hrib J', 'Zak A']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacology/therapeutic use', 'Antioxidants/adverse effects/therapeutic use', 'Atherosclerosis/chemically induced/etiology/metabolism/prevention & control', 'Disease Progression', 'Drug Therapy, Combination/adverse effects', 'Fibrinolytic Agents/adverse effects/pharmacology/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/therapeutic use', 'Hyperlipidemias/*drug therapy/metabolism/physiopathology', 'Hypolipidemic Agents/adverse effects/pharmacology/*therapeutic use', '*Models, Biological', 'Niacin/adverse effects/pharmacology/*therapeutic use', 'Receptors, G-Protein-Coupled/*antagonists & inhibitors/metabolism', 'Receptors, Nicotinic/metabolism', 'Vasodilator Agents/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27749252/
389,nicotinate,19878384,Mechanisms of flushing due to niacin and abolition of these effects.,"['Sood A', 'Arora R']","['Aspirin/therapeutic use', 'Dose-Response Relationship, Drug', 'Dyslipidemias/*drug therapy', 'Humans', 'Hypolipidemic Agents/adverse effects/therapeutic use', 'Indoles/therapeutic use', 'Niacin/*adverse effects/*therapeutic use', 'Pruritus/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/19878384/
390,nicotinate,21314634,What restricts the clinical use of nicotinic acid?,"['Kei A', 'Liberopoulos EN', 'Elisaf MS']","['Animals', 'Cardiovascular Diseases/*drug therapy/physiopathology', 'Cholesterol, HDL/blood', 'Clinical Trials as Topic', 'Humans', 'Hypolipidemic Agents/*adverse effects/pharmacology/therapeutic use', 'Lipids/blood', 'Lipoprotein(a)/blood', 'Niacin/*adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21314634/
391,nicotinate,26073392,Is HPS2-THRIVE the death knell for niacin?,"['Toth PP', 'Murthy AM', 'Sidhu MS', 'Boden WE']","['Clinical Trials as Topic', 'Humans', 'Hypolipidemic Agents/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Myocardial Infarction/*blood/*drug therapy', 'Niacin/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/26073392/
392,nicotinate,23357134,Nicotinic acid as a lipid-modifying drug--a review.,"['Julius U', 'Fischer S']","['Animals', 'Biomarkers/blood', 'Chemistry, Pharmaceutical', 'Humans', 'Hyperlipidemias/blood/*drug therapy', 'Hypolipidemic Agents/adverse effects/chemistry/*therapeutic use', 'Lipids/*blood', 'Niacin/adverse effects/chemistry/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23357134/
393,nicotinate,16760691,Dietary and nutraceutical options for managing the hypertriglyceridemic patient.,"['Pins JJ', 'Keenan JM']","['Dietary Carbohydrates/*administration & dosage/adverse effects', 'Energy Intake', 'Evidence-Based Medicine', 'Exercise', 'Fasting', 'Fish Oils/*therapeutic use', 'Humans', 'Hypertriglyceridemia/blood/etiology/*prevention & control', 'Metabolic Syndrome/complications', 'Niacin/*therapeutic use', 'Obesity/complications', 'Pantetheine/*analogs & derivatives/therapeutic use', 'Practice Guidelines as Topic', 'Risk Factors', 'Risk Reduction Behavior', 'Severity of Illness Index', 'Triglycerides/blood', 'Weight Loss']",https://pubmed.ncbi.nlm.nih.gov/16760691/
394,nicotinate,23948546,"Niacin, an old drug with a new twist.","['Song WL', 'FitzGerald GA']","['Animals', 'Dyslipidemias/*drug therapy', 'Humans', 'Hypolipidemic Agents/adverse effects/*therapeutic use', 'Lipoproteins, HDL/blood', 'Lipoproteins, LDL/blood', 'Niacin/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/23948546/
395,nicotinate,21893559,The facts behind niacin.,"['Hochholzer W', 'Berg DD', 'Giugliano RP']","['Biomarkers/metabolism', 'Cardiovascular Diseases/etiology/*prevention & control', 'Cholesterol, HDL/blood/drug effects', 'Cholesterol, LDL/blood/drug effects', 'Drug Therapy, Combination', 'Dyslipidemias/complications/drug therapy', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/therapeutic use', 'Hypolipidemic Agents/administration & dosage/pharmacology/*therapeutic use', 'Niacin/administration & dosage/pharmacology/*therapeutic use', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/21893559/
396,nicotinate,11374857,Evaluating niacin in its various forms.,['Knopp RH'],"['*Chemistry, Pharmaceutical', 'Cholesterol/*blood', 'Coronary Disease/*prevention & control', 'Delayed-Action Preparations', 'Dietary Fats/administration & dosage/metabolism', 'Dose-Response Relationship, Drug', 'Humans', 'Intestinal Absorption', 'Niacin/administration & dosage/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/11374857/
397,furosemide,27238657,Furosemide.,"['Carone L', 'Oxberry SG', 'Twycross R', 'Charlesworth S', 'Mihalyo M', 'Wilcock A']","['Diuretics/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Drug Interactions', 'Furosemide/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Hospice Care', 'Humans', 'Internet', 'Palliative Care']",https://pubmed.ncbi.nlm.nih.gov/27238657/
398,furosemide,34851962,Diuretic effect of co-administration of furosemide and albumin in comparison to furosemide therapy alone: An updated systematic review and meta-analysis.,"['Lee TH', 'Kuo G', 'Chang CH', 'Huang YT', 'Yen CL', 'Lee CC', 'Fan PC', 'Chen JJ']","['Albumins/*administration & dosage/therapeutic use', 'Diuretics/*administration & dosage/therapeutic use', 'Drug Combinations', 'Furosemide/*administration & dosage/therapeutic use', 'Humans', 'Nephrotic Syndrome/*drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/34851962/
399,furosemide,2185908,Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I).,"['Ponto LL', 'Schoenwald RD']","['Acute Kidney Injury/drug therapy', 'Furosemide/metabolism/*pharmacokinetics/pharmacology/therapeutic use', 'Heart Failure/drug therapy', 'Humans', 'Hypertension/drug therapy', 'Liver Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2185908/
400,furosemide,46960,Diuretic-induced oedema.,"['MacGregor GA', 'Tasker PR', 'de Wardener HE']","['Adult', 'Aldosterone/blood', 'Blood Volume', 'Body Weight', 'Chlorthalidone/adverse effects/therapeutic use', 'Diuretics/*adverse effects/therapeutic use', 'Edema/blood/*chemically induced/drug therapy/urine', 'Female', 'Furosemide/adverse effects/pharmacology/therapeutic use', 'Humans', 'Middle Aged', 'Potassium/administration & dosage/blood/urine', 'Renin/blood', 'Sodium/administration & dosage/blood/urine', 'Spironolactone/adverse effects/therapeutic use', 'Water-Electrolyte Balance/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/46960/
401,furosemide,7752014,Furosemide-associated fever.,"['Clegg HW', 'Riopel DA']","['Child, Preschool', 'Female', 'Fever of Unknown Origin/*chemically induced/diagnosis', 'Follow-Up Studies', 'Furosemide/*adverse effects/therapeutic use', 'Heart Failure/*drug therapy', 'Humans', 'Recurrence', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/7752014/
402,furosemide,9158273,Frusemide-induced bullous pemphigoid.,"['Panayiotou BN', 'Prasad MV', 'Zaman MN']","['Aged', 'Bumetanide/therapeutic use', 'Diuretics/*adverse effects/therapeutic use', 'Female', 'Furosemide/*adverse effects', 'Humans', 'Male', 'Pemphigoid, Bullous/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/9158273/
403,furosemide,2191821,Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).,"['Ponto LL', 'Schoenwald RD']","['Animals', 'Furosemide/*pharmacokinetics/pharmacology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/2191821/
404,furosemide,25786394,Intravenous Furosemide for Acute Decompensated Congestive Heart Failure: What Is the Evidence?,"['Owen DR', 'MacAllister R', 'Sofat R']","['Administration, Intravenous', 'Administration, Oral', 'Diuretics/*administration & dosage/adverse effects/pharmacokinetics', 'Evidence-Based Medicine', 'Furosemide/*administration & dosage/adverse effects/pharmacokinetics', 'Heart Failure/diagnosis/*drug therapy/physiopathology', 'Humans', 'Patient Selection', 'Practice Guidelines as Topic', 'Risk Factors', 'Treatment Outcome', 'Water-Electrolyte Balance/drug effects']",https://pubmed.ncbi.nlm.nih.gov/25786394/
405,furosemide,8425583,Inhaled loop diuretics as potential new anti-asthmatic drugs.,"['Bianco S', 'Pieroni MG', 'Refini RM', 'Robuschi M', 'Vaghi A', 'Sestini P']","['Administration, Inhalation', 'Animals', 'Asthma/*drug therapy', 'Bronchoconstriction/drug effects', 'Diuretics/*administration & dosage/pharmacology', 'Drug Evaluation', 'Drug Evaluation, Preclinical', 'Furosemide/administration & dosage', 'Humans', 'Loop of Henle/drug effects']",https://pubmed.ncbi.nlm.nih.gov/8425583/
406,furosemide,22825380,[Loop diuretics: facts and fallacies].,"['Meschi M', 'Detrenis S', 'Bianchi L', 'Sacco M', 'Bertorelli M', 'Boffetti F', 'Caiazza A', 'Savazzi G']","['Drinking', 'Drug Administration Routes', 'Edema/*drug therapy/etiology', 'Furosemide/administration & dosage/pharmacology/therapeutic use', 'Heart Failure/complications/physiopathology', 'Humans', 'Hydrostatic Pressure', 'Liver Cirrhosis/complications/physiopathology', 'Loop of Henle/drug effects/physiopathology', 'Natriuresis/drug effects', 'Nephrotic Syndrome/complications/physiopathology', 'Sodium Potassium Chloride Symporter Inhibitors/administration & dosage/pharmacology/*therapeutic use', 'Water-Electrolyte Imbalance/etiology/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/22825380/
407,furosemide,19333124,Advances in the pharmacological management of breathlessness.,"['Currow DC', 'Ward AM', 'Abernethy AP']","['Dyspnea/*drug therapy/therapy', 'Furosemide/administration & dosage/*therapeutic use', 'Humans', 'Morphine/*therapeutic use', 'Narcotics/*therapeutic use', 'Nebulizers and Vaporizers', 'Palliative Care', 'Sodium Potassium Chloride Symporter Inhibitors/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19333124/
408,furosemide,39579977,Hypertonic saline in acute decompensated heart failure (HSHF).,"['Agrawal S', 'Abhishek Batta S', 'Rao T', 'Selvam S']","['Humans', 'Saline Solution, Hypertonic/administration & dosage/therapeutic use', '*Heart Failure/drug therapy/physiopathology', 'Male', 'Female', 'Acute Disease', 'Middle Aged', '*Furosemide/therapeutic use/administration & dosage', 'Treatment Outcome', 'Aged', 'Diuretics/therapeutic use', 'Dose-Response Relationship, Drug']",https://pubmed.ncbi.nlm.nih.gov/39579977/
409,furosemide,24239195,Forced diuresis with the RenalGuard system: impact on contrast induced acute kidney injury.,['Solomon R'],"['Acute Kidney Injury/*chemically induced/*prevention & control', 'Contrast Media/*adverse effects', 'Diuresis/drug effects/physiology', 'Diuretics/*administration & dosage/pharmacology', 'Furosemide/*administration & dosage/pharmacology', 'Humans', 'Pilot Projects', 'Randomized Controlled Trials as Topic', 'Time Factors', 'Urinary Catheterization/methods']",https://pubmed.ncbi.nlm.nih.gov/24239195/
410,furosemide,8375728,"Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.","['Cornelison TL', 'Reed E']","['Animals', 'Antineoplastic Agents/*adverse effects', 'Carboplatin/adverse effects', 'Cisplatin/*adverse effects', '*Fluid Therapy', 'Furosemide/adverse effects/therapeutic use', 'Humans', 'Kidney/*drug effects/pathology/physiopathology', 'Mannitol/therapeutic use', 'Organoplatinum Compounds/*adverse effects', 'Saline Solution, Hypertonic/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8375728/
411,furosemide,357764,Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension.,"['Araoye MA', 'Chang MY', 'Khatri IM', 'Freis ED']","['Blood Pressure/*drug effects', 'Body Weight/drug effects', 'Clinical Trials as Topic', 'Furosemide/administration & dosage/pharmacology/*therapeutic use', 'Humans', 'Hydrochlorothiazide/administration & dosage/pharmacology/*therapeutic use', 'Hypertension/*drug therapy', 'Systole/drug effects']",https://pubmed.ncbi.nlm.nih.gov/357764/
412,furosemide,940030,Diuretic effect of furosemide in acute glomerulonephritis.,"['Pruitt AW', 'Boles A']","['Acute Disease', 'Administration, Oral', 'Adolescent', 'Blood Urea Nitrogen', 'Child', 'Child, Preschool', 'Diuresis/*drug effects', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Furosemide/administration & dosage/blood/*therapeutic use', 'Glomerulonephritis/blood/*drug therapy', 'Half-Life', 'Humans', 'Injections, Intravenous']",https://pubmed.ncbi.nlm.nih.gov/940030/
413,furosemide,5565464,Frusemide in heart failure of infancy.,['Richardson H'],"['Administration, Oral', 'Aortic Coarctation/drug therapy', 'Body Weight/drug effects', 'Chlorides/urine', 'Ductus Arteriosus, Patent/drug therapy', 'Female', 'Furosemide/administration & dosage/pharmacology/*therapeutic use', 'Heart Failure/*drug therapy/urine', 'Heart Septal Defects, Ventricular/drug therapy', 'Humans', 'Infant', 'Infant, Newborn', 'Infant, Newborn, Diseases/*drug therapy', 'Injections, Intramuscular', 'Male', 'Mitral Valve Stenosis/drug therapy', 'Osmolar Concentration', 'Potassium/urine', 'Pulmonary Edema/drug therapy', 'Respiration/drug effects', 'Sodium/urine', 'Urine']",https://pubmed.ncbi.nlm.nih.gov/5565464/
414,furosemide,319263,An optimal diuretic regimen for cirrhotic ascites. A controlled trial evaluating safety and efficacy of spironolactone and furosemide.,"['Fuller RK', 'Khambatta PB', 'Gobezie GC']","['Ascites/diet therapy/*drug therapy/etiology', 'Body Weight/drug effects', 'Clinical Trials as Topic', 'Diuretics/adverse effects', 'Furosemide/*therapeutic use', 'Humans', 'Liver Cirrhosis/*complications', 'Plasma Volume/drug effects', 'Sodium/administration & dosage', 'Spironolactone/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/319263/
415,furosemide,1994940,Oral labetalol in hypertensive urgencies.,"['Zell-Kanter M', 'Leikin JB']","['Administration, Oral', 'Adult', 'Blood Pressure/drug effects', 'Clinical Protocols/*standards', '*Emergencies', 'Emergency Service, Hospital', 'Female', 'Furosemide/administration & dosage/therapeutic use', 'Hospitals, University', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Illinois', 'Injections, Intravenous', 'Labetalol/administration & dosage/pharmacology/*therapeutic use', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/1994940/
416,furosemide,4550872,"Bumetanide: potent new ""loop"" diuretic.","['Asbury MJ', 'Gatenby PB', ""O'Sullivan S"", 'Bourke E']","['Administration, Oral', 'Adult', 'Aged', 'Butylamines/therapeutic use', 'Chlorides/urine', 'Clinical Trials as Topic', 'Diuretics/administration & dosage/adverse effects/*therapeutic use', 'Edema/drug therapy', 'Female', 'Furosemide/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Phenols/therapeutic use', 'Placebos', 'Potassium/urine', 'Sodium/urine', 'Sulfonamides/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/4550872/
417,megestrol,23543530,Megestrol acetate for treatment of anorexia-cachexia syndrome.,"['Ruiz Garcia V', 'Lopez-Briz E', 'Carbonell Sanchis R', 'Gonzalvez Perales JL', 'Bort-Marti S']","['Acquired Immunodeficiency Syndrome/complications', 'Anorexia/*drug therapy/etiology', 'Appetite Stimulants/adverse effects/*therapeutic use', 'Cachexia/*drug therapy/etiology', 'Humans', 'Megestrol Acetate/adverse effects/*therapeutic use', 'Neoplasms/complications', 'Randomized Controlled Trials as Topic', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/23543530/
418,megestrol,30229678,Efficacy and Safety of Appetite-Stimulating Medications in the Inpatient Setting.,"['Howard ML', 'Hossaini R', 'Tolar C', 'Gaviola ML']","['Adult', 'Appetite/*drug effects', 'Appetite Regulation/*drug effects', 'Appetite Stimulants/administration & dosage/*therapeutic use', 'Dronabinol/administration & dosage/therapeutic use', 'Eating/drug effects', 'Female', 'Humans', 'Inpatients', 'Male', 'Megestrol/administration & dosage/therapeutic use', 'Middle Aged', 'Mirtazapine/administration & dosage/therapeutic use', 'Retrospective Studies', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/30229678/
419,megestrol,26512437,An update on new orally administered contraceptives for women.,['Nelson AL'],"['Clinical Trials as Topic', 'Contraceptives, Oral/*administration & dosage/adverse effects', 'Estradiol/administration & dosage/adverse effects/analogs & derivatives', 'Estrogens/administration & dosage/adverse effects', 'Ethinyl Estradiol/administration & dosage/adverse effects', 'Female', 'Humans', 'Megestrol/administration & dosage/adverse effects', 'Nandrolone/administration & dosage/adverse effects/analogs & derivatives', 'Norpregnadienes/administration & dosage/adverse effects', 'Progestins/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/26512437/
420,megestrol,7773579,Management of cancer anorexia/cachexia.,['Loprinzi CL'],"['Anorexia/*drug therapy/etiology', 'Cachexia/*drug therapy/etiology', 'Controlled Clinical Trials as Topic', 'Double-Blind Method', 'Humans', 'Megestrol/*analogs & derivatives/therapeutic use', 'Megestrol Acetate', 'Multicenter Studies as Topic', 'Neoplasms/complications', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/7773579/
421,megestrol,24333799,"The ""newer"" progestogens and postmenopausal hormone therapy (HRT).",['Schindler AE'],"['Androstenes/*therapeutic use', 'Estradiol/administration & dosage/therapeutic use', 'Female', 'Humans', 'Megestrol/*therapeutic use', 'Nandrolone/*analogs & derivatives/therapeutic use', 'Norpregnadienes/*therapeutic use', 'Postmenopause', 'Progestins/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24333799/
422,megestrol,11727176,Implant contraception.,"['Meckstroth KR', 'Darney PD']","['Cervix Mucus/drug effects', 'Clinical Trials as Topic', 'Contraceptive Agents, Female/*administration & dosage/economics/pharmacology', 'Counseling', '*Desogestrel', 'Drug Implants/*administration & dosage', 'Endometrium/drug effects', 'Female', 'Humans', 'Levonorgestrel/administration & dosage/pharmacology', 'Megestrol/administration & dosage/*analogs & derivatives/pharmacology', 'Norprogesterones/administration & dosage/pharmacology', 'Ovulation/drug effects', 'Patient Satisfaction', 'Pregnancy', 'Progesterone Congeners/*administration & dosage/economics/pharmacology', 'Randomized Controlled Trials as Topic', 'Risk Factors', 'Vinyl Compounds/administration & dosage/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/11727176/
423,megestrol,19749678,[Nomegestrol acetate: clinical pharmacology].,['Lello S'],"['Biological Availability', 'Breast Diseases/drug therapy', 'Drug Therapy, Combination', 'Estradiol/administration & dosage/analogs & derivatives', 'Female', 'Hormone Replacement Therapy', 'Humans', 'Hypothalamo-Hypophyseal System/drug effects', 'Inactivation, Metabolic', 'Megestrol/adverse effects/chemistry/pharmacokinetics/*pharmacology/therapeutic use', 'Menopause', 'Menstruation Disturbances/drug therapy', 'Molecular Structure', 'Norpregnadienes/adverse effects/chemistry/pharmacokinetics/*pharmacology/therapeutic use', 'Ovulation Inhibition/drug effects', 'Protein Binding']",https://pubmed.ncbi.nlm.nih.gov/19749678/
424,megestrol,17722275,Megestrol acetate in cachexia and anorexia.,"['Yeh SS', 'Schuster MW']","['Anorexia/*drug therapy', 'Cachexia/*drug therapy', 'Clinical Trials as Topic/*trends', 'Drug Carriers/chemistry', 'Humans', 'Megestrol Acetate/adverse effects/*chemistry/*therapeutic use', 'Nanoparticles/chemistry']",https://pubmed.ncbi.nlm.nih.gov/17722275/
425,megestrol,7889638,Megestrol-induced Cushing's syndrome.,"['Steer KA', 'Kurtz AB', 'Honour JW']","['Adenocarcinoma/drug therapy', 'Adult', 'Cushing Syndrome/*chemically induced', 'Diabetes Mellitus, Type 1/complications', 'Female', 'Humans', 'Megestrol/*adverse effects', 'Uterine Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7889638/
426,megestrol,27187588,Metabolic impact of combined hormonal contraceptives containing estradiol.,"['Grandi G', 'Napolitano A', 'Cagnacci A']","['Blood Pressure/drug effects', 'Contraceptives, Oral, Combined/*administration & dosage/adverse effects', 'Contraceptives, Oral, Hormonal/*administration & dosage/adverse effects', 'Estradiol/*administration & dosage/adverse effects', 'Ethinyl Estradiol/administration & dosage/adverse effects', 'Hemostasis/drug effects', 'Humans', 'Lipid Metabolism/drug effects', 'Megestrol/administration & dosage', 'Nandrolone/administration & dosage/analogs & derivatives', 'Norpregnadienes/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27187588/
427,megestrol,17619035,Pharmacological treatment of geriatric cachexia: evidence and safety in perspective.,"['Yeh SS', 'Lovitt S', 'Schuster MW']","['Aged', 'Anabolic Agents/adverse effects/*therapeutic use', 'Appetite Stimulants/adverse effects/*therapeutic use', 'Cachexia/*drug therapy/etiology/physiopathology', 'Dronabinol/adverse effects/therapeutic use', '*Geriatrics', 'Humans', 'Megestrol Acetate/adverse effects/*therapeutic use', 'Parenteral Nutrition']",https://pubmed.ncbi.nlm.nih.gov/17619035/
428,megestrol,14751131,Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.,"['Fiorica JV', 'Brunetto VL', 'Hanjani P', 'Lentz SS', 'Mannel R', 'Andersen W']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Agents, Hormonal/administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Apoptosis/drug effects', 'Carcinoma, Endometrioid/drug therapy/pathology', 'Cell Differentiation/drug effects', 'Down-Regulation/drug effects', 'Drug Administration Schedule', 'Endometrial Neoplasms/*drug therapy/metabolism/pathology', 'Female', 'Humans', 'Megestrol Acetate/administration & dosage/adverse effects', 'Middle Aged', 'Receptors, Progesterone/metabolism', 'Tamoxifen/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/14751131/
429,megestrol,22611833,"[Zoely, a combined oral contraceptive, monophasic pill containing estradiol and nomegestrol acetate].","['Pintiaux A', 'Gaspard U', 'Nisolle M']","['Animals', 'Contraception/adverse effects/methods', 'Contraceptives, Oral, Combined/adverse effects/chemistry/*therapeutic use', 'Drug Design', 'Estradiol/*administration & dosage/adverse effects', 'Humans', 'Megestrol/*administration & dosage/adverse effects', 'Norpregnadienes/*administration & dosage/adverse effects', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/22611833/
430,megestrol,25076331,Quality of life in patients with pancreatic cancer.,"['Kiagia M', 'Syrigos KN', 'Saif MW']","['Cachexia/*drug therapy/etiology', 'Dronabinol/adverse effects/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Megestrol Acetate/adverse effects/therapeutic use', 'Pancreatectomy/adverse effects/methods', 'Pancreatic Neoplasms/*complications/surgery', '*Quality of Life', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/25076331/
431,megestrol,7360074,Hounding the pill.,['Smibert J'],"['Animals', 'Australia', 'Breast Neoplasms/*chemically induced', 'Dogs', 'Drug and Narcotic Control', 'Female', 'Humans', 'Mammary Neoplasms, Experimental/chemically induced', 'Megestrol/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/7360074/
432,megestrol,1721521,Management of anorexia-cachexia associated with cancer and HIV infection.,['Gorter R'],"['Anorexia/*drug therapy', 'Antineoplastic Agents/therapeutic use', 'Cachexia/*drug therapy', 'Dronabinol/therapeutic use', 'HIV Infections/*physiopathology', 'Humans', 'Hydrazines/therapeutic use', 'Megestrol/analogs & derivatives/therapeutic use', 'Megestrol Acetate', 'Metoclopramide/therapeutic use', 'Neoplasms/*physiopathology', 'Palliative Care/methods']",https://pubmed.ncbi.nlm.nih.gov/1721521/
433,megestrol,27218795,Pharmacy Report: Megestrol Acetate-Induced Adrenal Insufficiency.,"['Nanjappa S', 'Thai C', 'Shah S', 'Snyder M']","['Adrenal Insufficiency/*etiology', 'Aged', 'Humans', 'Male', 'Megestrol Acetate/*adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/27218795/
434,megestrol,11014096,[What's new in hormone replacement therapy for postmenopausal women? I. Advantages of hormone replacement therapy (HRT)].,"['Martin-Du Pan RC', 'Luzuy F']","['Aged', 'Alzheimer Disease/drug therapy', 'Cardiovascular Diseases/prevention & control', 'Cholesterol, HDL/blood', 'Depression/drug therapy', 'Dyspareunia/drug therapy', '*Estrogen Replacement Therapy', 'Female', 'Humans', 'Male', 'Megestrol/analogs & derivatives/therapeutic use', 'Middle Aged', 'Norpregnenes/therapeutic use', 'Osteoporosis/drug therapy', 'Postmenopause/*drug effects/physiology', 'Progesterone Congeners/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11014096/
435,megestrol,39031821,Dose-dependent effect of megestrol acetate supplementation in cancer patients with anorexia-cachexia syndrome: A meta-analysis.,"['Talebi S', 'Zeraattalab-Motlagh S', 'Barkhordar M', 'Vaezi M', 'Ghoreishy SM', 'Ghavami A', 'Hosseini Y', 'Travica N', 'Mohammadi H']","['Humans', '*Cachexia/etiology/drug therapy', '*Megestrol Acetate/therapeutic use/pharmacology', '*Neoplasms/complications', '*Anorexia/etiology/drug therapy', '*Dietary Supplements', 'Quality of Life', 'Dose-Response Relationship, Drug', 'Body Weight']",https://pubmed.ncbi.nlm.nih.gov/39031821/
436,megestrol,16144501,Review of cost-effectiveness analyses in hormonal therapies in advanced breast cancer.,"['Benedict A', 'Brown RE']","['Antineoplastic Agents, Hormonal/*economics/therapeutic use', 'Aromatase Inhibitors/economics', 'Breast Neoplasms/drug therapy/*economics/metabolism', 'Cost-Benefit Analysis', 'Decision Making', 'Female', 'Health Care Rationing', 'Health Expenditures', 'Humans', 'Megestrol/economics/therapeutic use', 'Models, Economic', 'Randomized Controlled Trials as Topic', 'Receptors, Estrogen/metabolism', 'Tamoxifen/economics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16144501/
437,pantoprazole,38875111,Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation.,"['Cook D', 'Deane A', 'Lauzier F', 'Zytaruk N', 'Guyatt G', 'Saunders L', 'Hardie M', 'Heels-Ansdell D', 'Alhazzani W', 'Marshall J', 'Muscedere J', 'Myburgh J', 'English S', 'Arabi YM', 'Ostermann M', 'Knowles S', 'Hammond N', 'Byrne KM', 'Chapman M', 'Venkatesh B', 'Young P', 'Rajbhandari D', 'Poole A', 'Al-Fares A', 'Reis G', 'Johnson D', 'Iqbal M', 'Hall R', 'Meade M', 'Hand L', 'Duan E', 'Clarke F', 'Dionne JC', 'Tsang JLY', 'Rochwerg B', 'Karachi T', 'Lamontagne F', ""D'Aragon F"", 'St Arnaud C', 'Reeve B', 'Geagea A', 'Niven D', 'Vazquez-Grande G', 'Zarychanski R', 'Ovakim D', 'Wood G', 'Burns KEA', 'Goffi A', 'Wilcox ME', 'Henderson W', 'Forrest D', 'Fowler R', 'Adhikari NKJ', 'Ball I', 'Mele T', 'Binnie A', 'Trop S', 'Mehta S', 'Morgan I', 'Loubani O', 'Vanstone M', 'Fiest K', 'Charbonney E', 'Cavayas YA', 'Archambault P', 'Rewa OG', 'Lau V', 'Kristof AS', 'Khwaja K', 'Williamson D', 'Kanji S', 'Sy E', 'Dennis B', 'Reynolds S', 'Marquis F', 'Lellouche F', 'Rahman A', 'Hosek P', 'Barletta JF', 'Cirrone R', 'Tutschka M', 'Xie F', 'Billot L', 'Thabane L', 'Finfer S']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', '*Critical Illness/therapy', 'Double-Blind Method', '*Gastrointestinal Hemorrhage/etiology/prevention & control', 'Intensive Care Units', '*Pantoprazole/therapeutic use/adverse effects/administration & dosage', '*Peptic Ulcer/prevention & control', 'Pneumonia, Ventilator-Associated/etiology', '*Proton Pump Inhibitors/therapeutic use/adverse effects/administration & dosage', '*Respiration, Artificial/adverse effects', 'Stress, Physiological']",https://pubmed.ncbi.nlm.nih.gov/38875111/
438,pantoprazole,36142643,Proton Pump Inhibitors and Bone Health: An Update Narrative Review.,"['Lespessailles E', 'Toumi H']","['2-Pyridinylmethylsulfinylbenzimidazoles', 'Adenosine Triphosphatases', 'Antacids', 'Bone Density', 'Dexlansoprazole', 'Esomeprazole', 'Humans', 'Lansoprazole', 'Omeprazole/pharmacology', '*Osteoporotic Fractures/drug therapy', 'Pantoprazole', '*Proton Pump Inhibitors/adverse effects', 'Rabeprazole', 'United States']",https://pubmed.ncbi.nlm.nih.gov/36142643/
439,pantoprazole,30354950,Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU.,"['Krag M', 'Marker S', 'Perner A', 'Wetterslev J', 'Wise MP', 'Schefold JC', 'Keus F', 'Guttormsen AB', 'Bendel S', 'Borthwick M', 'Lange T', 'Rasmussen BS', 'Siegemund M', 'Bundgaard H', 'Elkmann T', 'Jensen JV', 'Nielsen RD', 'Liboriussen L', 'Bestle MH', 'Elkjaer JM', 'Palmqvist DF', 'Backlund M', 'Laake JH', 'Badstolokken PM', 'Gronlund J', 'Breum O', 'Walli A', 'Winding R', 'Iversen S', 'Jarnvig IL', 'White JO', 'Brand B', 'Madsen MB', 'Quist L', 'Thornberg KJ', 'Moller A', 'Wiis J', 'Granholm A', 'Anthon CT', 'Meyhoff TS', 'Hjortrup PB', 'Aagaard SR', 'Andreasen JB', 'Sorensen CA', 'Haure P', 'Hauge J', 'Hollinger A', 'Scheuzger J', 'Tuchscherer D', 'Vuilliomenet T', 'Takala J', 'Jakob SM', 'Vang ML', 'Paelestik KB', 'Andersen KLD', 'van der Horst ICC', 'Dieperink W', 'Fjolner J', 'Kjer CKW', 'Solling C', 'Solling CG', 'Karttunen J', 'Morgan MPG', 'Sjobo B', 'Engstrom J', 'Agerholm-Larsen B', 'Moller MH']","['Aged', 'Critical Illness/mortality/*therapy', 'Female', 'Gastrointestinal Hemorrhage/epidemiology/*prevention & control', 'Humans', 'Injections, Intravenous', 'Intensive Care Units', 'Male', 'Middle Aged', 'Pantoprazole/adverse effects/*therapeutic use', 'Peptic Ulcer/*prevention & control', 'Proton Pump Inhibitors/adverse effects/*therapeutic use', 'Risk Factors', 'Single-Blind Method', 'Stress, Physiological', 'Survival Analysis']",https://pubmed.ncbi.nlm.nih.gov/30354950/
440,pantoprazole,16520709,Intravenous proton pump inhibitors.,['Baker DE'],"['2-Pyridinylmethylsulfinylbenzimidazoles', 'Anti-Ulcer Agents/*administration & dosage/pharmacokinetics', 'Benzimidazoles/*administration & dosage/pharmacokinetics', 'Biological Availability', 'Drug Interactions', 'Esomeprazole/*administration & dosage/*analogs & derivatives/pharmacokinetics', 'Humans', 'Hydrogen-Ion Concentration', 'Injections, Intravenous', 'Lansoprazole', 'Pantoprazole', '*Proton Pump Inhibitors', 'Stomach/chemistry', 'Sulfoxides/*administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/16520709/
441,pantoprazole,37635269,Pharmacological treatment of gastro-oesophageal reflux in children.,"['Tighe MP', 'Andrews E', 'Liddicoat I', 'Afzal NA', 'Hayen A', 'Beattie RM']","['Adolescent', 'Child', 'Humans', 'Infant', 'Infant, Newborn', '*Esomeprazole', '*Gastroesophageal Reflux/complications/drug therapy', 'Omeprazole', 'Pantoprazole', 'Proton Pump Inhibitors/therapeutic use', 'Rabeprazole', 'Ranitidine']",https://pubmed.ncbi.nlm.nih.gov/37635269/
442,pantoprazole,32711578,"Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.","['Ochoa D', 'Roman M', 'Cabaleiro T', 'Saiz-Rodriguez M', 'Mejia G', 'Abad-Santos F']","['Adult', 'Anti-Ulcer Agents/blood/*pharmacokinetics', 'Cross-Over Studies', 'Cytochrome P-450 CYP2C19/genetics', 'Dietary Fats/*administration & dosage', 'Fasting/metabolism', 'Female', '*Food-Drug Interactions', 'Genotype', 'Humans', 'Male', 'Omeprazole/blood/*pharmacokinetics', 'Pantoprazole/blood/*pharmacokinetics', 'Proton Pump Inhibitors/blood/*pharmacokinetics', 'Rabeprazole/blood/*pharmacokinetics', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32711578/
443,pantoprazole,27782887,"Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastric pH in extensive metabolizer patients with gastroesophageal reflux disease.","['Celebi A', 'Aydin D', 'Kocaman O', 'Konduk BT', 'Senturk O', 'Hulagu S']","['2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/pharmacology', 'Adult', 'Cross-Over Studies', 'Cytochrome P-450 CYP2C19/*metabolism', 'Double-Blind Method', 'Esomeprazole/administration & dosage/pharmacology', 'Female', 'Gastric Acid/*chemistry', 'Gastroesophageal Reflux/*drug therapy/genetics', 'Genotype', 'Humans', 'Hydrogen-Ion Concentration/*drug effects', 'Lansoprazole/administration & dosage/pharmacology', 'Male', 'Middle Aged', 'Pantoprazole', 'Proton Pump Inhibitors/administration & dosage/*pharmacology', 'Rabeprazole/administration & dosage/pharmacology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27782887/
444,pantoprazole,28913918,Clopidogrel in Critically Ill Patients.,"['Schoergenhofer C', 'Hobl EL', 'Schellongowski P', 'Heinz G', 'Speidl WS', 'Siller-Matula JM', 'Schmid M', 'Sunder-Plassmann R', 'Stimpfl T', 'Hackl M', 'Jilma B']","['Activation, Metabolic', 'Aged', 'Austria', 'Biomarkers/blood', 'Blood Platelets/*drug effects/metabolism', 'Cell Adhesion Molecules/blood', 'Clopidogrel/administration & dosage/adverse effects/blood/*pharmacokinetics', '*Critical Illness', 'Cytochrome P-450 CYP2C19/genetics/metabolism', 'Down-Regulation', 'Drug Monitoring/methods', 'Drug Resistance', 'Female', 'Half-Life', 'Humans', 'Male', 'Microfilament Proteins/blood', 'Middle Aged', 'Pantoprazole/administration & dosage/adverse effects/blood/*pharmacokinetics', 'Phosphoproteins/blood', 'Platelet Aggregation/*drug effects', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/blood/*pharmacokinetics', 'Platelet Function Tests', 'Proton Pump Inhibitors/administration & dosage/adverse effects/blood/*pharmacokinetics', 'Vasodilator-Stimulated Phosphoprotein']",https://pubmed.ncbi.nlm.nih.gov/28913918/
445,pantoprazole,15190384,Understanding NSAID-PPI-COX-2 interrelationships.,['Singh G'],"['2-Pyridinylmethylsulfinylbenzimidazoles', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Aspirin/adverse effects/therapeutic use', 'Benzimidazoles/therapeutic use', 'Cyclooxygenase Inhibitors/adverse effects/*therapeutic use', 'Gastroesophageal Reflux/*drug therapy', 'Helicobacter Infections/*drug therapy', '*Helicobacter pylori', 'Humans', 'Omeprazole/analogs & derivatives', 'Pantoprazole', '*Proton Pump Inhibitors', 'Randomized Controlled Trials as Topic', 'Sulfoxides/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15190384/
446,pantoprazole,31152740,"Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.","['Moayyedi P', 'Eikelboom JW', 'Bosch J', 'Connolly SJ', 'Dyal L', 'Shestakovska O', 'Leong D', 'Anand SS', 'Stork S', 'Branch KRH', 'Bhatt DL', 'Verhamme PB', ""O'Donnell M"", 'Maggioni AP', 'Lonn EM', 'Piegas LS', 'Ertl G', 'Keltai M', 'Bruns NC', 'Muehlhofer E', 'Dagenais GR', 'Kim JH', 'Hori M', 'Steg PG', 'Hart RG', 'Diaz R', 'Alings M', 'Widimsky P', 'Avezum A', 'Probstfield J', 'Zhu J', 'Liang Y', 'Lopez-Jaramillo P', 'Kakkar AK', 'Parkhomenko AN', 'Ryden L', 'Pogosova N', 'Dans AL', 'Lanas F', 'Commerford PJ', 'Torp-Pedersen C', 'Guzik TJ', 'Vinereanu D', 'Tonkin AM', 'Lewis BS', 'Felix C', 'Yusoff K', 'Metsarinne KP', 'Fox KAA', 'Yusuf S']","['Aged', 'Aspirin/*administration & dosage/adverse effects', 'Cardiovascular Diseases/diagnosis/*drug therapy', 'Double-Blind Method', 'Drug Administration Schedule', 'Enterocolitis, Pseudomembranous/chemically induced/microbiology', 'Factor Xa Inhibitors/*administration & dosage/adverse effects', 'Female', 'Gastrointestinal Hemorrhage/chemically induced/*prevention & control', 'Humans', 'Male', 'Middle Aged', 'Pantoprazole/*administration & dosage/adverse effects', 'Peripheral Arterial Disease/diagnosis/*drug therapy', 'Platelet Aggregation Inhibitors/*administration & dosage/adverse effects', 'Prospective Studies', 'Proton Pump Inhibitors/*administration & dosage/adverse effects', 'Risk Assessment', 'Risk Factors', 'Rivaroxaban/*administration & dosage/adverse effects', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31152740/
447,pantoprazole,38602780,The Effects of Pantoprazole on Kidney Outcomes: Post Hoc Observational Analysis from the COMPASS Trial.,"['Pyne L', 'Smyth A', 'Molnar AO', 'Moayyedi P', 'Muehlhofer E', 'Yusuf S', 'Eikelboom J', 'Bosch J', 'Walsh M']","['Humans', '*Pantoprazole/therapeutic use', '*Proton Pump Inhibitors/therapeutic use/adverse effects', 'Male', 'Female', 'Aged', 'Middle Aged', 'Glomerular Filtration Rate/drug effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38602780/
448,pantoprazole,11402494,Pantoprazole.,['Poole P'],"['2-Pyridinylmethylsulfinylbenzimidazoles', 'Anti-Ulcer Agents/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Benzimidazoles/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Enzyme Inhibitors/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Esophagitis/*drug therapy/etiology', 'Gastroesophageal Reflux/complications/*drug therapy', 'Humans', 'Omeprazole/analogs & derivatives', 'Pantoprazole', '*Proton Pump Inhibitors', 'Sulfoxides/adverse effects/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11402494/
449,pantoprazole,36194219,Effect of a Postoperative Multimodal Opioid-Sparing Protocol vs Standard Opioid Prescribing on Postoperative Opioid Consumption After Knee or Shoulder Arthroscopy: A Randomized Clinical Trial.,"['Gazendam A', 'Ekhtiari S', 'Horner NS', 'Simunovic N', 'Khan M', 'de Sa DL', 'Madden K', 'Ayeni OR']","['Acetaminophen/adverse effects/therapeutic use', 'Adult', '*Analgesics, Non-Narcotic/adverse effects/therapeutic use', '*Analgesics, Opioid/adverse effects/therapeutic use', 'Anti-Ulcer Agents/adverse effects/therapeutic use', '*Arthroscopy', 'Clinical Protocols', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hydromorphone/adverse effects/therapeutic use', '*Knee Joint/surgery', 'Male', 'Naproxen/adverse effects/therapeutic use', 'Ontario', '*Pain, Postoperative/drug therapy/etiology', 'Pantoprazole/adverse effects/therapeutic use', 'Patient Education as Topic', 'Postoperative Care', '*Shoulder Joint/surgery']",https://pubmed.ncbi.nlm.nih.gov/36194219/
450,pantoprazole,36174588,Pantoprazole Induced Acute Interstitial Nephritis in a Patient with Diabetic Ketoacidosis.,"['Tas N', 'Mengen E', 'Goncu S', 'Tasar S', 'Kiremitci S', 'Ucakturk A']","['Humans', 'Child', '*Diabetic Ketoacidosis/chemically induced/diagnosis/complications', 'Pantoprazole/adverse effects', 'Acute Disease', '*Pancreatitis/complications', '*Diabetes Mellitus, Type 1/complications/diagnosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36174588/
451,pantoprazole,29315506,Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.,"['Mangal N', 'Hamadeh IS', 'Arwood MJ', 'Cavallari LH', 'Samant TS', 'Klinker KP', 'Bulitta J', 'Schmidt S']","['Adult', 'Aged', 'Antifungal Agents/*administration & dosage/adverse effects/blood/pharmacokinetics', 'Aspergillosis/blood/diagnosis/*drug therapy/microbiology', 'Aspergillus/classification/drug effects', 'Candida/classification/drug effects', 'Candidiasis/blood/diagnosis/*drug therapy/microbiology', 'Cytochrome P-450 CYP2C19/genetics/metabolism', '*Drug Dosage Calculations', 'Drug Interactions', 'Drug Monitoring', 'Female', 'Genotype', 'Humans', 'Invasive Fungal Infections/blood/diagnosis/*drug therapy/microbiology', 'Male', 'Microbial Sensitivity Tests', 'Middle Aged', '*Models, Biological', 'Pantoprazole/adverse effects', 'Pharmacogenomic Variants', 'Phenotype', 'Proton Pump Inhibitors/adverse effects', 'Risk Assessment', 'Voriconazole/*administration & dosage/adverse effects/blood/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/29315506/
452,pantoprazole,39511890,Proton pump inhibitor attenuates acidic microenvironment to improve the therapeutic effects of MSLN-CAR-T cells on the brain metastasis.,"['Zhai X', 'Mao L', 'Kang Q', 'Liu J', 'Zhou Y', 'Wang J', 'Yang X', 'Wang D', 'Wang J', 'Li Y', 'Duan J', 'Zhang T', 'Lin S', 'Zhao T', 'Li J', 'Wu M', 'Yu S']","['*Tumor Microenvironment/drug effects', '*Mesothelin', 'Humans', 'Animals', 'Mice', '*Brain Neoplasms/secondary/drug therapy/therapy', 'Cell Line, Tumor', '*Proton Pump Inhibitors/pharmacology/therapeutic use', 'Female', 'Xenograft Model Antitumor Assays', 'Triple Negative Breast Neoplasms/drug therapy/pathology/therapy/metabolism', 'Immunotherapy, Adoptive/methods', 'Receptors, Chimeric Antigen/metabolism', 'Pantoprazole/pharmacology', 'Hydrogen-Ion Concentration']",https://pubmed.ncbi.nlm.nih.gov/39511890/
453,pantoprazole,36896929,Gastric calcinosis ulcer in a renal transplanted patient.,"['Olmedo Moreno C', 'Hernan Ocana P', 'Rodriguez Gil Y', 'Diaz Tasende J']","['Humans', 'Middle Aged', 'Female', '*Kidney Transplantation', '*Calcinosis/etiology/diagnostic imaging', 'Stomach Ulcer/etiology/complications', 'Endoscopy, Digestive System', 'Postoperative Complications/etiology', 'Pantoprazole/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36896929/
454,pantoprazole,26242498,[Proton Pump Inhibitor and High-dose Methotrexate: Two Cases Reports].,"['Evrard J', 'Farnier E', 'Carcel C', 'Lachenal F', 'Vial T', 'Pont E']","['2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/*adverse effects/pharmacokinetics', 'Acute Kidney Injury/*chemically induced/prevention & control/therapy', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/therapeutic use', 'Carcinoma, Squamous Cell/drug therapy', 'Combined Modality Therapy', 'Comorbidity', 'Cyclophosphamide/administration & dosage', 'Dose-Response Relationship, Drug', 'Doxorubicin/administration & dosage', 'Drug Eruptions/*etiology', 'Drug Interactions', 'Humans', 'Lymphoma, Large B-Cell, Diffuse/drug therapy', 'Male', 'Methotrexate/administration & dosage/*adverse effects/pharmacokinetics', 'Mucositis/*chemically induced', 'Omeprazole/administration & dosage/*adverse effects/pharmacokinetics', 'Otorhinolaryngologic Neoplasms/drug therapy', 'Pancytopenia/*chemically induced', 'Pantoprazole', 'Polypharmacy', 'Prednisone/administration & dosage', 'Proton Pump Inhibitors/administration & dosage/*adverse effects/pharmacokinetics/therapeutic use', 'Rituximab/administration & dosage', 'Vincristine/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/26242498/
455,pantoprazole,16569810,Pantoprazole-induced thrombocytopenia.,"['Watson TD', 'Stark JE', 'Vesta KS']","['2-Pyridinylmethylsulfinylbenzimidazoles', 'Adult', 'Benzimidazoles/administration & dosage/*adverse effects/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Omeprazole/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Pantoprazole', 'Platelet Count', 'Sulfoxides/administration & dosage/*adverse effects/therapeutic use', 'Thrombocytopenia/blood/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/16569810/
456,pantoprazole,38704520,Protocol implementation during the COVID-19 pandemic: experiences from a randomized trial of stress ulcer prophylaxis.,"['Dennis B', 'Deane A', 'Lauzier F', 'Zytaruk N', 'Hardie M', 'Hammond N', 'Finfer S', 'Arabi Y', 'Marshall J', 'Saunders L', 'Heels-Ansdell D', 'Myburgh J', 'Knowles S', 'Muscedere J', 'Ostermann M', 'Rajbhandari D', 'English S', 'Matic K', 'Venkatesh B', 'Al Fares A', 'Guyatt G', 'Alhazzani W', 'Mumtaz H', 'Poole A', 'Xie F', 'Thabane L', 'Hall R', 'Cook D']","['Humans', '*COVID-19/prevention & control/epidemiology', 'Pantoprazole/therapeutic use', 'SARS-CoV-2', 'Intensive Care Units/statistics & numerical data', 'Pandemics/prevention & control', 'Female', 'Respiration, Artificial/statistics & numerical data', 'Male', 'Clinical Protocols', 'Middle Aged', 'Gastrointestinal Hemorrhage/prevention & control', 'Anti-Ulcer Agents/therapeutic use/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38704520/
457,modafinil,35366192,Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals.,"['Schifano F', 'Catalani V', 'Sharif S', 'Napoletano F', 'Corkery JM', 'Arillotta D', 'Fergus S', 'Vento A', 'Guirguis A']","['Brain', '*Central Nervous System Stimulants/adverse effects', 'Cognition', 'Humans', '*Methylphenidate/pharmacology', 'Modafinil/pharmacology', '*Nootropic Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35366192/
458,modafinil,30468674,Modafinil and orexin system: interactions and medico-legal considerations.,"['Salerno M', 'Villano I', 'Nicolosi D', 'Longhitano L', 'Loreto C', 'Lovino A', 'Sessa F', 'Polito AN', 'Monda V', 'Chieffi S', 'Messina A', 'Monda M', 'Zammit C', 'Tafuri D', 'Messina G', 'Carotenuto M']","['Animals', 'Attention/drug effects/physiology', 'Central Nervous System/*drug effects/metabolism/physiology', 'Cognition/drug effects/physiology', 'Humans', 'Modafinil/metabolism/pharmacokinetics/*pharmacology', 'Neurons/drug effects/metabolism/physiology', 'Orexins/*metabolism', 'Wakefulness/*drug effects/physiology', 'Wakefulness-Promoting Agents/metabolism/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30468674/
459,modafinil,9628108,Idiopathic hypersomnia.,"['Billiard M', 'Merle C', 'Carlander B', 'Ondze B', 'Alvarez D', 'Besset A']","['Adolescent', 'Adult', 'Benzhydryl Compounds/adverse effects/therapeutic use', 'Central Nervous System Stimulants/therapeutic use', 'Child', 'Diagnosis, Differential', 'Disorders of Excessive Somnolence/*diagnosis/drug therapy/genetics', 'Female', 'Humans', 'Male', 'Modafinil', 'Pedigree', 'Polysomnography']",https://pubmed.ncbi.nlm.nih.gov/9628108/
460,modafinil,33085721,Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.,"['Elliott J', 'Johnston A', 'Husereau D', 'Kelly SE', 'Eagles C', 'Charach A', 'Hsieh SC', 'Bai Z', 'Hossain A', 'Skidmore B', 'Tsakonas E', 'Chojecki D', 'Mamdani M', 'Wells GA']","['Adult', 'Amphetamine/adverse effects/therapeutic use', 'Atomoxetine Hydrochloride/adverse effects/therapeutic use', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/epidemiology/pathology', 'Bayes Theorem', 'Bupropion/adverse effects/therapeutic use', 'Central Nervous System Stimulants/*adverse effects', 'Dextroamphetamine/adverse effects/therapeutic use', 'Drug-Related Side Effects and Adverse Reactions/classification/*epidemiology/pathology', 'Female', 'Guanfacine/adverse effects/therapeutic use', 'Humans', 'Lisdexamfetamine Dimesylate/adverse effects/therapeutic use', 'Male', 'Methylphenidate/adverse effects/therapeutic use', 'Modafinil/adverse effects/therapeutic use', 'Network Meta-Analysis', 'Quality of Life', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/33085721/
461,modafinil,31375202,Precision Medicine for Idiopathic Hypersomnia.,"['Arnulf I', 'Leu-Semenescu S', 'Dodet P']","['Central Nervous System Stimulants/therapeutic use', 'Clarithromycin/therapeutic use', 'Flumazenil/therapeutic use', 'GABA Modulators/*therapeutic use', 'Humans', 'Idiopathic Hypersomnia/*drug therapy/metabolism/physiopathology', 'Mazindol/therapeutic use', 'Modafinil/therapeutic use', 'Orexins/metabolism', 'Piperidines/therapeutic use', 'Polysomnography', 'Precision Medicine', 'Sleep', 'Sodium Oxybate/therapeutic use', 'Wakefulness', 'Wakefulness-Promoting Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31375202/
462,modafinil,34173288,European guideline and expert statements on the management of narcolepsy in adults and children.,"['Bassetti CLA', 'Kallweit U', 'Vignatelli L', 'Plazzi G', 'Lecendreux M', 'Baldin E', 'Dolenc-Groselj L', 'Jennum P', 'Khatami R', 'Manconi M', 'Mayer G', 'Partinen M', 'Pollmacher T', 'Reading P', 'Santamaria J', 'Sonka K', 'Dauvilliers Y', 'Lammers GJ']","['Adult', '*Cataplexy', 'Child', 'Humans', 'Modafinil/therapeutic use', '*Narcolepsy/diagnosis/drug therapy', 'Sleep', '*Sodium Oxybate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34173288/
463,modafinil,37194538,[Psychostimulants: An Overview].,"['Fukumoto S', 'Imanari E', 'Tomari S', 'Higashi T', 'Kosaka H']","['Humans', '*Central Nervous System Stimulants/therapeutic use', 'Lisdexamfetamine Dimesylate/therapeutic use', '*Attention Deficit Disorder with Hyperactivity/drug therapy', '*Methylphenidate/therapeutic use', 'Modafinil/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37194538/
464,modafinil,37921201,Headache improves with armodafinil.,['Barone DA'],"['Humans', 'Modafinil/therapeutic use', '*Narcolepsy', 'Caffeine/therapeutic use', '*Cataplexy', 'Headache/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37921201/
465,modafinil,33435717,A Review of Pharmacologic Neurostimulant Use During Rehabilitation and Recovery After Brain Injury.,"['Kakehi S', 'Tompkins DM']","['*Brain Injuries/drug therapy', 'Humans', 'Modafinil', 'Prospective Studies', 'Risk Assessment', '*Stroke']",https://pubmed.ncbi.nlm.nih.gov/33435717/
466,modafinil,38508480,Severe Fatigue in Inflammatory Bowel Disease: Dopaminergic Therapy With Modafinil or Vitamin Therapy With Thiamine.,"['Bager P', 'Hvas CL', 'Dahlerup JF']","['Humans', '*Modafinil/therapeutic use', '*Fatigue/drug therapy', '*Inflammatory Bowel Diseases/drug therapy/complications', '*Thiamine/therapeutic use', 'Treatment Outcome', 'Male', 'Female', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/38508480/
467,modafinil,36759544,In utero exposure to ADHD medication and long-term offspring outcomes.,"['Bang Madsen K', 'Robakis TK', 'Liu X', 'Momen N', 'Larsson H', 'Dreier JW', 'Kildegaard H', 'Groth JB', 'Newcorn JH', 'Hove Thomsen P', 'Munk-Olsen T', 'Bergink V']","['Adult', 'Child, Preschool', 'Female', 'Humans', 'Infant', 'Pregnancy', 'Amphetamines/adverse effects/therapeutic use', '*Attention Deficit Disorder with Hyperactivity/drug therapy', 'Clonidine/adverse effects/therapeutic use', 'Cohort Studies', 'Denmark/epidemiology', 'Gestational Age', '*Methylphenidate/adverse effects/therapeutic use', 'Modafinil/adverse effects/therapeutic use', '*Mothers/psychology', 'Neurodevelopmental Disorders/chemically induced', '*Prenatal Exposure Delayed Effects/chemically induced/epidemiology', 'Registries']",https://pubmed.ncbi.nlm.nih.gov/36759544/
468,modafinil,33201262,"Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine.","['Repantis D', 'Bovy L', 'Ohla K', 'Kuhn S', 'Dresler M']","['Adult', 'Attention/drug effects', 'Caffeine/*pharmacology', 'Central Nervous System Stimulants/*pharmacology', 'Cognition/*drug effects', 'Double-Blind Method', 'Fatigue/prevention & control', 'Humans', 'Male', 'Methylphenidate/*pharmacology', 'Modafinil/*pharmacology', 'Nootropic Agents/*pharmacology', 'Pilot Projects', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33201262/
469,modafinil,33242419,"Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.","['Nourbakhsh B', 'Revirajan N', 'Morris B', 'Cordano C', 'Creasman J', 'Manguinao M', 'Krysko K', 'Rutatangwa A', 'Auvray C', 'Aljarallah S', 'Jin C', 'Mowry E', 'McCulloch C', 'Waubant E']","['Adult', 'Amantadine/administration & dosage/adverse effects/*pharmacology', 'Central Nervous System Stimulants/administration & dosage/adverse effects/*pharmacology', 'Cross-Over Studies', 'Double-Blind Method', 'Drug Administration Schedule', '*Drug-Related Side Effects and Adverse Reactions', 'Fatigue/*drug therapy/*etiology', 'Female', 'Humans', 'Male', 'Methylphenidate/administration & dosage/adverse effects/*pharmacology', 'Middle Aged', 'Modafinil/administration & dosage/adverse effects/*pharmacology', 'Multiple Sclerosis/*complications', '*Outcome Assessment, Health Care', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/33242419/
470,modafinil,22310006,[Modafinil in the treatment of depression].,['Videbech P'],"['Antidepressive Agents/adverse effects/*therapeutic use', 'Benzhydryl Compounds/adverse effects/*therapeutic use', 'Bipolar Disorder/drug therapy', 'Central Nervous System Stimulants/adverse effects/*therapeutic use', 'Depressive Disorder/*drug therapy', 'Depressive Disorder, Major/drug therapy', 'Drug Interactions', 'Humans', 'Modafinil', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22310006/
471,modafinil,24107292,"Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.","['Dauvilliers Y', 'Bassetti C', 'Lammers GJ', 'Arnulf I', 'Mayer G', 'Rodenbeck A', 'Lehert P', 'Ding CL', 'Lecomte JM', 'Schwartz JC']","['Adult', 'Benzhydryl Compounds/administration & dosage/adverse effects/*pharmacology', 'Double-Blind Method', 'Female', 'Histamine Agonists/administration & dosage/adverse effects/*pharmacology', 'Humans', 'Male', 'Middle Aged', 'Modafinil', 'Narcolepsy/*drug therapy', 'Piperidines/administration & dosage/adverse effects/*pharmacology', 'Placebos', 'Severity of Illness Index', 'Treatment Outcome', 'Wakefulness-Promoting Agents/administration & dosage/adverse effects/*pharmacology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24107292/
472,modafinil,30767208,Modafinil protects hippocampal neurons by suppressing excessive autophagy and apoptosis in mice with sleep deprivation.,"['Cao Y', 'Li Q', 'Liu L', 'Wu H', 'Huang F', 'Wang C', 'Lan Y', 'Zheng F', 'Xing F', 'Zhou Q', 'Li Q', 'Shi H', 'Zhang B', 'Wang Z', 'Wu X']","['Animals', 'Apoptosis/*drug effects', 'Autophagy/*drug effects', 'Central Nervous System Stimulants/*pharmacology', 'Hippocampus/*drug effects', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Modafinil/*pharmacology', 'Neurons/*drug effects', 'Protective Agents/*pharmacology', 'Sleep Deprivation/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30767208/
473,modafinil,37155992,Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea : A Systematic Review and Network Meta-analysis.,"['Pitre T', 'Mah J', 'Roberts S', 'Desai K', 'Gu Y', 'Ryan C', 'Busse JW', 'Zeraatkar D']","['Humans', 'Autoreceptors', '*Disorders of Excessive Somnolence/drug therapy/etiology', 'Modafinil/adverse effects', 'Network Meta-Analysis', '*Sleep Apnea, Obstructive/complications/drug therapy', '*Wakefulness-Promoting Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37155992/
474,modafinil,34173695,European guideline and expert statements on the management of narcolepsy in adults and children.,"['Bassetti CLA', 'Kallweit U', 'Vignatelli L', 'Plazzi G', 'Lecendreux M', 'Baldin E', 'Dolenc-Groselj L', 'Jennum P', 'Khatami R', 'Manconi M', 'Mayer G', 'Partinen M', 'Pollmacher T', 'Reading P', 'Santamaria J', 'Sonka K', 'Dauvilliers Y', 'Lammers GJ']","['Adult', '*Cataplexy', 'Child', 'Humans', 'Modafinil/therapeutic use', '*Narcolepsy/diagnosis/drug therapy', 'Sleep', '*Sodium Oxybate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34173695/
475,modafinil,35670369,"Cognitive enhancement: Effects of methylphenidate, modafinil, and caffeine on latent memory and resting state functional connectivity in healthy adults.","['Becker M', 'Repantis D', 'Dresler M', 'Kuhn S']","['Adult', 'Brain/diagnostic imaging', 'Brain Mapping/methods', 'Caffeine/pharmacology', '*Central Nervous System Stimulants/pharmacology', 'Cognition', 'Double-Blind Method', 'Humans', 'Magnetic Resonance Imaging/methods', 'Male', '*Methylphenidate/pharmacology', 'Modafinil/pharmacology', 'Neural Pathways/diagnostic imaging']",https://pubmed.ncbi.nlm.nih.gov/35670369/
476,modafinil,32601988,Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.,"['Tardelli VS', 'Bisaga A', 'Arcadepani FB', 'Gerra G', 'Levin FR', 'Fidalgo TM']","['Amphetamine/therapeutic use', 'Central Nervous System Stimulants/*therapeutic use', 'Cocaine/therapeutic use', 'Double-Blind Method', 'Humans', 'Lisdexamfetamine Dimesylate/therapeutic use', 'Methylphenidate/therapeutic use', 'Modafinil/therapeutic use', 'Prescription Drugs/*therapeutic use', 'Randomized Controlled Trials as Topic/methods', 'Substance-Related Disorders/*diagnosis/*drug therapy/psychology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32601988/
477,EXEMESTANE,28862117,Hormone Therapy in Breast Cancer.,"['Draganescu M', 'Carmocan C']","['Antineoplastic Agents, Hormonal/*therapeutic use', 'Aromatase Inhibitors/administration & dosage', 'Breast Neoplasms/*drug therapy/pathology', 'Chemotherapy, Adjuvant', 'Disease-Free Survival', 'Estradiol/administration & dosage/analogs & derivatives', 'Female', 'Fulvestrant', 'Gonadotropin-Releasing Hormone/analogs & derivatives', 'Humans', '*Postmenopause', '*Premenopause', 'Quality of Life', 'Tamoxifen/administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28862117/
478,EXEMESTANE,29863451,Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.,"['Francis PA', 'Pagani O', 'Fleming GF', 'Walley BA', 'Colleoni M', 'Lang I', 'Gomez HL', 'Tondini C', 'Ciruelos E', 'Burstein HJ', 'Bonnefoi HR', 'Bellet M', 'Martino S', 'Geyer CE Jr', 'Goetz MP', 'Stearns V', 'Pinotti G', 'Puglisi F', 'Spazzapan S', 'Climent MA', 'Pavesi L', 'Ruhstaller T', 'Davidson NE', 'Coleman R', 'Debled M', 'Buchholz S', 'Ingle JN', 'Winer EP', 'Maibach R', 'Rabaglio-Poretti M', 'Ruepp B', 'Di Leo A', 'Coates AS', 'Gelber RD', 'Goldhirsch A', 'Regan MM']","['Adult', 'Androstadienes/adverse effects/*therapeutic use', 'Antineoplastic Agents, Hormonal/adverse effects/*therapeutic use', 'Aromatase Inhibitors/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy/surgery', 'Chemotherapy, Adjuvant', 'Disease-Free Survival', 'Female', 'Follow-Up Studies', 'Humans', 'Kaplan-Meier Estimate', 'Middle Aged', 'Neoplasm Recurrence, Local/*prevention & control', 'Premenopause', 'Receptor, ErbB-2', 'Tamoxifen/adverse effects/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29863451/
479,EXEMESTANE,22149876,Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.,"['Baselga J', 'Campone M', 'Piccart M', 'Burris HA 3rd', 'Rugo HS', 'Sahmoud T', 'Noguchi S', 'Gnant M', 'Pritchard KI', 'Lebrun F', 'Beck JT', 'Ito Y', 'Yardley D', 'Deleu I', 'Perez A', 'Bachelot T', 'Vittori L', 'Xu Z', 'Mukhopadhyay P', 'Lebwohl D', 'Hortobagyi GN']","['Adult', 'Aged', 'Aged, 80 and over', 'Androstadienes/adverse effects/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Aromatase Inhibitors/adverse effects/*therapeutic use', 'Bone Neoplasms/secondary', 'Breast Neoplasms/chemistry/*drug therapy', 'Disease-Free Survival', 'ErbB Receptors/analysis', 'Everolimus', 'Female', 'Humans', 'Kaplan-Meier Estimate', 'Middle Aged', 'Postmenopause', 'Recurrence', 'Sirolimus/adverse effects/*analogs & derivatives/therapeutic use', 'Stomatitis/chemically induced', 'TOR Serine-Threonine Kinases/*antagonists & inhibitors']",https://pubmed.ncbi.nlm.nih.gov/22149876/
480,EXEMESTANE,25231953,"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger.","['Piccart M', 'Hortobagyi GN', 'Campone M', 'Pritchard KI', 'Lebrun F', 'Ito Y', 'Noguchi S', 'Perez A', 'Rugo HS', 'Deleu I', 'Burris HA 3rd', 'Provencher L', 'Neven P', 'Gnant M', 'Shtivelband M', 'Wu C', 'Fan J', 'Feng W', 'Taran T', 'Baselga J']","['Androstadienes/adverse effects/*therapeutic use', 'Breast Neoplasms', 'Double-Blind Method', 'ErbB Receptors/metabolism', 'Everolimus', 'Female', 'Humans', 'Placebos', 'Sirolimus/adverse effects/*analogs & derivatives/therapeutic use', 'Survival Analysis']",https://pubmed.ncbi.nlm.nih.gov/25231953/
481,EXEMESTANE,22594760,Pharmacogenomics of third-generation aromatase inhibitors.,"['Turkistani A', 'Marsh S']","['Animals', 'Aromatase/genetics/*metabolism', 'Aromatase Inhibitors/adverse effects/pharmacokinetics/*therapeutic use', 'Breast Neoplasms/*drug therapy/enzymology/genetics', 'Female', 'Genotype', 'Humans', 'Patient Selection', '*Pharmacogenetics', 'Phenotype', 'Polymorphism, Genetic', 'Risk Assessment', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22594760/
482,EXEMESTANE,25495490,Adjuvant ovarian suppression in premenopausal breast cancer.,"['Francis PA', 'Regan MM', 'Fleming GF', 'Lang I', 'Ciruelos E', 'Bellet M', 'Bonnefoi HR', 'Climent MA', 'Da Prada GA', 'Burstein HJ', 'Martino S', 'Davidson NE', 'Geyer CE Jr', 'Walley BA', 'Coleman R', 'Kerbrat P', 'Buchholz S', 'Ingle JN', 'Winer EP', 'Rabaglio-Poretti M', 'Maibach R', 'Ruepp B', 'Giobbie-Hurder A', 'Price KN', 'Colleoni M', 'Viale G', 'Coates AS', 'Goldhirsch A', 'Gelber RD']","['Adult', 'Androstadienes/adverse effects/*therapeutic use', 'Antineoplastic Agents, Hormonal/adverse effects/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Aromatase Inhibitors/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy/radiotherapy/surgery', 'Chemotherapy, Adjuvant', 'Disease-Free Survival', 'Female', 'Humans', 'Mastectomy', 'Middle Aged', 'Premenopause', 'Tamoxifen/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25495490/
483,EXEMESTANE,27326977,Endocrine therapy for hormone treatment-naive advanced breast cancer.,"['Martin M', 'Lopez-Tarruella S', 'Gilarranz YJ']","['Anastrozole', 'Androstadienes/administration & dosage', 'Antineoplastic Agents, Hormonal/*administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Bevacizumab/administration & dosage', 'Breast Neoplasms/*drug therapy/*pathology', 'Clinical Trials, Phase II as Topic', 'Clinical Trials, Phase III as Topic', 'Estradiol/administration & dosage/analogs & derivatives', 'Female', 'Fulvestrant', 'Humans', 'Letrozole', 'Nitriles/administration & dosage', 'Piperazines/administration & dosage', 'Pyridines/administration & dosage', 'Randomized Controlled Trials as Topic', 'Tamoxifen/administration & dosage', 'Triazoles/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27326977/
484,EXEMESTANE,21617789,[Aromatase inhibitors and arthralgia].,"['Nagykalnai T', 'Landherr L', 'Meszaros E']","['Anastrozole', 'Androstadienes/adverse effects', 'Antineoplastic Agents, Hormonal/administration & dosage/*adverse effects', 'Aromatase Inhibitors/administration & dosage/*adverse effects', 'Arthralgia/*chemically induced/*therapy', 'Breast Neoplasms/*drug therapy', 'Chemotherapy, Adjuvant', 'Clinical Trials as Topic', 'Female', 'Humans', 'Letrozole', 'Medication Adherence', 'Neoplasms, Hormone-Dependent/*drug therapy', 'Nitriles/adverse effects', 'Postmenopause', 'Quality of Life', 'Risk Factors', 'Triazoles/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/21617789/
485,EXEMESTANE,24881463,Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.,"['Pagani O', 'Regan MM', 'Walley BA', 'Fleming GF', 'Colleoni M', 'Lang I', 'Gomez HL', 'Tondini C', 'Burstein HJ', 'Perez EA', 'Ciruelos E', 'Stearns V', 'Bonnefoi HR', 'Martino S', 'Geyer CE Jr', 'Pinotti G', 'Puglisi F', 'Crivellari D', 'Ruhstaller T', 'Winer EP', 'Rabaglio-Poretti M', 'Maibach R', 'Ruepp B', 'Giobbie-Hurder A', 'Price KN', 'Bernhard J', 'Luo W', 'Ribi K', 'Viale G', 'Coates AS', 'Gelber RD', 'Goldhirsch A', 'Francis PA']","['Adult', 'Androstadienes/adverse effects/*therapeutic use', 'Antineoplastic Agents, Hormonal/adverse effects/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Aromatase Inhibitors/adverse effects/therapeutic use', 'Breast Neoplasms/*drug therapy/radiotherapy/surgery', 'Chemotherapy, Adjuvant', 'Disease-Free Survival', 'Estradiol/blood', 'Female', 'Follow-Up Studies', 'Humans', 'Kaplan-Meier Estimate', 'Mastectomy', 'Middle Aged', 'Osteoporosis/chemically induced', 'Premenopause', 'Quality of Life', 'Tamoxifen/adverse effects/*therapeutic use', 'Triptorelin Pamoate/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24881463/
486,EXEMESTANE,26970130,Alternate dosing schedules for cancer chemopreventive agents.,"['Lazzeroni M', 'DeCensi A']","['Administration, Oral', 'Androstadienes/administration & dosage', 'Anticarcinogenic Agents/*administration & dosage', 'Antineoplastic Agents, Hormonal/*administration & dosage', 'Biomarkers, Tumor/analysis', 'Breast Neoplasms/chemistry/*prevention & control/surgery', 'Chemoprevention/methods', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Female', 'Humans', 'Ki-67 Antigen/analysis', 'Preoperative Care', 'Risk Factors', 'Tamoxifen/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/26970130/
487,EXEMESTANE,10551437,Exemestane.,"['Scott LJ', 'Wiseman LR']","['Androstadienes/pharmacokinetics/*therapeutic use', 'Antineoplastic Agents/pharmacokinetics/*therapeutic use', 'Breast Neoplasms/*drug therapy', 'Clinical Trials as Topic', 'Enzyme Inhibitors/pharmacokinetics/*therapeutic use', 'Female', 'Humans', 'Postmenopause/physiology']",https://pubmed.ncbi.nlm.nih.gov/10551437/
488,EXEMESTANE,28314691,"Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.","['Rugo HS', 'Seneviratne L', 'Beck JT', 'Glaspy JA', 'Peguero JA', 'Pluard TJ', 'Dhillon N', 'Hwang LC', 'Nangia C', 'Mayer IA', 'Meiller TF', 'Chambers MS', 'Sweetman RW', 'Sabo JR', 'Litton JK']","['Administration, Topical', 'Aged', 'Androstadienes/administration & dosage/adverse effects', 'Anti-Inflammatory Agents/administration & dosage/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/*adverse effects', 'Breast Neoplasms/chemistry/*drug therapy/pathology', 'Dexamethasone/administration & dosage/*therapeutic use', 'Drug Eruptions/etiology', 'Dyspnea/chemically induced', 'Everolimus/administration & dosage/*adverse effects', 'Female', 'Humans', 'Hyperglycemia/chemically induced', 'Middle Aged', 'Mouthwashes/therapeutic use', 'Neoplasm Metastasis', 'Pneumonia/chemically induced', 'Receptor, ErbB-2/analysis', 'Receptors, Estrogen/analysis', 'Receptors, Progesterone/analysis', 'Severity of Illness Index', 'Stomatitis/chemically induced/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/28314691/
489,EXEMESTANE,21922396,Initialization of adjuvant hormonal treatment for breast cancer.,"['Martinez Guisado A', 'Sanchez Munoz A', 'de la Cabeza Lomas Garrido M', 'Ruiz Borrego M', 'Bayo Calero J', 'de Toro Salas R', 'Gonzalez Mancha R', 'de la Haba Rodriguez J', 'Alba Conejo E']","['Adult', 'Age Factors', 'Aged', 'Anastrozole', 'Androstadienes/administration & dosage/adverse effects', 'Aromatase Inhibitors/*administration & dosage/adverse effects', 'Breast Neoplasms/*drug therapy/*mortality/pathology/surgery', 'Chemotherapy, Adjuvant', 'Disease-Free Survival', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Early Detection of Cancer', 'Female', 'Humans', 'Mastectomy/methods', 'Middle Aged', 'Neoplasm Staging', 'Nitriles/administration & dosage/adverse effects', 'Postmenopause/drug effects', 'Premenopause/drug effects', 'Prognosis', 'Randomized Controlled Trials as Topic', 'Risk Assessment', 'Survival Analysis', 'Tamoxifen/administration & dosage/adverse effects', 'Treatment Outcome', 'Triazoles/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/21922396/
490,EXEMESTANE,27107153,Are SOFT and TEXT results practice changing and how?,"['Pagani O', 'Regan MM', 'Francis PA']","['Adult', 'Androstadienes/*therapeutic use', 'Antineoplastic Agents/*therapeutic use', 'Aromatase Inhibitors/*therapeutic use', 'Breast Neoplasms/chemistry/*drug therapy', 'Clinical Trials, Phase III as Topic', 'Female', 'Humans', 'Ovary/drug effects', 'Premenopause', 'Randomized Controlled Trials as Topic', 'Receptor, ErbB-2/analysis', 'Tamoxifen/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27107153/
491,EXEMESTANE,18224388,Chemoprevention of breast cancer.,['Cuzick J'],"['Androstadienes/therapeutic use', 'Anticarcinogenic Agents/adverse effects/*therapeutic use', 'Aromatase Inhibitors/adverse effects/therapeutic use', 'Breast Neoplasms/*prevention & control', 'Chemoprevention', 'Clinical Trials as Topic', 'Female', 'Humans', 'Raloxifene Hydrochloride/therapeutic use', 'Tamoxifen/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18224388/
492,EXEMESTANE,27269946,Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.,"['Fribbens C', ""O'Leary B"", 'Kilburn L', 'Hrebien S', 'Garcia-Murillas I', 'Beaney M', 'Cristofanilli M', 'Andre F', 'Loi S', 'Loibl S', 'Jiang J', 'Bartlett CH', 'Koehler M', 'Dowsett M', 'Bliss JM', 'Johnston SR', 'Turner NC']","['Aged', 'Anastrozole', 'Androstadienes/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Breast Neoplasms/blood/*drug therapy/*genetics', 'DNA, Neoplasm/blood/genetics', 'Disease-Free Survival', 'Estradiol/administration & dosage/*analogs & derivatives/therapeutic use', 'Estrogen Receptor alpha/*blood/*genetics', 'Female', 'Fulvestrant', 'Humans', 'Middle Aged', 'Nitriles/administration & dosage', 'Piperazines/administration & dosage', 'Prospective Studies', 'Pyridines/administration & dosage', 'Retrospective Studies', 'Triazoles/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27269946/
493,EXEMESTANE,17461898,Neoadjuvant use of endocrine therapy in breast cancer.,"['Macaskill EJ', 'Dixon JM']","['Antineoplastic Agents, Hormonal/*therapeutic use', 'Aromatase Inhibitors/*therapeutic use', 'Breast Neoplasms/*drug therapy/surgery', 'Combined Modality Therapy', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Neoadjuvant Therapy/*methods', 'Pilot Projects', 'Randomized Controlled Trials as Topic', 'Receptors, Estrogen/drug effects', 'Survival Analysis', 'Tamoxifen/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/17461898/
494,EXEMESTANE,31494037,"Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.","['Giuliano M', 'Schettini F', 'Rognoni C', 'Milani M', 'Jerusalem G', 'Bachelot T', 'De Laurentiis M', 'Thomas G', 'De Placido P', 'Arpino G', 'De Placido S', 'Cristofanilli M', 'Giordano A', 'Puglisi F', 'Pistilli B', 'Prat A', 'Del Mastro L', 'Venturini S', 'Generali D']","['Aminopyridines/administration & dosage', 'Anastrozole/administration & dosage', 'Androstadienes/administration & dosage', 'Antineoplastic Agents, Hormonal/*administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Benzimidazoles/administration & dosage', 'Bevacizumab/administration & dosage', 'Breast Neoplasms/*drug therapy/*metabolism/pathology', 'Clinical Trials, Phase II as Topic', 'Clinical Trials, Phase III as Topic', 'Everolimus/administration & dosage', 'Female', 'Fulvestrant/administration & dosage', 'Humans', 'Letrozole/administration & dosage', 'Network Meta-Analysis', 'Paclitaxel/administration & dosage', 'Piperazines/administration & dosage', 'Postmenopause', 'Progression-Free Survival', 'Purines/administration & dosage', 'Pyridines/administration & dosage', 'Randomized Controlled Trials as Topic', 'Receptor, ErbB-2/metabolism', 'Receptors, Estrogen/metabolism', 'Receptors, Progesterone/metabolism']",https://pubmed.ncbi.nlm.nih.gov/31494037/
495,EXEMESTANE,24158787,Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.,"['Yardley DA', 'Noguchi S', 'Pritchard KI', 'Burris HA 3rd', 'Baselga J', 'Gnant M', 'Hortobagyi GN', 'Campone M', 'Pistilli B', 'Piccart M', 'Melichar B', 'Petrakova K', 'Arena FP', 'Erdkamp F', 'Harb WA', 'Feng W', 'Cahana A', 'Taran T', 'Lebwohl D', 'Rugo HS']","['Adult', 'Aged', 'Aged, 80 and over', 'Androstadienes/administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Bone Neoplasms/drug therapy/secondary', 'Breast Neoplasms/*drug therapy/metabolism/pathology', 'Disease-Free Survival', 'Double-Blind Method', 'Everolimus', 'Female', 'Humans', 'Liver Neoplasms/drug therapy/secondary', 'Lung Neoplasms/drug therapy/secondary', 'Middle Aged', 'Postmenopause', 'Receptors, Estrogen/metabolism', 'Receptors, Progesterone/metabolism', 'Sirolimus/administration & dosage/analogs & derivatives', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24158787/
496,EXEMESTANE,19945692,Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer.,"['Ghazi M', 'Roux C']","['Aromatase Inhibitors/*adverse effects', 'Bone Density Conservation Agents/administration & dosage', 'Breast Neoplasms/*drug therapy/*epidemiology', 'Female', 'Fractures, Bone/epidemiology/prevention & control', 'Humans', 'Osteoporosis, Postmenopausal/*chemically induced/*epidemiology', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/19945692/
497,trazodone,34994734,Treatment of insomnia - effect of trazodone and hypnotics on sleep.,"['Wichniak A', 'Wierzbicka AE', 'Jarema M']","['Humans', 'Hypnotics and Sedatives/therapeutic use', 'Sleep', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Sleep Quality', '*Trazodone/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/34994734/
498,trazodone,27744763,A review of trazodone use in psychiatric and medical conditions.,['Khouzam HR'],"['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Antidepressive Agents, Second-Generation/adverse effects/*therapeutic use', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Male', 'Mental Disorders/*drug therapy', 'Middle Aged', 'Selective Serotonin Reuptake Inhibitors/*therapeutic use', 'Trazodone/*pharmacology/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27744763/
499,trazodone,29761479,Antidepressants for insomnia in adults.,"['Everitt H', 'Baldwin DS', 'Stuart B', 'Lipinska G', 'Mayers A', 'Malizia AL', 'Manson CC', 'Wilson S']","['Adult', 'Antidepressive Agents/adverse effects/*therapeutic use', 'Antidepressive Agents, Tricyclic/adverse effects/therapeutic use', 'Fluoxetine/adverse effects/therapeutic use', 'Humans', 'Mianserin/adverse effects/therapeutic use', 'Paroxetine/adverse effects/therapeutic use', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/adverse effects/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Trazodone/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29761479/
500,trazodone,9262526,Antidepressant withdrawal reactions.,['Wolfe RM'],"['Adult', 'Amitriptyline/adverse effects', 'Antidepressive Agents/administration & dosage/*adverse effects', 'Antidepressive Agents, Tricyclic/adverse effects', 'Clomipramine/adverse effects', 'Cyclohexanols/adverse effects', 'Drug Administration Schedule', 'Female', 'Humans', 'Male', 'Monoamine Oxidase Inhibitors/adverse effects', 'Selective Serotonin Reuptake Inhibitors/adverse effects', '*Substance Withdrawal Syndrome/diagnosis/drug therapy', 'Trazodone/adverse effects', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/9262526/
501,trazodone,11199305,[Trazodone-induced priapism].,"['Correas Gomez MA', 'Portillo Martin JA', 'Martin Garcia B', 'Hernandez Rodriguez R', 'Gutierrez Banos JL', 'del Valle Schaan JI', 'Roca Edreira A', 'Rado Velazquez MA', 'Hernandez Castrillo A']","['Adult', 'Antidepressive Agents, Second-Generation/*adverse effects', 'Humans', 'Male', 'Priapism/*chemically induced', 'Trazodone/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11199305/
502,trazodone,33189083,Pharmacotherapies for sleep disturbances in dementia.,"['McCleery J', 'Sharpley AL']","['Alzheimer Disease/*complications', 'Azepines/adverse effects/therapeutic use', 'Caregiver Burden/drug therapy', 'Cognition/drug effects', 'Humans', 'Indenes/adverse effects/therapeutic use', 'Melatonin/adverse effects/therapeutic use', 'Pyridines/adverse effects/therapeutic use', 'Pyrimidines/adverse effects/therapeutic use', 'Randomized Controlled Trials as Topic', 'Sleep/drug effects/physiology', 'Sleep Wake Disorders/*drug therapy/etiology', 'Time Factors', 'Trazodone/adverse effects/therapeutic use', 'Triazoles/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33189083/
503,trazodone,3584080,Trazodone and priapism.,"['Warner MD', 'Peabody CA', 'Whiteford HA', 'Hollister LE']","['Adolescent', 'Adult', 'Age Factors', 'Dose-Response Relationship, Drug', 'Humans', 'Male', 'Middle Aged', 'Priapism/*chemically induced', 'Time Factors', 'Trazodone/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/3584080/
504,trazodone,6624973,Trazodone and priapism.,"['Scher M', 'Krieger JN', 'Juergens S']","['Combined Modality Therapy', 'Depressive Disorder/*drug therapy', 'Dose-Response Relationship, Drug', 'Humans', 'Male', 'Middle Aged', 'Piperazines/*adverse effects', 'Priapism/*chemically induced/therapy', 'Trazodone/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6624973/
505,trazodone,2310343,Trazodone-induced palinopsia.,"['Hughes MS', 'Lessell S']","['Adult', 'Afterimage/drug effects', 'Depression/drug therapy', 'Female', 'Hallucinations/*chemically induced', 'Humans', 'Male', 'Middle Aged', 'Trazodone/*adverse effects/therapeutic use', 'Vision Disorders/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/2310343/
506,trazodone,7021449,Trazodone in depression.,['Wheatley D'],"['Adult', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', 'Double-Blind Method', 'Female', 'Humans', 'Imipramine/therapeutic use', 'Male', 'Middle Aged', 'Piperazines/*administration & dosage', 'Sleep Stages/drug effects', 'Trazodone/*administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7021449/
507,trazodone,32888664,Trazodone-induced delirium: case report.,"['Pereira AT', 'Mota D', 'Ribeiro L', 'Rodrigues JD']","['Adult', 'Antidepressive Agents, Second-Generation/administration & dosage/*adverse effects', 'Delirium/*chemically induced', 'Female', 'Hospitalization', 'Humans', 'Trazodone/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32888664/
508,trazodone,7044154,Trazodone in depressed outpatients.,"['Rickels K', 'Case WG']","['Adult', 'Ambulatory Care', 'Amitriptyline/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy/psychology', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Piperazines/*therapeutic use', 'Trazodone/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7044154/
509,trazodone,38224591,Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis : A Randomized Clinical Trial.,"['Mehrotra R', 'Cukor D', 'McCurry SM', 'Rue T', 'Roumelioti ME', 'Heagerty PJ', 'Unruh M']","['Humans', '*Sleep Initiation and Maintenance Disorders/drug therapy', '*Trazodone/adverse effects', 'Renal Dialysis/adverse effects', 'Treatment Outcome', 'Research Design']",https://pubmed.ncbi.nlm.nih.gov/38224591/
510,trazodone,36634058,[Refractory ischemic priapism due to trazodone].,"['Vaesen F', 'Sempels M']","['Male', 'Humans', 'Adult', '*Priapism/chemically induced/drug therapy', 'Penis/surgery', '*Trazodone/adverse effects', 'Penile Erection']",https://pubmed.ncbi.nlm.nih.gov/36634058/
511,trazodone,3790881,Trazodone-induced mania.,"['Knobler HY', 'Itzchaky S', 'Emanuel D', 'Mester R', 'Maizel S']","['Adult', 'Aged', 'Bipolar Disorder/*chemically induced/complications/drug therapy', 'Depressive Disorder/drug therapy', 'Female', 'Humans', 'Male', 'Trazodone/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3790881/
512,trazodone,3236298,Antidepressant analgesia in rheumatoid arthritis.,"['Frank RG', 'Kashani JH', 'Parker JC', 'Beck NC', 'Brownlee-Duffeck M', 'Elliott TR', 'Haut AE', 'Atwood C', 'Smith E', 'Kay DR']","['Aged', 'Amitriptyline/therapeutic use', 'Antidepressive Agents/administration & dosage/*therapeutic use', 'Arthritis, Rheumatoid/complications/*drug therapy', 'Depression/drug therapy', 'Desipramine/therapeutic use', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Middle Aged', 'Pain/*drug therapy', 'Random Allocation', 'Trazodone/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3236298/
513,trazodone,38156419,Treatment of REM sleep behavior disorder with trazodone: report of 3 cases.,"['Barrow J', 'Vendrame M']","['Humans', '*Trazodone/therapeutic use', '*REM Sleep Behavior Disorder/drug therapy', 'Male', 'Female', 'Middle Aged', 'Polysomnography/drug effects', 'Adult', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38156419/
514,trazodone,3624508,Antidepressant-related akathisia.,"['Zubenko GS', 'Cohen BM', 'Lipinski JF Jr']","['Adult', '*Akathisia, Drug-Induced', 'Antidepressive Agents/*adverse effects/therapeutic use', 'Bipolar Disorder/complications/drug therapy', 'Depressive Disorder/complications/drug therapy', 'Female', 'Humans', 'Imipramine/adverse effects', 'Male', 'Middle Aged', 'Trazodone/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/3624508/
515,trazodone,2274996,A report of trazodone-associated laboratory abnormalities.,"['Perry PJ', 'Garvey MJ', 'Dunner DL', 'Rush AJ', 'Kyhl J']","['Double-Blind Method', 'Erythrocyte Count/drug effects', 'Female', 'Fluoxetine/*adverse effects/therapeutic use', 'Hematocrit/standards', 'Hemoglobins/*drug effects', 'Humans', 'Male', 'Reference Values', 'Trazodone/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2274996/
516,Telmisartan,37432701,Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.,"['Xie M', 'Tang T', 'Liang H']","['Humans', '*Antihypertensive Agents/therapeutic use', 'Losartan/pharmacology/therapeutic use', '*Hypertension/diagnosis/drug therapy', 'Telmisartan/pharmacology/therapeutic use', 'Irbesartan/pharmacology/therapeutic use', 'Angiotensin Receptor Antagonists/therapeutic use', 'Network Meta-Analysis', 'Hydrochlorothiazide/adverse effects', 'Valine/adverse effects', 'Drug Therapy, Combination', 'Angiotensin-Converting Enzyme Inhibitors/therapeutic use', 'Amlodipine/therapeutic use', 'Valsartan/therapeutic use', 'Tetrazoles/therapeutic use', 'Blood Pressure', 'Essential Hypertension/diagnosis/drug therapy/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37432701/
517,Telmisartan,32937023,Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.,"['Jin X', 'Kim MH', 'Han KH', 'Hong SJ', 'Ahn JC', 'Sung JH', 'Cho JM', 'Lee HC', 'Choi SY', 'Lee K', 'Kim WS', 'Rhee MY', 'Kim JH', 'Hong SP', 'Yoo BS', 'Cho EJ', 'Lee JH', 'Kim PJ', 'Park CG', 'Hyon MS', 'Shin JH', 'Lee SH', 'Sung KC', 'Hwang J', 'Kwon K', 'Chae IH', 'Seo JS', 'Kim H', 'Lee H', 'Cho Y', 'Kim HS']","['Aged', 'Amlodipine/*administration & dosage/therapeutic use', 'Antihypertensive Agents/therapeutic use', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Drug Combinations', 'Drug Therapy, Combination', '*Dyslipidemias/drug therapy', 'Female', 'Humans', '*Hypertension/drug therapy', 'Male', 'Middle Aged', 'Rosuvastatin Calcium/*administration & dosage/therapeutic use', 'Telmisartan/*administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32937023/
518,Telmisartan,30471331,Therapy resistance mediated by cancer stem cells.,"['Steinbichler TB', 'Dudas J', 'Skvortsov S', 'Ganswindt U', 'Riechelmann H', 'Skvortsova II']","['ATP-Binding Cassette Transporters/antagonists & inhibitors/genetics/metabolism', 'Chemoradiotherapy', 'DNA Repair/genetics', 'Drug Resistance, Neoplasm/drug effects/*genetics', 'Gene Expression Regulation, Neoplastic/drug effects/radiation effects', 'Humans', 'Neoplasms/*genetics/metabolism/therapy', 'Neoplastic Stem Cells/drug effects/*metabolism/radiation effects', 'Radiation Tolerance/drug effects/*genetics', 'Telmisartan/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30471331/
519,Telmisartan,26051689,Telmisartan.,"['Bakheit AH', 'Abd-Elgalil AA', 'Mustafa B', 'Haque A', 'Wani TA']","['Angiotensin II Type 1 Receptor Blockers/administration & dosage/adverse effects/*chemistry/pharmacokinetics', 'Animals', 'Antihypertensive Agents/administration & dosage/adverse effects/*chemistry/pharmacokinetics', 'Benzimidazoles/administration & dosage/adverse effects/*chemistry/pharmacokinetics', 'Benzoates/administration & dosage/adverse effects/*chemistry/pharmacokinetics', 'Blood Pressure/drug effects', 'Chemistry, Pharmaceutical', 'Drug Interactions', 'Drug Stability', 'Humans', 'Hypertension/drug therapy/physiopathology', 'Molecular Structure', 'Technology, Pharmaceutical/methods', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/26051689/
520,Telmisartan,38228033,Effects of telmisartan on metabolic syndrome components: a comprehensive review.,"['Imenshahidi M', 'Roohbakhsh A', 'Hosseinzadeh H']","['Humans', 'Telmisartan/pharmacology', 'Angiotensin Receptor Antagonists/pharmacology', '*Metabolic Syndrome/drug therapy', 'PPAR gamma/pharmacology', 'Prospective Studies', 'Angiotensin II Type 1 Receptor Blockers/pharmacology', 'Angiotensin-Converting Enzyme Inhibitors/pharmacology', 'Benzimidazoles/pharmacology', '*Hypertension/drug therapy', 'Antihypertensive Agents/pharmacology', 'Blood Pressure', 'Benzoates/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/38228033/
521,Telmisartan,38573089,Telmisartan-Induced Myotoxicity in Patients with Essential Hypertension.,"['Kara SC', 'Canpolat U']","['Humans', '*Myotoxicity', 'Telmisartan/adverse effects', 'Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors', 'Essential Hypertension/drug therapy', '*Drug-Related Side Effects and Adverse Reactions']",https://pubmed.ncbi.nlm.nih.gov/38573089/
522,Telmisartan,38319595,"Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double-blind, multicenter, therapeutic confirmatory, phase III clinical trial.","['Lee CJ', 'Kang WC', 'Ihm SH', 'Sohn IS', 'Woo JS', 'Kim JW', 'Hong SJ', 'Choi JH', 'Suh JW', 'Seo JB', 'Doh JH', 'Son JW', 'Park JH', 'Lee JH', 'Hong YJ', 'Heo JH', 'Shin J', 'Kang SM']","['Humans', 'Anticholesteremic Agents/therapeutic use', 'Cholesterol, LDL', 'Double-Blind Method', 'Drug Therapy, Combination/adverse effects', '*Dyslipidemias/drug therapy', '*Ezetimibe/therapeutic use', '*Hypertension/drug therapy', '*Rosuvastatin Calcium/therapeutic use', '*Telmisartan/therapeutic use', 'Treatment Outcome', 'Antihypertensive Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38319595/
523,Telmisartan,9878991,Telmisartan.,"['McClellan KJ', 'Markham A']","['*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/pharmacology/*therapeutic use', 'Animals', 'Antihypertensive Agents/pharmacokinetics/therapeutic use', 'Benzimidazoles/adverse effects/pharmacology/*therapeutic use', 'Benzoates/adverse effects/pharmacology/*therapeutic use', 'Biotransformation', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Half-Life', 'Humans', 'Hypertension/*drug therapy', 'Intestinal Absorption', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/9878991/
524,Telmisartan,33578449,An insight into the role of telmisartan as PPAR-gamma/alpha dual activator in the management of nonalcoholic fatty liver disease.,"['Devan AR', 'Nair B', 'Kumar AR', 'Nath LR']","['Humans', 'Liver', '*Non-alcoholic Fatty Liver Disease/drug therapy/etiology/metabolism', 'PPAR alpha/agonists/metabolism', 'PPAR gamma/agonists/metabolism', 'Telmisartan/metabolism/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33578449/
525,Telmisartan,39426836,"Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial.","['Rodgers A', 'Salam A', 'Schutte AE', 'Cushman WC', 'de Silva HA', 'Di Tanna GL', 'Grobbee DE', 'Narkiewicz K', 'Ojji DB', 'Poulter NR', 'Schlaich MP', 'Oparil S', 'Spiering W', 'Williams B', 'Wright JT Jr', 'Lakshman P', 'Uluwattage W', 'Hay P', 'Pereira T', 'Amarasena N', 'Ranasinghe G', 'Gianacas C', 'Shanthakumar M', 'Liu X', 'Wang N', 'Gnanenthiran SR', 'Whelton PK']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', '*Amlodipine/administration & dosage/adverse effects', '*Antihypertensive Agents/administration & dosage/adverse effects/therapeutic use', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Drug Combinations', '*Hypertension/drug therapy', '*Indapamide/administration & dosage/adverse effects/therapeutic use', '*Telmisartan/administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39426836/
526,Telmisartan,31965140,"Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries.","['Dehghan M', 'Mente A', 'Rangarajan S', 'Mohan V', 'Lear S', 'Swaminathan S', 'Wielgosz A', 'Seron P', 'Avezum A', 'Lopez-Jaramillo P', 'Turbide G', 'Chifamba J', 'AlHabib KF', 'Mohammadifard N', 'Szuba A', 'Khatib R', 'Altuntas Y', 'Liu X', 'Iqbal R', 'Rosengren A', 'Yusuf R', 'Smuts M', 'Yusufali A', 'Li N', 'Diaz R', 'Yusoff K', 'Kaur M', 'Soman B', 'Ismail N', 'Gupta R', 'Dans A', 'Sheridan P', 'Teo K', 'Anand SS', 'Yusuf S']","['Adult', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage', 'Cardiovascular Diseases/blood/drug therapy/*metabolism/*mortality', 'Eggs/*analysis', 'Female', 'Humans', 'Lipids/*blood', 'Male', 'Middle Aged', 'Proportional Hazards Models', 'Prospective Studies', 'Ramipril/administration & dosage', 'Telmisartan/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/31965140/
527,Telmisartan,17666193,Prevention of stroke in patients with hypertension.,['Dahlof B'],"['Angiotensin II Type 1 Receptor Blockers/administration & dosage/*therapeutic use', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*therapeutic use', 'Antihypertensive Agents/administration & dosage/*therapeutic use', 'Benzimidazoles/administration & dosage/*therapeutic use', 'Benzoates/administration & dosage/*therapeutic use', 'Europe/epidemiology', 'Humans', 'Hypertension/*complications', 'Stroke/complications/mortality/*prevention & control', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/17666193/
528,Telmisartan,39215620,Low-Dose Triple-Pill vs Standard-Care Protocols for Hypertension Treatment in Nigeria: A Randomized Clinical Trial.,"['Ojji DB', 'Salam A', 'Sani MU', 'Ogah OS', 'Schutte AE', 'Huffman MD', 'Pant R', 'Ghosh A', 'Dhurjati R', 'Lakshmi JK', 'Ripiye NR', 'Orji IA', 'Kana SA', 'Abdussalam T', 'Olawumi AL', 'Alfa IM', 'Orimolade OA', 'Ajayi MO', 'Rodgers A']","['Adult', 'Female', 'Humans', 'Male', 'Middle Aged', '*Amlodipine/administration & dosage/adverse effects', '*Antihypertensive Agents/administration & dosage/adverse effects', 'Black People', '*Blood Pressure/drug effects', 'Drug Combinations', '*Hypertension/diagnosis/drug therapy/epidemiology', '*Indapamide/administration & dosage/adverse effects', 'Nigeria/epidemiology', '*Telmisartan/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/39215620/
529,Telmisartan,27715071,[Current position of a fixed combination telmisartan with amlodipine in treatment of essential arterial hypertension].,['Sliva J'],"['Amlodipine/administration & dosage/*therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Benzimidazoles/administration & dosage/*therapeutic use', 'Benzoates/administration & dosage/*therapeutic use', 'Drug Combinations', 'Essential Hypertension', 'Humans', 'Hypertension/*drug therapy', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/27715071/
530,Telmisartan,39217570,Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension.,"['Rodgers A', 'Salam A', 'Schutte AE', 'Cushman WC', 'de Silva HA', 'Di Tanna GL', 'Grobbee D', 'Narkiewicz K', 'Ojji DB', 'Poulter NR', 'Schlaich MP', 'Oparil S', 'Spiering W', 'Williams B', 'Wright JT Jr', 'Gutierez A', 'Sanni A', 'Lakshman P', 'McMullen D', 'Ranasinghe G', 'Gianacas C', 'Shanthakumar M', 'Liu X', 'Wang N', 'Whelton P']","['Humans', '*Hypertension/drug therapy', 'Male', 'Female', 'Middle Aged', 'Double-Blind Method', '*Amlodipine/administration & dosage/adverse effects', '*Indapamide/administration & dosage/adverse effects', '*Antihypertensive Agents/administration & dosage/adverse effects', '*Telmisartan/administration & dosage', '*Drug Combinations', 'Treatment Outcome', 'Aged', 'Blood Pressure/drug effects', 'Dose-Response Relationship, Drug', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/39217570/
531,Telmisartan,17703634,Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension?,"['Maillard MP', 'Burnier M']","['Angiotensin II Type 1 Receptor Blockers/*pharmacology/therapeutic use', 'Antihypertensive Agents/*pharmacology/therapeutic use', 'Benzimidazoles/*pharmacology/therapeutic use', 'Benzoates/*pharmacology/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Hydrochlorothiazide/*pharmacology/therapeutic use', 'Hypertension/*drug therapy', 'Randomized Controlled Trials as Topic', 'Renin-Angiotensin System/drug effects', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/17703634/
532,Telmisartan,18221077,"Telmisartan, its potential therapeutic implications in cardiometabolic disorders.","['Yamagishi S', 'Nakamura K']","['Angiotensin II Type 1 Receptor Blockers/*therapeutic use', 'Animals', 'Benzimidazoles/*therapeutic use', 'Benzoates/*therapeutic use', 'Cardiovascular Diseases/*prevention & control', 'Diabetic Retinopathy/*drug therapy', 'Humans', '*Insulin Resistance', 'PPAR gamma/drug effects', 'Receptor for Advanced Glycation End Products', 'Receptors, Immunologic/drug effects', 'Renin-Angiotensin System/drug effects', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/18221077/
533,Telmisartan,30993607,The Possible Role of the Angiotensin System in the Pathophysiology of Schizophrenia: Implications for Pharmacotherapy.,"['Oh SJ', 'Fan X']","['Angiotensin II Type 1 Receptor Blockers/*therapeutic use', 'Cytokines/blood', 'Humans', 'Neurotransmitter Agents/*metabolism', 'Renin-Angiotensin System/*drug effects/immunology', 'Schizophrenia/*drug therapy/etiology/immunology/metabolism', 'Telmisartan/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30993607/
534,Telmisartan,15868116,Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers.,"['Kintscher U', 'Unger T']","['Angiotensin II Type 1 Receptor Blockers/*pharmacology/therapeutic use', 'Antihypertensive Agents/*pharmacology/therapeutic use', 'Benzimidazoles/pharmacology/therapeutic use', 'Benzoates/pharmacology/therapeutic use', 'Diabetes Mellitus, Type 2/*complications/*drug therapy', 'Diabetic Angiopathies/*prevention & control', 'Humans', 'Insulin Resistance/physiology', 'PPAR gamma/physiology', 'Renin-Angiotensin System/drug effects', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/15868116/
535,Telmisartan,35851888,"RP-HPLC method development and validation for simultaneous estimation of telmisartan, rosuvastatin calcium, and amlodipine besylate in combination.","['Mistry RP', 'Shah C', 'Jat R']","['*Amlodipine/therapeutic use', 'Antihypertensive Agents/therapeutic use', 'Chromatography, High Pressure Liquid', 'Humans', '*Hypertension/drug therapy', 'Rosuvastatin Calcium/therapeutic use', 'Telmisartan/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35851888/
536,Valdecoxib,15270001,[Etoricoxib (Arcoxia)].,"['Leclercq P', 'Malaise MG']","['Administration, Oral', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*therapeutic use', 'Arthritis, Gouty/*drug therapy', 'Arthritis, Rheumatoid/*drug therapy', 'Cyclooxygenase 2', 'Etoricoxib', 'Humans', 'Isoenzymes/antagonists & inhibitors', 'Membrane Proteins', 'Osteoarthritis/*drug therapy', 'Prostaglandin-Endoperoxide Synthases', 'Pyridines/administration & dosage/adverse effects/*therapeutic use', 'Sulfones/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15270001/
537,Valdecoxib,18182814,Etoricoxib-induced erythema-multiforme-like eruption.,"['Thirion L', 'Nikkels AF', 'Pierard GE']","['Aged', 'Arthritis/drug therapy', 'Cyclooxygenase 2 Inhibitors/*adverse effects', 'Drug Eruptions/*etiology/pathology', 'Erythema Multiforme/*chemically induced/pathology', 'Etoricoxib', 'Humans', 'Male', 'Pyridines/*adverse effects', 'Skin/pathology', 'Sulfones/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/18182814/
538,Valdecoxib,27697053,Nitric Oxide-NASIDS Donor Prodrugs as Hybrid Safe Anti-inflammatory Agents.,"['Abdellatif KR', 'Abdelall EK', 'Bakr RB']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/chemistry/*therapeutic use', 'Humans', 'Inflammation/*drug therapy', 'Molecular Structure', 'Nitric Oxide/chemistry/*therapeutic use', 'Prodrugs/chemistry/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27697053/
539,Valdecoxib,27150366,Medicinal Chemistry Perspective of Fused Isoxazole Derivatives.,"['Barmade MA', 'Murumkar PR', 'Sharma MK', 'Yadav MR']","['Antineoplastic Agents/chemistry/therapeutic use', 'Cardiovascular Diseases/drug therapy', 'Central Nervous System Diseases/drug therapy', '*Chemistry, Pharmaceutical', 'Humans', 'Hypoglycemic Agents/chemistry/therapeutic use', 'Isoxazoles/*chemistry/pharmacology/therapeutic use', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/27150366/
540,Valdecoxib,19667717,COX-2 selective inhibitors and heart health.,"['Simon LS', 'White WB']","['Adult', 'Cardiovascular Diseases/*chemically induced', 'Celecoxib', 'Child', 'Cyclooxygenase 2 Inhibitors/*adverse effects', 'Humans', 'Hypertension/chemically induced', 'Isoxazoles/adverse effects', 'Lactones/*adverse effects', 'Meta-Analysis as Topic', 'Prospective Studies', 'Pyrazoles/adverse effects', 'Randomized Controlled Trials as Topic', 'Sulfonamides/adverse effects', 'Sulfones/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/19667717/
541,Valdecoxib,12269850,Valdecoxib.,"['Ormrod D', 'Wellington K', 'Wagstaff AJ']","['Arthritis/drug therapy/metabolism', 'Clinical Trials as Topic/statistics & numerical data', 'Dysmenorrhea/drug therapy/metabolism', 'Female', 'Humans', 'Isoxazoles/chemistry/pharmacokinetics/*therapeutic use', 'Pain/*drug therapy/metabolism', 'Sulfonamides/chemistry/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12269850/
542,Valdecoxib,12852704,Valdecoxib: a review.,"['Chavez ML', 'DeKorte CJ']","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/*therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Clinical Trials as Topic', 'Dysmenorrhea/drug therapy', 'Enzyme Inhibitors/pharmacology/therapeutic use', 'Female', 'Humans', 'Isoxazoles/*pharmacology/*therapeutic use', 'Male', 'Osteoarthritis/drug therapy', 'Pain, Postoperative/drug therapy', 'Sulfonamides/*pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12852704/
543,Valdecoxib,12466002,Etoricoxib.,"['Cochrane DJ', 'Jarvis B', 'Keating GM']","['Administration, Oral', 'Arthritis/drug therapy', 'Back Pain/drug therapy', 'Clinical Trials as Topic', 'Cyclooxygenase 1', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/adverse effects/pharmacology/*therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Etoricoxib', 'Gout/drug therapy', 'Humans', 'Isoenzymes/antagonists & inhibitors', 'Membrane Proteins', 'Oral Surgical Procedures/adverse effects', 'Pain, Postoperative/drug therapy/etiology', 'Prostaglandin-Endoperoxide Synthases', 'Pyridines/adverse effects/pharmacology/*therapeutic use', 'Sulfones/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12466002/
544,Valdecoxib,15182039,[Valdecoxib (Bextra)].,"['Scheen AJ', 'Malaise M']","['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use', 'Dysmenorrhea/drug therapy', 'Enzyme Inhibitors/administration & dosage/*therapeutic use', 'Female', 'Humans', 'Infusions, Intravenous', 'Injections, Intramuscular', 'Isoxazoles/administration & dosage/*therapeutic use', 'Osteoarthritis/drug therapy', 'Pain, Postoperative/drug therapy', 'Prodrugs', 'Sulfonamides/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15182039/
545,Valdecoxib,27710942,Crystal structure of rofecoxib bound to human cyclooxygenase-2.,"['Orlando BJ', 'Malkowski MG']","['Amino Acid Motifs', 'Binding Sites', 'Celecoxib/*chemistry', 'Crystallography, X-Ray', 'Cyclooxygenase 2/*chemistry/genetics/metabolism', 'Cyclooxygenase 2 Inhibitors/*chemistry', 'Gene Expression', 'Humans', 'Kinetics', 'Lactones/*chemistry', 'Models, Molecular', 'Protein Binding', 'Protein Conformation, alpha-Helical', 'Protein Conformation, beta-Strand', 'Protein Interaction Domains and Motifs', 'Recombinant Proteins/chemistry/genetics/metabolism', 'Safety-Based Drug Withdrawals', 'Substrate Specificity', 'Sulfones/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/27710942/
546,Valdecoxib,12198983,Selecting new drugs for pain control: evidence-based decisions or clinical impressions?,['Jeske AH'],"['Acute Disease', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use', 'Chronic Disease', 'Clinical Trials as Topic/standards', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use', 'Evidence-Based Medicine', 'Facial Pain/*drug therapy', 'Humans', 'Isoenzymes/antagonists & inhibitors', 'Lactones/administration & dosage/*therapeutic use', 'Membrane Proteins', 'Oral Surgical Procedures/adverse effects', 'Pain, Postoperative/*drug therapy/etiology', 'Prostaglandin-Endoperoxide Synthases', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/12198983/
547,Valdecoxib,15335413,Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations.,"['Lazzaroni M', 'Bianchi Porro G']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Cyclooxygenase Inhibitors/*adverse effects', 'Gastrointestinal Diseases/*chemically induced', 'Humans', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/15335413/
548,Valdecoxib,12911075,Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population.,"['Smith HS', 'Baird W']","['Analgesics, Non-Narcotic/pharmacology/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Cyclooxygenase Inhibitors/pharmacology/*therapeutic use', 'Diclofenac/analogs & derivatives', 'Dose-Response Relationship, Drug', 'Etoricoxib', 'Humans', 'Isoxazoles/therapeutic use', 'Meloxicam', 'Organic Chemicals/therapeutic use', 'Pain/*drug therapy/physiopathology', 'Palliative Care/*methods', 'Pyridines/therapeutic use', 'Sulfonamides/therapeutic use', 'Sulfones/therapeutic use', 'Thiazines/pharmacology/*therapeutic use', 'Thiazoles/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12911075/
549,Valdecoxib,16082427,Gateways to clinical trials.,"['Bayes M', 'Rabasseda X', 'Prous JR']","['*Clinical Trials as Topic', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/16082427/
550,Valdecoxib,16202197,"Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications.","['Klasser GD', 'Epstein J']","['Acute Disease', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Celecoxib', 'Chronic Disease', 'Clinical Trials as Topic', 'Cyclooxygenase 2 Inhibitors/adverse effects', 'Humans', 'Isoxazoles/adverse effects', 'Lactones/adverse effects', 'Myocardial Infarction/*chemically induced', 'Peptic Ulcer/chemically induced', 'Pyrazoles/adverse effects', 'Sulfonamides/adverse effects', 'Sulfones/adverse effects', 'Toothache/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16202197/
551,Valdecoxib,15279595,The second generation of COX-2 inhibitors: clinical pharmacological point of view.,['Stichtenoth DO'],"['Arthritis/chemically induced', 'Cardiovascular Diseases/chemically induced', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/adverse effects/pharmacokinetics/*pharmacology', 'Gastrointestinal Diseases/chemically induced', 'Humans', 'Isoenzymes/*antagonists & inhibitors/chemistry', 'Membrane Proteins', 'Prostaglandin-Endoperoxide Synthases/chemistry']",https://pubmed.ncbi.nlm.nih.gov/15279595/
552,Valdecoxib,20524091,Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?,['Elliott WJ'],"['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacology/therapeutic use', 'Blood Pressure/*drug effects', 'Celecoxib', 'Cyclooxygenase 2 Inhibitors/*adverse effects/pharmacology/therapeutic use', 'Diclofenac/adverse effects/analogs & derivatives', 'Etoricoxib', 'Humans', 'Hypertension/*chemically induced', 'Isoxazoles/adverse effects', 'Lactones/adverse effects', 'Pyrazoles/adverse effects', 'Pyridines/adverse effects/pharmacology/therapeutic use', 'Risk', 'Risk Factors', 'Sulfonamides/adverse effects', 'Sulfones/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20524091/
553,Valdecoxib,37254803,Pharmacological inhibition of TRPV2 attenuates phagocytosis and lipopolysaccharide-induced migration of primary macrophages.,"['Raudszus R', 'Paulig A', 'Urban N', 'Deckers A', 'Grassle S', 'Vanderheiden S', 'Jung N', 'Brase S', 'Schaefer M', 'Hill K']","['Humans', 'Rats', 'Animals', '*Lipopolysaccharides/pharmacology', 'HEK293 Cells', '*Macrophages', 'Phagocytosis', 'Gene Expression', 'TRPV Cation Channels/genetics']",https://pubmed.ncbi.nlm.nih.gov/37254803/
554,Valdecoxib,23517091,Valdecoxib : the rise and fall of a COX-2 inhibitor.,"['Atukorala I', 'Hunter DJ']","['Animals', 'Arthritis, Rheumatoid/*drug therapy', 'Cyclooxygenase 2 Inhibitors/*administration & dosage/adverse effects', 'Humans', 'Isoxazoles/*administration & dosage/adverse effects', 'Osteoarthritis/*drug therapy', 'Sulfonamides/*administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23517091/
555,medroxyprogesterone,7090370,The menopause.,['Brenner PF'],"['Adult', 'Aging/drug effects', 'Arteriosclerosis/prevention & control', 'Calcium/therapeutic use', 'Climacteric/drug effects', 'Estrogens/adverse effects/therapeutic use', 'Female', 'Humans', 'Medroxyprogesterone/therapeutic use', '*Menopause/drug effects', 'Middle Aged', 'Osteoporosis/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/7090370/
556,medroxyprogesterone,1827623,The treatment of precocious puberty.,"['Wheeler MD', 'Styne DM']","['Androgen Antagonists/therapeutic use', 'Delayed-Action Preparations', 'Female', 'Gonadotropin-Releasing Hormone/administration & dosage/analogs & derivatives/therapeutic use', 'Humans', 'Ketoconazole/therapeutic use', 'Male', 'Medroxyprogesterone/analogs & derivatives/therapeutic use', 'Medroxyprogesterone Acetate', 'Puberty, Precocious/*drug therapy/psychology', 'Testolactone/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1827623/
557,medroxyprogesterone,22587648,Contraception and antiepileptic drugs.,"['Guillemette T', 'Yount SM']","['Anticonvulsants/*adverse effects/therapeutic use', 'Contraceptive Agents, Female/administration & dosage/*adverse effects', 'Drug Interactions', 'Epilepsy/drug therapy', 'Female', 'Health Knowledge, Attitudes, Practice', 'Humans', 'Medroxyprogesterone Acetate/administration & dosage/*adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/22587648/
558,medroxyprogesterone,20352562,Injectable contraception.,['Roy G'],"['Bone Density/drug effects', 'Contraceptive Agents, Female/*administration & dosage/adverse effects/*therapeutic use', 'Contraindications', 'Delayed-Action Preparations/administration & dosage/adverse effects/therapeutic use', 'Female', 'Humans', 'Injections', 'Medroxyprogesterone Acetate/administration & dosage/adverse effects/therapeutic use', 'Risk Assessment']",https://pubmed.ncbi.nlm.nih.gov/20352562/
559,medroxyprogesterone,2934522,Endometriosis.,"['Garner CH', 'Webster BW']","['Abortion, Spontaneous/etiology', 'Adult', 'Danazol/adverse effects/therapeutic use', 'Diagnosis, Differential', 'Diethylstilbestrol/adverse effects/therapeutic use', 'Dinoprost', '*Endometriosis/complications/diagnosis/etiology/nursing/pathology/physiopathology/psychology/surgery/therapy', 'Endometrium/pathology', 'Female', 'Humans', 'Infertility, Female/etiology', 'Male', 'Medroxyprogesterone/adverse effects/analogs & derivatives/therapeutic use', 'Medroxyprogesterone Acetate', 'Methyltestosterone/adverse effects/therapeutic use', 'Pain/drug therapy', 'Patient Education as Topic', 'Peritoneum/pathology', 'Phagocytosis', 'Pregnancy', 'Prostaglandins F/physiology', 'Spermatozoa']",https://pubmed.ncbi.nlm.nih.gov/2934522/
560,medroxyprogesterone,3158512,"Epilepsy, sex hormones, and antiepileptic drugs.","['Mattson RH', 'Cramer JA']","['Anovulation/physiopathology', 'Anticonvulsants/adverse effects/metabolism/*pharmacology', 'Contraceptives, Oral/pharmacology', 'Drug Interactions', 'Epilepsy/drug therapy/metabolism/*physiopathology', 'Erectile Dysfunction/chemically induced/physiopathology', 'Feedback', 'Female', 'Gonadal Steroid Hormones/metabolism/*physiology', 'Humans', 'Hypothalamo-Hypophyseal System/physiopathology', 'Kinetics', 'Libido/drug effects/physiology', 'Limbic System/physiopathology', 'Male', 'Medroxyprogesterone/analogs & derivatives/therapeutic use', 'Medroxyprogesterone Acetate', 'Menstruation', 'Pregnancy', 'Progesterone/blood']",https://pubmed.ncbi.nlm.nih.gov/3158512/
561,medroxyprogesterone,12380408,Hormones and weight change.,['Pelkman C'],"['Contraceptive Agents, Female/administration & dosage/*adverse effects', 'Delayed-Action Preparations/adverse effects', 'Double-Blind Method', 'Energy Intake/drug effects', 'Energy Metabolism/drug effects', 'Female', 'Humans', 'Injections, Intramuscular', 'Medroxyprogesterone Acetate/administration & dosage/*adverse effects', 'Randomized Controlled Trials as Topic', 'United States', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/12380408/
562,medroxyprogesterone,20601618,Menstrual manipulation: options for suppressing the cycle.,"['Hicks CW', 'Rome ES']","['Administration, Intravaginal', 'Contraceptive Agents, Female/administration & dosage/adverse effects/therapeutic use', 'Contraceptive Devices, Female', 'Contraceptives, Oral, Hormonal/administration & dosage/adverse effects/*therapeutic use', 'Desogestrel/administration & dosage/adverse effects/therapeutic use', 'Female', 'Humans', 'Intrauterine Devices', 'Medroxyprogesterone Acetate/administration & dosage/adverse effects/therapeutic use', 'Menstruation/*drug effects', 'Menstruation Disturbances/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20601618/
563,medroxyprogesterone,10986575,"Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the treatment of paraphilia.","['Reilly DR', 'Delva NJ', 'Hudson RW']","['Administration, Oral', 'Androgen Antagonists/*administration & dosage/adverse effects', 'Cyproterone Acetate/*administration & dosage/adverse effects', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Humans', 'Injections, Intramuscular', 'Leuprolide/*administration & dosage/adverse effects', 'Male', 'Medroxyprogesterone/*administration & dosage/adverse effects', 'Paraphilic Disorders/diagnosis/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/10986575/
564,medroxyprogesterone,6451987,Depo-Provera: a critical analysis.,['Minkin S'],"['Abnormalities, Drug-Induced/etiology', 'Animals', 'Breast Feeding', 'Contraceptive Agents, Female/*adverse effects', 'Dogs', 'Female', 'Haplorhini', 'Humans', 'Medroxyprogesterone/adverse effects/*analogs & derivatives', 'Medroxyprogesterone Acetate', 'Milk, Human/*drug effects', 'Neoplasms/*chemically induced', 'Pregnancy', 'United States', 'United States Food and Drug Administration', 'Uterine Neoplasms/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/6451987/
565,medroxyprogesterone,11723414,Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy.,"['Figueroa-Casas PR', 'Ettinger B', 'Delgado E', 'Javkin A', 'Vieder C']","['Clinical Trials as Topic', 'Drug Administration Schedule', 'Endometrial Hyperplasia/*chemically induced/*drug therapy', 'Estrogen Replacement Therapy/*adverse effects', 'Female', 'Humans', 'Medroxyprogesterone Acetate/administration & dosage/*therapeutic use', 'Progesterone Congeners/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11723414/
566,medroxyprogesterone,29172413,Contraception Update: Progestin-Only Implants and Injections.,"['Deshmukh P', 'Antell K', 'Brown EJ']","['Contraceptive Agents, Female/administration & dosage/adverse effects/*therapeutic use', 'Device Removal', '*Drug Implants', 'Drug Interactions', '*Family Planning Services', '*Family Practice', 'Female', 'Humans', 'Injections', 'Medroxyprogesterone Acetate/administration & dosage/adverse effects/*therapeutic use', '*Progestins', 'Weight Gain']",https://pubmed.ncbi.nlm.nih.gov/29172413/
567,medroxyprogesterone,2148027,Current status of high-dose progestins in breast cancer.,"['Abrams JS', 'Parnes H', 'Aisner J']","['Antineoplastic Agents/administration & dosage/therapeutic use', 'Breast Neoplasms/*drug therapy', 'Female', 'Humans', 'Medroxyprogesterone/administration & dosage/analogs & derivatives/therapeutic use', 'Medroxyprogesterone Acetate', 'Megestrol/administration & dosage/adverse effects/analogs & derivatives/therapeutic use', 'Megestrol Acetate', 'Progesterone Congeners/*administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2148027/
568,medroxyprogesterone,9609206,Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.,['Kaunitz AM'],"['Adolescent', 'Adult', 'Bone Density/drug effects', 'Carbamazepine/pharmacology', 'Clinical Trials as Topic', 'Contraception/*methods', 'Contraceptive Agents, Female/*administration & dosage/adverse effects', 'Contraindications', 'Delayed-Action Preparations', 'Drug Interactions', 'Female', 'Fertility/drug effects', 'Humans', 'Injections, Intramuscular', 'Lactation/drug effects', 'Libido/drug effects', 'Medroxyprogesterone Acetate/*administration & dosage/adverse effects', 'Menstruation Disturbances/chemically induced', 'Premenopause', 'Risk Factors', 'Smoking/adverse effects', 'Thromboembolism/chemically induced', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9609206/
569,medroxyprogesterone,31436540,Postpartum hormonal contraception in breastfeeding women.,"['Stanton TA', 'Blumenthal PD']","['*Breast Feeding', 'Contraception/*methods', 'Contraceptive Agents/adverse effects/*therapeutic use', 'Delayed-Action Preparations', 'Female', 'Gynecology/standards/trends', '*Health Knowledge, Attitudes, Practice', 'Hormonal Contraception', 'Humans', 'Infant', 'Infant, Newborn', 'Intrauterine Devices/adverse effects', 'Lactation/drug effects', 'Levonorgestrel/administration & dosage', 'Medroxyprogesterone Acetate/adverse effects/therapeutic use', 'Milk, Human/drug effects', 'Postpartum Period', 'Practice Guidelines as Topic', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/31436540/
570,medroxyprogesterone,5508511,"Medroxyprogesterone acetate and carbohydrate metabolism: measurement of glucose, insulin, and growth hormone during 6 months' time.","['Spellacy WN', 'McLeod AG', 'Buhi WC', 'Birk SA', 'McCreary SA']","['Adolescent', 'Adult', 'Age Factors', 'Blood Glucose/*analysis', 'Body Weight', '*Carbohydrate Metabolism', 'Contraceptive Agents/administration & dosage/*pharmacology', 'Female', 'Glucose Tolerance Test', 'Growth Hormone/*blood', 'Humans', 'Injections, Intramuscular', 'Insulin/*blood', 'Medroxyprogesterone/administration & dosage/*pharmacology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/5508511/
571,medroxyprogesterone,2525977,Injectable contraception.,['Kaunitz AM'],"['Contraceptive Agents, Female/*administration & dosage', 'Delayed-Action Preparations', 'Female', 'Humans', 'Injections, Intramuscular', 'Medroxyprogesterone/administration & dosage/analogs & derivatives', 'Medroxyprogesterone Acetate', 'Norethindrone/administration & dosage/analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/2525977/
572,medroxyprogesterone,2946605,Assessment of the potency of orally administered progestins in women.,"['King RJ', 'Whitehead MI']","['Administration, Oral', 'Adult', 'Age Factors', 'DNA/biosynthesis', 'Dose-Response Relationship, Drug', 'Drug Evaluation', 'Dydrogesterone/pharmacology', 'Endometrium/*drug effects/enzymology/metabolism', 'Estradiol Dehydrogenases/analysis', 'Female', 'Glycogen/metabolism', 'Humans', 'Isocitrate Dehydrogenase/analysis', 'Medroxyprogesterone/analogs & derivatives/pharmacology', 'Medroxyprogesterone Acetate', 'Menopause', 'Menstrual Cycle/drug effects', 'Middle Aged', 'Norethindrone/pharmacology', 'Norgestrel/pharmacology', 'Progesterone/pharmacology', 'Progesterone Congeners/administration & dosage/*pharmacology', 'Reference Values']",https://pubmed.ncbi.nlm.nih.gov/2946605/
573,medroxyprogesterone,31935387,An exploratory study of depot-medroxyprogesterone acetate and bone mineral density in adolescent and young adult women with cerebral palsy.,"['Roden RC', 'Noritz G', 'McKnight ER', 'Bonny AE']","['Adolescent', 'Bone Density/*drug effects', 'Case-Control Studies', 'Cerebral Palsy/*complications', 'Child, Preschool', 'Cohort Studies', 'Contraceptive Agents, Female/administration & dosage/*adverse effects', 'Cross-Sectional Studies', 'Female', 'Humans', 'Medroxyprogesterone Acetate/administration & dosage/*adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31935387/
574,medroxyprogesterone,2896429,Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone.,"['McConaghy N', 'Blaszczynski A', 'Kidson W']","['Adolescent', 'Adult', '*Behavior Therapy', 'Combined Modality Therapy', '*Desensitization, Psychologic', 'Humans', 'Imagination', 'Male', 'Medroxyprogesterone/adverse effects/*therapeutic use', 'Middle Aged', 'Paraphilic Disorders/drug therapy/*therapy', 'Recurrence', '*Sex Offenses', 'Testosterone/blood']",https://pubmed.ncbi.nlm.nih.gov/2896429/
575,Docetaxol,33186519,Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis.,"['Guccini I', 'Revandkar A', ""D'Ambrosio M"", 'Colucci M', 'Pasquini E', 'Mosole S', 'Troiani M', 'Brina D', 'Sheibani-Tezerji R', 'Elia AR', 'Rinaldi A', 'Pernigoni N', 'Ruschoff JH', 'Dettwiler S', 'De Marzo AM', 'Antonarakis ES', 'Borrelli C', 'Moor AE', 'Garcia-Escudero R', 'Alajati A', 'Attanasio G', 'Losa M', 'Moch H', 'Wild P', 'Egger G', 'Alimonti A']","['Animals', 'Cellular Senescence/drug effects', 'Docetaxel/*administration & dosage/pharmacology', '*Gene Deletion', 'Gene Expression Regulation, Neoplastic', 'Humans', 'Male', 'Matrix Metalloproteinases/metabolism', 'Mice', 'Neoplasm Metastasis', 'Neoplasm Transplantation', 'PC-3 Cells', 'PTEN Phosphohydrolase/*genetics', 'Prostatic Neoplasms/drug therapy/genetics/metabolism/*pathology', 'Tissue Inhibitor of Metalloproteinase-1/*genetics']",https://pubmed.ncbi.nlm.nih.gov/33186519/
576,Docetaxol,29384722,Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.,"['Kyriakopoulos CE', 'Chen YH', 'Carducci MA', 'Liu G', 'Jarrard DF', 'Hahn NM', 'Shevrin DH', 'Dreicer R', 'Hussain M', 'Eisenberger M', 'Kohli M', 'Plimack ER', 'Vogelzang NJ', 'Picus J', 'Cooney MM', 'Garcia JA', 'DiPaola RS', 'Sweeney CJ']","['Androgen Antagonists/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Docetaxel/*administration & dosage/adverse effects', 'Humans', 'Male', 'Neoplasm Metastasis', 'Neoplasms, Hormone-Dependent/*drug therapy/mortality/pathology', 'Prostatic Neoplasms/*drug therapy/mortality/pathology', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29384722/
577,Docetaxol,38722620,Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.,"['Hussain M', 'Fizazi K', 'Shore ND', 'Heidegger I', 'Smith MR', 'Tombal B', 'Saad F']","['Humans', 'Male', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use', '*Androgen Antagonists/therapeutic use', '*Prostatic Neoplasms/drug therapy/pathology/mortality', 'Treatment Outcome', 'Neoplasm Metastasis', 'Androgen Receptor Antagonists/therapeutic use', 'Docetaxel/therapeutic use/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38722620/
578,Docetaxol,30509740,"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.","['Cohen EEW', 'Soulieres D', 'Le Tourneau C', 'Dinis J', 'Licitra L', 'Ahn MJ', 'Soria A', 'Machiels JP', 'Mach N', 'Mehra R', 'Burtness B', 'Zhang P', 'Cheng J', 'Swaby RF', 'Harrington KJ']","['Aged', 'Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/therapeutic use', 'Cetuximab/administration & dosage/adverse effects/therapeutic use', 'Disease Progression', 'Docetaxel/administration & dosage/adverse effects', 'Drug Administration Schedule', 'Female', 'Head and Neck Neoplasms/*drug therapy/pathology', 'Humans', 'Kaplan-Meier Estimate', 'Male', 'Methotrexate/administration & dosage/adverse effects', 'Middle Aged', 'Neoplasm Recurrence, Local/*drug therapy', 'Squamous Cell Carcinoma of Head and Neck/*drug therapy/pathology/secondary']",https://pubmed.ncbi.nlm.nih.gov/30509740/
579,Docetaxol,36184068,"Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial.","['Zhou C', 'Huang D', 'Fan Y', 'Yu X', 'Liu Y', 'Shu Y', 'Ma Z', 'Wang Z', 'Cheng Y', 'Wang J', 'Hu S', 'Liu Z', 'Poddubskaya E', 'Disel U', 'Akopov A', 'Dvorkin M', 'Zheng W', 'Ma Y', 'Wang Y', 'Li S', 'Yu C', 'Rivalland G']","['Humans', 'Docetaxel/pharmacology/therapeutic use', 'B7-H1 Antigen/metabolism', '*Lung Neoplasms/pathology', '*Antineoplastic Agents/therapeutic use', '*Carcinoma, Non-Small-Cell Lung/pathology', 'Biomarkers']",https://pubmed.ncbi.nlm.nih.gov/36184068/
580,Docetaxol,38767468,Treatment of metastatic hormone-sensitive prostate cancer: from doublet therapy to triplet therapy.,"['Ye SJ', 'Huang RD', 'Fei X', 'Tao ZL', 'Liu WH', 'Ma Q']","['Humans', 'Male', '*Androgen Antagonists/therapeutic use', '*Prostatic Neoplasms/drug therapy/pathology', '*Docetaxel/therapeutic use/administration & dosage', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Prostatic Neoplasms, Castration-Resistant/drug therapy/pathology', 'Quality of Life', 'Antineoplastic Agents, Hormonal/therapeutic use/administration & dosage', 'Neoplasm Metastasis']",https://pubmed.ncbi.nlm.nih.gov/38767468/
581,Docetaxol,31345386,Induction chemotherapy in head and neck cancers: Results and controversies.,"['Gau M', 'Karabajakian A', 'Reverdy T', 'Neidhardt EM', 'Fayette J']","['Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects', 'Cetuximab/administration & dosage/adverse effects', 'Chemoradiotherapy/adverse effects/*methods', 'Cisplatin/administration & dosage/adverse effects', 'Docetaxel/administration & dosage/adverse effects', 'Fluorouracil/administration & dosage/adverse effects', 'Head and Neck Neoplasms/pathology/*therapy', 'Humans', 'Induction Chemotherapy/adverse effects/*methods', 'Laryngectomy/adverse effects', 'Larynx/drug effects/pathology/radiation effects/surgery', 'Neoplasm Staging', 'Organ Sparing Treatments/adverse effects/*methods', 'Progression-Free Survival', 'Randomized Controlled Trials as Topic', 'Squamous Cell Carcinoma of Head and Neck/pathology/*therapy']",https://pubmed.ncbi.nlm.nih.gov/31345386/
582,Docetaxol,38729054,Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.,"['Rescigno P', 'Porta N', 'Finneran L', 'Riisnaes R', 'Figueiredo I', 'Carreira S', 'Flohr P', 'Miranda S', 'Bertan C', 'Ferreira A', 'Crespo M', 'Rodrigues DN', 'Gurel B', 'Nobes J', 'Crabb S', 'Malik Z', 'Ralph C', 'McGovern U', 'Hoskin P', 'Jones RJ', 'Birtle A', 'Gale J', 'Sankey P', 'Jain S', 'McLaren D', 'Chadwick E', 'Espinasse A', 'Hall E', 'de Bono J']","['Humans', 'Male', '*Prostatic Neoplasms, Castration-Resistant/drug therapy/pathology', '*Phenylthiohydantoin/administration & dosage/therapeutic use/adverse effects', '*Benzamides', '*Docetaxel/administration & dosage/therapeutic use', 'Aged', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Middle Aged', '*Nitriles', 'Double-Blind Method', '*Pyrimidines/therapeutic use/administration & dosage/adverse effects', 'Androstenes/therapeutic use/administration & dosage', 'Aged, 80 and over', 'Pyrroles']",https://pubmed.ncbi.nlm.nih.gov/38729054/
583,Docetaxol,32749138,Current Development of Oral Taxane Formulations: A Review.,"['Chowdhury N', 'Singh M']","['Administration, Oral', 'Animals', 'Antineoplastic Agents/administration & dosage/chemistry/pharmacokinetics', 'Antineoplastic Agents, Phytogenic/administration & dosage/chemistry/pharmacokinetics', 'Clinical Trials as Topic', 'Docetaxel/*administration & dosage/chemistry/pharmacokinetics', 'Drug Carriers/administration & dosage/chemistry', 'Drug Compounding', 'Drug Delivery Systems', 'Humans', 'Lipids/administration & dosage/chemistry', 'Micelles', 'Nanoparticles/administration & dosage/chemistry', 'Paclitaxel/*administration & dosage/chemistry/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/32749138/
584,Docetaxol,31977388,Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.,"['Kinsey EN', 'Zhang T', 'Armstrong AJ']","['Androgen Antagonists/administration & dosage/adverse effects/economics', 'Androstenes/administration & dosage/adverse effects/economics', 'Antineoplastic Agents, Hormonal/*administration & dosage/adverse effects/economics', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects/economics', 'Benzamides', 'Chemoradiotherapy/economics/*methods/trends', 'Disease-Free Survival', 'Docetaxel/administration & dosage/adverse effects/economics', 'Drug Administration Schedule', 'Drug Costs', 'Humans', 'Male', 'Medical Oncology/economics/*methods/trends', 'Nitriles', 'Phenylthiohydantoin/administration & dosage/adverse effects/analogs & derivatives/economics', 'Prostatic Neoplasms/mortality/pathology/*therapy', 'Randomized Controlled Trials as Topic', 'Thiohydantoins/administration & dosage/adverse effects/economics', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/31977388/
585,Docetaxol,39223303,Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.,"['Wang T', 'Wang X', 'Ding G', 'Liu H', 'Ma X', 'Ma J', 'Cui Y', 'Wu J']","['Humans', 'Male', '*Androgen Antagonists/administration & dosage/adverse effects', '*Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects', 'Benzamides', 'Docetaxel/administration & dosage/therapeutic use', 'Neoplasm Metastasis', 'Network Meta-Analysis', 'Nitriles/therapeutic use/administration & dosage', 'Phenylthiohydantoin/therapeutic use/administration & dosage/adverse effects', 'Progression-Free Survival', '*Prostatic Neoplasms, Castration-Resistant/drug therapy/mortality/pathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39223303/
586,Docetaxol,32701855,The evolving options in metastatic castration-sensitive prostate cancer.,['Hamilou Z'],"['Androgen Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Androstenes/therapeutic use', 'Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use', 'Benzamides/therapeutic use', 'Docetaxel/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Male', 'Neoplasm Metastasis', 'Nitriles/therapeutic use', 'Phenylthiohydantoin/therapeutic use', 'Prostatic Neoplasms/*drug therapy/pathology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/32701855/
587,Docetaxol,30015691,Treatment of hormone-naive metastatic prostate cancer.,"['Hamilou Z', 'Saad F', 'Fizazi K']","['Androgen Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Androstenes/administration & dosage/adverse effects/*therapeutic use', 'Clinical Trials, Phase III as Topic', 'Docetaxel/administration & dosage/adverse effects/*therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Male', 'Neoplasm Metastasis', 'Prospective Studies', 'Prostatic Neoplasms/*drug therapy/mortality/pathology', 'Prostatic Neoplasms, Castration-Resistant/drug therapy/pathology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/30015691/
588,Docetaxol,29722038,Long-term abiraterone withdrawal syndrome.,"['Marin S', 'Querol R', 'Campins L', 'Miarons M', 'Font A', 'Lianes P']","['Abiraterone Acetate/administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use', 'Docetaxel/administration & dosage/adverse effects', 'Humans', 'Male', 'Prednisone/administration & dosage/adverse effects', 'Prostate-Specific Antigen/metabolism', 'Prostatic Neoplasms, Castration-Resistant/drug therapy/metabolism', 'Substance Withdrawal Syndrome/*etiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29722038/
589,Docetaxol,39250535,"Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.","['Ahn MJ', 'Tanaka K', 'Paz-Ares L', 'Cornelissen R', 'Girard N', 'Pons-Tostivint E', 'Vicente Baz D', 'Sugawara S', 'Cobo M', 'Perol M', 'Mascaux C', 'Poddubskaya E', 'Kitazono S', 'Hayashi H', 'Hong MH', 'Felip E', 'Hall R', 'Juan-Vidal O', 'Brungs D', 'Lu S', 'Garassino M', 'Chargualaf M', 'Zhang Y', 'Howarth P', 'Uema D', 'Lisberg A', 'Sands J']","['Humans', '*Docetaxel/therapeutic use/administration & dosage/adverse effects', '*Carcinoma, Non-Small-Cell Lung/drug therapy/pathology/mortality', '*Lung Neoplasms/drug therapy/pathology/mortality', 'Male', 'Middle Aged', 'Female', 'Aged', 'Adult', 'Aged, 80 and over', 'Progression-Free Survival', 'Immunoconjugates/therapeutic use/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/39250535/
590,Docetaxol,30382284,Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells.,"['Mikula-Pietrasik J', 'Witucka A', 'Pakula M', 'Uruski P', 'Begier-Krasinska B', 'Niklas A', 'Tykarski A', 'Ksiazek K']","['Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Carboplatin/administration & dosage/adverse effects', 'Cell Physiological Phenomena/*drug effects/genetics/physiology', 'Cisplatin/administration & dosage/adverse effects', 'Docetaxel/administration & dosage/adverse effects', 'Female', 'Humans', 'Models, Biological', 'Ovarian Neoplasms/*drug therapy/genetics/metabolism', 'Paclitaxel/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/30382284/
591,Docetaxol,38629735,Overcoming the Blood-Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma.,"['Hsu TI', 'Chen YP', 'Zhang RL', 'Chen ZA', 'Wu CH', 'Chang WC', 'Mou CY', 'Chan HW', 'Wu SH']","['*Temozolomide/chemistry/pharmacology/therapeutic use/pharmacokinetics', '*Glioblastoma/drug therapy/pathology/metabolism', '*Docetaxel/chemistry/pharmacology/pharmacokinetics/therapeutic use', '*Silicon Dioxide/chemistry', '*Blood-Brain Barrier/drug effects/metabolism', 'Animals', '*Nanoparticles/chemistry', 'Humans', 'Mice', '*Drug Resistance, Neoplasm/drug effects', 'Brain Neoplasms/drug therapy/pathology/metabolism', 'Cell Line, Tumor', 'Porosity', 'Drug Carriers/chemistry', 'Mice, Nude', 'Antineoplastic Agents/chemistry/pharmacology', 'Apoptosis/drug effects']",https://pubmed.ncbi.nlm.nih.gov/38629735/
592,Docetaxol,38565395,All-stage targeted red blood cell membrane-coated docetaxel nanocrystals for glioma treatment.,"['Ding Y', 'Xu Q', 'Chai Z', 'Wu S', 'Xu W', 'Wang J', 'Zhou J', 'Luo Z', 'Liu Y', 'Xie C', 'Lu L', 'Lu W']","['*Docetaxel/administration & dosage/pharmacokinetics/chemistry', '*Glioma/drug therapy', 'Animals', '*Nanoparticles/chemistry', '*Antineoplastic Agents/administration & dosage/pharmacokinetics/chemistry/therapeutic use', '*Erythrocyte Membrane/drug effects/chemistry', 'Cell Line, Tumor', '*Brain Neoplasms/drug therapy', 'Male', 'Drug Delivery Systems', 'Avidin/administration & dosage/chemistry', 'Humans', 'Biotin/chemistry/administration & dosage', 'Rats, Sprague-Dawley', 'Blood-Brain Barrier/metabolism', 'Mice, Inbred BALB C', 'Mice, Nude']",https://pubmed.ncbi.nlm.nih.gov/38565395/
593,Docetaxol,34969724,Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma.,"['Quesada S', 'Samalin E', 'Thezenas S', 'Khellaf L', 'Mourregot A', 'Portales F', 'Mazard T', 'Ychou M', 'Adenis A']","['Adenocarcinoma/blood/*drug therapy/pathology', 'Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects', 'CA-19-9 Antigen/blood', 'Carcinoembryonic Antigen/blood', 'Disease-Free Survival', 'Docetaxel/administration & dosage/adverse effects', 'Esophagogastric Junction/drug effects/pathology', 'Female', 'Fluorouracil/administration & dosage/adverse effects', 'Humans', 'Leucovorin/administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Neoadjuvant Therapy', 'Organoplatinum Compounds/administration & dosage/adverse effects', 'Oxaliplatin/administration & dosage/adverse effects', 'Perioperative Period', 'Proportional Hazards Models', 'Stomach Neoplasms/blood/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/34969724/
594,Docetaxol,36354057,NOAEL cancer therapy: a tumor targetable docetaxel-inorganic polymer nanohybrid prevents drug-induced neutropenia.,"['Jin GW', 'Choi G', 'Piao H', 'Rejinold NS', 'Asahina S', 'Choi SJ', 'Lee HJ', 'Choy JH']","['Humans', 'Docetaxel/pharmacology/therapeutic use', 'No-Observed-Adverse-Effect Level', 'Taxoids/adverse effects', 'Polymers/therapeutic use', '*Pancreatic Neoplasms/drug therapy', '*Neutropenia/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36354057/
595,orphenadrine,15276195,Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.,"['Chou R', 'Peterson K', 'Helfand M']","['Clinical Trials as Topic', 'Comorbidity', 'Evidence-Based Medicine/methods', 'Humans', 'Motor Neuron Disease/classification/*drug therapy/*epidemiology', 'Muscle Spasticity/classification/*drug therapy/*epidemiology', 'Musculoskeletal Diseases/classification/drug therapy/epidemiology', 'Neuromuscular Agents/*therapeutic use', 'Peripheral Nervous System Diseases/classification/*drug therapy/*epidemiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15276195/
596,orphenadrine,29079070,Pharmacologic Interventions for Intractable and Persistent Hiccups: A Systematic Review.,"['Polito NB', 'Fellows SE']","['Adrenergic Uptake Inhibitors/pharmacology/therapeutic use', 'Chlorpromazine/pharmacology/therapeutic use', 'Dopamine Antagonists/pharmacology/therapeutic use', 'Dopamine D2 Receptor Antagonists/pharmacology/therapeutic use', 'Emergency Service, Hospital/organization & administration', 'GABA-B Receptor Agonists/pharmacology/therapeutic use', 'Hiccup/*drug therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/29079070/
597,orphenadrine,35754070,Pharmacotherapy for Spine-Related Pain in Older Adults.,"['Fu JL', 'Perloff MD']","['Acetaminophen/therapeutic use', 'Aged', 'Analgesics, Opioid/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', '*Neuralgia/drug therapy', 'Pregabalin/adverse effects', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35754070/
598,orphenadrine,6999895,Centrally acting oral skeletal muscle relaxants.,['Elenbaas JK'],"['Analgesics/therapeutic use', 'Drug Combinations', 'Drug Evaluation', 'Humans', 'Hypnotics and Sedatives/therapeutic use', 'Kinetics', 'Muscle Relaxants, Central/metabolism/pharmacology/*therapeutic use', 'Placebos']",https://pubmed.ncbi.nlm.nih.gov/6999895/
599,orphenadrine,9195597,Dopamine/glutamate interactions in Parkinson's disease.,"['Lange KW', 'Kornhuber J', 'Riederer P']","['Animals', 'Basal Ganglia/physiopathology', 'Dopamine/*physiology', 'Excitatory Amino Acid Antagonists/therapeutic use', 'Glutamic Acid/*physiology', 'Humans', 'Parkinson Disease/drug therapy/*physiopathology', 'Synaptic Transmission/physiology']",https://pubmed.ncbi.nlm.nih.gov/9195597/
600,orphenadrine,11277,Extrapyramidal effects of neuroleptics.,"['Korczyn AD', 'Goldberg GJ']","['Adult', 'Age Factors', 'Antipsychotic Agents/adverse effects', 'Clinical Trials as Topic', 'Dyskinesia, Drug-Induced/physiopathology', 'Extrapyramidal Tracts/*drug effects', 'Female', 'Humans', 'Male', 'Middle Aged', 'Orphenadrine/therapeutic use', 'Parkinson Disease/drug therapy', 'Parkinson Disease, Secondary/*chemically induced', 'Phenothiazines', 'Sex Factors', 'Time Factors', 'Tranquilizing Agents/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11277/
601,orphenadrine,2083431,Review of oral skeletal muscle relaxants for the craniomandibular disorder (CMD) practitioner.,['Stanko JR'],"['Humans', '*Muscle Relaxants, Central/administration & dosage/pharmacology/therapeutic use', 'Muscle Spasticity/drug therapy', 'Temporomandibular Joint Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2083431/
602,orphenadrine,9889660,[Atypical acute dystonia].,"['Nielsen AS', 'Mors NP']","['Acute Disease', 'Adult', 'Antipsychotic Agents/*adverse effects', 'Aphonia/chemically induced/diagnosis', 'Dyskinesia, Drug-Induced/diagnosis', 'Dystonia/*chemically induced/diagnosis', 'Humans', 'Male', 'Muscle Relaxants, Central/*adverse effects', 'Orphenadrine/*adverse effects', 'Perphenazine/*adverse effects', 'Schizophrenia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9889660/
603,orphenadrine,6933954,Cardiotoxicity from orphenadrine intoxication in humans.,"['Malizia E', 'Sarcinelli L', 'Pascarella M', 'Ambrosini M', 'Smeriglio M', 'Russo A']","['Adolescent', 'Adult', 'Female', 'Heart Diseases/*chemically induced/physiopathology', 'Humans', 'Male', 'Orphenadrine/*poisoning', 'Suicide']",https://pubmed.ncbi.nlm.nih.gov/6933954/
604,orphenadrine,25445036,Effects of antihistamines on the function of human alpha7-nicotinic acetylcholine receptors.,"['Sadek B', 'Khanian SS', 'Ashoor A', 'Prytkova T', 'Ghattas MA', 'Atatreh N', 'Nurulain SM', 'Yang KH', 'Howarth FC', 'Oz M']","['Allosteric Regulation', 'Animals', 'Binding Sites', 'Cells, Cultured', 'Histamine H1 Antagonists/chemistry/metabolism/*pharmacology', 'Histamine H2 Antagonists/chemistry/metabolism/pharmacology', 'Histamine H3 Antagonists/chemistry/metabolism/pharmacology', 'Humans', 'Ketamine/chemistry/metabolism/pharmacology', 'Kinetics', '*Models, Molecular', 'Molecular Conformation', 'Molecular Docking Simulation', 'Nerve Tissue Proteins/*antagonists & inhibitors/genetics/metabolism', 'Oocytes/cytology/drug effects/metabolism', 'Protein Structure, Tertiary', 'Pyrilamine/chemistry/metabolism/*pharmacology', 'Recombinant Proteins/chemistry/metabolism', 'Xenopus laevis', 'alpha7 Nicotinic Acetylcholine Receptor/*antagonists & inhibitors/genetics/metabolism']",https://pubmed.ncbi.nlm.nih.gov/25445036/
605,orphenadrine,2578597,Analgesic effects of antihistaminics.,"['Rumore MM', 'Schlichting DA']","['*Analgesia', 'Anesthetics, Local/pharmacology', 'Animals', 'Anxiety/drug therapy', 'Bradykinin/pharmacology', 'Brain/metabolism', 'Calcium/metabolism', 'Cyclic AMP/metabolism', 'Cyclic GMP/metabolism', 'Drug Interactions', 'Female', 'Histamine H1 Antagonists/*pharmacology', 'Histamine Release', 'Humans', 'Kinetics', 'Muscle Contraction/drug effects', 'Narcotics/pharmacology', 'Nociceptors/drug effects', 'Prostaglandins/pharmacology', 'Structure-Activity Relationship', 'Uterine Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2578597/
606,orphenadrine,781839,Advances in the management of parkinson's disease.,['Marsden CD'],"['Amantadine/therapeutic use', 'Anesthesia', 'Humans', 'Levodopa/adverse effects/therapeutic use', 'Orphenadrine/therapeutic use', 'Parasympatholytics/therapeutic use', 'Parkinson Disease/diagnosis/*drug therapy/surgery', 'Social Adjustment', 'Trihexyphenidyl/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/781839/
607,orphenadrine,34184488,[The efficacy of the combination of diclofenac and orphenadrine in the treatment of dorsalgia].,"['Zyryanov SK', 'Butranova OI', 'Putsman GA']","['Adult', 'Analgesics', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', '*Diclofenac/therapeutic use', 'Humans', 'Moscow', '*Orphenadrine']",https://pubmed.ncbi.nlm.nih.gov/34184488/
608,orphenadrine,20890791,"Opiate sparing effect of fixed combination of diclophenac and orphenadrine after unilateral total hip arthroplasty: A double-blind, randomized, placebo-controlled, multi-centre clinical trial.","['Gombotz H', 'Lochner R', 'Sigl R', 'Blasl J', 'Herzer G', 'Trimmel H']","['Adult', 'Aged', 'Aged, 80 and over', 'Analgesics/adverse effects/*therapeutic use', '*Arthroplasty, Replacement, Hip', 'Diclofenac/adverse effects/*therapeutic use', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Humans', 'Male', 'Middle Aged', 'Narcotics/*administration & dosage', 'Orphenadrine/adverse effects/*therapeutic use', 'Pain Measurement', 'Pain, Postoperative/*drug therapy', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/20890791/
609,orphenadrine,6101910,Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. An investigation of mechanism.,"['Burnett GB', 'Prange AJ Jr', 'Wilson IC', 'Jolliff LA', 'Creese IC', 'Synder SH']","['Adult', 'Aged', 'Antiparkinson Agents/*adverse effects', 'Antipsychotic Agents/blood', 'Benztropine/adverse effects', 'Dopamine/metabolism', 'Dyskinesia, Drug-Induced/blood/*etiology/metabolism', 'Female', 'Growth Hormone/blood', 'Humans', 'Male', 'Middle Aged', 'Orphenadrine/adverse effects', 'Parasympatholytics/*adverse effects', 'Prolactin/blood', 'Sex Factors', 'Thyrotropin/blood', 'Trihexyphenidyl/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/6101910/
610,orphenadrine,24552880,Abuse liability of centrally acting non-opioid analgesics and muscle relaxants--a brief update based on a comparison of pharmacovigilance data and evidence from the literature.,"['Gahr M', 'Freudenmann RW', 'Eller J', 'Schonfeldt-Lecuona C']","['Adolescent', 'Adult', 'Aged', 'Analgesics, Non-Narcotic/*adverse effects', 'Central Nervous System Agents/adverse effects', 'Databases, Pharmaceutical', 'Female', 'Germany/epidemiology', 'Humans', 'Male', 'Middle Aged', 'Muscle Relaxants, Central/*adverse effects', '*Pharmacovigilance', 'Substance-Related Disorders/*epidemiology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24552880/
611,orphenadrine,800383,A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy.,"['Capstick N', 'Pudney H']","['Clinical Trials as Topic', 'Depression/chemically induced/*drug therapy', 'Fluphenazine/*adverse effects', 'Humans', 'Orphenadrine/*analogs & derivatives/*therapeutic use', 'Parkinson Disease, Secondary/chemically induced/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/800383/
612,orphenadrine,3760245,Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration.,"['Blyden GT', 'Greenblatt DJ', 'Scavone JM', 'Shader RI']","['Administration, Oral', 'Adult', 'Chromatography, Gas', 'Diphenhydramine/administration & dosage/*analogs & derivatives/*metabolism', 'Female', 'Half-Life', 'Humans', 'Injections, Intravenous', 'Kinetics', 'Male', 'Orphenadrine/metabolism']",https://pubmed.ncbi.nlm.nih.gov/3760245/
613,orphenadrine,216517,Prochlorperazine in childhood: side-effects.,"['Lankamp DJ', 'Willemse J', 'Pikaar SA', 'van Heyst AN']","['Adolescent', 'Child', 'Child, Preschool', 'Consciousness Disorders/chemically induced', 'Dyskinesia, Drug-Induced/etiology', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Male', 'Muscle Hypertonia/chemically induced', 'Nervous System Diseases/*chemically induced/drug therapy', 'Prochlorperazine/administration & dosage/*adverse effects/antagonists & inhibitors', 'Pyramidal Tracts']",https://pubmed.ncbi.nlm.nih.gov/216517/
614,orphenadrine,24579304,"Ex vivo percutaneous absorption of ketamine, bupivacaine, diclofenac, gabapentin, orphenadrine, and pentoxifylline: comparison of versatile cream vs. reference cream.","['Wang X', 'Black L']","['Administration, Cutaneous', 'Amines/pharmacokinetics', 'Analgesics/administration & dosage/*pharmacokinetics', 'Bupivacaine/pharmacokinetics', 'Chemistry, Pharmaceutical', 'Cyclohexanecarboxylic Acids/pharmacokinetics', 'Diclofenac/pharmacokinetics', 'Gabapentin', 'Humans', 'Ketamine/pharmacokinetics', 'Ointments', 'Orphenadrine/pharmacokinetics', 'Pentoxifylline/pharmacokinetics', '*Skin Absorption', 'gamma-Aminobutyric Acid/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/24579304/
615,Celestone,39575914,[Not Available].,"['Kofoed K', 'Skov L', 'Zachariae C']","['Humans', '*Psoriasis/drug therapy', '*Dermatologic Agents/administration & dosage/therapeutic use', '*Betamethasone/administration & dosage/therapeutic use', '*Calcitriol/analogs & derivatives/administration & dosage/therapeutic use', 'Calcineurin Inhibitors/therapeutic use/administration & dosage', 'Administration, Cutaneous', 'Administration, Topical', 'Drug Combinations', 'Adrenal Cortex Hormones/administration & dosage/therapeutic use/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/39575914/
616,Celestone,2186003,Penicillamine-induced pemphigus erythematosus.,"['Willemsen MJ', 'De Coninck AL', 'De Raeve LE', 'Roseeuw DI']","['Administration, Cutaneous', 'Arthritis, Rheumatoid/drug therapy', 'Betamethasone/administration & dosage/therapeutic use', 'Fluorescent Antibody Technique', 'Humans', 'Immunoglobulin M/analysis', 'Male', 'Middle Aged', 'Pemphigus/*chemically induced/immunology', 'Penicillamine/administration & dosage/adverse effects/therapeutic use', 'Skin/immunology/pathology']",https://pubmed.ncbi.nlm.nih.gov/2186003/
617,Celestone,38656759,Neurodevelopmental Outcomes After Late Preterm Antenatal Corticosteroids: The ALPS Follow-Up Study.,"['Gyamfi-Bannerman C', 'Clifton RG', 'Tita ATN', 'Blackwell SC', 'Longo M', 'de Voest JA', ""O'Shea TM"", 'Bousleiman SZ', 'Ortiz F', 'Rouse DJ', 'Metz TD', 'Saade GR', 'Rood KM', 'Heyborne KD', 'Thorp JM Jr', 'Swamy GK', 'Grobman WA', 'Gibson KS', 'El-Sayed YY', 'Macones GA']","['Child', 'Female', 'Humans', 'Infant, Newborn', 'Male', 'Pregnancy', '*Betamethasone/administration & dosage/adverse effects/therapeutic use', 'Child Development/drug effects', 'Follow-Up Studies', '*Glucocorticoids/administration & dosage/adverse effects/therapeutic use', 'Infant, Premature', '*Neurodevelopmental Disorders/chemically induced/epidemiology', 'Premature Birth/prevention & control', 'Prenatal Care', '*Prenatal Exposure Delayed Effects/chemically induced', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/38656759/
618,Celestone,17521858,[Paclitaxel-induced lupus].,"['Lortholary A', 'Cary-Ten Have Dallinga M', 'El Kouri C', 'Morineau N', 'Ramee JF']","['Aged', 'Anti-Inflammatory Agents/administration & dosage/therapeutic use', 'Antibodies, Antinuclear/analysis', 'Antineoplastic Agents, Phytogenic/*adverse effects/therapeutic use', 'Betamethasone/administration & dosage/analogs & derivatives/therapeutic use', 'Biopsy', 'Drug Therapy, Combination', 'Erythropoietin/administration & dosage/therapeutic use', 'Female', 'Humans', 'Lupus Erythematosus, Cutaneous/*chemically induced/diagnosis/drug therapy/immunology/pathology', 'Ovarian Neoplasms/drug therapy', 'Paclitaxel/*adverse effects', 'Recombinant Proteins', 'Recurrence', 'Skin/pathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17521858/
619,Celestone,16402537,[The calcipotriol-betamethasone dipropionate association].,"['Henry F', 'Flagothier C', 'Delvoye P', 'Pierard-Franchimont C', 'Pierard GE']","['Administration, Topical', 'Betamethasone/administration & dosage/*analogs & derivatives/therapeutic use', 'Calcitriol/administration & dosage/*analogs & derivatives/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Inflammation', 'Psoriasis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16402537/
620,Celestone,29895522,Repeat Antenatal Betamethasone and Cardiometabolic Outcomes.,"['Cartwright RD', 'Harding JE', 'Crowther CA', 'Cutfield WS', 'Battin MR', 'Dalziel SR', 'McKinlay CJD']","['Absorptiometry, Photon', 'Anthropometry', 'Australia', 'Betamethasone/administration & dosage/*adverse effects', 'Blood Pressure Monitoring, Ambulatory', 'Child', 'Child Development/drug effects', 'Child, Preschool', 'Double-Blind Method', 'Female', 'Fetal Growth Retardation/*drug therapy/physiopathology', 'Glucocorticoids/administration & dosage/*adverse effects', 'Glucose Tolerance Test', 'Humans', 'Infant', 'Infant, Newborn', 'Male', 'New Zealand', 'Pregnancy', 'Prenatal Exposure Delayed Effects/*epidemiology', 'Risk Factors', 'Spirometry']",https://pubmed.ncbi.nlm.nih.gov/29895522/
621,Celestone,15606220,Effects of glucocorticoids on fetal and neonatal lung development.,"['Grier DG', 'Halliday HL']","['Betamethasone/administration & dosage/pharmacology/therapeutic use', 'Female', '*Fetal Organ Maturity', 'Glucocorticoids/administration & dosage/pharmacology/*therapeutic use', 'Humans', 'Infant, Newborn', 'Lung/drug effects/*embryology', 'Pregnancy', 'Respiratory Distress Syndrome, Newborn/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/15606220/
622,Celestone,28659016,Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature.,"['Frieder J', 'Kivelevitch D', 'Menter A']","['Betamethasone/administration & dosage/*analogs & derivatives/therapeutic use', 'Calcitriol/administration & dosage/*analogs & derivatives/therapeutic use', 'Dermatologic Agents/*administration & dosage/therapeutic use', 'Drug Combinations', 'Humans', 'Psoriasis/*drug therapy', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/28659016/
623,Celestone,8075276,Intraocular blastomycosis: case report and review.,"['Lopez R', 'Mason JO', 'Parker JS', 'Pappas PG']","['Amphotericin B/administration & dosage/therapeutic use', 'Betamethasone/adverse effects/therapeutic use', '*Blastomycosis/diagnosis/drug therapy', 'Dermatomycoses/complications/diagnosis/microbiology', 'Drug Therapy, Combination', 'Humans', 'Iritis/diagnosis/drug therapy/*microbiology', 'Lung Diseases, Fungal/chemically induced/complications/diagnosis', 'Male', 'Miconazole/administration & dosage/therapeutic use', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/8075276/
624,Celestone,24529761,[Prenatal corticosteroids: short-term and long-term effects of multiple courses. Literature review in 2013].,"['Fuchs F', 'Audibert F', 'Senat MV']","['Adrenal Cortex Hormones/administration & dosage/*pharmacology', 'Betamethasone/administration & dosage/*pharmacology', 'Birth Weight/drug effects', 'Body Height/drug effects', 'Dexamethasone/administration & dosage/*pharmacology', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Evidence-Based Medicine', 'Female', 'Fetal Development/drug effects', 'Humans', 'Infant, Premature, Diseases/prevention & control', 'Pregnancy', 'Premature Birth/*prevention & control', '*Prenatal Care/methods', 'Respiratory Distress Syndrome, Newborn/*prevention & control', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24529761/
625,Celestone,16038572,The role of topical corticosteroids in bullous pemphigoid in the elderly.,"['Joly P', 'Fontaine J', 'Roujeau JC']","['Administration, Topical', 'Adrenal Cortex Hormones/*administration & dosage/adverse effects/*therapeutic use', 'Aged', 'Clobetasol/administration & dosage/analogs & derivatives/therapeutic use', 'Humans', 'Pemphigoid, Bullous/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16038572/
626,Celestone,15968261,A novel foam vehicle for delivery of topical corticosteroids.,"['Huang X', 'Tanojo H', 'Lenn J', 'Deng CH', 'Krochmal L']","['Administration, Cutaneous', 'Administration, Topical', 'Adrenal Cortex Hormones/*administration & dosage/pharmacokinetics/therapeutic use', 'Anti-Inflammatory Agents/*administration & dosage/pharmacokinetics/therapeutic use', 'Betamethasone/administration & dosage/pharmacokinetics', 'Body Water', 'Calcitriol/administration & dosage/analogs & derivatives/pharmacokinetics', 'Clindamycin/administration & dosage/pharmacokinetics', 'Clobetasol/administration & dosage/analogs & derivatives/pharmacokinetics', 'Dermatologic Agents/*administration & dosage/pharmacokinetics/therapeutic use', 'Dosage Forms', 'Hot Temperature', 'Humans', 'Ketoconazole/administration & dosage/pharmacokinetics', 'Ointments', 'Pharmaceutical Vehicles', 'Skin/drug effects/metabolism', 'Skin Absorption']",https://pubmed.ncbi.nlm.nih.gov/15968261/
627,Celestone,9691827,[Allergic rhinoconjunctivitis treated with intramuscular injection of glucocorticoid].,"['Dahl M', 'Laursen LC']","['Betamethasone/administration & dosage/adverse effects', 'Delayed-Action Preparations', 'Glucocorticoids/*administration & dosage/adverse effects', 'Humans', 'Injections, Intramuscular', 'Methylprednisolone/administration & dosage/adverse effects', 'Prednisolone/administration & dosage/adverse effects', 'Rhinitis, Allergic, Seasonal/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9691827/
628,Celestone,21575796,Potential risks and benefits of antenatal corticosteroid therapy prior to preterm birth in pregnancies complicated by severe fetal growth restriction.,"['Vidaeff AC', 'Blackwell SC']","['Adrenal Cortex Hormones/*administration & dosage/adverse effects/therapeutic use', 'Adult', 'Betamethasone/administration & dosage/adverse effects/therapeutic use', 'Dexamethasone/administration & dosage/adverse effects/therapeutic use', 'Female', 'Fetal Growth Retardation/*drug therapy', 'Humans', 'Infant, Newborn', 'Pregnancy', '*Pregnancy Complications', '*Premature Birth', 'Prenatal Care', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21575796/
629,Celestone,30261718,Calcipotriene plus betamethasone dipropionate in aerosol foam formulation: will this effective treatment for mild-to-moderate psoriasis change clinical practice?,"['Giovene GL', 'Giacomelli L']","['Administration, Cutaneous', 'Aerosols', 'Betamethasone/administration & dosage/adverse effects/*analogs & derivatives/pharmacokinetics', 'Biological Availability', 'Calcitriol/administration & dosage/adverse effects/*analogs & derivatives/pharmacokinetics', 'Dermatologic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Drug Combinations', 'Humans', 'Italy', 'Psoriasis/*drug therapy/pathology', 'Skin Absorption', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30261718/
630,Celestone,31272782,Long-Term Evaluation of Low-Dose Betamethasone for Ataxia Telangiectasia.,"['Hasegawa S', 'Kumada S', 'Tanuma N', 'Tsuji-Hosokawa A', 'Kashimada A', 'Mizuno T', 'Moriyama K', 'Sugawara Y', 'Shirai I', 'Miyata Y', 'Nishida H', 'Mashimo H', 'Hasegawa T', 'Hosokawa T', 'Hisakawa H', 'Uematsu M', 'Fujine A', 'Miyata R', 'Sakuma H', 'Kashimada K', 'Imai K', 'Morio T', 'Hayashi M', 'Mizutani S', 'Takagi M']","['Adolescent', 'Adrenal Gland Diseases/chemically induced', 'Ataxia Telangiectasia/*drug therapy', 'Betamethasone/administration & dosage/adverse effects/*pharmacology', 'Child', '*Drug-Related Side Effects and Adverse Reactions', 'Female', 'Glucocorticoids/administration & dosage/adverse effects/*pharmacology', 'Humans', 'Longitudinal Studies', 'Male', '*Outcome Assessment, Health Care', 'Peripheral Nervous System Diseases/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/31272782/
631,Celestone,14714924,Antenatal corticosteroids for fetal maturation in women at risk for preterm delivery.,"['Vidaeff AC', 'Doyle NM', 'Gilstrap LC 3rd']","['Adrenal Cortex Hormones/*administration & dosage/*pharmacology', 'Betamethasone/administration & dosage/pharmacology', 'Consensus Development Conferences, NIH as Topic', 'Dexamethasone/administration & dosage/pharmacology', 'Female', 'Fetal Membranes, Premature Rupture/*complications', 'Fetal Organ Maturity/*drug effects', 'Gestational Age', 'Humans', 'Obstetric Labor, Premature/*etiology/*prevention & control', 'Pregnancy', 'Pregnancy Outcome', 'United States']",https://pubmed.ncbi.nlm.nih.gov/14714924/
632,Celestone,15035454,Antenatal corticosteroid therapy: benefits and risks.,['Baud O'],"['Adrenal Cortex Hormones/adverse effects/*therapeutic use', 'Animals', 'Betamethasone/adverse effects/therapeutic use', 'Cerebral Palsy/prevention & control', 'Dexamethasone/adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', 'Embryonic and Fetal Development/drug effects', 'Female', 'Humans', 'Infant, Newborn', 'Pregnancy', 'Pregnancy Complications/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/15035454/
633,Celestone,2396837,Penile verrucous carcinoma.,"['Yeager JK', 'Findlay RF', 'McAleer IM']","['Administration, Topical', 'Aged', 'Betamethasone/*analogs & derivatives', 'Carcinoma, Papillary/*pathology', 'Child', 'Clobetasol/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Drug Administration Schedule', 'Female', 'Humans', 'Male', 'Middle Aged', 'Penile Neoplasms/*pathology', 'Photosensitivity Disorders/*drug therapy', 'Prurigo/*drug therapy/etiology', 'Skin/*pathology', 'Sunlight/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2396837/
634,Celestone,12454632,[Corticosteroid for fetal lung maturation: indication and treatment protocols].,['Senat MV'],"['Betamethasone/adverse effects/*therapeutic use', 'Female', 'Fetal Organ Maturity/drug effects', 'Fetus', 'France', 'Glucocorticoids/adverse effects/*therapeutic use', 'Humans', 'Infant, Newborn', 'Lung/*embryology', '*Practice Guidelines as Topic', 'Pregnancy', 'Pregnancy Trimester, Second', 'Pregnancy Trimester, Third', 'Randomized Controlled Trials as Topic', 'Respiratory Distress Syndrome, Newborn/*prevention & control', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12454632/
635,Lanicor,32464466,Digoxin: Pharmacology and toxicology-A review.,"['Patocka J', 'Nepovimova E', 'Wu W', 'Kuca K']","['Animals', 'Digoxin/*adverse effects/*pharmacology', 'Drug Interactions', 'Humans', 'Poisoning/therapy']",https://pubmed.ncbi.nlm.nih.gov/32464466/
636,Lanicor,9296249,Digoxin-macrolide drug interaction.,"['Bizjak ED', 'Mauro VF']","['Aged', 'Anti-Bacterial Agents/*pharmacology/therapeutic use', 'Biological Availability', 'Digoxin/*adverse effects/pharmacokinetics', 'Drug Interactions', 'Female', 'Humans', 'Macrolides', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/9296249/
637,Lanicor,29519345,Digoxin and Mortality in Patients With Atrial Fibrillation.,"['Lopes RD', 'Rordorf R', 'De Ferrari GM', 'Leonardi S', 'Thomas L', 'Wojdyla DM', 'Ridefelt P', 'Lawrence JH', 'De Caterina R', 'Vinereanu D', 'Hanna M', 'Flaker G', 'Al-Khatib SM', 'Hohnloser SH', 'Alexander JH', 'Granger CB', 'Wallentin L']","['Aged', 'Anti-Arrhythmia Agents/administration & dosage/adverse effects/blood/pharmacokinetics', '*Atrial Fibrillation/diagnosis/drug therapy/mortality', '*Cause of Death', 'Correlation of Data', '*Death, Sudden/epidemiology/etiology', '*Digoxin/administration & dosage/adverse effects/blood/pharmacokinetics', 'Female', '*Heart Failure/diagnosis/mortality', 'Humans', 'Male', 'Middle Aged', 'Outcome Assessment, Health Care', 'Risk Assessment/methods/statistics & numerical data', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/29519345/
638,Lanicor,26159635,Digoxin: The Art and Science.,['Ewy GA'],"['Aged', 'Cardiotonic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Digoxin/adverse effects/pharmacokinetics/*therapeutic use', 'Heart Failure, Systolic/*drug therapy', 'Humans', 'Tachycardia, Supraventricular/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26159635/
639,Lanicor,33351042,Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.,"['Kotecha D', 'Bunting KV', 'Gill SK', 'Mehta S', 'Stanbury M', 'Jones JC', 'Haynes S', 'Calvert MJ', 'Deeks JJ', 'Steeds RP', 'Strauss VY', 'Rahimi K', 'Camm AJ', 'Griffith M', 'Lip GYH', 'Townend JN', 'Kirchhof P']","['Adrenergic beta-1 Receptor Antagonists/therapeutic use', 'Aged', 'Aged, 80 and over', 'Anti-Arrhythmia Agents/adverse effects/pharmacology/*therapeutic use', 'Atrial Fibrillation/complications/*drug therapy/physiopathology', 'Bisoprolol/adverse effects/pharmacology/*therapeutic use', 'Digoxin/adverse effects/pharmacology/*therapeutic use', 'Female', 'Heart Failure/complications/drug therapy', 'Heart Rate/*drug effects', 'Humans', 'Male', 'Middle Aged', '*Quality of Life', 'Single-Blind Method', 'Stroke Volume']",https://pubmed.ncbi.nlm.nih.gov/33351042/
640,Lanicor,31237216,Digoxin in Atrial Fibrillation: An Old Topic Revisited.,"['Ferrari F', 'Santander IRMF', 'Stein R']","['Anti-Arrhythmia Agents/*adverse effects/pharmacology/*therapeutic use', 'Atrial Fibrillation/*drug therapy', 'Cross-Sectional Studies', 'Digoxin/*adverse effects/pharmacology/*therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/31237216/
641,Lanicor,6751790,Quinidine and digoxin. An important interaction.,"['Bigger JT Jr', 'Leahey EB Jr']","['Digoxin/adverse effects/*blood/pharmacology', 'Drug Interactions', 'Humans', 'Intestinal Absorption/drug effects', 'Kidney/metabolism', 'Myocardial Contraction/drug effects', 'Quinidine/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6751790/
642,Lanicor,27696142,Contemporary Controversies in Digoxin Use in Systolic Heart Failure.,"['Albert CL', 'Kamdar F', 'Hanna M']","['Cardiotonic Agents/adverse effects/*therapeutic use', 'Digoxin/adverse effects/*therapeutic use', 'Heart Failure, Systolic/*drug therapy', 'Humans', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27696142/
643,Lanicor,25944069,[A baby with digoxin toxicity].,"['Andrews LM', 'Puiman PJ', 'van der Sijs H', 'van Beynum IM']","['Antibodies/*administration & dosage', 'Cardiotonic Agents/*adverse effects/therapeutic use', 'Digoxin/*adverse effects/therapeutic use', 'Drug Overdose', 'Drug-Related Side Effects and Adverse Reactions', 'Humans', 'Hyperkalemia/chemically induced', 'Infant', 'Male', 'Medication Errors']",https://pubmed.ncbi.nlm.nih.gov/25944069/
644,Lanicor,30209692,Is There Still a Role for Digoxin in the Management of Atrial Fibrillation?,"['Washam JB', 'Patel MR']","['Atrial Fibrillation/*drug therapy', 'Digoxin/adverse effects/*therapeutic use', 'Heart Failure/prevention & control', 'Humans', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30209692/
645,Lanicor,12864722,Digoxin in heart failure and cardiac arrhythmias.,"['Campbell TJ', 'MacDonald PS']","['Anti-Arrhythmia Agents/adverse effects/pharmacology/*therapeutic use', 'Arrhythmias, Cardiac/*drug therapy', 'Digoxin/adverse effects/pharmacology/*therapeutic use', 'Heart Failure/*drug therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/12864722/
646,Lanicor,21988950,Digoxin: clinical highlights: a review of digoxin and its use in contemporary medicine.,"['Ehle M', 'Patel C', 'Giugliano RP']","['Atrial Fibrillation/complications/*drug therapy/physiopathology', 'Cardiotonic Agents/administration & dosage/adverse effects/pharmacokinetics', 'Clinical Protocols', '*Digoxin/administration & dosage/adverse effects/immunology/pharmacokinetics', 'Drug Administration Schedule', 'Drug Dosage Calculations', 'Drug Monitoring/*methods', 'Drug-Related Side Effects and Adverse Reactions/etiology/*physiopathology/therapy', 'Heart Failure/complications/*drug therapy/physiopathology', 'Heart Rate/drug effects', 'Humans', 'Immunoglobulin Fab Fragments/*therapeutic use', 'Myocardial Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/21988950/
647,Lanicor,1389200,The rational pharmacology of digoxin.,"['Heerdt PM', 'Heerdt ME']","['Digoxin/chemistry/pharmacokinetics/*pharmacology/therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/1389200/
648,Lanicor,23008361,Digoxin--'a friend or foe'.,['Kolev KK'],"['Aged', 'Anti-Arrhythmia Agents/*adverse effects/immunology/therapeutic use', 'Atrial Fibrillation/*drug therapy/etiology', 'Cardiotonic Agents/administration & dosage/adverse effects/*therapeutic use', 'Digitalis Glycosides/administration & dosage/adverse effects/*therapeutic use', 'Digoxin/*adverse effects/immunology/therapeutic use', 'Female', 'Heart Rate/drug effects', 'Humans', 'Immunoglobulin Fab Fragments/*therapeutic use', 'Stroke/complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/23008361/
649,Lanicor,7873474,Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.,"['Tauke J', 'Han D', 'Gheorghiade M']","['Adrenergic beta-Agonists/administration & dosage/pharmacology/*therapeutic use', 'Cardiotonic Agents/administration & dosage/pharmacology/*therapeutic use', 'Digoxin/administration & dosage/pharmacology/*therapeutic use', 'Double-Blind Method', 'Drug Evaluation', 'Electrophysiology', 'Heart Failure/*drug therapy/mortality', 'Hemodynamics/drug effects', 'Humans', 'Myocardial Contraction/*drug effects', 'Neurosecretory Systems/drug effects', 'Phosphodiesterase Inhibitors/administration & dosage/pharmacology/*therapeutic use', 'Pyrazines', 'Quinolines/administration & dosage/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7873474/
650,Lanicor,671662,Interaction between quinidine and digoxin.,"['Leahey EB Jr', 'Reiffel JA', 'Drusin RE', 'Heissenbuttel RH', 'Lovejoy WP', 'Bigger JT Jr']","['Aged', 'Anorexia/chemically induced', 'Arrhythmias, Cardiac/*drug therapy', 'Digoxin/*administration & dosage/adverse effects/blood', 'Drug Interactions', 'Female', 'Humans', 'Male', 'Middle Aged', 'Nausea/chemically induced', 'Quinidine/*administration & dosage/pharmacology', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/671662/
651,Lanicor,7037912,Digoxin use in the elderly.,['Stults BM'],"['Adult', 'Age Factors', 'Aged', 'Atrial Fibrillation/blood/drug therapy', 'Digoxin/adverse effects/blood/metabolism/*therapeutic use', 'Diuretics/therapeutic use', 'Drug Interactions', 'Half-Life', 'Heart Conduction System/physiopathology', 'Heart Failure/drug therapy', 'Heart Ventricles/physiopathology', 'Humans', 'Middle Aged', 'Monitoring, Physiologic', 'Patient Compliance', 'Quinidine/blood/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7037912/
652,Lanicor,9639187,Clarithromycin induced digoxin toxicity.,"['Nordt SP', 'Williams SR', 'Manoguerra AS', 'Clark RF']","['Adult', 'Anorexia/chemically induced', 'Anti-Arrhythmia Agents/*poisoning/therapeutic use', 'Anti-Bacterial Agents/*adverse effects/therapeutic use', 'Clarithromycin/*adverse effects/therapeutic use', 'Digoxin/*poisoning/therapeutic use', 'Drug Interactions', 'Drug Therapy, Combination', 'Emergency Service, Hospital', 'Humans', 'Male', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/9639187/
653,Lanicor,22216507,"Digoxin therapy: textbooks, theory and practice.","['Aronson JK', 'Grahame-Smith DG']","['Cardiotonic Agents/*therapeutic use', 'Digoxin/administration & dosage/pharmacokinetics/*therapeutic use', 'Drug Administration Schedule', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/22216507/
654,Lanicor,15868358,Digitalis in heart failure! Still applicable?,"['Hoppe UC', 'Erdmann E']","['Adrenergic beta-Antagonists/adverse effects/pharmacokinetics/therapeutic use', 'Atrial Fibrillation/blood/*drug therapy/mortality', 'Digitalis Glycosides/adverse effects/pharmacokinetics/*therapeutic use', 'Digoxin/adverse effects/pharmacokinetics/therapeutic use', 'Dose-Response Relationship, Drug', 'Heart Failure/blood/*drug therapy/mortality', 'Humans', 'Risk Factors', 'Sex Factors', 'Survival Analysis', 'Sympathetic Nervous System/drug effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15868358/
655,nitroglycerin,3120566,Nitrate tolerance.,['Parker JO'],"['Dosage Forms', 'Drug Tolerance', 'Hemodynamics/drug effects', 'Humans', 'Isosorbide Dinitrate/administration & dosage/pharmacology/*therapeutic use', 'Nitroglycerin/administration & dosage/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3120566/
656,nitroglycerin,19267787,Nitroglycerin headache and nitroglycerin-induced primary headaches from 1846 and onwards: a historical overview and an update.,"['Tfelt-Hansen PC', 'Tfelt-Hansen J']","['Headache Disorders, Primary/*chemically induced/*history', 'History, 19th Century', 'History, 20th Century', 'History, 21st Century', 'Humans', 'Nitroglycerin/*adverse effects', 'Vasodilator Agents/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/19267787/
657,nitroglycerin,4207612,Instability of nitroglycerin tablets.,['Mayer GA'],"['Angina Pectoris/drug therapy', '*Drug Stability', 'Headache/chemically induced', 'Humans', 'Middle Aged', 'Nitroglycerin/*administration & dosage/adverse effects/therapeutic use', 'Refrigeration', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/4207612/
658,nitroglycerin,18658016,Recent advances in the pharmacotherapy of chronic anal fissure: an update.,"['Medhi B', 'Rao RS', 'Prakash A', 'Prakash O', 'Kaman L', 'Pandhi P']","['Administration, Topical', 'Adrenergic alpha-Antagonists/administration & dosage', 'Anal Canal', 'Botulinum Toxins/*administration & dosage', 'Calcium Channel Blockers/administration & dosage', 'Chronic Disease/*drug therapy', 'Clinical Trials as Topic', 'Diltiazem/administration & dosage', 'Fissure in Ano/*drug therapy', 'Headache/chemically induced', 'Humans', 'Indoramin/administration & dosage', 'Injections, Intralesional', 'Lidocaine/administration & dosage', 'Nifedipine/administration & dosage', 'Nitroglycerin/*administration & dosage/adverse effects', 'Ointments']",https://pubmed.ncbi.nlm.nih.gov/18658016/
659,nitroglycerin,11723312,Progress in the understanding and treatment of chronic anal fissure.,"['McCallion K', 'Gardiner KR']","['Administration, Topical', 'Anal Canal/drug effects/surgery', 'Botulinum Toxins/therapeutic use', 'Calcium Channel Blockers/therapeutic use', 'Chronic Disease', 'Dilatation/methods', 'Fissure in Ano/etiology/*therapy', 'Humans', 'Nitric Oxide Donors/therapeutic use', 'Nitroglycerin/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/11723312/
660,nitroglycerin,121456,Glyceryl trinitrate ointment in angina pectoris.,"['Salem HH', 'Singh SP']","['Adult', 'Angina Pectoris/*drug therapy', 'Clinical Trials as Topic', 'Exercise Test', 'Female', 'Humans', 'Male', 'Middle Aged', 'Nitroglycerin/administration & dosage/*therapeutic use', 'Ointments', 'Placebos', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/121456/
661,nitroglycerin,21212965,A literature review on the role of chemical sphincterotomy after Milligan-Morgan hemorrhoidectomy.,"['Siddiqui MR', 'Abraham-Igwe C', 'Shangumanandan A', 'Grassi V', 'Swift I', 'Abulafi AM']","['Anal Canal/drug effects/*surgery', 'Analgesia', 'Botulinum Toxins/pharmacology/therapeutic use', 'Calcium Channel Blockers/pharmacology/therapeutic use', 'Digestive System Surgical Procedures/adverse effects/*methods', 'Health Planning Guidelines', 'Hemorrhoids/drug therapy/*surgery', 'Humans', 'Nitroglycerin/pharmacology/therapeutic use', 'Pain Measurement', 'Postoperative Complications/etiology', 'Randomized Controlled Trials as Topic', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/21212965/
662,nitroglycerin,3137070,Pharmacokinetics of organic nitrates in man: an overview.,['Bogaert MG'],"['Absorption', 'Administration, Cutaneous', 'Administration, Sublingual', 'Humans', 'Injections, Intravenous', 'Isosorbide Dinitrate/administration & dosage/analogs & derivatives/blood/*pharmacokinetics', 'Nitroglycerin/administration & dosage/blood/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/3137070/
663,nitroglycerin,8154634,Contact dermatitis from nitroglycerin.,"['de la Fuente Prieto R', 'Armentia Medina A', 'Diez Perez JM']","['Administration, Topical', 'Aged', 'Angina Pectoris/drug therapy', 'Dermatitis, Allergic Contact/*etiology', 'Humans', 'Male', 'Middle Aged', 'Nitroglycerin/administration & dosage/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8154634/
664,nitroglycerin,27213950,RNA Sequencing of Trigeminal Ganglia in Rattus Norvegicus after Glyceryl Trinitrate Infusion with Relevance to Migraine.,"['Hougaard Pedersen S', 'Maretty L', 'Ramachandran R', 'Sibbesen JA', 'Yakimov V', 'Elgaard-Christensen R', 'Hansen TF', 'Krogh A', 'Olesen J', 'Jansen-Olesen I']","['Animals', 'Disease Models, Animal', 'Gene Expression Profiling', 'Gene Expression Regulation/drug effects', 'Infusions, Intraventricular', 'Male', 'Migraine Disorders/*chemically induced/*genetics/metabolism', 'Nitroglycerin/administration & dosage/*adverse effects', 'Rats', 'Rats, Sprague-Dawley', 'Sequence Analysis, RNA', 'Trigeminal Ganglion/*drug effects/*metabolism', 'Vasodilator Agents/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27213950/
665,nitroglycerin,3113911,Treatment of acute anginal attacks with nitrates.,['Nyberg G'],"['Administration, Oral', 'Angina Pectoris/*drug therapy', 'Humans', 'Nitrates/*therapeutic use', 'Nitroglycerin/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3113911/
666,nitroglycerin,26027641,Use of nitrates in ischemic heart disease.,"['Giuseppe C', 'Paul J', 'Hans-Ulrich I']","['Angina Pectoris/drug therapy', 'Coronary Artery Disease/chemically induced/drug therapy', 'Delayed-Action Preparations', 'Drug Tolerance', 'Humans', 'Myocardial Ischemia/*drug therapy', 'Nitrates/administration & dosage/adverse effects/*therapeutic use', 'Nitroglycerin']",https://pubmed.ncbi.nlm.nih.gov/26027641/
667,nitroglycerin,3129802,Nitroglycerine-induced volume loading.,"['Bunt TJ', 'Manczuk M', 'Varley KV']","['Aorta, Abdominal', 'Aortic Aneurysm/*surgery', 'Coronary Disease/complications', 'Drug Evaluation', 'Heart Ventricles/physiopathology', 'Hemodynamics/drug effects', 'Humans', 'Intraoperative Care', 'Intraoperative Complications/*prevention & control', 'Myocardial Infarction/*prevention & control', 'Nitroglycerin/*administration & dosage/pharmacology/therapeutic use', '*Premedication', 'Risk', 'Stroke Volume']",https://pubmed.ncbi.nlm.nih.gov/3129802/
668,nitroglycerin,10584234,[Pharmacological profiles of sildenafil (VIAGRA) in the treatment of erectile dysfunction: efficacy and drug interaction with nitrate].,['Omote M'],"['Animals', 'Blood Pressure/drug effects', 'Cyclic GMP/metabolism', 'Dogs', 'Drug Interactions', 'Erectile Dysfunction/*drug therapy', 'Humans', 'Male', 'Nitric Oxide/metabolism/physiology', 'Nitric Oxide Donors/pharmacology', 'Nitroglycerin/*pharmacology', 'Penile Erection/drug effects', 'Penis/metabolism', 'Phosphodiesterase Inhibitors/*pharmacology/therapeutic use', 'Piperazines/*pharmacology/therapeutic use', 'Purines', 'Rabbits', 'Sildenafil Citrate', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/10584234/
669,nitroglycerin,10696937,Cut or paste? The use of glyceryl trinitrate paste in the treatment of acute and chronic anal fissure.,"['Ward DI', 'Miller BJ', 'Schache DJ', 'Cohen JR', 'Theile DE']","['Acute Disease', 'Chronic Disease', 'Combined Modality Therapy', 'Fissure in Ano/*drug therapy/surgery', 'Humans', 'Nitroglycerin/*administration & dosage', 'Ointments', 'Vasodilator Agents/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/10696937/
670,nitroglycerin,1576038,Nitrates.,['Kuhn M'],"['Cardiovascular Diseases/*drug therapy', 'Coronary Disease/drug therapy/nursing', 'Drug Interactions', 'Hemodynamics/drug effects', 'Humans', 'Isosorbide Dinitrate/therapeutic use', 'Nitrates/adverse effects/pharmacology/*therapeutic use', 'Nitroglycerin/administration & dosage/therapeutic use', 'Patient Education as Topic']",https://pubmed.ncbi.nlm.nih.gov/1576038/
671,nitroglycerin,10524660,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,"['Christiansen I', 'Thomsen LL', 'Daugaard D', 'Ulrich V', 'Olesen J']","['Adult', 'Analgesics/therapeutic use', 'Female', 'Hemodynamics/drug effects', 'Humans', 'Male', 'Migraine with Aura/*complications/metabolism', 'Migraine without Aura/*chemically induced/complications/drug therapy/metabolism', 'Nitric Oxide/*physiology', 'Nitroglycerin/*adverse effects', 'Pain Measurement', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/10524660/
672,nitroglycerin,28598453,Effectiveness of 0.2% Glyceryl Trinitrate and 0.5% Nifedipine in the Treatment of Chronic Anal Fissure.,"['Shrestha SK', 'Thapa PB', 'Maharjan DK', 'Tamang TY']","['Drug Therapy, Combination', 'Female', 'Fissure in Ano/*drug therapy', 'Humans', 'Male', 'Middle Aged', 'Nifedipine/*therapeutic use', 'Nitroglycerin/*therapeutic use', 'Prospective Studies', 'Treatment Outcome', 'Vasodilator Agents/*therapeutic use', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/28598453/
673,nitroglycerin,17443133,Inhibition of PKC beta by ruboxistaurin does not enhance the acute blood pressure response to nitroglycerin.,"['Benson C', 'Seger M', 'Voelker J']","['Administration, Oral', 'Adrenergic beta-Antagonists/therapeutic use', 'Aged', 'Angina Pectoris/drug therapy/physiopathology', 'Blood Pressure/*drug effects', 'Chronic Disease', 'Cross-Over Studies', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Administration Schedule', 'Drug Interactions', 'Enzyme Inhibitors/administration & dosage/adverse effects/pharmacology', 'Female', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hypotension, Orthostatic/chemically induced', 'Indoles/administration & dosage/adverse effects/*pharmacology', 'Infusions, Intravenous', 'Male', 'Maleimides/administration & dosage/adverse effects/*pharmacology', 'Middle Aged', 'Nitroglycerin/administration & dosage/adverse effects/*pharmacology', 'Protein Kinase C/*antagonists & inhibitors', 'Protein Kinase C beta', 'Treatment Outcome', 'Vasodilator Agents/administration & dosage/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/17443133/
674,nitroglycerin,32778123,Efficacy of Glyceryl trinitrate (GTN) to facilitate the rewarming process during cardiopulmonary bypass.,"['Mullane D', 'Lenihan M', 'Hanley C', 'Wall T', 'Bukowska I', 'Griffin M', 'Flood G']","['Aged', 'Body Temperature/drug effects', 'Cardiopulmonary Bypass/adverse effects/*methods', 'Humans', 'Hypothermia, Induced/methods', 'Infusions, Intravenous', 'Lactic Acid/blood', 'Middle Aged', 'Nitroglycerin/*administration & dosage', 'Prospective Studies', '*Rewarming', 'Time Factors', 'Vasodilator Agents/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/32778123/
675,azathioprine,30465775,Grand round: Autoimmune hepatitis.,"['Trivedi PJ', 'Hubscher SG', 'Heneghan M', 'Gleeson D', 'Hirschfield GM']","['Adolescent', 'Adult', 'Anti-Inflammatory Agents/administration & dosage/*therapeutic use', 'Azathioprine/administration & dosage/adverse effects/*therapeutic use', 'Clinical Decision-Making', 'Complementary Therapies', 'Drug Tolerance', 'Female', 'Hepatitis, Autoimmune/classification/diagnosis/*drug therapy/*immunology', 'Humans', 'Immunosuppressive Agents/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Precision Medicine/methods', 'Prednisolone/administration & dosage/*therapeutic use', 'Recurrence', 'Risk Factors', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30465775/
676,azathioprine,30783322,Management of myasthenia gravis during pregnancy.,"['Bansal R', 'Goyal MK', 'Modi M']","['Azathioprine/administration & dosage/adverse effects/therapeutic use', 'Cholinesterase Inhibitors/administration & dosage/adverse effects/therapeutic use', '*Disease Management', 'Female', 'Humans', 'Immunosuppressive Agents/administration & dosage/adverse effects/therapeutic use', 'Myasthenia Gravis/*drug therapy', 'Practice Guidelines as Topic', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Pregnancy Outcome', 'Prenatal Care', 'Pyridostigmine Bromide/administration & dosage/adverse effects/therapeutic use', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/30783322/
677,azathioprine,3511372,Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.,"['Austin HA 3rd', 'Klippel JH', 'Balow JE', 'le Riche NG', 'Steinberg AD', 'Plotz PH', 'Decker JL']","['Administration, Oral', 'Adult', 'Azathioprine/administration & dosage/adverse effects/*therapeutic use', 'Biopsy', 'Clinical Trials as Topic', 'Creatinine/blood', 'Cyclophosphamide/administration & dosage/adverse effects/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Glomerulonephritis/*drug therapy/etiology/physiopathology', 'Humans', 'Injections, Intravenous', 'Kidney/pathology', 'Kidney Failure, Chronic/etiology', 'Lupus Erythematosus, Systemic/*complications', 'Male', 'Prednisone/administration & dosage/adverse effects/*therapeutic use', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/3511372/
678,azathioprine,9608317,Update on immunosuppressive therapy.,"['Singer NG', 'McCune WJ']","['Adult', 'Arthritis, Juvenile/drug therapy', 'Azathioprine/adverse effects/therapeutic use', 'Behcet Syndrome/drug therapy', 'Child', 'Cladribine/therapeutic use', 'Cyclophosphamide/administration & dosage/therapeutic use', 'Cyclosporine/therapeutic use', 'Drug Therapy, Combination', 'Granulomatosis with Polyangiitis/drug therapy', 'Humans', 'Hydroxychloroquine/administration & dosage/adverse effects/therapeutic use', 'Immunosuppressive Agents/administration & dosage/adverse effects/*therapeutic use', 'Liver/drug effects/injuries', 'Lung/drug effects', 'Lung Injury', 'Lupus Erythematosus, Systemic/drug therapy', 'Methotrexate/administration & dosage/adverse effects/therapeutic use', 'Pemphigoid, Benign Mucous Membrane/drug therapy', 'Retina/drug effects', 'Tacrolimus/therapeutic use', 'Thalidomide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9608317/
679,azathioprine,25352005,[Optimized thiopurine treatment in chronic inflammatory bowel disease].,"['Kiszka-Kanowitz M', 'Theede K', 'Nielsen AM']","['Algorithms', 'Allopurinol/administration & dosage/adverse effects/metabolism/therapeutic use', 'Antimetabolites/administration & dosage/adverse effects/metabolism/therapeutic use', 'Azathioprine/administration & dosage/adverse effects/metabolism/*therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Humans', 'Immunosuppressive Agents/administration & dosage/adverse effects/metabolism/*therapeutic use', 'Inflammatory Bowel Diseases/*drug therapy', 'Mercaptopurine/administration & dosage/adverse effects/metabolism/*therapeutic use', 'Methyltransferases/administration & dosage/adverse effects/metabolism/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25352005/
680,azathioprine,12765471,Immunosuppressive drug use in pregnancy.,['Petri M'],"['Adrenal Cortex Hormones/adverse effects/pharmacokinetics/therapeutic use', 'Azathioprine/adverse effects/pharmacokinetics/therapeutic use', 'Breast Feeding', 'Cyclophosphamide/adverse effects/pharmacokinetics/therapeutic use', 'Cyclosporine/adverse effects/pharmacokinetics/therapeutic use', 'Female', 'Fetal Diseases/chemically induced', 'Humans', 'Hydroxychloroquine/adverse effects/pharmacokinetics/therapeutic use', 'Immunosuppressive Agents/*adverse effects/pharmacokinetics/*therapeutic use', 'Lupus Erythematosus, Systemic/prevention & control', 'Maternal-Fetal Exchange', 'Mycophenolic Acid/adverse effects/analogs & derivatives/pharmacokinetics/therapeutic use', 'Pregnancy', 'Pregnancy Complications/chemically induced/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/12765471/
681,azathioprine,20949566,Optimizing thiopurine therapy in inflammatory bowel disease.,"['Chevaux JB', 'Peyrin-Biroulet L', 'Sparrow MP']","['Azathioprine/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Immunosuppressive Agents/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Inflammatory Bowel Diseases/*drug therapy', 'Mercaptopurine/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Methyltransferases/metabolism']",https://pubmed.ncbi.nlm.nih.gov/20949566/
682,azathioprine,24438369,Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use.,"['Min MX', 'Weinberg DI', 'McCabe RP']","['Allopurinol/administration & dosage/adverse effects/*therapeutic use', 'Azathioprine/administration & dosage/adverse effects/therapeutic use', 'Drug Monitoring', 'Drug Therapy, Combination', 'Humans', 'Immunosuppressive Agents/administration & dosage/adverse effects/*therapeutic use', 'Inflammatory Bowel Diseases/*drug therapy', 'Mercaptopurine/administration & dosage/adverse effects/therapeutic use', 'Practice Guidelines as Topic']",https://pubmed.ncbi.nlm.nih.gov/24438369/
683,azathioprine,25443224,[Role of thiopurine agents in ulcerative colitis].,"['Chaparro M', 'Gisbert JP']","['Azathioprine/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Colitis, Ulcerative/*drug therapy', 'Crohn Disease/drug therapy', 'Disease Susceptibility', 'Dose-Response Relationship, Drug', 'Humans', 'Immunocompromised Host', 'Immunosuppressive Agents/administration & dosage/pharmacology/*therapeutic use', 'Infections/etiology', 'Mercaptopurine/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Meta-Analysis as Topic', 'Neoplasms/etiology', 'Prodrugs/pharmacokinetics', 'Remission Induction', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25443224/
684,azathioprine,21674420,"Immunosuppressive and cytotoxic therapy: pharmacology, toxicities, and monitoring.","['Wang T', 'Weigt SS', 'Belperio JA', 'Lynch JP 3rd']","['Adrenal Cortex Hormones/*administration & dosage/adverse effects/pharmacology/therapeutic use', '*Anti-Inflammatory Agents/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*drug therapy', 'Azathioprine/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Cyclophosphamide/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Humans', '*Immunosuppressive Agents/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Methotrexate/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Mycophenolic Acid/administration & dosage/adverse effects/analogs & derivatives/pharmacology/therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/21674420/
685,azathioprine,29421584,Effective long-term solution to therapeutic remission in Inflammatory Bowel Disease: Role of Azathioprine.,"['Adam L', 'Phulukdaree A', 'Soma P']","['Azathioprine/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Immunosuppressive Agents/administration & dosage/adverse effects/*therapeutic use', 'Inflammatory Bowel Diseases/*drug therapy/enzymology/immunology', 'Methyltransferases/genetics', 'Polymorphism, Single Nucleotide', 'Remission Induction']",https://pubmed.ncbi.nlm.nih.gov/29421584/
686,azathioprine,25166425,"Progressive, reversible sensorineural hearing loss caused by azathioprine.","['Jenkinson PW', 'Syed MI', 'Mcclymont L']","['Audiometry, Pure-Tone', 'Azathioprine/*adverse effects/*therapeutic use', 'Female', 'Hearing Loss, Sensorineural/*diagnosis/*etiology', 'Humans', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/25166425/
687,azathioprine,4103984,Cyclophosphamide and human organ transplantation.,"['Starzl TE', 'Halgrimson CG', 'Penn I', 'Martineau G', 'Schroter G', 'Amemiya H', 'Putnam CW', 'Groth CG']","['Administration, Oral', 'Adolescent', 'Adult', 'Animals', 'Antilymphocyte Serum/administration & dosage', 'Azathioprine/administration & dosage/adverse effects', 'Cadaver', 'Consanguinity', 'Cyclophosphamide/administration & dosage/*therapeutic use', 'Drug Synergism', 'Female', 'Follow-Up Studies', 'Graft Rejection', 'Histocompatibility', 'Horses', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Injections, Intramuscular', '*Kidney Transplantation', '*Liver Transplantation', 'Male', 'Middle Aged', 'Postoperative Complications', 'Prednisone/administration & dosage', 'Time Factors', 'Transplantation Immunology', 'Transplantation, Homologous']",https://pubmed.ncbi.nlm.nih.gov/4103984/
688,azathioprine,25378092,Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.,"['Mozaffari S', 'Abdolghaffari AH', 'Nikfar S', 'Abdollahi M']","['Adult', 'Azathioprine/administration & dosage/*adverse effects/therapeutic use', 'Female', 'Humans', 'Inflammatory Bowel Diseases/*drug therapy/epidemiology/immunology', 'Infliximab/administration & dosage/*adverse effects/therapeutic use', 'Pregnancy', 'Pregnancy Complications/*drug therapy/epidemiology/immunology', 'Pregnancy Outcome/*epidemiology', 'Prenatal Exposure Delayed Effects/chemically induced/*epidemiology', 'Tumor Necrosis Factor-alpha/*immunology']",https://pubmed.ncbi.nlm.nih.gov/25378092/
689,azathioprine,31862300,Impact of Azathioprine use in chronic hypersensitivity pneumonitis patients.,"['Terras Alexandre A', 'Martins N', 'Raimundo S', 'Melo N', 'Catetano Mota P', 'Novais E Bastos H', 'Pereira JM', 'Cunha R', 'Guimaraes S', 'Souto Moura C', 'Morais A']","['Adult', 'Aged', 'Aged, 80 and over', 'Alveolitis, Extrinsic Allergic/*drug therapy', 'Azathioprine/adverse effects/*therapeutic use', 'Carbon Monoxide', 'Chronic Disease/drug therapy', 'Female', 'Humans', 'Immunosuppressive Agents/adverse effects/*therapeutic use', 'Longitudinal Studies', 'Lung/drug effects', 'Male', 'Middle Aged', 'Respiratory Function Tests', 'Retrospective Studies', 'Total Lung Capacity/drug effects', 'Treatment Outcome', 'Vital Capacity/drug effects']",https://pubmed.ncbi.nlm.nih.gov/31862300/
690,azathioprine,29775790,Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients.,"['Simsek M', 'Meijer B', 'Ramsoekh D', 'Bouma G', 'van der Wouden EJ', 'den Hartog B', 'de Vries AC', 'Hoentjen F', 'Dijkstra G', 'de Boer SY', 'Jansen JM', 'van der Meulen AE', 'Beukers R', 'Brink MA', 'Steinhauser T', 'Oldenburg B', 'Gilissen LP', 'Naber TH', 'Verhagen MA', 'de Boer NKH', 'Mulder CJJ']","['Adolescent', 'Adult', 'Aged', 'Azathioprine/administration & dosage/*adverse effects', 'Female', 'Humans', 'Hyperplasia/chemically induced/*pathology', 'Inflammatory Bowel Diseases/complications/*drug therapy/*pathology', 'Liver Diseases/*pathology', 'Male', 'Mercaptopurine/administration & dosage/*adverse effects', 'Middle Aged', 'Thioguanine/administration & dosage/*adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29775790/
691,azathioprine,30753377,Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study].,"['Hisamatsu T', 'Matsumoto T', 'Watanabe K', 'Nakase H', 'Motoya S', 'Yoshimura N', 'Ishida T', 'Kato S', 'Nakagawa T', 'Esaki M', 'Nagahori M', 'Matsui T', 'Naito Y', 'Kanai T', 'Suzuki Y', 'Nojima M', 'Watanabe M', 'Hibi T']","['Adalimumab/administration & dosage/*therapeutic use', 'Adolescent', 'Adult', 'Aged', 'Anti-Inflammatory Agents/administration & dosage/*therapeutic use', 'Azathioprine/administration & dosage/*adverse effects/therapeutic use', 'Crohn Disease/*drug therapy', 'Drug Therapy, Combination/adverse effects', 'Female', 'Humans', 'Immunosuppressive Agents/administration & dosage/*adverse effects/therapeutic use', 'Japan', 'Kaplan-Meier Estimate', 'Male', 'Middle Aged', 'Patient Dropouts/statistics & numerical data', 'Prospective Studies', 'Risk Factors', 'Sex Factors', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30753377/
692,azathioprine,22170192,Safety of azathioprine use during pregnancy.,"['Natekar A', 'Pupco A', 'Bozzo P', 'Koren G']","['Antimetabolites/*adverse effects/therapeutic use', 'Azathioprine/*adverse effects/therapeutic use', 'Female', 'Humans', 'Immunosuppressive Agents/*adverse effects/therapeutic use', 'Pregnancy', '*Pregnancy Outcome']",https://pubmed.ncbi.nlm.nih.gov/22170192/
693,azathioprine,4884653,Azathioprine in rheumatoid arthritis.,"['Mason M', 'Currey HL', 'Barnes CG', 'Dunne JF', 'Hazleman BL', 'Strickland ID']","['Arthritis, Rheumatoid/*drug therapy', 'Azathioprine/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Drug Synergism', 'Female', 'Humans', 'Male', 'Middle Aged', 'Placebos', 'Prednisolone/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/4884653/
694,glipizide,26204670,HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.,"['Confederat L', 'Constantin S', 'Lupascu F', 'Panzariu A', 'Hancianu M', 'Profire L']","['Chlorpropamide/adverse effects', '*Diabetes Mellitus, Type 2/drug therapy', 'Gliclazide/adverse effects', 'Glipizide/adverse effects', 'Glyburide/adverse effects', 'Humans', 'Hypoglycemia/*chemically induced', 'Hypoglycemic Agents/administration & dosage/*adverse effects', 'Risk Factors', 'Sulfonylurea Compounds/administration & dosage/*adverse effects', 'Tolbutamide/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/26204670/
695,glipizide,37714605,The Patient Faints in the Waiting Area with a Suspected Hypoglycemic Event.,"['Chmieliauskaite M', 'Grosh MD', 'Syed A', 'Pinto A']","['Female', 'Humans', 'Aged', '*Hypoglycemic Agents/adverse effects', '*Hypoglycemia/chemically induced', 'Sulfonylurea Compounds/adverse effects', 'Glipizide']",https://pubmed.ncbi.nlm.nih.gov/37714605/
696,glipizide,34721294,Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.,"['Zhang YS', 'Zheng YD', 'Yuan Y', 'Chen SC', 'Xie BC']","['Diabetes Mellitus, Type 2/*drug therapy', 'Fractures, Bone/*etiology', 'Humans', 'Hypoglycemic Agents/*adverse effects/therapeutic use', 'Network Meta-Analysis', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/34721294/
697,glipizide,19366943,Use of hypoglycemic drugs during lactation.,"['Glatstein MM', 'Djokanovic N', 'Garcia-Bournissen F', 'Finkelstein Y', 'Koren G']","['Administration, Oral', 'Breast Feeding', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug-Related Side Effects and Adverse Reactions', 'Female', 'Glipizide/administration & dosage/adverse effects', 'Glyburide/administration & dosage/adverse effects', 'Humans', 'Hypoglycemic Agents/*administration & dosage/adverse effects', 'Infant, Newborn', 'Lactation/*drug effects', 'Maternal Welfare', 'Milk, Human/drug effects', 'Pregnancy', 'Pregnancy in Diabetics/drug therapy', 'Risk Assessment', 'Sulfonylurea Compounds/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/19366943/
698,glipizide,30246878,Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.,"['Lo C', 'Toyama T', 'Wang Y', 'Lin J', 'Hirakawa Y', 'Jun M', 'Cass A', 'Hawley CM', 'Pilmore H', 'Badve SV', 'Perkovic V', 'Zoungas S']","['Cause of Death', 'Diabetes Mellitus/blood/*drug therapy/mortality', 'Diabetic Nephropathies/blood/*drug therapy/mortality', 'Dipeptidyl-Peptidase IV Inhibitors/therapeutic use', 'Glipizide/adverse effects/therapeutic use', 'Glucagon-Like Peptide 1/agonists', 'Glycated Hemoglobin/drug effects', 'Humans', 'Hypoglycemic Agents/adverse effects/*therapeutic use', 'Insulin/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Renal Insufficiency, Chronic/blood/*drug therapy/mortality', 'Sitagliptin Phosphate/adverse effects/therapeutic use', 'Sodium-Glucose Transporter 2', 'Sodium-Glucose Transporter 2 Inhibitors', 'Thiazolidinediones/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30246878/
699,glipizide,16596036,Antihypertensive pharmacobezoar.,"['Prisant LM', 'Spaulding VC']","['Antihypertensive Agents/*administration & dosage/*adverse effects', 'Bezoars/*etiology', 'Calcium Channel Blockers/administration & dosage', 'Drug Delivery Systems/*adverse effects', 'Gastrointestinal Diseases/*etiology', 'Humans', 'Isradipine/administration & dosage/adverse effects', 'Nifedipine/administration & dosage', 'Postoperative Complications/etiology', 'Tablets', 'Verapamil/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16596036/
700,glipizide,15200348,The role of sulphonylureas in the management of type 2 diabetes mellitus.,['Rendell M'],"['Benzamides/therapeutic use', 'Clinical Trials as Topic', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Therapy, Combination', 'Humans', 'Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use', 'Insulin/therapeutic use', 'Sulfonylurea Compounds/administration & dosage/adverse effects/*therapeutic use', 'Treatment Failure']",https://pubmed.ncbi.nlm.nih.gov/15200348/
701,glipizide,27796819,Sulfonylurea Poisoning in a Healthy Toddler.,"['Kumar S', 'Choudhary A', 'Ali M', 'Gupta V', 'Muralidharan J', 'Singhi SC']","['Gastrointestinal Agents/therapeutic use', 'Glipizide/*poisoning', 'Glucose/therapeutic use', 'Humans', 'Hypoglycemic Agents/*poisoning', 'Infant', 'Male', 'Octreotide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27796819/
702,glipizide,3931464,Pharmacokinetics of glyburide.,['Pearson JG'],"['Acute Kidney Injury/metabolism', 'Blood Glucose/analysis', 'Dose-Response Relationship, Drug', 'Fasting', 'Glipizide/metabolism', 'Glyburide/*metabolism/urine', 'Humans', 'Kidney/metabolism', 'Kinetics', 'Liver/metabolism']",https://pubmed.ncbi.nlm.nih.gov/3931464/
703,glipizide,389600,Glipizide: a review of its pharmacological properties and therapeutic use.,"['Brogden RN', 'Heel RC', 'Pakes GE', 'Speight TM', 'Avery GS']","['Animals', 'Diabetes Mellitus/drug therapy', 'Fatty Acids/blood', 'Glipizide/administration & dosage/adverse effects/metabolism/*pharmacology/therapeutic use', 'Glucagon/blood', 'Humans', 'Hypoglycemic Agents', 'Kinetics', 'Sulfonylurea Compounds/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/389600/
704,glipizide,30471177,Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?,"['Cordiner RLM', 'Pearson ER']","['Diabetes Mellitus/drug therapy/genetics/metabolism', 'Diabetes Mellitus, Type 2/*drug therapy', 'Dipeptidyl-Peptidase IV Inhibitors/therapeutic use', 'Dose-Response Relationship, Drug', 'Gliclazide/therapeutic use', 'Glipizide/therapeutic use', 'Glyburide/therapeutic use', 'History, 20th Century', 'History, 21st Century', 'Humans', 'Hypoglycemic Agents/*therapeutic use', 'Insulin Secretion', 'Insulin-Secreting Cells/drug effects/metabolism', 'Metformin/therapeutic use', 'Sodium-Glucose Transporter 2 Inhibitors/therapeutic use', 'Sulfonylurea Compounds/history/pharmacology/*therapeutic use', 'Treatment Failure', 'Glucagon-Like Peptide-1 Receptor Agonists']",https://pubmed.ncbi.nlm.nih.gov/30471177/
705,glipizide,27292155,Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis.,"['Qi C', 'Bin Li', 'Yang Y', 'Yang Y', 'Li J', 'Zhou Q', 'Wen Y', 'Zeng C', 'Zheng L', 'Zhang Q', 'Li J', 'He X', 'Zhou J', 'Shao C', 'Wang L']","['Angiogenesis Inhibitors/*pharmacology/therapeutic use', 'Animals', 'Antigens, Polyomavirus Transforming/*genetics', 'Cell Line, Tumor', 'Cell Proliferation/drug effects', 'Disease Progression', 'Down-Regulation/drug effects', 'Glipizide/*pharmacology/therapeutic use', 'Human Umbilical Vein Endothelial Cells', 'Humans', 'Liver Neoplasms/pathology/prevention & control/secondary', 'Male', 'Mice', 'Mice, Inbred BALB C', 'Mice, Inbred C57BL', 'Mice, Transgenic', 'Models, Animal', 'Neovascularization, Physiologic/*drug effects', 'Prostatic Neoplasms/drug therapy/metabolism/pathology', 'Rats', 'Rats, Sprague-Dawley', 'Signal Transduction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/27292155/
706,glipizide,3082015,Oral sulfonylureas for the treatment of type II diabetes: an update.,"['Shank WA Jr', 'Morrison AD']","['Administration, Oral', 'Chlorpropamide/adverse effects', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Hypersensitivity/etiology', 'Glipizide/administration & dosage/metabolism/therapeutic use', 'Glyburide/administration & dosage/metabolism/therapeutic use', 'Humans', 'Insulin Resistance', 'Kinetics', 'Liver/metabolism', 'Nausea/chemically induced', 'Patient Education as Topic', 'Sulfonylurea Compounds/administration & dosage/metabolism/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3082015/
707,glipizide,6656850,Drug-induced reversal of early diabetic microangiopathy.,"['Camerini-Davalos RA', 'Velasco C', 'Glasser M', 'Bloodworth JM Jr']","['Adult', 'Basement Membrane/ultrastructure', 'Blood Glucose/metabolism', 'Capillaries/ultrastructure', 'Diabetic Angiopathies/*drug therapy/pathology', 'Female', 'Glipizide/*therapeutic use', 'Glucose Tolerance Test', 'Humans', 'Male', 'Middle Aged', 'Muscles/blood supply', 'Prediabetic State/*drug therapy/pathology', 'Sulfonylurea Compounds/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6656850/
708,glipizide,3925246,Sulfonylureas in the treatment of diabetes mellitus--1985.,['Gerich JE'],"['Blood Glucose/metabolism', 'Body Weight', 'Diabetes Mellitus, Type 1/therapy', 'Diabetes Mellitus, Type 2/diet therapy/*drug therapy', 'Drug Therapy, Combination', 'Glipizide/pharmacology', 'Glyburide/pharmacology', 'Humans', 'Hypoglycemia/etiology', 'Insulin/metabolism/therapeutic use', 'Pancreas/metabolism', 'Sulfonylurea Compounds/administration & dosage/adverse effects/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3925246/
709,glipizide,15979893,Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening.,"['Srinivasan K', 'Viswanad B', 'Asrat L', 'Kaul CL', 'Ramarao P']","['Animals', 'Blood Glucose/analysis', 'Cholesterol/blood', 'Diabetes Mellitus, Experimental/*chemically induced/drug therapy/*etiology', 'Dietary Fats/*administration & dosage', 'Glipizide/pharmacology', 'Glucose Tolerance Test', 'Hypoglycemic Agents/*pharmacology', 'Insulin/blood', 'Male', 'Pioglitazone', 'Rats', 'Rats, Sprague-Dawley', 'Streptozocin', 'Thiazolidinediones/pharmacology', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/15979893/
710,glipizide,8992534,[Glipizide--a short-acting sulphonylurea derivative].,['Ogonowski J'],"['Aged', 'Diabetes Mellitus/*drug therapy', 'Drug Therapy, Combination', 'Glipizide/*pharmacology', 'Humans', 'Hypoglycemic Agents/*pharmacology', 'Insulin/administration & dosage', 'Remission Induction']",https://pubmed.ncbi.nlm.nih.gov/8992534/
711,glipizide,6369969,Long-term safety and efficacy of glipizide.,"['Feinglos MN', 'Lebovitz HE']","['Blood Glucose/metabolism', 'Diabetes Mellitus, Type 2/*drug therapy/metabolism', 'Female', 'Glipizide/adverse effects/*therapeutic use', 'Glucose Tolerance Test', 'Humans', 'Insulin/metabolism', 'Insulin Resistance', 'Male', 'Middle Aged', 'Sulfonylurea Compounds/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6369969/
712,glipizide,12517365,"Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.","['Rogers JF', 'Nafziger AN', 'Bertino JS Jr']","['Anti-Arrhythmia Agents/metabolism', 'Antidepressive Agents, Tricyclic/metabolism', 'Aryl Hydrocarbon Hydroxylases/metabolism', 'Codeine/metabolism', 'Cytochrome P-450 CYP2C19', 'Cytochrome P-450 CYP2C9', 'Cytochrome P-450 CYP2D6/metabolism', 'Cytochrome P-450 Enzyme System/*metabolism', 'Diazepam/metabolism', 'Genotype', 'Glipizide/metabolism', 'Humans', 'Mixed Function Oxygenases/metabolism', 'Omeprazole/metabolism', 'Pharmacogenetics', 'Phenotype', 'Phenytoin/metabolism', 'Warfarin/metabolism']",https://pubmed.ncbi.nlm.nih.gov/12517365/
713,doxepin,37549414,Insomnia Management: A Review and Update.,['Shaha DP'],"['Humans', '*Sleep Initiation and Maintenance Disorders/diagnosis/drug therapy', 'Sleep', 'Zolpidem', 'Doxepin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/37549414/
714,doxepin,35843245,Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.,"['De Crescenzo F', ""D'Alo GL"", 'Ostinelli EG', 'Ciabattini M', 'Di Franco V', 'Watanabe N', 'Kurtulmus A', 'Tomlinson A', 'Mitrova Z', 'Foti F', 'Del Giovane C', 'Quested DJ', 'Cowen PJ', 'Barbui C', 'Amato L', 'Efthimiou O', 'Cipriani A']","['Adult', 'Benzodiazepines/therapeutic use', 'Doxepin/therapeutic use', 'Eszopiclone/therapeutic use', 'Humans', 'Melatonin/therapeutic use', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Zolpidem/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35843245/
715,doxepin,28671376,Insomnia: Pharmacologic Therapy.,"['Matheson E', 'Hainer BL']","['Benzodiazepines/administration & dosage/therapeutic use', 'Doxepin/administration & dosage/therapeutic use', 'Humans', 'Hypnotics and Sedatives/administration & dosage/therapeutic use', 'Melatonin/administration & dosage/agonists/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/28671376/
716,doxepin,29487083,"Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery.","['Atkin T', 'Comai S', 'Gobbi G']","['Benzodiazepines/adverse effects/pharmacology/*therapeutic use', 'Drug Discovery/*methods', 'Humans', 'Hypnotics and Sedatives/adverse effects/pharmacology/*therapeutic use', 'Pharmacology, Clinical/*methods', 'Precision Medicine', 'Sleep Aids, Pharmaceutical/adverse effects/pharmacology/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/29487083/
717,doxepin,28791566,Effects of Antidepressants on Sleep.,"['Wichniak A', 'Wierzbicka A', 'Walecka M', 'Jernajczyk W']","['Antidepressive Agents/administration & dosage/*adverse effects', 'Depressive Disorder/*drug therapy', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Humans', 'Sleep/*drug effects', 'Sleep Wake Disorders/*chemically induced', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/28791566/
718,doxepin,1361426,Urticaria and angioedema.,"['Davidson AE', 'Miller SD', 'Settipane G', 'Klein D']","['Acute Disease', 'Adrenal Cortex Hormones/therapeutic use', 'Angioedema/etiology/*physiopathology/therapy', 'Chronic Disease', 'Doxepin/therapeutic use', 'Drug Therapy, Combination', 'Histamine H1 Antagonists/therapeutic use', 'Histamine H2 Antagonists/therapeutic use', 'Humans', 'Urticaria/etiology/*physiopathology/therapy']",https://pubmed.ncbi.nlm.nih.gov/1361426/
719,doxepin,29562618,Transdermal and Topical Drug Administration in the Treatment of Pain.,"['Leppert W', 'Malec-Milewska M', 'Zajaczkowska R', 'Wordliczek J']","['Administration, Cutaneous', 'Administration, Topical', 'Analgesics/*administration & dosage/*therapeutic use', 'Analgesics, Opioid/administration & dosage/therapeutic use', 'Animals', 'Humans', 'Pain/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/29562618/
720,doxepin,12389450,[Cold-induced urticaria].,"['Delorme N', 'Drouet M', 'Thibaudeau A', 'Verret JL']","['Acetates/therapeutic use', 'Adrenal Cortex Hormones/therapeutic use', 'Aminophylline/administration & dosage/therapeutic use', 'Cold Temperature/*adverse effects', 'Cyclopropanes', 'Doxepin/therapeutic use', 'Drug Therapy, Combination', 'Female', 'Genes, Dominant', 'Histamine H1 Antagonists/therapeutic use', 'Humans', 'Hypotension/etiology', 'Male', 'Quinolines/therapeutic use', 'Stanozolol/therapeutic use', 'Sulfides', 'Terbutaline/administration & dosage/therapeutic use', 'Urticaria/diagnosis/drug therapy/*etiology/genetics/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/12389450/
721,doxepin,27826702,Structural Analysis of the Histamine H(1) Receptor.,"['Shiroishi M', 'Kobayashi T']","['Animals', 'Binding Sites/physiology', 'Doxepin/chemistry/pharmacology', 'Histamine/chemistry/metabolism', 'Histamine Antagonists/chemistry/pharmacology', 'Histamine H1 Antagonists/chemistry/metabolism', 'Humans', 'Protein Binding/drug effects', 'Receptors, Histamine H1/*chemistry/metabolism']",https://pubmed.ncbi.nlm.nih.gov/27826702/
722,doxepin,37821573,Pharmacological interventions for antipsychotic-related sialorrhea: a systematic review and network meta-analysis of randomized trials.,"['Fornaro M', 'Caiazza C', 'Solini N', 'De Prisco M', 'Billeci M', 'Vannini M', 'Shorr R', 'Caiolo S', 'Lussignoli M', 'Siskind D', 'Pigato G', 'Barone A', 'Sambataro F', 'de Bartolomeis A', 'Correll CU', 'Solmi M']","['Adult', 'Humans', '*Antipsychotic Agents/adverse effects', '*Clozapine/therapeutic use', 'Sulpiride/adverse effects', 'Amisulpride/adverse effects', '*Sialorrhea/chemically induced/drug therapy', 'Doxepin/adverse effects', 'Amitriptyline/adverse effects', 'Network Meta-Analysis', 'Propantheline/adverse effects', 'Trihexyphenidyl/adverse effects', 'Metoclopramide/adverse effects', 'Chlorpheniramine/adverse effects', 'Astemizole/adverse effects', 'Randomized Controlled Trials as Topic', 'Cyproheptadine/adverse effects', 'Diphenhydramine/adverse effects', 'Ipratropium/adverse effects', 'Atropine Derivatives/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37821573/
723,doxepin,39746731,Insomnia in older adults: A review of treatment options.,"['Leon-Barriera R', 'Chaplin MM', 'Kaur J', 'Modesto-Lowe V']","['Humans', '*Sleep Initiation and Maintenance Disorders/therapy/etiology', 'Aged', '*Hypnotics and Sedatives/therapeutic use/adverse effects', '*Cognitive Behavioral Therapy/methods', 'Melatonin/therapeutic use', 'Indenes/therapeutic use', 'Orexin Receptor Antagonists/therapeutic use/adverse effects', 'Doxepin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39746731/
724,doxepin,30990550,Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial.,"['Sio TT', 'Le-Rademacher JG', 'Leenstra JL', 'Loprinzi CL', 'Rine G', 'Curtis A', 'Singh AK', 'Martenson JA Jr', 'Novotny PJ', 'Tan AD', 'Qin R', 'Ko SJ', 'Reiter PL', 'Miller RC']","['Administration, Topical', 'Adult', 'Aged', 'Aged, 80 and over', 'Antacids/*therapeutic use', 'Diphenhydramine/adverse effects/*therapeutic use', 'Double-Blind Method', 'Doxepin/adverse effects/*therapeutic use', 'Fatigue/chemically induced', 'Female', 'Head and Neck Neoplasms/*radiotherapy', 'Humans', 'Lidocaine/adverse effects/*therapeutic use', 'Linear Models', 'Male', 'Middle Aged', '*Mouthwashes', 'Pain/drug therapy', 'Radiation Injuries/*drug therapy', 'Stomatitis/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/30990550/
725,doxepin,6612411,Doxepin and tinnitus.,"['Golden RN', 'Evans DL', 'Nau CH Jr']","['Aged', 'Depressive Disorder/drug therapy', 'Doxepin/*adverse effects', 'Female', 'Humans', 'Tinnitus/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/6612411/
726,doxepin,2878798,"Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.","['Benfield P', 'Heel RC', 'Lewis SP']","['Animals', 'Cardiovascular System/drug effects', 'Central Nervous System/drug effects', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', 'Drug Interactions', 'Endocrine Glands/drug effects', '*Fluoxetine/administration & dosage/adverse effects/metabolism/pharmacology/therapeutic use', 'Humans', 'Kinetics', 'Neurotransmitter Agents/metabolism', '*Propylamines/administration & dosage/adverse effects/metabolism/pharmacology/therapeutic use', 'Receptors, Neurotransmitter/metabolism', 'Serotonin/metabolism']",https://pubmed.ncbi.nlm.nih.gov/2878798/
727,doxepin,27578080,Neurologic Itch Management.,['Savk E'],"['Acupuncture Therapy', 'Amines/therapeutic use', 'Anesthetics, Local/*therapeutic use', 'Anticonvulsants/*therapeutic use', 'Antipruritics/*therapeutic use', 'Botulinum Toxins, Type A/therapeutic use', 'Calcineurin Inhibitors/therapeutic use', 'Cannabinoid Receptor Agonists/therapeutic use', 'Capsaicin/therapeutic use', 'Cyclohexanecarboxylic Acids/therapeutic use', 'Doxepin/therapeutic use', 'Gabapentin', 'Humans', 'Neuromuscular Agents/*therapeutic use', 'Peripheral Nervous System Diseases/complications/*therapy', 'Phototherapy', 'Physical Therapy Modalities', 'Pregabalin/therapeutic use', 'Pruritus/etiology/*therapy', 'Tacrolimus/therapeutic use', 'Transcranial Magnetic Stimulation', 'Transcutaneous Electric Nerve Stimulation', 'gamma-Aminobutyric Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27578080/
728,doxepin,8517180,Death due to overdose of antidepressants: experiences from Norway.,['Retterstol N'],"['Adolescent', 'Adult', 'Aged', 'Amitriptyline/poisoning', 'Antidepressive Agents/*poisoning', 'Doxepin/poisoning', 'Drug Overdose/mortality', 'Female', 'Humans', 'Male', 'Middle Aged', 'Norway/epidemiology', 'Suicide/*statistics & numerical data']",https://pubmed.ncbi.nlm.nih.gov/8517180/
729,doxepin,9437474,"Mirtazapine, an antidepressant.",['Puzantian T'],"['Animals', 'Antidepressive Agents, Tricyclic/pharmacokinetics/pharmacology/*therapeutic use', 'Depressive Disorder/*drug therapy/psychology', 'Humans', 'Mianserin/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Mirtazapine']",https://pubmed.ncbi.nlm.nih.gov/9437474/
730,doxepin,15359567,The role of metabolites in bioequivalence.,"['Midha KK', 'Rawson MJ', 'Hubbard JW']","['Area Under Curve', 'Biotransformation', 'Clinical Trials as Topic', 'Doxepin/*analogs & derivatives/pharmacokinetics', 'Guidelines as Topic', 'Humans', 'Liver/metabolism', 'Nortriptyline/*analogs & derivatives/pharmacokinetics', 'Pharmaceutical Preparations/*metabolism', '*Pharmacokinetics', 'Therapeutic Equivalency', 'United States', 'United States Food and Drug Administration/legislation & jurisprudence']",https://pubmed.ncbi.nlm.nih.gov/15359567/
731,doxepin,12469964,Topical tacrolimus: a new therapy for atopic dermatitis.,['Russell JJ'],"['Administration, Cutaneous', 'Clinical Trials as Topic', 'Dermatitis, Atopic/*drug therapy', 'Dermatologic Agents/*administration & dosage/adverse effects/pharmacology', 'Humans', 'Immunosuppressive Agents/*administration & dosage/adverse effects/pharmacology', 'Tacrolimus/*administration & dosage/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/12469964/
732,Gefitinib,33466795,Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.,"['Ohmori T', 'Yamaoka T', 'Ando K', 'Kusumoto S', 'Kishino Y', 'Manabe R', 'Sagara H']","['Acrylamides/adverse effects/therapeutic use', 'Afatinib/adverse effects/therapeutic use', 'Aniline Compounds/adverse effects/therapeutic use', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics', 'ErbB Receptors/*antagonists & inhibitors/genetics', 'Gefitinib/adverse effects/therapeutic use', 'Humans', 'Lung Diseases, Interstitial/chemically induced/*diagnosis', 'Lung Injury/chemically induced/*diagnosis', 'Lung Neoplasms/*drug therapy/genetics', 'Mutation', 'Protein Kinase Inhibitors/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33466795/
733,Gefitinib,32778129,FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.,"['Sun C', 'Gao W', 'Liu J', 'Cheng H', 'Hao J']","['A549 Cells', 'Animals', 'Antineoplastic Agents/pharmacology/*therapeutic use', 'Apoptosis/drug effects/physiology', 'Carcinoma, Non-Small-Cell Lung/drug therapy/*metabolism/pathology', 'Cell Survival/drug effects/physiology', 'Drug Resistance, Neoplasm/drug effects/*physiology', 'Fibrinogen/antagonists & inhibitors/*biosynthesis', 'Gefitinib/pharmacology/*therapeutic use', 'Humans', 'Lung Neoplasms/drug therapy/*metabolism/pathology', 'Mice', 'Mice, Inbred BALB C', 'Mice, Nude', 'Xenograft Model Antitumor Assays/methods']",https://pubmed.ncbi.nlm.nih.gov/32778129/
734,Gefitinib,29978332,Metastatic and triple-negative breast cancer: challenges and treatment options.,"['Al-Mahmood S', 'Sapiezynski J', 'Garbuzenko OB', 'Minko T']","['Animals', 'Biomarkers, Tumor/*metabolism', 'Clinical Trials as Topic', 'Combined Modality Therapy/*methods', 'ErbB Receptors/antagonists & inhibitors', 'Female', 'Gefitinib/therapeutic use', 'Genetic Therapy', 'Humans', 'Neoplasm Metastasis', 'Prognosis', 'RNA, Small Interfering/administration & dosage', 'Triple Negative Breast Neoplasms/metabolism/*therapy']",https://pubmed.ncbi.nlm.nih.gov/29978332/
735,Gefitinib,31411950,Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.,"['Noronha V', 'Patil VM', 'Joshi A', 'Menon N', 'Chougule A', 'Mahajan A', 'Janu A', 'Purandare N', 'Kumar R', 'More S', 'Goud S', 'Kadam N', 'Daware N', 'Bhattacharjee A', 'Shah S', 'Yadav A', 'Trivedi V', 'Behel V', 'Dutt A', 'Banavali SD', 'Prabhash K']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Carboplatin/administration & dosage/adverse effects', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/enzymology/genetics', 'ErbB Receptors/antagonists & inhibitors/genetics', 'Female', 'Gefitinib/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Lung Neoplasms/*drug therapy/enzymology/genetics', 'Male', 'Middle Aged', 'Mutation', 'Pemetrexed/administration & dosage/adverse effects', 'Progression-Free Survival', 'Protein Kinase Inhibitors/adverse effects/therapeutic use', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/31411950/
736,Gefitinib,21119248,Geftinib.,"['Gupta A', 'Raina V']","['Antineoplastic Agents/adverse effects/pharmacology/*therapeutic use', 'ErbB Receptors/genetics', 'Gefitinib', 'Humans', 'Mutation', 'Neoplasms/*drug therapy/ethnology', 'Quinazolines/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21119248/
737,Gefitinib,35960896,Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR.,"['Miyauchi E', 'Morita S', 'Nakamura A', 'Hosomi Y', 'Watanabe K', 'Ikeda S', 'Seike M', 'Fujita Y', 'Minato K', 'Ko R', 'Harada T', 'Hagiwara K', 'Kobayashi K', 'Nukiwa T', 'Inoue A']","['Humans', '*Carcinoma, Non-Small-Cell Lung/drug therapy/genetics', 'Gefitinib/therapeutic use', 'Pemetrexed', '*Lung Neoplasms/drug therapy/genetics', 'Protein Kinase Inhibitors/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'ErbB Receptors/genetics', 'Mutation']",https://pubmed.ncbi.nlm.nih.gov/35960896/
738,Gefitinib,36738759,"Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial.","['Horne AW', 'Tong S', 'Moakes CA', 'Middleton LJ', 'Duncan WC', 'Mol BW', 'Whitaker LHR', 'Jurkovic D', 'Coomarasamy A', 'Nunes N', 'Holland T', 'Clarke F', 'Doust AM', 'Daniels JP']","['Pregnancy', 'Female', 'Humans', '*Methotrexate', 'Gefitinib/therapeutic use', '*Pregnancy, Ectopic/chemically induced/drug therapy', 'Proportional Hazards Models', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/36738759/
739,Gefitinib,24794908,Gefitinib.,"['Rahman AF', 'Korashy HM', 'Kassem MG']","['Animals', 'Antineoplastic Agents/*analysis/*chemistry/pharmacokinetics/therapeutic use', 'Carcinoma, Non-Small-Cell Lung/drug therapy/metabolism', 'Chemistry, Pharmaceutical', 'Drug Resistance, Neoplasm', 'ErbB Receptors/antagonists & inhibitors', 'Gefitinib', 'Humans', 'Lung Neoplasms/drug therapy/metabolism', 'Quinazolines/*analysis/*chemistry/pharmacokinetics/therapeutic use', 'Solubility']",https://pubmed.ncbi.nlm.nih.gov/24794908/
740,Gefitinib,33332190,Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.,"['Zhong WZ', 'Wang Q', 'Mao WM', 'Xu ST', 'Wu L', 'Wei YC', 'Liu YY', 'Chen C', 'Cheng Y', 'Yin R', 'Yang F', 'Ren SX', 'Li XF', 'Li J', 'Huang C', 'Liu ZD', 'Xu S', 'Chen KN', 'Xu SD', 'Liu LX', 'Yu P', 'Wang BH', 'Ma HT', 'Yang JJ', 'Yan HH', 'Yang XN', 'Liu SY', 'Zhou Q', 'Wu YL']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/mortality/pathology', 'Chemotherapy, Adjuvant', 'China', 'Cisplatin/adverse effects/*therapeutic use', 'Disease-Free Survival', 'ErbB Receptors/genetics', 'Female', 'Gefitinib/adverse effects/*therapeutic use', 'Humans', 'Lung Neoplasms/*drug therapy/genetics/mortality/pathology', 'Male', 'Middle Aged', '*Mutation', 'Neoplasm Staging', 'Time Factors', 'Vinorelbine/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33332190/
741,Gefitinib,37392558,Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC.,"['Liu WJ', 'Wang L', 'Zhou FM', 'Liu SW', 'Wang W', 'Zhao EJ', 'Yao QJ', 'Li W', 'Zhao YQ', 'Shi Z', 'Qiu JG', 'Jiang BH']","['Humans', 'Carcinogenesis', '*Carcinoma, Non-Small-Cell Lung/drug therapy/genetics', 'Cell Line, Tumor', 'Drug Resistance, Neoplasm/genetics', 'ErbB Receptors', 'Gefitinib/pharmacology/therapeutic use', 'Interleukin-8/genetics', '*Lung Neoplasms/drug therapy/genetics', 'Mutation', 'NADPH Oxidase 4/genetics', '*Tyrosine Kinase Inhibitors/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/37392558/
742,Gefitinib,34707044,Rhabdomyolysis Caused by Gefitinib Overdose.,"['Obayashi S', 'Tomomatsu K', 'Urata M', 'Tanaka J', 'Niimi K', 'Hayama N', 'Oguma T', 'Asano K', 'Ito Y']","['*Antineoplastic Agents/adverse effects', '*Carcinoma, Non-Small-Cell Lung/drug therapy', 'ErbB Receptors/genetics', 'Gefitinib/adverse effects', 'Humans', '*Lung Neoplasms/drug therapy', 'Mutation', 'Protein Kinase Inhibitors/therapeutic use', 'Quinazolines/adverse effects', '*Rhabdomyolysis/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34707044/
743,Gefitinib,37463108,NAT10-mediated ac4C tRNA modification promotes EGFR mRNA translation and gefitinib resistance in cancer.,"['Wei W', 'Zhang S', 'Han H', 'Wang X', 'Zheng S', 'Wang Z', 'Yang C', 'Wang L', 'Ma J', 'Guo S', 'Wang J', 'Liu L', 'Choe J', 'Lin S']","['Animals', 'Mice', 'ErbB Receptors/genetics', 'Gefitinib/pharmacology/therapeutic use', '*Neoplasms', 'Protein Biosynthesis', '*RNA, Transfer/genetics', 'Humans', 'Cell Line, Tumor', '*N-Terminal Acetyltransferases/genetics', 'Drug Resistance, Neoplasm']",https://pubmed.ncbi.nlm.nih.gov/37463108/
744,Gefitinib,37146936,Reprogramming of TAMs via the STAT3/CD47-SIRPalpha axis promotes acquired resistance to EGFR-TKIs in lung cancer.,"['Lu J', 'Li J', 'Lin Z', 'Li H', 'Lou L', 'Ding W', 'Ouyang S', 'Wu Y', 'Wen Y', 'Chen X', 'Yue P', 'Wang Y', 'Liu P', 'Lu J', 'Zhang J', 'Feng W', 'Zhang X']","['Humans', 'Gefitinib/pharmacology/therapeutic use', '*ErbB Receptors/metabolism', 'Tumor-Associated Macrophages/metabolism', 'Protein Kinase Inhibitors/pharmacology/therapeutic use', 'Drug Resistance, Neoplasm', 'Cell Line, Tumor', '*Lung Neoplasms/drug therapy/genetics/pathology', 'Tumor Microenvironment', 'STAT3 Transcription Factor/metabolism']",https://pubmed.ncbi.nlm.nih.gov/37146936/
745,Gefitinib,36753281,"Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study.","['Hou X', 'Li M', 'Wu G', 'Feng W', 'Su J', 'Jiang H', 'Jiang G', 'Chen J', 'Zhang B', 'You Z', 'Liu Q', 'Chen L']","['Female', 'Humans', 'Male', 'Middle Aged', '*Brain Neoplasms/drug therapy/genetics', '*Carcinoma, Non-Small-Cell Lung/drug therapy/genetics', 'ErbB Receptors/genetics', '*Gefitinib/therapeutic use/adverse effects', '*Lung Neoplasms/drug therapy/genetics', 'Prospective Studies', 'Protein Kinase Inhibitors', 'Adult', 'Aged', 'Aged, 80 and over']",https://pubmed.ncbi.nlm.nih.gov/36753281/
746,Gefitinib,34118816,Gefitinib-associated lichen planus pigmentosus-like eruption.,"['Chuenwipasakul D', 'Wititsuwannakul J', 'Asawanonda P', 'Rerknimitr P']","['Antineoplastic Agents/*adverse effects/therapeutic use', 'Carcinoma, Non-Small-Cell Lung/drug therapy', 'Drug Eruptions/*etiology', 'Female', 'Gefitinib/*adverse effects/therapeutic use', 'Humans', 'Hyperpigmentation/*chemically induced', 'Lichen Planus/*chemically induced', 'Lung Neoplasms/drug therapy', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/34118816/
747,Gefitinib,30358009,Novel application of metformin combined with targeted drugs on anticancer treatment.,"['Deng J', 'Peng M', 'Wang Z', 'Zhou S', 'Xiao D', 'Deng J', 'Yang X', 'Peng J', 'Yang X']","['Administration, Intravesical', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Drug Resistance, Neoplasm/*drug effects', 'Gefitinib/administration & dosage', 'Humans', 'Metformin/administration & dosage', 'Molecular Targeted Therapy/*methods', 'Treatment Outcome', 'Urinary Bladder Neoplasms/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30358009/
748,Gefitinib,12381224,Gefitinib.,"['Culy CR', 'Faulds D']","['Administration, Oral', 'Animals', 'Antineoplastic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Biological Availability', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology', 'Clinical Trials, Phase I as Topic', 'Clinical Trials, Phase II as Topic', 'ErbB Receptors/*antagonists & inhibitors', 'Gefitinib', 'Humans', 'Inhibitory Concentration 50', 'Lung Neoplasms/*drug therapy/pathology', 'Quinazolines/adverse effects/pharmacokinetics/*therapeutic use', 'Signal Transduction/drug effects', 'Treatment Outcome', 'Tumor Cells, Cultured']",https://pubmed.ncbi.nlm.nih.gov/12381224/
749,Gefitinib,33331989,Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.,"['Mok TS', 'Cheng Y', 'Zhou X', 'Lee KH', 'Nakagawa K', 'Niho S', 'Chawla A', 'Rosell R', 'Corral J', 'Migliorino MR', 'Pluzanski A', 'Noonan K', 'Tang Y', 'Pastel M', 'Wilner KD', 'Wu YL']","['Aged', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*pharmacology', 'Carcinoma, Non-Small-Cell Lung/diagnosis/*drug therapy/metabolism', 'Dose-Response Relationship, Drug', 'ErbB Receptors/antagonists & inhibitors/genetics/metabolism', 'Female', 'Gefitinib/administration & dosage/*pharmacology', 'Humans', 'Lung Neoplasms/diagnosis/*drug therapy/metabolism', 'Male', 'Mutation', 'Protein Kinase Inhibitors/administration & dosage/*pharmacology', 'Quinazolinones/administration & dosage/*pharmacology', 'Survival Analysis']",https://pubmed.ncbi.nlm.nih.gov/33331989/
750,Gefitinib,16610973,Gefitinib: an adverse effects profile.,['Cersosimo RJ'],"['Aged', 'Antineoplastic Agents/administration & dosage/*adverse effects', 'Carcinoma, Non-Small-Cell Lung/drug therapy', 'Diarrhea/chemically induced', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'ErbB Receptors/*antagonists & inhibitors', 'Exanthema/chemically induced', 'Female', 'Gefitinib', 'Humans', 'Lung Diseases, Interstitial/chemically induced', 'Lung Neoplasms/drug therapy', 'Male', 'Middle Aged', 'Quinazolines/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16610973/
751,Gefitinib,31682542,Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.,"['Hosomi Y', 'Morita S', 'Sugawara S', 'Kato T', 'Fukuhara T', 'Gemma A', 'Takahashi K', 'Fujita Y', 'Harada T', 'Minato K', 'Takamura K', 'Hagiwara K', 'Kobayashi K', 'Nukiwa T', 'Inoue A']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Carboplatin/administration & dosage/adverse effects', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/enzymology/genetics', 'ErbB Receptors/antagonists & inhibitors/genetics', 'Female', 'Gefitinib/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Lung Neoplasms/*drug therapy/enzymology/genetics', 'Male', 'Middle Aged', 'Mutation', 'Pemetrexed/administration & dosage/adverse effects', 'Progression-Free Survival', 'Protein Kinase Inhibitors/adverse effects/therapeutic use', 'Quality of Life', 'Survival Rate']",https://pubmed.ncbi.nlm.nih.gov/31682542/
752,duloxetine,36791450,Fibromyalgia: Diagnosis and Management.,"['Winslow BT', 'Vandal C', 'Dang L']","['Humans', 'Female', '*Fibromyalgia/diagnosis/therapy', '*Chronic Pain/drug therapy', 'Pregabalin/therapeutic use', 'Analgesics/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36791450/
753,duloxetine,37670573,Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy.,"['Jang HN', 'Oh TJ']","['United States', 'Humans', '*Diabetic Neuropathies/complications/drug therapy', 'Capsaicin/therapeutic use', 'Quality of Life', 'Duloxetine Hydrochloride/therapeutic use', '*Neuralgia/drug therapy/etiology', '*Diabetes Mellitus/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37670573/
754,duloxetine,21366359,Duloxetine: clinical pharmacokinetics and drug interactions.,"['Knadler MP', 'Lobo E', 'Chappell J', 'Bergstrom R']","['Adrenergic Uptake Inhibitors/administration & dosage/adverse effects/*pharmacokinetics', 'Adult', 'Aged', 'Animals', 'Drug Interactions', 'Duloxetine Hydrochloride', 'Female', 'Humans', 'Male', 'Middle Aged', 'Pharmacogenetics', 'Risk Assessment', 'Risk Factors', 'Selective Serotonin Reuptake Inhibitors/administration & dosage/adverse effects/*pharmacokinetics', 'Thiophenes/administration & dosage/adverse effects/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/21366359/
755,duloxetine,25952601,Burning mouth syndrome: a review and update.,"['Silvestre FJ', 'Silvestre-Rangil J', 'Lopez-Jornet P']","['Adult', 'Age Distribution', 'Aged', 'Algorithms', 'Amisulpride', 'Antidepressive Agents/therapeutic use', '*Burning Mouth Syndrome/diagnosis/epidemiology/physiopathology/psychology/therapy', 'Clonazepam/therapeutic use', 'Deficiency Diseases/complications', 'Dentures/adverse effects', 'Duloxetine Hydrochloride/therapeutic use', 'Female', 'Humans', 'Male', 'Menopause', 'Middle Aged', 'Mood Disorders/epidemiology', 'Nerve Fibers, Unmyelinated/physiology', 'Orthodontic Appliances', 'Sex Distribution', 'Sulpiride/analogs & derivatives/therapeutic use', 'Tongue Habits']",https://pubmed.ncbi.nlm.nih.gov/25952601/
756,duloxetine,37183813,Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions.,"['Fagan HA', 'Baldwin DS']","['Humans', '*Anti-Anxiety Agents/therapeutic use', 'Anxiety Disorders/drug therapy/psychology', 'Duloxetine Hydrochloride/therapeutic use', 'Pregabalin/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37183813/
757,duloxetine,37085164,Combination therapy for painful diabetic neuropathy is safe and effective.,"['Saul H', 'Deeney B', 'Imison C', 'Tesfaye S']","['Humans', '*Diabetic Neuropathies/drug therapy', 'Pregabalin/therapeutic use', 'Analgesics/therapeutic use', 'Amitriptyline/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use', 'Treatment Outcome', 'Double-Blind Method', '*Diabetes Mellitus']",https://pubmed.ncbi.nlm.nih.gov/37085164/
758,duloxetine,30016772,Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.,"['Fava GA', 'Benasi G', 'Lucente M', 'Offidani E', 'Cosci F', 'Guidi J']","['Adrenergic Uptake Inhibitors/*adverse effects/therapeutic use', 'Desvenlafaxine Succinate/adverse effects/therapeutic use', 'Duloxetine Hydrochloride/adverse effects/therapeutic use', 'Humans', 'Mood Disorders/drug therapy', '*Randomized Controlled Trials as Topic', 'Substance Withdrawal Syndrome/*diagnosis', 'Venlafaxine Hydrochloride/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30016772/
759,duloxetine,38950403,Medication-Induced Weight Change Across Common Antidepressant Treatments : A Target Trial Emulation Study.,"['Petimar J', 'Young JG', 'Yu H', 'Rifas-Shiman SL', 'Daley MF', 'Heerman WJ', 'Janicke DM', 'Jones WS', 'Lewis KH', 'Lin PD', 'Prentice C', 'Merriman JW', 'Toh S', 'Block JP']","['Humans', '*Antidepressive Agents/therapeutic use/adverse effects', 'Female', 'Male', '*Weight Gain/drug effects', 'Middle Aged', 'Adult', 'Bupropion/therapeutic use/adverse effects', 'Citalopram/therapeutic use/adverse effects', 'Duloxetine Hydrochloride/therapeutic use/adverse effects', 'Aged']",https://pubmed.ncbi.nlm.nih.gov/38950403/
760,duloxetine,30838456,Serotonin and Norepinephrine Reuptake Inhibitors.,['Shelton RC'],"['Antidepressive Agents/chemistry/*pharmacology', 'Desvenlafaxine Succinate/*chemistry', 'Duloxetine Hydrochloride/chemistry/*pharmacology', 'Humans', '*Serotonin/pharmacology', '*Serotonin and Noradrenaline Reuptake Inhibitors/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30838456/
761,duloxetine,37461044,Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis.,"['Migliorini F', 'Maffulli N', 'Eschweiler J', 'Baroncini A', 'Bell A', 'Colarossi G']","['Humans', 'Female', 'Adult', 'Middle Aged', 'Male', 'Duloxetine Hydrochloride/therapeutic use', '*Fibromyalgia/drug therapy/chemically induced', 'Thiophenes/adverse effects', 'Treatment Outcome', 'Pain/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37461044/
762,duloxetine,28293734,[Chemotherapy-induced peripheral neuropathy and neuropathic pain].,"['Schuler U', 'Heller S']","['Antineoplastic Agents/*adverse effects', 'Cryotherapy', 'Duloxetine Hydrochloride/therapeutic use', 'Humans', 'Neuralgia/*chemically induced/prevention & control/therapy', 'Peripheral Nervous System Diseases/*chemically induced/prevention & control/therapy', 'Physical Therapy Modalities', 'Randomized Controlled Trials as Topic', 'Venlafaxine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28293734/
763,duloxetine,35522835,Duloxetine-Associated Photodistributed Erythema Multiforme.,"['Gay P', 'Niezen S', 'Saenz-Davila B', 'Arellano-Mendoza I', 'Mercadillo P', 'Tirado-Sanchez A']","['Duloxetine Hydrochloride/adverse effects', '*Erythema Multiforme/chemically induced/diagnosis', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/35522835/
764,duloxetine,34497420,Bioaccumulation of therapeutic drugs by human gut bacteria.,"['Klunemann M', 'Andrejev S', 'Blasche S', 'Mateus A', 'Phapale P', 'Devendran S', 'Vappiani J', 'Simon B', 'Scott TA', 'Kafkia E', 'Konstantinidis D', 'Zirngibl K', 'Mastrorilli E', 'Banzhaf M', 'Mackmull MT', 'Hovelmann F', 'Nesme L', 'Brochado AR', 'Maier L', 'Bock T', 'Periwal V', 'Kumar M', 'Kim Y', 'Tramontano M', 'Schultz C', 'Beck M', 'Hennig J', 'Zimmermann M', 'Sevin DC', 'Cabreiro F', 'Savitski MM', 'Bork P', 'Typas A', 'Patil KR']","['Animals', 'Antidepressive Agents/metabolism/pharmacokinetics', 'Bacteria/*metabolism', '*Bioaccumulation', 'Caenorhabditis elegans/metabolism', 'Cells/metabolism', 'Click Chemistry', 'Duloxetine Hydrochloride/adverse effects/*metabolism/pharmacokinetics', 'Gastrointestinal Microbiome/*physiology', 'Humans', 'Metabolomics', 'Models, Animal', 'Proteomics', 'Reproducibility of Results']",https://pubmed.ncbi.nlm.nih.gov/34497420/
765,duloxetine,35587348,Comparison of Amitriptyline and US Food and Drug Administration-Approved Treatments for Fibromyalgia: A Systematic Review and Network Meta-analysis.,"['Farag HM', 'Yunusa I', 'Goswami H', 'Sultan I', 'Doucette JA', 'Eguale T']","['Amitriptyline/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use', 'Fatigue/drug therapy', 'Female', '*Fibromyalgia/drug therapy', 'Humans', 'Male', 'Middle Aged', 'Milnacipran/therapeutic use', 'Network Meta-Analysis', 'Pain/drug therapy', 'Pregabalin/therapeutic use', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/35587348/
766,duloxetine,36890758,[Medical Treatment of Chronic Pain].,['Nodera H'],"['Humans', 'Analgesics/therapeutic use/adverse effects', '*Chronic Pain/drug therapy/chemically induced', 'Pregabalin/therapeutic use', 'Gabapentin/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use', '*Diabetic Neuropathies/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36890758/
767,duloxetine,29279555,Pharmacotherapy for Neuropathic Pain in Japan.,"['Masuda R', 'Ajimi J', 'Murata T']","['Aged', 'Algorithms', 'Amines/*administration & dosage/adverse effects', 'Analgesics, Opioid/*administration & dosage/adverse effects', 'Anticonvulsants/*administration & dosage/adverse effects', 'Antidepressive Agents/*administration & dosage/adverse effects', 'Cyclohexanecarboxylic Acids/*administration & dosage/adverse effects', 'Drug Administration Schedule', 'Duloxetine Hydrochloride/*administration & dosage/adverse effects', 'Female', 'Gabapentin', 'Humans', 'Japan', 'Neuralgia/classification/*drug therapy', 'Pain Management', 'Pregabalin/*administration & dosage/adverse effects', 'gamma-Aminobutyric Acid/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/29279555/
768,duloxetine,38574212,Diabetic Peripheral Neuropathy: Prevention and Treatment.,"['Bragg S', 'Marrison ST', 'Haley S']","['Humans', '*Diabetic Neuropathies/diagnosis/prevention & control', 'Duloxetine Hydrochloride/therapeutic use', 'Capsaicin/therapeutic use', 'Gabapentin/therapeutic use', 'Pregabalin/therapeutic use', 'Pain/drug therapy', '*Diabetes Mellitus/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38574212/
769,duloxetine,31290965,"Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).","['Fedgchin M', 'Trivedi M', 'Daly EJ', 'Melkote R', 'Lane R', 'Lim P', 'Vitagliano D', 'Blier P', 'Fava M', 'Liebowitz M', 'Ravindran A', 'Gaillard R', 'Ameele HVD', 'Preskorn S', 'Manji H', 'Hough D', 'Drevets WC', 'Singh JB']","['Administration, Intranasal', 'Administration, Oral', 'Adolescent', 'Adult', 'Antidepressive Agents/administration & dosage/*adverse effects/*therapeutic use', 'Citalopram/therapeutic use', 'Delayed-Action Preparations/therapeutic use', 'Depressive Disorder, Treatment-Resistant/*drug therapy', 'Double-Blind Method', 'Drug Therapy, Combination/adverse effects', 'Duloxetine Hydrochloride/therapeutic use', 'Female', 'Humans', 'Ketamine/administration & dosage/*adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Sertraline/therapeutic use', 'Treatment Outcome', 'Venlafaxine Hydrochloride/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31290965/
770,duloxetine,30877484,Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial.,"['Bidari A', 'Moazen-Zadeh E', 'Ghavidel-Parsa B', 'Rahmani S', 'Hosseini S', 'Hassankhani A']","['Adult', 'Chronic Pain/*drug therapy', 'Depression/*drug therapy', 'Drug Administration Schedule', 'Duloxetine Hydrochloride/*administration & dosage/therapeutic use', 'Female', 'Fibromyalgia/complications/*drug therapy', 'Humans', 'Medication Adherence', 'Middle Aged', 'Pregabalin/*administration & dosage/therapeutic use', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30877484/
771,duloxetine,27289172,Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.,"['Cipriani A', 'Zhou X', 'Del Giovane C', 'Hetrick SE', 'Qin B', 'Whittington C', 'Coghill D', 'Zhang Y', 'Hazell P', 'Leucht S', 'Cuijpers P', 'Pu J', 'Cohen D', 'Ravindran AV', 'Liu Y', 'Michael KD', 'Yang L', 'Liu L', 'Xie P']","['Adolescent', 'Amitriptyline/administration & dosage/adverse effects', 'Antidepressive Agents/*administration & dosage/*adverse effects', 'Bayes Theorem', 'Child', 'Citalopram/administration & dosage/adverse effects', 'Clomipramine/administration & dosage/adverse effects', 'Confounding Factors, Epidemiologic', 'Depressive Disorder, Major/*drug therapy', 'Desipramine/administration & dosage/adverse effects', 'Double-Blind Method', 'Drug Administration Schedule', 'Duloxetine Hydrochloride/administration & dosage/adverse effects', 'Evidence-Based Medicine', 'Fluoxetine/administration & dosage/adverse effects', 'Humans', 'Imipramine/administration & dosage/adverse effects', 'Mianserin/administration & dosage/adverse effects/analogs & derivatives', 'Mirtazapine', 'Nortriptyline/administration & dosage/adverse effects', 'Paroxetine/administration & dosage/adverse effects', 'Piperazines', 'Randomized Controlled Trials as Topic', 'Research Design', 'Sertraline/administration & dosage/adverse effects', 'Treatment Outcome', 'Triazoles/administration & dosage/adverse effects', 'Venlafaxine Hydrochloride/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27289172/
772,indomethacin,2658608,Indomethacin-induced oligohydramnios.,"['Goldenberg RL', 'Davis RO', 'Baker RC']","['Adult', 'Amniotic Fluid/*drug effects', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Indomethacin/administration & dosage/*adverse effects', 'Obstetric Labor, Premature/prevention & control', 'Pregnancy', 'Ultrasonography', 'Uterine Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2658608/
773,indomethacin,7982337,Treatment of polyhydramnios with indomethacin.,"['Kramer WB', 'Van den Veyver IB', 'Kirshon B']","['Amniotic Fluid/drug effects', 'Contraindications', 'Cyclooxygenase Inhibitors/therapeutic use', 'Female', 'Fetal Monitoring', 'Fetus/drug effects', 'Humans', 'Indomethacin/adverse effects/pharmacology/*therapeutic use', 'Polyhydramnios/*drug therapy/etiology', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/7982337/
774,indomethacin,8504626,Pharmacokinetics of indomethacin in the elderly.,"['Oberbauer R', 'Krivanek P', 'Turnheim K']","['Administration, Oral', 'Adult', 'Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Indomethacin/administration & dosage/*pharmacokinetics', 'Injections, Intravenous', 'Intestinal Absorption', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/8504626/
775,indomethacin,935518,"Prostaglandins, indomethacin and dysmenorrhea.","['Lundstrom V', 'Green K', 'Wiqvist N']","['Diarrhea/chemically induced', 'Dysmenorrhea/*drug therapy/physiopathology', 'Female', 'Humans', 'Indomethacin/adverse effects/pharmacology/*therapeutic use', 'Menstruation', 'Nausea/chemically induced', 'Prostaglandins F/*blood', 'Uterine Contraction/*drug effects', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/935518/
776,indomethacin,2800992,Indomethacin as an analgesic after hysterectomy.,"['Engel C', 'Lund B', 'Kristensen SS', 'Axel C', 'Nielsen JB']","['Administration, Rectal', 'Adolescent', 'Adult', 'Double-Blind Method', 'Female', 'Hemorrhage/physiopathology', 'Humans', 'Hysterectomy/*adverse effects', 'Indomethacin/administration & dosage/*therapeutic use', 'Injections, Intravenous', 'Middle Aged', 'Morphine Derivatives/therapeutic use', 'Nicotinic Acids/therapeutic use', 'Pain Measurement', 'Pain, Postoperative/*prevention & control', 'Placebos', '*Premedication', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/2800992/
777,indomethacin,1346283,Indomethacin and postprandial gallbladder emptying.,"[""O'Donnell LJ"", 'Wilson P', 'Guest P', 'Catnach SM', 'McLean A', 'Wickham JE', 'Fairclough PD']","['Adult', 'Cholelithiasis/physiopathology/*prevention & control', 'Drug Administration Schedule', '*Eating', 'Female', 'Gallbladder Emptying/*drug effects/physiology', 'Humans', 'Indomethacin/administration & dosage/*therapeutic use', 'Male', 'Middle Aged', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/1346283/
778,indomethacin,7671547,Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment.,['Hammerman C'],"['Ductus Arteriosus/anatomy & histology/drug effects/physiology', 'Ductus Arteriosus, Patent/*drug therapy/pathology/*physiopathology', 'Female', 'Humans', 'Indomethacin/administration & dosage/pharmacology/*therapeutic use', 'Infant, Newborn', '*Infant, Premature', 'Infant, Premature, Diseases/*drug therapy/*physiopathology', 'Oxygen/blood', 'Pregnancy', 'Prostaglandins/*physiology']",https://pubmed.ncbi.nlm.nih.gov/7671547/
779,indomethacin,26409201,Novel nanostructured supramolecular hydrogels for the topical delivery of anionic drugs.,"['Limon D', 'Amirthalingam E', 'Rodrigues M', 'Halbaut L', 'Andrade B', 'Garduno-Ramirez ML', 'Amabilino DB', 'Perez-Garcia L', 'Calpena AC']","['Administration, Cutaneous', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects/metabolism/pharmacology', 'Dermatitis/drug therapy', 'Drug Compounding', 'Drug Delivery Systems/adverse effects', 'Drug Liberation', 'Drug Stability', 'Humans', 'Hydrogels', 'Ibuprofen/*administration & dosage/adverse effects/metabolism/pharmacology', 'Imidazoles/adverse effects/*chemistry', 'In Vitro Techniques', 'Indomethacin/*administration & dosage/adverse effects/metabolism/pharmacology', 'Nanofibers/adverse effects/chemistry', 'Nanostructures/adverse effects/*chemistry', 'Rabbits', 'Skin Absorption', 'Skin Tests', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/26409201/
780,indomethacin,16125046,Antiprostaglandin drugs.,"['Vermillion ST', 'Robinson CJ']","['Cyclooxygenase Inhibitors/adverse effects/pharmacokinetics/*therapeutic use', 'Female', 'Fetal Monitoring', 'Humans', 'Indomethacin/adverse effects/pharmacokinetics/*therapeutic use', 'Obstetric Labor, Premature/*drug therapy', 'Pregnancy', 'Safety']",https://pubmed.ncbi.nlm.nih.gov/16125046/
781,indomethacin,6391883,Indomethacin sustained-release?,['Green JA'],"['Clinical Trials as Topic', 'Delayed-Action Preparations', 'Humans', 'Indomethacin/*administration & dosage/adverse effects/blood/metabolism/therapeutic use', 'Kinetics']",https://pubmed.ncbi.nlm.nih.gov/6391883/
782,indomethacin,7386499,Indomethacin-associated acute renal failure.,"['Gary NE', 'Dodelson R', 'Eisinger RP']","['Acute Kidney Injury/*chemically induced', 'Humans', 'Hypertension/chemically induced', 'Indomethacin/*adverse effects/therapeutic use', 'Kidney Glomerulus/drug effects', 'Male', 'Middle Aged', 'Proteinuria/chemically induced', 'Tendinopathy/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7386499/
783,indomethacin,24896759,Pharmacologic prophylaxis alone is not adequate to prevent post-ERCP pancreatitis.,"['Arain MA', 'Freeman ML']","['Cholangiopancreatography, Endoscopic Retrograde/*adverse effects', 'Drug Therapy, Combination', 'Humans', 'Indomethacin/administration & dosage/*therapeutic use', 'Nitrates/administration & dosage/*therapeutic use', 'Pancreatitis/drug therapy/etiology/*prevention & control', 'Risk Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24896759/
784,indomethacin,3963018,Flurbiprofen in the treatment of ankylosing spondylitis. A comparison with indomethacin.,"['Lomen PL', 'Turner LF', 'Lamborn KR', 'Brinn EL']","['Adolescent', 'Adult', 'Drug Evaluation', 'Female', 'Flurbiprofen/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Indomethacin/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Pain/*drug therapy', 'Propionates/*therapeutic use', 'Spondylitis, Ankylosing/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3963018/
785,indomethacin,28611459,Smart pH-sensitive nanoassemblies with cleavable PEGylation for tumor targeted drug delivery.,"['Zhao G', 'Long L', 'Zhang L', 'Peng M', 'Cui T', 'Wen X', 'Zhou X', 'Sun L', 'Che L']","['Animals', 'Antineoplastic Agents/administration & dosage/chemistry/pharmacokinetics', 'Cell Proliferation/*drug effects', 'Docetaxel/*administration & dosage/chemistry/pharmacokinetics', 'Drug Carriers/*administration & dosage/chemistry', '*Drug Delivery Systems', 'Humans', 'Hydrogen-Ion Concentration', 'Indomethacin/administration & dosage/chemistry/pharmacokinetics', 'Male', 'Nanostructures/administration & dosage/chemistry', 'Neoplasms, Experimental/*drug therapy/pathology', 'Polyethylene Glycols/*chemistry', 'Polyethyleneimine/*chemistry', 'Rats', 'Rats, Sprague-Dawley', 'Tissue Distribution', 'Tumor Cells, Cultured']",https://pubmed.ncbi.nlm.nih.gov/28611459/
786,indomethacin,1617881,Polyhydramnios: does reducing the amniotic fluid volume decrease the incidence of prematurity?,['Rodriguez MH'],"['Amniocentesis/methods/standards', 'Clinical Trials as Topic', 'Combined Modality Therapy', 'Female', 'Humans', 'Incidence', 'Indomethacin/administration & dosage/pharmacokinetics/therapeutic use', 'Obstetric Labor, Premature/epidemiology/*etiology', 'Polyhydramnios/complications/diagnostic imaging/*therapy', 'Pregnancy', 'Pregnancy Outcome', 'Ultrasonography, Prenatal']",https://pubmed.ncbi.nlm.nih.gov/1617881/
787,indomethacin,165855,Peripheral neuropathy and indomethacin.,"['Eade OE', 'Acheson ED', 'Cuthbert MF', 'Hawkes CH']","['Aged', 'Arthritis, Rheumatoid/complications/drug therapy', 'Female', 'Humans', 'Indomethacin/*adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Movement', 'Peripheral Nervous System Diseases/*chemically induced/complications/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/165855/
788,indomethacin,389838,A comparative study with indomethacin and combined indomethacin sodium-salicylate in rheumatoid arthritis.,"['Torgyan S', 'Wagner L', 'Neumann T', 'Pakuts B', 'Csanyi M']","['Adult', 'Aged', 'Arthritis, Rheumatoid/*drug therapy', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Humans', 'Indomethacin/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Sodium Salicylate/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/389838/
789,indomethacin,29228444,Rectal indomethacin or intravenous gabexate mesylate as prophylaxis for acute pancreatitis post-endoscopic retrograde cholangiopancreatography.,"['Guglielmi V', 'Tutino M', 'Guerra V', 'Giorgio P']","['Acute Disease', 'Administration, Intravenous', 'Administration, Rectal', 'Aged', 'Aged, 80 and over', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/economics/*therapeutic use', 'Cholangiopancreatography, Endoscopic Retrograde/*adverse effects/economics', 'Costs and Cost Analysis', 'Female', 'Gabexate/*administration & dosage/economics/*therapeutic use', 'Humans', 'Indomethacin/*administration & dosage/economics/*therapeutic use', 'Male', 'Middle Aged', 'Pancreatitis/economics/*etiology/*prevention & control', 'Retrospective Studies', 'Serine Proteinase Inhibitors/*administration & dosage/economics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29228444/
790,indomethacin,22288307,Acute nephrotoxicity of NSAID from the foetus to the adult.,"['Musu M', 'Finco G', 'Antonucci R', 'Polati E', 'Sanna D', 'Evangelista M', 'Ribuffo D', 'Schweiger V', 'Fanos V']","['Acute Kidney Injury/*chemically induced/epidemiology/pathology', 'Adult', 'Age Factors', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects/pharmacokinetics', 'Child', 'Female', 'Humans', 'Indomethacin/administration & dosage/*adverse effects/pharmacokinetics', 'Infant, Newborn', 'Pregnancy', 'Prenatal Exposure Delayed Effects', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/22288307/
791,indomethacin,356250,The long-term efficacy and tolerability of Voltaren (diclofenac sodium) and indomethacin in rheumatoid arthritis.,['Bijlsma A'],"['Adult', 'Arthritis, Rheumatoid/*drug therapy', 'Central Nervous System/drug effects', 'Clinical Trials as Topic', 'Diclofenac/administration & dosage/adverse effects/*therapeutic use', 'Digestive System/drug effects', 'Double-Blind Method', 'Drug Evaluation', 'Female', 'Follow-Up Studies', 'Humans', 'Indomethacin/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Phenylacetates/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/356250/
792,amlodipine,9156957,Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties.,['van Zwieten PA'],"['Amlodipine/*pharmacokinetics/*pharmacology', 'Angina Pectoris/drug therapy', 'Animals', 'Humans', 'Hypertension/drug therapy', 'In Vitro Techniques']",https://pubmed.ncbi.nlm.nih.gov/9156957/
793,amlodipine,32937023,Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.,"['Jin X', 'Kim MH', 'Han KH', 'Hong SJ', 'Ahn JC', 'Sung JH', 'Cho JM', 'Lee HC', 'Choi SY', 'Lee K', 'Kim WS', 'Rhee MY', 'Kim JH', 'Hong SP', 'Yoo BS', 'Cho EJ', 'Lee JH', 'Kim PJ', 'Park CG', 'Hyon MS', 'Shin JH', 'Lee SH', 'Sung KC', 'Hwang J', 'Kwon K', 'Chae IH', 'Seo JS', 'Kim H', 'Lee H', 'Cho Y', 'Kim HS']","['Aged', 'Amlodipine/*administration & dosage/therapeutic use', 'Antihypertensive Agents/therapeutic use', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Drug Combinations', 'Drug Therapy, Combination', '*Dyslipidemias/drug therapy', 'Female', 'Humans', '*Hypertension/drug therapy', 'Male', 'Middle Aged', 'Rosuvastatin Calcium/*administration & dosage/therapeutic use', 'Telmisartan/*administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32937023/
794,amlodipine,27731568,Amlodipine-Induced Gingival Overgrowth.,"['Jayanthi R', 'Rajan PB']","['Adult', 'Aged', 'Amlodipine/administration & dosage/*adverse effects', 'Antihypertensive Agents/therapeutic use', 'Calcium Channel Blockers/administration & dosage/*adverse effects', 'Female', 'Gingival Overgrowth/*chemically induced', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/27731568/
795,amlodipine,8195445,Amlodipine-induced gingival overgrowth.,"['Seymour RA', 'Ellis JS', 'Thomason JM', 'Monkman S', 'Idle JR']","['Adult', 'Aged', 'Amlodipine/*adverse effects/analysis/blood/pharmacokinetics', 'Collagen', 'Dental Plaque Index', 'Epithelium/pathology', 'Female', 'Fibroblasts/pathology', 'Gingival Crevicular Fluid/chemistry', 'Gingival Hyperplasia/*chemically induced/pathology', 'Humans', 'Male', 'Middle Aged', 'Periodontal Index', 'Periodontal Pocket/complications']",https://pubmed.ncbi.nlm.nih.gov/8195445/
796,amlodipine,33430665,Calcium Channel Blockers in Conjunction with Standard Iron-Chelating Agents for beta-Thalassemia Major: Systematic Literature Search.,"['Alali MA', 'Alanazi KMA', 'Alsayil SN', 'Omari Z', 'Shaaban A']","['Amlodipine/administration & dosage/adverse effects/therapeutic use', 'Biomarkers', 'Calcium Channel Blockers/administration & dosage/adverse effects/*therapeutic use', 'Chelation Therapy', 'Drug Therapy, Combination', 'Humans', 'Iron Chelating Agents/administration & dosage/adverse effects/*therapeutic use', 'Iron Overload/diagnosis/*drug therapy/*etiology/metabolism', 'Magnetic Resonance Imaging', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'beta-Thalassemia/*complications/diagnosis/genetics']",https://pubmed.ncbi.nlm.nih.gov/33430665/
797,amlodipine,19405551,Olmesartan medoxomil/amlodipine.,"['Sanford M', 'Keam SJ']","['Amlodipine/adverse effects/pharmacology/*therapeutic use', 'Antihypertensive Agents/adverse effects/pharmacology/therapeutic use', 'Drug Combinations', 'Humans', 'Hypertension/*drug therapy', 'Imidazoles/adverse effects/pharmacology/*therapeutic use', 'Olmesartan Medoxomil', 'Randomized Controlled Trials as Topic', 'Tetrazoles/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/19405551/
798,amlodipine,39426836,"Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial.","['Rodgers A', 'Salam A', 'Schutte AE', 'Cushman WC', 'de Silva HA', 'Di Tanna GL', 'Grobbee DE', 'Narkiewicz K', 'Ojji DB', 'Poulter NR', 'Schlaich MP', 'Oparil S', 'Spiering W', 'Williams B', 'Wright JT Jr', 'Lakshman P', 'Uluwattage W', 'Hay P', 'Pereira T', 'Amarasena N', 'Ranasinghe G', 'Gianacas C', 'Shanthakumar M', 'Liu X', 'Wang N', 'Gnanenthiran SR', 'Whelton PK']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', '*Amlodipine/administration & dosage/adverse effects', '*Antihypertensive Agents/administration & dosage/adverse effects/therapeutic use', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Drug Combinations', '*Hypertension/drug therapy', '*Indapamide/administration & dosage/adverse effects/therapeutic use', '*Telmisartan/administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39426836/
799,amlodipine,25268343,Cutaneous adverse reactions to calcium channel blockers.,"['Tuchinda P', 'Kulthanan K', 'Khankham S', 'Jongjarearnprasert K', 'Dhana N']","['Adolescent', 'Adult', 'Amlodipine/administration & dosage/*adverse effects', 'Calcium Channel Blockers/administration & dosage/*adverse effects', 'Diltiazem/administration & dosage/*adverse effects', 'Drug Eruptions/*epidemiology', 'Female', 'Humans', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/25268343/
800,amlodipine,10437993,Amlodipine treatment of cocaine dependence.,"['Malcolm R', 'Brady KT', 'Moore J', 'Kajdasz D']","['Adult', 'Amlodipine/adverse effects/*therapeutic use', 'Calcium Channel Blockers/adverse effects/*therapeutic use', 'Cocaine-Related Disorders/*drug therapy', 'Female', 'Humans', 'Male', 'Middle Aged', 'Motivation']",https://pubmed.ncbi.nlm.nih.gov/10437993/
801,amlodipine,27715071,[Current position of a fixed combination telmisartan with amlodipine in treatment of essential arterial hypertension].,['Sliva J'],"['Amlodipine/administration & dosage/*therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Benzimidazoles/administration & dosage/*therapeutic use', 'Benzoates/administration & dosage/*therapeutic use', 'Drug Combinations', 'Essential Hypertension', 'Humans', 'Hypertension/*drug therapy', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/27715071/
802,amlodipine,23324513,Antidepressant-selective gynecomastia.,"['Kaufman KR', 'Podolsky D', 'Greenman D', 'Madraswala R']","['Aged', 'Amlodipine/administration & dosage/adverse effects/therapeutic use', 'Antidepressive Agents/administration & dosage/*adverse effects/therapeutic use', 'Depressive Disorder, Major/*drug therapy', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Drug Therapy, Combination', 'Duloxetine Hydrochloride', 'Fluorobenzenes/administration & dosage/adverse effects/therapeutic use', 'Gynecomastia/*chemically induced', 'Humans', 'Male', 'Pyrimidines/administration & dosage/adverse effects/therapeutic use', 'Rosuvastatin Calcium', 'Sertraline/administration & dosage/adverse effects/therapeutic use', 'Sulfonamides/administration & dosage/adverse effects/therapeutic use', 'Thiophenes/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23324513/
803,amlodipine,24121218,[Advantages of ramipril/amlodipin fixed combination therapy. When should we use it?].,['Simonyi G'],"['Amlodipine/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Antihypertensive Agents/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Blood Pressure/*drug effects', 'Calcium Channel Blockers/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Drug Administration Schedule', 'Drug Combinations', 'Humans', 'Hungary', 'Hypertension/*drug therapy/metabolism/physiopathology', 'Ramipril/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'Assessment of Medication Adherence']",https://pubmed.ncbi.nlm.nih.gov/24121218/
804,amlodipine,25331664,"[Myopathy and rhabdomyolysis after treatment with simvastatin, amlodipine, and roxithromycin].","['Skovbolling SL', 'Lindelof M']","['Aged', 'Amlodipine/administration & dosage/*adverse effects/therapeutic use', 'Anti-Bacterial Agents/administration & dosage/*adverse effects/therapeutic use', 'Antihypertensive Agents/administration & dosage/*adverse effects/therapeutic use', 'Drug Interactions', 'Humans', 'Hypertension/drug therapy', 'Male', 'Muscular Diseases/*chemically induced/pathology', 'Rhabdomyolysis/*chemically induced/pathology', 'Roxithromycin/administration & dosage/*adverse effects/therapeutic use', 'Simvastatin/administration & dosage/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25331664/
805,amlodipine,27250611,[What are the effects of fixed-dose combination of candesartan and amlodipine].,"['Vitovec J', 'Spinar J']","['Amlodipine/*administration & dosage', 'Antihypertensive Agents/*administration & dosage', 'Benzimidazoles/*administration & dosage', 'Biphenyl Compounds', 'Drug Combinations', 'Humans', 'Hypertension/drug therapy', 'Tetrazoles/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27250611/
806,amlodipine,30362840,Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain.,"['Angeli F', 'Trapasso M', 'Signorotti S', 'Verdecchia P', 'Reboldi G']","['Amlodipine/*administration & dosage/adverse effects/pharmacology', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/pharmacology', 'Antihypertensive Agents/administration & dosage/adverse effects/pharmacology', 'Celecoxib/*administration & dosage/adverse effects/pharmacology', 'Drug Combinations', 'Humans', 'Hypertension/*drug therapy/etiology', 'Osteoarthritis/complications/*drug therapy', 'Pain/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/30362840/
807,amlodipine,23094638,The effects of telmisartan and amlodipine in treatment-naive and previously treated hypertensive patients: a subanalysis from a 4 x 4 factorial design study.,"['Punzi HA', 'Dahlof B', 'Webster D', 'Majul CR', 'Oigman W', 'Olvera R', 'Seeber M', 'Kobe M', 'Schumacher H']","['Adult', 'Aged', 'Amlodipine/adverse effects/pharmacology/*therapeutic use', 'Antihypertensive Agents/adverse effects/pharmacology/*therapeutic use', 'Benzimidazoles/adverse effects/pharmacology/*therapeutic use', 'Benzoates/adverse effects/pharmacology/*therapeutic use', 'Blood Pressure/drug effects/physiology', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Telmisartan', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23094638/
808,amlodipine,26432745,Missing diagnosis: gingival hypertrophy due to amlodipine.,"['Tomar LR', 'Aggarwal A']","['Amlodipine/*adverse effects/therapeutic use', 'Calcium Channel Blockers/adverse effects/therapeutic use', '*Diagnostic Errors', 'Female', 'Gingiva/drug effects/*pathology', 'Gingival Hypertrophy/*chemically induced/diagnosis', 'Humans', 'Hypertension/drug therapy', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/26432745/
809,amlodipine,10437739,Safety and efficacy of angiotensin II receptor antagonists.,['Neutel JM'],"['Amlodipine/adverse effects/therapeutic use', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Follow-Up Studies', 'Humans', 'Hypertension/*drug therapy', 'Monitoring, Physiologic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10437739/
810,amlodipine,38584159,"Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.","['Huffman MD', 'Baldridge AS', 'Lazar D', 'Abbas H', 'Mejia J', 'Flowers FM', 'Quintana A', 'Jackson A', 'Kandula NR', 'Lloyd-Jones DM', 'Persell SD', 'Khan SS', 'Paparello JJ', 'Chopra A', 'Tripathi P', 'Vu MH', 'Chow CK', 'Ciolino JD']","['Humans', 'Female', 'Male', '*Hypertension/drug therapy', 'Middle Aged', '*Biphenyl Compounds', '*Antihypertensive Agents/therapeutic use/adverse effects/administration & dosage', 'Double-Blind Method', '*Benzimidazoles/therapeutic use/adverse effects/administration & dosage', '*Amlodipine/administration & dosage/adverse effects/therapeutic use', '*Tetrazoles/therapeutic use/adverse effects/administration & dosage', '*Blood Pressure/drug effects', 'Aged', 'Treatment Outcome', '*Bisoprolol/therapeutic use/administration & dosage', 'Indapamide/therapeutic use/administration & dosage/adverse effects', 'Adult', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/38584159/
811,methylphenidate,35507282,Current Pharmacological Treatments for ADHD.,"['Groom MJ', 'Cortese S']","['Adolescent', 'Adult', 'Atomoxetine Hydrochloride/pharmacology/therapeutic use', '*Attention Deficit Disorder with Hyperactivity/drug therapy', '*Central Nervous System Stimulants/adverse effects', 'Child', '*Drug-Related Side Effects and Adverse Reactions', 'Humans', '*Methylphenidate/pharmacology/therapeutic use', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/35507282/
812,methylphenidate,32715789,"An update on the clinical pharmacology of methylphenidate: therapeutic efficacy, abuse potential and future considerations.","['Shellenberg TP', 'Stoops WW', 'Lile JA', 'Rush CR']","['Abuse-Deterrent Formulations', 'Adult', 'Attention Deficit Disorder with Hyperactivity/drug therapy', 'Central Nervous System Stimulants/*administration & dosage/adverse effects/pharmacology', 'Child', 'Humans', 'Methylphenidate/*administration & dosage/adverse effects/pharmacology', 'Substance-Related Disorders/*epidemiology']",https://pubmed.ncbi.nlm.nih.gov/32715789/
813,methylphenidate,33242419,"Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.","['Nourbakhsh B', 'Revirajan N', 'Morris B', 'Cordano C', 'Creasman J', 'Manguinao M', 'Krysko K', 'Rutatangwa A', 'Auvray C', 'Aljarallah S', 'Jin C', 'Mowry E', 'McCulloch C', 'Waubant E']","['Adult', 'Amantadine/administration & dosage/adverse effects/*pharmacology', 'Central Nervous System Stimulants/administration & dosage/adverse effects/*pharmacology', 'Cross-Over Studies', 'Double-Blind Method', 'Drug Administration Schedule', '*Drug-Related Side Effects and Adverse Reactions', 'Fatigue/*drug therapy/*etiology', 'Female', 'Humans', 'Male', 'Methylphenidate/administration & dosage/adverse effects/*pharmacology', 'Middle Aged', 'Modafinil/administration & dosage/adverse effects/*pharmacology', 'Multiple Sclerosis/*complications', '*Outcome Assessment, Health Care', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/33242419/
814,methylphenidate,1251235,Methylphenidate: a review.,"['Oettinger L Jr', 'Majovski LV']","['Attention Deficit Disorder with Hyperactivity/drug therapy/therapy', 'Humans', 'Hyperkinesis/drug therapy', 'Methylphenidate/administration & dosage/adverse effects/metabolism/*therapeutic use', 'Substance-Related Disorders/etiology']",https://pubmed.ncbi.nlm.nih.gov/1251235/
815,methylphenidate,28277842,An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder.,"['Groenman AP', 'Schweren LJ', 'Dietrich A', 'Hoekstra PJ']","['Animals', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/physiopathology', 'Brain/drug effects', 'Central Nervous System Stimulants/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Methylphenidate/administration & dosage/adverse effects/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/28277842/
816,methylphenidate,12014596,Methylphenidate-related growth impairment.,"['Holtkamp K', 'Peters-Wallraf B', 'Wuller S', 'Pfaaffle R', 'Herpertz-Dahlmann B']","['Attention Deficit Disorder with Hyperactivity/*drug therapy', 'Body Height/drug effects', 'Central Nervous System Stimulants/*adverse effects/*therapeutic use', 'Child', 'Growth Disorders/*chemically induced', 'Humans', 'Male', 'Methylphenidate/*adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12014596/
817,methylphenidate,12506813,Ritalin revisited: does it really help in neurological injury?,['Kajs-Wyllie M'],"['Attention Deficit Disorder with Hyperactivity/drug therapy', 'Brain Injuries/*drug therapy/nursing', 'Brain Neoplasms/drug therapy', 'Central Nervous System Stimulants/adverse effects/pharmacokinetics/*therapeutic use', 'Coma/drug therapy', 'Depression/drug therapy', 'Female', 'Humans', 'Male', 'Methylphenidate/adverse effects/pharmacokinetics/*therapeutic use', 'Nervous System Diseases/*drug therapy/nursing']",https://pubmed.ncbi.nlm.nih.gov/12506813/
818,methylphenidate,15006715,Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children.,"['Kociancic T', 'Reed MD', 'Findling RL']","['Appetite/drug effects', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/physiopathology', 'Central Nervous System Stimulants/*adverse effects/pharmacology/therapeutic use', 'Child', 'Dextroamphetamine/*adverse effects/pharmacology/therapeutic use', 'Humans', 'Methylphenidate/*adverse effects/pharmacology/therapeutic use', 'Sleep/drug effects', 'Tic Disorders/*etiology']",https://pubmed.ncbi.nlm.nih.gov/15006715/
819,methylphenidate,22377977,[Methylphenidate misuse].,"['Bruggisser M', 'Bodmer M', 'Liechti ME']","['Attention Deficit Disorder with Hyperactivity/blood/drug therapy', '*Central Nervous System Stimulants/adverse effects/pharmacokinetics/therapeutic use', 'Cross-Sectional Studies', 'Humans', 'Incidence', 'Metabolic Clearance Rate/physiology', '*Methylphenidate/adverse effects/pharmacokinetics/therapeutic use', 'Substance-Related Disorders/blood/*epidemiology', 'Switzerland']",https://pubmed.ncbi.nlm.nih.gov/22377977/
820,methylphenidate,17872810,Exposure to attention deficit hyperactivity disorder medications during pregnancy.,"['Humphreys C', 'Garcia-Bournissen F', 'Ito S', 'Koren G']","['Abnormalities, Drug-Induced/*prevention & control', 'Atomoxetine Hydrochloride', 'Attention Deficit Disorder with Hyperactivity/diagnosis/*drug therapy', 'Central Nervous System Stimulants/*adverse effects/therapeutic use', 'Congenital Abnormalities', 'Decision Making', 'Drug-Related Side Effects and Adverse Reactions', 'Female', 'Humans', 'Infant, Newborn', 'Methylphenidate/adverse effects/therapeutic use', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Propylamines/adverse effects/therapeutic use', 'Risk Assessment']",https://pubmed.ncbi.nlm.nih.gov/17872810/
821,methylphenidate,17020437,"Osmotic, controlled-release methylphenidate for the treatment of ADHD.","['Coghill D', 'Seth S']","['Adolescent', 'Adult', 'Attention Deficit Disorder with Hyperactivity/*drug therapy', 'Central Nervous System Stimulants/administration & dosage/adverse effects/*therapeutic use', 'Chemistry, Pharmaceutical/*methods', 'Child', 'Child, Preschool', 'Delayed-Action Preparations', 'Half-Life', 'Humans', 'Methylphenidate/metabolism/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/17020437/
822,methylphenidate,16789796,Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children.,"['Anderson VR', 'Scott LJ']","['Administration, Cutaneous', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/psychology', 'Central Nervous System Stimulants/*administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Child', 'Clinical Trials as Topic', 'Humans', 'Methylphenidate/*administration & dosage/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16789796/
823,methylphenidate,37878348,Treatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis.,"['Farhat LC', 'Flores JM', 'Avila-Quintero VJ', 'Polanczyk GV', 'Cipriani A', 'Furukawa TA', 'Bloch MH', 'Cortese S']","['Humans', '*Attention Deficit Disorder with Hyperactivity/drug therapy', '*Central Nervous System Stimulants/administration & dosage/adverse effects', 'Adult', '*Methylphenidate/administration & dosage/adverse effects', 'Dose-Response Relationship, Drug', 'Treatment Outcome', 'Amphetamines/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37878348/
824,methylphenidate,12558545,Methylphenidate and intracortical excitability: opposite effects in healthy subjects and attention-deficit hyperactivity disorder.,"['Moll GH', 'Heinrich H', 'Rothenberger A']","['Adult', 'Attention Deficit Disorder with Hyperactivity/*drug therapy', 'Central Nervous System Stimulants/*pharmacology/*therapeutic use', 'Cerebral Cortex/*drug effects', 'Female', 'Humans', 'Male', 'Methylphenidate/*pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12558545/
825,methylphenidate,22298228,"Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.","['Batra AS', 'Alexander ME', 'Silka MJ']","['Amphetamines/adverse effects/*therapeutic use', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/epidemiology/pathology', 'Central Nervous System Stimulants/adverse effects/*therapeutic use', 'Coronary Artery Disease', 'Death, Sudden, Cardiac', 'Evidence-Based Medicine', 'Heart Defects, Congenital/*complications/epidemiology/pathology', 'Humans', 'Methylphenidate/adverse effects/*therapeutic use', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/22298228/
826,methylphenidate,14594346,Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations.,"['Markowitz JS', 'Straughn AB', 'Patrick KS']","['Attention Deficit Disorder with Hyperactivity/diagnosis/*drug therapy', 'Delayed-Action Preparations', 'Dopamine Uptake Inhibitors/administration & dosage/pharmacokinetics/*therapeutic use', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Male', 'Methylphenidate/administration & dosage/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Sex Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/14594346/
827,methylphenidate,33730752,Perception-Action Integration Is Modulated by the Catecholaminergic System Depending on Learning Experience.,"['Eggert E', 'Bluschke A', 'Takacs A', 'Kleimaker M', 'Munchau A', 'Roessner V', 'Muckschel M', 'Beste C']","['Adult', 'Central Nervous System Stimulants/administration & dosage/*pharmacology', 'Cross-Over Studies', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Methylphenidate/administration & dosage/*pharmacology', 'Motor Activity/*drug effects', 'Neurotransmitter Agents/administration & dosage/*pharmacology', 'Psychomotor Performance/*drug effects', 'Visual Perception/*drug effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33730752/
828,methylphenidate,14529325,Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient.,['Kollins SH'],"['Adult', 'Animals', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/epidemiology', 'Brain/drug effects/metabolism', 'Central Nervous System Stimulants/*adverse effects/therapeutic use', 'Cocaine/pharmacokinetics', 'Dextroamphetamine/adverse effects/pharmacokinetics/therapeutic use', 'Humans', 'Methylphenidate/*adverse effects/pharmacokinetics/therapeutic use', 'Reinforcement, Psychology', 'Substance-Related Disorders/epidemiology/*etiology/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/14529325/
829,methylphenidate,12211419,MethyPatch Noven.,"['Sane N', 'McGough JJ']","['Administration, Cutaneous', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/psychology', 'Central Nervous System Stimulants/*administration & dosage/adverse effects/chemical synthesis/metabolism/pharmacology/*therapeutic use', 'Clinical Trials, Phase I as Topic', 'Clinical Trials, Phase II as Topic', 'Clinical Trials, Phase III as Topic', 'Humans', 'Methylphenidate/*administration & dosage/adverse effects/chemical synthesis/metabolism/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12211419/
830,methylphenidate,15943544,"Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD.","['Pelham WE', 'Burrows-Maclean L', 'Gnagy EM', 'Fabiano GA', 'Coles EK', 'Tresco KE', 'Chacko A', 'Wymbs BT', 'Wienke AL', 'Walker KS', 'Hoffman MT']","['Administration, Cutaneous', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/psychology/*therapy', 'Behavior', '*Behavior Therapy', 'Central Nervous System Stimulants/*administration & dosage/adverse effects/*therapeutic use', 'Child', 'Combined Modality Therapy', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Male', 'Methylphenidate/*administration & dosage/adverse effects/*therapeutic use', 'Psychiatric Status Rating Scales', 'Stress, Psychological/psychology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15943544/
831,dipyridamole,10493274,Extended-release dipyridamole/aspirin.,"['Hervey PS', 'Goa KL']","['Animals', 'Aspirin/pharmacokinetics/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Delayed-Action Preparations/pharmacokinetics/pharmacology/*therapeutic use', 'Dipyridamole/pharmacokinetics/pharmacology/*therapeutic use', 'Drug Combinations', 'Humans', 'Platelet Aggregation Inhibitors/pharmacokinetics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10493274/
832,dipyridamole,20955431,Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia.,"['Melani A', 'Cipriani S', 'Corti F', 'Pedata F']","['Animals', 'Brain Ischemia/*drug therapy/psychology', 'Carotid Artery, Common', 'Dipyridamole/*administration & dosage', 'Disease Models, Animal', 'Humans', 'Infusions, Intravenous', 'Memory/drug effects', 'Neuroprotective Agents/administration & dosage', 'Rats', 'Stroke/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/20955431/
833,dipyridamole,1298987,Hypoxemia in thalassemia.,"['Fucharoen S', 'Winichagoon P', 'Siritanaratkul N', 'Sonakul D', 'Chantaraksri U', 'Bunyaratvej A', 'Piankijagum A', 'Wasi P']","['Aspirin/administration & dosage/pharmacology/therapeutic use', 'Blood Gas Analysis', 'Dipyridamole/administration & dosage/pharmacology/therapeutic use', 'Follow-Up Studies', 'Heart Failure/etiology', 'Humans', 'Hypoxia/blood/drug therapy/*etiology', '*Platelet Aggregation', 'Pulmonary Circulation', 'Pulmonary Heart Disease/etiology', 'Splenectomy', 'Thalassemia/*complications/surgery']",https://pubmed.ncbi.nlm.nih.gov/1298987/
834,dipyridamole,18367036,Use of antiplatelet agents to prevent stroke: what is the role for combinations of medications?,"['Schwartz NE', 'Albers GW']","['Aspirin/administration & dosage/adverse effects', 'Clinical Trials as Topic/statistics & numerical data', 'Clopidogrel', 'Dipyridamole/administration & dosage/adverse effects', 'Drug Interactions/physiology', 'Drug Therapy, Combination', 'Hemorrhage/chemically induced/physiopathology', 'Humans', 'Platelet Aggregation Inhibitors/*administration & dosage/*adverse effects', 'Risk Assessment', 'Stroke/*drug therapy/physiopathology/*prevention & control', 'Ticlopidine/administration & dosage/adverse effects/analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/18367036/
835,dipyridamole,7025599,Antiplatelet therapy.,['Sloan RW'],"['Anticoagulants/therapeutic use', 'Arteriosclerosis/drug therapy/physiopathology', 'Aspirin/pharmacology/*therapeutic use', 'Blood Platelets/drug effects/physiology', 'Coronary Disease/drug therapy/physiopathology', 'Dipyridamole/pharmacology/*therapeutic use', 'Epoprostenol/adverse effects', 'Female', 'Heart Valve Prosthesis', 'Humans', 'Male', 'Platelet Aggregation/*drug effects', 'Sulfinpyrazone/pharmacology/*therapeutic use', 'Thrombophlebitis/drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/7025599/
836,dipyridamole,2656267,Dipyridamole-echocardiography test: historical background and physiologic basis.,['Picano E'],"['Coronary Disease/*diagnosis', '*Dipyridamole/adverse effects/physiology', 'Echocardiography/*methods', 'Exercise Test', 'Humans', 'Ischemia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/2656267/
837,dipyridamole,19671560,Ischemic stroke followed by acute thrombocytopenia: a double iatrogenic whammy.,"['Adams C', 'Dhirendra A', 'Ames PR']","['Acute Disease', 'Adult', 'Brain Ischemia/*chemically induced/drug therapy', 'Dipyridamole/administration & dosage/*adverse effects', 'Female', 'Hemorrhage/*chemically induced/drug therapy', 'Humans', 'Iatrogenic Disease', 'Platelet Aggregation Inhibitors/administration & dosage/*adverse effects', 'Serotonin 5-HT1 Receptor Agonists/administration & dosage/*adverse effects', 'Stroke/*chemically induced/drug therapy', 'Sumatriptan/administration & dosage/*adverse effects', 'Thrombocytopenia/*chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19671560/
838,dipyridamole,10847250,Update on antiplatelet therapy for stroke prevention.,"['Sacco RL', 'Elkind MS']","['Aspirin/administration & dosage', 'Clinical Trials as Topic', 'Delayed-Action Preparations', 'Dipyridamole/administration & dosage', 'Dose-Response Relationship, Drug', 'Humans', 'Ischemic Attack, Transient/complications', 'Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use', 'Risk Factors', 'Stroke/etiology/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/10847250/
839,dipyridamole,18173959,Antiplatelet therapy for stroke prevention.,['Hankey GJ'],"['Anticoagulants/adverse effects/therapeutic use', 'Aspirin/adverse effects/*therapeutic use', 'Atherosclerosis/complications', 'Atrial Fibrillation/complications', 'Clinical Trials as Topic', 'Clopidogrel', 'Dipyridamole/adverse effects/*therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Platelet Aggregation Inhibitors/adverse effects/*therapeutic use', 'Stroke/etiology/*prevention & control', 'Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18173959/
840,dipyridamole,10453294,Dipyridamole stress echocardiography.,"['Picano E', 'Sicari R', 'Varga A']","['Adrenergic beta-Agonists', 'Cardiotonic Agents', 'Clinical Protocols', 'Coronary Disease/*diagnostic imaging/metabolism', '*Dipyridamole/administration & dosage/adverse effects', 'Dobutamine', 'Echocardiography/*methods', 'Electrocardiography', '*Exercise Test', 'Humans', 'Prognosis', 'Sensitivity and Specificity', '*Vasodilator Agents/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/10453294/
841,dipyridamole,12765506,Antiplatelet drugs.,"['Hankey GJ', 'Eikelboom JW']","['Aspirin/pharmacology/therapeutic use', 'Clopidogrel', 'Dipyridamole/pharmacology/therapeutic use', 'Humans', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors', 'Primary Prevention', 'Pulmonary Embolism/prevention & control', 'Thrombosis/*drug therapy/physiopathology', 'Ticlopidine/analogs & derivatives/pharmacology/therapeutic use', 'Venous Thrombosis/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/12765506/
842,dipyridamole,17288680,ESPRIT study design and outcomes--a critical appraisal.,['Einhaupl K'],"['Aspirin/administration & dosage/adverse effects/*therapeutic use', 'Biomarkers', 'Brain Ischemia/epidemiology/prevention & control', 'Dipyridamole/administration & dosage/adverse effects/*therapeutic use', 'Drug Therapy, Combination', 'Fibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use', 'Hemorrhage/chemically induced/epidemiology', 'Humans', 'Myocardial Infarction/epidemiology/prevention & control', 'Patient Dropouts/statistics & numerical data', 'Prospective Studies', 'Research Design', 'Stroke/epidemiology/*prevention & control', 'Treatment Outcome', 'Vascular Diseases/mortality']",https://pubmed.ncbi.nlm.nih.gov/17288680/
843,dipyridamole,26021241,Association between coronary flow reserve and exercise capacity.,"['Eroglu S', 'Sade LE', 'Polat E', 'Bozbas H', 'Muderrisoglu H']","['Adult', 'Aged', 'Blood Flow Velocity/*physiology', 'Cardiovascular Physiological Phenomena/drug effects', 'Coronary Circulation/drug effects/physiology', 'Coronary Vessels/physiopathology', 'Diastole/drug effects/physiology', 'Dipyridamole/administration & dosage/adverse effects', 'Echocardiography, Doppler/methods', 'Echocardiography, Doppler, Pulsed', 'Exercise/*physiology', 'Exercise Test/methods', 'Female', 'Humans', 'Male', 'Microvessels/physiopathology', 'Middle Aged', 'Observer Variation']",https://pubmed.ncbi.nlm.nih.gov/26021241/
844,dipyridamole,3555016,Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis.,"['Chan MK', 'Kwan SY', 'Chan KW', 'Yeung CK']","['Adult', 'Aspirin/administration & dosage/*therapeutic use', 'Blood Platelets/*drug effects', 'Clinical Trials as Topic', 'Creatinine/blood', 'Delayed-Action Preparations', 'Dipyridamole/administration & dosage/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Glomerular Mesangium', 'Glomerulonephritis, IGA/*drug therapy', 'Humans', 'Immunoglobulin G/analysis', 'Male', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/3555016/
845,dipyridamole,31804544,Dipyridamole-loaded 3D-printed bioceramic scaffolds stimulate pediatric bone regeneration in vivo without disruption of craniofacial growth through facial maturity.,"['Wang MM', 'Flores RL', 'Witek L', 'Torroni A', 'Ibrahim A', 'Wang Z', 'Liss HA', 'Cronstein BN', 'Lopez CD', 'Maliha SG', 'Coelho PG']","['Animals', 'Bioprinting/methods', 'Bone Regeneration/*drug effects', 'Calcium Phosphates/adverse effects/chemistry', 'Ceramics/adverse effects/chemistry', 'Child', 'Child Development/drug effects', 'Dipyridamole/*administration & dosage/adverse effects', 'Disease Models, Animal', 'Guided Tissue Regeneration/*methods', 'Humans', 'Maxillofacial Development/drug effects', 'Models, Animal', 'Printing, Three-Dimensional', 'Rabbits', 'Skull/drug effects/growth & development/*injuries', 'Tissue Engineering/methods', 'Tissue Scaffolds/adverse effects/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/31804544/
846,dipyridamole,382146,Antiplatelet drugs in thromboembolism.,['Hirsh J'],"['Anticoagulants/administration & dosage', 'Aspirin/administration & dosage/*therapeutic use', 'Blood Platelets/*drug effects', 'Coronary Disease/prevention & control', 'Dipyridamole/administration & dosage/*therapeutic use', 'Drug Therapy, Combination', 'Heart Valve Prosthesis', 'Humans', 'Sulfinpyrazone/administration & dosage/*therapeutic use', 'Thromboembolism/*prevention & control', 'Thrombophlebitis/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/382146/
847,dipyridamole,3717855,Dipyridamole-induced epistaxis.,"['Mittelman M', 'Ogarten U', 'Lewinski U', 'Djaldetti M']","['Aged', 'Dipyridamole/*adverse effects', 'Epistaxis/*chemically induced', 'Humans', 'Male', 'Platelet Aggregation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/3717855/
848,dipyridamole,845612,Transient ischaemic attacks and increased platelet aggregability associated with oral contraceptives. Treatment with dipyridamole and aspirin.,['Mazal S'],"['Adult', 'Aspirin/*therapeutic use', 'Contraceptives, Oral/*adverse effects', 'Dipyridamole/*therapeutic use', 'Female', 'Humans', 'Ischemic Attack, Transient/*chemically induced/drug therapy', 'Platelet Aggregation/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/845612/
849,dipyridamole,21415156,Use of aspirin associates with longer primary patency of hemodialysis grafts.,"['Dixon BS', 'Beck GJ', 'Dember LM', 'Vazquez MA', 'Greenberg A', 'Delmez JA', 'Allon M', 'Himmelfarb J', 'Hu B', 'Greene T', 'Radeva MK', 'Davidson IJ', 'Ikizler TA', 'Braden GL', 'Lawson JH', 'Cotton JR Jr', 'Kusek JW', 'Feldman HI']","['Adult', 'Aged', '*Arteriovenous Shunt, Surgical/adverse effects', 'Aspirin/adverse effects/pharmacology/*therapeutic use', 'Aspirin, Dipyridamole Drug Combination', 'Chronic Disease', 'Dipyridamole/adverse effects/pharmacology/therapeutic use', 'Drug Combinations', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Humans', 'Kidney Diseases/*therapy', 'Male', 'Middle Aged', 'Platelet Aggregation Inhibitors/adverse effects/pharmacology/*therapeutic use', 'Proportional Hazards Models', 'Renal Dialysis/*methods', 'Thrombosis/etiology/prevention & control', 'Treatment Outcome', '*Vascular Patency/drug effects']",https://pubmed.ncbi.nlm.nih.gov/21415156/
850,dipyridamole,25697566,Dipyridamole: a drug with unrecognized antioxidant activity.,"['Ciacciarelli M', 'Zerbinati C', 'Violi F', 'Iuliano L']","['Animals', 'Antioxidants/chemistry/*pharmacology/therapeutic use', 'Cardiovascular Diseases/drug therapy/metabolism', 'Central Nervous System Diseases/drug therapy/metabolism', 'Dipyridamole/chemistry/*pharmacology/therapeutic use', 'Drug Discovery', 'Humans', 'Neoplasms/drug therapy/metabolism', 'Oxidative Stress/*drug effects', 'Vasodilator Agents/chemistry/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25697566/
851,Sorafenib,38382875,Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.,"['Sangro B', 'Chan SL', 'Kelley RK', 'Lau G', 'Kudo M', 'Sukeepaisarnjaroen W', 'Yarchoan M', 'De Toni EN', 'Furuse J', 'Kang YK', 'Galle PR', 'Rimassa L', 'Heurgue A', 'Tam VC', 'Van Dao T', 'Thungappa SC', 'Breder V', 'Ostapenko Y', 'Reig M', 'Makowsky M', 'Paskow MJ', 'Gupta C', 'Kurland JF', 'Negro A', 'Abou-Alfa GK']","['Humans', '*Carcinoma, Hepatocellular/drug therapy/mortality/pathology', '*Liver Neoplasms/drug therapy/mortality/pathology', 'Male', 'Female', '*Antibodies, Monoclonal/administration & dosage/adverse effects/therapeutic use', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects/administration & dosage', '*Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects/therapeutic use', 'Middle Aged', 'Aged', 'Sorafenib/administration & dosage/therapeutic use/adverse effects', 'Survival Rate', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/38382875/
852,Sorafenib,38319892,Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.,"['Abou-Alfa GK', 'Lau G', 'Kudo M', 'Chan SL', 'Kelley RK', 'Furuse J', 'Sukeepaisarnjaroen W', 'Kang YK', 'Van Dao T', 'De Toni EN', 'Rimassa L', 'Breder V', 'Vasilyev A', 'Heurgue A', 'Tam VC', 'Mody K', 'Thungappa SC', 'Ostapenko Y', 'Yau T', 'Azevedo S', 'Varela M', 'Cheng AL', 'Qin S', 'Galle PR', 'Ali S', 'Marcovitz M', 'Makowsky M', 'He P', 'Kurland JF', 'Negro A', 'Sangro B']","['Humans', '*Carcinoma, Hepatocellular/drug therapy/mortality/pathology', '*Liver Neoplasms/drug therapy/mortality/pathology', 'Male', '*Antibodies, Monoclonal/therapeutic use/administration & dosage/adverse effects', 'Female', 'Middle Aged', '*Antibodies, Monoclonal, Humanized/therapeutic use/administration & dosage/adverse effects', 'Aged', '*Sorafenib/therapeutic use/administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Adult', 'Antineoplastic Agents, Immunological/therapeutic use/adverse effects/administration & dosage', 'Aged, 80 and over']",https://pubmed.ncbi.nlm.nih.gov/38319892/
853,Sorafenib,32532960,The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects.,"['Tang W', 'Chen Z', 'Zhang W', 'Cheng Y', 'Zhang B', 'Wu F', 'Wang Q', 'Wang S', 'Rong D', 'Reiter FP', 'De Toni EN', 'Wang X']","['Apoptosis/drug effects', 'Carcinoma, Hepatocellular/*drug therapy/genetics/pathology', 'Cell Proliferation/drug effects', 'Drug Resistance, Neoplasm/drug effects/*genetics', 'Humans', 'Liver Neoplasms/*drug therapy/genetics/pathology', 'Sorafenib/adverse effects/*therapeutic use', 'Tumor Microenvironment/drug effects']",https://pubmed.ncbi.nlm.nih.gov/32532960/
854,Sorafenib,30993651,Lenvatinib: A Review in Hepatocellular Carcinoma.,"['Al-Salama ZT', 'Syed YY', 'Scott LJ']","['Antineoplastic Agents/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Carcinoma, Hepatocellular/*drug therapy', 'Dose-Response Relationship, Drug', 'Humans', 'Liver Neoplasms/*drug therapy', 'Phenylurea Compounds/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Protein Kinase Inhibitors/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Quinolines/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Sorafenib/pharmacology/therapeutic use', 'Treatment Outcome', 'Tyrosine/antagonists & inhibitors']",https://pubmed.ncbi.nlm.nih.gov/30993651/
855,Sorafenib,31918403,The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma.,"['Xia S', 'Pan Y', 'Liang Y', 'Xu J', 'Cai X']","['Carcinoma, Hepatocellular/*drug therapy/*metabolism/pathology', '*Drug Resistance, Neoplasm/drug effects', 'Epigenesis, Genetic/drug effects', 'Humans', 'Liver Neoplasms/*drug therapy/*metabolism/pathology', 'Sorafenib/pharmacology/*therapeutic use', '*Tumor Microenvironment/drug effects/genetics']",https://pubmed.ncbi.nlm.nih.gov/31918403/
856,Sorafenib,29915898,Regorafenib: A Review in Hepatocellular Carcinoma.,"['Heo YA', 'Syed YY']","['Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use', 'Carcinoma, Hepatocellular/*drug therapy', 'Disease Progression', 'Disease-Free Survival', 'Drug Approval', 'Humans', 'Liver Neoplasms/*drug therapy', 'Phenylurea Compounds/administration & dosage/adverse effects/*therapeutic use', 'Protein Kinase Inhibitors/administration & dosage/adverse effects/*therapeutic use', 'Pyridines/administration & dosage/adverse effects/*therapeutic use', 'Sorafenib/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29915898/
857,Sorafenib,32699265,Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma.,"['Li ZJ', 'Dai HQ', 'Huang XW', 'Feng J', 'Deng JH', 'Wang ZX', 'Yang XM', 'Liu YJ', 'Wu Y', 'Chen PH', 'Shi H', 'Wang JG', 'Zhou J', 'Lu GD']","['Animals', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/pharmacology', 'Artesunate/administration & dosage/*pharmacology', 'Carcinoma, Hepatocellular/*drug therapy/pathology', 'Cell Line, Tumor', 'Drug Synergism', 'Ferroptosis/drug effects', 'Humans', 'Lipid Peroxidation/drug effects', 'Liver Neoplasms/*drug therapy/pathology', 'Male', 'Mice', 'Mice, Inbred BALB C', 'Mice, Nude', 'Oxidative Stress/drug effects', 'Sorafenib/administration & dosage/*pharmacology', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/32699265/
858,Sorafenib,33859758,Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.,"['Kong FH', 'Ye QF', 'Miao XY', 'Liu X', 'Huang SQ', 'Xiong L', 'Wen Y', 'Zhang ZJ']","['Animals', 'Antineoplastic Agents/*pharmacology/*therapeutic use', 'Carcinoma, Hepatocellular/*drug therapy', 'Drug Delivery Systems/methods', 'Humans', 'Liver Neoplasms/*drug therapy', 'Nanoparticles/*chemistry', 'Sorafenib/*pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33859758/
859,Sorafenib,30575484,Sorafenib for Advanced and Refractory Desmoid Tumors.,"['Gounder MM', 'Mahoney MR', 'Van Tine BA', 'Ravi V', 'Attia S', 'Deshpande HA', 'Gupta AA', 'Milhem MM', 'Conry RM', 'Movva S', 'Pishvaian MJ', 'Riedel RF', 'Sabagh T', 'Tap WD', 'Horvat N', 'Basch E', 'Schwartz LH', 'Maki RG', 'Agaram NP', 'Lefkowitz RA', 'Mazaheri Y', 'Yamashita R', 'Wright JJ', 'Dueck AC', 'Schwartz GK']","['Adolescent', 'Adult', 'Aged', 'Antineoplastic Agents/adverse effects/*therapeutic use', 'Double-Blind Method', 'Female', 'Desmoid Tumors/*drug therapy/mortality', 'Follow-Up Studies', 'Humans', 'Kaplan-Meier Estimate', 'Male', 'Middle Aged', 'Progression-Free Survival', 'Sorafenib/adverse effects/*therapeutic use', 'Survival Rate', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30575484/
860,Sorafenib,32375062,Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis.,"['Jian C', 'Fu J', 'Cheng X', 'Shen LJ', 'Ji YX', 'Wang X', 'Pan S', 'Tian H', 'Tian S', 'Liao R', 'Song K', 'Wang HP', 'Zhang X', 'Wang Y', 'Huang Z', 'She ZG', 'Zhang XJ', 'Zhu L', 'Li H']","['Animals', 'Antineoplastic Agents/*pharmacology', 'Carcinoma, Hepatocellular/*drug therapy/metabolism', 'Cell Line', 'Dose-Response Relationship, Drug', 'Humans', 'Liver Neoplasms/*drug therapy/metabolism', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Mitochondria/*drug effects/metabolism', 'Non-alcoholic Fatty Liver Disease/*drug therapy/metabolism', 'Sorafenib/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/32375062/
861,Sorafenib,38458013,Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma.,"['Dong R', 'Wang T', 'Dong W', 'Zhu H', 'Liu Q', 'Liang H', 'Chen X', 'Zhang B', 'Zhang X']","['Humans', 'Sorafenib/pharmacology/therapeutic use', '*Carcinoma, Hepatocellular/pathology', '*Antineoplastic Agents/pharmacology/therapeutic use', '*Liver Neoplasms/pathology', 'Cell Line, Tumor', 'Cell Proliferation', 'Drug Resistance, Neoplasm']",https://pubmed.ncbi.nlm.nih.gov/38458013/
862,Sorafenib,34185551,"Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.","['Qin S', 'Bi F', 'Gu S', 'Bai Y', 'Chen Z', 'Wang Z', 'Ying J', 'Lu Y', 'Meng Z', 'Pan H', 'Yang P', 'Zhang H', 'Chen X', 'Xu A', 'Cui C', 'Zhu B', 'Wu J', 'Xin X', 'Wang J', 'Shan J', 'Chen J', 'Zheng Z', 'Xu L', 'Wen X', 'You Z', 'Ren Z', 'Liu X', 'Qiu M', 'Wu L', 'Chen F']","['Antineoplastic Combined Chemotherapy Protocols/pharmacology/*therapeutic use', 'Carcinoma, Hepatocellular/*drug therapy', 'Female', 'Humans', 'Liver Neoplasms/*drug therapy', 'Male', 'Middle Aged', 'Neoplasm Metastasis', 'Pyridines/pharmacology/*therapeutic use', 'Sorafenib/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34185551/
863,Sorafenib,36202608,Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer.,['Baste Rotllan N'],"['*Carcinoma', 'Humans', 'Immunocompromised Host', 'Sorafenib/adverse effects', '*Thyroid Neoplasms/drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/36202608/
864,Sorafenib,38151184,Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040.,"['El-Khoueiry AB', 'Trojan J', 'Meyer T', 'Yau T', 'Melero I', 'Kudo M', 'Hsu C', 'Kim TY', 'Choo SP', 'Kang YK', 'Yeo W', 'Chopra A', 'Soleymani S', 'Yao J', 'Neely J', 'Tschaika M', 'Welling TH', 'Sangro B']","['Humans', 'Nivolumab/adverse effects', '*Carcinoma, Hepatocellular/drug therapy', 'Sorafenib/therapeutic use', 'B7-H1 Antigen/metabolism', 'Follow-Up Studies', '*Liver Neoplasms/drug therapy', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Ipilimumab/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38151184/
865,Sorafenib,36202606,Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer.,['Herranz UA'],"['*Adenocarcinoma/drug therapy', '*Antineoplastic Agents/adverse effects', 'Humans', 'Iodine Radioisotopes/therapeutic use', 'Phenylurea Compounds/adverse effects', 'Protein Kinase Inhibitors/adverse effects', 'Quinolines', 'Sorafenib/therapeutic use', '*Thyroid Neoplasms/drug therapy/pathology/radiotherapy']",https://pubmed.ncbi.nlm.nih.gov/36202606/
866,Sorafenib,39002440,Research progress of sorafenib drug delivery system in the treatment of hepatocellular carcinoma: An update.,"['Fan QQ', 'Tian H', 'Cheng JX', 'Zou JB', 'Luan F', 'Qiao JX', 'Zhang D', 'Tian Y', 'Zhai BT', 'Guo DY']","['Humans', '*Carcinoma, Hepatocellular/drug therapy/pathology', '*Sorafenib/administration & dosage/therapeutic use', '*Liver Neoplasms/drug therapy/pathology', '*Antineoplastic Agents/administration & dosage/therapeutic use', '*Drug Delivery Systems/methods', 'Animals', 'Nanoparticles', 'Drug Resistance, Neoplasm']",https://pubmed.ncbi.nlm.nih.gov/39002440/
867,Sorafenib,30220234,Lenvatinib as a therapy for unresectable hepatocellular carcinoma.,"['Spallanzani A', 'Orsi G', 'Andrikou K', 'Gelsomino F', 'Rimini M', 'Riggi L', 'Cascinu S']","['Antineoplastic Agents/administration & dosage/adverse effects/pharmacology', 'Carcinoma, Hepatocellular/*drug therapy/pathology', 'Humans', 'Liver Neoplasms/*drug therapy/pathology', 'Phenylurea Compounds/*administration & dosage/adverse effects/pharmacology', 'Protein Kinase Inhibitors/administration & dosage/adverse effects/pharmacology', 'Quinolines/*administration & dosage/adverse effects/pharmacology', 'Sorafenib/administration & dosage', 'Survival Rate']",https://pubmed.ncbi.nlm.nih.gov/30220234/
868,Sorafenib,31801872,"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.","['Kudo M', 'Ueshima K', 'Ikeda M', 'Torimura T', 'Tanabe N', 'Aikata H', 'Izumi N', 'Yamasaki T', 'Nojiri S', 'Hino K', 'Tsumura H', 'Kuzuya T', 'Isoda N', 'Yasui K', 'Aino H', 'Ido A', 'Kawabe N', 'Nakao K', 'Wada Y', 'Yokosuka O', 'Yoshimura K', 'Okusaka T', 'Furuse J', 'Kokudo N', 'Okita K', 'Johnson PJ', 'Arai Y']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Agents/adverse effects/*therapeutic use', 'Carcinoma, Hepatocellular/*therapy', '*Chemoembolization, Therapeutic/adverse effects', 'Combined Modality Therapy', 'Disease Progression', 'Female', 'Humans', 'Liver Neoplasms/*therapy', 'Male', 'Middle Aged', 'Progression-Free Survival', 'Prospective Studies', 'Sorafenib/adverse effects/*therapeutic use', 'Survival Rate']",https://pubmed.ncbi.nlm.nih.gov/31801872/
869,Sorafenib,35395582,"Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.","['Brown ZJ', 'Gregory S', 'Hewitt DB', 'Iacono S', 'Choe J', 'Labiner HE', 'Pawlik TM']","['Antibodies, Monoclonal', '*Carcinoma, Hepatocellular/pathology', 'Humans', 'Immune Checkpoint Inhibitors/adverse effects', '*Liver Neoplasms/pathology', 'Sorafenib/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35395582/
870,Sorafenib,33536280,Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate.,"['Kong FE', 'Li GM', 'Tang YQ', 'Xi SY', 'Loong JHC', 'Li MM', 'Li HL', 'Cheng W', 'Zhu WJ', 'Mo JQ', 'Gong YF', 'Tang H', 'Zhao Y', 'Zhang Y', 'Ma S', 'Guan XY', 'Ma NF', 'Xie MB', 'Liu M']","['*Antineoplastic Agents/pharmacology', '*Carcinoma, Hepatocellular/drug therapy', 'Cell Line, Tumor', 'Cell Proliferation', 'Drug Resistance, Neoplasm', 'Humans', '*Immunoconjugates/therapeutic use', '*Liver Neoplasms/drug therapy', 'Neoplasm Recurrence, Local', 'Sorafenib/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33536280/
871,zonisamide,36194365,Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.,"['Strzelczyk A', 'Schubert-Bast S']","['*Autism Spectrum Disorder', 'Bromides', '*Cannabidiol', 'Clobazam', 'Cognition', 'Ethosuximide', 'Everolimus', 'Felbamate', 'Fenfluramine', 'Humans', 'Lacosamide', 'Lamotrigine', 'Levetiracetam', 'Pregabalin', '*Spasms, Infantile', 'Sulfides', 'Topiramate', 'Valproic Acid', 'Vigabatrin', 'Zinc Compounds', 'Zonisamide']",https://pubmed.ncbi.nlm.nih.gov/36194365/
872,zonisamide,10530691,Zonisamide.,['Leppik IE'],"['Adult', 'Animals', 'Anticonvulsants/pharmacokinetics/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Disease Models, Animal', 'Drug Administration Schedule', 'Epilepsies, Myoclonic/drug therapy', 'Epilepsy/*drug therapy', 'Humans', 'Isoxazoles/pharmacokinetics/pharmacology/*therapeutic use', 'Treatment Outcome', 'Zonisamide']",https://pubmed.ncbi.nlm.nih.gov/10530691/
873,zonisamide,30680679,Pharmacological Management of Dementia with Lewy Bodies.,"['Hershey LA', 'Coleman-Jackson R']","['Age Factors', 'Aged', 'Anticonvulsants/administration & dosage', 'Antiparkinson Agents/administration & dosage', 'Cholinesterase Inhibitors/administration & dosage', 'Clinical Trials, Phase II as Topic', 'Clonazepam/administration & dosage', 'Humans', 'Levodopa/administration & dosage', 'Lewy Body Disease/diagnosis/*drug therapy', 'Melatonin/administration & dosage', 'Randomized Controlled Trials as Topic', 'Zonisamide/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/30680679/
874,zonisamide,38460459,Teratogenicity of zonisamide and other little-used antiseizure medications.,"['Vajda FJE', ""O'Brien TJ"", 'Graham JE', 'Hitchcock AA', 'Perucca P', 'Lander CM', 'Eadie MJ']","['Humans', '*Zonisamide/adverse effects', '*Anticonvulsants/adverse effects', 'Female', 'Pregnancy', 'Australia', 'Isoxazoles/adverse effects', 'Abnormalities, Drug-Induced/etiology', 'Registries', 'Epilepsy/drug therapy', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/38460459/
875,zonisamide,33838757,"The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.","['Marson A', 'Burnside G', 'Appleton R', 'Smith D', 'Leach JP', 'Sills G', 'Tudur-Smith C', 'Plumpton C', 'Hughes DA', 'Williamson P', 'Baker GA', 'Balabanova S', 'Taylor C', 'Brown R', 'Hindley D', 'Howell S', 'Maguire M', 'Mohanraj R', 'Smith PE']","['Administration, Oral', 'Adolescent', 'Adult', 'Aged', 'Anticonvulsants/*adverse effects', 'Child', '*Cost-Benefit Analysis', 'Epilepsies, Partial/*drug therapy', 'Female', 'Humans', 'Lamotrigine/*therapeutic use', 'Levetiracetam/*therapeutic use', 'Male', 'Middle Aged', '*Treatment Outcome', 'Young Adult', 'Zonisamide/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33838757/
876,zonisamide,26089654,Zonisamide in the management of epilepsy in the elderly.,"['Romigi A', 'Femia EA', 'Fattore C', 'Vitrani G', 'Di Gennaro G', 'Franco V']","['Aged', 'Anticonvulsants/adverse effects/pharmacology/*therapeutic use', 'Drug Therapy, Combination', 'Epilepsy/*drug therapy', 'Humans', 'Isoxazoles/adverse effects/pharmacology/*therapeutic use', 'Zonisamide']",https://pubmed.ncbi.nlm.nih.gov/26089654/
877,zonisamide,34204137,Glycine Receptors in Spinal Nociceptive Control-An Update.,"['Zeilhofer HU', 'Werynska K', 'Gingras J', 'Yevenes GE']","['Animals', 'Endocannabinoids/pharmacology', 'Humans', 'Nociception/drug effects/*physiology', 'Propofol/pharmacology', 'Protein Structure, Secondary', 'Receptors, Glycine/*agonists/chemistry/*metabolism', 'Spinal Cord Dorsal Horn/drug effects/*metabolism', 'Zonisamide/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/34204137/
878,zonisamide,34931602,Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.,"['Marson AG', 'Burnside G', 'Appleton R', 'Smith D', 'Leach JP', 'Sills G', 'Tudur-Smith C', 'Plumpton CO', 'Hughes DA', 'Williamson PR', 'Baker G', 'Balabanova S', 'Taylor C', 'Brown R', 'Hindley D', 'Howell S', 'Maguire M', 'Mohanraj R', 'Smith PE']","['Child, Preschool', 'Female', 'Humans', 'Cost-Benefit Analysis', '*Epilepsies, Partial/drug therapy', '*Epilepsy/drug therapy', '*Lamotrigine/therapeutic use', '*Levetiracetam/therapeutic use', 'Quality of Life', '*Valproic Acid/therapeutic use', '*Zonisamide/therapeutic use', 'Child', 'Adolescent', 'Young Adult', 'Adult', 'Middle Aged', 'Aged', 'Aged, 80 and over', 'Male']",https://pubmed.ncbi.nlm.nih.gov/34931602/
879,zonisamide,36193017,Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force.,"['Tomson T', 'Battino D', 'Bromley R', 'Kochen S', 'Meador KJ', 'Pennell PB', 'Thomas SV']","['Breast Feeding', '*Cannabidiol', 'Carbamazepine/therapeutic use', 'Child', 'Clobazam/therapeutic use', 'Clonazepam/therapeutic use', '*Epilepsy/drug therapy', 'Ethosuximide/therapeutic use', 'Everolimus/therapeutic use', 'Felbamate/therapeutic use', 'Female', 'Fenfluramine/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', 'Infant', 'Lacosamide', 'Lamotrigine/therapeutic use', 'Levetiracetam/therapeutic use', 'Oxcarbazepine', 'Phenobarbital/therapeutic use', 'Phenytoin/therapeutic use', 'Prospective Studies', 'Tiagabine', 'Topiramate', 'Valproic Acid/therapeutic use', 'Vigabatrin/therapeutic use', 'Zonisamide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36193017/
880,zonisamide,29733555,[The role of zonisamide in the treatment of women with epilepsy].,['Juhos V'],"['Anticonvulsants/*therapeutic use', 'Epilepsy/*drug therapy', 'Female', 'Humans', 'Isoxazoles/*therapeutic use', 'Zonisamide']",https://pubmed.ncbi.nlm.nih.gov/29733555/
881,zonisamide,24522856,Zonisamide as a treatment for partial epileptic seizures: a systematic review.,"['Cox JH', 'Seri S', 'Cavanna AE']","['Anticonvulsants/*therapeutic use', 'Epilepsies, Partial/*drug therapy', 'Humans', 'Isoxazoles/*therapeutic use', 'Treatment Outcome', 'Zonisamide']",https://pubmed.ncbi.nlm.nih.gov/24522856/
882,zonisamide,35157004,Antiseizure Medication Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study.,"['Pennell PB', 'Karanam A', 'Meador KJ', 'Gerard E', 'Kalayjian L', 'Penovich P', 'Matthews A', 'McElrath TM', 'Birnbaum AK']","['Adult', '*Anticonvulsants/adverse effects', 'Carbamazepine/therapeutic use', '*Epilepsy/drug therapy', 'Female', 'Humans', 'Lacosamide/therapeutic use', 'Lamotrigine/therapeutic use', 'Levetiracetam/therapeutic use', 'Oxcarbazepine/therapeutic use', 'Pregnancy', 'Prospective Studies', 'Topiramate/therapeutic use', 'Zonisamide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35157004/
883,zonisamide,19195742,[New antiepileptic drugs].,['Rouvel-Tallec A'],"['Amines/*therapeutic use', 'Anticonvulsants/adverse effects/*therapeutic use', 'Carbamazepine/analogs & derivatives/therapeutic use', 'Cyclohexanecarboxylic Acids/*therapeutic use', 'Epilepsies, Partial/drug therapy', 'Epilepsy/*drug therapy', 'Gabapentin', 'Humans', 'Isoxazoles/therapeutic use', 'Lamotrigine', 'Levetiracetam', 'Oxcarbazepine', 'Piracetam/analogs & derivatives/therapeutic use', 'Pregabalin', 'Triazines/*therapeutic use', 'Zonisamide', 'gamma-Aminobutyric Acid/analogs & derivatives/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19195742/
884,zonisamide,25556809,Tardive dyskinesia (syndrome): Current concept and modern approaches to its management.,"['Lerner PP', 'Miodownik C', 'Lerner V']","['Adrenergic Uptake Inhibitors/therapeutic use', 'Adrenergic beta-Antagonists/therapeutic use', 'Amantadine/therapeutic use', 'Anticonvulsants/therapeutic use', 'Antioxidants/therapeutic use', 'Antipsychotic Agents/*adverse effects', 'Clonazepam/therapeutic use', 'Dopamine Agents/therapeutic use', 'Drugs, Chinese Herbal/therapeutic use', 'Fatty Acids, Omega-3/therapeutic use', 'Ginkgo biloba', 'Humans', 'Isoleucine/therapeutic use', 'Isoxazoles/therapeutic use', 'Leucine/therapeutic use', 'Levetiracetam', 'Melatonin/therapeutic use', 'Movement Disorders/*drug therapy/etiology', 'Nootropic Agents/therapeutic use', 'Piracetam/analogs & derivatives/therapeutic use', 'Plant Extracts/therapeutic use', 'Propranolol/therapeutic use', 'Pyridoxine/therapeutic use', 'Resveratrol', 'Stilbenes/therapeutic use', 'Tetrabenazine/therapeutic use', 'Valine/therapeutic use', 'Vitamins/therapeutic use', 'Zonisamide', 'alpha-Tocopherol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25556809/
885,zonisamide,27546759,Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.,"['Smetana KS', 'Cook AM', 'Bastin ML', 'Oyler DR']","['Acetamides/administration & dosage', 'Acute Kidney Injury/complications/*therapy', 'Amines/administration & dosage', 'Anticonvulsants/*administration & dosage/adverse effects', 'Carbamates/administration & dosage', 'Critical Illness', 'Cyclohexanecarboxylic Acids/administration & dosage', 'Dibenzazepines/administration & dosage', 'Dose-Response Relationship, Drug', 'Ethosuximide/administration & dosage', 'Felbamate', 'Fructose/administration & dosage/analogs & derivatives', 'Gabapentin', 'Humans', 'Isoxazoles/administration & dosage', 'Lacosamide', 'Lamotrigine', 'Levetiracetam', 'Phenobarbital/administration & dosage', 'Phenylcarbamates/administration & dosage', 'Phenylenediamines/administration & dosage', 'Phenytoin/administration & dosage', 'Piracetam/administration & dosage/analogs & derivatives', 'Propylene Glycols/administration & dosage', '*Renal Dialysis', 'Renal Replacement Therapy', 'Seizures/complications/*drug therapy', 'Topiramate', 'Triazines/administration & dosage', 'Valproic Acid/administration & dosage', 'Zonisamide', 'gamma-Aminobutyric Acid/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27546759/
886,zonisamide,8019658,Developments in antiepileptic drug therapy.,"['Walker MC', 'Sander JW']","['Anticonvulsants/adverse effects/pharmacokinetics/*therapeutic use', 'Brain/drug effects/physiopathology', 'Dose-Response Relationship, Drug', 'Electroencephalography/drug effects', 'Epilepsy/blood/*drug therapy', 'Humans', 'Synaptic Transmission/drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/8019658/
887,zonisamide,38165339,Comparative Risk of Major Congenital Malformations With Antiseizure Medication Combinations vs Valproate Monotherapy in Pregnancy.,"['Cohen JM', 'Alvestad S', 'Suarez EA', 'Schaffer A', 'Selmer RM', 'Havard A', 'Bateman BT', 'Cesta CE', 'Zoega H', 'Odsbu I', 'Huybrechts KF', 'Kjerpeseth LJ', 'Straub L', 'Leinonen MK', 'Bjork MH', 'Norgaard M', 'Gissler M', 'Ulrichsen SP', 'Hernandez-Diaz S', 'Tomson T', 'Furu K']","['Female', 'Humans', 'Pregnancy', 'Cohort Studies', '*Epilepsy, Generalized', 'Lamotrigine/therapeutic use', 'Levetiracetam', 'Topiramate', '*Valproic Acid/adverse effects', 'Zonisamide', 'Infant, Newborn', 'Drug Combinations']",https://pubmed.ncbi.nlm.nih.gov/38165339/
888,zonisamide,34092044,Zonisamide-responsive myoclonus in SEMA6B-associated progressive myoclonic epilepsy.,"['Herzog R', 'Hellenbroich Y', 'Bruggemann N', 'Lohmann K', 'Grimmel M', 'Haack TB', 'von Spiczak S', 'Munchau A']","['Anticonvulsants/*therapeutic use', 'Female', 'Humans', 'Myoclonic Epilepsies, Progressive/diagnosis/*drug therapy/*genetics', 'Pedigree', 'Semaphorins/*genetics', 'Exome Sequencing/methods', 'Young Adult', 'Zonisamide/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34092044/
889,zonisamide,17030393,Novel anticonvulsant drugs.,"['Stefan H', 'Feuerstein TJ']","['Amines/therapeutic use', 'Animals', 'Anticonvulsants/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Carbamazepine/analogs & derivatives/therapeutic use', 'Cyclohexanecarboxylic Acids/therapeutic use', 'Epilepsy/*drug therapy', 'Fructose/analogs & derivatives/therapeutic use', 'Gabapentin', 'Humans', 'Isoxazoles/therapeutic use', 'Lamotrigine', 'Levetiracetam', 'Nipecotic Acids/therapeutic use', 'Piracetam/analogs & derivatives/therapeutic use', 'Pregabalin', 'Tiagabine', 'Topiramate', 'Treatment Outcome', 'Triazines/therapeutic use', 'Zonisamide', 'gamma-Aminobutyric Acid/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17030393/
890,zonisamide,20196486,"[The discovery of an antiparkinsonian drug, zonisamide].",['Murata M'],"['Animals', 'Anticonvulsants/*therapeutic use', 'Dopamine/biosynthesis', 'Humans', 'Isoxazoles/*therapeutic use', 'Male', 'Middle Aged', 'Parkinson Disease/*drug therapy', 'Rats', 'Zonisamide']",https://pubmed.ncbi.nlm.nih.gov/20196486/
891,naratriptan,18223456,Triptans in pregnancy.,"['Soldin OP', 'Dahlin J', ""O'Mara DM""]","['Animals', 'Female', 'Humans', 'Migraine Disorders/*drug therapy', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Pregnancy Outcome', '*Prenatal Exposure Delayed Effects', 'Serotonin Receptor Agonists/*adverse effects', 'Tryptamines/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/18223456/
892,naratriptan,25877672,Acute Migraine Treatment in Adults.,['Becker WJ'],"['Adult', 'Analgesics, Opioid/administration & dosage', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage', 'Caffeine/administration & dosage', 'Dihydroergotamine/administration & dosage', 'Drug Administration Schedule', 'Female', 'Humans', 'Male', 'Migraine Disorders/*diagnosis/*drug therapy', 'Pain Management/*methods', 'Serotonin Receptor Agonists/administration & dosage', 'Treatment Outcome', 'Tryptamines/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/25877672/
893,naratriptan,27910087,Menstrual Migraine and Treatment Options: Review.,"['Maasumi K', 'Tepper SJ', 'Kriegler JS']","['Female', 'Humans', 'Menstruation/drug effects/physiology', 'Migraine Disorders/*drug therapy/physiopathology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/27910087/
894,naratriptan,25600718,The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies.,"['Marmura MJ', 'Silberstein SD', 'Schwedt TJ']","['Adult', 'Anti-Inflammatory Agents/*therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Serotonin Receptor Agonists/*therapeutic use', 'Societies, Medical/standards/statistics & numerical data']",https://pubmed.ncbi.nlm.nih.gov/25600718/
895,naratriptan,19126376,Clinical aspects of perimenstrual headaches.,['Taylor FR'],"['Female', 'Headache/diagnosis/*etiology/*therapy', 'Humans', 'Migraine without Aura/diagnosis/etiology/therapy', 'Premenstrual Syndrome/*complications/diagnosis/*therapy', 'Randomized Controlled Trials as Topic/methods']",https://pubmed.ncbi.nlm.nih.gov/19126376/
896,naratriptan,12498013,Eletriptan Pfizer.,"['Strijbos PJ', 'Parsons AA', 'Fugelli A']","['Animals', 'Clinical Trials as Topic/methods/statistics & numerical data', 'Drug Industry/legislation & jurisprudence/*methods', 'Humans', 'Indoles/chemistry/*pharmacology/*therapeutic use', 'Pyrrolidines/chemistry/*pharmacology/*therapeutic use', 'Serotonin Receptor Agonists/pharmacology/therapeutic use', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/12498013/
897,naratriptan,17955173,Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment.,['Tfelt-Hansen P'],"['Administration, Oral', 'Biological Availability', 'Humans', 'Infusions, Parenteral', 'Injections, Subcutaneous', 'Migraine Disorders/*drug therapy/physiopathology', 'Piperidines/*administration & dosage/blood/pharmacokinetics', 'Serotonin Receptor Agonists/*administration & dosage/blood/pharmacokinetics', 'Sumatriptan/*administration & dosage/blood/pharmacokinetics', 'Time Factors', 'Treatment Outcome', 'Tryptamines/*administration & dosage/blood/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/17955173/
898,naratriptan,39293828,Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis.,"['Karlsson WK', 'Ostinelli EG', 'Zhuang ZA', 'Kokoti L', 'Christensen RH', 'Al-Khazali HM', 'Deligianni CI', 'Tomlinson A', 'Ashina H', 'Ruiz de la Torre E', 'Diener HC', 'Cipriani A', 'Ashina M']","['Adult', 'Humans', '*Migraine Disorders/diagnosis/drug therapy', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'Tryptamines/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39293828/
899,naratriptan,12463278,Naratriptan.,['Massiou H'],"['Humans', 'Indoles/adverse effects/*therapeutic use', 'Migraine Disorders/*drug therapy', 'Piperidines/adverse effects/*therapeutic use', 'Serotonin Receptor Agonists/adverse effects/*therapeutic use', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/12463278/
900,naratriptan,11575714,Donitriptan (Pierre Fabre).,['Dukat M'],"['Animals', 'Clinical Trials, Phase I as Topic', 'Drug Evaluation, Preclinical', '*Drugs, Investigational', 'Humans', 'Migraine Disorders/drug therapy', 'Molecular Structure', 'Nitriles/chemistry/*pharmacology/therapeutic use/toxicity', 'Piperazines/chemistry/*pharmacology/therapeutic use/toxicity', 'Serotonin Receptor Agonists/chemistry/*pharmacology/therapeutic use', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/11575714/
901,naratriptan,26252584,Acute Migraine Treatment.,['Becker WJ'],"['Acute Disease', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Dihydroergotamine/*therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Tryptamines/*therapeutic use', 'Vasoconstrictor Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26252584/
902,naratriptan,15934888,Eletriptan review.,"['Farkkila M', 'Kallela M']","['Clinical Trials as Topic/statistics & numerical data', 'Dose-Response Relationship, Drug', 'Humans', 'Migraine Disorders/*drug therapy/metabolism', 'Pyrrolidines/metabolism/*therapeutic use', 'Serotonin Receptor Agonists/metabolism/*therapeutic use', 'Tryptamines/metabolism/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15934888/
903,naratriptan,12117355,Mechanisms of action of the 5-HT1B/1D receptor agonists.,"['Tepper SJ', 'Rapoport AM', 'Sheftell FD']","['Carbazoles/pharmacology', 'Humans', 'Indoles/pharmacology', 'Migraine Disorders/*drug therapy/*metabolism', 'Oxazolidinones/pharmacology', 'Piperidines/pharmacology', 'Pyrrolidines/pharmacology', 'Receptor, Serotonin, 5-HT1B', 'Receptor, Serotonin, 5-HT1D', 'Receptors, Serotonin/*drug effects', 'Serotonin Receptor Agonists/*pharmacology', 'Sumatriptan/pharmacology', 'Triazoles/pharmacology', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/12117355/
904,naratriptan,10463349,Antimigraine drugs.,"['Diener HC', 'Kaube H', 'Limmroth V']","['Analgesics/*therapeutic use', 'Antiemetics/*therapeutic use', 'Ergotamine/*therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Serotonin Receptor Agonists/therapeutic use', 'Vasoconstrictor Agents/*therapeutic use', 'Vomiting/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/10463349/
905,naratriptan,10643958,Newer intranasal migraine medications.,"['Logemann CD', 'Rankin LM']","['Administration, Intranasal', 'Administration, Oral', 'Analgesics, Non-Narcotic/*administration & dosage', 'Clinical Trials as Topic', 'Dihydroergotamine/*administration & dosage', 'Half-Life', 'Humans', 'Indoles/administration & dosage', 'Migraine Disorders/*drug therapy', 'Oxazoles/administration & dosage', '*Oxazolidinones', 'Piperidines/administration & dosage', 'Recurrence', 'Serotonin Receptor Agonists/*administration & dosage', 'Sumatriptan/*administration & dosage', 'Triazoles/administration & dosage', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/10643958/
906,naratriptan,31389059,Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect.,"['Tfelt-Hansen P', 'Messlinger K']","['Administration, Oral', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacokinetics', 'Arteries/drug effects/innervation', 'Calcitonin Gene-Related Peptide Receptor Antagonists/administration & dosage/*pharmacokinetics', 'Humans', 'Migraine Disorders/*drug therapy/physiopathology', 'Nociception/drug effects/physiology', '*Randomized Controlled Trials as Topic', 'Serotonin 5-HT1 Receptor Agonists/administration & dosage/*pharmacokinetics', 'Thalamus/drug effects/physiopathology', 'Time Factors', 'Treatment Outcome', 'Trigeminal Ganglion/drug effects/physiopathology', 'Vasoconstriction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/31389059/
907,naratriptan,16389295,Preclinical neuropharmacology of naratriptan.,['Lambert GA'],"['Analgesia', 'Animals', 'Cardiovascular Diseases/chemically induced', 'Humans', 'Migraine Disorders/drug therapy', 'Piperidines/adverse effects/cerebrospinal fluid/chemistry/pharmacokinetics/*pharmacology/therapeutic use', 'Serotonin Receptor Agonists/adverse effects/cerebrospinal fluid/chemistry/pharmacokinetics/*pharmacology/therapeutic use', 'Tryptamines/adverse effects/cerebrospinal fluid/chemistry/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16389295/
908,naratriptan,9916496,[Zolmitriptan].,"['Monseu G', 'Sternon J']","['Chemistry, Pharmaceutical', 'Humans', 'Indoles/therapeutic use', 'Migraine Disorders/*drug therapy', 'Oxazoles/economics/pharmacokinetics/pharmacology/*therapeutic use', '*Oxazolidinones', 'Piperidines/therapeutic use', 'Serotonin Receptor Agonists/economics/pharmacokinetics/pharmacology/*therapeutic use', 'Sumatriptan/therapeutic use', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/9916496/
909,naratriptan,19538745,Triptans and troponin: a case report.,"['Weder CR', 'Schneemann M']","['Acute Coronary Syndrome/*chemically induced/diagnosis', 'Aged', 'Electrocardiography', 'Female', 'Humans', 'Migraine Disorders/drug therapy', 'Piperidines/administration & dosage/*adverse effects/therapeutic use', 'Serotonin Agents/administration & dosage/*adverse effects/therapeutic use', 'Treatment Outcome', 'Troponin T/*blood', 'Tryptamines/administration & dosage/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19538745/
910,naratriptan,12830928,Pharmacological approaches to migraine.,['Diener HCh'],"['Adrenergic beta-Antagonists/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Calcium Channel Blockers/therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Vasoconstrictor Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12830928/
911,mirtazapine,34823736,Understanding Stimulant Use and Use Disorders in a New Era.,"['Ciccarone D', 'Shoptaw S']","['Adrenergic alpha-2 Receptor Antagonists/therapeutic use', 'Adult', 'Anticonvulsants/therapeutic use', 'Behavior Therapy/methods', 'Bupropion/therapeutic use', 'Central Nervous System Stimulants/*adverse effects/pharmacology', 'Cocaine-Related Disorders/drug therapy/*epidemiology/mortality', 'Cognitive Dysfunction/chemically induced/epidemiology', 'Comorbidity', 'Dopamine Uptake Inhibitors/therapeutic use', 'Female', 'Humans', 'Illicit Drugs/adverse effects/pharmacology', 'Male', 'Mental Disorders/chemically induced/epidemiology', 'Methamphetamine/*adverse effects/pharmacology', 'Mirtazapine/therapeutic use', 'Neurobiology', 'Neurodegenerative Diseases/chemically induced/epidemiology', 'Opiate Overdose/*epidemiology/mortality', 'Substance Withdrawal Syndrome/*therapy', 'Topiramate/therapeutic use', 'Transgender Persons', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/34823736/
912,mirtazapine,35234292,Pharmacotherapy for post traumatic stress disorder (PTSD).,"['Williams T', 'Phillips NJ', 'Stein DJ', 'Ipser JC']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Amitriptyline/therapeutic use', 'Antidepressive Agents/therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', '*Antipsychotic Agents/therapeutic use', 'Humans', 'Middle Aged', 'Mirtazapine/therapeutic use', 'Paroxetine/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Stress Disorders, Post-Traumatic/drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/35234292/
913,mirtazapine,31178367,"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.","['Furukawa TA', 'Cipriani A', 'Cowen PJ', 'Leucht S', 'Egger M', 'Salanti G']","['Depressive Disorder, Major/*drug therapy', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Humans', 'Mirtazapine/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Serotonin Agents/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/*therapeutic use', 'Venlafaxine Hydrochloride/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31178367/
914,mirtazapine,36253442,Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.,"['Kishi T', 'Ikuta T', 'Sakuma K', 'Okuya M', 'Hatano M', 'Matsuda Y', 'Iwata N']","['Female', 'Humans', 'Adult', '*Depressive Disorder, Major/drug therapy', 'Duloxetine Hydrochloride/therapeutic use', 'Sertraline/therapeutic use', 'Citalopram/therapeutic use', 'Venlafaxine Hydrochloride/therapeutic use', 'Vortioxetine/therapeutic use', 'Fluoxetine/therapeutic use', 'Paroxetine/therapeutic use', 'Mirtazapine/therapeutic use', 'Amitriptyline/therapeutic use', 'Desvenlafaxine Succinate/therapeutic use', 'Fluvoxamine/therapeutic use', 'Reboxetine/therapeutic use', 'Network Meta-Analysis', 'Antidepressive Agents/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/36253442/
915,mirtazapine,11607047,A review of the pharmacological and clinical profile of mirtazapine.,"['Anttila SA', 'Leinonen EV']","['Animals', 'Antidepressive Agents, Tricyclic/*therapeutic use', 'Drug Interactions', 'Humans', 'Mianserin/adverse effects/*analogs & derivatives/pharmacology/*therapeutic use', 'Mirtazapine']",https://pubmed.ncbi.nlm.nih.gov/11607047/
916,mirtazapine,30081645,Clinical Management of Bleeding Risk With Antidepressants.,"['Bixby AL', 'VandenBerg A', 'Bostwick JR']","['Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Antidepressive Agents/administration & dosage/*adverse effects', 'Bupropion/adverse effects', 'Gastrointestinal Hemorrhage/chemically induced/epidemiology', 'Hemorrhage/*chemically induced/epidemiology/*therapy', 'Humans', 'Mirtazapine/adverse effects', 'Risk Factors', 'Selective Serotonin Reuptake Inhibitors/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/30081645/
917,mirtazapine,34029378,New generation antidepressants for depression in children and adolescents: a network meta-analysis.,"['Hetrick SE', 'McKenzie JE', 'Bailey AP', 'Sharma V', 'Moller CI', 'Badcock PB', 'Cox GR', 'Merry SN', 'Meader N']","['Adolescent', 'Antidepressive Agents/adverse effects/*therapeutic use', 'Bias', 'Child', 'Citalopram/therapeutic use', 'Depressive Disorder, Major/*drug therapy/psychology', 'Desvenlafaxine Succinate/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use', 'Female', 'Fluoxetine/therapeutic use', 'Humans', 'Male', 'Mirtazapine/therapeutic use', 'Network Meta-Analysis', 'Paroxetine/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Sertraline/therapeutic use', 'Suicidal Ideation', 'Venlafaxine Hydrochloride/therapeutic use', 'Vilazodone Hydrochloride/therapeutic use', 'Vortioxetine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34029378/
918,mirtazapine,30229678,Efficacy and Safety of Appetite-Stimulating Medications in the Inpatient Setting.,"['Howard ML', 'Hossaini R', 'Tolar C', 'Gaviola ML']","['Adult', 'Appetite/*drug effects', 'Appetite Regulation/*drug effects', 'Appetite Stimulants/administration & dosage/*therapeutic use', 'Dronabinol/administration & dosage/therapeutic use', 'Eating/drug effects', 'Female', 'Humans', 'Inpatients', 'Male', 'Megestrol/administration & dosage/therapeutic use', 'Middle Aged', 'Mirtazapine/administration & dosage/therapeutic use', 'Retrospective Studies', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/30229678/
919,mirtazapine,38451521,Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-Analysis.,"['Gerolymos C', 'Barazer R', 'Yon DK', 'Loundou A', 'Boyer L', 'Fond G']","['Humans', '*Antipsychotic Agents/adverse effects', 'Biperiden', 'Cyproheptadine', 'Gallopamil', 'Mianserin', 'Mirtazapine/therapeutic use', 'Network Meta-Analysis', 'Propranolol', 'Randomized Controlled Trials as Topic', 'Trazodone', 'Vitamin B 6', '*Akathisia, Drug-Induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38451521/
920,mirtazapine,34051293,Mirtazapine in Cancer-Associated Anorexia and Cachexia: A Double-Blind Placebo-Controlled Randomized Trial.,"['Hunter CN', 'Abdel-Aal HH', 'Elsherief WA', 'Farag DE', 'Riad NM', 'Alsirafy SA']","['Anorexia/drug therapy/etiology', '*Cachexia/drug therapy/etiology', 'Double-Blind Method', 'Hand Strength', 'Humans', 'Mirtazapine/therapeutic use', '*Neoplasms/complications']",https://pubmed.ncbi.nlm.nih.gov/34051293/
921,mirtazapine,29862972,[Antipsychotic induced rhabdomyolysis].,"['Ratnam C', 'Saguin E', 'Keou S', 'Plantamura J', 'Mennessier C', 'Lahutte B', 'Delacour H']","['Adult', 'Antipsychotic Agents/*adverse effects/therapeutic use', 'Humans', 'Male', 'Mianserin/adverse effects/*analogs & derivatives/therapeutic use', 'Mirtazapine', 'Rhabdomyolysis/*chemically induced/diagnosis', 'Stress Disorders, Post-Traumatic/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/29862972/
922,mirtazapine,37943296,Pharmacological update of mirtazapine: a narrative literature review.,"['Hassanein EHM', 'Althagafy HS', 'Baraka MA', 'Abd-Alhameed EK', 'Ibrahim IM']","['Humans', '*Mirtazapine/therapeutic use/pharmacology', 'Animals', 'Antidepressive Agents/therapeutic use/pharmacology', 'Antidepressive Agents, Tricyclic/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37943296/
923,mirtazapine,38403888,The risk of antidepressant-induced hyponatremia: A meta-analysis of antidepressant classes and compounds.,"['Gheysens T', 'Van Den Eede F', 'De Picker L']","['Humans', '*Hyponatremia/chemically induced/epidemiology', '*Antidepressive Agents/adverse effects', 'Selective Serotonin Reuptake Inhibitors/adverse effects', 'Mirtazapine/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38403888/
924,mirtazapine,38206631,Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial.,"['Arrieta O', 'Cardenas-Fernandez D', 'Rodriguez-Mayoral O', 'Gutierrez-Torres S', 'Castanares D', 'Flores-Estrada D', 'Reyes E', 'Lopez D', 'Barragan P', 'Soberanis Pina P', 'Cardona AF', 'Turcott JG']","['Aged', 'Female', 'Humans', 'Male', 'Middle Aged', 'Anorexia/drug therapy/etiology', 'Appetite Stimulants/therapeutic use', '*Carcinoma, Non-Small-Cell Lung/complications/drug therapy', 'Double-Blind Method', '*Lung Neoplasms/complications/drug therapy', 'Mirtazapine/therapeutic use', 'Quality of Life/psychology', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/38206631/
925,mirtazapine,36999619,Antidepressants for the treatment of depression in people with cancer.,"['Vita G', 'Compri B', 'Matcham F', 'Barbui C', 'Ostuzzi G']","['Adult', 'Humans', 'Antidepressive Agents/therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Depression/drug therapy/etiology', '*Depressive Disorder, Major/drug therapy', 'Mirtazapine/therapeutic use', '*Neoplasms/drug therapy', 'Selective Serotonin Reuptake Inhibitors']",https://pubmed.ncbi.nlm.nih.gov/36999619/
926,mirtazapine,37467797,Relationship between circulating mitochondrial DNA and microRNA in patients with major depression.,"['Ogata H', 'Higasa K', 'Kageyama Y', 'Tahara H', 'Shimamoto A', 'Takekita Y', 'Koshikawa Y', 'Nonen S', 'Kato T', 'Kinoshita T', 'Kato M']","['Humans', '*MicroRNAs/genetics/metabolism', 'DNA, Mitochondrial', '*Depressive Disorder, Major/drug therapy/genetics', 'Mirtazapine/therapeutic use', 'Depression', '*Cell-Free Nucleic Acids/genetics/metabolism', 'Mitochondria/metabolism', 'Selective Serotonin Reuptake Inhibitors/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37467797/
927,mirtazapine,12647431,[Mirtazapine--an antidepressant].,['Landowski J'],"['*Antidepressive Agents, Tricyclic/administration & dosage/pharmacology', 'Anxiety/etiology', 'Depressive Disorder/complications/*drug therapy', 'Dose-Response Relationship, Drug', 'Humans', '*Mianserin/administration & dosage/analogs & derivatives/pharmacology', 'Mirtazapine', 'Sleep Initiation and Maintenance Disorders/etiology', 'Syndrome', 'Thinness/etiology']",https://pubmed.ncbi.nlm.nih.gov/12647431/
928,mirtazapine,34688369,"Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.","['Banerjee S', 'High J', 'Stirling S', 'Shepstone L', 'Swart AM', 'Telling T', 'Henderson C', 'Ballard C', 'Bentham P', 'Burns A', 'Farina N', 'Fox C', 'Francis P', 'Howard R', 'Knapp M', 'Leroi I', 'Livingston G', 'Nilforooshan R', 'Nurock S', ""O'Brien J"", 'Price A', 'Thomas AJ', 'Tabet N']","['Aged, 80 and over', '*Anti-Anxiety Agents/adverse effects/therapeutic use', 'Brief Psychiatric Rating Scale', 'Caregivers/psychology', 'Dementia/*complications', 'Double-Blind Method', 'Female', 'Humans', 'Male', '*Mirtazapine/adverse effects/therapeutic use', 'Psychomotor Agitation/*drug therapy', 'Quality of Life/psychology', 'United Kingdom']",https://pubmed.ncbi.nlm.nih.gov/34688369/
929,mirtazapine,33432919,Residual daytime effects of esmirtazapine.,['Ivgy-May N'],"['Disease Progression', 'Double-Blind Method', 'Humans', 'Mirtazapine', '*Sleep Initiation and Maintenance Disorders']",https://pubmed.ncbi.nlm.nih.gov/33432919/
930,mirtazapine,36470132,Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment.,"['Yeh TC', 'Correll CU', 'Yang FC', 'Chen MH', 'Tseng PT', 'Hsu CW', 'Carvalho AF', 'Stubbs B', 'Thompson T', 'Chu CS', 'Yu CL', 'Il Shin J', 'Yang SN', 'Tu YK', 'Liang CS']","['Humans', '*Clozapine/therapeutic use', 'Network Meta-Analysis', 'Entropy', 'Memantine', 'Mirtazapine/pharmacology/therapeutic use', '*Antipsychotic Agents/therapeutic use', '*Schizophrenia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36470132/
931,Anzemet,33075160,Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.,"['Weibel S', 'Rucker G', 'Eberhart LH', 'Pace NL', 'Hartl HM', 'Jordan OL', 'Mayer D', 'Riemer M', 'Schaefer MS', 'Raj D', 'Backhaus I', 'Helf A', 'Schlesinger T', 'Kienbaum P', 'Kranke P']","['Adult', 'Anesthesia, General/*adverse effects', 'Antiemetics/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', '*Network Meta-Analysis', 'Placebos/therapeutic use', 'Postoperative Nausea and Vomiting/*prevention & control', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/33075160/
932,Anzemet,34784425,Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.,"['Piechotta V', 'Adams A', 'Haque M', 'Scheckel B', 'Kreuzberger N', 'Monsef I', 'Jordan K', 'Kuhr K', 'Skoetz N']","['Adult', '*Antiemetics/therapeutic use', '*Antineoplastic Agents/adverse effects', 'Humans', 'Nausea/chemically induced/drug therapy/prevention & control', 'Network Meta-Analysis', 'Palonosetron/therapeutic use', 'Randomized Controlled Trials as Topic', 'Vomiting/chemically induced/drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/34784425/
933,Anzemet,14988742,Gateways to clinical trials.,"['Bayes M', 'Rabasseda X', 'Prous JR']","['Clinical Trials as Topic/*statistics & numerical data', 'Databases, Factual/*statistics & numerical data', 'Humans', 'Statistics as Topic']",https://pubmed.ncbi.nlm.nih.gov/14988742/
934,Anzemet,15139789,Palonosetron.,"['Siddiqui MA', 'Scott LJ']","['Antiemetics/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Antineoplastic Agents/adverse effects', 'Humans', 'Injections, Intravenous', 'Isoquinolines/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Nausea/chemically induced/prevention & control', 'Neoplasms/drug therapy', 'Palonosetron', 'Quinuclidines/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Randomized Controlled Trials as Topic', '*Serotonin 5-HT3 Receptor Antagonists', 'Vomiting/chemically induced/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/15139789/
935,Anzemet,16176471,Update on anti-emetics for chemotherapy-induced emesis.,['Olver IN'],"['Administration, Oral', 'Antiemetics/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use', 'Australia', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Granisetron/therapeutic use', 'Humans', 'Indoles/therapeutic use', 'Isoquinolines/therapeutic use', 'Male', 'Neoplasms/drug therapy', 'Ondansetron/therapeutic use', 'Palonosetron', 'Patient Satisfaction', 'Prognosis', '*Quality of Life', 'Quinolizines/therapeutic use', 'Quinuclidines/therapeutic use', 'Treatment Outcome', 'Tropisetron', 'Vomiting/*chemically induced/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/16176471/
936,Anzemet,16608997,New antiemetic drugs.,"['Roila F', 'Fatigoni S']","['Antiemetics/classification/*therapeutic use', 'Antineoplastic Agents/*adverse effects', 'Aprepitant', 'Dexamethasone/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Isoquinolines/*therapeutic use', 'Medical Oncology', 'Morpholines/*therapeutic use', 'Nausea/chemically induced/drug therapy/*prevention & control', 'Neoplasms/drug therapy', 'Palonosetron', 'Quinuclidines/*therapeutic use', 'Receptors, Serotonin, 5-HT3/therapeutic use', 'Serotonin Antagonists/therapeutic use', 'Vomiting/chemically induced/drug therapy/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/16608997/
937,Anzemet,17309673,Systemic anticancer therapy in gynecological cancer patients with renal dysfunction.,"['Li YF', 'Fu S', 'Hu W', 'Liu JH', 'Finkel KW', 'Gershenson DM', 'Kavanagh JJ']","['Antineoplastic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Female', 'Genital Neoplasms, Female/*complications/*drug therapy/metabolism', 'Humans', 'Kidney Diseases/*complications/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/17309673/
938,Anzemet,20034341,Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines.,"['Dupuis LL', 'Nathan PC']","['Acupuncture', 'Antiemetics/administration & dosage/adverse effects/*therapeutic use', 'Antineoplastic Agents/*adverse effects', 'Cannabinoids/therapeutic use', 'Drug Combinations', 'Electrocardiography/drug effects', 'Glucocorticoids/therapeutic use', 'Guideline Adherence', 'Headache/chemically induced', 'Humans', 'Nausea/*chemically induced/*drug therapy/therapy', 'Neurokinin-1 Receptor Antagonists', 'Pediatrics', 'Practice Guidelines as Topic', 'Serotonin Antagonists/therapeutic use', 'Vomiting/*chemically induced/*drug therapy/therapy']",https://pubmed.ncbi.nlm.nih.gov/20034341/
939,Anzemet,12416899,5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications.,['Blower PR'],"['Aged', 'Antiemetics/*metabolism/pharmacology', 'Cytochrome P-450 Enzyme System/genetics/*metabolism', 'Drug Interactions', 'Granisetron/*metabolism/pharmacology', 'Humans', 'Indoles/*metabolism/pharmacology', 'Ondansetron/*metabolism/pharmacology', 'Polymorphism, Genetic', 'Quinolizines/*metabolism/pharmacology', 'Receptors, Serotonin', 'Receptors, Serotonin, 5-HT3', 'Serotonin Antagonists/*metabolism/pharmacology', 'Tropisetron']",https://pubmed.ncbi.nlm.nih.gov/12416899/
940,Anzemet,11854548,The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?,['Keefe DL'],"['Aged', 'Antiemetics/*adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/*adverse effects', 'Drug Interactions', 'Electrocardiography/*drug effects', 'Granisetron/adverse effects', 'Heart Failure/*chemically induced', 'Humans', 'Indoles/*adverse effects', 'Middle Aged', 'Nausea/chemically induced/drug therapy', 'Neoplasms/drug therapy', 'Ondansetron/adverse effects', 'Quinolizines/*adverse effects', 'Serotonin Antagonists/*adverse effects', 'Vomiting/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11854548/
941,Anzemet,16528908,The role of 5-HT3 receptor antagonists in preventing postoperative nausea and vomiting.,"['Board T', 'Board R']","['Adult', 'Algorithms', 'Antiemetics/pharmacology/*therapeutic use', 'Child', 'Dexamethasone/therapeutic use', 'Drug Administration Schedule', 'Drug Monitoring/nursing', 'Drug Therapy, Combination', 'Evidence-Based Medicine', 'Granisetron/therapeutic use', 'Humans', 'Indoles/therapeutic use', 'Isoquinolines/therapeutic use', ""Nurse's Role"", 'Nursing Assessment', 'Ondansetron/pharmacology/*therapeutic use', 'Operating Room Nursing/organization & administration', 'Palonosetron', 'Patient Selection', 'Postoperative Nausea and Vomiting/etiology/nursing/physiopathology/*prevention & control', 'Practice Guidelines as Topic', 'Quinolizines/therapeutic use', 'Quinuclidines/therapeutic use', 'Risk Assessment', 'Risk Factors', '*Serotonin 5-HT3 Receptor Antagonists', 'Serotonin Antagonists/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16528908/
942,Anzemet,15333401,Single-dose parenteral pharmacological interventions for the prevention of postoperative shivering: a quantitative systematic review of randomized controlled trials.,"['Kranke P', 'Eberhart LH', 'Roewer N', 'Tramer MR']","['Clonidine/therapeutic use', 'Dose-Response Relationship, Drug', 'Humans', 'Nefopam/therapeutic use', 'Postoperative Complications/*prevention & control', 'Randomized Controlled Trials as Topic', 'Shivering/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/15333401/
943,Anzemet,8879888,Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis.,['Perez EA'],"['Administration, Oral', 'Antineoplastic Agents/adverse effects', 'Dexamethasone/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Granisetron/*administration & dosage/therapeutic use', 'Humans', 'Injections, Intravenous', 'Metoclopramide/administration & dosage/therapeutic use', 'Nausea/chemically induced/prevention & control', 'Ondansetron/therapeutic use', 'Serotonin Antagonists/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8879888/
944,Anzemet,9510981,The effect of food on the bioavailability of dolasetron mesylate tablets.,"['Lippert C', 'Keung A', 'Arumugham T', 'Eller M', 'Hahne W', 'Weir S']","['Adult', 'Area Under Curve', 'Biological Availability', 'Chromatography, Liquid', 'Cross-Over Studies', 'Fasting/metabolism', '*Food-Drug Interactions', 'Half-Life', 'Humans', 'Indoles/*pharmacokinetics', 'Mass Spectrometry', 'Quinolizines/*pharmacokinetics', 'Serotonin Antagonists/*pharmacokinetics', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/9510981/
945,Anzemet,16192915,Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting.,['Janicki PK'],"['Cytochrome P-450 CYP2D6/genetics/*metabolism', 'Cytochrome P-450 Enzyme System/metabolism', 'Genotype', 'Humans', 'Postoperative Nausea and Vomiting/enzymology/*prevention & control', '*Serotonin 5-HT3 Receptor Antagonists', 'Serotonin Antagonists/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16192915/
946,Anzemet,11772810,Dolasetron for preventing postanesthetic shivering.,"['Piper SN', 'Rohm KD', 'Maleck WH', 'Fent MT', 'Suttner SW', 'Boldt J']","['Abdomen/surgery', 'Analgesics/therapeutic use', 'Anesthesia/*adverse effects', 'Body Temperature', 'Clonidine/administration & dosage/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Indoles/administration & dosage/*therapeutic use', 'Male', 'Middle Aged', 'Pain, Postoperative/drug therapy', 'Postoperative Complications/*prevention & control', 'Prospective Studies', 'Quinolizines/administration & dosage/*therapeutic use', 'Serotonin Antagonists/administration & dosage/*therapeutic use', 'Shivering/*drug effects', 'Urologic Surgical Procedures']",https://pubmed.ncbi.nlm.nih.gov/11772810/
947,Anzemet,18083478,Dolasetron-induced torsades de pointes.,"['Turner S', 'Mathews L', 'Pandharipande P', 'Thompson R']","['Adrenergic beta-Antagonists/administration & dosage', 'Amiodarone/administration & dosage', 'Anti-Arrhythmia Agents/administration & dosage', 'Antiemetics/administration & dosage/*adverse effects', 'Cardiopulmonary Resuscitation', 'Electrocardiography', 'Female', 'Follow-Up Studies', 'Graves Disease/complications/drug therapy', 'Humans', 'Hypertension/complications/drug therapy', 'Hypotension/drug therapy', 'Indoles/administration & dosage/*adverse effects', 'Intraoperative Complications/drug therapy', 'Intubation, Intratracheal', 'Meningeal Neoplasms/*surgery', 'Meningioma/*surgery', 'Middle Aged', 'Postoperative Complications/therapy', 'Propanolamines/administration & dosage', 'Quinolizines/administration & dosage/*adverse effects', 'Risk Factors', 'Torsades de Pointes/*chemically induced', 'Vasoconstrictor Agents/administration & dosage', 'Vasopressins/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/18083478/
948,Anzemet,12184469,Progress in preventing chemotherapy-induced nausea and vomiting.,['Markman M'],"['Antiemetics/*therapeutic use', 'Antineoplastic Agents/*adverse effects', 'Dexamethasone/therapeutic use', 'Granisetron/therapeutic use', 'Humans', 'Indoles/therapeutic use', 'Nausea/chemically induced/*prevention & control', 'Neurotransmitter Agents/physiology', 'Ondansetron/therapeutic use', 'Quinolizines/therapeutic use', 'Vomiting/chemically induced/*prevention & control/psychology']",https://pubmed.ncbi.nlm.nih.gov/12184469/
949,Anzemet,8704077,[Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].,"['Alon E', 'Biro P']","['Antiemetics/*administration & dosage/adverse effects/pharmacokinetics', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Granisetron/administration & dosage/adverse effects/pharmacokinetics', 'Humans', 'Indoles/administration & dosage/adverse effects/pharmacokinetics', 'Infusions, Intravenous', 'Nausea/*drug therapy/etiology', 'Ondansetron/administration & dosage/adverse effects/pharmacokinetics', 'Postoperative Complications/*drug therapy/etiology', 'Quinolizines/administration & dosage/adverse effects/pharmacokinetics', 'Serotonin Antagonists/*administration & dosage/adverse effects/pharmacokinetics', 'Tropisetron', 'Vomiting/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/8704077/
950,Anzemet,26415702,The modulation of carbonyl reductase 1 by polyphenols.,"['Bousova I', 'Skalova L', 'Soucek P', 'Matouskova P']","['Alcohol Oxidoreductases/*antagonists & inhibitors/biosynthesis/genetics/*metabolism', 'Animals', 'Bupropion/metabolism', 'Butanones/metabolism', 'Butyrophenones/metabolism', 'Daunorubicin/metabolism', 'Doxorubicin/metabolism', 'Gene Expression Regulation, Enzymologic', 'Haloperidol/metabolism', 'Humans', 'Indoles/metabolism', 'Nabumetone', 'Neoplasms/enzymology', 'Phenylpropionates/metabolism', 'Polyphenols/*pharmacology', 'Quinolizines/metabolism', 'Substrate Specificity', 'Xenobiotics/metabolism']",https://pubmed.ncbi.nlm.nih.gov/26415702/
951,Sunitinib,33657295,Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.,"['Choueiri TK', 'Powles T', 'Burotto M', 'Escudier B', 'Bourlon MT', 'Zurawski B', 'Oyervides Juarez VM', 'Hsieh JJ', 'Basso U', 'Shah AY', 'Suarez C', 'Hamzaj A', 'Goh JC', 'Barrios C', 'Richardet M', 'Porta C', 'Kowalyszyn R', 'Feregrino JP', 'Zolnierek J', 'Pook D', 'Kessler ER', 'Tomita Y', 'Mizuno R', 'Bedke J', 'Zhang J', 'Maurer MA', 'Simsek B', 'Ejzykowicz F', 'Schwab GM', 'Apolo AB', 'Motzer RJ']","['Adult', 'Aged', 'Aged, 80 and over', 'Anilides/*administration & dosage/adverse effects', 'Antineoplastic Agents/adverse effects/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'B7-H1 Antigen/antagonists & inhibitors', 'Carcinoma, Renal Cell/*drug therapy/mortality', 'Female', 'Humans', 'Intention to Treat Analysis', 'Kidney Neoplasms/*drug therapy/mortality', 'Male', 'Middle Aged', 'Nivolumab/*administration & dosage/adverse effects', 'Progression-Free Survival', 'Proportional Hazards Models', 'Pyridines/*administration & dosage/adverse effects', 'Quality of Life', 'Receptor Protein-Tyrosine Kinases/antagonists & inhibitors', 'Sunitinib/adverse effects/*therapeutic use', 'Survival Analysis']",https://pubmed.ncbi.nlm.nih.gov/33657295/
952,Sunitinib,33616314,Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.,"['Motzer R', 'Alekseev B', 'Rha SY', 'Porta C', 'Eto M', 'Powles T', 'Grunwald V', 'Hutson TE', 'Kopyltsov E', 'Mendez-Vidal MJ', 'Kozlov V', 'Alyasova A', 'Hong SH', 'Kapoor A', 'Alonso Gordoa T', 'Merchan JR', 'Winquist E', 'Maroto P', 'Goh JC', 'Kim M', 'Gurney H', 'Patel V', 'Peer A', 'Procopio G', 'Takagi T', 'Melichar B', 'Rolland F', 'De Giorgi U', 'Wong S', 'Bedke J', 'Schmidinger M', 'Dutcus CE', 'Smith AD', 'Dutta L', 'Mody K', 'Perini RF', 'Xing D', 'Choueiri TK']","['Adult', 'Aged', 'Aged, 80 and over', 'Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects', 'Antineoplastic Agents/adverse effects/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Carcinoma, Renal Cell/*drug therapy/mortality', 'Everolimus/*administration & dosage/adverse effects', 'Female', 'Humans', 'Kidney Neoplasms/*drug therapy/mortality', 'Male', 'Middle Aged', 'Phenylurea Compounds/*administration & dosage/adverse effects', 'Programmed Cell Death 1 Receptor/*antagonists & inhibitors', 'Progression-Free Survival', 'Protein Kinase Inhibitors/therapeutic use', 'Quinolines/*administration & dosage/adverse effects', 'Sunitinib/adverse effects/therapeutic use', 'Survival Analysis']",https://pubmed.ncbi.nlm.nih.gov/33616314/
953,Sunitinib,30779529,Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.,"['Rini BI', 'Plimack ER', 'Stus V', 'Gafanov R', 'Hawkins R', 'Nosov D', 'Pouliot F', 'Alekseev B', 'Soulieres D', 'Melichar B', 'Vynnychenko I', 'Kryzhanivska A', 'Bondarenko I', 'Azevedo SJ', 'Borchiellini D', 'Szczylik C', 'Markus M', 'McDermott RS', 'Bedke J', 'Tartas S', 'Chang YH', 'Tamada S', 'Shou Q', 'Perini RF', 'Chen M', 'Atkins MB', 'Powles T']","['Administration, Intravenous', 'Adult', 'Aged', 'Aged, 80 and over', 'Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects', 'Antineoplastic Agents/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Axitinib/*administration & dosage/adverse effects', 'Carcinoma, Renal Cell/*drug therapy/mortality', 'Female', 'Humans', 'Intention to Treat Analysis', 'Kidney Neoplasms/*drug therapy/mortality', 'Male', 'Middle Aged', 'Programmed Cell Death 1 Receptor/*antagonists & inhibitors', 'Progression-Free Survival', 'Single-Blind Method', 'Sunitinib/adverse effects/*therapeutic use', 'Survival Rate']",https://pubmed.ncbi.nlm.nih.gov/30779529/
954,Sunitinib,30779531,Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.,"['Motzer RJ', 'Penkov K', 'Haanen J', 'Rini B', 'Albiges L', 'Campbell MT', 'Venugopal B', 'Kollmannsberger C', 'Negrier S', 'Uemura M', 'Lee JL', 'Vasiliev A', 'Miller WH Jr', 'Gurney H', 'Schmidinger M', 'Larkin J', 'Atkins MB', 'Bedke J', 'Alekseev B', 'Wang J', 'Mariani M', 'Robbins PB', 'Chudnovsky A', 'Fowst C', 'Hariharan S', 'Huang B', 'di Pietro A', 'Choueiri TK']","['Administration, Intravenous', 'Adult', 'Aged', 'Aged, 80 and over', 'Antibodies, Monoclonal/*administration & dosage/adverse effects', 'Antibodies, Monoclonal, Humanized', 'Antineoplastic Agents/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Axitinib/*administration & dosage/adverse effects', 'Carcinoma, Renal Cell/*drug therapy/mortality', 'Female', 'Humans', 'Kidney Neoplasms/*drug therapy/mortality', 'Male', 'Middle Aged', 'Programmed Cell Death 1 Receptor/*antagonists & inhibitors', 'Progression-Free Survival', 'Single-Blind Method', 'Sunitinib/adverse effects/*therapeutic use', 'Survival Rate']",https://pubmed.ncbi.nlm.nih.gov/30779531/
955,Sunitinib,37500340,Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.,"['Plimack ER', 'Powles T', 'Stus V', 'Gafanov R', 'Nosov D', 'Waddell T', 'Alekseev B', 'Pouliot F', 'Melichar B', 'Soulieres D', 'Borchiellini D', 'McDermott RS', 'Vynnychenko I', 'Chang YH', 'Tamada S', 'Atkins MB', 'Li C', 'Perini R', 'Molife LR', 'Bedke J', 'Rini BI']","['Humans', '*Carcinoma, Renal Cell/pathology', 'Axitinib/adverse effects', 'Sunitinib/therapeutic use', 'Follow-Up Studies', '*Kidney Neoplasms/pathology', 'Antineoplastic Combined Chemotherapy Protocols']",https://pubmed.ncbi.nlm.nih.gov/37500340/
956,Sunitinib,35688173,"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.","['Motzer RJ', 'Powles T', 'Burotto M', 'Escudier B', 'Bourlon MT', 'Shah AY', 'Suarez C', 'Hamzaj A', 'Porta C', 'Hocking CM', 'Kessler ER', 'Gurney H', 'Tomita Y', 'Bedke J', 'Zhang J', 'Simsek B', 'Scheffold C', 'Apolo AB', 'Choueiri TK']","['Anilides', '*Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'B7-H1 Antigen', '*Carcinoma, Renal Cell/drug therapy/pathology', 'Follow-Up Studies', 'Humans', '*Kidney Neoplasms/drug therapy/pathology', 'Nivolumab/therapeutic use', 'Pyridines', 'Sunitinib/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35688173/
957,Sunitinib,33157048,Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.,"['Motzer RJ', 'Banchereau R', 'Hamidi H', 'Powles T', 'McDermott D', 'Atkins MB', 'Escudier B', 'Liu LF', 'Leng N', 'Abbas AR', 'Fan J', 'Koeppen H', 'Lin J', 'Carroll S', 'Hashimoto K', 'Mariathasan S', 'Green M', 'Tayama D', 'Hegde PS', 'Schiff C', 'Huseni MA', 'Rini B']","['Angiogenesis Inhibitors/pharmacology/*therapeutic use', 'Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/pharmacology/*therapeutic use', 'Bevacizumab/pharmacology/therapeutic use', 'Biomarkers, Tumor/*genetics', 'Carcinoma, Renal Cell/*drug therapy/genetics', 'Clinical Trials, Phase III as Topic', 'Computational Biology/methods', 'Gene Expression Profiling', 'Gene Expression Regulation, Neoplastic/drug effects', 'Humans', 'Immune Checkpoint Inhibitors/pharmacology/*therapeutic use', 'Kidney Neoplasms/*drug therapy/genetics', 'Prognosis', 'Randomized Controlled Trials as Topic', 'Sequence Analysis, RNA', 'Sunitinib/pharmacology/therapeutic use', 'Treatment Outcome', 'Unsupervised Machine Learning']",https://pubmed.ncbi.nlm.nih.gov/33157048/
958,Sunitinib,34508696,The thermogenic activity of adjacent adipocytes fuels the progression of ccRCC and compromises anti-tumor therapeutic efficacy.,"['Wei G', 'Sun H', 'Dong K', 'Hu L', 'Wang Q', 'Zhuang Q', 'Zhu Y', 'Zhang X', 'Shao Y', 'Tang H', 'Li Z', 'Chen S', 'Lu J', 'Wang Y', 'Gan X', 'Zhong TP', 'Gui D', 'Hu X', 'Wang L', 'Liu J']","['Adipocytes/metabolism', '*Carcinoma, Renal Cell/pathology', 'Cell Line, Tumor', 'Humans', '*Kidney Neoplasms/pathology', 'Sunitinib/pharmacology/therapeutic use', 'Thermogenesis']",https://pubmed.ncbi.nlm.nih.gov/34508696/
959,Sunitinib,29867230,Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.,"['McDermott DF', 'Huseni MA', 'Atkins MB', 'Motzer RJ', 'Rini BI', 'Escudier B', 'Fong L', 'Joseph RW', 'Pal SK', 'Reeves JA', 'Sznol M', 'Hainsworth J', 'Rathmell WK', 'Stadler WM', 'Hutson T', 'Gore ME', 'Ravaud A', 'Bracarda S', 'Suarez C', 'Danielli R', 'Gruenwald V', 'Choueiri TK', 'Nickles D', 'Jhunjhunwala S', 'Piault-Louis E', 'Thobhani A', 'Qiu J', 'Chen DS', 'Hegde PS', 'Schiff C', 'Fine GD', 'Powles T']","['Adult', 'Aged', 'Aged, 80 and over', 'Antibodies, Monoclonal/adverse effects/pharmacology/*therapeutic use', 'Antibodies, Monoclonal, Humanized', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/pharmacology/*therapeutic use', 'Bevacizumab/adverse effects/pharmacology/*therapeutic use', 'Carcinoma, Renal Cell/*drug therapy/*genetics', 'Female', 'Gene Expression Profiling', 'Gene Expression Regulation, Neoplastic', 'Humans', 'Kaplan-Meier Estimate', 'Kidney Neoplasms/*drug therapy/*genetics', 'Male', 'Middle Aged', 'Mutation/genetics', 'Sunitinib/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29867230/
960,Sunitinib,31068088,Gastrointestinal stromal tumor - A review of clinical studies.,['Khoshnood A'],"['Antineoplastic Agents/pharmacology/therapeutic use', 'Clinical Trials as Topic/*methods', 'Drug Resistance, Neoplasm/drug effects/physiology', 'Gastrointestinal Neoplasms/*drug therapy/*epidemiology', 'Gastrointestinal Stromal Tumors/*drug therapy/*epidemiology', 'Humans', 'Imatinib Mesylate/pharmacology/therapeutic use', 'Phenylurea Compounds/pharmacology/therapeutic use', 'Protein Kinase Inhibitors/therapeutic use', 'Pyridines/pharmacology/therapeutic use', 'Sunitinib/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31068088/
961,Sunitinib,33284113,"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.","['Powles T', 'Plimack ER', 'Soulieres D', 'Waddell T', 'Stus V', 'Gafanov R', 'Nosov D', 'Pouliot F', 'Melichar B', 'Vynnychenko I', 'Azevedo SJ', 'Borchiellini D', 'McDermott RS', 'Bedke J', 'Tamada S', 'Yin L', 'Chen M', 'Molife LR', 'Atkins MB', 'Rini BI']","['Aged', 'Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects', 'Antineoplastic Agents, Immunological/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects', 'Axitinib/*administration & dosage/adverse effects', 'Carcinoma, Renal Cell/*drug therapy/mortality/pathology', 'Female', 'Humans', 'Kidney Neoplasms/*drug therapy/mortality/pathology', 'Male', 'Middle Aged', 'Progression-Free Survival', 'Protein Kinase Inhibitors/*administration & dosage/adverse effects', 'Sunitinib/*administration & dosage/adverse effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/33284113/
962,Sunitinib,33592176,"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.","['Pal SK', 'Tangen C', 'Thompson IM Jr', 'Balzer-Haas N', 'George DJ', 'Heng DYC', 'Shuch B', 'Stein M', 'Tretiakova M', 'Humphrey P', 'Adeniran A', 'Narayan V', 'Bjarnason GA', 'Vaishampayan U', 'Alva A', 'Zhang T', 'Cole S', 'Plets M', 'Wright J', 'Lara PN Jr']","['Aged', 'Anilides/*administration & dosage/adverse effects', 'Canada', 'Carcinoma, Renal Cell/*drug therapy/mortality', 'Crizotinib/administration & dosage/adverse effects', 'Female', 'Humans', 'Kidney Neoplasms/*drug therapy/mortality', 'Male', 'Middle Aged', 'Progression-Free Survival', 'Protein Kinase Inhibitors/*administration & dosage/adverse effects', 'Proto-Oncogene Proteins c-met/drug effects', 'Pyrazines/administration & dosage/adverse effects', 'Pyridines/*administration & dosage/adverse effects', 'Sunitinib/*administration & dosage/adverse effects', 'Triazines/administration & dosage/adverse effects', 'United States']",https://pubmed.ncbi.nlm.nih.gov/33592176/
963,Sunitinib,30543350,Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.,"['Bex A', 'Mulders P', 'Jewett M', 'Wagstaff J', 'van Thienen JV', 'Blank CU', 'van Velthoven R', 'Del Pilar Laguna M', 'Wood L', 'van Melick HHE', 'Aarts MJ', 'Lattouf JB', 'Powles T', 'de Jong Md PhD IJ', 'Rottey S', 'Tombal B', 'Marreaud S', 'Collette S', 'Collette L', 'Haanen J']","['Aged', 'Antineoplastic Agents/*administration & dosage/adverse effects', 'Canada', 'Carcinoma, Renal Cell/mortality/secondary/*therapy', 'Chemotherapy, Adjuvant', 'Cytoreduction Surgical Procedures/adverse effects/*methods/mortality', 'Disease Progression', 'Drug Administration Schedule', 'Europe', 'Female', 'Humans', 'Kidney Neoplasms/mortality/pathology/*therapy', 'Male', 'Middle Aged', '*Neoadjuvant Therapy/adverse effects', '*Nephrectomy/adverse effects/mortality', 'Progression-Free Survival', 'Protein Kinase Inhibitors/*administration & dosage/adverse effects', 'Sunitinib/*administration & dosage/adverse effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/30543350/
964,Sunitinib,34940781,"Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.","['Motzer RJ', 'Powles T', 'Atkins MB', 'Escudier B', 'McDermott DF', 'Alekseev BY', 'Lee JL', 'Suarez C', 'Stroyakovskiy D', 'De Giorgi U', 'Donskov F', 'Mellado B', 'Banchereau R', 'Hamidi H', 'Khan O', 'Craine V', 'Huseni M', 'Flinn N', 'Dubey S', 'Rini BI']","['Adult', 'Aged', 'Antibodies, Monoclonal, Humanized', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Bevacizumab', '*Carcinoma, Renal Cell/drug therapy/genetics', 'Female', 'Humans', '*Kidney Neoplasms/drug therapy/genetics', 'Male', 'Middle Aged', 'Sunitinib/therapeutic use', 'Vascular Endothelial Growth Factor A']",https://pubmed.ncbi.nlm.nih.gov/34940781/
965,Sunitinib,32873572,Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.,"['Tannir NM', 'Signoretti S', 'Choueiri TK', 'McDermott DF', 'Motzer RJ', 'Flaifel A', 'Pignon JC', 'Ficial M', 'Frontera OA', 'George S', 'Powles T', 'Donskov F', 'Harrison MR', 'Barthelemy P', 'Tykodi SS', 'Kocsis J', 'Ravaud A', 'Rodriguez-Cid JR', 'Pal SK', 'Murad AM', 'Ishii Y', 'Saggi SS', 'McHenry MB', 'Rini BI']","['Antineoplastic Combined Chemotherapy Protocols/adverse effects', '*Carcinoma, Renal Cell/drug therapy', 'Hippo Signaling Pathway', 'Humans', 'Immunotherapy', 'Ipilimumab/adverse effects', '*Kidney Neoplasms/drug therapy', 'Nivolumab/adverse effects', 'Protein Serine-Threonine Kinases', 'Sunitinib/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32873572/
966,Sunitinib,31155535,[Toward Personalized Cancer Therapy with Oral Molecular-targeted Agents].,"['Yamaguchi H', 'Takasaki S', 'Kikuchi M', 'Kawasaki Y', 'Arai Y', 'Mano N']","['Administration, Oral', 'Antineoplastic Agents/*administration & dosage/*adverse effects/pharmacokinetics', 'Asian People', 'Carcinoma, Renal Cell/*drug therapy', 'Drug Monitoring', 'Humans', 'Imatinib Mesylate/administration & dosage/adverse effects/pharmacokinetics', 'Kidney Neoplasms/*drug therapy', '*Molecular Targeted Therapy', '*Precision Medicine/methods', 'Sunitinib/administration & dosage/adverse effects/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/31155535/
967,Sunitinib,39098455,Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial.,"['Tannir NM', 'Albiges L', 'McDermott DF', 'Burotto M', 'Choueiri TK', 'Hammers HJ', 'Barthelemy P', 'Plimack ER', 'Porta C', 'George S', 'Donskov F', 'Atkins MB', 'Gurney H', 'Kollmannsberger CK', 'Grimm MO', 'Barrios C', 'Tomita Y', 'Castellano D', 'Grunwald V', 'Rini BI', 'Jiang R', 'Desilva H', 'Fedorov V', 'Lee CW', 'Motzer RJ']","['Humans', '*Sunitinib/administration & dosage/therapeutic use/adverse effects', '*Carcinoma, Renal Cell/drug therapy/pathology/mortality', '*Ipilimumab/administration & dosage/adverse effects/therapeutic use', '*Kidney Neoplasms/drug therapy/pathology/mortality', '*Nivolumab/administration & dosage/adverse effects/therapeutic use', 'Follow-Up Studies', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Male', 'Female', 'Middle Aged', 'Aged', 'Progression-Free Survival', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/39098455/
968,Sunitinib,32895571,Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.,"['Motzer RJ', 'Robbins PB', 'Powles T', 'Albiges L', 'Haanen JB', 'Larkin J', 'Mu XJ', 'Ching KA', 'Uemura M', 'Pal SK', 'Alekseev B', 'Gravis G', 'Campbell MT', 'Penkov K', 'Lee JL', 'Hariharan S', 'Wang X', 'Zhang W', 'Wang J', 'Chudnovsky A', 'di Pietro A', 'Donahue AC', 'Choueiri TK']","['Adolescent', 'Adult', 'Aged', 'Antibodies, Monoclonal/administration & dosage/adverse effects', 'Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects', 'Axitinib/*administration & dosage/adverse effects', 'Biomarkers, Tumor/*genetics', 'Carcinoma, Renal Cell/*drug therapy/genetics/pathology', 'Female', 'Gene Expression Regulation, Neoplastic/drug effects', 'Humans', 'Kidney/drug effects/pathology', 'Male', 'Middle Aged', 'Progression-Free Survival', 'Sunitinib/*administration & dosage/adverse effects', 'Transcriptome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32895571/
969,Sunitinib,31427204,"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.","['Motzer RJ', 'Rini BI', 'McDermott DF', 'Aren Frontera O', 'Hammers HJ', 'Carducci MA', 'Salman P', 'Escudier B', 'Beuselinck B', 'Amin A', 'Porta C', 'George S', 'Neiman V', 'Bracarda S', 'Tykodi SS', 'Barthelemy P', 'Leibowitz-Amit R', 'Plimack ER', 'Oosting SF', 'Redman B', 'Melichar B', 'Powles T', 'Nathan P', 'Oudard S', 'Pook D', 'Choueiri TK', 'Donskov F', 'Grimm MO', 'Gurney H', 'Heng DYC', 'Kollmannsberger CK', 'Harrison MR', 'Tomita Y', 'Duran I', 'Grunwald V', 'McHenry MB', 'Mekan S', 'Tannir NM']","['Alanine Transaminase/blood', 'Amylases/blood', 'Antineoplastic Agents/adverse effects/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Carcinoma, Renal Cell/*drug therapy', 'Fatigue/chemically induced', 'Follow-Up Studies', 'Humans', 'Hypertension/chemically induced', 'Intention to Treat Analysis', 'Ipilimumab/administration & dosage', 'Kidney Neoplasms/*drug therapy', 'Lipase/blood', 'Nivolumab/administration & dosage', 'Paresthesia/chemically induced', 'Progression-Free Survival', 'Sunitinib/adverse effects/*therapeutic use', 'Survival Rate']",https://pubmed.ncbi.nlm.nih.gov/31427204/
970,Sunitinib,32339648,Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.,"['Choueiri TK', 'Motzer RJ', 'Rini BI', 'Haanen J', 'Campbell MT', 'Venugopal B', 'Kollmannsberger C', 'Gravis-Mescam G', 'Uemura M', 'Lee JL', 'Grimm MO', 'Gurney H', 'Schmidinger M', 'Larkin J', 'Atkins MB', 'Pal SK', 'Wang J', 'Mariani M', 'Krishnaswami S', 'Cislo P', 'Chudnovsky A', 'Fowst C', 'Huang B', 'di Pietro A', 'Albiges L']","['Antibodies, Monoclonal, Humanized', 'Axitinib', '*Carcinoma, Renal Cell/drug therapy', 'Humans', '*Kidney Neoplasms/drug therapy', 'Sunitinib/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32339648/
971,Atazanavir,28579422,Atazanavir-Associated Crystalline Nephropathy.,"['Santoriello D', 'Al-Nabulsi M', 'Reddy A', 'Salamera J', ""D'Agati VD"", 'Markowitz GS']","['Atazanavir Sulfate/*adverse effects', 'Crystallization', 'HIV Protease Inhibitors/*adverse effects', 'Humans', 'Kidney Diseases/*chemically induced', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/28579422/
972,Atazanavir,35538801,Azapeptides -A History of Synthetic Milestones and Key Examples.,"['Fan Cheng K', 'VanPatten S', 'He M', 'Al-Abed Y']","['Humans', '*Peptidomimetics', '*Aza Compounds/chemistry', 'Atazanavir Sulfate', 'Goserelin', '*HIV Infections', 'Peptides/chemistry', 'Amino Acids/chemistry', 'Carbon', 'Nitrogen']",https://pubmed.ncbi.nlm.nih.gov/35538801/
973,Atazanavir,33299085,Identifying side effects of commonly used drugs in the treatment of Covid 19.,"['Aygun I', 'Kaya M', 'Alhajj R']","['Atazanavir Sulfate/adverse effects/*therapeutic use', 'COVID-19/*metabolism/pathology', 'Drug Interactions', 'Heparin/adverse effects/*therapeutic use', 'Humans', 'SARS-CoV-2/*metabolism', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/33299085/
974,Atazanavir,31939539,HIV-related nephropathy: new aspects of an old paradigm.,"['Reghine EL', 'Foresto RD', 'Kirsztajn GM']","['AIDS-Associated Nephropathy/*etiology/pathology', 'Acute Kidney Injury/*etiology/pathology', 'Anti-HIV Agents/adverse effects', 'Antiretroviral Therapy, Highly Active/adverse effects', 'Atazanavir Sulfate/adverse effects', 'Chronic Disease', 'HIV Infections/*complications/drug therapy', 'Humans', 'Kidney/pathology', 'Risk Factors', 'Tenofovir/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/31939539/
975,Atazanavir,26545091,Drug updates and approvals: 2015 in review.,"['Klibanov OM', 'Phan D', 'Ferguson K']","['Amlodipine/therapeutic use', 'Antibodies, Monoclonal/administration & dosage', 'Antibodies, Monoclonal, Humanized', 'Atazanavir Sulfate/therapeutic use', 'Azabicyclo Compounds/therapeutic use', 'Benzazepines/therapeutic use', 'Ceftazidime/therapeutic use', 'Cobicistat/therapeutic use', '*Drug Approval', 'Drug Combinations', 'Humans', 'Injections, Subcutaneous', 'Ivabradine', 'Liraglutide/therapeutic use', 'Nurse Practitioners', 'Perindopril/therapeutic use', 'Pyridines/therapeutic use', 'Thiazoles/therapeutic use', 'United States', '*United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/26545091/
976,Atazanavir,32061722,Laser ablation for pharmaceutical nanoformulations: Multi-drug nanoencapsulation and theranostics for HIV.,"['Singh A', 'Kutscher HL', 'Bulmahn JC', 'Mahajan SD', 'He GS', 'Prasad PN']","['Atazanavir Sulfate/chemical synthesis/chemistry/pharmacology', 'Blood-Brain Barrier/drug effects', 'Curcumin/chemical synthesis/chemistry/pharmacology', 'Drug Carriers/chemical synthesis/chemistry/pharmacology', '*Drug Compounding', 'HIV Infections/*drug therapy/virology', 'HIV-1/drug effects/pathogenicity', 'Humans', 'Laser Therapy', 'Nanoparticles/*chemistry/therapeutic use', 'Precision Medicine', 'Ritonavir/chemical synthesis/chemistry/pharmacology', 'Theranostic Nanomedicine/*trends']",https://pubmed.ncbi.nlm.nih.gov/32061722/
977,Atazanavir,12225250,Atazanavir: a novel HIV-1 protease inhibitor.,['Piliero PJ'],"['Animals', 'Atazanavir Sulfate', 'Clinical Trials as Topic/statistics & numerical data', 'HIV Infections/*drug therapy/enzymology', 'HIV Protease Inhibitors/chemistry/pharmacokinetics/*therapeutic use', 'HIV-1/drug effects/*enzymology', 'Humans', 'Oligopeptides/chemistry/pharmacokinetics/*therapeutic use', 'Pyridines/chemistry/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12225250/
978,Atazanavir,17376023,Atazanavir: simplicity and convenience in different scenarios.,['Perez-Elias MJ'],"['Area Under Curve', 'Atazanavir Sulfate', 'Drug Interactions', 'Female', 'HIV Infections/*drug therapy', 'HIV Protease Inhibitors/adverse effects/pharmacology/*therapeutic use', '*HIV-1', 'Half-Life', 'Humans', 'Male', 'Multicenter Studies as Topic', 'Oligopeptides/adverse effects/pharmacology/*therapeutic use', 'Pyridines/adverse effects/pharmacology/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17376023/
979,Atazanavir,28595364,Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?,"['Metsu D', 'Toutain PL', 'Chatelut E', 'Delobel P', 'Gandia P']","['Atazanavir Sulfate/adverse effects/chemistry/*pharmacokinetics/therapeutic use', 'Blood Proteins/chemistry/metabolism', 'Darunavir/adverse effects/chemistry/*pharmacokinetics/therapeutic use', 'Dose-Response Relationship, Drug', 'Female', 'HIV Infections/*drug therapy/metabolism', 'HIV Protease Inhibitors/adverse effects/chemistry/*pharmacokinetics/therapeutic use', 'Hepatocytes/drug effects/metabolism', 'Humans', 'Pregnancy', 'Protein Binding']",https://pubmed.ncbi.nlm.nih.gov/28595364/
980,Atazanavir,20116616,[Adverse effects of atazanavir].,"['Palacios R', 'Gonzalez M', 'Ruiz J', 'Santos J']","['Anti-HIV Agents/administration & dosage/adverse effects/therapeutic use', 'Atazanavir Sulfate', 'Carbohydrate Metabolism/drug effects', 'Clinical Trials as Topic', 'Drug Interactions', 'Drug Therapy, Combination', 'Dyslipidemias/chemically induced', 'Gastrointestinal Diseases/chemically induced', 'Glucose/metabolism', 'HIV Infections/*drug therapy', 'HIV Protease Inhibitors/administration & dosage/*adverse effects/pharmacology/therapeutic use', 'Humans', 'Hyperbilirubinemia/*chemically induced', 'Hyperinsulinism/chemically induced', 'Insulin Resistance', 'Oligopeptides/administration & dosage/*adverse effects/pharmacology/therapeutic use', 'Pyridines/administration & dosage/*adverse effects/pharmacology/therapeutic use', 'Urolithiasis/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/20116616/
981,Atazanavir,27190354,Renal effects of novel antiretroviral drugs.,"['Milburn J', 'Jones R', 'Levy JB']","['Adenine/adverse effects/analogs & derivatives', 'Alanine', 'Anti-HIV Agents/*adverse effects', 'Atazanavir Sulfate/adverse effects', 'Cobicistat/adverse effects', 'Creatinine', 'Disease Progression', 'HIV Infections/complications/*drug therapy', 'Heterocyclic Compounds, 3-Ring/adverse effects', 'Humans', 'Oxazines', 'Piperazines', 'Proteinuria/chemically induced/complications', 'Pyridones', 'Quinolones/adverse effects', 'Raltegravir Potassium/adverse effects', 'Renal Insufficiency, Chronic/*chemically induced/complications/metabolism', 'Tenofovir/analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/27190354/
982,Atazanavir,25392858,Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint.,"['Cattaneo D', 'Baldelli S', 'Castoldi S', 'Charbe N', 'Cozzi V', 'Fucile S', 'Clementi E']","['Anti-Retroviral Agents/*administration & dosage/*pharmacokinetics', 'Atazanavir Sulfate', 'Drug Monitoring', 'HIV Infections/*drug therapy', 'Humans', 'Lopinavir/administration & dosage/pharmacokinetics', 'Nevirapine/administration & dosage/pharmacokinetics', 'Oligopeptides/administration & dosage/pharmacokinetics', 'Plasma/*chemistry', 'Pyridines/administration & dosage/pharmacokinetics', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/25392858/
983,Atazanavir,31638397,Interplay of Supersaturation and Solubilization: Lack of Correlation between Concentration-Based Supersaturation Measurements and Membrane Transport Rates in Simulated and Aspirated Human Fluids.,"['Elkhabaz A', 'Moseson DE', 'Brouwers J', 'Augustijns P', 'Taylor LS']","['Atazanavir Sulfate/*administration & dosage/*chemistry', 'Biological Transport/*drug effects/*physiology', 'Body Fluids/*metabolism', 'Chemistry, Pharmaceutical/methods', 'Crystallization', 'Diffusion', 'Humans', 'Kinetics', 'Solubility', 'Thermodynamics', 'Triazoles/*administration & dosage/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/31638397/
984,Atazanavir,29735845,A first-line antiretroviral therapy-resistant HIV patient with rhinoentomophthoromycosis.,"['Dhurat R', 'Kothavade RJ', 'Kumar A']","['Adult', 'Anti-Retroviral Agents/*therapeutic use', 'Antifungal Agents/*therapeutic use', 'Atazanavir Sulfate/therapeutic use', 'Conidiobolus/*drug effects', '*Drug Resistance, Fungal', 'Drug Resistance, Viral', 'HIV Infections', 'Humans', 'Immunocompromised Host', 'Itraconazole/*therapeutic use', 'Lamivudine/therapeutic use', 'Male', 'Potassium Iodide/therapeutic use', 'Ritonavir/therapeutic use', 'Tenofovir/therapeutic use', 'Zygomycosis/complications/*drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/29735845/
985,Atazanavir,31562781,Association of Pharmacogenetic Markers With Atazanavir Exposure in HIV-Infected Women.,"['Tamraz B', 'Huang Y', 'French AL', 'Kassaye S', 'Anastos K', 'Nowicki MJ', 'Gange S', 'Gustafson DR', 'Bacchetti P', 'Greenblatt RM', 'Hysi PG', 'Aouizerat BE']","['ATP Binding Cassette Transporter, Subfamily B/genetics', 'Area Under Curve', 'Atazanavir Sulfate/administration & dosage/*pharmacokinetics', 'Chromatography, High Pressure Liquid', 'Citrus sinensis', 'Cytochrome P-450 CYP3A Inhibitors/pharmacology', 'Diarrhea/epidemiology', 'Dose-Response Relationship, Drug', 'Female', 'Genotype', 'HIV Infections/*drug therapy/epidemiology', 'HIV Protease Inhibitors/administration & dosage/*pharmacokinetics', 'Hair/chemistry', 'Heroin Dependence/epidemiology', 'Humans', 'Hydrogen-Ion Concentration', 'Longitudinal Studies', 'MicroRNAs', 'Polymorphism, Single Nucleotide', 'Racial Groups', 'Receptors, Cell Surface/*genetics', 'Tandem Mass Spectrometry']",https://pubmed.ncbi.nlm.nih.gov/31562781/
986,Atazanavir,34727835,Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients.,"['Singkham N', 'Avihingsanon A', 'Brundage RC', 'Birnbaum AK', 'Thammajaruk N', 'Ruxrungtham K', 'Bunupuradah T', 'Kiertiburanakul S', 'Chetchotisakd P', 'Punyawudho B']","['Adult', '*Anti-HIV Agents', 'Atazanavir Sulfate/adverse effects', 'Female', '*HIV Infections/drug therapy', 'Humans', 'Liver-Specific Organic Anion Transporter 1/genetics', 'Male', 'Pharmacogenetics', 'Ritonavir', 'Thailand']",https://pubmed.ncbi.nlm.nih.gov/34727835/
987,Atazanavir,28134625,Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs.,"['Gnanadhas DP', 'Dash PK', 'Sillman B', 'Bade AN', 'Lin Z', 'Palandri DL', 'Gautam N', 'Alnouti Y', 'Gelbard HA', 'McMillan J', 'Mosley RL', 'Edagwa B', 'Gendelman HE', 'Gorantla S']","['Acquired Immunodeficiency Syndrome/*drug therapy/metabolism', 'Animals', 'Anti-Retroviral Agents/*pharmacology', 'Atazanavir Sulfate/pharmacology', 'Autophagy/*drug effects', 'Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/metabolism', 'Female', 'HIV-1/*metabolism', 'Heterocyclic Compounds, 3-Ring/pharmacology', 'Humans', 'Macrophages/*metabolism', 'Male', 'Mice', '*Nanoparticles', 'Oxazines', 'Piperazines', 'Pyridines/pharmacology', 'Pyridones', 'Pyrroles/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/28134625/
988,Atazanavir,26026666,Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice.,"['Puligujja P', 'Arainga M', 'Dash P', 'Palandri D', 'Mosley RL', 'Gorantla S', 'Poluektova L', 'McMillan J', 'Gendelman HE']","['Animals', 'Anti-Retroviral Agents/administration & dosage/*pharmacokinetics', 'Atazanavir Sulfate/administration & dosage/pharmacokinetics', 'CD4 Lymphocyte Count', 'Delayed-Action Preparations/administration & dosage/*pharmacokinetics', 'Drug Carriers/administration & dosage/*metabolism', 'Folate Receptors, GPI-Anchored/*metabolism', 'Folic Acid/administration & dosage/metabolism', 'HIV Infections/drug therapy', 'Humans', 'Injections, Intramuscular', 'Mice, SCID', 'Nanomedicine/*methods', 'Nanoparticles/administration & dosage/*metabolism', 'Poloxamer/administration & dosage/metabolism', 'RNA, Viral/blood', 'Ritonavir/administration & dosage/pharmacokinetics', 'Treatment Outcome', 'Viral Load']",https://pubmed.ncbi.nlm.nih.gov/26026666/
989,Atazanavir,15353575,Atazanavir.,"['Orrick JJ', 'Steinhart CR']","['Atazanavir Sulfate', 'Clinical Trials as Topic', 'Drug Interactions', 'Drug Resistance, Viral', 'HIV Infections/drug therapy/virology', '*HIV Protease Inhibitors/adverse effects/pharmacokinetics/therapeutic use', 'Humans', 'In Vitro Techniques', '*Oligopeptides/adverse effects/pharmacokinetics/therapeutic use', '*Pyridines/adverse effects/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15353575/
990,Atazanavir,29232276,Contemporary protease inhibitors and cardiovascular risk.,"['Lundgren J', 'Mocroft A', 'Ryom L']","['Antiretroviral Therapy, Highly Active/*adverse effects/methods', 'Atazanavir Sulfate/adverse effects/therapeutic use', 'Cardiovascular Diseases/*chemically induced/*epidemiology', 'Darunavir/adverse effects/therapeutic use', 'HIV Infections/*complications/*drug therapy', 'HIV Protease Inhibitors/*adverse effects/*therapeutic use', 'Humans', 'Risk Assessment', 'Ritonavir/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29232276/
991,Telithromycin,15748096,Treatment of Legionnaires' disease.,['Amsden GW'],"['Anti-Bacterial Agents/administration & dosage/*therapeutic use', 'Drug Administration Schedule', 'Humans', 'Infusions, Intravenous', ""Legionnaires' Disease/*drug therapy"", 'Prognosis', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15748096/
992,Telithromycin,28432048,Solithromycin: A novel ketolide antibiotic.,"['Buege MJ', 'Brown JE', 'Aitken SL']","['Animals', 'Anti-Bacterial Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Chemical and Drug Induced Liver Injury/epidemiology/metabolism', 'Community-Acquired Infections/drug therapy/epidemiology/metabolism', 'Drug Approval/*methods', 'Drug Resistance, Bacterial/*drug effects/physiology', 'Humans', 'Ketolides/adverse effects/pharmacokinetics/therapeutic use', 'Macrolides/adverse effects/pharmacokinetics/*therapeutic use', 'Microbial Sensitivity Tests/methods', 'Pneumonia, Bacterial/*drug therapy/epidemiology/metabolism', 'Triazoles/adverse effects/pharmacokinetics/*therapeutic use', 'United States/epidemiology', 'United States Food and Drug Administration/standards']",https://pubmed.ncbi.nlm.nih.gov/28432048/
993,Telithromycin,16669927,Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia.,['File TM Jr'],"['Anti-Infective Agents/*therapeutic use', 'Community-Acquired Infections/*drug therapy/economics/*microbiology', 'Drug Resistance, Multiple, Bacterial', 'Fluoroquinolones/*therapeutic use', 'Humans', 'Ketolides/therapeutic use', 'Pneumonia, Pneumococcal/*drug therapy/economics/*microbiology', 'Streptococcus pneumoniae/*growth & development']",https://pubmed.ncbi.nlm.nih.gov/16669927/
994,Telithromycin,15308279,"Macrolides and ketolides: azithromycin, clarithromycin, telithromycin.",['Zuckerman JM'],"['Anti-Bacterial Agents/*pharmacology/therapeutic use', 'Azithromycin/*pharmacology/therapeutic use', 'Bacterial Infections/drug therapy', 'Clarithromycin/*pharmacology/therapeutic use', 'Humans', 'Ketolides/*pharmacology/therapeutic use', 'Macrolides/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15308279/
995,Telithromycin,16816494,Antibiotics for treatment of resistant gram-positive coccal infections.,"['Al-Tatari H', 'Abdel-Haq N', 'Chearskul P', 'Asmar B']","['Anti-Bacterial Agents/pharmacology/*therapeutic use', 'Drug Resistance, Bacterial', 'Gram-Positive Bacterial Infections/*drug therapy', 'Humans', 'Ketolides/therapeutic use', 'Minocycline/analogs & derivatives/therapeutic use', 'Peptides, Cyclic/therapeutic use', 'Tigecycline']",https://pubmed.ncbi.nlm.nih.gov/16816494/
996,Telithromycin,12604549,Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae.,"['Betriu C', 'Culebras E', 'Gomez M', 'Rodriguez-Avial I', 'Sanchez BA', 'Agreda MC', 'Picazo JJ']","['Anti-Bacterial Agents/*pharmacology', 'Clindamycin/*pharmacology', 'Cross Infection/epidemiology/microbiology/prevention & control', 'Drug Resistance, Bacterial', 'Erythromycin/*pharmacology', 'Humans', 'Infant, Newborn', '*Ketolides', '*Macrolides', 'Microbial Sensitivity Tests', 'Spain/epidemiology', 'Streptococcal Infections/epidemiology/microbiology/prevention & control', 'Streptococcus agalactiae/*drug effects', 'Tetracycline Resistance']",https://pubmed.ncbi.nlm.nih.gov/12604549/
997,Telithromycin,12615850,Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide.,"['Ackermann G', 'Rodloff AC']","['Animals', 'Anti-Bacterial Agents/chemistry/*pharmacology/*therapeutic use', 'Base Sequence', 'Clinical Trials as Topic/statistics & numerical data/trends', 'Drug Resistance, Bacterial/physiology', 'Humans', '*Ketolides', '*Macrolides', 'Molecular Sequence Data', 'RNA, Bacterial/antagonists & inhibitors/genetics', 'Respiratory Tract Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/12615850/
998,Telithromycin,15100978,[Telithromycin].,['Benes J'],"['*Anti-Bacterial Agents/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Drug Interactions', 'Drug Resistance', 'Humans', '*Ketolides', '*Macrolides/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Microbial Sensitivity Tests']",https://pubmed.ncbi.nlm.nih.gov/15100978/
999,Telithromycin,17414839,Drug-induced liver disease in 2006.,"['Arundel C', 'Lewis JH']","['Acetaminophen/adverse effects', 'Analgesics, Non-Narcotic/*adverse effects', 'Animals', 'Anti-Bacterial Agents/*adverse effects', '*Chemical and Drug Induced Liver Injury', 'Diagnosis, Differential', 'Global Health', 'Humans', 'Liver Diseases/diagnosis/epidemiology', 'Morbidity/trends', 'Prognosis', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/17414839/
1000,Telithromycin,20210729,"Antibiotic-induced liver toxicity: mechanisms, clinical features and causality assessment.","['Robles M', 'Toscano E', 'Cotta J', 'Lucena MI', 'Andrade RJ']","['Animals', 'Anti-Bacterial Agents/*adverse effects/therapeutic use', 'Chemical and Drug Induced Liver Injury/*etiology/genetics/physiopathology', 'Genotype', 'Humans', 'Risk Factors', 'Severity of Illness Index', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/20210729/
1001,Telithromycin,17116439,Macrolide and ketolide resistance with Streptococcus pneumoniae.,['Doern GV'],"['Anti-Bacterial Agents/*pharmacology', 'Azithromycin/therapeutic use', 'Bacterial Proteins/physiology', 'Clarithromycin/therapeutic use', '*Drug Resistance, Bacterial', 'Humans', 'Ketolides/*pharmacology', 'Macrolides/*pharmacology', 'Membrane Proteins/physiology', 'Pneumococcal Infections/drug therapy', 'Streptococcus pneumoniae/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/17116439/
1002,Telithromycin,14996620,Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin.,['Nicolau DP'],"['Anti-Infective Agents/pharmacology/*therapeutic use', 'Community-Acquired Infections/*drug therapy', 'Humans', '*Ketolides', 'Macrolides/*therapeutic use', 'Respiratory Tract Infections/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/14996620/
1003,Telithromycin,14691648,Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling.,['Nicolau DP'],"['Anti-Bacterial Agents/*pharmacokinetics/*pharmacology/therapeutic use', 'Bacteria/drug effects', 'Bacterial Infections/*drug therapy/microbiology', 'Humans', '*Ketolides', 'Macrolides/*pharmacokinetics/*pharmacology/therapeutic use', 'Microbial Sensitivity Tests', '*Monte Carlo Method', 'Predictive Value of Tests', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/14691648/
1004,Telithromycin,21517774,Significant breakthroughs in search for anti-infectious agents derived from erythromycin A.,"['Ma X', 'Ma S']","['Animals', 'Anti-Infective Agents/adverse effects/chemical synthesis/*chemistry/*pharmacology', 'Bacteria/drug effects', 'Drug Discovery/*methods', 'Drug Resistance, Bacterial/drug effects', 'Erythromycin/adverse effects/*analogs & derivatives/chemical synthesis/*pharmacology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/21517774/
1005,Telithromycin,16527540,Old dogs that learn new tricks: modified antimicrobial agents that escape pre-existing resistance mechanisms.,"['Schwarz S', 'Kehrenberg C']","['Animals', 'Anti-Bacterial Agents/chemistry/*pharmacology', 'Bacterial Infections/drug therapy/veterinary', '*Drug Design', 'Drug Resistance, Microbial', 'Humans', 'Ketolides/chemistry/pharmacology', 'Technology, Pharmaceutical/trends', 'Thiamphenicol/analogs & derivatives/chemistry/pharmacology', 'Veterinary Drugs/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16527540/
1006,Telithromycin,11524946,[Ribosomal antibiotics].,"[""Man'kin AS""]","['Acetamides/metabolism/pharmacology', 'Animals', 'Anti-Bacterial Agents/metabolism/*pharmacology', 'Binding Sites/genetics', 'Drug Resistance', 'Humans', '*Ketolides', 'Linezolid', '*Macrolides', 'Mutation', 'Oxazolidinones/metabolism/pharmacology', 'Protein Biosynthesis/drug effects', 'Protein Synthesis Inhibitors/metabolism/pharmacology', 'Ribosomes/*drug effects/genetics/metabolism']",https://pubmed.ncbi.nlm.nih.gov/11524946/
1007,Telithromycin,12533275,Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.,['Stratton CW'],"['Anti-Bacterial Agents/*pharmacology/therapeutic use', '*Drug Resistance, Bacterial/genetics', 'Drug Therapy, Combination', 'Gram-Negative Bacteria/*drug effects/growth & development', 'Gram-Negative Bacterial Infections/drug therapy/microbiology', 'Humans', '*Ketolides', '*Macrolides', 'Pneumonia, Pneumococcal/drug therapy/microbiology', 'Respiratory Tract Infections/drug therapy/*microbiology', 'Streptococcus pneumoniae/*drug effects/growth & development']",https://pubmed.ncbi.nlm.nih.gov/12533275/
1008,Telithromycin,25154307,The wobbly status of ketolides: where do we stand?,['Georgopapadakou NH'],"['Anti-Bacterial Agents/adverse effects/chemistry/*pharmacology', 'Bacteria/drug effects/isolation & purification', 'Chemical and Drug Induced Liver Injury/etiology', 'Community-Acquired Infections/drug therapy/microbiology', 'Drug Approval', 'Drug Design', 'Drug Resistance, Bacterial', 'Humans', 'Ketolides/adverse effects/chemistry/*pharmacology', 'Pneumonia, Bacterial/*drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/25154307/
1009,Telithromycin,12324249,Ketolides: the future of the macrolides?,"['Nilius AM', 'Ma Z']","['Anti-Bacterial Agents/chemistry/*pharmacology/therapeutic use', 'Bacteria/drug effects/genetics/metabolism', 'Bacterial Infections/*drug therapy/microbiology', '*Bacterial Proteins', 'Drug Resistance, Microbial', 'Erythromycin/*analogs & derivatives/chemistry/*pharmacology/therapeutic use', 'Humans', '*Ketolides', '*Macrolides', 'Methyltransferases/metabolism', 'Ribosomes/genetics']",https://pubmed.ncbi.nlm.nih.gov/12324249/
1010,Telithromycin,15561871,Glucocorticoids increase in vitro and in vivo activities of antibiotics against Chlamydophila pneumoniae.,"['Caronzolo D', 'Lucini V', 'Pannacci M', 'Grosso S', 'Colleoni F', 'Fraschini F', 'Scaglione F']","['Animals', 'Anti-Bacterial Agents/*pharmacology/*therapeutic use', 'Anti-Inflammatory Agents/pharmacology/therapeutic use', 'Azithromycin/pharmacology/therapeutic use', 'Cell Line', 'Chlamydophila Infections/*drug therapy/microbiology', 'Chlamydophila pneumoniae/*drug effects', 'Dexamethasone/pharmacology/therapeutic use', 'Drug Synergism', 'Glucocorticoids/*pharmacology/*therapeutic use', 'Humans', 'Ketolides/pharmacology/therapeutic use', 'Levofloxacin', 'Mice', 'Mice, Inbred BALB C', 'Microbial Sensitivity Tests', 'Ofloxacin/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15561871/
1011,risperidone,33341539,Antipsychotics and hemodialysis: A systematic review.,"['Sutar R', 'Atlani MK', 'Chaudhary P']","['*Antipsychotic Agents/adverse effects', 'Benzodiazepines', 'Humans', 'Olanzapine', 'Renal Dialysis', 'Risperidone/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33341539/
1012,risperidone,24794100,Role of atypical antipsychotics in the treatment of generalized anxiety disorder.,"['Hershenberg R', 'Gros DF', 'Brawman-Mintzer O']","['Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use', 'Anxiety Disorders/*drug therapy/psychology', 'Aripiprazole', 'Benzodiazepines/administration & dosage/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Dibenzothiazepines/administration & dosage/adverse effects/therapeutic use', 'Generalization, Psychological/*drug effects', 'Humans', 'Olanzapine', 'Piperazines/administration & dosage/adverse effects/therapeutic use', 'Quetiapine Fumarate', 'Quinolones/administration & dosage/adverse effects/therapeutic use', 'Risperidone/administration & dosage/adverse effects/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24794100/
1013,risperidone,12151468,Risperidone in children with autism and serious behavioral problems.,"['McCracken JT', 'McGough J', 'Shah B', 'Cronin P', 'Hong D', 'Aman MG', 'Arnold LE', 'Lindsay R', 'Nash P', 'Hollway J', 'McDougle CJ', 'Posey D', 'Swiezy N', 'Kohn A', 'Scahill L', 'Martin A', 'Koenig K', 'Volkmar F', 'Carroll D', 'Lancor A', 'Tierney E', 'Ghuman J', 'Gonzalez NM', 'Grados M', 'Vitiello B', 'Ritz L', 'Davies M', 'Robinson J', 'McMahon D']","['Adolescent', 'Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use', 'Autistic Disorder/*drug therapy/psychology', 'Child', 'Child Behavior/drug effects', 'Child, Preschool', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Risperidone/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12151468/
1014,risperidone,11869410,Drug-induced extrapyramidal reactions.,"['Teoh L', 'Allen H', 'Kowalenko N']","['Antipsychotic Agents/administration & dosage/*adverse effects', 'Attention Deficit Disorder with Hyperactivity/complications/*drug therapy', 'Basal Ganglia Diseases/*chemically induced', 'Child', 'Drug Therapy, Combination', 'Humans', 'Male', 'New South Wales', 'Risperidone/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11869410/
1015,risperidone,21294670,Aripiprazole for the treatment of irritability associated with autism.,"['Farmer CA', 'Aman MG']","['Antipsychotic Agents/adverse effects/pharmacokinetics/therapeutic use', 'Aripiprazole', 'Autistic Disorder/*drug therapy', 'Humans', 'Irritable Mood/*drug effects', 'Piperazines/adverse effects/pharmacokinetics/*therapeutic use', 'Quinolones/adverse effects/pharmacokinetics/*therapeutic use', 'Risperidone/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21294670/
1016,risperidone,11584985,Long-term safety of risperidone.,['Davidson M'],"['Aged', 'Antipsychotic Agents/*adverse effects/pharmacokinetics/therapeutic use', 'Basal Ganglia Diseases/chemically induced/epidemiology', 'Cholinesterase Inhibitors/adverse effects/therapeutic use', 'Clinical Trials as Topic/statistics & numerical data', 'Dementia/*drug therapy/psychology', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Dyskinesia, Drug-Induced/epidemiology/etiology', 'Humans', 'Incidence', 'Receptors, Dopamine/drug effects/metabolism', 'Receptors, Histamine/drug effects/metabolism', 'Receptors, Muscarinic/drug effects/metabolism', 'Risperidone/*adverse effects/pharmacokinetics/therapeutic use', 'Treatment Outcome', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/11584985/
1017,risperidone,8690833,Pharmacokinetics of clozapine and risperidone: a review of recent literature.,"['Byerly MJ', 'DeVane CL']","['Antipsychotic Agents/administration & dosage/adverse effects/*pharmacokinetics', 'Biological Availability', 'Clozapine/administration & dosage/adverse effects/*pharmacokinetics', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Humans', 'Metabolic Clearance Rate/physiology', 'Risperidone/administration & dosage/adverse effects/*pharmacokinetics', 'Schizophrenia/*blood/drug therapy', '*Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/8690833/
1018,risperidone,22964442,Does a normalizing electroencephalogram in benign childhood epilepsy with centrotemporal spikes abort attention deficit hyperactivity disorder?,"['Schneebaum-Sender N', 'Goldberg-Stern H', 'Fattal-Valevski A', 'Kramer U']","['Age of Onset', 'Anticonvulsants/adverse effects/*therapeutic use', 'Attention/drug effects', 'Attention Deficit Disorder with Hyperactivity/drug therapy/etiology/genetics/*prevention & control', 'Central Nervous System Stimulants/*therapeutic use', 'Child', 'Child, Preschool', 'Drug Evaluation', 'Drug Therapy, Combination', '*Electroencephalography/drug effects', 'Epilepsy/complications', 'Epilepsy, Rolandic/drug therapy/*physiopathology', 'Female', 'Humans', 'Infant', 'Male', 'Methylphenidate/administration & dosage/*therapeutic use', 'Retrospective Studies', 'Risperidone/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22964442/
1019,risperidone,18281731,Paliperidone for schizophrenia.,"['Dolder C', 'Nelson M', 'Deyo Z']","['Antipsychotic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Controlled Clinical Trials as Topic', 'Delayed-Action Preparations', 'Drug Interactions', 'Humans', 'Isoxazoles/*administration & dosage/adverse effects/pharmacokinetics', 'Paliperidone Palmitate', 'Pyrimidines/*administration & dosage/adverse effects/pharmacokinetics', 'Risperidone/metabolism/therapeutic use', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18281731/
1020,risperidone,16822092,Risks versus benefits of different types of long-acting injectable antipsychotics.,['McEvoy JP'],"['Administration, Oral', 'Antipsychotic Agents/*administration & dosage/pharmacokinetics/therapeutic use', 'Fluphenazine/administration & dosage/analogs & derivatives/pharmacokinetics/therapeutic use', 'Haloperidol/administration & dosage/analogs & derivatives/pharmacokinetics/therapeutic use', 'Health Care Costs', 'Humans', 'Injections, Intramuscular', 'Microspheres', 'Quality of Life', 'Risk Assessment', 'Risperidone/administration & dosage/pharmacokinetics/therapeutic use', 'Schizophrenia/diagnosis/*drug therapy', '*Schizophrenic Psychology', 'Secondary Prevention', '*Treatment Refusal']",https://pubmed.ncbi.nlm.nih.gov/16822092/
1021,risperidone,15522979,Long-acting injectable risperidone.,"['Ehret MJ', 'Fuller MA']","['*Antipsychotic Agents/adverse effects/pharmacology/therapeutic use', 'Delayed-Action Preparations', 'Drug Administration Schedule', 'Humans', 'Injections, Intramuscular', 'Randomized Controlled Trials as Topic', '*Risperidone/adverse effects/pharmacology/therapeutic use', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15522979/
1022,risperidone,29695153,Classics in Chemical Neuroscience: Risperidone.,"['Chopko TC', 'Lindsley CW']","['Animals', 'Humans', 'Mental Disorders/drug therapy', 'Risperidone/adverse effects/chemistry/pharmacology/*therapeutic use', 'Serotonin Antagonists/adverse effects/chemistry/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29695153/
1023,risperidone,9562211,Risperidone-induced tardive dyskinesia.,['Silberbauer C'],"['Adult', 'Antipsychotic Agents/*adverse effects/therapeutic use', 'Dyskinesia, Drug-Induced/*physiopathology', 'Humans', 'Male', 'Risperidone/*adverse effects/therapeutic use', 'Schizophrenia/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9562211/
1024,risperidone,10724129,"Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.",['Glazer WM'],"['Antipsychotic Agents/*adverse effects/pharmacology/therapeutic use', 'Basal Ganglia Diseases/*chemically induced', 'Benzodiazepines', 'Brain/drug effects', 'Clozapine/adverse effects/pharmacology/therapeutic use', 'Dibenzothiazepines/adverse effects/pharmacology/therapeutic use', 'Humans', 'Movement Disorders/*etiology', 'Olanzapine', 'Pirenzepine/adverse effects/analogs & derivatives/pharmacology/therapeutic use', 'Quetiapine Fumarate', 'Receptors, Dopamine/drug effects', 'Receptors, Serotonin/drug effects', 'Risk Factors', 'Risperidone/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10724129/
1025,risperidone,19102665,"Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.",['Keith S'],"['Antipsychotic Agents/*administration & dosage/adverse effects/economics', 'Bipolar Disorder/drug therapy/economics', 'Clinical Trials as Topic', 'Cost-Benefit Analysis', 'Delayed-Action Preparations/economics/*therapeutic use', 'Humans', 'Medication Adherence', 'Risperidone/*administration & dosage/adverse effects/economics', 'Schizophrenia/*drug therapy/economics']",https://pubmed.ncbi.nlm.nih.gov/19102665/
1026,risperidone,9448664,The treatment of psychosis in late life.,"['Zayas EM', 'Grossberg GT']","['Age Factors', 'Aged', 'Antipsychotic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Clozapine/adverse effects/pharmacokinetics/therapeutic use', 'Decision Trees', 'Delirium/diagnosis/drug therapy', 'Diagnosis, Differential', 'Drug Administration Schedule', 'Female', 'Half-Life', 'Humans', 'Male', 'Middle Aged', 'Nursing Homes/legislation & jurisprudence', 'Psychotic Disorders/diagnosis/*drug therapy/epidemiology', 'Risk Factors', 'Risperidone/adverse effects/pharmacokinetics/therapeutic use', 'United States']",https://pubmed.ncbi.nlm.nih.gov/9448664/
1027,risperidone,11232752,Weight change and atypical antipsychotic treatment in patients with schizophrenia.,"['Jones B', 'Basson BR', 'Walker DJ', 'Crawford AM', 'Kinon BJ']","['Antipsychotic Agents/administration & dosage/*adverse effects/therapeutic use', 'Behavior Therapy/methods', 'Benzodiazepines', 'Dose-Response Relationship, Drug', 'Follow-Up Studies', 'Haloperidol/administration & dosage/adverse effects/therapeutic use', 'Health Behavior', 'Humans', 'Obesity/chemically induced/prevention & control', 'Olanzapine', 'Pirenzepine/administration & dosage/*adverse effects/*analogs & derivatives/therapeutic use', 'Risperidone/administration & dosage/adverse effects/therapeutic use', 'Schizophrenia/*drug therapy', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/11232752/
1028,risperidone,33074724,CYP2D6 and Antipsychotic Treatment Outcomes in Children and Youth: A Systematic Review.,"['Maruf AA', 'Stein K', 'Arnold PD', 'Aitchison KJ', 'Muller DJ', 'Bousman C']","['Adolescent', 'Antipsychotic Agents/*therapeutic use', 'Child', 'Cytochrome P-450 CYP2D6/*genetics', '*Drug-Related Side Effects and Adverse Reactions', 'Humans', '*Pharmacogenetics', '*Risperidone/pharmacokinetics/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33074724/
1029,risperidone,17376539,"Blood pressure, heart rate, and anxiety in schizophrenia.","['Townsend MH', 'Baier MB', 'Becker JE', 'Ritchie MA']","['Adult', 'Antipsychotic Agents/adverse effects/therapeutic use', 'Anxiety/*diagnosis/drug therapy/psychology', '*Blood Pressure/drug effects', 'Female', '*Heart Rate/drug effects', 'Humans', 'Male', 'Middle Aged', 'Risperidone/adverse effects/therapeutic use', 'Schizophrenia/*diagnosis/drug therapy', '*Schizophrenic Psychology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17376539/
1030,risperidone,31661992,The preclinical discovery and development of paliperidone for the treatment of schizophrenia.,"['Wesolowska A', 'Jastrzebska-Wiesek M', 'Cios A', 'Partyka A']","['Adolescent', 'Adult', 'Animals', 'Antipsychotic Agents/*administration & dosage/adverse effects/pharmacology', 'Drug Development', 'Drug Discovery', 'Drug Interactions', 'Humans', 'Paliperidone Palmitate/*administration & dosage/adverse effects/pharmacology', 'Psychotic Disorders/drug therapy/physiopathology', 'Risperidone/administration & dosage/pharmacokinetics', 'Schizophrenia/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/31661992/
1031,temazepam,22929751,[Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics].,"['Vinkers CH', 'Tijdink JK', 'Luykx JJ', 'Vis R']","['Anti-Anxiety Agents/*pharmacokinetics', 'Anxiety/*drug therapy', 'Area Under Curve', 'Benzodiazepines/*pharmacokinetics', 'Half-Life', 'Humans', 'Kinetics', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22929751/
1032,temazepam,82859,One man's poison.,['Hunter A'],"['Capsules', 'Clinical Trials as Topic', 'Diphenhydramine/administration & dosage', 'Drug Combinations', 'Drug Evaluation', 'Flurazepam/administration & dosage', 'Humans', 'Methaqualone/administration & dosage', 'Nitrazepam/administration & dosage', 'Sleep/*drug effects', 'Temazepam/administration & dosage', '*Travel']",https://pubmed.ncbi.nlm.nih.gov/82859/
1033,temazepam,27751669,Review of Safety and Efficacy of Sleep Medicines in Older Adults.,"['Schroeck JL', 'Ford J', 'Conway EL', 'Kurtzhalts KE', 'Gee ME', 'Vollmer KA', 'Mergenhagen KA']","['Aged', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Middle Aged', 'Randomized Controlled Trials as Topic', 'Sleep/*drug effects', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27751669/
1034,temazepam,21963855,Checkpoint control and cancer.,"['Medema RH', 'Macurek L']","['Apoptosis', 'Cell Cycle', 'Cell Cycle Checkpoints/drug effects/*physiology', '*DNA Damage', '*DNA Repair', 'Humans', 'Neoplasms/*genetics', 'Protein Kinases/metabolism', 'Temazepam']",https://pubmed.ncbi.nlm.nih.gov/21963855/
1035,temazepam,17384366,Serotonin syndrome.,"['Evans CE', 'Sebastian J']","['Adult', 'Diphenhydramine/*poisoning', 'Drug Overdose', 'Female', 'Glasgow Coma Scale', 'Humans', 'Paroxetine/*poisoning', 'Serotonin Syndrome/*chemically induced', 'Temazepam/*poisoning']",https://pubmed.ncbi.nlm.nih.gov/17384366/
1036,temazepam,9022890,Benzodiazepine misuse by drug addicts.,"['Garretty DJ', 'Wolff K', 'Hay AW', 'Raistrick D']","['Alcoholism/drug therapy', 'Benzodiazepines/*therapeutic use/*urine', 'Chromatography, High Pressure Liquid/methods', 'Diazepam/therapeutic use/urine', 'Humans', 'Narcotics', 'Nitrazepam/therapeutic use/urine', 'Nordazepam/therapeutic use/urine', 'Substance-Related Disorders/drug therapy/*epidemiology', 'Temazepam/therapeutic use/urine']",https://pubmed.ncbi.nlm.nih.gov/9022890/
1037,temazepam,6142469,Pharmacokinetics of benzodiazepine hypnotics.,"['Greenblatt DJ', 'Divoll M', 'Abernethy DR', 'Locniskar A', 'Shader RI']","['Anti-Anxiety Agents/*metabolism', 'Biotransformation', 'Drug Utilization', 'Flurazepam/metabolism', 'Humans', 'Kinetics', 'Temazepam/metabolism', 'Triazolam/metabolism', 'United States']",https://pubmed.ncbi.nlm.nih.gov/6142469/
1038,temazepam,1354722,Oral benzodiazepines and conscious sedation: a review.,['Loeffler PM'],"['Administration, Oral', 'Alprazolam/administration & dosage', 'Ambulatory Surgical Procedures', 'Anti-Anxiety Agents/*administration & dosage/pharmacology', 'Conscious Sedation/*methods', 'Diazepam/administration & dosage', 'Flurazepam/administration & dosage', 'Humans', 'Lorazepam/administration & dosage', 'Midazolam/administration & dosage', 'Oxazepam/administration & dosage', 'Premedication', 'Receptors, GABA-A/physiology', 'Temazepam/administration & dosage', 'Triazolam/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/1354722/
1039,temazepam,2071567,The beneficial and adverse effects of hypnotics.,"['Balter MB', 'Uhlenhuth EH']","['Adolescent', 'Adult', 'Aged', 'Attitude to Health', 'Benzodiazepines/adverse effects/*therapeutic use', 'Data Collection', 'Drug Prescriptions/standards', 'Evaluation Studies as Topic', 'Female', 'Flurazepam/adverse effects/therapeutic use', 'Humans', 'Hypnotics and Sedatives/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Nonprescription Drugs/adverse effects/standards', 'Sleep Initiation and Maintenance Disorders/*drug therapy/psychology', 'Telephone', 'Temazepam/adverse effects/therapeutic use', 'Triazolam/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2071567/
1040,temazepam,1680124,A review of the safety profiles of benzodiazepine hypnotics.,"['Roth T', 'Roehrs TA']","['Aged', 'Anti-Anxiety Agents/*adverse effects', 'Benzodiazepines/adverse effects', 'Central Nervous System/drug effects', 'Flurazepam/adverse effects', 'Half-Life', 'Humans', 'Hypnotics and Sedatives/*adverse effects', 'Middle Aged', 'Psychomotor Performance/drug effects', 'Sleep/drug effects', 'Sleep Initiation and Maintenance Disorders/chemically induced/drug therapy', 'Temazepam/adverse effects', 'Triazolam/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/1680124/
1041,temazepam,19450355,Insomnia in the elderly.,"['Montgomery P', 'Lilly J']","['Aged', 'Cognitive Behavioral Therapy', 'Flurazepam/pharmacology', 'Humans', 'Risk Factors', '*Sleep/drug effects', '*Sleep Initiation and Maintenance Disorders', 'Temazepam']",https://pubmed.ncbi.nlm.nih.gov/19450355/
1042,temazepam,2904371,Pharmacokinetics of a new sublingual formulation of temazepam.,"['Russell WJ', 'Badcock NR', 'Frewin DB', 'Sansom LN']","['Administration, Oral', 'Administration, Sublingual', 'Adolescent', 'Adult', 'Anti-Anxiety Agents/*pharmacokinetics', 'Half-Life', 'Humans', 'Male', 'Metabolic Clearance Rate', 'Middle Aged', 'Random Allocation', 'Temazepam/administration & dosage/blood/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/2904371/
1043,temazepam,7791648,Sleep problems.,['Flamer HE'],"['Aged', 'Anti-Anxiety Agents/therapeutic use', 'Benzodiazepines', 'Humans', 'Hypnotics and Sedatives/administration & dosage/therapeutic use', 'Movement Disorders/diagnosis', 'Sleep Apnea Syndromes/diagnosis', 'Sleep Wake Disorders/diagnosis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7791648/
1044,temazepam,2071884,A comparison of the hypnotic effects of temazepam capsules and temazepam elixir.,"['Patel AG', 'Gura R', 'Kurian T', 'Lambert MT', 'Steinert J', 'Priest RG']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Dosage Forms', 'Double-Blind Method', 'Female', 'Humans', '*Hypnotics and Sedatives', 'Male', 'Middle Aged', 'Sleep/drug effects', 'Temazepam/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/2071884/
1045,temazepam,11975400,[Adverse renal effects of legal and illicit drugs].,['Orth SR'],"['Acute Kidney Injury/chemically induced', 'Adolescent', 'Adult', 'Alcoholism/complications', 'Amphetamines/adverse effects', 'Anti-Anxiety Agents/adverse effects', 'Benzodiazepines/adverse effects', 'Cocaine/adverse effects', '*Drug-Related Side Effects and Adverse Reactions', 'Hallucinogens/adverse effects', 'Heroin/adverse effects', 'Humans', 'Illicit Drugs/*adverse effects', 'Kidney/*drug effects', 'Kidney Diseases/*chemically induced', 'Kidney Failure, Chronic/chemically induced', 'Male', 'N-Methyl-3,4-methylenedioxyamphetamine/adverse effects', 'Narcotics/adverse effects', 'Nephrotic Syndrome/chemically induced', 'Odds Ratio', 'Risk Factors', 'Smoking/adverse effects', 'Smoking Cessation', 'Substance-Related Disorders/*complications', 'Temazepam/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11975400/
1046,temazepam,2876901,Pharmacokinetics of temazepam in geriatric patients.,"['Klem K', 'Murray GR', 'Laake K']","['Aged', 'Aged, 80 and over', 'Anti-Anxiety Agents/*metabolism', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Kinetics', 'Male', 'Temazepam/blood/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/2876901/
1047,temazepam,6106488,Pharmacokinetics of benzodiazepines. Short-acting versus long-acting.,"['Breimer DD', 'Jochemsen R', 'von Albert HH']","['Anti-Anxiety Agents/administration & dosage/*metabolism/pharmacology', 'Benzodiazepines', 'Biotransformation', 'Half-Life', 'Humans', 'Kinetics']",https://pubmed.ncbi.nlm.nih.gov/6106488/
1048,temazepam,1539877,Pneumocephalus following nasotracheal intubation.,"['Conetta R', 'Nierman DM']","['Aged', 'Cerebral Hemorrhage/etiology', 'Drug Overdose', 'Female', 'Humans', 'Intubation, Intratracheal/*adverse effects', 'Nose', 'Pneumocephalus/complications/diagnostic imaging/*etiology', 'Poisoning/therapy', 'Suicide, Attempted', 'Temazepam/poisoning', 'Tomography, X-Ray Computed']",https://pubmed.ncbi.nlm.nih.gov/1539877/
1049,temazepam,23674942,Nocturnal temazepam in the treatment of narcolepsy.,"['Kansagra S', 'Walter R', 'Vaughn B']","['Adolescent', 'Adult', 'Aged', 'Child', 'Drug Administration Schedule', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*therapeutic use', 'Middle Aged', 'Narcolepsy/*drug therapy', 'Polysomnography/methods', 'Retrospective Studies', 'Temazepam/administration & dosage/*therapeutic use', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/23674942/
1050,temazepam,2183493,"Triazolam--an ""abused drug"" by the lay press?","['Schneider PJ', 'Perry PJ']","['Amnesia/etiology/psychology', '*Communication', 'Humans', '*Mass Media', 'Psychoses, Substance-Induced/psychology', 'Substance Withdrawal Syndrome/psychology', 'Triazolam/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2183493/
1051,CAPECITABINE,29152729,Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.,"['Amstutz U', 'Henricks LM', 'Offer SM', 'Barbarino J', 'Schellens JHM', 'Swen JJ', 'Klein TE', 'McLeod HL', 'Caudle KE', 'Diasio RB', 'Schwab M']","['Antimetabolites, Antineoplastic/*administration & dosage/adverse effects/pharmacokinetics', 'Capecitabine/*administration & dosage/adverse effects/pharmacokinetics', 'Clinical Decision-Making', 'Dihydrouracil Dehydrogenase (NADP)/*genetics/metabolism', 'Drug Dosage Calculations', 'Fluorouracil/*administration & dosage/adverse effects/pharmacokinetics', 'Genotype', 'Humans', 'Patient Selection', 'Pharmacogenetics/*standards', 'Pharmacogenomic Testing/*standards', '*Pharmacogenomic Variants', 'Phenotype', 'Precision Medicine/*standards', 'Predictive Value of Tests']",https://pubmed.ncbi.nlm.nih.gov/29152729/
1052,CAPECITABINE,37594133,5‑Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review).,"['Alzahrani SM', 'Al Doghaither HA', 'Al-Ghafari AB', 'Pushparaj PN']","['Humans', 'Capecitabine/adverse effects', '*Fluorouracil/therapeutic use', 'Cell Division', 'Cell Membrane', '*Colorectal Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37594133/
1053,CAPECITABINE,38412399,Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.,"['Santhosh A', 'Sharma A', 'Bakhshi S', 'Kumar A', 'Sharma V', 'Malik PS', 'Pramanik R', 'Gogia A', 'Prasad CP', 'Sehgal T', 'Gund S', 'Dev A', 'Cheung WY', 'Pandey RM', 'Kumar S', 'Gupta I', 'Batra A']","['Humans', '*Capecitabine/adverse effects/administration & dosage/therapeutic use', 'Double-Blind Method', '*Hand-Foot Syndrome/prevention & control/etiology', '*Diclofenac/adverse effects/administration & dosage/analogs & derivatives', 'Female', 'Male', 'Middle Aged', 'Aged', '*Antimetabolites, Antineoplastic/adverse effects/administration & dosage', 'Breast Neoplasms/drug therapy', 'Administration, Topical', 'Adult', 'Gastrointestinal Neoplasms/drug therapy', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38412399/
1054,CAPECITABINE,30341682,Pyrotinib: First Global Approval.,['Blair HA'],"['*Acrylamides/administration & dosage/adverse effects/therapeutic use', '*Aminoquinolines/administration & dosage/adverse effects/therapeutic use', 'Anthracyclines/pharmacology', '*Antineoplastic Agents/administration & dosage/therapeutic use', 'Breast Neoplasms/*drug therapy/pathology', 'Bridged-Ring Compounds/pharmacology', 'Capecitabine/pharmacology/therapeutic use', 'Humans', '*Protein Kinase Inhibitors/administration & dosage/adverse effects/therapeutic use', 'Receptor, ErbB-2/*antagonists & inhibitors', 'Taxoids/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30341682/
1055,CAPECITABINE,33300950,Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.,"['Wang X', 'Wang SS', 'Huang H', 'Cai L', 'Zhao L', 'Peng RJ', 'Lin Y', 'Tang J', 'Zeng J', 'Zhang LH', 'Ke YL', 'Wang XM', 'Liu XM', 'Chen QJ', 'Zhang AQ', 'Xu F', 'Bi XW', 'Huang JJ', 'Li JB', 'Pang DM', 'Xue C', 'Shi YX', 'He ZY', 'Lin HX', 'An X', 'Xia W', 'Cao Y', 'Guo Y', 'Su YH', 'Hua X', 'Wang XY', 'Hong RX', 'Jiang KK', 'Song CG', 'Huang ZZ', 'Shi W', 'Zhong YY', 'Yuan ZY']","['Adult', 'Capecitabine/*administration & dosage/adverse effects', 'Chemotherapy, Adjuvant', 'Disease-Free Survival', 'Drug Administration Schedule', 'Female', 'Follow-Up Studies', 'Hand-Foot Syndrome/etiology', 'Humans', 'Maintenance Chemotherapy', 'Mastectomy', 'Middle Aged', 'Neoplasm Grading', 'Neoplasm Staging', 'Neoplasm, Residual', 'Observation', 'Triple Negative Breast Neoplasms/*drug therapy/mortality/pathology/surgery']",https://pubmed.ncbi.nlm.nih.gov/33300950/
1056,CAPECITABINE,38381429,Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer.,"['Li Y', 'Pan C', 'Gao Y', 'Zhang L', 'Ji D', 'Cui X', 'Zhang X', 'Cai Y', 'Zhang Y', 'Yao Y', 'Wang L', 'Leng J', 'Zhan T', 'Wu D', 'Gao Z', 'Sun YS', 'Li Z', 'Luo H', 'Wu A']","['Humans', '*Rectal Neoplasms/therapy/genetics/pathology', 'Female', 'Male', 'Middle Aged', '*Neoadjuvant Therapy', '*DNA Mismatch Repair', '*Capecitabine/therapeutic use/administration & dosage', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Immune Checkpoint Inhibitors/therapeutic use', 'Oxaliplatin/therapeutic use', 'Antibodies, Monoclonal, Humanized/therapeutic use', 'Adult', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38381429/
1057,CAPECITABINE,35200546,Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors.,"['Al-Toubah T', 'Morse B', 'Strosberg J']","['Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Capecitabine/therapeutic use', 'Humans', '*Neuroendocrine Tumors/drug therapy/pathology', 'Retrospective Studies', 'Temozolomide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35200546/
1058,CAPECITABINE,39550662,[Not Available].,"['Fiordelisi M', 'Masucci S', 'Bianco A', 'Bellero M', 'Toma D', 'Campo N', 'Zichi C', 'Marino D', 'Sperti E', 'Valabrega G', 'Cena C', 'Fazzina G', 'Gasco A']","['Humans', 'Adenocarcinoma/drug therapy', '*Capecitabine/adverse effects/administration & dosage', 'Clinical Decision-Making', 'Dietary Supplements', '*Herb-Drug Interactions', '*Pharmacists', 'Plant Preparations/adverse effects/administration & dosage', 'Professional Role', 'Rectal Neoplasms/drug therapy', '*Artificial Intelligence']",https://pubmed.ncbi.nlm.nih.gov/39550662/
1059,CAPECITABINE,29252007,A review of capecitabine-based adjuvant therapy for gastric cancer in the Chinese population.,"['Cheng X', 'Lu Y']","['Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Capecitabine/adverse effects/*therapeutic use', '*Chemotherapy, Adjuvant', 'China/epidemiology', 'Combined Modality Therapy', 'Deoxycytidine/analogs & derivatives/therapeutic use', 'Disease-Free Survival', 'Fluorouracil/analogs & derivatives/therapeutic use', 'Gastrectomy', 'Humans', 'Oxaloacetates', 'Stomach Neoplasms/*drug therapy/epidemiology/pathology/*surgery']",https://pubmed.ncbi.nlm.nih.gov/29252007/
1060,CAPECITABINE,30348537,DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.,"['Henricks LM', 'Lunenburg CATC', 'de Man FM', 'Meulendijks D', 'Frederix GWJ', 'Kienhuis E', 'Creemers GJ', 'Baars A', 'Dezentje VO', 'Imholz ALT', 'Jeurissen FJF', 'Portielje JEA', 'Jansen RLH', 'Hamberg P', 'Ten Tije AJ', 'Droogendijk HJ', 'Koopman M', 'Nieboer P', 'van de Poel MHW', 'Mandigers CMPW', 'Rosing H', 'Beijnen JH', 'Werkhoven EV', 'van Kuilenburg ABP', 'van Schaik RHN', 'Mathijssen RHJ', 'Swen JJ', 'Gelderblom H', 'Cats A', 'Guchelaar HJ', 'Schellens JHM']","['Aged', 'Antimetabolites, Antineoplastic/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Capecitabine/*administration & dosage/adverse effects', 'Case-Control Studies', 'Dihydrouracil Dehydrogenase (NADP)/*genetics', 'Female', 'Fluorouracil/*administration & dosage/adverse effects', 'Gene Frequency', 'Heterozygote', 'Homozygote', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/*drug therapy/enzymology/pathology', 'Netherlands', '*Pharmacogenomic Variants', 'Prospective Studies', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30348537/
1061,CAPECITABINE,38684357,Capecitabine-induced severe adverse events-therapeutic drug monitoring and DPYD-gene analysis are recommended.,"['Perera J', 'Susstrunk J', 'Thurneysen C', 'Steinemann D']","['Humans', '*Capecitabine/adverse effects/therapeutic use', '*Drug Monitoring/methods', '*Antimetabolites, Antineoplastic/adverse effects/therapeutic use', 'Male', '*Dihydrouracil Dehydrogenase (NADP)/genetics', 'Middle Aged', 'Female', 'Aged', 'Colectomy', 'Genotype']",https://pubmed.ncbi.nlm.nih.gov/38684357/
1062,CAPECITABINE,38950321,Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH).,"['Xia F', 'Wang Y', 'Wang H', 'Shen L', 'Xiang Z', 'Zhao Y', 'Zhang H', 'Wan J', 'Zhang H', 'Wang Y', 'Wu R', 'Wang J', 'Yang W', 'Zhou M', 'Zhou S', 'Chen Y', 'Zhang Z', 'Wu X', 'Xuan Y', 'Wang R', 'Sun Y', 'Tong T', 'Zhang X', 'Wang L', 'Huang D', 'Sheng W', 'Yan H', 'Yang X', 'Shen Y', 'Xu Y', 'Zhao R', 'Mo M', 'Cai G', 'Cai S', 'Xu Y', 'Zhang Z']","['Humans', '*Rectal Neoplasms/therapy/genetics/pathology', '*Neoadjuvant Therapy/adverse effects', 'Male', 'Middle Aged', 'Female', 'Aged', '*DNA Mismatch Repair', 'Prospective Studies', 'Adult', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Adenocarcinoma/therapy/genetics/pathology/drug therapy', 'Microsatellite Instability', 'Immunotherapy/methods', 'Capecitabine/administration & dosage/therapeutic use', 'Oxaliplatin/therapeutic use/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38950321/
1063,CAPECITABINE,38547438,Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.,"['Gallois C', 'Shi Q', 'Pederson LD', 'Andre T', 'Iveson TJ', 'Sobrero AF', 'Alberts S', 'de Gramont A', 'Meyerhardt JA', 'George T', 'Schmoll HE', 'Souglakos I', 'Harkin A', 'Labianca R', 'Sinicrope FA', 'Oki E', 'Shields AF', 'Boukovinas I', 'Kerr R', 'Lonardi S', 'Yothers G', 'Yoshino T', 'Goldberg RM', 'Taieb J', 'Papamichael D']","['Humans', '*Oxaliplatin/administration & dosage/therapeutic use/adverse effects', '*Colonic Neoplasms/drug therapy/pathology/mortality', 'Aged', 'Chemotherapy, Adjuvant', 'Female', 'Male', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', '*Organoplatinum Compounds/administration & dosage/adverse effects/therapeutic use', '*Neoplasm Staging', 'Age Factors', '*Capecitabine/administration & dosage/adverse effects/therapeutic use', '*Leucovorin/administration & dosage/therapeutic use/adverse effects', 'Middle Aged', 'Fluorouracil/administration & dosage/adverse effects', 'Disease-Free Survival', 'Aged, 80 and over']",https://pubmed.ncbi.nlm.nih.gov/38547438/
1064,CAPECITABINE,32541327,Adjuvant chemotherapy in colon cancer: state of the art and future perspectives.,['Iveson T'],"['Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Capecitabine/administration & dosage/adverse effects', 'Chemotherapy, Adjuvant', 'Circulating Tumor DNA/genetics', 'Colonic Neoplasms/*drug therapy/genetics/pathology', 'Fluorouracil/administration & dosage/adverse effects', 'Humans', 'Neoplasm Staging', 'Oxaliplatin/administration & dosage/adverse effects', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/32541327/
1065,CAPECITABINE,28978604,Oxaliplatin-induced posterior reversible encephalopathy syndrome (PRES).,"['Janjua TK', 'Hassan M', 'Afridi HK', 'Zahid NA']","['Adenocarcinoma/drug therapy', 'Antineoplastic Combined Chemotherapy Protocols/*adverse effects', 'Anus Neoplasms/drug therapy', 'Capecitabine/administration & dosage/*adverse effects', 'Diagnosis, Differential', 'Humans', 'Magnetic Resonance Imaging', 'Male', 'Organoplatinum Compounds/administration & dosage/*adverse effects', 'Oxaliplatin', 'Posterior Leukoencephalopathy Syndrome/chemically induced/*diagnosis/diagnostic imaging', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28978604/
1066,CAPECITABINE,38101610,Dihydroartemisinin inhibits the development of colorectal cancer by GSK-3beta/TCF7/MMP9 pathway and synergies with capecitabine.,"['Dai X', 'Chen W', 'Qiao Y', 'Chen X', 'Chen Y', 'Zhang K', 'Zhang Q', 'Duan X', 'Li X', 'Zhao J', 'Tian F', 'Liu K', 'Dong Z', 'Lu J']","['Humans', 'Capecitabine/pharmacology/therapeutic use', 'Glycogen Synthase Kinase 3 beta', '*Colorectal Neoplasms/pathology', 'Matrix Metalloproteinase 9', 'Molecular Docking Simulation', 'Cell Line, Tumor', 'Cell Proliferation', 'T Cell Transcription Factor 1', '*Artemisinins']",https://pubmed.ncbi.nlm.nih.gov/38101610/
1067,CAPECITABINE,38820768,Immune modulation of the liver metastatic colorectal cancer microenvironment via the oral CAPOX-mediated cGAS-STING pathway.,"['Park SJ', 'Kweon S', 'Moyo MK', 'Kim HR', 'Choi JU', 'Lee NK', 'Maharjan R', 'Cho YS', 'Park JW', 'Byun Y']","['*Tumor Microenvironment/drug effects', '*Colorectal Neoplasms/drug therapy/pathology/immunology', 'Animals', '*Membrane Proteins/metabolism', '*Oxaliplatin/pharmacology/therapeutic use/administration & dosage', '*Liver Neoplasms/secondary/drug therapy/pathology/immunology', 'Administration, Oral', 'Cell Line, Tumor', '*Nucleotidyltransferases/metabolism', 'Mice', 'Mice, Inbred BALB C', 'Capecitabine/pharmacology/therapeutic use/administration & dosage', 'Humans', 'Signal Transduction/drug effects', 'Female', 'Deoxycholic Acid/chemistry/pharmacology', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use/pharmacology', 'Tumor-Associated Macrophages/drug effects/immunology/metabolism']",https://pubmed.ncbi.nlm.nih.gov/38820768/
1068,CAPECITABINE,29117285,Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine.,"['Cubiro X', 'Planas-Ciudad S', 'Garcia-Muret MP', 'Puig L']","['Administration, Topical', 'Aged', 'Angiolymphoid Hyperplasia with Eosinophilia/*chemically induced/*drug therapy', 'Antimetabolites, Antineoplastic/*adverse effects/therapeutic use', 'Capecitabine/*adverse effects/therapeutic use', 'Cohort Studies', 'Female', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/drug therapy/pathology', 'Paronychia/*chemically induced/*drug therapy', 'Prognosis', 'Retrospective Studies', 'Timolol/*administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29117285/
1069,CAPECITABINE,34100299,Gender-dependent association of TYMS-TSER polymorphism with 5-fluorouracil or capecitabine-based chemotherapy toxicity.,"['Ioannou C', 'Ragia G', 'Balgkouranidou I', 'Xenidis N', 'Amarantidis K', 'Koukaki T', 'Biziota E', 'Kakolyris S', 'Manolopoulos VG']","['Adult', 'Aged', 'Aged, 80 and over', 'Antimetabolites, Antineoplastic/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage', 'Capecitabine/*administration & dosage/adverse effects', 'Female', 'Fluorouracil/*administration & dosage/adverse effects', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/drug therapy/genetics', 'Polymorphism, Genetic/*genetics', '*Sex Characteristics', 'Thymidylate Synthase/*genetics']",https://pubmed.ncbi.nlm.nih.gov/34100299/
1070,CAPECITABINE,38870931,"First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial.","['Wang ZX', 'Peng J', 'Liang X', 'Cheng Y', 'Deng Y', 'Chen K', 'Zhang M', 'Zhang J', 'Wang W', 'Cao B', 'Jin Y', 'Sun M', 'Lin Y', 'Luo S', 'Li Z', 'Yang L', 'Ke Y', 'Yu H', 'Li J', 'Wang Q', 'Zhu J', 'Wang F', 'Xu RH']","['Humans', '*Colorectal Neoplasms/drug therapy/pathology/genetics', 'Double-Blind Method', 'Middle Aged', 'Male', 'Female', 'Aged', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Adult', '*Capecitabine/therapeutic use/administration & dosage/adverse effects', 'Bevacizumab/therapeutic use', 'Progression-Free Survival', 'Antibodies, Monoclonal, Humanized/therapeutic use/adverse effects/administration & dosage', 'Adenocarcinoma/drug therapy/pathology', 'Microsatellite Instability/drug effects', 'Oxaloacetates']",https://pubmed.ncbi.nlm.nih.gov/38870931/
1071,bupivacaine,28708665,Hyperbaric Versus Isobaric Bupivacaine for Spinal Anesthesia: Systematic Review and Meta-analysis for Adult Patients Undergoing Noncesarean Delivery Surgery.,"['Uppal V', 'Retter S', 'Shanthanna H', 'Prabhakar C', 'McKeen DM']","['Anesthesia, Obstetrical/adverse effects/*methods', 'Anesthesia, Spinal/adverse effects/*methods', 'Anesthetics, Local/*administration & dosage/adverse effects/chemistry', 'Bupivacaine/*administration & dosage/adverse effects/chemistry', 'Chi-Square Distribution', '*Delivery, Obstetric/adverse effects', 'Drug Compounding', 'Female', 'Humans', 'Motor Activity/drug effects', 'Odds Ratio', 'Pain Measurement', 'Pain Threshold/drug effects', 'Pregnancy', 'Risk Factors', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28708665/
1072,bupivacaine,9777312,Levobupivacaine.,"['McClellan KJ', 'Spencer CM']","['Anesthetics, Local/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Animals', 'Bupivacaine/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Humans', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/9777312/
1073,bupivacaine,20831925,Long-acting local anesthetics and perioperative pain management.,"['Gordon SM', 'Mischenko AV', 'Dionne RA']","['Anesthesia, Dental/*methods', 'Anesthetics, Local/adverse effects/*pharmacology/therapeutic use', 'Bupivacaine/adverse effects/*pharmacology/therapeutic use', 'Humans', 'Inflammation/chemically induced', 'Nociceptors/drug effects', 'Pain Perception/drug effects', 'Pain, Postoperative/*prevention & control', 'Perioperative Care/methods', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/20831925/
1074,bupivacaine,27460467,[Sectio and Brugada syndrome].,"['Ammundsen HB', 'Ekelund K', 'Afshari A', 'Albrechtsen CK']","['Adult', 'Anesthetics, Local/adverse effects/*therapeutic use', 'Brugada Syndrome/*complications', 'Bupivacaine/adverse effects/*therapeutic use', '*Cesarean Section', 'Electrocardiography', 'Female', 'Humans', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/27460467/
1075,bupivacaine,25896736,[Ultrasound-guided cutaneous intercostal branches nerves block: A good analgesic alternative for gallbladder open surgery].,"['Fernandez Martin MT', 'Lopez Alvarez S', 'Mozo Herrera G', 'Platero Burgos JJ']","['Aged', 'Aged, 80 and over', 'Anesthetics, Local/*administration & dosage/therapeutic use', 'Bupivacaine/administration & dosage/*analogs & derivatives/therapeutic use', 'Cholecystectomy/*methods', 'Cholecystitis/surgery', 'Emergencies', 'Female', 'Humans', 'Intercostal Nerves/*drug effects', 'Levobupivacaine', 'Male', 'Nerve Block/*methods', 'Pain Management', 'Pain, Postoperative/*prevention & control', '*Ultrasonography, Interventional']",https://pubmed.ncbi.nlm.nih.gov/25896736/
1076,bupivacaine,24332361,[Inadvertent epidural infusion of paracetamol].,"['Charco Roca LM', 'Ortiz Sanchez VE', 'del Pino Moreno AL']","['Acetaminophen/administration & dosage/*adverse effects', 'Analgesia, Epidural', 'Bupivacaine/analogs & derivatives', 'Epidural Space', 'Female', 'Humans', 'Hysterectomy', 'Infusions, Spinal', 'Levobupivacaine', '*Medication Errors', 'Middle Aged', 'Pain, Postoperative/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24332361/
1077,bupivacaine,16455227,[Local anaesthetics: what can the pure S enantiomers contribute?].,"['Mazoit JX', 'Baujard C']","['Age Factors', 'Amides/adverse effects/*chemistry/pharmacokinetics', 'Anesthetics, Local/adverse effects/*chemistry/pharmacokinetics', 'Blood Proteins/drug effects', 'Blood Vessels/drug effects', 'Bupivacaine/adverse effects/analogs & derivatives/chemistry/pharmacokinetics', 'Child', 'Child, Preschool', 'Erythrocytes/drug effects', 'Heart/drug effects', 'Heart Rate/drug effects', 'Humans', 'Infant', 'Levobupivacaine', 'Metabolic Clearance Rate', 'Ropivacaine', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/16455227/
1078,bupivacaine,24815964,Liposomal bupivacaine and clinical outcomes.,"['Tong YC', 'Kaye AD', 'Urman RD']","['Anesthetics, Local/*administration & dosage/adverse effects/pharmacokinetics', 'Bupivacaine/*administration & dosage/adverse effects/pharmacokinetics', 'Drug Design', 'Humans', 'Length of Stay', 'Liposomes', 'Nerve Block/methods', 'Pain, Postoperative/*drug therapy', 'Patient Satisfaction', 'Perioperative Care/methods']",https://pubmed.ncbi.nlm.nih.gov/24815964/
1079,bupivacaine,24264554,Monoplegia after combined spinal epidural anesthesia.,"['Balaban O', 'Gurkan Y', 'Kus A', 'Toker K', 'Solak M']","['Adult', 'Anesthesia, Epidural/*adverse effects', 'Anesthesia, Spinal/*adverse effects', 'Bupivacaine/administration & dosage/adverse effects/analogs & derivatives', 'Diagnosis, Differential', 'Female', 'Fentanyl/administration & dosage/adverse effects', 'Hemiplegia/chemically induced/*diagnosis/rehabilitation', 'Humans', 'Levobupivacaine', 'Magnetic Resonance Imaging', 'Postoperative Complications/chemically induced/*diagnosis/rehabilitation', 'Varicose Veins/surgery', 'Vascular Surgical Procedures']",https://pubmed.ncbi.nlm.nih.gov/24264554/
1080,bupivacaine,23629121,Local anesthetics in liposuction: considerations for new practice advisory guidelines to improve patient safety.,"['Pace MM', 'Chatterjee A', 'Merrill DG', 'Stotland MA', 'Ridgway EB']","['Ambulatory Surgical Procedures/*standards', 'Anesthesia, Local/*standards', 'Anesthetics, Local/*administration & dosage/adverse effects/pharmacokinetics', 'Bupivacaine/administration & dosage/adverse effects/pharmacokinetics', 'Humans', 'Lidocaine/administration & dosage/adverse effects/pharmacokinetics', 'Lipectomy/*standards', 'Patient Safety', '*Practice Guidelines as Topic']",https://pubmed.ncbi.nlm.nih.gov/23629121/
1081,bupivacaine,7880656,Interaction between baricity (glucose concentration) and other factors influencing intrathecal drug spread.,"['Sanderson P', 'Read J', 'Littlewood DG', 'McKeown D', 'Wildsmith JA']","['Aged', 'Aged, 80 and over', '*Anesthesia, Endotracheal', 'Bupivacaine/*administration & dosage/chemistry/metabolism/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Drug Carriers', 'Drug Interactions', 'Female', 'Glucose/*administration & dosage/pharmacokinetics', 'Humans', 'Male', 'Middle Aged', 'Nerve Block', 'Spinal Puncture', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/7880656/
1082,bupivacaine,2923766,Plain bupivacaine: 0.5% or 0.25% for spinal analgesia?,"['Nielsen TH', 'Kristoffersen E', 'Olsen KH', 'Larsen HV', 'Husegaard HC', 'Wernberg M']","['Aged', '*Anesthesia, Spinal', 'Bupivacaine/*administration & dosage/pharmacology', 'Drug Evaluation', 'Humans', 'Male', 'Middle Aged', 'Motor Neurons/drug effects', 'Prostatectomy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2923766/
1083,bupivacaine,34228280,Bupivacaine/Meloxicam Prolonged Release: A Review in Postoperative Pain.,['Blair HA'],"['Analgesics, Opioid/administration & dosage', 'Anesthetics, Local/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Bupivacaine/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Delayed-Action Preparations', 'Drug Combinations', 'Drug Interactions', 'Humans', 'Meloxicam/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Pain, Postoperative/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34228280/
1084,bupivacaine,27687419,Myoclonus-like involuntary movements following cesarean delivery epidural anesthesia.,"['Kang HY', 'Lee SW', 'Hong EP', 'Sim YH', 'Lee SM', 'Park SW', 'Kang JM']","['Administration, Intravenous', 'Adult', 'Anesthesia Recovery Period', 'Anesthesia, Epidural/*adverse effects', 'Anesthesia, Obstetrical/*adverse effects', 'Anesthetics, Local/administration & dosage', 'Anticonvulsants/administration & dosage/*therapeutic use', 'Bupivacaine/administration & dosage/analogs & derivatives', '*Cesarean Section', 'Female', 'Humans', 'Injections, Epidural', 'Levobupivacaine', 'Lidocaine/administration & dosage', 'Midazolam/administration & dosage/*therapeutic use', 'Myoclonus/*drug therapy/*etiology', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/27687419/
1085,bupivacaine,24496170,Dislocation of a femur fracture after femoral nerve block.,"['Maric S', 'Robinson A', 'Vandepitte C', 'Hadzic A']","['Bupivacaine/administration & dosage/adverse effects/*analogs & derivatives', 'Female', 'Femoral Fractures/*diagnostic imaging/etiology', 'Femoral Nerve/*drug effects/physiology', 'Humans', 'Joint Dislocations/*diagnostic imaging/etiology', 'Levobupivacaine', 'Middle Aged', 'Nerve Block/*adverse effects', 'Radiography']",https://pubmed.ncbi.nlm.nih.gov/24496170/
1086,bupivacaine,7008819,Effect of baricity on spinal anaesthesia with bupivacaine.,"['Chambers WA', 'Edstrom HH', 'Scott DB']","['Adolescent', 'Adult', 'Aged', '*Anesthesia, Spinal', 'Bupivacaine/*administration & dosage/pharmacology', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Hemodynamics/drug effects', 'Humans', 'Middle Aged', 'Nerve Block', 'Solutions', 'Specific Gravity', 'Subarachnoid Space', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/7008819/
1087,bupivacaine,26356108,[Intrathecal bupivacaine and allergic reaction].,"['Gulec H', 'Babayigit M', 'Kutuk S', 'Kurtay A', 'Tutal Z', 'Horasanli E']","['Anesthetics, Local/administration & dosage/*adverse effects', 'Bupivacaine/administration & dosage/*adverse effects', 'Diagnosis, Differential', 'Drug Hypersensitivity/*diagnosis/etiology', 'Humans', 'Injections, Spinal/*adverse effects', 'Male', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/26356108/
1088,bupivacaine,28450776,Brainstem Anesthesia after Retrobulbar Block: A Case Report and Review of Literature.,"['Tolesa K', 'Gebreal GW']","['Anesthetics, Local/administration & dosage/*adverse effects', 'Apnea/chemically induced', 'Brain Stem/*drug effects', 'Bupivacaine/administration & dosage/*adverse effects', 'Glaucoma/surgery', 'Humans', 'Hypotension/chemically induced', 'Male', 'Middle Aged', 'Trabeculectomy/*adverse effects/methods', 'Unconsciousness/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/28450776/
1089,bupivacaine,24673599,Priapism following continuous thoracic epidural anaesthesia: emergency or a benign condition?,"['Fransen van de Putte EE', 'Ananias HJ', 'Gi NP', 'de Boer HD']","['Anesthesia, Epidural/*adverse effects', 'Anesthetics, Local/administration & dosage/*adverse effects', 'Bupivacaine/administration & dosage/adverse effects/*analogs & derivatives', '*Emergencies', 'Humans', 'Levobupivacaine', 'Male', 'Middle Aged', 'Morphine/therapeutic use', 'Narcotics/therapeutic use', 'Nephrectomy', 'Pain, Postoperative/drug therapy/therapy', 'Parasympathetic Nervous System/physiopathology', 'Penis/blood supply/innervation', 'Postoperative Complications/*etiology', 'Priapism/*etiology/physiopathology', 'Sufentanil/administration & dosage/*adverse effects', 'Sympathetic Nervous System/drug effects/physiopathology', 'Thoracic Vertebrae']",https://pubmed.ncbi.nlm.nih.gov/24673599/
1090,bupivacaine,8238138,"The effect of intrapartum epidural analgesia on nulliparous labor: a randomized, controlled, prospective trial.","['Thorp JA', 'Hu DH', 'Albin RM', 'McNitt J', 'Meyer BA', 'Cohen GR', 'Yeast JD']","['Adult', 'Analgesia, Epidural/*adverse effects', 'Analgesia, Obstetrical/*adverse effects', 'Analysis of Variance', 'Apgar Score', 'Bupivacaine/adverse effects/therapeutic use', 'Cesarean Section/statistics & numerical data', 'Delivery, Obstetric', 'Female', 'Fetal Blood/chemistry/drug effects', 'Humans', 'Injections, Intravenous', 'Labor Presentation', 'Labor, Obstetric/*drug effects', 'Meperidine/administration & dosage/therapeutic use', 'Oxytocin/therapeutic use', 'Pain Measurement', 'Parity', 'Pregnancy', 'Promethazine/administration & dosage/therapeutic use', 'Prospective Studies', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/8238138/
1091,rosiglitazone,31776781,Thiazolidinediones: the Forgotten Diabetes Medications.,['Lebovitz HE'],"['Diabetes Mellitus, Type 2/*drug therapy', 'Humans', 'Hypoglycemic Agents/adverse effects/*therapeutic use', 'Insulin Resistance', 'Pioglitazone/adverse effects/therapeutic use', 'Rosiglitazone/adverse effects/therapeutic use', 'Thiazolidinediones/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31776781/
1092,rosiglitazone,35180475,ACSL4 deficiency confers protection against ferroptosis-mediated acute kidney injury.,"['Wang Y', 'Zhang M', 'Bi R', 'Su Y', 'Quan F', 'Lin Y', 'Yue C', 'Cui X', 'Zhao Q', 'Liu S', 'Yang Y', 'Zhang D', 'Cao Q', 'Gao X']","['*Acute Kidney Injury/metabolism', 'Animals', 'Coenzyme A Ligases/genetics', 'Female', '*Ferroptosis/genetics', 'Humans', 'Male', 'Mice', 'Rosiglitazone/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/35180475/
1093,rosiglitazone,30645973,Gain Fat-Lose Metastasis: Converting Invasive Breast Cancer Cells into Adipocytes Inhibits Cancer Metastasis.,"['Ishay-Ronen D', 'Diepenbruck M', 'Kalathur RKR', 'Sugiyama N', 'Tiede S', 'Ivanek R', 'Bantug G', 'Morini MF', 'Wang J', 'Hess C', 'Christofori G']","['3T3-L1 Cells', 'Adipocytes/*cytology', 'Adipogenesis', 'Animals', 'Breast Neoplasms/*drug therapy/metabolism', 'Cell Line, Tumor', 'Cell Movement', 'Cell Transdifferentiation/*drug effects', 'Epithelial-Mesenchymal Transition/drug effects', 'Female', 'Flavonoids/*administration & dosage/pharmacology', 'Humans', 'Mice', 'Neoplasm Metastasis/*drug therapy', 'Neoplasm Transplantation', 'Proto-Oncogene Proteins c-met/metabolism', 'Rosiglitazone/*administration & dosage/therapeutic use', 'Signal Transduction/drug effects', 'Transforming Growth Factor beta/metabolism']",https://pubmed.ncbi.nlm.nih.gov/30645973/
1094,rosiglitazone,38594496,PPARgamma alleviates preeclampsia development by regulating lipid metabolism and ferroptosis.,"['Lai W', 'Yu L', 'Deng Y']","['Humans', 'Female', 'Pregnancy', 'Rats', 'Animals', 'Rosiglitazone/pharmacology/metabolism', 'PPAR gamma/metabolism', 'Lipid Metabolism', 'Placenta/metabolism', '*Pre-Eclampsia/drug therapy/prevention & control/metabolism', 'NF-E2-Related Factor 2/metabolism', '*Ferroptosis', 'Hypoxia/metabolism', 'Lipids']",https://pubmed.ncbi.nlm.nih.gov/38594496/
1095,rosiglitazone,24563375,Systematic reviews to ascertain the safety of diabetes medications.,"['Gionfriddo MR', 'Morey-Vargas OL', 'Brito JP', 'Leppin AL', 'Murad MH', 'Montori VM']","['Acidosis, Lactic/chemically induced', 'Blood Glucose/*drug effects', 'Diabetes Mellitus, Type 2/*drug therapy', 'Evidence-Based Medicine', 'Female', 'Fractures, Bone/chemically induced', 'Glycated Hemoglobin/*drug effects', 'Glycine/administration & dosage/adverse effects/analogs & derivatives', 'Humans', 'Hypoglycemic Agents/*administration & dosage/adverse effects', 'Male', 'Meta-Analysis as Topic', 'Metformin/administration & dosage/adverse effects', 'Oxazoles/administration & dosage/adverse effects', 'Pancreatic Neoplasms/chemically induced', 'Risk Assessment', 'Rosiglitazone', 'Thiazolidinediones/administration & dosage/adverse effects', 'Urinary Bladder Neoplasms/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/24563375/
1096,rosiglitazone,33674341,"ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.","['Zhou T', 'Liu J', 'Xie Y', 'Yuan S', 'Guo Y', 'Bai W', 'Zhao K', 'Jiang W', 'Wang H', 'Wang H', 'Zhao T', 'Huang C', 'Gao S', 'Wang X', 'Yang S', 'Hao J']","['Animals', 'Cohort Studies', 'Disease Models, Animal', 'Humans', 'Hypoglycemic Agents/pharmacology', 'Mice', 'Mice, Inbred BALB C', 'Neoplastic Stem Cells/*drug effects/metabolism', 'Pancreatic Neoplasms/metabolism/*pathology', 'Pancreatic Stellate Cells/*drug effects/metabolism', 'Receptors, CXCR4/*metabolism', 'Rosiglitazone/*pharmacology', 'Transcription Factors/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/33674341/
1097,rosiglitazone,26690770,Thiazolidinediones improve flow-mediated dilation: a meta-analysis of randomized clinical trials.,"['Stojanovic M', 'Prostran M', 'Radenkovic M']","['Animals', 'Endothelium, Vascular/drug effects', 'Humans', 'Pioglitazone', 'Randomized Controlled Trials as Topic', 'Rosiglitazone', 'Thiazolidinediones/*pharmacology/*therapeutic use', 'Vasodilation/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/26690770/
1098,rosiglitazone,38605183,Adipose tissue macrophages secrete small extracellular vesicles that mediate rosiglitazone-induced insulin sensitization.,"['Rohm TV', 'Castellani Gomes Dos Reis F', 'Isaac R', 'Murphy C', 'Cunha E Rocha K', 'Bandyopadhyay G', 'Gao H', 'Libster AM', 'Zapata RC', 'Lee YS', 'Ying W', 'Miciano C', 'Wang A', 'Olefsky JM']","['Animals', '*Rosiglitazone/pharmacology', '*Extracellular Vesicles/metabolism/drug effects', 'Mice', '*Insulin Resistance', '*Macrophages/metabolism/drug effects', '*Adipose Tissue/metabolism/drug effects', 'Male', 'Humans', 'MicroRNAs/genetics/metabolism', 'Obesity/metabolism', 'Insulin/metabolism', 'Adipocytes/metabolism/drug effects', 'Mice, Inbred C57BL']",https://pubmed.ncbi.nlm.nih.gov/38605183/
1099,rosiglitazone,10400405,Rosiglitazone.,"['Balfour JA', 'Plosker GL']","['Animals', 'Blood Glucose/*drug effects', 'Clinical Trials as Topic', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Interactions', 'Humans', 'Hypoglycemic Agents/*pharmacology', 'Insulin/*metabolism', 'Islets of Langerhans/*drug effects', 'Polypharmacy', 'Rosiglitazone', 'Thiazoles/adverse effects/pharmacology/*therapeutic use', '*Thiazolidinediones']",https://pubmed.ncbi.nlm.nih.gov/10400405/
1100,rosiglitazone,20977573,Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?,"['Schernthaner G', 'Chilton RJ']","['Cardiovascular Diseases/*chemically induced', 'Diabetes Mellitus, Type 2/complications/*drug therapy', 'Diabetic Angiopathies/*chemically induced', 'Female', 'Humans', 'Male', '*Meta-Analysis as Topic', 'Randomized Controlled Trials as Topic', 'Risk Factors', 'Rosiglitazone', 'Thiazolidinediones/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/20977573/
1101,rosiglitazone,11410214,Lessons from the glitazones: a story of drug development.,['Gale EA'],"['Adverse Drug Reaction Reporting Systems', 'Chemical and Drug Induced Liver Injury/etiology', 'Chromans/administration & dosage/*adverse effects', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Approval/*legislation & jurisprudence', 'Drug Therapy, Combination', 'Europe', 'Humans', 'Hypoglycemic Agents/administration & dosage/*adverse effects', 'Liver Failure/chemically induced', 'Pioglitazone', 'Rosiglitazone', 'Thiazoles/administration & dosage/*adverse effects', '*Thiazolidinediones', 'Troglitazone', 'United States']",https://pubmed.ncbi.nlm.nih.gov/11410214/
1102,rosiglitazone,32353383,LINCS dataset-based repositioning of rosiglitazone as a potential anti-human adenovirus drug.,"['Wang X', 'He S', 'Zhou Z', 'Bo X', 'Qi D', 'Fu X', 'Wang Z', 'Yang J', 'Wang S']","['A549 Cells', 'Adenovirus Infections, Human/drug therapy/virology', 'Adenoviruses, Human/*drug effects/physiology', 'Algorithms', 'Animals', 'Antiviral Agents/pharmacology/*therapeutic use', '*Databases, Pharmaceutical', '*Drug Repositioning', 'Epithelial Cells/drug effects/virology', 'Female', 'Humans', 'Immunocompromised Host', 'Mice', 'Mice, SCID', 'Rosiglitazone/pharmacology/*therapeutic use', 'Virus Replication/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/32353383/
1103,rosiglitazone,37864473,Decellularization-Based Modification Strategy for Bioactive Xenografts Promoting Tendon Repair.,"['Jin H', 'Kang Y', 'Gao H', 'Lin Z', 'Huang D', 'Zheng Z', 'Zhao J', 'Wang L', 'Jiang J']","['Humans', 'Rats', 'Animals', 'Heterografts', 'Rosiglitazone/pharmacology', '*Extracellular Matrix', '*Inflammation', 'Collagen', 'Tendons', 'Tissue Engineering', 'Tissue Scaffolds']",https://pubmed.ncbi.nlm.nih.gov/37864473/
1104,rosiglitazone,38131378,PPARgamma agonist treatment reduces fibroadipose tissue in secondary lymphedema by exhausting fibroadipogenic PDGFRalpha+ mesenchymal cells.,"['Chen Z', 'Ghavimi SAA', 'Wu M', 'McNamara J', 'Barreiro O', 'Maridas D', 'Kratchmarov R', 'Siegel A', 'Djeddi S', 'Gutierrez-Arcelus M', 'Brennan PJ', 'Padera TP', 'von Andrian U', 'Mehrara B', 'Greene AK', 'Kahn CR', 'Orgill DP', 'Sinha I', 'Rosen V', 'Agarwal S']","['Male', 'Female', 'Humans', 'Mice', 'Animals', '*Receptor, Platelet-Derived Growth Factor alpha', 'PPAR gamma', 'Rosiglitazone/pharmacology/therapeutic use', '*Lymphedema/drug therapy', 'Fibrosis']",https://pubmed.ncbi.nlm.nih.gov/38131378/
1105,rosiglitazone,15163284,Rosiglitazone plus metformin: combination therapy for Type 2 diabetes.,"['Del Prato S', 'Volpe L']","['Clinical Trials as Topic', 'Diabetes Mellitus, Type 2/*drug therapy', 'Dose-Response Relationship, Drug', 'Drug Combinations', 'Humans', 'Hypoglycemic Agents/administration & dosage/pharmacology/*therapeutic use', 'Metformin/administration & dosage/pharmacology/*therapeutic use', 'Rosiglitazone', 'Thiazoles/administration & dosage/pharmacology/*therapeutic use', 'Thiazolidinediones/administration & dosage/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15163284/
1106,rosiglitazone,30142096,Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes: a pathophysiology-based review of clinical implications.,"['Bajaj HS', 'Al-Jabri B', 'Verma S']","['Biomarkers/blood', 'Blood Glucose/drug effects/metabolism', 'Blood Pressure/drug effects/*physiology', '*Cardiovascular Diseases/etiology/physiopathology/prevention & control', 'Diabetes Mellitus, Type 2/blood/complications/*drug therapy', 'Humans', 'Hypoglycemic Agents/therapeutic use', 'Lipids/blood', 'Prognosis', 'Rosiglitazone/*therapeutic use', '*Glucagon-Like Peptide-1 Receptor Agonists']",https://pubmed.ncbi.nlm.nih.gov/30142096/
1107,rosiglitazone,17975488,"Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus ""off-target"" effectors.",['Nemenoff RA'],"['Animals', 'Antineoplastic Agents/*therapeutic use', 'Humans', 'Lung Neoplasms/*drug therapy/metabolism', 'PPAR gamma/*metabolism', 'Pioglitazone', 'Rosiglitazone', 'Signal Transduction/*drug effects', 'Thiazolidinediones/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17975488/
1108,rosiglitazone,19162510,Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer.,"['Inamoto T', 'Shah JB', 'Kamat AM']","['Adjuvants, Immunologic/administration & dosage/therapeutic use', 'Animals', 'Antineoplastic Agents/pharmacology/*therapeutic use', 'Apoptosis/drug effects', 'BCG Vaccine/administration & dosage/therapeutic use', 'Disease Progression', 'Humans', 'Neoplasm Invasiveness', 'PPAR gamma/*agonists/*metabolism', 'Rosiglitazone', 'Thiazolidinediones/pharmacology/*therapeutic use', 'Urinary Bladder Neoplasms/*drug therapy/*metabolism/pathology']",https://pubmed.ncbi.nlm.nih.gov/19162510/
1109,rosiglitazone,17569897,Rosiglitazone and implications for pharmacovigilance.,['Kazi D'],"['Clinical Trials as Topic', 'Diabetes Mellitus, Type 2/*drug therapy', 'Humans', 'Hypoglycemic Agents/*adverse effects', 'Meta-Analysis as Topic', 'Product Surveillance, Postmarketing', 'Rosiglitazone', 'Thiazolidinediones/*adverse effects', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/17569897/
1110,rosiglitazone,21102545,Therapy: The second time as farce: rosiglitazone and the regulators.,['Gale EA'],"['Chromans/adverse effects/therapeutic use', 'Diabetes Mellitus/drug therapy', 'Humans', 'Hypoglycemic Agents/adverse effects/*therapeutic use', 'Rosiglitazone', 'Thiazolidinediones/adverse effects/*therapeutic use', 'Troglitazone']",https://pubmed.ncbi.nlm.nih.gov/21102545/
1111,alosetron,35695704,Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility.,"['Savarino E', 'Zingone F', 'Barberio B', 'Marasco G', 'Akyuz F', 'Akpinar H', 'Barboi O', 'Bodini G', 'Bor S', 'Chiarioni G', 'Cristian G', 'Corsetti M', 'Di Sabatino A', 'Dimitriu AM', 'Drug V', 'Dumitrascu DL', 'Ford AC', 'Hauser G', 'Nakov R', 'Patel N', 'Pohl D', 'Sfarti C', 'Serra J', 'Simren M', 'Suciu A', 'Tack J', 'Toruner M', 'Walters J', 'Cremon C', 'Barbara G']","['Bile Acids and Salts/therapeutic use', 'Diarrhea/diagnosis/etiology/therapy', '*Gastroenterology', 'Gastrointestinal Agents/therapeutic use', 'Humans', '*Irritable Bowel Syndrome/diagnosis/epidemiology/therapy']",https://pubmed.ncbi.nlm.nih.gov/35695704/
1112,alosetron,35738725,AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.,"['Lembo A', 'Sultan S', 'Chang L', 'Heidelbaugh JJ', 'Smalley W', 'Verne GN']","['Antidepressive Agents, Tricyclic/therapeutic use', 'Diarrhea/diagnosis/drug therapy/etiology', 'Gastrointestinal Agents/therapeutic use', 'Humans', '*Irritable Bowel Syndrome/complications/diagnosis/drug therapy', 'Loperamide/adverse effects', 'Rifaximin/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35738725/
1113,alosetron,29709540,Implications of Pharmacogenomics to the Management of IBS.,['Camilleri M'],"['Anti-Anxiety Agents/*pharmacokinetics/therapeutic use', 'Antidepressive Agents, Tricyclic/*pharmacokinetics/therapeutic use', 'Antiemetics/*pharmacokinetics/therapeutic use', 'Biological Variation, Individual', 'Cytochrome P-450 Enzyme System/*genetics/metabolism', 'Humans', 'Inactivation, Metabolic/genetics', 'Irritable Bowel Syndrome/*drug therapy', 'Pharmacogenetics', 'Proton Pump Inhibitors/*pharmacokinetics/therapeutic use', 'Serotonin and Noradrenaline Reuptake Inhibitors/*pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29709540/
1114,alosetron,31025114,Update on Pharmacotherapy for Irritable Bowel Syndrome.,"['Munjal A', 'Dedania B', 'Cash B']","['Gastrointestinal Agents/therapeutic use', 'Humans', 'Irritable Bowel Syndrome/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31025114/
1115,alosetron,23130604,Clinical trials in irritable bowel syndrome: a review.,"['Ervin CM', 'Mangel AW']","['Alprostadil/analogs & derivatives/therapeutic use', 'Benzamides/therapeutic use', 'Biphenyl Compounds/therapeutic use', 'Bridged Bicyclo Compounds, Heterocyclic/therapeutic use', 'Carbolines/therapeutic use', 'Dose-Response Relationship, Drug', 'Gastrointestinal Agents/*therapeutic use', 'Humans', 'Indoles/therapeutic use', 'Irritable Bowel Syndrome/*drug therapy', 'Lubiprostone', 'Peptides/therapeutic use', 'Phenylalanine/analogs & derivatives/therapeutic use', 'Phloroglucinol/analogs & derivatives/therapeutic use', '*Randomized Controlled Trials as Topic', 'Rifamycins/therapeutic use', 'Rifaximin']",https://pubmed.ncbi.nlm.nih.gov/23130604/
1116,alosetron,17241888,The serotonin signaling system: from basic understanding to drug development for functional GI disorders.,"['Gershon MD', 'Tack J']","['Animals', '*Drug Design', 'Gastrointestinal Diseases/*drug therapy/*physiopathology', 'Gastrointestinal Tract/innervation/physiology', 'Humans', 'Serotonin/*physiology', 'Signal Transduction/drug effects/*physiology']",https://pubmed.ncbi.nlm.nih.gov/17241888/
1117,alosetron,18420501,Clinical practice. Irritable bowel syndrome.,['Mayer EA'],"['Adult', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Carbolines/therapeutic use', '*Cognitive Behavioral Therapy', 'Desipramine/therapeutic use', 'Female', 'Gastrointestinal Agents/*therapeutic use', 'Humans', 'Indoles/therapeutic use', 'Irritable Bowel Syndrome/diagnosis/etiology/psychology/*therapy', 'Male', 'Parasympatholytics/therapeutic use', 'Practice Guidelines as Topic']",https://pubmed.ncbi.nlm.nih.gov/18420501/
1118,alosetron,22296841,Irritable bowel syndrome.,"['Ford AC', 'Vandvik PO']","['Humans', '*Irritable Bowel Syndrome/drug therapy', '*Loperamide/administration & dosage', 'Parasympatholytics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22296841/
1119,alosetron,17195419,Irritable bowel syndrome: a practical review.,"['Podovei M', 'Kuo B']","['Antidepressive Agents/therapeutic use', 'Carbolines/therapeutic use', 'Dietary Fiber/administration & dosage', 'Food Hypersensitivity/complications', 'Gastrointestinal Agents/therapeutic use', 'Gastrointestinal Motility', 'Humans', 'Indoles/therapeutic use', 'Irritable Bowel Syndrome/*diagnosis/*drug therapy/epidemiology/physiopathology', 'Parasympatholytics/therapeutic use', 'Prevalence', 'Retrospective Studies', 'Serotonin Antagonists/therapeutic use', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/17195419/
1120,alosetron,15324710,Functional dyspepsia: drugs for new (and old) therapeutic targets.,"['Cremonini F', 'Delgado-Aros S', 'Talley NJ']","['Dyspepsia/*drug therapy/physiopathology', 'Gastric Acid/metabolism', 'Gastric Emptying/drug effects', 'Gastrointestinal Agents/*therapeutic use', 'Gastrointestinal Motility/drug effects', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/15324710/
1121,alosetron,21718578,Irritable bowel syndrome.,"['Ford AC', 'Vandvik PO']","['Antidepressive Agents, Tricyclic/therapeutic use', 'Colonic Diseases, Functional/drug therapy', 'Humans', 'Hypnosis', '*Irritable Bowel Syndrome/diagnosis', '*Loperamide/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Surveys and Questionnaires']",https://pubmed.ncbi.nlm.nih.gov/21718578/
1122,alosetron,21398180,Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome.,['Spiller RC'],"['Animals', 'Humans', 'Irritable Bowel Syndrome/*drug therapy/*metabolism', 'Molecular Targeted Therapy', 'Receptors, Serotonin, 5-HT3/*metabolism', 'Serotonin/metabolism', 'Serotonin 5-HT3 Receptor Agonists/*pharmacology/therapeutic use', 'Serotonin 5-HT3 Receptor Antagonists/*pharmacology/therapeutic use', 'Serotonin Plasma Membrane Transport Proteins/metabolism']",https://pubmed.ncbi.nlm.nih.gov/21398180/
1123,alosetron,22339099,The shortcomings of clinical trials assessing the efficacy of probiotics in irritable bowel syndrome.,"['Rogers NJ', 'Mousa SA']","['Bacteria', 'Clinical Trials as Topic/*methods/standards', 'Humans', 'Irritable Bowel Syndrome/*drug therapy', 'Placebo Effect', 'Probiotics/*therapeutic use', '*Research Design', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22339099/
1124,alosetron,26558923,Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.,"['Nee J', 'Zakari M', 'Lembo AJ']","['Antidepressive Agents, Tricyclic/therapeutic use', 'Antidiarrheals/*therapeutic use', 'Carbolines/therapeutic use', 'Diarrhea/*drug therapy/physiopathology', 'Gastrointestinal Agents/*therapeutic use', 'Humans', 'Imidazoles/therapeutic use', 'Irritable Bowel Syndrome/*drug therapy/physiopathology', 'Loperamide/therapeutic use', 'Phenylalanine/analogs & derivatives/therapeutic use', 'Receptors, Opioid/agonists', 'Rifamycins/therapeutic use', 'Rifaximin']",https://pubmed.ncbi.nlm.nih.gov/26558923/
1125,alosetron,38366822,Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs.,"['Mozaffari S', 'Nikfar S', 'Abdollahi M']","['Humans', 'Diarrhea/drug therapy', 'Drugs, Investigational/pharmacology/therapeutic use', 'Gastrointestinal Agents/pharmacology/therapeutic use', '*Heterocyclic Compounds, 2-Ring', '*Irritable Bowel Syndrome/drug therapy', 'Quality of Life', 'Clinical Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/38366822/
1126,alosetron,18855852,Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm.,"['Moayyedi P', 'Cranney A']","['Age Factors', 'Calcium/*metabolism', 'Dose-Response Relationship, Drug', 'Gastroesophageal Reflux/*drug therapy', 'Global Health', 'Hip Fractures/*chemically induced/epidemiology/metabolism', 'Humans', 'Incidence', 'Intestinal Absorption/*drug effects', 'Prognosis', 'Proton Pump Inhibitors/administration & dosage/*adverse effects', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/18855852/
1127,alosetron,17490849,[Irritable bowel syndrome: current treatment options].,['Ducrotte P'],"['Antidepressive Agents/therapeutic use', 'Humans', 'Irritable Bowel Syndrome/immunology/*therapy', 'Serotonin Receptor Agonists/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17490849/
1128,alosetron,12968980,Evaluation of drug treatment in irritable bowel syndrome.,['Talley NJ'],"['Anti-Anxiety Agents/therapeutic use', 'Antidepressive Agents/therapeutic use', 'Antidiarrheals/therapeutic use', 'Cathartics/therapeutic use', 'Colonic Diseases, Functional/*drug therapy/etiology', 'Drug Design', 'Forecasting', 'Humans', 'Parasympatholytics/therapeutic use', 'Serotonin Receptor Agonists/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12968980/
1129,alosetron,10776833,Alosetron.,"['Balfour JA', 'Goa KL', 'Perry CM']","['Adult', 'Animals', 'Area Under Curve', 'Biological Availability', '*Carbolines/pharmacology/therapeutic use', 'Colonic Diseases, Functional/*drug therapy', 'Constipation/chemically induced', 'Dogs', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Intestinal Absorption', 'Male', 'Randomized Controlled Trials as Topic', '*Serotonin Antagonists/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10776833/
1130,alosetron,16042907,Diagnosis and treatment of irritable bowel syndrome: state of the art.,"['Tillisch K', 'Chang L']","['Anti-Bacterial Agents/therapeutic use', 'Antidiarrheals/therapeutic use', 'Cathartics/therapeutic use', 'Complementary Therapies', 'Diet', 'Humans', 'Irritable Bowel Syndrome/*diagnosis/physiopathology/*therapy', 'Parasympatholytics/therapeutic use', 'Psychotherapy', 'Serotonin Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16042907/
1131,Pioglitazone,32942898,[Pioglitazone].,['Karasek D'],"['*Cardiovascular Diseases/drug therapy', '*Diabetes Mellitus, Type 2/drug therapy', 'Humans', 'Hypoglycemic Agents/adverse effects', 'Pioglitazone', '*Thiazolidinediones/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32942898/
1132,Pioglitazone,31776781,Thiazolidinediones: the Forgotten Diabetes Medications.,['Lebovitz HE'],"['Diabetes Mellitus, Type 2/*drug therapy', 'Humans', 'Hypoglycemic Agents/adverse effects/*therapeutic use', 'Insulin Resistance', 'Pioglitazone/adverse effects/therapeutic use', 'Rosiglitazone/adverse effects/therapeutic use', 'Thiazolidinediones/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31776781/
1133,Pioglitazone,32296231,Oncocrinology.,"['Kalra S', 'Priya G', 'Bhattacharya S', 'Sahay R']","['Antineoplastic Agents/adverse effects', 'Antineoplastic Agents, Hormonal/adverse effects/therapeutic use', 'Biomarkers, Tumor/metabolism', 'Breast Neoplasms/etiology', 'Endocrine Gland Neoplasms/complications/etiology/metabolism/therapy', 'Endocrine System Diseases/complications/etiology/metabolism/therapy', '*Endocrinology', 'Estrogen Replacement Therapy/adverse effects', 'Humans', 'Hypoglycemic Agents/adverse effects', '*Medical Oncology', 'Neoplasms/complications/etiology/metabolism/therapy', 'Obesity/complications/metabolism', 'Paraneoplastic Syndromes/etiology/metabolism', 'Pioglitazone/adverse effects', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/32296231/
1134,Pioglitazone,30706731,"Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes.","['DeFronzo RA', 'Inzucchi S', 'Abdul-Ghani M', 'Nissen SE']","['Animals', 'Biomarkers/blood', 'Blood Glucose/*drug effects/metabolism', 'Cardiovascular Diseases/economics/epidemiology/*prevention & control', 'Cost-Benefit Analysis', 'Diabetes Mellitus, Type 2/blood/*drug therapy/economics/epidemiology', 'Drug Costs', 'Glycated Hemoglobin/metabolism', 'Humans', 'Hypoglycemic Agents/adverse effects/economics/*therapeutic use', 'Insulin Resistance', 'Pioglitazone/adverse effects/economics/*therapeutic use', 'Risk Assessment', 'Risk Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30706731/
1135,Pioglitazone,30411635,Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults.,"['Ogawa Y', 'Yoneda M', 'Kobayashi T', 'Honda Y', 'Kessoku T', 'Imajo K', 'Saito S', 'Nakajima A']","['Adult', 'Diet', 'Disease Progression', 'Drug Development/*methods', 'Humans', 'Life Style', 'Non-alcoholic Fatty Liver Disease/*drug therapy', 'Pioglitazone/therapeutic use', 'Vitamin E/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30411635/
1136,Pioglitazone,38117497,Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes.,"['Yen FS', 'Wei JC', 'Yu TS', 'Hung YT', 'Hsu CC', 'Hwu CM']","['Adult', 'Humans', 'Male', 'Middle Aged', 'Cohort Studies', '*Diabetes Mellitus, Type 2/complications/drug therapy', '*Diabetic Retinopathy/chemically induced/epidemiology', 'Pioglitazone/adverse effects', '*Retinal Diseases', 'Sulfonylurea Compounds/adverse effects', '*Sodium-Glucose Transporter 2 Inhibitors/therapeutic use', 'Aged', 'Female']",https://pubmed.ncbi.nlm.nih.gov/38117497/
1137,Pioglitazone,17728845,Pioglitazone and metformin.,"['Hill NR', 'Matthews DR']","['Animals', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Combinations', 'Humans', '*Hypoglycemic Agents/administration & dosage/adverse effects/pharmacology/therapeutic use', '*Metformin/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Pioglitazone', 'Therapeutic Equivalency', '*Thiazolidinediones/administration & dosage/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17728845/
1138,Pioglitazone,31255176,Dietary fructose-induced gut dysbiosis promotes mouse hippocampal neuroinflammation: a benefit of short-chain fatty acids.,"['Li JM', 'Yu R', 'Zhang LP', 'Wen SY', 'Wang SJ', 'Zhang XY', 'Xu Q', 'Kong LD']","['Animals', 'Doublecortin Protein', 'Dysbiosis/*chemically induced', 'Fatty Acids, Volatile/*administration & dosage', 'Fructose/*adverse effects', 'Gastrointestinal Microbiome', 'Hippocampus/*drug effects/pathology', 'Inflammasomes', 'Inflammation/*chemically induced', 'Intestinal Mucosa/drug effects/microbiology', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Neuroimmunomodulation/drug effects', 'Pioglitazone/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/31255176/
1139,Pioglitazone,31149341,A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH).,"['Povsic M', 'Oliver L', 'Jiandani NR', 'Perry R', 'Bottomley J']","['Clinical Trials, Phase II as Topic', 'Clinical Trials, Phase III as Topic', 'Guidelines as Topic', 'Humans', 'Life Style', 'Non-alcoholic Fatty Liver Disease/*drug therapy/prevention & control', 'Pioglitazone/*therapeutic use', 'Vitamin E/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31149341/
1140,Pioglitazone,37869901,"Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis.","['Kuate Defo A', 'Bakula V', 'Pisaturo A', 'Labos C', 'Wing SS', 'Daskalopoulou SS']","['Humans', '*Dementia/epidemiology/prevention & control', '*Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology', '*Dipeptidyl-Peptidase IV Inhibitors/adverse effects', 'Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/therapeutic use', 'Glycoside Hydrolase Inhibitors', 'Hypoglycemic Agents/adverse effects', 'Insulin/therapeutic use', '*Metformin/adverse effects', 'Pioglitazone/therapeutic use', '*Sodium-Glucose Transporter 2 Inhibitors/therapeutic use', 'Sulfonylurea Compounds/adverse effects', 'Systematic Reviews as Topic', '*Thiazolidinediones/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37869901/
1141,Pioglitazone,32237916,Current and new pharmacotherapy options for non-alcoholic steatohepatitis.,"['Sumida Y', 'Yoneda M', 'Ogawa Y', 'Yoneda M', 'Okanoue T', 'Nakajima A']","['Chenodeoxycholic Acid/administration & dosage/*analogs & derivatives/therapeutic use', 'Clinical Trials as Topic', 'Fibroblast Growth Factors/agonists', 'Glucagon-Like Peptides/administration & dosage/*therapeutic use', 'Humans', 'Liver Cirrhosis/*drug therapy/metabolism/pathology', 'Non-alcoholic Fatty Liver Disease/*drug therapy/metabolism/pathology', 'Peroxisome Proliferator-Activated Receptors/agonists', 'Pioglitazone/administration & dosage/*therapeutic use', 'Receptors, Cytoplasmic and Nuclear/agonists', 'Treatment Outcome', 'Vitamin E/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32237916/
1142,Pioglitazone,34020670,Exosomes derived from pioglitazone-pretreated MSCs accelerate diabetic wound healing through enhancing angiogenesis.,"['Hu Y', 'Tao R', 'Chen L', 'Xiong Y', 'Xue H', 'Hu L', 'Yan C', 'Xie X', 'Lin Z', 'Panayi AC', 'Mi B', 'Liu G']","['Angiogenesis Inducing Agents/pharmacology', 'Animals', 'Cell Movement/drug effects', 'Cell Proliferation/drug effects', 'Cell Survival/drug effects', 'Collagen/metabolism', 'Diabetes Mellitus/*metabolism', 'Diabetes Mellitus, Experimental', 'Exosomes/*metabolism', 'Human Umbilical Vein Endothelial Cells/drug effects', 'Humans', 'Male', 'Mesenchymal Stem Cells/*metabolism', 'Phosphatidylinositol 3-Kinases/metabolism', 'Pioglitazone/*metabolism/*pharmacology', 'Rats', 'Rats, Sprague-Dawley', 'Skin/drug effects', 'Wound Healing/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/34020670/
1143,Pioglitazone,37923895,A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF-beta signaling in hepatic stellate cells.,"['Kasahara N', 'Imi Y', 'Amano R', 'Shinohara M', 'Okada K', 'Hosokawa Y', 'Imamori M', 'Tomimoto C', 'Kunisawa J', 'Kishino S', 'Ogawa J', 'Ogawa W', 'Hosooka T']","['Mice', 'Humans', 'Animals', '*Non-alcoholic Fatty Liver Disease/pathology', 'Pioglitazone/pharmacology', 'Linoleic Acid/metabolism', 'Hepatic Stellate Cells/metabolism', '*Gastrointestinal Microbiome', 'Mice, Inbred C57BL', 'Liver/metabolism', 'Liver Cirrhosis/pathology', 'Fibrosis', 'Diet, High-Fat/adverse effects', 'Transforming Growth Factor beta/metabolism']",https://pubmed.ncbi.nlm.nih.gov/37923895/
1144,Pioglitazone,26690770,Thiazolidinediones improve flow-mediated dilation: a meta-analysis of randomized clinical trials.,"['Stojanovic M', 'Prostran M', 'Radenkovic M']","['Animals', 'Endothelium, Vascular/drug effects', 'Humans', 'Pioglitazone', 'Randomized Controlled Trials as Topic', 'Rosiglitazone', 'Thiazolidinediones/*pharmacology/*therapeutic use', 'Vasodilation/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/26690770/
1145,Pioglitazone,37393546,[Rediscovery of pioglitazone].,"['Pokoly B', 'Somogyi A']","['Humans', 'Pioglitazone/therapeutic use', '*Diabetes Mellitus, Type 2/drug therapy/complications', 'Hypoglycemic Agents/therapeutic use', 'Prospective Studies', '*Thiazolidinediones/therapeutic use', '*Cardiovascular Diseases/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/37393546/
1146,Pioglitazone,29695452,PPARgamma agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation.,"['Legchenko E', 'Chouvarine P', 'Borchert P', 'Fernandez-Gonzalez A', 'Snay E', 'Meier M', 'Maegel L', 'Mitsialis SA', 'Rog-Zielinska EA', 'Kourembanas S', 'Jonigk D', 'Hansmann G']","['Fatty Acids/*metabolism', 'Female', 'Heart Failure/*drug therapy/*metabolism', 'Hemodynamics/drug effects', 'Humans', 'Hypertension, Pulmonary/*drug therapy/*metabolism', 'Male', 'Oxidation-Reduction/drug effects', 'PPAR gamma/agonists/*metabolism', 'Pioglitazone/*therapeutic use', 'Ventricular Dysfunction, Right/*drug therapy/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/29695452/
1147,Pioglitazone,36401449,Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.,"['Zhao Y', 'Zhao W', 'Wang H', 'Zhao Y', 'Bu H', 'Takahashi H']","['Humans', 'United States', '*Non-alcoholic Fatty Liver Disease/drug therapy', 'Pioglitazone/therapeutic use', '*Insulin Resistance', 'Insulin', 'Glycated Hemoglobin']",https://pubmed.ncbi.nlm.nih.gov/36401449/
1148,Pioglitazone,30472322,Diabetes Care for Patients Experiencing Homelessness: Beyond Metformin and Sulfonylureas.,"['Brooks LK', 'Kalyanaraman N', 'Malek R']","['Diabetes Mellitus, Type 2/*drug therapy', 'Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use', 'Glucagon-Like Peptide 1/agonists', '*Ill-Housed Persons', 'Humans', 'Hypoglycemic Agents/pharmacology/*therapeutic use', 'PPAR gamma/agonists', 'Pioglitazone/pharmacology/therapeutic use', 'Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30472322/
1149,Pioglitazone,37974258,Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials.,"['Deng M', 'Wen Y', 'Yan J', 'Fan Y', 'Wang Z', 'Zhang R', 'Ren L', 'Ba Y', 'Wang H', 'Lu Q', 'Fan H']","['Humans', '*Diabetes Mellitus, Type 2/drug therapy', 'Exenatide/therapeutic use', 'Hypoglycemic Agents/pharmacology', 'Liraglutide/therapeutic use', '*Non-alcoholic Fatty Liver Disease/drug therapy', 'Network Meta-Analysis', 'Pioglitazone/therapeutic use', '*Insulin Resistance', 'Bayes Theorem']",https://pubmed.ncbi.nlm.nih.gov/37974258/
1150,Pioglitazone,38425186,"A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.","['Lim S', 'Lee SH', 'Min KW', 'Lee CB', 'Kim SY', 'Yoo HJ', 'Kim NH', 'Kim JH', 'Oh S', 'Won JC', 'Kwon HS', 'Kim MK', 'Park JH', 'Jeong IK', 'Kim S']","['Humans', '*Glucosides/therapeutic use/adverse effects/administration & dosage', '*Pioglitazone/therapeutic use', '*Diabetes Mellitus, Type 2/drug therapy/blood', '*Metformin/therapeutic use/adverse effects', '*Benzhydryl Compounds/therapeutic use/adverse effects', 'Double-Blind Method', 'Male', 'Female', 'Middle Aged', '*Hypoglycemic Agents/therapeutic use/adverse effects', '*Glycated Hemoglobin/analysis/drug effects/metabolism', '*Drug Therapy, Combination', 'Treatment Outcome', 'Thiazolidinediones/therapeutic use/adverse effects', 'Aged', 'Insulin Resistance', 'Sodium-Glucose Transporter 2 Inhibitors/therapeutic use/adverse effects', 'Blood Glucose/drug effects/metabolism', 'Waist Circumference/drug effects', 'Republic of Korea', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/38425186/
1151,carvedilol,36897563,Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.,"['Turco L', 'Reiberger T', 'Vitale G', 'La Mura V']","['Humans', 'Carvedilol/therapeutic use', 'Propranolol', '*Esophageal and Gastric Varices/etiology/complications', 'Ascites/etiology/complications', 'Gastrointestinal Hemorrhage/drug therapy/etiology', 'Adrenergic beta-Antagonists/therapeutic use', '*Hypertension, Portal/complications/drug therapy', 'Liver Cirrhosis']",https://pubmed.ncbi.nlm.nih.gov/36897563/
1152,carvedilol,35661713,Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.,"['Villanueva C', 'Torres F', 'Sarin SK', 'Shah HA', 'Tripathi D', 'Brujats A', 'Rodrigues SG', 'Bhardwaj A', 'Azam Z', 'Hayes PC', 'Jindal A', 'Abid S', 'Alvarado E', 'Bosch J']","['Adrenergic beta-Antagonists/therapeutic use', 'Ascites/complications', 'Carvedilol/therapeutic use', '*Esophageal and Gastric Varices/complications/prevention & control', 'Humans', '*Hypertension, Portal/complications/drug therapy', 'Liver Cirrhosis/complications/drug therapy', 'Portal Pressure', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/35661713/
1153,carvedilol,11356434,Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.,['Dargie HJ'],"['Adrenergic beta-Antagonists/administration & dosage/*therapeutic use', 'Adult', 'Aged', 'Aged, 80 and over', 'Carbazoles/administration & dosage/*therapeutic use', 'Carvedilol', 'Drug Administration Schedule', 'Endpoint Determination', 'Female', 'Humans', 'Male', 'Middle Aged', 'Myocardial Infarction/complications/*drug therapy/mortality', 'Propanolamines/administration & dosage/*therapeutic use', 'Treatment Outcome', 'Ventricular Dysfunction, Left/*complications']",https://pubmed.ncbi.nlm.nih.gov/11356434/
1154,carvedilol,32094236,BRASH syndrome.,"['Srivastava S', 'Kemnic T', 'Hildebrandt KR']","['Antihypertensive Agents/adverse effects', '*Atrioventricular Block', '*Bradycardia', 'Bumetanide/adverse effects', 'Carvedilol/adverse effects', 'Female', 'Humans', '*Hyperkalemia', 'Metolazone/adverse effects', 'Middle Aged', '*Renal Insufficiency', '*Shock', 'Syndrome', 'Vasoconstrictor Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32094236/
1155,carvedilol,30372514,"Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.","['Zacharias AP', 'Jeyaraj R', 'Hobolth L', 'Bendtsen F', 'Gluud LL', 'Morgan MY']","['Adrenergic beta-Antagonists/adverse effects/*therapeutic use', 'Adult', 'Carvedilol/adverse effects/*therapeutic use', 'Esophageal and Gastric Varices/complications/*drug therapy/mortality', 'Gastrointestinal Hemorrhage/mortality/*prevention & control', 'Humans', 'Liver Cirrhosis/complications/*drug therapy/mortality', 'Nadolol/adverse effects/*therapeutic use', 'Primary Prevention', 'Propranolol/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Secondary Prevention']",https://pubmed.ncbi.nlm.nih.gov/30372514/
1156,carvedilol,30372864,Carvedilol attenuates liver fibrosis by suppressing autophagy and promoting apoptosis in hepatic stellate cells.,"['Meng D', 'Li Z', 'Wang G', 'Ling L', 'Wu Y', 'Zhang C']","['Antioxidants/pharmacology/*therapeutic use', 'Apoptosis/*drug effects/physiology', 'Autophagy/*drug effects/physiology', 'Carvedilol/pharmacology/*therapeutic use', 'Cell Line', 'Dose-Response Relationship, Drug', 'Hepatic Stellate Cells/*drug effects/metabolism', 'Humans', 'Liver Cirrhosis/*drug therapy/metabolism/pathology']",https://pubmed.ncbi.nlm.nih.gov/30372864/
1157,carvedilol,35842118,Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis.,"['Jachs M', 'Hartl L', 'Simbrunner B', 'Bauer D', 'Paternostro R', 'Balcar L', 'Hofer B', 'Pfisterer N', 'Schwarz M', 'Scheiner B', 'Stattermayer AF', 'Pinter M', 'Trauner M', 'Mandorfer M', 'Reiberger T']","['Humans', 'Propranolol/therapeutic use', 'Carvedilol/therapeutic use', '*Esophageal and Gastric Varices/complications', 'Retrospective Studies', 'Gastrointestinal Hemorrhage/prevention & control/etiology', 'Adrenergic beta-Antagonists/therapeutic use', 'Hemodynamics', 'Liver Cirrhosis/complications', '*Varicose Veins/complications']",https://pubmed.ncbi.nlm.nih.gov/35842118/
1158,carvedilol,30153268,Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.,"['Watanabe H', 'Ozasa N', 'Morimoto T', 'Shiomi H', 'Bingyuan B', 'Suwa S', 'Nakagawa Y', 'Izumi C', 'Kadota K', 'Ikeguchi S', 'Hibi K', 'Furukawa Y', 'Kaji S', 'Suzuki T', 'Akao M', 'Inada T', 'Hayashi Y', 'Nanasato M', 'Okutsu M', 'Kametani R', 'Sone T', 'Sugimura Y', 'Kawai K', 'Abe M', 'Kaneko H', 'Nakamura S', 'Kimura T']","['Aged', 'Carvedilol/*therapeutic use', 'Combined Modality Therapy', 'Female', 'Humans', 'Male', 'Middle Aged', '*Percutaneous Coronary Intervention', 'ST Elevation Myocardial Infarction/*drug therapy/*surgery', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30153268/
1159,carvedilol,37850394,Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-beta-Blocking R-Enantiomer Carvedilol.,"['Seo K', 'Yamamoto Y', 'Kirillova A', 'Kawana M', 'Yadav S', 'Huang Y', 'Wang Q', 'Lane KV', 'Pruitt BL', 'Perez MV', 'Bernstein D', 'Wu JC', 'Wheeler MT', 'Parikh VN', 'Ashley EA']","['Humans', 'Mice', 'Animals', 'Carvedilol/pharmacology/therapeutic use', '*Metoprolol/therapeutic use', 'Ryanodine Receptor Calcium Release Channel/metabolism', '*Cardiomyopathy, Hypertrophic/complications/drug therapy', 'Arrhythmias, Cardiac/drug therapy/metabolism', 'Adrenergic beta-Antagonists/pharmacology/therapeutic use', 'Myocytes, Cardiac/metabolism', 'Verapamil/therapeutic use', 'Receptors, Adrenergic/metabolism']",https://pubmed.ncbi.nlm.nih.gov/37850394/
1160,carvedilol,20206876,Cocaine and beta-blockers: the paradigm.,['Damodaran S'],"['Acute Coronary Syndrome/chemically induced/drug therapy', 'Adrenergic beta-Antagonists/pharmacology/*therapeutic use', 'Brain/drug effects', 'Carbazoles/pharmacology/therapeutic use', 'Cardiovascular System/drug effects', 'Carvedilol', 'Cocaine/*adverse effects/antagonists & inhibitors', 'Cocaine-Related Disorders/complications', 'Humans', 'Propanolamines/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20206876/
1161,carvedilol,33243993,beta-arrestin 2 as an activator of cGAS-STING signaling and target of viral immune evasion.,"['Zhang Y', 'Li M', 'Li L', 'Qian G', 'Wang Y', 'Chen Z', 'Liu J', 'Fang C', 'Huang F', 'Guo D', 'Zou Q', 'Chu Y', 'Yan D']","['Animals', 'Carvedilol/*pharmacology/therapeutic use', 'Disease Models, Animal', 'Drug Repositioning', 'HEK293 Cells', 'Herpesvirus 1, Human/immunology', 'Humans', 'Immune Evasion/drug effects/*immunology', 'Interferon-beta/metabolism', 'Macrophages, Peritoneal/immunology/metabolism', 'Male', 'Membrane Proteins/*metabolism', 'Mice', 'Nucleotidyltransferases/*metabolism', 'Primary Cell Culture', 'Proteolysis/drug effects', 'RAW 264.7 Cells', 'RNA-Seq', 'Sendai virus/immunology', 'Signal Transduction/drug effects/immunology', 'Vesiculovirus/immunology', 'Virus Diseases/drug therapy/*immunology/virology', 'beta-Arrestin 2/agonists/genetics/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/33243993/
1162,carvedilol,39067870,Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the 'CAVARLY TRIAL'.,"['Tevethia HV', 'Pande A', 'Vijayaraghavan R', 'Kumar G', 'Sarin SK']","['Humans', '*Esophageal and Gastric Varices/etiology', '*Carvedilol/therapeutic use', 'Male', 'Female', 'Ligation/methods', 'Middle Aged', '*Gastrointestinal Hemorrhage/prevention & control/etiology', '*Liver Cirrhosis/complications', 'Prospective Studies', '*Adrenergic beta-Antagonists/therapeutic use', 'Combined Modality Therapy', '*Propanolamines/therapeutic use', 'Carbazoles/therapeutic use', 'Treatment Outcome', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/39067870/
1163,carvedilol,17686376,The vasodilatory beta-blockers.,"['Pedersen ME', 'Cockcroft JR']","['Adrenergic beta-Antagonists/adverse effects/*pharmacology/*therapeutic use', 'Antihypertensive Agents/pharmacology/therapeutic use', 'Antioxidants/pharmacology/therapeutic use', 'Atenolol/pharmacology/therapeutic use', 'Benzopyrans/pharmacology/therapeutic use', 'Blood Pressure/drug effects', 'Carbazoles/pharmacology/therapeutic use', 'Cardiac Output/drug effects', 'Cardiovascular Diseases/physiopathology/prevention & control', 'Carvedilol', 'Endothelium, Vascular/*drug effects', 'Ethanolamines/pharmacology/therapeutic use', 'Hemodynamics/*drug effects', 'Humans', 'Labetalol/pharmacology/therapeutic use', 'Nebivolol', 'Propanolamines/pharmacology/therapeutic use', 'Vascular Resistance/drug effects', 'Vasodilation/*drug effects', 'Ventricular Function, Left/drug effects']",https://pubmed.ncbi.nlm.nih.gov/17686376/
1164,carvedilol,30673046,Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers.,"['Barbosa RR', 'Bourguignon TB', 'Torres LD', 'Arruda LS', 'Jacques TM', 'Serpa RG', 'Calil OA', 'Barbosa LFM']","['Adrenergic beta-Antagonists/*pharmacology/therapeutic use', 'Adult', 'Anthracyclines/*adverse effects', 'Cardiotonic Agents/*pharmacology/therapeutic use', 'Cardiotoxicity/prevention & control', 'Carvedilol/pharmacology/therapeutic use', 'Heart Diseases/*chemically induced/*prevention & control', 'Humans', 'Reproducibility of Results', 'Stroke Volume']",https://pubmed.ncbi.nlm.nih.gov/30673046/
1165,carvedilol,38432893,Successful Management of a Pregnant Patient with Danon Cardiomyopathy.,"['Inoue W', 'Motoki H', 'Yoshie K', 'Kuwahara K']","['Female', 'Pregnancy', 'Humans', 'Adult', 'Cesarean Section', '*Cardiomyopathies/complications/drug therapy', '*Heart Failure/drug therapy/etiology', 'Carvedilol/therapeutic use', '*Ventricular Dysfunction, Left']",https://pubmed.ncbi.nlm.nih.gov/38432893/
1166,carvedilol,37746692,"Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.","['Henriksen PA', 'Hall P', 'MacPherson IR', 'Joshi SS', 'Singh T', 'Maclean M', 'Lewis S', 'Rodriguez A', 'Fletcher A', 'Everett RJ', 'Stavert H', 'Broom A', 'Eddie L', 'Primrose L', 'McVicars H', 'McKay P', 'Borley A', 'Rowntree C', 'Lord S', 'Collins G', 'Radford J', 'Guppy A', 'Williams MC', 'Japp A', 'Payne JR', 'Newby DE', 'Mills NL', 'Oikonomidou O', 'Lang NN']","['Humans', 'Female', 'Middle Aged', 'Male', '*Anthracyclines/adverse effects', 'Troponin I', 'Stroke Volume', 'Carvedilol/therapeutic use', 'Cardiotoxicity/etiology', 'Ventricular Function, Left', 'Prospective Studies', 'Antibiotics, Antineoplastic/pharmacology', '*Breast Neoplasms/drug therapy', 'Adrenergic beta-Antagonists/therapeutic use/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/37746692/
1167,carvedilol,18488879,Carvedilol in the treatment of elderly patients with chronic heart failure.,"['Witte KK', 'Clark AL']","['Adrenergic beta-Antagonists/administration & dosage/pharmacology/*therapeutic use', 'Aged', 'Angiotensin-Converting Enzyme Inhibitors/pharmacology/therapeutic use', 'Arrhythmias, Cardiac/prevention & control', 'Carbazoles/pharmacology/*therapeutic use', 'Carvedilol', 'Chronic Disease', 'Comorbidity', 'Digoxin/pharmacology/therapeutic use', 'Heart Failure/drug therapy/epidemiology/*prevention & control', 'Humans', 'Propanolamines/pharmacology/*therapeutic use', 'Ventricular Dysfunction, Left/epidemiology', 'Ventricular Remodeling/drug effects']",https://pubmed.ncbi.nlm.nih.gov/18488879/
1168,carvedilol,36402762,How Carvedilol activates beta(2)-adrenoceptors.,"['Benkel T', 'Zimmermann M', 'Zeiner J', 'Bravo S', 'Merten N', 'Lim VJY', 'Matthees ESF', 'Drube J', 'Miess-Tanneberg E', 'Malan D', 'Szpakowska M', 'Monteleone S', 'Grimes J', 'Koszegi Z', 'Lanoiselee Y', ""O'Brien S"", 'Pavlaki N', 'Dobberstein N', 'Inoue A', 'Nikolaev V', 'Calebiro D', 'Chevigne A', 'Sasse P', 'Schulz S', 'Hoffmann C', 'Kolb P', 'Waldhoer M', 'Simon K', 'Gomeza J', 'Kostenis E']","['Humans', 'Carvedilol/pharmacology', '*Adrenergic beta-Antagonists/pharmacology', 'Receptors, Adrenergic, beta-2/genetics', '*Myocardial Infarction/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36402762/
1169,carvedilol,15144930,beta-Blockers in hypertension: is carvedilol different?,"['Messerli FH', 'Grossman E']","['Adrenergic beta-Antagonists/*pharmacology', 'Antihypertensive Agents/*pharmacology', 'Carbazoles/*pharmacology', 'Carvedilol', 'Hemodynamics/drug effects', 'Humans', 'Hypertension/*drug therapy', 'Propanolamines/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/15144930/
1170,rabeprazole,36142643,Proton Pump Inhibitors and Bone Health: An Update Narrative Review.,"['Lespessailles E', 'Toumi H']","['2-Pyridinylmethylsulfinylbenzimidazoles', 'Adenosine Triphosphatases', 'Antacids', 'Bone Density', 'Dexlansoprazole', 'Esomeprazole', 'Humans', 'Lansoprazole', 'Omeprazole/pharmacology', '*Osteoporotic Fractures/drug therapy', 'Pantoprazole', '*Proton Pump Inhibitors/adverse effects', 'Rabeprazole', 'United States']",https://pubmed.ncbi.nlm.nih.gov/36142643/
1171,rabeprazole,32711578,"Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.","['Ochoa D', 'Roman M', 'Cabaleiro T', 'Saiz-Rodriguez M', 'Mejia G', 'Abad-Santos F']","['Adult', 'Anti-Ulcer Agents/blood/*pharmacokinetics', 'Cross-Over Studies', 'Cytochrome P-450 CYP2C19/genetics', 'Dietary Fats/*administration & dosage', 'Fasting/metabolism', 'Female', '*Food-Drug Interactions', 'Genotype', 'Humans', 'Male', 'Omeprazole/blood/*pharmacokinetics', 'Pantoprazole/blood/*pharmacokinetics', 'Proton Pump Inhibitors/blood/*pharmacokinetics', 'Rabeprazole/blood/*pharmacokinetics', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32711578/
1172,rabeprazole,27782887,"Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastric pH in extensive metabolizer patients with gastroesophageal reflux disease.","['Celebi A', 'Aydin D', 'Kocaman O', 'Konduk BT', 'Senturk O', 'Hulagu S']","['2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/pharmacology', 'Adult', 'Cross-Over Studies', 'Cytochrome P-450 CYP2C19/*metabolism', 'Double-Blind Method', 'Esomeprazole/administration & dosage/pharmacology', 'Female', 'Gastric Acid/*chemistry', 'Gastroesophageal Reflux/*drug therapy/genetics', 'Genotype', 'Humans', 'Hydrogen-Ion Concentration/*drug effects', 'Lansoprazole/administration & dosage/pharmacology', 'Male', 'Middle Aged', 'Pantoprazole', 'Proton Pump Inhibitors/administration & dosage/*pharmacology', 'Rabeprazole/administration & dosage/pharmacology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27782887/
1173,rabeprazole,28294690,Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview.,"['Dash RP', 'Rais R', 'Srinivas NR']","['Animals', 'Drug Interactions', 'Gastroesophageal Reflux/*drug therapy/*metabolism', 'Humans', 'Peptic Ulcer/*drug therapy/*metabolism', 'Proton Pump Inhibitors/*pharmacokinetics/therapeutic use', 'Rabeprazole/*pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28294690/
1174,rabeprazole,9506245,Rabeprazole.,"['Prakash A', 'Faulds D']","['2-Pyridinylmethylsulfinylbenzimidazoles', 'Anti-Ulcer Agents/pharmacokinetics/*therapeutic use', 'Benzimidazoles/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Enzyme Inhibitors/pharmacokinetics/*therapeutic use', 'Helicobacter Infections/*drug therapy', 'Humans', 'Omeprazole/analogs & derivatives', 'Peptic Ulcer/*drug therapy', '*Proton Pump Inhibitors', 'Rabeprazole']",https://pubmed.ncbi.nlm.nih.gov/9506245/
1175,rabeprazole,23111465,Do proton pump inhibitors protect against cancer progression in GERD?,"['Miyashita T', 'Shah FA', 'Harmon JW', 'Marti GP', 'Matsui D', 'Okamoto K', 'Makino I', 'Hayashi H', 'Oyama K', 'Nakagawara H', 'Tajima H', 'Fujita H', 'Takamura H', 'Murakami M', 'Ninomiya I', 'Kitagawa H', 'Fushida S', 'Fujimura T', 'Ohta T']","['Adenocarcinoma/etiology/*prevention & control', 'Animals', 'Anti-Inflammatory Agents', '*Antineoplastic Agents', 'Antioxidants', 'Barrett Esophagus/complications/drug therapy', '*Disease Progression', 'Esophageal Neoplasms/etiology/*prevention & control', 'Gastroesophageal Reflux/*complications/drug therapy', 'Humans', 'Immunologic Factors', 'Lansoprazole', 'Neutrophils/immunology', 'Omeprazole', 'Proton Pump Inhibitors/adverse effects/*pharmacology/*therapeutic use', 'Rabeprazole']",https://pubmed.ncbi.nlm.nih.gov/23111465/
1176,rabeprazole,36657136,Efficacy and safety comparative study of dexrabeprazole vs. esomeprazole for the treatment of gastroesophageal reflux disease.,"['Abdo-Francis JM', 'Cabrera-Alvarez G', 'Martinez-Torres H', 'Remes-Troche JM']","['Humans', '*Esomeprazole/adverse effects', 'Rabeprazole/therapeutic use', 'Prospective Studies', 'Treatment Outcome', '*Gastroesophageal Reflux/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36657136/
1177,rabeprazole,26193978,Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.,"['Sakurai Y', 'Mori Y', 'Okamoto H', 'Nishimura A', 'Komura E', 'Araki T', 'Shiramoto M']","['Adult', 'Cross-Over Studies', 'Esomeprazole/administration & dosage/adverse effects/*therapeutic use', 'Gastric Acid', 'Humans', 'Hydrogen-Ion Concentration', 'Male', 'Middle Aged', 'Proton Pump Inhibitors/*therapeutic use', 'Pyrroles/administration & dosage/adverse effects/*therapeutic use', 'Rabeprazole/administration & dosage/adverse effects/*therapeutic use', 'Research Design', 'Sulfonamides/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26193978/
1178,rabeprazole,12152963,Proton pump inhibitors: an update.,"['Vanderhoff BT', 'Tahboub RM']","['2-Pyridinylmethylsulfinylbenzimidazoles', 'Benzimidazoles/pharmacokinetics/pharmacology/therapeutic use', 'Drug Interactions', 'Esomeprazole', 'Gastroesophageal Reflux/*drug therapy', 'Humans', 'Lansoprazole', 'Omeprazole/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Pantoprazole', 'Peptic Ulcer/drug therapy', '*Proton Pump Inhibitors', 'Rabeprazole', 'Sulfoxides/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12152963/
1179,rabeprazole,38454589,Fixed drug combination (levosulpiride and rabeprazole)-induced atypical Parkinsonian's disorders with associated anxiety and low-lying depression.,"['Tandon VR', 'Ismail SH', 'Singh A']","['Humans', '*Tremor/chemically induced', 'Rabeprazole/adverse effects', '*Depression/chemically induced/drug therapy', 'Anxiety', 'Drug Combinations', 'Sulpiride/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/38454589/
1180,rabeprazole,14680443,Review of rabeprazole in the treatment of gastro-oesophageal reflux disease.,['Thjodleifsson B'],"['2-Pyridinylmethylsulfinylbenzimidazoles', 'Anti-Ulcer Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Benzimidazoles/adverse effects/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Cost-Benefit Analysis', 'Drug Interactions', 'Gastric Acid/metabolism', 'Gastroesophageal Reflux/*drug therapy', 'Humans', 'Omeprazole/analogs & derivatives', '*Proton Pump Inhibitors', 'Rabeprazole']",https://pubmed.ncbi.nlm.nih.gov/14680443/
1181,rabeprazole,39188111,Efficacy and safety of tegoprazan- and rabeprazole-based concomitant therapies for Helicobacter pylori infection: Real-world evidence.,"['Jung BW', 'Park CH', 'Jung YS']","['*Helicobacter Infections/drug therapy', '*Rabeprazole/administration & dosage/adverse effects', 'Humans', '*Helicobacter pylori/drug effects', 'Male', 'Female', 'Retrospective Studies', 'Middle Aged', '*Drug Therapy, Combination', 'Treatment Outcome', '*Proton Pump Inhibitors/administration & dosage/adverse effects', '*Sulfonamides/administration & dosage/adverse effects', 'Aged', 'Adult', 'Anti-Bacterial Agents/administration & dosage/adverse effects', 'Pyrroles']",https://pubmed.ncbi.nlm.nih.gov/39188111/
1182,rabeprazole,32270780,Multiple widespread fixed drug eruption caused by rabeprazole.,"['Gupta S', 'Gupta S', 'Mahendra A', 'Yadav A']","['Adult', 'Adverse Drug Reaction Reporting Systems', 'Drug Eruptions/*diagnosis', 'Drug-Related Side Effects and Adverse Reactions/*diagnosis', 'Gastritis/diagnosis/*drug therapy', 'Humans', 'Male', 'Rabeprazole/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32270780/
1183,rabeprazole,21528060,Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy.,"['Sugimoto M', 'Nishino M', 'Kodaira C', 'Yamade M', 'Uotani T', 'Ikuma M', 'Umemura K', 'Furuta T']","['2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use', 'Adolescent', 'Adult', 'Anti-Ulcer Agents/therapeutic use', '*Drug Resistance', 'Gastroesophageal Reflux/diagnosis/*therapy', 'Humans', 'Hydrogen-Ion Concentration', 'Proton Pump Inhibitors/*therapeutic use', 'Rabeprazole', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/21528060/
1184,rabeprazole,18451374,Recognizing doxycycline-induced esophageal ulcers in dental practice: a case report and review.,"['Segelnick SL', 'Weinberg MA']","['2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use', 'Adult', 'Anti-Bacterial Agents/*adverse effects', 'Anti-Ulcer Agents/therapeutic use', 'Collagen', 'Diet Therapy', 'Doxycycline/*adverse effects', 'Esophageal Diseases/*chemically induced/diagnosis/therapy', 'Female', 'Gingival Recession/*surgery', 'Humans', 'Patient Education as Topic', 'Postoperative Care', 'Proton Pump Inhibitors/therapeutic use', 'Rabeprazole', 'Skin, Artificial', 'Ulcer/*chemically induced/diagnosis/therapy']",https://pubmed.ncbi.nlm.nih.gov/18451374/
1185,rabeprazole,25495411,"Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.","['Roman M', 'Ochoa D', 'Sanchez-Rojas SD', 'Talegon M', 'Prieto-Perez R', 'Rivas A', 'Abad-Santos F', 'Cabaleiro T']","['2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/*pharmacokinetics', 'Adult', 'Cytochrome P-450 CYP2C19/*genetics', 'Female', 'Genetic Association Studies', 'Genotype', 'Humans', 'Inactivation, Metabolic/genetics', 'Male', 'Omeprazole/administration & dosage/*pharmacokinetics', 'Pantoprazole', 'Polymorphism, Genetic', 'Rabeprazole/administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/25495411/
1186,rabeprazole,27299490,[Switching to a generic drugA blessing or a curse?].,"['Ebbelaar CF', 'Lammers HA', 'Schobben AF']","['2-Pyridinylmethylsulfinylbenzimidazoles/*therapeutic use', 'Anti-Ulcer Agents/*therapeutic use', 'Drugs, Generic/*therapeutic use', 'Esomeprazole/*therapeutic use', 'Humans', 'Pantoprazole', 'Rabeprazole/*therapeutic use', 'Treatment Outcome', 'Zollinger-Ellison Syndrome/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27299490/
1187,rabeprazole,27464849,Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers.,"['Kagawa T', 'Iwamuro M', 'Ishikawa S', 'Ishida M', 'Kuraoka S', 'Sasaki K', 'Sakakihara I', 'Izumikawa K', 'Yamamoto K', 'Takahashi S', 'Tanaka S', 'Matsuura M', 'Hasui T', 'Wato M', 'Inaba T']","['Adenoma/surgery', 'Aged', 'Aged, 80 and over', 'Endoscopic Mucosal Resection/*adverse effects', 'Female', 'Gastrointestinal Hemorrhage/etiology/*prevention & control', 'Humans', 'Male', 'Middle Aged', 'Postoperative Complications/*drug therapy', 'Proton Pump Inhibitors/*therapeutic use', 'Pyrroles/*therapeutic use', 'Rabeprazole/therapeutic use', 'Stomach Neoplasms/surgery', 'Stomach Ulcer/*drug therapy/*etiology', 'Sulfonamides/*therapeutic use', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/27464849/
1188,rabeprazole,25318791,Iron-deficiency anemia caused by a proton pump inhibitor.,"['Hashimoto R', 'Matsuda T', 'Chonan A']","['Anemia, Iron-Deficiency/*chemically induced', 'Famotidine/therapeutic use', 'Gastroesophageal Reflux/drug therapy', 'Humans', 'Male', 'Middle Aged', 'Proton Pump Inhibitors/*adverse effects/therapeutic use', 'Rabeprazole/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/25318791/
1189,rabeprazole,22081052,"Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.","['Tominaga K', 'Iwakiri R', 'Fujimoto K', 'Fujiwara Y', 'Tanaka M', 'Shimoyama Y', 'Umegaki E', 'Higuchi K', 'Kusano M', 'Arakawa T']","['2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/adverse effects/*therapeutic use', 'Adult', 'Aged', 'Aged, 80 and over', 'Body Mass Index', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Drugs, Chinese Herbal/administration & dosage/adverse effects/*therapeutic use', 'Female', 'Gastroesophageal Reflux/*drug therapy/physiopathology', 'Humans', 'Japan', 'Male', 'Middle Aged', 'Proton Pump Inhibitors/administration & dosage/adverse effects/*therapeutic use', 'Rabeprazole', 'Sex Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22081052/
1190,losartan,26051686,Losartan: Comprehensive Profile.,"['Al-Majed AR', 'Assiri E', 'Khalil NY', 'Abdel-Aziz HA']","['Angiotensin II Type 1 Receptor Blockers/*chemistry/pharmacokinetics/pharmacology', 'Animals', 'Antihypertensive Agents/*chemistry/pharmacokinetics/pharmacology', 'Blood Pressure/drug effects', 'Chemistry, Pharmaceutical', 'Drug Stability', 'Humans', 'Hypertension/drug therapy/physiopathology', 'Losartan/*chemistry/pharmacokinetics/pharmacology', 'Molecular Structure', 'Technology, Pharmaceutical/methods']",https://pubmed.ncbi.nlm.nih.gov/26051686/
1191,losartan,16029066,Clinical pharmacokinetics of losartan.,"['Sica DA', 'Gehr TW', 'Ghosh S']","['Angiotensin II Type 1 Receptor Blockers/adverse effects/*pharmacokinetics/pharmacology', 'Antihypertensive Agents/adverse effects/pharmacokinetics/pharmacology', 'Diabetic Nephropathies/prevention & control', 'Humans', 'Hypertension/drug therapy', 'Losartan/adverse effects/*pharmacokinetics/pharmacology', 'Prodrugs/adverse effects/*pharmacokinetics/pharmacology', 'Stroke/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/16029066/
1192,losartan,34580111,"Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma.","['Regan DP', 'Chow L', 'Das S', 'Haines L', 'Palmer E', 'Kurihara JN', 'Coy JW', 'Mathias A', 'Thamm DH', 'Gustafson DL', 'Dow SW']","['Animals', '*Bone Neoplasms/drug therapy/veterinary', '*Dog Diseases/drug therapy', 'Dogs', 'Humans', 'Leukocytes, Mononuclear', 'Losartan/pharmacology/therapeutic use', 'Mice', 'Monocytes', '*Osteosarcoma/drug therapy/veterinary']",https://pubmed.ncbi.nlm.nih.gov/34580111/
1193,losartan,10914449,Angiotensin receptor antagonists.,"['Wong W', 'Howes L']","['Angiotensin II/antagonists & inhibitors', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use', 'Antihypertensive Agents/adverse effects/pharmacology/*therapeutic use', 'Benzimidazoles/adverse effects/pharmacology/therapeutic use', 'Benzoates/adverse effects/pharmacology/therapeutic use', 'Biphenyl Compounds/adverse effects/pharmacology/therapeutic use', 'Humans', 'Hypertension/*drug therapy', 'Irbesartan', 'Losartan/adverse effects/pharmacology/therapeutic use', 'Telmisartan', 'Tetrazoles/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10914449/
1194,losartan,34831368,Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70.,"['Costantino VV', 'Gil Lorenzo AF', 'Bocanegra V', 'Valles PG']","['Animals', 'Epithelial-Mesenchymal Transition/drug effects', 'HSP70 Heat-Shock Proteins/*metabolism', 'Humans', 'Hypertension, Renal/*drug therapy', 'Kidney/drug effects/*pathology', 'Losartan/pharmacology/*therapeutic use', 'Nephritis/*drug therapy', 'Protective Agents/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34831368/
1195,losartan,31630573,Current Status of Angiotensin Receptor Blocker Recalls.,"['Gunasekaran PM', 'Chertow GM', 'Bhalla V', 'Byrd JB']","['Angiotensin Receptor Antagonists/pharmacology/*therapeutic use', 'Antihypertensive Agents/*adverse effects/therapeutic use', 'Carcinogens/*pharmacology', 'Drug Recalls/*legislation & jurisprudence/statistics & numerical data', 'Drug Utilization/statistics & numerical data', 'Female', 'Humans', 'Hypertension/diagnosis/*drug therapy', 'Losartan/*adverse effects/therapeutic use', 'Male', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/31630573/
1196,losartan,37965705,A Rare Case of Losartan-Induced Visceral Angioedema.,"['Rosas S', 'Fowler A', 'Stodgill E', 'Deyo-Svendsen M', 'Phillips M']","['Humans', '*Losartan/adverse effects', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects', 'Angiotensin Receptor Antagonists/therapeutic use', 'Renin-Angiotensin System', '*Angioedema/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37965705/
1197,losartan,32397766,A review of clinically significant drug-drug interactions involving angiotensin II receptor antagonists and antiepileptic drugs.,"['Rusek M', 'Czuczwar SJ']","['Angiotensin Receptor Antagonists/*administration & dosage/pharmacokinetics/pharmacology', 'Animals', 'Anticonvulsants/*administration & dosage/pharmacology', 'Drug Interactions', 'Humans', 'Losartan/administration & dosage/pharmacokinetics/pharmacology', 'Neuroprotective Agents/administration & dosage/pharmacokinetics/pharmacology', 'Renin-Angiotensin System/*drug effects', 'Seizures/drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/32397766/
1198,losartan,16050407,[Renin-angiotensin system in diabetic nephropathy].,['Luno J'],"['Albuminuria/diagnosis', 'Angiotensin II Type 1 Receptor Blockers/administration & dosage/therapeutic use', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage/therapeutic use', 'Animals', 'Antihypertensive Agents/administration & dosage/therapeutic use', 'Benzimidazoles/administration & dosage/therapeutic use', 'Benzoates/administration & dosage/therapeutic use', 'Blood Glucose/analysis', 'Diabetes Mellitus, Type 2/complications', 'Diabetic Nephropathies/blood/*physiopathology/*prevention & control', 'Disease Progression', 'Drug Therapy, Combination', 'Homeostasis', 'Humans', 'Lisinopril/administration & dosage/therapeutic use', 'Losartan/administration & dosage/therapeutic use', 'Meta-Analysis as Topic', 'Randomized Controlled Trials as Topic', 'Renin-Angiotensin System/*drug effects/physiology', 'Risk Factors', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/16050407/
1199,losartan,38573840,Topical Losartan for Treating Corneal Haze After Ultraviolet-A/Riboflavin Collagen Cross-Linking.,"['Rodgers EG', 'Al-Mohtaseb Z', 'Chen AJ']","['Humans', '*Losartan/administration & dosage/therapeutic use', 'Male', '*Riboflavin/therapeutic use', '*Collagen/metabolism', '*Cross-Linking Reagents', 'Young Adult', '*Corneal Opacity/drug therapy/etiology', '*Ultraviolet Rays', '*Photosensitizing Agents/therapeutic use', '*Visual Acuity', 'Keratoconus/drug therapy', 'Corneal Stroma/metabolism/drug effects', 'Angiotensin II Type 1 Receptor Blockers/therapeutic use/administration & dosage', 'Photochemotherapy/methods', 'Ophthalmic Solutions', 'Administration, Topical']",https://pubmed.ncbi.nlm.nih.gov/38573840/
1200,losartan,10772441,Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema.,"['Warner KK', 'Visconti JA', 'Tschampel MM']","['Angioedema/chemically induced/*drug therapy', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects', 'Humans', 'Losartan/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10772441/
1201,losartan,25271811,Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.,"['Rakugi H', 'Tsuchihashi T', 'Shimada K', 'Numaguchi H', 'Nishida C', 'Yamaguchi H', 'Shirakawa M', 'Azuma K', 'Fujita KP']","['Aged', '*Amlodipine/administration & dosage/adverse effects', 'Antihypertensive Agents/administration & dosage/adverse effects', 'Blood Pressure/*drug effects', 'Drug Combinations', 'Drug Monitoring/methods', 'Essential Hypertension', 'Female', 'Humans', '*Hydrochlorothiazide/administration & dosage/adverse effects', '*Hypertension/diagnosis/drug therapy/physiopathology', 'Japan', '*Losartan/administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25271811/
1202,losartan,23093500,Losartan-induced coronary artery spasm.,"['Josefsson J', 'Frobert O']","['Antihypertensive Agents/*adverse effects', 'Coronary Vasospasm/*chemically induced/complications', 'Coronary Vessels/*drug effects', 'Female', 'Humans', 'Losartan/*adverse effects', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/23093500/
1203,losartan,30092110,Potential Usefulness of Losartan as an Antifibrotic Agent and Adjunct to Platelet-Rich Plasma Therapy to Improve Muscle Healing and Cartilage Repair and Prevent Adhesion Formation.,"['Huard J', 'Bolia I', 'Briggs K', 'Utsunomiya H', 'Lowe WR', 'Philippon MJ']","['Animals', 'Antifibrinolytic Agents/*therapeutic use', 'Cartilage/drug effects', 'Disease Models, Animal', 'Fibrosis/drug therapy', 'Humans', 'Losartan/*therapeutic use', 'Muscle, Skeletal/drug effects', 'Orthopedic Procedures/adverse effects', '*Platelet-Rich Plasma', 'Postoperative Complications/prevention & control', 'Tissue Adhesions/*prevention & control', 'Transforming Growth Factor beta/*antagonists & inhibitors', 'Transforming Growth Factor beta1', 'Wound Healing']",https://pubmed.ncbi.nlm.nih.gov/30092110/
1204,losartan,19092813,Inhibition of the renin-angiotensin system: is more better?,"['Anderson S', 'Komers R']","['Angiotensin II Type 1 Receptor Blockers/therapeutic use', 'Animals', 'Diabetic Nephropathies/*drug therapy', 'Dose-Response Relationship, Drug', 'Humans', 'Kidney Glomerulus/pathology', 'Losartan/administration & dosage/therapeutic use', 'Proteinuria/drug therapy', 'Rats', 'Renin-Angiotensin System/*drug effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/19092813/
1205,losartan,10423107,Angiotensin II receptor antagonists and hypertension.,"['Mimran A', 'Ribstein J', 'DuCailar G']","['Angiotensin II/antagonists & inhibitors', '*Angiotensin Receptor Antagonists', 'Antihypertensive Agents/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Female', 'Heart/drug effects', 'Humans', 'Hydrochlorothiazide/pharmacokinetics/pharmacology', 'Hypertension/*drug therapy', 'Kidney Diseases/drug therapy', 'Losartan/pharmacokinetics/pharmacology', 'Male', 'Vascular Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/10423107/
1206,losartan,39325643,Effects of Losartan on Patients Hospitalized for Acute COVID-19: A Randomized Controlled Trial.,"['Tran KC', 'Asfar P', 'Cheng M', 'Demiselle J', 'Singer J', 'Lee T', 'Sweet D', 'Boyd J', 'Walley K', 'Haljan G', 'Sharif O', 'Geri G', 'Auchabie J', 'Quenot JP', 'Lee TC', 'Tsang J', 'Meziani F', 'Lamontagne F', 'Dubee V', 'Lasocki S', 'Ovakim D', 'Wood G', 'Turgeon A', 'Cohen Y', 'Lebas E', 'Goudelin M', 'Forrest D', 'Teale A', 'Mira JP', 'Fowler R', 'Daneman N', 'Adhikari NKJ', 'Gousseff M', 'Leroy P', 'Plantefeve G', 'Rispal P', 'Courtois R', 'Winston B', 'Reynolds S', 'Birks P', 'Bienvenu B', 'Tadie JM', 'Talarmin JP', 'Ansart S', 'Russell JA']","['Humans', '*Losartan/therapeutic use/adverse effects/administration & dosage', 'Male', 'Female', 'Aged', 'Middle Aged', '*Hospitalization', '*COVID-19/mortality', '*COVID-19 Drug Treatment', 'France/epidemiology', 'Hospital Mortality', 'SARS-CoV-2/drug effects', 'Canada/epidemiology', 'Aged, 80 and over', 'Treatment Outcome', 'Hypotension/chemically induced', 'Angiotensin II Type 1 Receptor Blockers/therapeutic use/adverse effects/administration & dosage', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/39325643/
1207,losartan,23250713,Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.,"['Caletti MG', 'Balestracci A', 'Missoni M', 'Vezzani C']","['Angiotensin II Type 1 Receptor Blockers/adverse effects/therapeutic use', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use', 'Child', 'Child, Preschool', 'Diarrhea/complications/diagnosis/*drug therapy', 'Drug Therapy, Combination', 'Enalapril/adverse effects/*therapeutic use', 'Female', 'Hemolytic-Uremic Syndrome/complications/diagnosis/*drug therapy', 'Humans', 'Infant', 'Losartan/adverse effects/*therapeutic use', 'Male', 'Proteinuria/diagnosis/*drug therapy/etiology', 'Retrospective Studies', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23250713/
1208,losartan,11888349,Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema?,"['Howes LG', 'Tran D']","['Angioedema/*chemically induced', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/*adverse effects/therapeutic use', 'Antihypertensive Agents/adverse effects/*therapeutic use', 'Benzimidazoles/adverse effects/therapeutic use', 'Benzoates/adverse effects/therapeutic use', 'Biphenyl Compounds/adverse effects/therapeutic use', 'Blood Pressure/*drug effects', 'Humans', 'Irbesartan', 'Losartan/adverse effects/therapeutic use', 'Telmisartan', 'Tetrazoles/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11888349/
1209,losartan,36586717,The effects of losartan or angiotensin II receptor antagonists on cartilage: a systematic review.,"['Yamaura K', 'Nelson AL', 'Nishimura H', 'Rutledge JC', 'Ravuri SK', 'Bahney C', 'Philippon MJ', 'Huard J']","['Animals', 'Humans', 'Angiotensin II Type 2 Receptor Blockers', 'Angiotensin Receptor Antagonists', 'Cartilage', '*Losartan/pharmacology/therapeutic use', '*Osteoarthritis']",https://pubmed.ncbi.nlm.nih.gov/36586717/
1210,cimetidine,6312110,Ranitidine.,['Strum WB'],"['Aged', 'Animals', 'Chemical Phenomena', 'Chemistry', 'Cimetidine/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Duodenal Ulcer/drug therapy', 'Humans', 'Male', 'Mice', 'Ranitidine/adverse effects/metabolism/*therapeutic use', 'Rats', 'Stomach Ulcer/drug therapy', 'Zollinger-Ellison Syndrome/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6312110/
1211,cimetidine,86721,Cimetidine and gastric cancer.,"['Elder JB', 'Ganguli PC', 'Gillespie IE']","['Adenocarcinoma/*chemically induced', 'Adult', 'Aged', 'Cimetidine/*adverse effects/analogs & derivatives/metabolism/therapeutic use', 'Female', 'Guanidines/*adverse effects', 'Humans', 'Male', 'Middle Aged', 'Nitroso Compounds/metabolism', 'Peptic Ulcer/drug therapy', 'Stomach Neoplasms/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/86721/
1212,cimetidine,6375965,Cimetidine for stress-ulcer prophylaxis.,"['Greene WL', 'Bollinger RR']","['Antacids/adverse effects/therapeutic use', 'Cimetidine/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Gastric Juice/drug effects/metabolism', 'Gastric Mucosa/drug effects/metabolism', 'Humans', 'Peptic Ulcer/physiopathology/*prevention & control', 'Random Allocation', 'Stress, Physiological/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/6375965/
1213,cimetidine,2874464,Actions of cimetidine and ranitidine at some cholinergic sites: implications in toxicology and anesthesia.,"['Gwee MC', 'Cheah LS']","['*Anesthesia', 'Animals', 'Antihypertensive Agents/adverse effects', 'Bradycardia/chemically induced', 'Cholinesterase Inhibitors/pharmacology', 'Cimetidine/*adverse effects/pharmacology/therapeutic use', 'Confusion/chemically induced', 'Cytochrome P-450 Enzyme System/pharmacology', 'Diarrhea/chemically induced', 'Drug Interactions', 'Erectile Dysfunction/chemically induced', 'Ganglionic Blockers/pharmacology', 'Hemodynamics/drug effects', 'Humans', 'Male', 'Mixed Function Oxygenases/antagonists & inhibitors', 'Neuromuscular Blocking Agents/pharmacology', 'Peptic Ulcer/drug therapy', 'Ranitidine/*adverse effects/pharmacology/therapeutic use', 'Receptors, Cholinergic/*drug effects/physiology', 'Receptors, Histamine H2/drug effects', 'Zollinger-Ellison Syndrome/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2874464/
1214,cimetidine,11243017,[About paracetamol again].,"['Hazai E', 'Monostory K', 'Bakos A', 'Zacher G', 'Vereczkey L']","['Acetaminophen/administration & dosage/*adverse effects/pharmacokinetics', 'Acetylcysteine/therapeutic use', 'Analgesics, Non-Narcotic/administration & dosage/*adverse effects/pharmacokinetics', 'Antidotes/therapeutic use', 'Cimetidine/therapeutic use', 'Drug Overdose', 'Humans', 'Liver/*drug effects', 'Liver Failure, Acute/*chemically induced/drug therapy/metabolism/prevention & control/*therapy']",https://pubmed.ncbi.nlm.nih.gov/11243017/
1215,cimetidine,6733633,Cimetidine-induced fever.,"['Landolfo K', 'Low DE', 'Rogers AG']","['Administration, Oral', 'Aged', 'Cimetidine/administration & dosage/*adverse effects', 'Duodenal Ulcer/drug therapy', 'Female', 'Fever/*chemically induced', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/6733633/
1216,cimetidine,620916,Safety of cimetidine.,"['Kruss DM', 'Littman A']","['Aspartate Aminotransferases/blood', 'Cimetidine/*adverse effects/pharmacology/therapeutic use', 'Creatinine/blood', 'Drug Interactions', 'Guanidines/*adverse effects', 'Humans', 'Liver/enzymology', 'Risk', 'Substance Withdrawal Syndrome']",https://pubmed.ncbi.nlm.nih.gov/620916/
1217,cimetidine,7751419,Clinical aspects of cardiovascular effects of H2-receptor antagonists.,"['Hinrichsen H', 'Halabi A', 'Kirch W']","['Animals', 'Atrioventricular Node/drug effects', 'Blood Pressure/drug effects', 'Bradycardia/chemically induced', 'Cardiovascular System/*drug effects', 'Cimetidine/adverse effects/pharmacology', 'Electrocardiography/drug effects', 'Heart Rate/drug effects', 'Hemodynamics/drug effects', 'Histamine H2 Antagonists/chemistry/*pharmacology', 'Humans', 'Ranitidine/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/7751419/
1218,cimetidine,6146287,Medical management of gastric ulcer.,['LaBrooy SJ'],"['Aged', 'Animals', 'Antacids/*therapeutic use', 'Carbenoxolone/administration & dosage/*therapeutic use', 'Cimetidine/administration & dosage/therapeutic use', 'Clinical Trials as Topic', 'Dogs', 'Double-Blind Method', 'Gastric Acid/metabolism', 'Glycyrrhetinic Acid/*analogs & derivatives', 'Histamine H2 Antagonists/*therapeutic use', 'Humans', 'Ranitidine/therapeutic use', 'Recurrence', 'Stomach Ulcer/*drug therapy/etiology/metabolism']",https://pubmed.ncbi.nlm.nih.gov/6146287/
1219,cimetidine,387498,"Clinical effects of trithiozine, a newer gastric anti-secretory agent.",['Pellegrini R'],"['Anti-Ulcer Agents/administration & dosage/adverse effects/*therapeutic use', 'Cimetidine/therapeutic use', 'Clinical Trials as Topic', 'Depression, Chemical', 'Double-Blind Method', 'Gastric Juice/*metabolism', 'Humans', 'Morpholines/administration & dosage/adverse effects/*therapeutic use', 'Peptic Ulcer/*drug therapy', 'Placebos', 'Propantheline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/387498/
1220,cimetidine,6990675,Cimetidine in the prevention of acid aspiration during anesthesia.,"['Kirkegaard P', 'Sorensen O', 'Kirkegaard P']","['Adult', 'Anesthesia, General/*adverse effects', 'Anesthesia, Inhalation/adverse effects', 'Cimetidine/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Gastric Juice/analysis/drug effects', 'Guanidines/*therapeutic use', 'Humans', 'Hydrogen-Ion Concentration', 'Middle Aged', 'Placebos', 'Pneumonia, Aspiration/*prevention & control', 'Premedication', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/6990675/
1221,cimetidine,388168,Cimetidine and gastric ulcer healing: a double-blind controlled trial.,"['Landecker KD', 'Crawford J', 'Hunt JH', 'Gillespie P', 'Piper DW']","['Chronic Disease', 'Cimetidine/administration & dosage/*therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Guanidines/*therapeutic use', 'Humans', 'Male', 'Outpatients', 'Random Allocation', 'Stomach Ulcer/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/388168/
1222,cimetidine,4057034,"Cimetidine as pre-anesthetic agent for cesarean section: perinatal effects on the infant, the placental transfer of cimetidine and its elimination in the infants.","['Qvist N', 'Storm K', 'Holmskov A']","['*Cesarean Section', 'Cimetidine/adverse effects/*blood/therapeutic use', 'Double-Blind Method', 'Female', 'Humans', '*Infant, Newborn', '*Maternal-Fetal Exchange', '*Preanesthetic Medication', 'Pregnancy', 'Prospective Studies', 'Umbilical Veins']",https://pubmed.ncbi.nlm.nih.gov/4057034/
1223,cimetidine,2979221,Review: post-marketing surveillance of the safety of cimetidine--the problems of data interpretation.,"['Jones DG', 'Langman MJ', 'Lawson DH', 'Vessey MP']","['Adult', 'Cimetidine/*adverse effects/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', '*Product Surveillance, Postmarketing', 'Safety']",https://pubmed.ncbi.nlm.nih.gov/2979221/
1224,cimetidine,1289197,[Cimetidine hepatitis].,"['Zaidenstein R', 'Cohen N', 'Golik A']","['Acute Disease', 'Adult', 'Arthritis, Rheumatoid/complications', 'Chemical and Drug Induced Liver Injury/*etiology', 'Cimetidine/*adverse effects/therapeutic use', 'Duodenal Ulcer/complications/drug therapy', 'Humans', 'Male']",https://pubmed.ncbi.nlm.nih.gov/1289197/
1225,cimetidine,2271376,The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man.,"['Coleman MD', 'Scott AK', 'Breckenridge AM', 'Park BK']","['Adult', 'Cimetidine/administration & dosage/*pharmacology', 'Dapsone/administration & dosage/*metabolism/pharmacokinetics', 'Humans', 'Hydroxylation/drug effects', 'Male', 'Methemoglobinemia/blood']",https://pubmed.ncbi.nlm.nih.gov/2271376/
1226,cimetidine,3570585,Treatment of female androgenetic alopecia with cimetidine.,['Aram H'],"['Adult', 'Alopecia/*drug therapy/etiology', 'Androgen Antagonists/therapeutic use', 'Androgens/physiology', 'Cimetidine/administration & dosage/pharmacology/*therapeutic use', 'Drug Evaluation', 'Female', 'Follow-Up Studies', 'Humans', 'Middle Aged', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3570585/
1227,cimetidine,8844752,Treatment of molluscum contagiosum with oral cimetidine: clinical experience in 13 patients.,"['Dohil M', 'Prendiville JS']","['Administration, Oral', 'Child', 'Child, Preschool', 'Cimetidine/administration & dosage/*therapeutic use', 'Facial Dermatoses/drug therapy/virology', 'Female', 'Histamine H2 Antagonists/administration & dosage/*therapeutic use', 'Humans', 'Immunocompetence', 'Infant', 'Male', 'Molluscum Contagiosum/*drug therapy', 'Remission Induction', 'Treatment Refusal']",https://pubmed.ncbi.nlm.nih.gov/8844752/
1228,cimetidine,2277761,Ascorbic acid prevents cimetidine-induced decrease of serum hydrocortisone concentrations.,"['Boidin MP', 'Stuurman A', 'Erdmann W']","['Abdomen/surgery', 'Aged', 'Ascorbic Acid/*pharmacology', 'Cimetidine/*adverse effects/therapeutic use', 'Humans', 'Hydrocortisone/*blood', 'Middle Aged', 'Prospective Studies', 'Vascular Surgical Procedures']",https://pubmed.ncbi.nlm.nih.gov/2277761/
1229,cimetidine,3859910,The risk of gastric dysplasia in medical long-term treatment of peptic ulcer disease.,"['Di Mario F', 'Farinati F', 'Cardin F']","['Adult', 'Aged', 'Anti-Ulcer Agents/administration & dosage/*adverse effects', 'Benzodiazepinones/administration & dosage/adverse effects', 'Cimetidine/administration & dosage/adverse effects', 'Female', 'Humans', 'Male', 'Middle Aged', 'Peptic Ulcer/*drug therapy', 'Pirenzepine', 'Ranitidine/administration & dosage/adverse effects', 'Risk', 'Stomach/*drug effects/pathology', 'Stomach Neoplasms/*chemically induced', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3859910/
1230,ketoconazole,2546775,New antifungal agents.,['Graybill JR'],"['*Aminoglycosides', 'Anti-Bacterial Agents/therapeutic use', 'Antifungal Agents/pharmacology/*therapeutic use', 'Azoles/therapeutic use', 'Echinocandins', 'Fluconazole', 'Fungi/*drug effects', 'Humans', 'Itraconazole', 'Ketoconazole/analogs & derivatives/therapeutic use', 'Mycoses/*drug therapy', 'Peptides/therapeutic use', '*Peptides, Cyclic', 'Triazoles/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2546775/
1231,ketoconazole,18038701,The role of ketoconazole in seborrheic dermatitis.,"['Borgers M', 'Degreef H']","['Administration, Topical', 'Antifungal Agents/administration & dosage/*pharmacology', 'Dermatitis, Seborrheic/*drug therapy/microbiology', 'Dermatomycoses/complications/*drug therapy', 'Gels', 'Humans', 'Ketoconazole/administration & dosage/*pharmacology', '*Malassezia']",https://pubmed.ncbi.nlm.nih.gov/18038701/
1232,ketoconazole,12956199,The use of oral antifungal agents to treat onychomycosis.,"['Gupta AK', 'Ryder JE']","['Administration, Oral', 'Antifungal Agents/administration & dosage/*therapeutic use', 'Drug Interactions', 'Fluconazole/administration & dosage/adverse effects/therapeutic use', 'Griseofulvin/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Itraconazole/administration & dosage/adverse effects/therapeutic use', 'Ketoconazole/administration & dosage/adverse effects/therapeutic use', 'Naphthalenes/administration & dosage/adverse effects/therapeutic use', 'Onychomycosis/diagnosis/*drug therapy/microbiology/pathology', 'Terbinafine']",https://pubmed.ncbi.nlm.nih.gov/12956199/
1233,ketoconazole,2170472,Itraconazole in tinea versicolor: a review.,['Delescluse J'],"['Antifungal Agents/adverse effects/*therapeutic use', 'Humans', 'Itraconazole', 'Ketoconazole/adverse effects/*analogs & derivatives/therapeutic use', 'Tinea Versicolor/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2170472/
1234,ketoconazole,19454093,Seborrhoeic dermatitis.,"['Manriquez JJ', 'Uribe P']","['Administration, Oral', 'Administration, Topical', '*Dermatitis, Seborrheic/drug therapy', 'Face', 'Humans', '*Ketoconazole/administration & dosage', 'Lithium/therapeutic use', 'Malassezia', 'Remission Induction', 'Scalp Dermatoses']",https://pubmed.ncbi.nlm.nih.gov/19454093/
1235,ketoconazole,2172333,Treatment of chromoblastomycosis.,"['Tuffanelli L', 'Milburn PB']","['Antifungal Agents/administration & dosage/*therapeutic use', 'Chromoblastomycosis/*drug therapy', 'Drug Administration Schedule', 'Humans', 'Itraconazole', 'Ketoconazole/administration & dosage/*analogs & derivatives/therapeutic use', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/2172333/
1236,ketoconazole,1918469,"Tinea versicolor: epidemiologic, clinical, and therapeutic aspects.","['Borelli D', 'Jacobs PH', 'Nall L']","['Adult', 'Diagnosis, Differential', 'Female', 'Humans', 'Ketoconazole/administration & dosage/adverse effects/pharmacology', 'Male', 'Recurrence', 'Terminology as Topic', '*Tinea Versicolor/drug therapy/epidemiology/etiology']",https://pubmed.ncbi.nlm.nih.gov/1918469/
1237,ketoconazole,18793935,Medical treatments for male and female pattern hair loss.,"['Rogers NE', 'Avram MR']","['Adult', 'Alopecia/*therapy', 'Androgen Antagonists/pharmacology/therapeutic use', 'Azasteroids/pharmacology/therapeutic use', 'Drug Therapy, Combination', 'Dutasteride', 'Female', 'Finasteride/therapeutic use', 'Hair/transplantation', 'Humans', 'Hyperhidrosis/chemically induced', 'Ketoconazole/therapeutic use', 'Male', 'Minoxidil/adverse effects/pharmacology/therapeutic use', 'Phototherapy', 'Prostate/drug effects', 'Sperm Count', 'Tretinoin/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/18793935/
1238,ketoconazole,4062088,Ketoconazole therapy for endemic blastomycosis.,"['Bradsher RW', 'Rice DC', 'Abernathy RS']","['Adult', 'Aged', 'Blastomycosis/*drug therapy', 'Endocrine System Diseases/chemically induced', 'Female', 'Humans', 'Ketoconazole/adverse effects/blood/*therapeutic use', 'Lung Diseases, Fungal/drug therapy', 'Male', 'Middle Aged', 'Nausea/chemically induced', 'Pneumonia/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/4062088/
1239,ketoconazole,2161523,The triazole antifungal agents: a review of itraconazole and fluconazole.,"['Bailey EM', 'Krakovsky DJ', 'Rybak MJ']","['Antifungal Agents/adverse effects/*pharmacokinetics/pharmacology', 'Aspergillus/drug effects', 'Candida albicans/drug effects', 'Chemical Phenomena', 'Chemistry', 'Clinical Trials as Topic', 'Cryptococcus neoformans/drug effects', 'Fluconazole/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Half-Life', 'Humans', 'Itraconazole', 'Ketoconazole/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Metabolic Clearance Rate']",https://pubmed.ncbi.nlm.nih.gov/2161523/
1240,ketoconazole,2670371,Systemic candidiasis.,['Ray TL'],"['Amphotericin B/administration & dosage/therapeutic use', '*Candidiasis/drug therapy/epidemiology/microbiology', 'Flucytosine/therapeutic use', 'Humans', 'Immune Tolerance', 'Ketoconazole/adverse effects/therapeutic use', 'Neoplasms/complications/drug therapy', 'Opportunistic Infections/drug therapy/epidemiology/microbiology', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/2670371/
1241,ketoconazole,29360892,Long-term pubic dermatitis diagnosed as white piedra.,['Landero J'],"['Administration, Topical', 'Antifungal Agents/administration & dosage/*therapeutic use', 'Dermatitis/*diagnosis', 'Dermoscopy/methods', 'Groin', 'Hair', 'Humans', 'Ketoconazole/administration & dosage/*therapeutic use', 'Male', 'Middle Aged', 'Piedra/*diagnosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/29360892/
1242,ketoconazole,2170477,Itraconazole treatment of phaeohyphomycosis.,"['Sharkey PK', 'Graybill JR', 'Rinaldi MG', 'Stevens DA', 'Tucker RM', 'Peterie JD', 'Hoeprich PD', 'Greer DL', 'Frenkel L', 'Counts GW', 'et al.']","['Adult', 'Aged', 'Antifungal Agents/adverse effects/*therapeutic use', 'Child', 'Child, Preschool', 'Drug Administration Schedule', 'Female', 'Humans', 'Itraconazole', 'Ketoconazole/adverse effects/*analogs & derivatives/therapeutic use', 'Male', 'Microbial Sensitivity Tests', 'Middle Aged', 'Mycoses/*drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/2170477/
1243,ketoconazole,2670368,Coccidioidomycosis.,['Hobbs ER'],"['Adult', 'Age Factors', 'Amphotericin B/administration & dosage/adverse effects/therapeutic use', 'Arizona', 'Biopsy', 'Child', 'Child, Preschool', '*Coccidioidomycosis/diagnosis/drug therapy/epidemiology/microbiology', 'Dermatomycoses/pathology', 'Female', 'Humans', 'Immune Tolerance', 'Ketoconazole/administration & dosage/adverse effects/therapeutic use', 'Male', 'Pregnancy', 'Serologic Tests', 'Sex Factors', 'Skin Tests/methods']",https://pubmed.ncbi.nlm.nih.gov/2670368/
1244,ketoconazole,1926909,Ketoconazole in the treatment of pityriasis versicolor: international review of clinical trials.,"['Goodless DR', 'Ramos-Caro FA', 'Flowers FP']","['Humans', 'Ketoconazole/adverse effects/*therapeutic use', 'Tinea Versicolor/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1926909/
1245,ketoconazole,11218451,Antimycotic agents in oral candidosis: an overview: 2. Treatment of oral candidosis.,"['Ellepola AN', 'Samaranayake LP']","['Amphotericin B/administration & dosage/therapeutic use', 'Antifungal Agents/administration & dosage/adverse effects/classification/*therapeutic use', 'Candida/drug effects/growth & development/pathogenicity', 'Candidiasis, Oral/*drug therapy', 'Clotrimazole/administration & dosage/therapeutic use', 'Drug Interactions', 'Drug Resistance, Microbial', 'Fluconazole/administration & dosage/therapeutic use', 'Humans', 'Itraconazole/administration & dosage/therapeutic use', 'Ketoconazole/administration & dosage/therapeutic use', 'Miconazole/administration & dosage/therapeutic use', 'Nystatin/administration & dosage/therapeutic use', 'Virulence/drug effects']",https://pubmed.ncbi.nlm.nih.gov/11218451/
1246,ketoconazole,1653679,Itraconazole in the treatment of coccidioidomycosis.,"['Diaz M', 'Puente R', 'de Hoyos LA', 'Cruz S']","['Adult', 'Antifungal Agents/adverse effects/*therapeutic use', 'Coccidioidomycosis/*drug therapy', 'Female', 'Humans', 'Itraconazole', 'Ketoconazole/adverse effects/*analogs & derivatives/therapeutic use', 'Lung Diseases, Fungal/*drug therapy', 'Male', 'Prospective Studies', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/1653679/
1247,ketoconazole,8362113,[Value of ketoconazole in the treatment of Cushing disease].,"['Pascal V', 'Denet S', 'Weryha G', 'Kaminski P', 'Leclere J', 'Hartemann P']","['Adult', 'Aged', 'Cushing Syndrome/*drug therapy', 'Drug Resistance', 'Female', 'Humans', 'Ketoconazole/adverse effects/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/8362113/
1248,ketoconazole,32981763,The myringoplasty of the perforation with otomycosis.,['Lou Z'],"['Antifungal Agents/*administration & dosage', 'Ear Cartilage/surgery', 'Endoscopy/*methods', 'Humans', 'Intraoperative Care', 'Ketoconazole/*administration & dosage/adverse effects', 'Myringoplasty/*methods', 'Otomycosis/*drug therapy/*surgery', 'Tympanic Membrane Perforation/*surgery']",https://pubmed.ncbi.nlm.nih.gov/32981763/
1249,ketoconazole,2846299,Treatment of systemic fungal infections: recent progress and current problems.,"['Walsh TJ', 'Pizzo A']","['Amphotericin B/adverse effects/pharmacokinetics/therapeutic use', 'Antifungal Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Chemical Phenomena', 'Chemistry', 'Fluconazole', 'Flucytosine/adverse effects/pharmacokinetics/therapeutic use', 'Humans', 'Itraconazole', 'Ketoconazole/adverse effects/analogs & derivatives/pharmacokinetics/therapeutic use', 'Miconazole/adverse effects/pharmacokinetics/therapeutic use', 'Mycoses/*drug therapy', 'Triazoles/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2846299/
1250,rizatriptan,18223456,Triptans in pregnancy.,"['Soldin OP', 'Dahlin J', ""O'Mara DM""]","['Animals', 'Female', 'Humans', 'Migraine Disorders/*drug therapy', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Pregnancy Outcome', '*Prenatal Exposure Delayed Effects', 'Serotonin Receptor Agonists/*adverse effects', 'Tryptamines/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/18223456/
1251,rizatriptan,25877672,Acute Migraine Treatment in Adults.,['Becker WJ'],"['Adult', 'Analgesics, Opioid/administration & dosage', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage', 'Caffeine/administration & dosage', 'Dihydroergotamine/administration & dosage', 'Drug Administration Schedule', 'Female', 'Humans', 'Male', 'Migraine Disorders/*diagnosis/*drug therapy', 'Pain Management/*methods', 'Serotonin Receptor Agonists/administration & dosage', 'Treatment Outcome', 'Tryptamines/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/25877672/
1252,rizatriptan,27910087,Menstrual Migraine and Treatment Options: Review.,"['Maasumi K', 'Tepper SJ', 'Kriegler JS']","['Female', 'Humans', 'Menstruation/drug effects/physiology', 'Migraine Disorders/*drug therapy/physiopathology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/27910087/
1253,rizatriptan,34633423,Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis.,"['Yang CP', 'Liang CS', 'Chang CM', 'Yang CC', 'Shih PH', 'Yau YC', 'Tang KT', 'Wang SJ']","['Adult', 'Female', 'Humans', 'Male', 'Migraine Disorders/*drug therapy/physiopathology', 'Tryptamines/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34633423/
1254,rizatriptan,26178694,Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.,"['Cameron C', 'Kelly S', 'Hsieh SC', 'Murphy M', 'Chen L', 'Kotb A', 'Peterson J', 'Coyle D', 'Skidmore B', 'Gomes T', 'Clifford T', 'Wells G']","['Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Drug Administration Schedule', 'Humans', 'Migraine Disorders/diagnosis/*drug therapy/*epidemiology', 'Oxazolidinones/therapeutic use', 'Randomized Controlled Trials as Topic/methods', 'Serotonin 5-HT1 Receptor Agonists/therapeutic use', 'Treatment Outcome', 'Tryptamines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26178694/
1255,rizatriptan,25600718,The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies.,"['Marmura MJ', 'Silberstein SD', 'Schwedt TJ']","['Adult', 'Anti-Inflammatory Agents/*therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Serotonin Receptor Agonists/*therapeutic use', 'Societies, Medical/standards/statistics & numerical data']",https://pubmed.ncbi.nlm.nih.gov/25600718/
1256,rizatriptan,28782480,Recent Progress in Biological Activities of Indole and Indole Alkaloids.,"['Singh TP', 'Singh OM']","['Analgesics/chemistry/pharmacology', 'Animals', 'Anti-Infective Agents/chemistry/pharmacology', 'Anti-Inflammatory Agents, Non-Steroidal/chemistry/pharmacology', 'Antihypertensive Agents/chemistry/pharmacology', 'Antimalarials/chemistry/pharmacology', 'Antineoplastic Agents/chemistry/pharmacology', 'Biological Products/chemistry/*pharmacology', 'Enzyme Inhibitors/chemistry/pharmacology', 'Humans', 'Indoles/chemistry/*pharmacology', 'Tubulin Modulators/chemistry/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/28782480/
1257,rizatriptan,20367203,Efficacy and tolerability of rizatriptan 10 mg compared with sumatriptan 100 mg: an evidence-based analysis.,['Gobel H'],"['Double-Blind Method', 'Evidence-Based Medicine', 'Humans', 'Meta-Analysis as Topic', 'Migraine Disorders/*drug therapy', 'Patient Preference', 'Randomized Controlled Trials as Topic', 'Serotonin Receptor Agonists/*therapeutic use', 'Sumatriptan/*therapeutic use', 'Triazoles/*therapeutic use', 'Tryptamines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20367203/
1258,rizatriptan,28258578,Aquaporin-Targeted Therapeutics: State-of-the-Field.,"['Tradtrantip L', 'Jin BJ', 'Yao X', 'Anderson MO', 'Verkman AS']","['Animals', 'Aquaporin 4/*antagonists & inhibitors/genetics/metabolism', 'Biological Transport', 'Brain Edema/*drug therapy/genetics/metabolism/pathology', 'Gene Expression Regulation', 'Humans', 'Molecular Targeted Therapy', 'Neuromyelitis Optica/*drug therapy/genetics/metabolism/pathology', 'Osmolar Concentration', 'Osmotic Pressure', 'Protein Isoforms/antagonists & inhibitors/genetics/metabolism', 'Sumatriptan/pharmacology', 'Thiadiazoles/*pharmacology', 'Triazoles/pharmacology', 'Tryptamines/pharmacology', 'Water/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/28258578/
1259,rizatriptan,39293828,Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis.,"['Karlsson WK', 'Ostinelli EG', 'Zhuang ZA', 'Kokoti L', 'Christensen RH', 'Al-Khazali HM', 'Deligianni CI', 'Tomlinson A', 'Ashina H', 'Ruiz de la Torre E', 'Diener HC', 'Cipriani A', 'Ashina M']","['Adult', 'Humans', '*Migraine Disorders/diagnosis/drug therapy', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'Tryptamines/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39293828/
1260,rizatriptan,19126376,Clinical aspects of perimenstrual headaches.,['Taylor FR'],"['Female', 'Headache/diagnosis/*etiology/*therapy', 'Humans', 'Migraine without Aura/diagnosis/etiology/therapy', 'Premenstrual Syndrome/*complications/diagnosis/*therapy', 'Randomized Controlled Trials as Topic/methods']",https://pubmed.ncbi.nlm.nih.gov/19126376/
1261,rizatriptan,16162083,Rizatriptan in migraine.,"['Krymchantowski AV', 'Bigal ME']","['Dose-Response Relationship, Drug', 'Drug Tolerance', 'Drug-Related Side Effects and Adverse Reactions', 'Expert Testimony', 'Humans', 'Meta-Analysis as Topic', 'Migraine Disorders/*drug therapy', 'Serotonin Receptor Agonists/chemistry/metabolism/pharmacology/*therapeutic use', 'Triazoles/chemistry/metabolism/pharmacology/*therapeutic use', 'Tryptamines/chemistry/metabolism/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16162083/
1262,rizatriptan,11089513,Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan.,"['Goadsby PJ', 'Hargreaves RJ']","['Humans', 'Migraine Disorders/*drug therapy/*physiopathology', 'Serotonin Receptor Agonists/pharmacology/*therapeutic use', 'Triazoles/pharmacology/*therapeutic use', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/11089513/
1263,rizatriptan,19161563,Ten years of rizatriptan: from development to clinical science and future directions.,"['Hargreaves RJ', 'Lines CR', 'Rapoport AM', 'Ho TW', 'Sheftell FD']","['Animals', 'Drug Design', 'Drug Evaluation/trends', 'Drug Therapy/trends', 'History, 20th Century', 'History, 21st Century', 'Humans', 'Migraine Disorders/*drug therapy/history', 'Randomized Controlled Trials as Topic', '*Serotonin Receptor Agonists/history/pharmacology/therapeutic use', '*Triazoles/history/pharmacology/therapeutic use', '*Tryptamines/history/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19161563/
1264,rizatriptan,10463349,Antimigraine drugs.,"['Diener HC', 'Kaube H', 'Limmroth V']","['Analgesics/*therapeutic use', 'Antiemetics/*therapeutic use', 'Ergotamine/*therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Serotonin Receptor Agonists/therapeutic use', 'Vasoconstrictor Agents/*therapeutic use', 'Vomiting/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/10463349/
1265,rizatriptan,26252584,Acute Migraine Treatment.,['Becker WJ'],"['Acute Disease', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Dihydroergotamine/*therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Tryptamines/*therapeutic use', 'Vasoconstrictor Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26252584/
1266,rizatriptan,11206864,Evidence-based analysis of a migraine treatment drug comparison trial.,"['Gawel M', 'Wiebe S']","['Adult', '*Clinical Trials as Topic', '*Evidence-Based Medicine', 'Female', 'Humans', 'Migraine Disorders/*drug therapy', 'Sumatriptan/administration & dosage', 'Triazoles/administration & dosage', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/11206864/
1267,rizatriptan,12117355,Mechanisms of action of the 5-HT1B/1D receptor agonists.,"['Tepper SJ', 'Rapoport AM', 'Sheftell FD']","['Carbazoles/pharmacology', 'Humans', 'Indoles/pharmacology', 'Migraine Disorders/*drug therapy/*metabolism', 'Oxazolidinones/pharmacology', 'Piperidines/pharmacology', 'Pyrrolidines/pharmacology', 'Receptor, Serotonin, 5-HT1B', 'Receptor, Serotonin, 5-HT1D', 'Receptors, Serotonin/*drug effects', 'Serotonin Receptor Agonists/*pharmacology', 'Sumatriptan/pharmacology', 'Triazoles/pharmacology', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/12117355/
1268,rizatriptan,21437713,"Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register.",['Tfelt-Hansen PC'],"['*Double-Blind Method', 'Germany', 'Humans', 'Migraine Disorders/*drug therapy', 'Piperidines/*therapeutic use', '*Randomized Controlled Trials as Topic', 'Registries', 'Serotonin 5-HT1 Receptor Agonists/*therapeutic use', 'Tryptamines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21437713/
1269,rizatriptan,31389059,Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect.,"['Tfelt-Hansen P', 'Messlinger K']","['Administration, Oral', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacokinetics', 'Arteries/drug effects/innervation', 'Calcitonin Gene-Related Peptide Receptor Antagonists/administration & dosage/*pharmacokinetics', 'Humans', 'Migraine Disorders/*drug therapy/physiopathology', 'Nociception/drug effects/physiology', '*Randomized Controlled Trials as Topic', 'Serotonin 5-HT1 Receptor Agonists/administration & dosage/*pharmacokinetics', 'Thalamus/drug effects/physiopathology', 'Time Factors', 'Treatment Outcome', 'Trigeminal Ganglion/drug effects/physiopathology', 'Vasoconstriction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/31389059/
1270,citalopram,17375980,The clinical pharmacokinetics of escitalopram.,['Rao N'],"['Adolescent', 'Adult', 'Age Factors', 'Aged', 'Anxiety Disorders/*drug therapy', 'Child', 'Citalopram/administration & dosage/*pharmacokinetics', 'Depression/*drug therapy', 'Drug Interactions', 'Humans', 'Liver Diseases', 'Renal Insufficiency', 'Selective Serotonin Reuptake Inhibitors/administration & dosage/*pharmacokinetics', 'Sex Factors']",https://pubmed.ncbi.nlm.nih.gov/17375980/
1271,citalopram,38950403,Medication-Induced Weight Change Across Common Antidepressant Treatments : A Target Trial Emulation Study.,"['Petimar J', 'Young JG', 'Yu H', 'Rifas-Shiman SL', 'Daley MF', 'Heerman WJ', 'Janicke DM', 'Jones WS', 'Lewis KH', 'Lin PD', 'Prentice C', 'Merriman JW', 'Toh S', 'Block JP']","['Humans', '*Antidepressive Agents/therapeutic use/adverse effects', 'Female', 'Male', '*Weight Gain/drug effects', 'Middle Aged', 'Adult', 'Bupropion/therapeutic use/adverse effects', 'Citalopram/therapeutic use/adverse effects', 'Duloxetine Hydrochloride/therapeutic use/adverse effects', 'Aged']",https://pubmed.ncbi.nlm.nih.gov/38950403/
1272,citalopram,24424469,"A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?","['Sanchez C', 'Reines EH', 'Montgomery SA']","['Allosteric Site', 'Animals', 'Antidepressive Agents, Second-Generation/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Citalopram/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Depression/drug therapy/metabolism', 'Depressive Disorder, Major/drug therapy/metabolism', 'Drug Interactions', '*Evidence-Based Medicine', 'Humans', '*Models, Biological', 'Nerve Tissue Proteins/antagonists & inhibitors/chemistry/metabolism', 'Paroxetine/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Serotonin Plasma Membrane Transport Proteins/chemistry/metabolism', 'Selective Serotonin Reuptake Inhibitors/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Sertraline/adverse effects/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24424469/
1273,citalopram,39382900,Mindfulness Meditation vs Escitalopram for Treatment of Anxiety Disorders: Secondary Analysis of a Randomized Clinical Trial.,"['Hu H', 'Mete M', 'Rustgi NK', 'Washington CI', 'Sanghavi K', 'Dutton MA', 'Simon NM', 'Baker AW', 'Bui E', 'Hoge EA']","['Humans', '*Mindfulness/methods', '*Anxiety Disorders/drug therapy/therapy', 'Female', 'Male', 'Adult', '*Meditation/methods', '*Escitalopram/therapeutic use', 'Middle Aged', 'Treatment Outcome', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Citalopram/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39382900/
1274,citalopram,38520045,Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.,"['Erritzoe D', 'Barba T', 'Spriggs MJ', 'Rosas FE', 'Nutt DJ', 'Carhart-Harris R']","['Humans', '*Psilocybin/administration & dosage/pharmacology/adverse effects', '*Depressive Disorder, Major/drug therapy', 'Adult', 'Male', '*Selective Serotonin Reuptake Inhibitors/administration & dosage/adverse effects/pharmacology', 'Female', '*Hallucinogens/administration & dosage/adverse effects/pharmacology', '*Escitalopram/administration & dosage/pharmacology', 'Middle Aged', 'Treatment Outcome', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/38520045/
1275,citalopram,24625921,The non-antidepressant effects of citalopram: a clinician's perspective.,"['Richter T', 'Paluch Z', 'Alusik S']","['Citalopram/administration & dosage/adverse effects/*pharmacology', 'Humans', 'Hyponatremia/*chemically induced', 'Osteoporosis/*chemically induced', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/*pharmacology', 'Romano-Ward Syndrome/*chemically induced', 'Serotonin Antagonists/administration & dosage/adverse effects/*pharmacology', 'Serotonin Syndrome/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/24625921/
1276,citalopram,11336616,Citalopram: a comprehensive review.,['Pollock BG'],"['Alcoholism/drug therapy', 'Antidepressive Agents, Second-Generation/*therapeutic use', 'Anxiety Disorders/drug therapy', 'Citalopram/adverse effects/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Dementia/drug therapy', 'Depression/drug therapy', 'Drug Interactions', 'Female', 'Humans', 'Premenstrual Syndrome/drug therapy', 'Selective Serotonin Reuptake Inhibitors/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11336616/
1277,citalopram,38001423,Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis.,"['Yin J', 'Song X', 'Wang C', 'Lin X', 'Miao M']","['Humans', '*Depressive Disorder, Major/drug therapy', 'Escitalopram', 'Citalopram/therapeutic use', 'Antidepressive Agents/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38001423/
1278,citalopram,39533789,[Expectancies and SSRI treatment of social anxiety disorder].,"['Wahlstedt K', 'Furmark T']","['Humans', '*Selective Serotonin Reuptake Inhibitors/therapeutic use/pharmacology', '*Phobia, Social/drug therapy', 'Treatment Outcome', 'Escitalopram/therapeutic use/pharmacology', 'Cognitive Behavioral Therapy', 'Citalopram/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39533789/
1279,citalopram,34743319,"Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.","['Becker AM', 'Holze F', 'Grandinetti T', 'Klaiber A', 'Toedtli VE', 'Kolaczynska KE', 'Duthaler U', 'Varghese N', 'Eckert A', 'Grunblatt E', 'Liechti ME']","['Antidepressive Agents/adverse effects', '*Brain-Derived Neurotrophic Factor/genetics', 'Citalopram/adverse effects', 'Cross-Over Studies', 'Double-Blind Method', '*Escitalopram', 'Healthy Volunteers', 'Humans', 'Psilocybin/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/34743319/
1280,citalopram,38851804,Modulation of serotonin transporter expression by escitalopram under inflammation.,"['Mena S', 'Cruikshank A', 'Best J', 'Nijhout HF', 'Reed MC', 'Hashemi P']","['*Serotonin Plasma Membrane Transport Proteins/metabolism', 'Animals', '*Selective Serotonin Reuptake Inhibitors/pharmacology', 'Mice', '*Inflammation/drug therapy/metabolism', '*Escitalopram/pharmacology', 'Hippocampus/metabolism/drug effects', 'Serotonin/metabolism', 'Humans', 'Citalopram/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/38851804/
1281,citalopram,18345966,Escitalopram in the treatment of obsessive-compulsive disorder.,['Zohar J'],"['Citalopram/adverse effects/*therapeutic use', 'Clinical Trials, Phase III as Topic', 'Double-Blind Method', 'Drug Approval', 'Humans', 'Obsessive-Compulsive Disorder/diagnosis/*drug therapy/psychology', 'Randomized Controlled Trials as Topic', 'Secondary Prevention', 'Selective Serotonin Reuptake Inhibitors/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18345966/
1282,citalopram,15045034,Escitalopram.,"['Aronson S', 'Delgado P']","['Antidepressive Agents, Second-Generation/adverse effects/pharmacokinetics/*therapeutic use', 'Citalopram/adverse effects/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Depressive Disorder, Major/*drug therapy', 'Humans', 'Selective Serotonin Reuptake Inhibitors/adverse effects/pharmacokinetics/*therapeutic use', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/15045034/
1283,citalopram,39163659,A large-scale observational comparison of antidepressants and their effects.,"['Heinz MV', 'Yom-Tov E', 'Mackin DM', 'Matsumura R', 'Jacobson NC']","['Humans', '*Selective Serotonin Reuptake Inhibitors/adverse effects/pharmacology', '*Fluvoxamine/adverse effects/pharmacology', '*Citalopram/adverse effects', 'Male', 'Adult', 'Female', 'Antidepressive Agents/adverse effects', 'Fluoxetine/adverse effects', 'Proportional Hazards Models', 'Paroxetine/adverse effects', 'Escitalopram/pharmacology/administration & dosage', 'Sertraline/adverse effects', 'Depression/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/39163659/
1284,citalopram,38326352,"Functional brain responses to emotional faces after three to five weeks of intake of escitalopram in healthy individuals: a double-blind, placebo-controlled randomised study.","['Armand S', 'Langley C', 'Johansen A', 'Ozenne B', 'Overgaard-Hansen O', 'Larsen K', 'Jensen PS', 'Knudsen GM', 'Sahakian BJ', 'Stenbaek DS', 'Fisher PM']","['Humans', '*Escitalopram', '*Citalopram/therapeutic use', 'Emotions/physiology', 'Selective Serotonin Reuptake Inhibitors/pharmacology', 'Brain/diagnostic imaging', 'Magnetic Resonance Imaging', 'Double-Blind Method', 'Facial Expression']",https://pubmed.ncbi.nlm.nih.gov/38326352/
1285,citalopram,32112511,Escitalopram for recurrent isolated sleep paralysis.,"['Hintze JP', 'Gault D']","['Adult', 'Citalopram/pharmacology/*therapeutic use', 'Female', 'Humans', 'Male', 'Selective Serotonin Reuptake Inhibitors/pharmacology/*therapeutic use', 'Sleep Paralysis/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32112511/
1286,citalopram,12474611,Escitalopram: efficacy and tolerability in the treatment of depression.,['Baldwin DS'],"['Antidepressive Agents, Second-Generation/adverse effects/*therapeutic use', 'Anxiety Disorders/drug therapy', 'Citalopram/adverse effects/*therapeutic use', 'Depressive Disorder/*drug therapy', 'Humans', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12474611/
1287,citalopram,17934195,Serotonergic anti-depressants and ethanol withdrawal syndrome: a review.,['Uzbay IT'],"['Alcohol Drinking/adverse effects/psychology', 'Animals', 'Antidepressive Agents/*therapeutic use', 'Citalopram/therapeutic use', 'Ethanol/administration & dosage/*adverse effects', 'Fluoxetine/therapeutic use', 'Humans', 'Hypericum', 'Motor Activity/drug effects', 'Plant Extracts/therapeutic use', 'Rats', 'Rats, Wistar', 'Serotonin Agents/*therapeutic use', 'Serotonin Antagonists/therapeutic use', 'Substance Withdrawal Syndrome/*drug therapy/*metabolism/psychology']",https://pubmed.ncbi.nlm.nih.gov/17934195/
1288,citalopram,38536761,Perspectives on the impact of vortioxetine on the treatment armamentarium of major depressive disorder.,"['Cuomo A', 'Barilla G', 'Cattolico M', 'Pardossi S', 'Mariantoni E', 'Koukouna D', 'Carmellini P', 'Fagiolini A']","['Antidepressive Agents/administration & dosage/therapeutic use', 'Anxiety/complications', 'Cognitive Dysfunction/complications/drug therapy', '*Depressive Disorder, Major/complications/drug therapy/psychology', 'Emotions/drug effects', 'Escitalopram/administration & dosage/therapeutic use', 'Post-Acute COVID-19 Syndrome/complications', 'Precision Medicine', 'Selective Serotonin Reuptake Inhibitors/administration & dosage/therapeutic use', 'Serotonin/metabolism', '*Vortioxetine/administration & dosage/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Humans', 'Neurotransmitter Agents/metabolism', 'Animals']",https://pubmed.ncbi.nlm.nih.gov/38536761/
1289,citalopram,38247730,Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.,"['Szigeti B', 'Weiss B', 'Rosas FE', 'Erritzoe D', 'Nutt D', 'Carhart-Harris R']","['Humans', '*Psilocybin/pharmacology/administration & dosage/therapeutic use', 'Male', 'Adult', 'Female', '*Depressive Disorder, Major/drug therapy', '*Suggestion', 'Double-Blind Method', 'Middle Aged', '*Escitalopram/pharmacology', 'Hallucinogens/pharmacology/administration & dosage', 'Anticipation, Psychological/drug effects', 'Treatment Outcome', 'Citalopram/therapeutic use/pharmacology/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38247730/
1290,ibuprofen,391117,Ibuprofen.,['Kantor TG'],"['Analgesics', 'Anti-Inflammatory Agents', 'Arthritis/drug therapy', 'Digestive System/drug effects', 'Drug Interactions', 'Humans', 'Ibuprofen/administration & dosage/adverse effects/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/391117/
1291,ibuprofen,36477458,Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.,"['Hundscheid T', 'Onland W', 'Kooi EMW', 'Vijlbrief DC', 'de Vries WB', 'Dijkman KP', 'van Kaam AH', 'Villamor E', 'Kroon AA', 'Visser R', 'Mulder-de Tollenaer SM', 'De Bisschop B', 'Dijk PH', 'Avino D', 'Hocq C', 'Zecic A', 'Meeus M', 'de Baat T', 'Derriks F', 'Henriksen TB', 'Kyng KJ', 'Donders R', 'Nuytemans DHGM', 'Van Overmeire B', 'Mulder AL', 'de Boode WP']","['Humans', 'Infant', 'Infant, Newborn', '*Bronchopulmonary Dysplasia/etiology', '*Ductus Arteriosus, Patent/diagnostic imaging/drug therapy/mortality/therapy', 'Echocardiography', '*Enterocolitis, Necrotizing/etiology', '*Ibuprofen/administration & dosage/adverse effects/therapeutic use', 'Indomethacin/adverse effects/therapeutic use', 'Infant, Extremely Premature', 'Infant, Low Birth Weight', 'Infant, Newborn, Diseases/drug therapy/therapy', '*Watchful Waiting']",https://pubmed.ncbi.nlm.nih.gov/36477458/
1292,ibuprofen,19949916,"Ibuprofen: pharmacology, efficacy and safety.",['Rainsford KD'],"['Adult', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*pharmacology', 'Child', 'Dose-Response Relationship, Drug', 'Fever/drug therapy/physiopathology', 'Humans', 'Ibuprofen/administration & dosage/adverse effects/*pharmacology', 'Inflammation/*drug therapy/physiopathology', 'Nonprescription Drugs/administration & dosage/adverse effects/pharmacology', 'Pain/drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/19949916/
1293,ibuprofen,36903343,Ibuprofen: Toxicology and Biodegradation of an Emerging Contaminant.,"['Jan-Roblero J', 'Cruz-Maya JA']","['Humans', 'Ibuprofen/chemistry', 'Bacteria', 'Biodegradation, Environmental', '*Drug-Related Side Effects and Adverse Reactions', 'Technology', '*Water Pollutants, Chemical/analysis']",https://pubmed.ncbi.nlm.nih.gov/36903343/
1294,ibuprofen,33224416,Ibuprofen versus paracetamol for treating fever in preschool children in Nigeria: a randomized clinical trial of effectiveness and safety.,"['Alaje EO', 'Udoh EE', 'Akande PA', 'Odey FA', 'Meremikwu MM']","['Acetaminophen/*administration & dosage/adverse effects', 'Antipyretics/*administration & dosage/adverse effects', 'Body Temperature/drug effects', 'Child, Preschool', 'Female', 'Fever/*drug therapy', 'Hospitals, Teaching', 'Humans', 'Ibuprofen/*administration & dosage/adverse effects', 'Infant', 'Male', 'Nigeria', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/33224416/
1295,ibuprofen,20150507,Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review.,"['Pierce CA', 'Voss B']","['Acetaminophen/adverse effects/*therapeutic use', 'Adult', 'Age Factors', 'Analgesics, Non-Narcotic/adverse effects/*therapeutic use', 'Child', 'Female', 'Fever/drug therapy', 'Humans', 'Ibuprofen/adverse effects/*therapeutic use', 'Male', 'Odds Ratio', 'Pain/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/20150507/
1296,ibuprofen,2000781,Ibuprofen: a monograph.,['Aycock DG'],"['Drug Interactions', 'Humans', '*Ibuprofen/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2000781/
1297,ibuprofen,28516288,Efficacy and Safety of Ibuprofen in Infants Aged Between 3 and 6 Months.,"['Ziesenitz VC', 'Zutter A', 'Erb TO', 'van den Anker JN']","['Analgesia', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*therapeutic use', 'Fever/drug therapy', 'Humans', 'Ibuprofen/administration & dosage/adverse effects/*therapeutic use', 'Infant', 'Pain/drug therapy', 'Pain Management']",https://pubmed.ncbi.nlm.nih.gov/28516288/
1298,ibuprofen,39318339,Short-term Dual Therapy or Mono Therapy With Acetaminophen and Ibuprofen for Fever: A Network Meta-Analysis.,"['De la Cruz-Mena JE', 'Veroniki AA', 'Acosta-Reyes J', 'Estupinan-Bohorquez A', 'Ibarra JA', 'Pana MC', 'Sierra JM', 'Florez ID']","['Child', 'Humans', '*Acetaminophen/therapeutic use/administration & dosage', 'Analgesics, Non-Narcotic/therapeutic use/administration & dosage', '*Antipyretics/therapeutic use/administration & dosage', 'Drug Therapy, Combination', '*Fever/drug therapy', '*Ibuprofen/therapeutic use/administration & dosage', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/39318339/
1299,ibuprofen,26334726,Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration.,"['Atkinson HC', 'Stanescu I', 'Frampton C', 'Salem II', 'Beasley CP', 'Robson R']","['Acetaminophen/*administration & dosage/adverse effects/blood/*pharmacokinetics', 'Administration, Intravenous', 'Administration, Oral', 'Adolescent', 'Adult', 'Area Under Curve', 'Biological Availability', 'Cross-Over Studies', 'Drug Combinations', 'Female', 'Healthy Volunteers', 'Humans', 'Ibuprofen/*administration & dosage/adverse effects/blood/*pharmacokinetics', 'Male', 'Middle Aged', 'Therapeutic Equivalency', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/26334726/
1300,ibuprofen,34655316,"Analgesic effect of oral ibuprofen 400, 600, and 800 mg; paracetamol 500 and 1000 mg; and paracetamol 1000 mg plus 60 mg codeine in acute postoperative pain: a single-dose, randomized, placebo-controlled, and double-blind study.","['Lyngstad G', 'Skjelbred P', 'Swanson DM', 'Skoglund LA']","['Acetaminophen/administration & dosage/adverse effects/*therapeutic use', 'Adolescent', 'Adult', 'Analgesics/administration & dosage/adverse effects/*therapeutic use', 'Codeine/administration & dosage/adverse effects/*therapeutic use', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Combinations', 'Drug Therapy, Combination', 'Female', 'Humans', 'Ibuprofen/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Pain Measurement', 'Pain, Postoperative/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/34655316/
1301,ibuprofen,30569859,Molecular Modeling Approaches for the Prediction of Selected Pharmacokinetic Properties.,"['Petito ES', 'Foster DJR', 'Ward MB', 'Sykes MJ']","['Administration, Oral', 'Humans', 'Ibuprofen/administration & dosage/chemistry/*pharmacokinetics', '*Models, Molecular', 'Quantitative Structure-Activity Relationship', 'Serum Albumin, Human/chemistry/drug effects', 'Warfarin/administration & dosage/chemistry/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/30569859/
1302,ibuprofen,21815877,New therapeutic strategies for the treatment of patent ductus arteriosus in preterm infants.,['Dani C'],"['Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage', 'Ductus Arteriosus, Patent/*drug therapy', 'Humans', 'Ibuprofen/*administration & dosage', 'Infant, Newborn', 'Infant, Premature', 'Infant, Premature, Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21815877/
1303,ibuprofen,11713940,Stevens-Johnson Syndrome and cholestatic hepatitis.,"['Morelli MS', ""O'Brien FX""]","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects', 'Chemical and Drug Induced Liver Injury/*etiology', 'Cholestasis/*etiology', 'Female', 'Humans', 'Ibuprofen/administration & dosage/adverse effects', 'Stevens-Johnson Syndrome/*etiology']",https://pubmed.ncbi.nlm.nih.gov/11713940/
1304,ibuprofen,19462922,Rationale for faster oral delivery to overcome the pathophysiology associated with dental pain--biopharmaceutic and pharmacokinetic challenges.,['Srinivas NR'],"['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacokinetics/*therapeutic use', 'Biopharmaceutics', 'Chemistry, Pharmaceutical', 'Humans', 'Ibuprofen/administration & dosage/pharmacokinetics/therapeutic use', 'Intestinal Absorption', 'Meloxicam', 'Thiazines/administration & dosage/pharmacokinetics/therapeutic use', 'Thiazoles/administration & dosage/pharmacokinetics/therapeutic use', 'Toothache/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19462922/
1305,ibuprofen,11467102,Ibuprofen to rofecoxib: what does it all mean and what do I do now?,"['Varga J', 'Dickman A']","['Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Drug Administration Schedule', 'Drug Costs', 'Gastrointestinal Diseases/chemically induced', 'Humans', 'Ibuprofen/adverse effects/classification/economics/*therapeutic use', 'Lactones/classification/economics/*therapeutic use', 'Neoplasms/complications', 'Pain/*drug therapy/etiology/prevention & control', '*Patient Selection', 'Risk Factors', 'Sulfones', 'Terminal Care/methods']",https://pubmed.ncbi.nlm.nih.gov/11467102/
1306,ibuprofen,9013378,"Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen.",['Evans AM'],"['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/*pharmacology', 'Humans', 'Ibuprofen/pharmacokinetics/*pharmacology/therapeutic use', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/9013378/
1307,ibuprofen,17137543,Is any one analgesic superior for episodic tension-type headache?,"['Verhagen AP', 'Damen L', 'Berger MY', 'Passchier J', 'Merlijn V', 'Koes BW']","['Acetaminophen/therapeutic use', 'Analgesics/*classification/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Chronic Disease', 'Diclofenac/therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Humans', 'Ibuprofen/adverse effects/*therapeutic use', 'Ketoprofen/therapeutic use', 'Naproxen/therapeutic use', 'Nonprescription Drugs/adverse effects/*therapeutic use', 'Secondary Prevention', 'Tension-Type Headache/*drug therapy/prevention & control', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17137543/
1308,ibuprofen,30544105,Effective Ibuprofen Desensitization in a Patient with Myopericarditis.,"['Cortellini G', 'Lippolis D', 'Amati S', 'Piovaccari G', 'Cortellini F', 'Ballardini G']","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects/immunology', 'Desensitization, Immunologic/*methods', 'Drug Administration Schedule', 'Drug Hypersensitivity/diagnosis/immunology/*prevention & control', 'Humans', 'Ibuprofen/*administration & dosage/adverse effects/immunology', 'Male', 'Myocarditis/diagnosis/*drug therapy/immunology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30544105/
1309,leflunomide,30173215,Rheumatoid Arthritis: A Brief Overview of the Treatment.,"['Bullock J', 'Rizvi SAA', 'Saleh AM', 'Ahmed SS', 'Do DP', 'Ansari RA', 'Ahmed J']","['Adrenal Cortex Hormones/adverse effects/therapeutic use', 'Analgesics, Opioid/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use', 'Antibodies, Monoclonal, Humanized/therapeutic use', 'Antirheumatic Agents/adverse effects/therapeutic use', 'Arthritis, Rheumatoid/complications/*drug therapy/surgery', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Interleukin 1 Receptor Antagonist Protein/therapeutic use', 'Leflunomide/therapeutic use', 'Physical Therapy Modalities', 'Risk Factors', 'Tumor Necrosis Factor-alpha/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30173215/
1310,leflunomide,30114347,Takayasu arteritis: an update.,"['Keser G', 'Aksu K', 'Direskeneli H']","['Antibodies, Monoclonal, Humanized/therapeutic use', 'Biomarkers/metabolism', 'Endovascular Procedures/*methods', 'Guidelines as Topic', 'Humans', 'Immunosuppressive Agents/*therapeutic use', 'Leflunomide/therapeutic use', 'Physical Examination', 'Prognosis', 'Radiology, Interventional', '*Takayasu Arteritis/diagnosis/physiopathology/therapy']",https://pubmed.ncbi.nlm.nih.gov/30114347/
1311,leflunomide,21962758,Leflunomide in dermatology.,['Boyd AS'],"['Humans', 'Immunosuppressive Agents/adverse effects/*therapeutic use', 'Isoxazoles/adverse effects/*therapeutic use', 'Leflunomide', 'Psoriasis/drug therapy', 'Skin Diseases/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21962758/
1312,leflunomide,39504368,Mitochondrial elongation impairs breast cancer metastasis.,"['Minarrieta L', 'Annis MG', 'Audet-Delage Y', 'Kuasne H', 'Pacis A', 'St-Louis C', 'Nowakowski A', 'Biondini M', 'Khacho M', 'Park M', 'Siegel PM', 'St-Pierre J']","['Humans', '*Breast Neoplasms/pathology/metabolism/genetics', 'Female', '*Mitochondria/metabolism/pathology', '*Mitochondrial Dynamics/drug effects', 'Animals', 'Cell Line, Tumor', '*Neoplasm Metastasis', 'Mice', 'Mitochondrial Proteins/metabolism/genetics', 'Leflunomide/pharmacology', 'Dynamins/metabolism/genetics']",https://pubmed.ncbi.nlm.nih.gov/39504368/
1313,leflunomide,36710223,"Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases.","['Ibarra Barrueta O', 'Garcia Martin E', 'Lopez Sanchez P', 'Ramirez Herraiz E', 'Merino Bohorquez V', 'Ais Larisgoitia A']","['Pregnancy', 'Humans', 'Male', 'Female', '*Antirheumatic Agents/adverse effects', 'Breast Feeding', 'Leflunomide/therapeutic use', 'Prospective Studies', 'Tumor Necrosis Factor Inhibitors', 'Immunosuppressive Agents/adverse effects', 'Fertility']",https://pubmed.ncbi.nlm.nih.gov/36710223/
1314,leflunomide,12661795,Leflunomide.,"['Cohen SB', 'Iqbal I']","['Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Clinical Trials as Topic', 'Female', 'Humans', 'Immunosuppressive Agents/adverse effects/*therapeutic use', 'Isoxazoles/adverse effects/*therapeutic use', 'Leflunomide', 'Male', 'Middle Aged', 'Product Surveillance, Postmarketing', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12661795/
1315,leflunomide,28867467,Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis.,"['Alfaro-Lara R', 'Espinosa-Ortega HF', 'Arce-Salinas CA']","['Alanine Transaminase/blood', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Antirheumatic Agents/adverse effects/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Aspartate Aminotransferases/blood', 'C-Reactive Protein/analysis', 'Chemical and Drug Induced Liver Injury/etiology', 'Clinical Trials as Topic', 'Disability Evaluation', 'Drug Therapy, Combination', 'Gastrointestinal Diseases/chemically induced', 'Humans', 'Immunosuppressive Agents/adverse effects/*therapeutic use', 'Leflunomide/adverse effects/*therapeutic use', 'Methotrexate/adverse effects/*therapeutic use', 'Treatment Outcome', 'gamma-Glutamyltransferase/analysis']",https://pubmed.ncbi.nlm.nih.gov/28867467/
1316,leflunomide,29357281,Leflunomide: A promising drug with good antitumor potential.,"['Zhang C', 'Chu M']","['Angiogenesis Inhibitors/pharmacology/therapeutic use', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use', 'Antineoplastic Agents/pharmacology/*therapeutic use', 'Enzyme Inhibitors/pharmacology/therapeutic use', 'Humans', 'Immunologic Factors/pharmacology/therapeutic use', 'Isoxazoles/pharmacology/*therapeutic use', 'Leflunomide', 'Neoplasms/*drug therapy/pathology', 'Neoplastic Stem Cells/drug effects/pathology']",https://pubmed.ncbi.nlm.nih.gov/29357281/
1317,leflunomide,27283340,Challenges and treatment options for rheumatoid arthritis during pregnancy.,"['Gerosa M', 'Schioppo T', 'Meroni PL']","['Antirheumatic Agents/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy/*epidemiology', 'Biological Products/therapeutic use', 'Female', 'Humans', 'Hydroxychloroquine/therapeutic use', 'Isoxazoles/therapeutic use', 'Leflunomide', 'Methotrexate/therapeutic use', 'Pregnancy', 'Pregnancy Complications/*drug therapy/*epidemiology', 'Sulfasalazine/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27283340/
1318,leflunomide,14971821,Leflunomide-induced acute hepatitis.,"['Sevilla-Mantilla C', 'Ortega L', 'Agundez JA', 'Fernandez-Gutierrez B', 'Ladero JM', 'Diaz-Rubio M']","['Adjuvants, Immunologic/*adverse effects/therapeutic use', 'Aged', 'Anion Exchange Resins/therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Chemical and Drug Induced Liver Injury/drug therapy/*etiology/pathology', 'Cholestyramine Resin/therapeutic use', 'Female', 'Humans', 'Isoxazoles/*adverse effects/therapeutic use', 'Leflunomide', 'Liver/pathology']",https://pubmed.ncbi.nlm.nih.gov/14971821/
1319,leflunomide,31324351,[Treatment of giant cell arteritis].,"['Samson M', 'Greigert H', 'Ghesquiere T', 'Bonnotte B']","['Abatacept/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Antibodies, Monoclonal, Humanized/*therapeutic use', 'Aspirin/therapeutic use', 'Azathioprine/therapeutic use', 'Drug Administration Schedule', 'Giant Cell Arteritis/complications/*drug therapy', 'Glucocorticoids/administration & dosage/*therapeutic use', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Leflunomide/therapeutic use', 'Methotrexate/*therapeutic use', 'Prednisone/*therapeutic use', 'Ustekinumab/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31324351/
1320,leflunomide,17094333,Leflunomide in clinical practice.,"['Pinto P', 'Dougados M']","['Antirheumatic Agents/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Drug Therapy, Combination', 'Humans', 'Isoxazoles/*therapeutic use', 'Leflunomide']",https://pubmed.ncbi.nlm.nih.gov/17094333/
1321,leflunomide,39320955,Leflunomide nanocarriers: a new prospect of therapeutic applications.,['Zewail M'],"['*Leflunomide/chemistry/therapeutic use/pharmacology/pharmacokinetics', 'Humans', '*Hydroxybutyrates/chemistry', '*Antirheumatic Agents/administration & dosage/pharmacokinetics/chemistry/therapeutic use/pharmacology', '*Toluidines/chemistry/therapeutic use/pharmacokinetics', 'Animals', 'Nanoparticles/chemistry', 'Nitriles/chemistry', 'Drug Carriers/chemistry', 'Crotonates/chemistry/therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Neoplasms/drug therapy', 'Multiple Sclerosis/drug therapy', 'Isoxazoles/chemistry/pharmacokinetics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39320955/
1322,leflunomide,12003373,Leflunomide for the treatment of rheumatoid arthritis and autoimmunity.,"['Sanders S', 'Harisdangkul V']","['Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Autoimmune Diseases/*drug therapy', 'Clinical Trials as Topic', 'Humans', 'Isoxazoles/adverse effects/*therapeutic use', 'Leflunomide']",https://pubmed.ncbi.nlm.nih.gov/12003373/
1323,leflunomide,12783594,Leflunomide for the treatment of rheumatoid arthritis.,"['Miceli-Richard C', 'Dougados M']","['Arthritis, Rheumatoid/*drug therapy', 'Clinical Trials as Topic', 'Contraindications', 'Drug Therapy, Combination', 'Humans', 'Immunosuppressive Agents/adverse effects/*pharmacology', 'Isoxazoles/adverse effects/*pharmacology', 'Leflunomide', 'Practice Guidelines as Topic']",https://pubmed.ncbi.nlm.nih.gov/12783594/
1324,leflunomide,22961090,Leflunomide: friend or foe for systemic lupus erythematosus?,"['Wu GC', 'Xu XD', 'Huang Q', 'Wu H']","['Animals', 'Autoimmunity', 'Humans', 'Immunosuppressive Agents/*therapeutic use', 'Isoxazoles/adverse effects/pharmacology/*therapeutic use', 'Leflunomide', 'Lupus Erythematosus, Systemic/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22961090/
1325,leflunomide,15182800,Leflunomide-induced aseptic meningitis.,"['Cohen JD', 'Jorgensen C', 'Sany J']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Humans', 'Isoxazoles/*adverse effects/therapeutic use', 'Leflunomide', 'Male', 'Meningitis, Aseptic/*chemically induced', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/15182800/
1326,leflunomide,29039518,Leflunomide inhibits proliferation and tumorigenesis of oral squamous cell carcinoma.,"['Ren A', 'Fu G', 'Qiu Y', 'Cui H']","['Animals', 'Apoptosis/drug effects', 'Carcinogenesis/*drug effects', 'Carcinoma, Squamous Cell/*etiology/*pathology', 'Cell Cycle/drug effects', 'Cell Line, Tumor', 'Cell Proliferation/drug effects', 'Disease Models, Animal', 'Humans', 'Isoxazoles/*pharmacology', 'Leflunomide', 'Mice', 'Mouth Neoplasms/*etiology/*pathology', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/29039518/
1327,leflunomide,32356683,Noninfectious aortitis: A case report.,"['Jaikaran O', 'Nicoara M', 'Hingorani A']","['Abdominal Pain/etiology', 'Aged', 'Aortitis/diagnostic imaging/drug therapy/*etiology', 'Back Pain/etiology', 'Glucocorticoids/therapeutic use', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Leflunomide/therapeutic use', 'Male', 'Methylprednisolone/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32356683/
1328,leflunomide,15172042,Leflunomide.,"['Cannon GW', 'Kremer JM']","['Antirheumatic Agents/*pharmacology/therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Clinical Trials as Topic', 'Drug Monitoring/methods', 'Drug Therapy, Combination', 'Humans', 'Immunosuppressive Agents/*pharmacology/therapeutic use', 'Isoxazoles/*pharmacology/therapeutic use', 'Joints/drug effects/pathology', 'Leflunomide', 'Liver/drug effects/pathology', 'Methotrexate/*therapeutic use', 'Models, Animal']",https://pubmed.ncbi.nlm.nih.gov/15172042/
1329,famciclovir,29431387,Herpes Zoster and Postherpetic Neuralgia: Prevention and Management.,"['Saguil A', 'Kane S', 'Mercado M', 'Lauters R']","['Antiviral Agents/therapeutic use', 'Female', 'Herpes Zoster/complications/*drug therapy/prevention & control', 'Herpes Zoster Vaccine/*administration & dosage', 'Humans', 'Male', 'Neuralgia, Postherpetic/*drug therapy/prevention & control', 'Skin/pathology/virology']",https://pubmed.ncbi.nlm.nih.gov/29431387/
1330,famciclovir,28971780,Herpes Labialis: An Update.,"['Leung AKC', 'Barankin B']","['Administration, Cutaneous', 'Administration, Oral', 'Antiviral Agents/*administration & dosage/pharmacokinetics', 'Herpes Labialis/*drug therapy/virology', 'Humans', 'Pain/drug therapy/etiology', 'Patents as Topic', '*Quality of Life', 'Recurrence', 'Time Factors', 'Virus Shedding/drug effects']",https://pubmed.ncbi.nlm.nih.gov/28971780/
1331,famciclovir,17143845,Recommendations for the management of herpes zoster.,"['Dworkin RH', 'Johnson RW', 'Breuer J', 'Gnann JW', 'Levin MJ', 'Backonja M', 'Betts RF', 'Gershon AA', 'Haanpaa ML', 'McKendrick MW', 'Nurmikko TJ', 'Oaklander AL', 'Oxman MN', 'Pavan-Langston D', 'Petersen KL', 'Rowbotham MC', 'Schmader KE', 'Stacey BR', 'Tyring SK', 'van Wijck AJ', 'Wallace MS', 'Wassilew SW', 'Whitley RJ']","['2-Aminopurine/analogs & derivatives/therapeutic use', 'Acyclovir/analogs & derivatives/therapeutic use', 'Analgesics/therapeutic use', 'Anti-Inflammatory Agents/therapeutic use', 'Antiviral Agents/*therapeutic use', 'Bromodeoxyuridine/analogs & derivatives/therapeutic use', 'Famciclovir', 'Herpes Zoster/complications/*drug therapy/epidemiology/physiopathology', 'Herpesvirus 3, Human/pathogenicity', 'Humans', 'Immunocompetence', 'Immunocompromised Host', 'Valacyclovir', 'Valine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17143845/
1332,famciclovir,23343513,Selective anti-herpesvirus agents.,['De Clercq E'],"['Animals', 'Antiviral Agents/*chemistry/pharmacology/*therapeutic use', 'Cytomegalovirus/*drug effects', 'Herpesviridae Infections/*drug therapy', 'Herpesvirus 3, Human/*drug effects', 'Humans', 'Simplexvirus/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/23343513/
1333,famciclovir,33672709,Advances and Perspectives in the Management of Varicella-Zoster Virus Infections.,"['Andrei G', 'Snoeck R']","['Antiviral Agents/*pharmacology', 'Encephalitis, Varicella Zoster/*drug therapy', 'Herpesvirus 3, Human/*drug effects', 'Humans', 'Microbial Sensitivity Tests', 'Pyrimidine Nucleosides/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/33672709/
1334,famciclovir,19615937,A perspective on antiviral resistance.,['Griffiths PD'],"['Antiviral Agents/*pharmacology', '*Drug Resistance, Viral', 'HIV/*drug effects', 'Hepatitis B virus/*drug effects', 'Humans', 'Orthomyxoviridae/*drug effects', 'Simplexvirus/*drug effects', 'Virus Diseases/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19615937/
1335,famciclovir,8063023,Acyclovir--and beyond.,['Darby G'],"['Acyclovir/analogs & derivatives/*therapeutic use', 'Arabinofuranosyluracil/analogs & derivatives/therapeutic use', 'Cytomegalovirus Infections/drug therapy', 'Ganciclovir/therapeutic use', 'Guanine', 'Herpes Simplex/*drug therapy', 'Herpesvirus 3, Human/drug effects', 'Humans', 'Valacyclovir', 'Valine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8063023/
1336,famciclovir,8582118,Pharmacokinetics of new antiherpetic agents.,['Rolan P'],"['2-Aminopurine/analogs & derivatives/pharmacokinetics', 'Acyclovir/analogs & derivatives/pharmacokinetics', 'Animals', 'Antiviral Agents/*pharmacokinetics/therapeutic use', 'Famciclovir', 'Guanine', 'Herpesviridae Infections/*drug therapy/metabolism', 'Humans', 'Prodrugs/pharmacokinetics', 'Valacyclovir', 'Valine/analogs & derivatives/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/8582118/
1337,famciclovir,9875415,Current status of anti-HBV chemotherapy.,"['Hong JH', 'Choi Y', 'Chun BK', 'Lee K', 'Chu CK']","['Animals', 'Antiviral Agents/*pharmacology/*therapeutic use', 'Hepatitis B/*drug therapy/prevention & control/virology', 'Hepatitis B virus/*drug effects', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/9875415/
1338,famciclovir,21486500,Chickenpox.,"['Breuer J', 'Fifer H']","['*Chickenpox/immunology', '*Chickenpox Vaccine/administration & dosage', 'Evidence-Based Medicine', 'Humans', 'Immunocompromised Host', 'Incidence', 'India', 'Vaccines, Attenuated/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/21486500/
1339,famciclovir,18337531,Treatment of herpes zoster.,"['Opstelten W', 'Eekhof J', 'Neven AK', 'Verheij T']","['2-Aminopurine/administration & dosage/analogs & derivatives/therapeutic use', 'Acyclovir/administration & dosage/analogs & derivatives/therapeutic use', 'Antiviral Agents/administration & dosage/*therapeutic use', 'Famciclovir', 'Glucocorticoids/administration & dosage/*therapeutic use', 'Herpes Zoster/*drug therapy', 'Herpes Zoster Ophthalmicus/*drug therapy/prevention & control', 'Humans', 'Neuralgia, Postherpetic/*drug therapy/prevention & control', 'Prednisolone/administration & dosage/therapeutic use', 'Time Factors', 'Valacyclovir', 'Valine/administration & dosage/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18337531/
1340,famciclovir,15934343,[Antiherpetic therapy].,"['Dediulescu L', 'Dediulescu DF']","['2-Aminopurine/*analogs & derivatives/therapeutic use', 'Acyclovir/*analogs & derivatives/therapeutic use', '*Antiviral Agents/therapeutic use', 'Bromodeoxyuridine/*analogs & derivatives/therapeutic use', 'Cidofovir', 'Cytosine/*analogs & derivatives/therapeutic use', 'Drug Combinations', 'Famciclovir', 'Foscarnet/therapeutic use', 'Ganciclovir/therapeutic use', 'Humans', 'Idoxuridine/therapeutic use', '*Keratitis, Herpetic/drug therapy', 'Oligonucleotides/therapeutic use', 'Ophthalmic Solutions', 'Organophosphonates/therapeutic use', 'Treatment Outcome', 'Valacyclovir', 'Valine/*analogs & derivatives/therapeutic use', 'Vidarabine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15934343/
1341,famciclovir,22568134,[Anti alpha-herpesvirus drugs].,"['Koshizuka T', 'Suzutani T']","['Antiviral Agents/*pharmacology', 'Herpes Simplex/drug therapy', 'Herpesvirus 1, Human/*drug effects', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/22568134/
1342,famciclovir,17029141,Recurrent benign lymphocytic meningitis.,"['Shalabi M', 'Whitley RJ']","['2-Aminopurine/analogs & derivatives/therapeutic use', 'Acyclovir/analogs & derivatives/therapeutic use', 'Adult', 'Aged', 'Antiviral Agents/*therapeutic use', 'Famciclovir', 'Female', '*Herpesvirus 2, Human', 'Humans', 'Male', 'Meningitis, Viral/*prevention & control', 'Middle Aged', 'Recurrence', 'Valacyclovir', 'Valine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17029141/
1343,famciclovir,23235944,Emerging concepts in the management of acute retinal necrosis.,"['Wong RW', 'Jumper JM', 'McDonald HR', 'Johnson RN', 'Fu A', 'Lujan BJ', 'Cunningham ET Jr']","['2-Aminopurine/analogs & derivatives/therapeutic use', 'Acyclovir/analogs & derivatives/therapeutic use', 'Antiviral Agents/therapeutic use', 'Cytomegalovirus Retinitis/diagnosis/therapy/virology', 'Eye Infections, Viral/*diagnosis/*therapy/virology', 'Famciclovir', 'Fluorescein Angiography', 'Ganciclovir/analogs & derivatives/therapeutic use', 'Herpes Simplex/diagnosis/therapy/virology', 'Humans', 'Laser Coagulation', 'Retinal Necrosis Syndrome, Acute/*diagnosis/*therapy/virology', 'Valacyclovir', 'Valganciclovir', 'Valine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23235944/
1344,famciclovir,16556084,Genital herpes: antiviral therapy for symptom relief and prevention of transmission.,"['Gupta R', 'Wald A']","['2-Aminopurine/analogs & derivatives/therapeutic use', 'Acyclovir/analogs & derivatives/therapeutic use', 'Antiviral Agents/*therapeutic use', 'Clinical Trials as Topic/statistics & numerical data', 'Famciclovir', 'Female', 'Herpes Genitalis/drug therapy/*prevention & control/*transmission', 'Humans', 'Male', 'Valacyclovir', 'Valine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16556084/
1345,famciclovir,29896665,Antiviral Drugs Against Alphaherpesvirus.,['Shiraki K'],"['Acyclovir/administration & dosage/analogs & derivatives', 'Animals', 'Antiviral Agents/*administration & dosage', 'Clinical Trials as Topic', 'Guanine', 'Herpes Simplex/*drug therapy/virology', 'Herpes Zoster/*drug therapy/virology', 'Herpesvirus 3, Human/drug effects/genetics/physiology', 'Humans', 'Oxadiazoles/administration & dosage', 'Simplexvirus/drug effects/genetics/physiology']",https://pubmed.ncbi.nlm.nih.gov/29896665/
1346,famciclovir,9675639,Antiviral therapy of herpes simplex and varicella-zoster virus infections.,['Wutzler P'],"['2-Aminopurine/analogs & derivatives/therapeutic use', 'Acyclovir/analogs & derivatives/therapeutic use', 'Administration, Oral', 'Antiviral Agents/*therapeutic use', 'Arabinofuranosyluracil/analogs & derivatives/therapeutic use', 'Bromodeoxyuridine/analogs & derivatives/therapeutic use', 'Chickenpox/drug therapy', 'Drug Resistance, Microbial', 'Encephalitis, Viral/mortality', 'Famciclovir', 'Herpes Genitalis/drug therapy', 'Herpes Labialis/drug therapy', 'Herpes Simplex/*drug therapy', 'Herpes Zoster/*drug therapy', 'Humans', 'Immunocompromised Host/drug effects', 'Prodrugs/therapeutic use', 'Simplexvirus', 'Valacyclovir', 'Valine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9675639/
1347,famciclovir,34443515,Synthesis and Biological Evaluation of Amidinourea Derivatives against Herpes Simplex Viruses.,"['Toscani A', 'Denaro R', 'Pacheco SFC', 'Biolatti M', 'Anselmi S', ""Dell'Oste V"", 'Castagnolo D']","['Acyclovir/adverse effects/pharmacology', 'Antiviral Agents/pharmacology', 'Drug Resistance, Viral/genetics', 'Guanidine/*analogs & derivatives/chemical synthesis/pharmacology', 'Herpes Simplex/*drug therapy/virology', 'Herpesvirus 1, Human/*drug effects/pathogenicity', 'Humans', 'Simplexvirus/*drug effects/genetics/pathogenicity', 'Urea/*analogs & derivatives/chemical synthesis/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/34443515/
1348,famciclovir,15341504,Brivudin (bromovinyl deoxyuridine).,"['Keam SJ', 'Chapman TM', 'Figgitt DP']","['Acute Disease', 'Antiviral Agents/administration & dosage/adverse effects/*therapeutic use', 'Bromodeoxyuridine/administration & dosage/adverse effects/*analogs & derivatives/*therapeutic use', 'Herpes Zoster/*drug therapy', 'Humans', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/15341504/
1349,tolbutamide,26204670,HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.,"['Confederat L', 'Constantin S', 'Lupascu F', 'Panzariu A', 'Hancianu M', 'Profire L']","['Chlorpropamide/adverse effects', '*Diabetes Mellitus, Type 2/drug therapy', 'Gliclazide/adverse effects', 'Glipizide/adverse effects', 'Glyburide/adverse effects', 'Humans', 'Hypoglycemia/*chemically induced', 'Hypoglycemic Agents/administration & dosage/*adverse effects', 'Risk Factors', 'Sulfonylurea Compounds/administration & dosage/*adverse effects', 'Tolbutamide/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/26204670/
1350,tolbutamide,6236351,High-chromium yeast for acne?,['McCarty M'],"['Acne Vulgaris/*drug therapy', 'Chromium/*therapeutic use', 'Fatty Acids, Essential/metabolism', 'Humans', 'Insulin/therapeutic use', 'Male', 'Tolbutamide/therapeutic use', '*Yeasts']",https://pubmed.ncbi.nlm.nih.gov/6236351/
1351,tolbutamide,18771934,K(ATP)-channels and glucose-regulated glucagon secretion.,"['Rorsman P', 'Salehi SA', 'Abdulkader F', 'Braun M', 'MacDonald PE']","['Animals', 'Diabetes Mellitus/metabolism/therapy', 'Glucagon/*metabolism', 'Glucagon-Secreting Cells/*drug effects/metabolism/physiology', 'Glucose/*pharmacology', 'Humans', 'Hypoglycemic Agents/pharmacology', 'KATP Channels/*physiology', 'Membrane Potentials/drug effects/physiology', 'Models, Biological', 'Paracrine Communication/physiology', 'Tolbutamide/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/18771934/
1352,tolbutamide,14676228,Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?,"['Meier JJ', 'Gallwitz B', 'Schmidt WE', 'Mugge A', 'Nauck MA']","['Animals', 'Cardiovascular Agents/*therapeutic use', 'Catheterization/methods', 'Diabetes Mellitus, Type 2/drug therapy/mortality', 'Humans', 'Hypoglycemic Agents/*adverse effects/therapeutic use', 'Ischemic Preconditioning, Myocardial/*methods', 'Models, Biological', 'Myocardial Ischemia/mortality/*therapy', 'Randomized Controlled Trials as Topic', 'Sulfonylurea Compounds/*adverse effects', 'Tolbutamide/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/14676228/
1353,tolbutamide,797503,Drug metabolism in thyroid disease.,['Eichelbaum M'],"['Administration, Oral', 'Aminopyrine/metabolism', 'Anticoagulants/administration & dosage/metabolism', 'Antipyrine/metabolism', 'Digitalis Glycosides/metabolism', 'Hormones/metabolism', 'Humans', 'Kinetics', 'Methimazole/metabolism', 'Pharmaceutical Preparations/*metabolism', 'Propylthiouracil/metabolism', 'Riboflavin/metabolism', 'Steroids/metabolism', 'Thyroid Diseases/*metabolism', 'Tolbutamide/metabolism']",https://pubmed.ncbi.nlm.nih.gov/797503/
1354,tolbutamide,838166,Tolbutamide-induced hemolytic anemia.,"['Malacarne P', 'Castaldi G', 'Bertusi M', 'Zavagli G']","['Aged', 'Anemia, Hemolytic/*chemically induced/immunology', 'Diabetes Complications', 'Diabetes Mellitus/drug therapy/immunology', 'Female', 'Humans', 'Immunoglobulin G/metabolism', 'Tolbutamide/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/838166/
1355,tolbutamide,14140001,RATES OF DISSOLUTION OF TOLBUTAMIDE TABLETS.,"['BRUDNEY N', 'STEWART DJ', 'EUSTACE BT']","['*Absorption', 'Canada', '*Chemistry, Pharmaceutical', '*Gastrointestinal Tract', 'Humans', '*Legislation, Medical', '*Research', '*Solubility', '*Tablets', '*Tolbutamide']",https://pubmed.ncbi.nlm.nih.gov/14140001/
1356,tolbutamide,12205699,Likelihood methods for measuring statistical evidence.,['Blume JD'],"['Biometry/*methods', 'Cardiovascular Diseases/mortality', 'Diabetes Mellitus, Type 2/drug therapy', 'Evidence-Based Medicine/*methods', 'Humans', 'Hypoglycemic Agents/adverse effects/therapeutic use', '*Likelihood Functions', 'Multicenter Studies as Topic/methods', 'Randomized Controlled Trials as Topic/methods', 'Tolbutamide/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12205699/
1357,tolbutamide,24730468,The in-vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity.,"['Mooiman KD', 'Goey AK', 'Huijbregts TJ', 'Maas-Bakker RF', 'Beijnen JH', 'Schellens JH', 'Meijerman I']","['Aryl Hydrocarbon Hydroxylases/*metabolism', '*Camellia sinensis', 'Complementary Therapies', 'Coumarins/*metabolism', '*Herb-Drug Interactions', 'Humans', 'Microsomes, Liver/drug effects', 'Silybum marianum/*chemistry', 'Plant Extracts/*pharmacology', 'Silybin', 'Silymarin/pharmacology', 'Tolbutamide/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/24730468/
1358,tolbutamide,8529502,Extrapancreatic effects of sulfonylurea drugs.,"['Kaku K', 'Inoue Y', 'Kaneko T']","['Animals', 'Diabetes Mellitus, Type 2/drug therapy/metabolism', 'Gluconeogenesis/drug effects', 'Glycolysis/drug effects', 'Humans', 'Hypoglycemic Agents/*pharmacology/therapeutic use', 'Islets of Langerhans/physiology', 'Liver/drug effects/*metabolism', 'Models, Biological', 'Phosphofructokinase-1/metabolism', 'Phosphofructokinase-2', 'Phosphoric Monoester Hydrolases/metabolism', 'Sulfonylurea Compounds/*pharmacology/therapeutic use', 'Tolbutamide/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8529502/
1359,tolbutamide,6376026,Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man.,"['Pfeifer MA', 'Halter JB', 'Judzewitsch RG', 'Beard JC', 'Best JD', 'Ward WK', 'Porte D Jr']","['Chlorpropamide/pharmacology', 'Diabetes Mellitus, Type 2/drug therapy/physiopathology', 'Feedback', 'Glucagon/metabolism', 'Glucose/pharmacology', 'Humans', 'Hypoglycemic Agents/*pharmacology/therapeutic use', 'Insulin/metabolism', 'Insulin Secretion', 'Islets of Langerhans/*drug effects', 'Liver/drug effects/metabolism', 'Sulfonylurea Compounds/*pharmacology/therapeutic use', 'Time Factors', 'Tolbutamide/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6376026/
1360,tolbutamide,668788,m-Trifluoromethyl-alpha-ethylbenzhydrol: a new enzyme inducer.,"['Gachalyi B', 'Kaldor A', 'Szeberenyi S']","['Adult', 'Animals', 'Antipyrine/metabolism', 'Benzhydryl Compounds/*pharmacology', 'Enzyme Induction/*drug effects', 'Female', 'Glucaric Acid/metabolism', 'Half-Life', 'Humans', 'Male', 'Mice', 'Mice, Inbred Strains', 'Middle Aged', 'Rats', 'Rats, Inbred Strains', 'Species Specificity', 'Tolbutamide/metabolism']",https://pubmed.ncbi.nlm.nih.gov/668788/
1361,tolbutamide,1013004,Drug-induced hyponatraemia in psychogenic polydipsia.,"['Gossain VV', 'Hagen GA', 'Sugawara M']","['Humans', 'Hydrochlorothiazide/*adverse effects', 'Hyponatremia/*chemically induced', 'Male', 'Middle Aged', '*Psychophysiologic Disorders', 'Schizophrenia/complications', '*Thirst', 'Tolbutamide/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/1013004/
1362,tolbutamide,5005518,Glibenclamide therapy in diabetes mellitus.,"['Bhattia SK', 'Hadden DR', 'Montgomery DA', 'Weaver JA']","['Adult', 'Aged', 'Blood Glucose/analysis', 'Chlorpropamide/administration & dosage', 'Diabetes Mellitus/*drug therapy', 'Female', 'Humans', 'Hypoglycemic Agents/*administration & dosage/adverse effects', 'Long-Term Care', 'Male', 'Middle Aged', 'Tolbutamide/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/5005518/
1363,tolbutamide,32863324,Phenotypic analysis of human CYP2C9 polymorphisms using fluorine-substituted tolbutamide.,"['Kitamura Y', 'Saeki KI']","['Cytochrome P-450 CYP2C9/genetics/*metabolism', 'Fluorine/*chemistry', 'Humans', 'Hydroxylation', 'Oxidation-Reduction', 'Phenotype', '*Polymorphism, Genetic', 'Tolbutamide/chemistry/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/32863324/
1364,tolbutamide,6443808,Chlorpropamide-induced hyponatremia: incidence and risk factors.,"['Kadowaki T', 'Hagura R', 'Kajinuma H', 'Kuzuya N', 'Yoshida S']","['Adult', 'Aged', 'Aged, 80 and over', 'Blood Glucose/analysis', 'Chlorpropamide/*adverse effects/therapeutic use', 'Creatine/blood', 'Diabetes Mellitus, Type 2/blood/drug therapy', 'Female', 'Glyburide/adverse effects/therapeutic use', 'Humans', 'Hyponatremia/*chemically induced', 'Male', 'Middle Aged', 'Retrospective Studies', 'Risk Factors', 'Tolbutamide/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6443808/
1365,tolbutamide,6626438,The effect of cimetidine on tolbutamide kinetics.,"['Dey NG', 'Castleden CM', 'Ward J', 'Cornhill J', 'McBurney A']","['Adult', 'Cimetidine/blood/*pharmacology', 'Drug Interactions', 'Female', 'Half-Life', 'Humans', 'Kinetics', 'Male', 'Tolbutamide/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/6626438/
1366,tolbutamide,502108,Suicidal overdoses with hypoglycemic agents.,['Bobzien WF 3rd'],"['Adolescent', 'Adult', 'Female', 'Glucagon/therapeutic use', 'Glucose', 'Humans', 'Hypoglycemia/chemically induced/*drug therapy', 'Insulin, Isophane/*poisoning', '*Suicide, Attempted', 'Sulfonylurea Compounds', 'Tolbutamide/*poisoning']",https://pubmed.ncbi.nlm.nih.gov/502108/
1367,tolbutamide,5327883,Inhibition of insulin release by norepinephrine in man.,"['Porte D Jr', 'Williams RH']","['Adult', 'Blood Glucose', 'Female', 'Glucose', 'Humans', 'In Vitro Techniques', 'Insulin/*metabolism', 'Islets of Langerhans/*drug effects', 'Male', 'Norepinephrine/*pharmacology', 'Tolbutamide/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/5327883/
1368,Imatinib,38820078,Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.,"['Hochhaus A', 'Wang J', 'Kim DW', 'Kim DDH', 'Mayer J', 'Goh YT', 'le Coutre P', 'Takahashi N', 'Kim I', 'Etienne G', 'Andorsky D', 'Issa GC', 'Larson RA', 'Bombaci F', 'Kapoor S', 'McCulloch T', 'Malek K', 'Yau L', 'Ifrah S', 'Hoch M', 'Cortes JE', 'Hughes TP']","['Adult', 'Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Male', 'Middle Aged', 'Young Adult', '*Antineoplastic Agents/administration & dosage/adverse effects', '*Fusion Proteins, bcr-abl/antagonists & inhibitors/genetics', '*Imatinib Mesylate/therapeutic use/adverse effects', 'Kaplan-Meier Estimate', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy', 'Niacinamide/administration & dosage/adverse effects/analogs & derivatives', '*Pyrazoles/administration & dosage/adverse effects', '*Tyrosine Kinase Inhibitors/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38820078/
1369,Imatinib,34002056,Kinase drug discovery 20 years after imatinib: progress and future directions.,"['Cohen P', 'Cross D', 'Janne PA']","['Animals', 'Antineoplastic Agents/pharmacology/*therapeutic use', 'Drug Delivery Systems', 'Drug Discovery/*trends', 'Drug Resistance, Neoplasm', 'Humans', 'Imatinib Mesylate/pharmacology/*therapeutic use', 'Protein Kinase Inhibitors/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34002056/
1370,Imatinib,38722621,Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.,"['Jabbour E', 'Kantarjian HM', 'Aldoss I', 'Montesinos P', 'Leonard JT', 'Gomez-Almaguer D', 'Baer MR', 'Gambacorti-Passerini C', 'McCloskey J', 'Minami Y', 'Papayannidis C', 'Rocha V', 'Rousselot P', 'Vachhani P', 'Wang ES', 'Wang B', 'Hennessy M', 'Vorog A', 'Patel N', 'Yeh T', 'Ribera JM']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', 'Young Adult', '*Antineoplastic Agents/therapeutic use/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Fusion Proteins, bcr-abl/genetics', '*Imatinib Mesylate/therapeutic use/adverse effects', '*Imidazoles/therapeutic use/adverse effects/administration & dosage', 'Philadelphia Chromosome', '*Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/genetics', 'Progression-Free Survival', 'Protein Kinase Inhibitors/therapeutic use/adverse effects', '*Pyridazines/therapeutic use/adverse effects', 'Remission Induction', 'Adolescent']",https://pubmed.ncbi.nlm.nih.gov/38722621/
1371,Imatinib,33768564,Imatinib-induced eruptive nevi.,"['Hamie L', 'Sawaya RT', 'Abbas O']","['Adolescent', 'Humans', 'Male', '*Antineoplastic Agents/adverse effects/therapeutic use', '*Imatinib Mesylate/adverse effects/therapeutic use', '*Nevus, Pigmented/chemically induced/pathology', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy', 'Protein Kinase Inhibitors/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33768564/
1372,Imatinib,30504305,The argument for using imatinib in CML.,"['Claudiani S', 'Apperley JF']","['Clinical Trials as Topic', 'Humans', 'Imatinib Mesylate/adverse effects/*therapeutic use', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/*drug therapy', '*Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/30504305/
1373,Imatinib,38884296,[IMATINIB INDUCED EDEMA].,"['Olshanskiy D', 'Ben Varon H', 'Mouallem M']","['Humans', '*Imatinib Mesylate/adverse effects/administration & dosage', '*Edema/chemically induced', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy', '*Protein Kinase Inhibitors/adverse effects/administration & dosage', '*Antineoplastic Agents/adverse effects/administration & dosage', 'Male', 'Middle Aged', 'Female']",https://pubmed.ncbi.nlm.nih.gov/38884296/
1374,Imatinib,30199910,[Chronic Myelogenous Leukemia].,"['Hochhaus A', 'Eigendorff E', 'Ernst T']","['Aniline Compounds/adverse effects/therapeutic use', 'Antineoplastic Agents/adverse effects/*therapeutic use', 'Blast Crisis/drug therapy', 'Cytogenetic Analysis', 'Dasatinib/adverse effects/therapeutic use', 'Drug Monitoring', 'Female', 'Humans', 'Imatinib Mesylate/adverse effects/therapeutic use', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/*drug therapy/genetics', 'Mutation/drug effects', 'Nitriles/adverse effects/therapeutic use', 'Pregnancy', 'Pregnancy Complications, Hematologic/*drug therapy', 'Pregnancy Complications, Neoplastic/*drug therapy', 'Prognosis', 'Protein Kinase Inhibitors/adverse effects/*therapeutic use', 'Protein-Tyrosine Kinases/antagonists & inhibitors', 'Pyrimidines/adverse effects/therapeutic use', 'Quinolines/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30199910/
1375,Imatinib,35680144,Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension.,"['Galkin A', 'Sitapara R', 'Clemons B', 'Garcia E', 'Kennedy M', 'Guimond D', 'Carter LL', 'Douthitt A', 'Osterhout R', 'Gandjeva A', 'Slee D', 'Salter-Cid L', 'Tuder RM', 'Zisman LS']","['Rats', 'Humans', 'Animals', '*Pulmonary Arterial Hypertension', 'Imatinib Mesylate/pharmacology/metabolism/therapeutic use', 'Monocrotaline', '*Hypertension, Pulmonary', 'Familial Primary Pulmonary Hypertension', 'Pulmonary Artery', 'Protein Kinase Inhibitors/pharmacology/therapeutic use', 'Hypoxia', '*MicroRNAs/metabolism', 'Disease Models, Animal']",https://pubmed.ncbi.nlm.nih.gov/35680144/
1376,Imatinib,38634915,Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.,"['Jain AG', 'Gesiotto Q', 'Ball S', 'Nodzon L', 'Rodriguez A', 'Chan O', 'Padron E', 'Kuykendall A', 'Komrokji R', 'Sallman DA', 'Lancet JE', 'Pinilla-Ibarz J', 'Sweet K']","['Humans', '*Dasatinib/adverse effects/administration & dosage/therapeutic use', 'Male', 'Female', 'Middle Aged', '*Protein Kinase Inhibitors/adverse effects/therapeutic use/administration & dosage', 'Aged', '*Pleural Effusion/chemically induced/epidemiology', 'Adult', 'Incidence', 'Leukemia, Myeloid, Chronic-Phase/drug therapy', 'Aged, 80 and over', 'Quinolines/adverse effects/administration & dosage/therapeutic use', 'Nitriles/adverse effects/therapeutic use', 'Drug Substitution', 'Aniline Compounds/adverse effects/therapeutic use/administration & dosage', 'Imatinib Mesylate/adverse effects/administration & dosage/therapeutic use', 'Young Adult', 'Retrospective Studies', 'Pyrimidines/adverse effects/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38634915/
1377,Imatinib,31155535,[Toward Personalized Cancer Therapy with Oral Molecular-targeted Agents].,"['Yamaguchi H', 'Takasaki S', 'Kikuchi M', 'Kawasaki Y', 'Arai Y', 'Mano N']","['Administration, Oral', 'Antineoplastic Agents/*administration & dosage/*adverse effects/pharmacokinetics', 'Asian People', 'Carcinoma, Renal Cell/*drug therapy', 'Drug Monitoring', 'Humans', 'Imatinib Mesylate/administration & dosage/adverse effects/pharmacokinetics', 'Kidney Neoplasms/*drug therapy', '*Molecular Targeted Therapy', '*Precision Medicine/methods', 'Sunitinib/administration & dosage/adverse effects/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/31155535/
1378,Imatinib,32166445,Towards point of care systems for the therapeutic drug monitoring of imatinib.,"['Pearce CM', 'Resmini M']","['Antineoplastic Agents/administration & dosage/*blood/pharmacokinetics', 'Chromatography, Liquid/methods', 'Drug Monitoring/*instrumentation', 'Electrochemical Techniques/methods', 'Enzyme-Linked Immunosorbent Assay/methods', 'Humans', 'Imatinib Mesylate/administration & dosage/*blood/pharmacokinetics', 'Limit of Detection', '*Point-of-Care Systems', 'Protein Kinase Inhibitors/administration & dosage/*blood/pharmacokinetics', 'Reproducibility of Results', 'Spectrophotometry, Ultraviolet/methods', 'Spectrum Analysis, Raman/methods', 'Tandem Mass Spectrometry/methods']",https://pubmed.ncbi.nlm.nih.gov/32166445/
1379,Imatinib,26969425,[Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?].,"['Jovelet C', 'Broutin S', 'Gil S', 'Mir O', 'Paci A']","['Abnormalities, Drug-Induced', 'Adult', 'Antineoplastic Agents/*adverse effects/pharmacokinetics', 'Dasatinib/adverse effects', 'Erlotinib Hydrochloride/adverse effects', 'Female', 'Fetus/*drug effects', 'Gefitinib', 'Humans', 'Imatinib Mesylate/adverse effects/pharmacokinetics', 'Lapatinib', 'Maternal Age', 'Placenta/metabolism', 'Pregnancy', 'Pregnancy Complications, Neoplastic/*drug therapy/metabolism', 'Protein Kinase Inhibitors/*adverse effects/pharmacokinetics', 'Protein-Tyrosine Kinases/*antagonists & inhibitors/pharmacokinetics', 'Pyrimidines/adverse effects', 'Quinazolines/adverse effects', 'Risk']",https://pubmed.ncbi.nlm.nih.gov/26969425/
1380,Imatinib,15796158,Clinical pharmacokinetics of imatinib mesylate.,"['Leveque D', 'Maloisel F']","['Administration, Oral', 'Antineoplastic Agents/administration & dosage/*pharmacokinetics', 'Benzamides', 'Drug Interactions', 'Enzyme Inhibitors/*therapeutic use', 'Gastrointestinal Neoplasms/*drug therapy', 'Humans', 'Imatinib Mesylate', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy', 'Piperazines/administration & dosage/*pharmacokinetics', 'Protein-Tyrosine Kinases/*antagonists & inhibitors', 'Pyrimidines/administration & dosage/*pharmacokinetics', 'Stromal Cells/drug effects']",https://pubmed.ncbi.nlm.nih.gov/15796158/
1381,Imatinib,29463446,How to treat chronic myeloid leukemia (CML) in older adults.,"['Luskin MR', 'DeAngelo DJ']","['Aged', 'Aniline Compounds/*administration & dosage/adverse effects', 'Dose-Response Relationship, Drug', 'Humans', 'Imatinib Mesylate/*administration & dosage/adverse effects', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy/genetics', 'Nitriles/*administration & dosage/adverse effects', 'Protein Kinase Inhibitors/*administration & dosage/adverse effects', 'Protein-Tyrosine Kinases/*antagonists & inhibitors', 'Quinolines/*administration & dosage/adverse effects', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/29463446/
1382,Imatinib,27100618,Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.,"['Samis J', 'Lee P', 'Zimmerman D', 'Arceci RJ', 'Suttorp M', 'Hijiya N']","['Adrenal Glands/drug effects', 'Aniline Compounds/adverse effects/therapeutic use', 'Antineoplastic Agents/adverse effects/therapeutic use', 'Bone Remodeling/drug effects', 'Child', 'Dasatinib/adverse effects/therapeutic use', 'Endocrine System/*drug effects/*pathology', 'Endocrine System Diseases/*chemically induced', 'Fusion Proteins, bcr-abl/antagonists & inhibitors', 'Glucose Metabolism Disorders/chemically induced', 'Humans', 'Imatinib Mesylate/adverse effects/therapeutic use', 'Imidazoles/adverse effects/therapeutic use', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy', 'Nitriles/adverse effects/therapeutic use', 'Protein Kinase Inhibitors/*adverse effects/*therapeutic use', 'Pyridazines/adverse effects/therapeutic use', 'Pyrimidines/adverse effects/therapeutic use', 'Quinolines/adverse effects/therapeutic use', 'Thyroid Gland/drug effects']",https://pubmed.ncbi.nlm.nih.gov/27100618/
1383,Imatinib,35473395,Lichenoid drug eruption associated with imatinib mesylate therapy.,"['Alexandris D', 'Alevizopoulos N', 'Marinos L', 'Kanellis G', 'Gakiopoulou C']","['Humans', 'Imatinib Mesylate/adverse effects', '*Lichenoid Eruptions/chemically induced/diagnosis/pathology', '*Drug Eruptions/diagnosis/etiology', '*Lichen Planus/chemically induced', 'Protein Kinase Inhibitors/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35473395/
1384,Imatinib,28589771,Imatinib mesylate in desmoplastic small round cell tumors.,"['De Sanctis R', 'Bertuzzi A', 'Bisogno G', 'Carli M', 'Ferrari A', 'Comandone A', 'Santoro A']","['Adolescent', 'Adult', 'Child', 'Desmoplastic Small Round Cell Tumor/*drug therapy/*genetics/pathology', 'Female', 'Gene Expression Regulation, Neoplastic/drug effects', 'Humans', 'Imatinib Mesylate/*administration & dosage/adverse effects', 'Italy', 'Male', 'Patient Selection', 'Proto-Oncogene Proteins c-kit/antagonists & inhibitors/genetics', 'Receptor, Platelet-Derived Growth Factor alpha/antagonists & inhibitors/genetics', 'Treatment Failure', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28589771/
1385,Imatinib,38772691,Imatinib-induced ulcerative colitis.,"['Ma Z', 'Zhao J', 'Li S', 'Gao F', 'Zhang C', 'Wu L', 'Lin Y']","['Humans', '*Imatinib Mesylate/adverse effects/therapeutic use', '*Colitis, Ulcerative/drug therapy', 'Male', 'Middle Aged', '*Gastrointestinal Stromal Tumors/drug therapy', '*Antineoplastic Agents/adverse effects/therapeutic use', 'Protein Kinase Inhibitors/adverse effects/therapeutic use', 'Diarrhea/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/38772691/
1386,Imatinib,39102630,Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study.,"['Yeung DT', 'Shanmuganathan N', 'Reynolds J', 'Branford S', 'Walia M', 'Yong ASM', 'Shortt J', 'Chee L', 'Viiala N', 'Cunningham I', 'Ross DM', ""D'Souza A"", 'Wright M', 'Harrup R', 'Forsyth C', 'Filshie R', 'Lane S', 'Browett P', 'Grove C', 'Grigg AP', 'Hughes TP']","['Humans', 'Male', 'Middle Aged', 'Female', 'Aged', 'Adult', 'Aged, 80 and over', '*Leukemia, Myeloid, Chronic-Phase/drug therapy', 'Fusion Proteins, bcr-abl/antagonists & inhibitors/genetics', 'Young Adult', 'Antineoplastic Agents/therapeutic use/adverse effects', 'Protein Kinase Inhibitors/therapeutic use/adverse effects/administration & dosage', 'Pyrimidines/therapeutic use/adverse effects/administration & dosage', 'Treatment Outcome', 'Imatinib Mesylate/therapeutic use/adverse effects/administration & dosage', 'Follow-Up Studies', 'Niacinamide/analogs & derivatives', 'Pyrazoles']",https://pubmed.ncbi.nlm.nih.gov/39102630/
1387,Imatinib,31313559,Imatinib Mesylate Induced Erythroderma.,"['Lunge S', 'Bhise R']","['Antineoplastic Agents/*adverse effects', 'Dermatitis, Exfoliative/*chemically induced', 'Exanthema', 'Female', 'Humans', 'Imatinib Mesylate/*adverse effects', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/31313559/
1388,nefazodone,10086478,Mechanism of action of antidepressant medications.,['Feighner JP'],"['Antidepressive Agents/*pharmacology/therapeutic use', 'Antidepressive Agents, Tricyclic/history/pharmacology/therapeutic use', 'Cyclohexanols/pharmacology/therapeutic use', 'Depressive Disorder/*drug therapy', 'Down-Regulation/drug effects', 'History, 20th Century', 'Humans', 'Monoamine Oxidase Inhibitors/history/pharmacology/therapeutic use', 'Receptors, Adrenergic/drug effects', 'Receptors, Adrenergic, beta/drug effects', 'Receptors, Dopamine/drug effects', 'Receptors, Glucocorticoid/drug effects', 'Receptors, Serotonin/drug effects', 'Selective Serotonin Reuptake Inhibitors/pharmacology/therapeutic use', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/10086478/
1389,nefazodone,9090573,Pharmacology of antidepressants.,['Frazer A'],"['Antidepressive Agents/adverse effects/*pharmacology/*therapeutic use', 'Antidepressive Agents, Second-Generation/pharmacology', 'Brain/*drug effects/metabolism', 'Depressive Disorder/*drug therapy', 'Humans', 'Monoamine Oxidase Inhibitors/pharmacology', 'Norepinephrine/metabolism', 'Receptor, Serotonin, 5-HT2A', 'Receptors, Adrenergic, alpha-1/metabolism', 'Receptors, Histamine H1/metabolism', 'Receptors, Muscarinic/metabolism', 'Receptors, Serotonin/metabolism', 'Serotonin/metabolism']",https://pubmed.ncbi.nlm.nih.gov/9090573/
1390,nefazodone,36253442,Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.,"['Kishi T', 'Ikuta T', 'Sakuma K', 'Okuya M', 'Hatano M', 'Matsuda Y', 'Iwata N']","['Female', 'Humans', 'Adult', '*Depressive Disorder, Major/drug therapy', 'Duloxetine Hydrochloride/therapeutic use', 'Sertraline/therapeutic use', 'Citalopram/therapeutic use', 'Venlafaxine Hydrochloride/therapeutic use', 'Vortioxetine/therapeutic use', 'Fluoxetine/therapeutic use', 'Paroxetine/therapeutic use', 'Mirtazapine/therapeutic use', 'Amitriptyline/therapeutic use', 'Desvenlafaxine Succinate/therapeutic use', 'Fluvoxamine/therapeutic use', 'Reboxetine/therapeutic use', 'Network Meta-Analysis', 'Antidepressive Agents/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/36253442/
1391,nefazodone,7500370,Antidepressant-induced orgasm disorder.,['Segraves RT'],"['Antidepressive Agents/*adverse effects', 'Drug Therapy, Combination', 'Ejaculation/drug effects', 'Female', 'Humans', 'Male', 'Orgasm/*drug effects', 'Prevalence', 'Selective Serotonin Reuptake Inhibitors/adverse effects', 'Sexual Dysfunction, Physiological/*chemically induced/drug therapy/epidemiology/physiopathology/therapy', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/7500370/
1392,nefazodone,23914755,Liver injury associated with antidepressants.,"['Park SH', 'Ishino R']","['Animals', 'Antidepressive Agents/administration & dosage/*adverse effects/therapeutic use', 'Chemical and Drug Induced Liver Injury/diagnosis/epidemiology/*etiology', 'Drug Interactions', 'Drug Monitoring/*methods', 'Humans', 'Liver Function Tests', 'Risk Factors', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/23914755/
1393,nefazodone,10926053,Weight gain and antidepressants.,['Fava M'],"['Antidepressive Agents/*adverse effects/therapeutic use', 'Antidepressive Agents, Tricyclic/adverse effects/therapeutic use', 'Depressive Disorder/*drug therapy', 'Female', 'Humans', 'Male', 'Monoamine Oxidase Inhibitors/adverse effects/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/adverse effects/therapeutic use', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/10926053/
1394,nefazodone,19440080,Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.,"['Serretti A', 'Chiesa A']","['Antidepressive Agents/*adverse effects', 'Arousal/drug effects', 'Female', 'Humans', 'Male', 'Orgasm/drug effects', 'Sex Factors', 'Sexual Dysfunctions, Psychological/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/19440080/
1395,nefazodone,12904104,Antidepressant-induced hepatotoxicity.,"['Lucena MI', 'Carvajal A', 'Andrade RJ', 'Velasco A']","['Antidepressive Agents/*adverse effects/chemistry/therapeutic use', 'Antidepressive Agents, Second-Generation/adverse effects/chemistry/therapeutic use', 'Antidepressive Agents, Tricyclic/adverse effects/chemistry/therapeutic use', 'Chemical and Drug Induced Liver Injury/*etiology/prevention & control/therapy', 'Chemical and Drug Induced Liver Injury, Chronic/etiology/prevention & control/therapy', 'Depressive Disorder/drug therapy/etiology', 'Humans', 'Monoamine Oxidase Inhibitors/adverse effects/chemistry/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/adverse effects/chemistry/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12904104/
1396,nefazodone,9554321,Antidepressant-induced sexual dysfunction.,['Segraves RT'],"['Antidepressive Agents/*adverse effects', 'Antidepressive Agents, Second-Generation/adverse effects', 'Bupropion/adverse effects', 'Female', 'Humans', 'Libido/drug effects', 'Male', 'Piperazines', 'Selective Serotonin Reuptake Inhibitors/adverse effects', 'Sexual Dysfunctions, Psychological/*chemically induced/drug therapy', 'Triazoles/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/9554321/
1397,nefazodone,28822709,The influence of antidepressants on restless legs syndrome and periodic limb movements: A systematic review.,"['Kolla BP', 'Mansukhani MP', 'Bostwick JM']","['Antidepressive Agents/*adverse effects', '*Comorbidity', 'Cross-Sectional Studies', 'Humans', 'Prospective Studies', 'Restless Legs Syndrome/*complications', 'Sleep/drug effects']",https://pubmed.ncbi.nlm.nih.gov/28822709/
1398,nefazodone,20726290,Best practice guide for the treatment of nightmare disorder in adults.,"['Aurora RN', 'Zak RS', 'Auerbach SH', 'Casey KR', 'Chowdhuri S', 'Karippot A', 'Maganti RK', 'Ramar K', 'Kristo DA', 'Bista SR', 'Lamm CI', 'Morgenthaler TI']","['Adult', 'Clonidine/therapeutic use', 'Cognitive Behavioral Therapy/methods', 'Dreams/drug effects/*psychology', 'Evidence-Based Medicine', 'Eye Movement Desensitization Reprocessing', 'Humans', 'Hypnosis', 'Norepinephrine/antagonists & inhibitors', 'Prazosin/therapeutic use', 'Psychotropic Drugs/therapeutic use', 'Randomized Controlled Trials as Topic', 'Relaxation Therapy', 'Stress Disorders, Post-Traumatic/diagnosis/*therapy']",https://pubmed.ncbi.nlm.nih.gov/20726290/
1399,nefazodone,33459228,"HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview.","['Balasubramanian R', 'Maideen NMP']","['ATP Binding Cassette Transporter, Subfamily B, Member 1/*metabolism', 'Anti-Infective Agents', 'Anticonvulsants', 'Antiviral Agents', 'Cardiovascular Agents', 'Colchicine', 'Contraceptives, Oral', 'Cytochrome P-450 CYP3A/*metabolism', 'Drug Interactions', 'Fibric Acids', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/blood/*pharmacology', 'Immunosuppressive Agents', 'Organic Anion Transporters/*metabolism', 'Phosphodiesterase 5 Inhibitors', 'Piperazines', 'Triazoles', 'Warfarin']",https://pubmed.ncbi.nlm.nih.gov/33459228/
1400,nefazodone,9227670,Safety and tolerability of the new antidepressants.,['Nelson JC'],"['Antidepressive Agents, Second-Generation/*adverse effects/*therapeutic use', 'Antidepressive Agents, Tricyclic/adverse effects/therapeutic use', 'Cyclohexanols/adverse effects/therapeutic use', 'Depressive Disorder/*drug therapy', 'Headache/chemically induced', 'Humans', 'Mianserin/adverse effects/analogs & derivatives/therapeutic use', 'Mirtazapine', 'Nausea/chemically induced', 'Piperazines', 'Selective Serotonin Reuptake Inhibitors/*adverse effects/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/chemically induced', 'Triazoles/adverse effects/therapeutic use', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/9227670/
1401,nefazodone,16236049,Mirtazapine-induced arthralgia.,"['Passier A', 'van Puijenbroek E']","['Adult', 'Antidepressive Agents, Tricyclic/*adverse effects', 'Arthralgia/*chemically induced', 'Depressive Disorder/*drug therapy', 'Female', 'Humans', 'Male', 'Mianserin/adverse effects/*analogs & derivatives', 'Middle Aged', 'Mirtazapine']",https://pubmed.ncbi.nlm.nih.gov/16236049/
1402,nefazodone,25894359,Treatment of Sleep Disturbances in Post-Traumatic Stress Disorder: A Review of the Literature.,"['Brownlow JA', 'Harb GC', 'Ross RJ']","['Antipsychotic Agents/therapeutic use', '*Cognitive Behavioral Therapy', 'Dreams', '*Eye Movement Desensitization Reprocessing', 'Fluvoxamine/therapeutic use', 'Humans', 'Piperazines', 'Prazosin/therapeutic use', 'REM Sleep Behavior Disorder/therapy', 'Restless Legs Syndrome/therapy', 'Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', 'Sleep', 'Sleep Apnea, Obstructive/therapy', 'Sleep Initiation and Maintenance Disorders/therapy', 'Sleep Wake Disorders/psychology/*therapy', 'Stress Disorders, Post-Traumatic/*psychology/therapy', 'Trazodone/therapeutic use', 'Triazoles/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25894359/
1403,nefazodone,11568979,"Depression, sleep physiology, and antidepressant drugs.","['Winokur A', 'Gary KA', 'Rodner S', 'Rae-Red C', 'Fernando AT', 'Szuba MP']","['Antidepressive Agents/*therapeutic use', 'Depressive Disorder/*drug therapy/*physiopathology', 'Humans', 'Polysomnography', 'Sleep/*drug effects/*physiology']",https://pubmed.ncbi.nlm.nih.gov/11568979/
1404,nefazodone,10468320,Nefazodone-induced clitoral priapism.,"['Brodie-Meijer CC', 'Diemont WL', 'Buijs PJ']","['Antidepressive Agents, Second-Generation/*adverse effects/therapeutic use', 'Clitoris/*drug effects', 'Depressive Disorder/complications/drug therapy', 'Female', 'Humans', 'Middle Aged', 'Piperazines', 'Triazoles/*adverse effects/therapeutic use', 'Vaginal Diseases/*chemically induced/pathology']",https://pubmed.ncbi.nlm.nih.gov/10468320/
1405,nefazodone,27091414,Antidepressants and Driving in Older Adults: A Systematic Review.,"['Cameron DH', 'Rapoport MJ']","['Age Factors', 'Aged', 'Aged, 80 and over', 'Aging', 'Antidepressive Agents/administration & dosage/*adverse effects', '*Automobile Driving/psychology', 'Cohort Studies', 'Cross-Over Studies', 'Depression/complications/*drug therapy', 'Humans', 'Middle Aged', 'Retrospective Studies', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/27091414/
1406,nefazodone,27289172,Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.,"['Cipriani A', 'Zhou X', 'Del Giovane C', 'Hetrick SE', 'Qin B', 'Whittington C', 'Coghill D', 'Zhang Y', 'Hazell P', 'Leucht S', 'Cuijpers P', 'Pu J', 'Cohen D', 'Ravindran AV', 'Liu Y', 'Michael KD', 'Yang L', 'Liu L', 'Xie P']","['Adolescent', 'Amitriptyline/administration & dosage/adverse effects', 'Antidepressive Agents/*administration & dosage/*adverse effects', 'Bayes Theorem', 'Child', 'Citalopram/administration & dosage/adverse effects', 'Clomipramine/administration & dosage/adverse effects', 'Confounding Factors, Epidemiologic', 'Depressive Disorder, Major/*drug therapy', 'Desipramine/administration & dosage/adverse effects', 'Double-Blind Method', 'Drug Administration Schedule', 'Duloxetine Hydrochloride/administration & dosage/adverse effects', 'Evidence-Based Medicine', 'Fluoxetine/administration & dosage/adverse effects', 'Humans', 'Imipramine/administration & dosage/adverse effects', 'Mianserin/administration & dosage/adverse effects/analogs & derivatives', 'Mirtazapine', 'Nortriptyline/administration & dosage/adverse effects', 'Paroxetine/administration & dosage/adverse effects', 'Piperazines', 'Randomized Controlled Trials as Topic', 'Research Design', 'Sertraline/administration & dosage/adverse effects', 'Treatment Outcome', 'Triazoles/administration & dosage/adverse effects', 'Venlafaxine Hydrochloride/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27289172/
1407,nefazodone,11519152,[Serotonin-noradrenaline reuptake inhibitors(SNRIs)].,['Ishigooka J'],"['Adrenergic Uptake Inhibitors/adverse effects/*pharmacology/therapeutic use', 'Antidepressive Agents/adverse effects/*pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Cyclohexanols/adverse effects/pharmacology/therapeutic use', 'Cyclopropanes/adverse effects/pharmacology/therapeutic use', 'Depressive Disorder, Major/drug therapy', 'Humans', 'Milnacipran', 'Selective Serotonin Reuptake Inhibitors/adverse effects/*pharmacology/therapeutic use', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/11519152/
1408,cefepime,37837651,Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial.,"['Qian ET', 'Casey JD', 'Wright A', 'Wang L', 'Shotwell MS', 'Siemann JK', 'Dear ML', 'Stollings JL', 'Lloyd BD', 'Marvi TK', 'Seitz KP', 'Nelson GE', 'Wright PW', 'Siew ED', 'Dennis BM', 'Wrenn JO', 'Andereck JW', 'Han JH', 'Self WH', 'Semler MW', 'Rice TW']","['Humans', 'Adult', 'Female', 'Middle Aged', 'Male', 'Anti-Bacterial Agents/adverse effects', 'Cefepime/adverse effects', 'Coma', 'Piperacillin/adverse effects', 'Drug Therapy, Combination', 'Retrospective Studies', 'Piperacillin, Tazobactam Drug Combination/adverse effects', '*Sepsis/complications', '*Acute Kidney Injury/etiology', 'Kidney', '*Delirium']",https://pubmed.ncbi.nlm.nih.gov/37837651/
1409,cefepime,38739397,Mortality of Patients With Sepsis Administered Piperacillin-Tazobactam vs Cefepime.,"['Chanderraj R', 'Admon AJ', 'He Y', 'Nuppnau M', 'Albin OR', 'Prescott HC', 'Dickson RP', 'Sjoding MW']","['Humans', '*Cefepime/administration & dosage/therapeutic use', '*Piperacillin, Tazobactam Drug Combination/administration & dosage/therapeutic use', 'Male', '*Anti-Bacterial Agents/administration & dosage/therapeutic use', 'Female', '*Sepsis/drug therapy/mortality', 'Retrospective Studies', 'Aged', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/38739397/
1410,cefepime,36194218,Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.,"['Kaye KS', 'Belley A', 'Barth P', 'Lahlou O', 'Knechtle P', 'Motta P', 'Velicitat P']","['Acute Disease', '*Anti-Bacterial Agents/administration & dosage/adverse effects/therapeutic use', '*Cefepime/administration & dosage/adverse effects/therapeutic use', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Gram-Negative Bacterial Infections/drug therapy', 'Humans', 'Infusions, Intravenous', 'Male', 'Middle Aged', '*Piperacillin, Tazobactam Drug Combination/administration & dosage/adverse effects/therapeutic use', '*Pyelonephritis/drug therapy/microbiology', '*Urinary Tract Infections/complications/drug therapy/microbiology', '*beta-Lactamase Inhibitors/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36194218/
1411,cefepime,38354140,Cefepime-Taniborbactam in Complicated Urinary Tract Infection.,"['Wagenlehner FM', 'Gasink LB', 'McGovern PC', 'Moeck G', 'McLeroth P', 'Dorr M', 'Dane A', 'Henkel T']","['Adult', 'Aged', 'Humans', 'Middle Aged', 'Administration, Intravenous', '*Anti-Bacterial Agents/administration & dosage/adverse effects/therapeutic use', 'Bacteremia/drug therapy/microbiology', 'beta-Lactamases/administration & dosage/adverse effects/therapeutic use', '*Borinic Acids/administration & dosage/adverse effects/therapeutic use', '*Carboxylic Acids/administration & dosage/adverse effects/therapeutic use', '*Cefepime/administration & dosage/adverse effects/therapeutic use', 'Drug Therapy, Combination', 'Hospitalization', '*Meropenem/administration & dosage/adverse effects/therapeutic use', 'Microbial Sensitivity Tests', 'Pyelonephritis/drug therapy/microbiology', '*Urinary Tract Infections/drug therapy/microbiology', 'Drug Resistance, Bacterial']",https://pubmed.ncbi.nlm.nih.gov/38354140/
1412,cefepime,29137682,Cefepime-induced neurotoxicity: a systematic review.,"['Payne LE', 'Gagnon DJ', 'Riker RR', 'Seder DB', 'Glisic EK', 'Morris JG', 'Fraser GL']","['Anti-Bacterial Agents/adverse effects/therapeutic use', 'Cefepime', 'Cephalosporins/*adverse effects/therapeutic use', 'Consciousness Disorders/chemically induced', 'Drug-Related Side Effects and Adverse Reactions/diagnosis', 'Humans', 'Neurotoxicity Syndromes/complications/*etiology/physiopathology', 'Seizures/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/29137682/
1413,cefepime,35764774,Clinical Pharmacokinetics and Pharmacodynamics of Cefepime.,"['Pais GM', 'Chang J', 'Barreto EF', 'Stitt G', 'Downes KJ', 'Alshaer MH', 'Lesnicki E', 'Panchal V', 'Bruzzone M', 'Bumanglag AV', 'Burke SN', 'Scheetz MH']","['Adult', '*Anti-Bacterial Agents/pharmacokinetics', 'Cefepime/pharmacology', '*Cephalosporins/pharmacology/therapeutic use', 'Critical Illness', 'Humans', 'Microbial Sensitivity Tests']",https://pubmed.ncbi.nlm.nih.gov/35764774/
1414,cefepime,31778052,[Cefepime-induced encephalopathy].,"['Muradbegovic J', 'Leidi A', 'Serratrice J']","['Anti-Bacterial Agents/adverse effects/supply & distribution/therapeutic use', 'Brain Diseases/blood/*chemically induced/diagnosis', 'Cefepime/administration & dosage/*adverse effects/blood/therapeutic use', 'Humans', 'Renal Insufficiency/blood/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31778052/
1415,cefepime,35971666,Cefepime-induced neurotoxicity: systematic review.,"['Maan G', 'Keitoku K', 'Kimura N', 'Sawada H', 'Pham A', 'Yeo J', 'Hagiya H', 'Nishimura Y']","['Humans', 'Cefepime/adverse effects', 'Cephalosporins/adverse effects', 'Anti-Bacterial Agents/adverse effects', '*Neurotoxicity Syndromes/etiology', '*Brain Diseases/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/35971666/
1416,cefepime,37846592,Antibiotic therapy for nonfermenting Gram-negative bacilli infections: future perspectives.,"['Bassetti M', 'Castaldo N', 'Fantin A', 'Giacobbe DR', 'Vena A']","['Humans', 'Cefepime/pharmacology/therapeutic use', '*Gram-Negative Bacterial Infections/drug therapy/microbiology', 'Anti-Bacterial Agents/pharmacology/therapeutic use', 'Gram-Negative Bacteria', 'Cephalosporins/therapeutic use', 'Microbial Sensitivity Tests']",https://pubmed.ncbi.nlm.nih.gov/37846592/
1417,cefepime,30882137,Antibiotic Therapy for Pseudomonas aeruginosa Bloodstream Infections: How Long Is Long Enough?,"['Fabre V', 'Amoah J', 'Cosgrove SE', 'Tamma PD']","['Aged', 'Bacteremia/*drug therapy/*microbiology', 'Cefepime/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Piperacillin, Tazobactam Drug Combination/*therapeutic use', 'Pseudomonas aeruginosa/*drug effects/*pathogenicity']",https://pubmed.ncbi.nlm.nih.gov/30882137/
1418,cefepime,36374566,Subcutaneously administered antibiotics: a review.,"['Jumpertz M', 'Guilhaumou R', 'Million M', 'Parola P', 'Lagier JC', 'Brouqui P', 'Cassir N']","['Humans', '*Anti-Bacterial Agents/adverse effects', 'Ertapenem', '*Ceftriaxone', 'Teicoplanin', 'Cefepime']",https://pubmed.ncbi.nlm.nih.gov/36374566/
1419,cefepime,36745895,"In complicated UTI or pyelonephritis, cefepime-enmetazobactam increased success vs. piperacillin-tazobactam at 14 d.",['Maki DG'],"['Humans', 'Anti-Bacterial Agents/therapeutic use', 'Cefepime/therapeutic use', 'Piperacillin, Tazobactam Drug Combination/therapeutic use', '*Pyelonephritis/drug therapy', '*Urinary Tract Infections/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/36745895/
1420,cefepime,35904000,"Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.","['Lasarte-Monterrubio C', 'Fraile-Ribot PA', 'Vazquez-Ucha JC', 'Cabot G', 'Guijarro-Sanchez P', 'Alonso-Garcia I', 'Rumbo-Feal S', 'Galan-Sanchez F', 'Beceiro A', 'Arca-Suarez J', 'Oliver A', 'Bou G']","['Anti-Bacterial Agents/pharmacology/therapeutic use', 'Azabicyclo Compounds/pharmacology/therapeutic use', 'Borinic Acids', 'Carboxylic Acids', 'Cefepime/pharmacology/therapeutic use', '*Ceftazidime/pharmacology/therapeutic use', 'Cephalosporins/pharmacology/therapeutic use', 'Cyclooctanes', 'Humans', 'Imipenem/pharmacology/therapeutic use', 'Piperidines', '*Pseudomonas Infections/drug therapy', 'Pseudomonas aeruginosa/genetics', 'Tazobactam/pharmacology/therapeutic use', 'beta-Lactamases/genetics', 'Cefiderocol']",https://pubmed.ncbi.nlm.nih.gov/35904000/
1421,cefepime,38761353,Cefepime/Enmetazobactam: First Approval.,['Keam SJ'],"['Humans', '*Anti-Bacterial Agents/pharmacology/therapeutic use/administration & dosage', 'beta-Lactamase Inhibitors/pharmacology/therapeutic use/administration & dosage', '*Cefepime/pharmacology/therapeutic use', 'Cephalosporins/therapeutic use/pharmacology', '*Drug Approval', 'Drug Combinations', 'Drug Resistance, Multiple, Bacterial/drug effects', 'Gram-Negative Bacteria/drug effects', 'Gram-Negative Bacterial Infections/drug therapy', 'Pyelonephritis/drug therapy/microbiology', 'United States', '*Urinary Tract Infections/drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/38761353/
1422,cefepime,23127270,Pediatric cefepime neurotoxicity.,"['Landgrave LC', 'Lock JL', 'Whitmore JM', 'Belcher CE']","['Acute Kidney Injury/*chemically induced', 'Adolescent', 'Anti-Bacterial Agents/*adverse effects', 'Cefepime', 'Cephalosporins/*adverse effects', 'Female', 'Humans', 'Neurotoxicity Syndromes/*diagnosis']",https://pubmed.ncbi.nlm.nih.gov/23127270/
1423,cefepime,34729808,A Case of Cefepime-Induced Immune Thrombocytopenia.,"['Bystrom R', 'Wungwattana M', 'Tchekmedyian V']","['Adult', 'Blood Platelets', 'Cefepime/adverse effects', 'Humans', 'Male', '*Purpura, Thrombocytopenic, Idiopathic/chemically induced/diagnosis', '*Thrombocytopenia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/34729808/
1424,cefepime,37993680,Cefepime versus carbapenems for treatment of AmpC beta-lactamase-producing Enterobacterales bloodstream infections.,"['Herrmann J', 'Burgener-Gasser AV', 'Goldenberger D', 'Roth J', 'Weisser M', 'Tamma PD', 'Tschudin-Sutter S']","['Humans', 'Cefepime/adverse effects', 'Anti-Bacterial Agents/adverse effects', 'Carbapenems/adverse effects', 'Cephalosporins/adverse effects', 'Retrospective Studies', 'Hospital Mortality', '*Enterobacteriaceae Infections/drug therapy/microbiology', 'beta-Lactamases', '*Sepsis/drug therapy', '*Gammaproteobacteria', 'Microbial Sensitivity Tests', '*Bacterial Proteins']",https://pubmed.ncbi.nlm.nih.gov/37993680/
1425,cefepime,37028731,Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC beta-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study.,"['Maillard A', 'Delory T', 'Bernier J', 'Villa A', 'Chaibi K', 'Escaut L', 'Contejean A', 'Bercot B', 'Robert J', 'El Alaoui F', 'Tankovic J', 'Poupet H', 'Cuzon G', 'Lafaurie M', 'Surgers L', 'Joseph A', 'Paccoud O', 'Molina JM', 'Bleibtreu A']","['Humans', 'Cefepime/therapeutic use', '*Piperacillin/therapeutic use', '*Carbapenems/therapeutic use', 'Retrospective Studies', 'Anti-Bacterial Agents/therapeutic use', 'beta-Lactamases', 'Piperacillin, Tazobactam Drug Combination/therapeutic use', 'Cephalosporins/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37028731/
1426,cefepime,30968302,Cefepime challenge after piperacillin/tazobactam-induced thrombocytopenia.,"['Beaulieu C', 'Kurczewski L', 'Yajnik V']","['Adult', 'Anti-Bacterial Agents/pharmacology', 'Cefepime/pharmacology/*therapeutic use', 'Female', 'Humans', '*Immunity, Humoral', 'Male', 'Piperacillin/adverse effects', 'Piperacillin, Tazobactam Drug Combination/adverse effects', 'Pneumonia, Aspiration/drug therapy', 'Tazobactam/adverse effects', 'Thrombocytopenia/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/30968302/
1427,cefepime,38733970,Cefepime-taniborbactam and CERTAIN-1: Can we treat carbapenem-resistant infections?,"['Bassetti M', 'Giacobbe DR']","['*Cefepime/therapeutic use/pharmacology', 'Humans', '*Anti-Bacterial Agents/therapeutic use/pharmacology', '*Carbapenems/therapeutic use/pharmacology', '*Urinary Tract Infections/drug therapy/microbiology', 'Cephalosporins/therapeutic use/pharmacology', 'Pyelonephritis/drug therapy/microbiology', 'Drug Combinations', 'Gram-Negative Bacterial Infections/drug therapy', 'Meropenem/therapeutic use/pharmacology', 'Borinic Acids', 'Carboxylic Acids']",https://pubmed.ncbi.nlm.nih.gov/38733970/
1428,promethazine,25233954,Pink urine.,"['Verhoeven E', 'Capron A', 'Hantson P']","['Alcoholism/pathology', 'Crystallization', 'Ethanol/blood', 'Humans', 'Hydrogen-Ion Concentration', 'Male', 'Middle Aged', 'Pentanoic Acids/urine', 'Promethazine/blood/therapeutic use/urine', 'Tablets/administration & dosage/poisoning', 'Uric Acid/urine', 'Valerian/*poisoning']",https://pubmed.ncbi.nlm.nih.gov/25233954/
1429,promethazine,27170253,Meniere's disease.,"['Nakashima T', 'Pyykko I', 'Arroll MA', 'Casselbrant ML', 'Foster CA', 'Manzoor NF', 'Megerian CA', 'Naganawa S', 'Young YH']","['Antiemetics/pharmacology/therapeutic use', 'Audiometry/methods', 'Benzodiazepines/pharmacology/therapeutic use', 'Catheter Ablation/methods', 'Dimenhydrinate/pharmacology/therapeutic use', 'Ear, Inner/pathology/physiopathology', 'Endolymph/metabolism', 'Ganglia, Sensory/abnormalities/injuries', 'Hearing Loss/etiology', 'Humans', 'Magnetic Resonance Imaging/methods', 'Meclizine/pharmacology/therapeutic use', 'Meniere Disease/*complications/epidemiology/*physiopathology', 'Promethazine/pharmacology/therapeutic use', 'Quality of Life/psychology', 'Tinnitus/etiology', 'Vertigo/etiology']",https://pubmed.ncbi.nlm.nih.gov/27170253/
1430,promethazine,6928910,Intramuscular sedation technique.,"['Jensen ST', 'Coke JM', 'Cohen L']","['Anesthesia, Dental/*methods', 'Anesthesia, General/*methods', 'Buttocks', 'Humans', 'Hypnotics and Sedatives/administration & dosage', 'Injections, Intramuscular/methods', 'Meperidine/administration & dosage/pharmacology', 'Promethazine/administration & dosage', 'Respiration/drug effects']",https://pubmed.ncbi.nlm.nih.gov/6928910/
1431,promethazine,3615241,Promethazine-induced dystonic reaction.,"['DeGrandi T', 'Simon JE']","['Acute Disease', 'Adolescent', 'Dystonia/*chemically induced/drug therapy', 'Female', 'Gastroenteritis/complications', 'Humans', 'Promethazine/*adverse effects/therapeutic use', 'Suppositories', 'Vomiting/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/3615241/
1432,promethazine,7874402,Approach to the dizzy patient.,['Baloh RW'],"['Anxiety Disorders/*complications/psychology', 'Brain Diseases/*complications/physiopathology', 'Diazepam/administration & dosage/therapeutic use', 'Dizziness/*etiology/physiopathology', 'Heart Diseases/*complications/physiopathology', 'Humans', 'Meclizine/administration & dosage/therapeutic use', 'Meniere Disease/*complications', 'Migraine Disorders/*complications', 'Prochlorperazine/administration & dosage/therapeutic use', 'Promethazine/administration & dosage/therapeutic use', 'Proprioception', 'Scopolamine/administration & dosage/therapeutic use', 'Substance-Related Disorders/*complications/physiopathology', 'Time Factors', 'Vertebrobasilar Insufficiency/*complications', 'Vertigo/drug therapy/*etiology', 'Vestibular Diseases/*complications/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/7874402/
1433,promethazine,27725018,Angio-oedema associated with colistin.,"['Abulfathi AA', 'Greyling T', 'Makiwane M', 'Esser M', 'Decloedt E']","['Acinetobacter baumannii/isolation & purification', '*Angioedema/chemically induced/diagnosis/physiopathology/therapy', 'Anti-Allergic Agents/administration & dosage', 'Anti-Bacterial Agents/administration & dosage/adverse effects', 'Colistin/administration & dosage/*adverse effects', 'Diagnosis, Differential', 'Female', 'Humans', 'Hydrocortisone/*administration & dosage', 'Middle Aged', 'Promethazine/*administration & dosage', 'Sepsis/diagnosis/*drug therapy/etiology', 'Treatment Outcome', 'Urinary Tract Infections/*complications/microbiology', 'Withholding Treatment']",https://pubmed.ncbi.nlm.nih.gov/27725018/
1434,promethazine,11764306,Standard treatment: the role of antihistamines.,['Merk HF'],"['Cyclizine/therapeutic use', 'Cytochrome P-450 Enzyme System/biosynthesis', 'Diphenhydramine/therapeutic use', 'Electrocardiography/adverse effects', 'Histamine H1 Antagonists/*therapeutic use', 'Humans', 'Promethazine/therapeutic use', 'Pyrilamine/therapeutic use', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11764306/
1435,promethazine,8443849,Nasal ketamine for paediatric premedication.,"['Weksler N', 'Ovadia L', 'Muati G', 'Stav A']","['Administration, Intranasal', 'Anesthesia Recovery Period', 'Anesthesia, Inhalation', 'Child, Preschool', '*Conscious Sedation', 'Double-Blind Method', 'Female', 'Humans', 'Injections, Intramuscular', 'Ketamine/administration & dosage/*therapeutic use', 'Male', 'Meperidine/administration & dosage/therapeutic use', '*Preanesthetic Medication', 'Promethazine/administration & dosage/therapeutic use', 'Salivation/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/8443849/
1436,promethazine,36183207,Use of tracking drugs for the search of intra-hospital adverse reactions: a pharmacovigilance study.,"['Correa Benedet Baesso K', 'Zapelini do Nascimento D', 'De Sa Soares A', 'Schuelter-Trevisol F']","['Adverse Drug Reaction Reporting Systems', 'Cross-Sectional Studies', 'Diphenhydramine/adverse effects', '*Drug-Related Side Effects and Adverse Reactions/epidemiology', 'Flumazenil', 'Hospitals', 'Humans', 'Loperamide', 'Naloxone', '*Pharmacovigilance', 'Promethazine']",https://pubmed.ncbi.nlm.nih.gov/36183207/
1437,promethazine,37122169,"Promethazine inhibits efflux, enhances antifungal susceptibility and disrupts biofilm structure and functioning in Trichosporon.","['Aguiar ALR', 'Silva BND', 'Fiallos NM', 'Pereira LMG', 'Silva ML', 'Souza PFSM', 'Portela FVM', 'Sidrim JJC', 'Rocha MFG', 'Castelo-Branco DSCM', 'Cordeiro RA']","['Microbial Sensitivity Tests', 'Basidiomycota', 'Promethazine/pharmacology/metabolism', '*Trichosporon', 'Plankton', '*Antifungal Agents/pharmacology/metabolism', 'Biofilms', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/37122169/
1438,promethazine,39699316,Injectable promethazine in clinics and hospitals: What's the alternative?,"['Overholser A', 'Sizemore M', 'Czech E']","['Humans', '*Promethazine/administration & dosage', 'Injections', 'Injections, Subcutaneous']",https://pubmed.ncbi.nlm.nih.gov/39699316/
1439,promethazine,2677941,"Lytic/""DPT"" cocktail: time for rational and safe alternatives.","['Snodgrass WR', 'Dodge WF']","['Child', 'Child, Preschool', 'Chlorpromazine/administration & dosage/adverse effects', 'Diazepam/administration & dosage/pharmacology', 'Drug Combinations/*adverse effects', 'Humans', 'Infant', 'Meperidine/administration & dosage/adverse effects', 'Midazolam/administration & dosage/pharmacology', 'Morphine/administration & dosage/pharmacology', 'Preanesthetic Medication/*adverse effects', 'Promethazine/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2677941/
1440,promethazine,24350243,Topical promethazine side effects: our experience and review of the literature.,"['Cantisani C', 'Ricci S', 'Grieco T', 'Paolino G', 'Faina V', 'Silvestri E', 'Calvieri S']","['Epidermis/*drug effects/*metabolism', 'Histamine H1 Antagonists/adverse effects/therapeutic use', 'Humans', 'Inflammation/drug therapy', 'Promethazine/*adverse effects/*therapeutic use', 'Skin Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24350243/
1441,promethazine,11543005,Pharmacotherapeutics in space.,['Putcha L'],"['Acetaminophen/administration & dosage/pharmacokinetics', '*Aerospace Medicine', 'Analgesics, Non-Narcotic/administration & dosage/pharmacokinetics', 'Headache/drug therapy', 'Histamine H1 Antagonists/administration & dosage/pharmacokinetics', 'Humans', 'Muscarinic Antagonists/pharmacokinetics', '*Pharmacology, Clinical', 'Promethazine/administration & dosage/pharmacokinetics', 'Saliva/*metabolism', 'Scopolamine/administration & dosage/pharmacokinetics', '*Space Flight', 'Space Motion Sickness/drug therapy', '*Weightlessness']",https://pubmed.ncbi.nlm.nih.gov/11543005/
1442,promethazine,3675502,Mechanisms of antimotion sickness drugs.,"['Wood CD', 'Manno JE', 'Wood MJ', 'Manno BR', 'Redetzki HM']","['Adult', 'Dextroamphetamine/*therapeutic use', 'Dimenhydrinate/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Motion Sickness/*prevention & control', 'Placebos', 'Promethazine/*therapeutic use', 'Scopolamine/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3675502/
1443,promethazine,33351859,Targeting bioenergetics is key to counteracting the drug-tolerant state of biofilm-grown bacteria.,"['Donnert M', 'Elsheikh S', 'Arce-Rodriguez A', 'Pawar V', 'Braubach P', 'Jonigk D', 'Haverich A', 'Weiss S', 'Musken M', 'Haussler S']","['Animals', 'Biofilms/*drug effects', 'Drug Tolerance/physiology', 'Energy Metabolism/*drug effects', 'Humans', 'Mice', 'Mice, Inbred BALB C', 'Promethazine/*pharmacology', 'Pseudomonas Infections', 'Pseudomonas aeruginosa/*drug effects/*physiology']",https://pubmed.ncbi.nlm.nih.gov/33351859/
1444,promethazine,8746124,Successful cancer therapy with promethazine: the rationale.,['Jones GR'],"['Antineoplastic Agents/adverse effects/*therapeutic use', 'Breast Neoplasms/drug therapy', 'Chlorpromazine/therapeutic use', 'Cyclophosphamide/therapeutic use', 'Female', 'Humans', 'Male', 'Neoplasms/*drug therapy/pathology', 'Pancreatic Neoplasms/drug therapy', 'Phenothiazines/therapeutic use', 'Promethazine/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8746124/
1445,promethazine,404894,Intraarterial analgesia in peripheral arteriography.,"['Guthaner DF', 'Silverman JF', 'Hayden WG', 'Wexler L']","['*Analgesia', '*Angiography', 'Diazepam', 'Humans', 'Injections, Intra-Arterial', 'Lidocaine/*administration & dosage', 'Meperidine', 'Premedication', 'Promethazine']",https://pubmed.ncbi.nlm.nih.gov/404894/
1446,promethazine,11538042,Comparison of efficacy of ginger with various antimotion sickness drugs.,"['Wood CD', 'Manno JE', 'Wood MJ', 'Manno BR', 'Mims ME']","['Administration, Oral', 'Adolescent', 'Adult', 'Antiemetics/administration & dosage/*therapeutic use', 'Dextroamphetamine/*therapeutic use', 'Dimenhydrinate/administration & dosage/therapeutic use', 'Female', 'Humans', 'Male', 'Motion Sickness/drug therapy/*prevention & control', 'Plants, Medicinal/*metabolism', 'Promethazine/administration & dosage/therapeutic use', 'Rotation', 'Scopolamine/administration & dosage/therapeutic use', 'Spices']",https://pubmed.ncbi.nlm.nih.gov/11538042/
1447,promethazine,33858904,Promethazine-induced delirium with perceptual abnormalities: are we thinking broadly when assessing patients?,"['Abeysundera H', 'Craig B', 'Pullich Z']","['*Delirium/chemically induced/diagnosis', 'Humans', 'Nonprescription Drugs/adverse effects', 'Promethazine/adverse effects', '*Substance-Related Disorders']",https://pubmed.ncbi.nlm.nih.gov/33858904/
1448,beclomethasone,6792963,Beclomethasone dipropionate.,['Williams MH Jr'],"['Aerosols', 'Asthma/*drug therapy', 'Beclomethasone/administration & dosage/adverse effects/*therapeutic use', 'Candidiasis, Oral/etiology', 'Humans', 'Long-Term Care', 'Lung Diseases, Obstructive/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6792963/
1449,beclomethasone,26653155,Beclomethasone HFA for the treatment of allergic rhinitis.,['Mansfield LE'],"['Administration, Inhalation', 'Administration, Intranasal', 'Beclomethasone/pharmacokinetics/pharmacology/*therapeutic use', 'Chronic Disease', 'Glucocorticoids/pharmacokinetics/pharmacology/*therapeutic use', 'Humans', 'Metered Dose Inhalers', 'Patient Compliance', 'Rhinitis, Allergic/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26653155/
1450,beclomethasone,26938578,Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma.,"['Crisafulli E', 'Zanini A', 'Pisi G', 'Pignatti P', 'Poli G', 'Scuri M', 'Chetta A']","['Administration, Inhalation', 'Anti-Asthmatic Agents/administration & dosage/*therapeutic use', 'Asthma/*drug therapy', 'Beclomethasone/administration & dosage/*therapeutic use', 'Drug Combinations', 'Dry Powder Inhalers', 'Formoterol Fumarate/administration & dosage/*therapeutic use', 'Humans', 'Metered Dose Inhalers', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26938578/
1451,beclomethasone,27340255,High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma.,"['Corradi M', 'Spinola M', 'Petruzzelli S', 'Kuna P']","['Administration, Inhalation', 'Adrenal Cortex Hormones/administration & dosage', 'Anti-Asthmatic Agents/administration & dosage/adverse effects', 'Asthma/*drug therapy/physiopathology', 'Beclomethasone/*administration & dosage/adverse effects', 'Bronchodilator Agents/administration & dosage', 'Dose-Response Relationship, Drug', 'Drug Combinations', 'Formoterol Fumarate/*administration & dosage/adverse effects', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/27340255/
1452,beclomethasone,36952367,Beclometasone inhaler-induced recovery of refractory peri-ileostomy skin complications.,"['McDonald M', 'Connelly TM', 'Brett A', 'McCullough P', 'Cooke F', 'Neary P']","['Humans', 'Male', 'Female', '*Ileostomy', '*Beclomethasone/therapeutic use', 'Quality of Life', 'Postoperative Complications', 'Nebulizers and Vaporizers']",https://pubmed.ncbi.nlm.nih.gov/36952367/
1453,beclomethasone,16029067,Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices.,"['Derom E', 'Pauwels RA']","['Administration, Inhalation', 'Aerosol Propellants', 'Anti-Asthmatic Agents/*administration & dosage/pharmacokinetics/pharmacology', 'Anti-Inflammatory Agents/administration & dosage/pharmacokinetics/pharmacology', 'Asthma/drug therapy', 'Beclomethasone/*administration & dosage/pharmacokinetics/pharmacology', 'Glucocorticoids/pharmacokinetics/pharmacology', 'Humans', '*Hydrocarbons, Fluorinated', 'Therapeutic Equivalency']",https://pubmed.ncbi.nlm.nih.gov/16029067/
1454,beclomethasone,27309985,Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease.,"['Singh D', 'Corradi M', 'Spinola M', 'Petruzzelli S', 'Papi A']","['Administration, Inhalation', 'Beclomethasone/administration & dosage/*therapeutic use', 'Drug Combinations', 'Formoterol Fumarate/administration & dosage/*therapeutic use', 'Humans', 'Pulmonary Disease, Chronic Obstructive/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27309985/
1455,beclomethasone,17530144,The properties of inhaled corticosteroids: similarities and differences.,['Barnes NC'],"['Administration, Inhalation', 'Adrenal Glands/drug effects', 'Anti-Asthmatic Agents/pharmacology/therapeutic use', 'Asthma/*drug therapy', 'Beclomethasone/pharmacology/therapeutic use', 'Bone and Bones/drug effects', 'Dose-Response Relationship, Drug', 'Glucocorticoids/*administration & dosage/*pharmacology', 'Growth/drug effects', 'Hoarseness/*chemically induced', 'Humans', 'Nebulizers and Vaporizers', 'Practice Guidelines as Topic', 'Pregnenediones/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17530144/
1456,beclomethasone,9850357,Improved delivery of inhaled steroids to the large and small airways.,['Leach CL'],"['Administration, Inhalation', '*Aerosol Propellants', 'Anti-Inflammatory Agents/*administration & dosage/therapeutic use', 'Asthma/*drug therapy', 'Beclomethasone/administration & dosage/therapeutic use', 'Bronchi/diagnostic imaging/drug effects', 'Drug Delivery Systems', 'Humans', 'Hydrocarbons, Fluorinated', 'Lung/diagnostic imaging/*drug effects', 'Nebulizers and Vaporizers', 'Particle Size', 'Pulmonary Alveoli/diagnostic imaging/drug effects', 'Radionuclide Imaging', 'Technetium']",https://pubmed.ncbi.nlm.nih.gov/9850357/
1457,beclomethasone,19583452,The role of oral beclometasone dipropionate in the treatment of gastrointestinal Graft-versus-Host Disease.,"['Doan PL', 'Chao NJ']","['Animals', 'Anti-Inflammatory Agents/pharmacokinetics/*therapeutic use', 'Beclomethasone/pharmacokinetics/*therapeutic use', 'Biological Availability', 'Clinical Trials as Topic', 'Gastrointestinal Diseases/*drug therapy/pathology', 'Graft vs Host Disease/*drug therapy/pathology', 'Humans', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/19583452/
1458,beclomethasone,11334133,Inhaled corticosteroids reduce growth. Or do they?,['Brand PL'],"['Administration, Inhalation', 'Androstadienes/administration & dosage/adverse effects/pharmacokinetics', 'Anti-Asthmatic Agents/administration & dosage/adverse effects/pharmacokinetics', 'Asthma/*drug therapy/physiopathology', 'Beclomethasone/administration & dosage/adverse effects', 'Biological Availability', 'Bronchodilator Agents/administration & dosage/adverse effects/pharmacokinetics', 'Budesonide/administration & dosage/adverse effects/pharmacokinetics', 'Child', 'Dose-Response Relationship, Drug', 'Fluticasone', 'Glucocorticoids/administration & dosage/*adverse effects/pharmacokinetics', 'Growth/*drug effects', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/11334133/
1459,beclomethasone,6393075,Corticosteroid aerosols in the treatment of asthma.,"['Tse CS', 'Bernstein IL']","['Adrenal Cortex Hormones/administration & dosage/adverse effects/metabolism/*therapeutic use', 'Aerosols', 'Asthma/*drug therapy', 'Beclomethasone/adverse effects/metabolism/therapeutic use', 'Budesonide', 'Chemical Phenomena', 'Chemistry', 'Fluocinolone Acetonide/analogs & derivatives/metabolism/therapeutic use', 'Humans', 'Kinetics', 'Pregnenediones/metabolism/therapeutic use', 'Structure-Activity Relationship', 'Triamcinolone Acetonide/metabolism/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6393075/
1460,beclomethasone,9850358,Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics.,"['Seale JP', 'Harrison LI']","['Administration, Inhalation', 'Adolescent', 'Adult', 'Aerosol Propellants', 'Anti-Inflammatory Agents/*administration & dosage/pharmacokinetics/therapeutic use', 'Asthma/drug therapy', 'Beclomethasone/*administration & dosage/pharmacokinetics/therapeutic use', 'Chlorofluorocarbons', 'Cross-Over Studies', 'Drug Administration Schedule', 'Female', 'Humans', 'Hydrocarbons, Fluorinated', 'Lung/*drug effects', 'Male', 'Middle Aged', 'Particle Size', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/9850358/
1461,beclomethasone,6793795,Steroids in allergic disease.,['Webb DR'],"['Administration, Intranasal', 'Adrenal Cortex Hormones/adverse effects/pharmacology/*therapeutic use', 'Asthma/drug therapy', 'Beclomethasone/administration & dosage/adverse effects/therapeutic use', 'Cataract/chemically induced', 'Cushing Syndrome/chemically induced', 'Humans', 'Hypersensitivity/*drug therapy', 'Hypersensitivity, Immediate/drug therapy', 'Long-Term Care', 'Nasal Polyps/chemically induced', 'Osteonecrosis/chemically induced', 'Osteoporosis/chemically induced', 'Prednisone/therapeutic use', 'Rhinitis/drug therapy', 'Sleep Initiation and Maintenance Disorders/chemically induced', 'Stress, Physiological/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/6793795/
1462,beclomethasone,15311725,The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone diproprionate extrafine aerosol) in asthma (part 1): an update of clinical experience in adults.,"['Van Schayck CP', 'Donnell D']","['Adult', 'Androstadienes/adverse effects/*therapeutic use', 'Anti-Asthmatic Agents/adverse effects/*therapeutic use', 'Asthma/*drug therapy', 'Beclomethasone/adverse effects/*therapeutic use', 'Double-Blind Method', 'Fluticasone', 'Forced Expiratory Volume', 'Humans', 'Hydrocarbons, Fluorinated/adverse effects/*therapeutic use', 'Multicenter Studies as Topic', 'Peak Expiratory Flow Rate', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'Vital Capacity']",https://pubmed.ncbi.nlm.nih.gov/15311725/
1463,beclomethasone,19075804,Oral beclomethasone: a review of its use in inflammatory bowel disease.,"['Danese S', 'Angelucci E', 'Marconi S', 'Repici A', 'Malesci A']","['Administration, Oral', 'Beclomethasone/*administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Drug Tolerance', 'Drug-Related Side Effects and Adverse Reactions', 'Humans', 'Inflammatory Bowel Diseases/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19075804/
1464,beclomethasone,811455,Beclomethasone dipropionate: II: Allergic rhinitis and other conditions.,"['Brogden RN', 'Pinder RM', 'Sawyer PR', 'Speight TM', 'Avery GS']","['Administration, Intranasal', 'Adrenal Glands/drug effects', 'Adult', 'Beclomethasone/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Child', 'Chronic Disease', 'Clinical Trials as Topic', 'Cromolyn Sodium/therapeutic use', 'Drug Evaluation', 'Humans', 'Hydrocortisone/blood', 'Methylprednisolone/*analogs & derivatives', 'Nasal Polyps/drug therapy', 'Placebos', 'Rhinitis, Allergic, Seasonal/*drug therapy', 'Seasons']",https://pubmed.ncbi.nlm.nih.gov/811455/
1465,beclomethasone,29689043,[Treatment of allergic and vasomotor rhinitis: the role of beclomethasone dipropionate and hyaluronic acid (with high molecular weight).].,"['Ciprandi G', 'Gelardi M']","['Administration, Intranasal', 'Aerosols', 'Anti-Inflammatory Agents/administration & dosage/adverse effects/pharmacology', 'Beclomethasone/*administration & dosage/adverse effects/pharmacology', 'Humans', 'Hyaluronic Acid/*administration & dosage/pharmacology', 'Molecular Weight', 'Rhinitis, Allergic/*drug therapy/pathology', 'Rhinitis, Vasomotor/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/29689043/
1466,beclomethasone,24321801,"Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.","['Papi A', 'Corradi M', 'Pigeon-Francisco C', 'Baronio R', 'Siergiejko Z', 'Petruzzelli S', 'Fabbri LM', 'Rabe KF']","['Administration, Inhalation', 'Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Albuterol/administration & dosage/therapeutic use', 'Anti-Asthmatic Agents/administration & dosage/*therapeutic use', 'Asthma/*drug therapy', 'Beclomethasone/administration & dosage/*therapeutic use', 'Double-Blind Method', 'Drug Combinations', 'Ethanolamines/administration & dosage/*therapeutic use', 'Female', 'Forced Expiratory Volume', 'Formoterol Fumarate', 'Humans', 'Male', 'Middle Aged', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24321801/
1467,loratadine,35396016,Loratadine.,"['AlMasoud N', 'Bakheit AH', 'Alshammari MFM', 'Abdel-Aziz HA', 'AlRabiah H']","['Humans', '*Hypersensitivity', '*Loratadine/chemistry/pharmacology/therapeutic use', 'Mass Spectrometry', 'Solubility', 'X-Ray Diffraction']",https://pubmed.ncbi.nlm.nih.gov/35396016/
1468,loratadine,25397904,H1-antihistamines for chronic spontaneous urticaria.,"['Sharma M', 'Bennett C', 'Cohen SN', 'Carter B']","['Cetirizine/therapeutic use', 'Cyproheptadine/analogs & derivatives/therapeutic use', 'Histamine H1 Antagonists/adverse effects/*therapeutic use', 'Humans', 'Hydroxyzine/therapeutic use', 'Loratadine/analogs & derivatives/therapeutic use', 'Randomized Controlled Trials as Topic', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/25397904/
1469,loratadine,18336052,"Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.","['Devillier P', 'Roche N', 'Faisy C']","['Cetirizine/adverse effects/pharmacokinetics/*pharmacology', 'Drug Interactions', 'Histamine H1 Antagonists, Non-Sedating/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Loratadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Rhinitis, Allergic, Perennial/drug therapy', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Terfenadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18336052/
1470,loratadine,12549956,Desloratadine: a nonsedating antihistamine.,"['Limon L', 'Kockler DR']","['Adult', 'Area Under Curve', 'Child', 'Female', 'Half-Life', '*Histamine H1 Antagonists, Non-Sedating/blood/pharmacokinetics/therapeutic use', 'Humans', '*Loratadine/analogs & derivatives/blood/pharmacokinetics/therapeutic use', 'Male', 'Randomized Controlled Trials as Topic', 'Rhinitis, Allergic, Seasonal/*drug therapy', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/12549956/
1471,loratadine,33893956,Antihistamines Modulate Functional Activity of Macrophages.,"['Plekhova NG', 'Eliseeva EV', 'Dubnyak IN']","['Animals', 'Cells, Cultured', 'Histamine Antagonists/*pharmacology', 'Humans', 'Hypersensitivity/metabolism', 'Loratadine/analogs & derivatives/pharmacology', 'Macrophages, Peritoneal/*drug effects/*metabolism', 'Mice']",https://pubmed.ncbi.nlm.nih.gov/33893956/
1472,loratadine,38368709,Discovery of the novel and potent histamine H1 receptor antagonists for treatment of allergic diseases.,"['Chu Z', 'Cen L', 'Xu Q', 'Lin G', 'Mo J', 'Shao L', 'Zhao Y', 'Li J', 'Ye W', 'Fang T', 'Ren W', 'Zhu Q', 'He G', 'Xu Y']","['Humans', '*Histamine H1 Antagonists/pharmacology/therapeutic use', 'Receptors, Histamine H1/therapeutic use', 'Loratadine/pharmacology/therapeutic use/*analogs & derivatives', '*Hypersensitivity/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38368709/
1473,loratadine,9152563,Loratadine in the treatment of urticaria.,['Monroe EW'],"['Arrhythmias, Cardiac/chemically induced', 'Histamine H1 Antagonists/adverse effects/*therapeutic use', 'Humans', 'Loratadine/adverse effects/*therapeutic use', 'Urticaria/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/9152563/
1474,loratadine,11964751,Are antihistamines useful in managing asthma?,['Wilson AM'],"['Acetates/agonists/metabolism', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use', 'Asthma/*drug therapy/prevention & control', 'Bronchospirometry/methods', 'Cetirizine/pharmacology', 'Cyclopropanes', 'Drug Therapy, Combination', 'Histamine H1 Antagonists/metabolism/pharmacology/*therapeutic use', 'Humans', 'Loratadine/agonists/analogs & derivatives/*metabolism/pharmacology', 'Mannitol/administration & dosage/*metabolism', 'Quinolines/agonists/metabolism', 'Rhinitis/metabolism', 'Sulfides', 'Terfenadine/*analogs & derivatives/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/11964751/
1475,loratadine,11583068,Triamcinolone: new and old indications.,['Doggrell SA'],"['Administration, Intranasal', 'Adult', 'Aerosols', 'Androstadienes/therapeutic use', 'Anti-Inflammatory Agents/*therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Astemizole/therapeutic use', 'Asthma/drug therapy', 'Child', 'Clinical Trials as Topic', 'Conjunctivitis, Allergic/drug therapy', 'Dose-Response Relationship, Drug', 'Fluticasone', 'Humans', 'Injections, Intramuscular', 'Loratadine/therapeutic use', 'Lung Diseases, Obstructive/drug therapy', 'Macular Degeneration/drug therapy', 'Molecular Structure', 'Nasal Mucosa/drug effects', 'Rhinitis, Allergic, Perennial/etiology', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Structure-Activity Relationship', 'Triamcinolone/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11583068/
1476,loratadine,11243502,Desloratadine in the treatment of chronic idiopathic urticaria.,"['Ring J', 'Hein R', 'Gauger A']","['Cholinergic Antagonists/pharmacology/*therapeutic use', 'Chronic Disease', 'Cytokines/drug effects', 'Histamine H1 Antagonists/pharmacology/*therapeutic use', 'Humans', 'Loratadine/analogs & derivatives/pharmacology/*therapeutic use', 'Severity of Illness Index', 'Time Factors', 'Treatment Outcome', 'Urticaria/*drug therapy/etiology/immunology']",https://pubmed.ncbi.nlm.nih.gov/11243502/
1477,loratadine,11398910,Desloratadine.,"['McClellan K', 'Jarvis B']","['Asthma/drug therapy', 'Clinical Trials as Topic', 'Drug Interactions', 'Histamine H1 Antagonists/*therapeutic use', 'Humans', 'Loratadine/analogs & derivatives/pharmacokinetics/pharmacology/*therapeutic use', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11398910/
1478,loratadine,10444237,Cardiovascular profile of loratadine.,"['Hey JA', 'Affrime M', 'Cobert B', 'Kreutner W', 'Cuss FM']","['Animals', 'Cardiovascular System/*drug effects', '*Cation Transport Proteins', '*DNA-Binding Proteins', 'Drug Interactions', 'ERG1 Potassium Channel', 'Electrocardiography/drug effects', 'Ether-A-Go-Go Potassium Channels', 'Histamine H1 Antagonists/*adverse effects', 'Humans', 'Loratadine/*adverse effects', 'Potassium Channels/drug effects', '*Potassium Channels, Voltage-Gated', '*Trans-Activators', 'Transcriptional Regulator ERG']",https://pubmed.ncbi.nlm.nih.gov/10444237/
1479,loratadine,28458435,Ciprofloxacin induced acute generallised exanthematous pustulosis.,"['Foti C', 'Romita P', 'Zanframundo G', 'Mastrolonardo M', 'Angelini G', 'Calogiuri G', 'Nettis E', 'Bonamonte D']","['Acute Generalized Exanthematous Pustulosis/*etiology/pathology', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Ciprofloxacin/administration & dosage/*adverse effects', 'Drug Eruptions/*etiology/pathology', 'Female', 'Fever/etiology', 'Humans', 'Intertrigo/drug therapy', 'Loratadine/administration & dosage/analogs & derivatives', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/28458435/
1480,loratadine,15245363,Antihistamines: do they work? Further well-controlled trials involving larger samples are needed.,"['Fumagalli F', 'Baiardini I', 'Pasquali M', 'Compalati E', 'Guerra L', 'Massacane P', 'Canonica GW']","['Anti-Allergic Agents/*therapeutic use', 'Anti-Inflammatory Agents/therapeutic use', 'Cetirizine/therapeutic use', 'Histamine H1 Antagonists/*therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/therapeutic use', 'Humans', 'Hypersensitivity/*drug therapy', 'Loratadine/*analogs & derivatives/therapeutic use', 'Piperazines/therapeutic use', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/15245363/
1481,loratadine,19473112,Desloratadine and pseudoephedrine combination therapy as a comprehensive treatment for allergic rhinitis and nasal congestion.,['Anolik R'],"['Clinical Trials as Topic', 'Drug Combinations', 'Histamine H1 Antagonists, Non-Sedating/pharmacology/*therapeutic use', 'Humans', 'Loratadine/*analogs & derivatives/pharmacology/therapeutic use', 'Nasal Decongestants/pharmacology/*therapeutic use', 'Nasal Obstruction/*drug therapy', 'Pseudoephedrine/pharmacology/*therapeutic use', 'Quality of Life', 'Rhinitis, Allergic, Perennial/*drug therapy', 'Rhinitis, Allergic, Seasonal/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19473112/
1482,loratadine,38163866,Loratidine is associated with improved prognosis and exerts antineoplastic effects via apoptotic and pyroptotic crosstalk in lung cancer.,"['Liu X', 'Zhong R', 'Huang J', 'Chen Z', 'Xu H', 'Lin L', 'Cai Q', 'He M', 'Lao S', 'Deng H', 'Li C', 'Li J', 'Zheng Y', 'Liu X', 'Zeng R', 'He J', 'Liang W']","['Animals', 'Humans', '*Lung Neoplasms/drug therapy/genetics/pathology', 'Loratadine/pharmacology/therapeutic use', 'Retrospective Studies', 'Caspase 8', '*Antineoplastic Agents/pharmacology/therapeutic use', 'Apoptosis', 'Prognosis']",https://pubmed.ncbi.nlm.nih.gov/38163866/
1483,loratadine,17176780,Effect of desloratadine on the control of morning symptoms in patients with seasonal and perennial allergic rhinitis.,['Schenkel EJ'],"['Animals', 'Circadian Rhythm/*drug effects/physiology', 'Histamine H1 Antagonists, Non-Sedating/pharmacology/*therapeutic use', 'Humans', 'Loratadine/adverse effects/*analogs & derivatives/pharmacology/therapeutic use', 'Rhinitis, Allergic, Perennial/*drug therapy/*physiopathology', 'Rhinitis, Allergic, Seasonal/*drug therapy/*physiopathology']",https://pubmed.ncbi.nlm.nih.gov/17176780/
1484,loratadine,25752982,Loratadine analogues as MAGL inhibitors.,"['Patel JZ', 'Ahenkorah S', 'Vaara M', 'Staszewski M', 'Adams Y', 'Laitinen T', 'Navia-Paldanius D', 'Parkkari T', 'Savinainen JR', 'Walczynski K', 'Laitinen JT', 'Nevalainen TJ']","['Amidohydrolases/antagonists & inhibitors/metabolism', 'Dose-Response Relationship, Drug', 'Enzyme Inhibitors/chemical synthesis/chemistry/*pharmacology', 'Humans', 'Loratadine/chemical synthesis/chemistry/*pharmacology', 'Models, Molecular', 'Molecular Structure', 'Monoacylglycerol Lipases/*antagonists & inhibitors/metabolism', 'Recombinant Proteins/metabolism', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/25752982/
1485,loratadine,32043642,Desloratadine inhibits heterotopic ossification by suppression of BMP2-Smad1/5/8 signaling.,"['Kusano T', 'Nakatani M', 'Ishiguro N', 'Ohno K', 'Yamamoto N', 'Morita M', 'Yamada H', 'Uezumi A', 'Tsuchida K']","['Animals', 'Bone Morphogenetic Protein 2/*physiology', 'Cell Differentiation/drug effects', 'Loratadine/*analogs & derivatives/pharmacology/therapeutic use', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Ossification, Heterotopic/*prevention & control', 'Osteogenesis/drug effects', 'Receptor, Platelet-Derived Growth Factor alpha/analysis', 'Signal Transduction/drug effects', 'Smad Proteins/*physiology']",https://pubmed.ncbi.nlm.nih.gov/32043642/
1486,loratadine,29380864,The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria.,"['Choonhakarn C', 'Chaowattanapanit S', 'Julanon N']","['Adult', 'Chronic Disease', 'Female', 'Histamine H1 Antagonists, Non-Sedating/*administration & dosage/adverse effects', 'Humans', 'Loratadine/administration & dosage/adverse effects/*analogs & derivatives', 'Maintenance Chemotherapy/methods', 'Male', 'Middle Aged', 'Recurrence', 'Remission Induction/methods', 'Retreatment', 'Retrospective Studies', 'Treatment Outcome', 'Urticaria/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29380864/
1487,meperidine,9564390,Intrathecal pethidine: pharmacology and clinical applications.,['Ngan Kee WD'],"['Adjuvants, Anesthesia/administration & dosage/*pharmacology', 'Analgesics, Opioid/administration & dosage/*pharmacology', '*Anesthesia, Spinal', 'Humans', 'Injections, Spinal', 'Meperidine/administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/9564390/
1488,meperidine,6928910,Intramuscular sedation technique.,"['Jensen ST', 'Coke JM', 'Cohen L']","['Anesthesia, Dental/*methods', 'Anesthesia, General/*methods', 'Buttocks', 'Humans', 'Hypnotics and Sedatives/administration & dosage', 'Injections, Intramuscular/methods', 'Meperidine/administration & dosage/pharmacology', 'Promethazine/administration & dosage', 'Respiration/drug effects']",https://pubmed.ncbi.nlm.nih.gov/6928910/
1489,meperidine,16114176,Nonpharmacological treatment options for epilepsy.,"['Sheth RD', 'Stafstrom CE', 'Hsu D']","['Allylamine/administration & dosage/analogs & derivatives', 'Biofeedback, Psychology/*methods', 'Diet Therapy/*methods', 'Drug Combinations', 'Electric Stimulation/*methods', 'Electroencephalography/methods', 'Epilepsy/classification/*therapy', 'Humans', 'Meperidine/administration & dosage/analogs & derivatives', 'Neurosurgery/*methods', 'Pyridoxine/therapeutic use', 'Vagus Nerve/physiopathology/radiation effects']",https://pubmed.ncbi.nlm.nih.gov/16114176/
1490,meperidine,8443849,Nasal ketamine for paediatric premedication.,"['Weksler N', 'Ovadia L', 'Muati G', 'Stav A']","['Administration, Intranasal', 'Anesthesia Recovery Period', 'Anesthesia, Inhalation', 'Child, Preschool', '*Conscious Sedation', 'Double-Blind Method', 'Female', 'Humans', 'Injections, Intramuscular', 'Ketamine/administration & dosage/*therapeutic use', 'Male', 'Meperidine/administration & dosage/therapeutic use', '*Preanesthetic Medication', 'Promethazine/administration & dosage/therapeutic use', 'Salivation/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/8443849/
1491,meperidine,1585886,Lethal effects of normeperidine.,['Jiraki K'],"['Adult', 'Cholinesterase Inhibitors/pharmacokinetics/*poisoning', 'Half-Life', 'Humans', 'Kidney Failure, Chronic/*complications/etiology', 'Male', 'Meperidine/administration & dosage/*analogs & derivatives/*pharmacokinetics/poisoning', 'Substance-Related Disorders/*complications']",https://pubmed.ncbi.nlm.nih.gov/1585886/
1492,meperidine,12819163,Naloxone for narcotic exposed newborn infants: systematic review.,"['McGuire W', 'Fowlie PW']","['Analgesia, Obstetrical/*adverse effects', 'Analgesics, Opioid/*adverse effects/therapeutic use', 'Female', 'Humans', 'Infant, Newborn', 'Intensive Care, Neonatal', 'Meperidine/*adverse effects/therapeutic use', 'Naloxone/*therapeutic use', 'Narcotic Antagonists/*therapeutic use', 'Pregnancy', '*Prenatal Exposure Delayed Effects', 'Randomized Controlled Trials as Topic', 'Respiration, Artificial']",https://pubmed.ncbi.nlm.nih.gov/12819163/
1493,meperidine,11574125,Effect of epidural analgesia on the fetal heart rate.,['Capogna G'],"['Analgesics, Opioid/administration & dosage/therapeutic use', 'Anesthesia, Epidural/*adverse effects', 'Clinical Trials as Topic', 'Female', 'Heart Rate, Fetal/*drug effects', 'Humans', 'Hypotension/physiopathology', 'Meperidine/administration & dosage/therapeutic use', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/physiopathology', 'Sufentanil/administration & dosage/therapeutic use', 'Uterine Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/11574125/
1494,meperidine,8239638,Postoperative narcotic analgesic administration.,['McDonald DD'],"['Adolescent', 'Adult', '*Appendectomy', 'Drug Utilization', 'Female', 'Humans', 'Length of Stay/statistics & numerical data', 'Male', 'Meperidine/administration & dosage/therapeutic use', 'Middle Aged', 'Narcotics/administration & dosage/*therapeutic use', 'Pain, Postoperative/*drug therapy/nursing', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/8239638/
1495,meperidine,2677941,"Lytic/""DPT"" cocktail: time for rational and safe alternatives.","['Snodgrass WR', 'Dodge WF']","['Child', 'Child, Preschool', 'Chlorpromazine/administration & dosage/adverse effects', 'Diazepam/administration & dosage/pharmacology', 'Drug Combinations/*adverse effects', 'Humans', 'Infant', 'Meperidine/administration & dosage/adverse effects', 'Midazolam/administration & dosage/pharmacology', 'Morphine/administration & dosage/pharmacology', 'Preanesthetic Medication/*adverse effects', 'Promethazine/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2677941/
1496,meperidine,9619217,Epidural pethidine: pharmacology and clinical experience.,['Ngan Kee WD'],"['Analgesia, Obstetrical', 'Analgesia, Patient-Controlled', 'Analgesics, Opioid/administration & dosage/*pharmacology', '*Anesthesia, Epidural', 'Female', 'Humans', 'Injections, Epidural', 'Meperidine/administration & dosage/*pharmacology', 'Pain, Postoperative/drug therapy', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/9619217/
1497,meperidine,2354093,Analgesic efficacy of perioperative buccal morphine.,"['Manara AR', 'Bodenham AR', 'Park GR']","['Administration, Buccal', 'Adult', 'Delayed-Action Preparations', 'Female', 'Humans', 'Injections, Intramuscular', 'Meperidine/administration & dosage', 'Morphine/administration & dosage/adverse effects/*therapeutic use', 'Pain Measurement', 'Pain, Postoperative/*drug therapy', 'Patient Acceptance of Health Care', 'Random Allocation', 'Taste/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2354093/
1498,meperidine,3605428,Meperidine-induced delirium.,"['Eisendrath SJ', 'Goldman B', 'Douglas J', 'Dimatteo L', 'Van Dyke C']","['Adult', 'Aged', 'Delirium/*chemically induced', 'Drug Interactions', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Meperidine/*adverse effects/pharmacology', 'Middle Aged', 'Parasympatholytics/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/3605428/
1499,meperidine,3355732,Patient-controlled analgesia with extradural morphine or pethidine.,"['Sjostrom S', 'Hartvig D', 'Tamsen A']","['Adult', 'Female', 'Humans', 'Injections, Epidural', 'Male', 'Meperidine/*administration & dosage/blood/therapeutic use', 'Middle Aged', 'Morphine/*administration & dosage/blood/therapeutic use', 'Pain, Postoperative/*drug therapy', 'Self Administration', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3355732/
1500,meperidine,2568289,Pharmacokinetics of meperidine in pregnancy.,"['Todd EL', 'Stafford DT', 'Bucovaz ET', 'Morrison JC']","['Female', 'Fetal Distress/chemically induced', 'Fetus/metabolism', 'Humans', 'Injections, Intravenous', 'Meperidine/administration & dosage/adverse effects/*pharmacokinetics', 'Pregnancy/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/2568289/
1501,meperidine,337983,Comparison of nefopam and pethidine in postoperative pain.,"['Tigerstedt I', 'Sipponen J', 'Tammisto T', 'Turunen M']","['Clinical Trials as Topic', 'Double-Blind Method', 'Humans', 'Meperidine/administration & dosage/*therapeutic use', 'Nefopam/administration & dosage/*therapeutic use', 'Oxazocines/*therapeutic use', 'Pain, Postoperative/*drug therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/337983/
1502,meperidine,8007042,Meperidine neurotoxicity after organ transplantation.,"['Adair JC', 'Gilmore RL']","['Adult', 'Central Nervous System/*drug effects', 'Humans', '*Kidney Transplantation', 'Male', 'Meperidine/*adverse effects/blood', '*Pancreas Transplantation', 'Pancreatitis/drug therapy', 'Postoperative Complications/*chemically induced/drug therapy/physiopathology', 'Seizures/chemically induced/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/8007042/
1503,meperidine,1609533,[Effectiveness and tolerance of tramadol with or without an antiemetic and pethidine in obstetric analgesia].,"['Kainz C', 'Joura E', 'Obwegeser R', 'Plockinger B', 'Gruber W']","['Adult', 'Analgesia, Obstetrical/*methods', 'Cardiotocography/drug effects', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Infant, Newborn', 'Injections, Intramuscular', 'Meperidine/*administration & dosage/adverse effects', 'Oxytocin/administration & dosage', 'Pain Measurement', 'Pregnancy', 'Prospective Studies', 'Tramadol/*administration & dosage/adverse effects', 'Triflupromazine/*administration & dosage/adverse effects', 'Uterine Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/1609533/
1504,meperidine,11782820,Meperidine: a critical review.,"['Latta KS', 'Ginsberg B', 'Barkin RL']","['*Adjuvants, Anesthesia/pharmacokinetics/pharmacology/therapeutic use', '*Analgesics, Opioid/pharmacokinetics/pharmacology/therapeutic use', 'Animals', 'Central Nervous System/drug effects', 'Clinical Trials as Topic', 'Humans', '*Meperidine/pharmacokinetics/pharmacology/therapeutic use', 'Muscle, Smooth/drug effects', 'Pain/drug therapy', 'Respiration/drug effects']",https://pubmed.ncbi.nlm.nih.gov/11782820/
1505,meperidine,2719235,Epidural pethidine or fentanyl during caesarean section: a double-blind comparison.,['Paech MJ'],"['Adult', '*Anesthesia, Obstetrical', '*Cesarean Section', 'Double-Blind Method', 'Female', 'Fentanyl/*administration & dosage/adverse effects', 'Humans', 'Injections, Epidural', 'Meperidine/*administration & dosage/adverse effects', 'Pain, Postoperative/*prevention & control', 'Pregnancy', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/2719235/
1506,meperidine,4913784,Comparison of pentazocine and pethidine in labour.,"['Mowat J', 'Garrey MM']","['Adolescent', 'Adult', '*Anesthesia, Obstetrical', 'Clinical Trials as Topic', 'Female', 'Humans', 'Infant, Newborn', 'Injections, Intramuscular', '*Labor, Obstetric', 'Meperidine/*administration & dosage/adverse effects', 'Pentazocine/*administration & dosage/adverse effects', 'Physical Examination', 'Pre-Eclampsia', 'Pregnancy', 'Statistics as Topic', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/4913784/
1507,venlafaxine,36749328,Management of Menopausal Symptoms: A Review.,"['Crandall CJ', 'Mehta JM', 'Manson JE']","['Female', 'Humans', '*Estrogen Replacement Therapy/methods', 'Estrogens/therapeutic use', 'Estrogens, Conjugated (USP)/adverse effects', 'Hot Flashes/drug therapy/etiology', 'Medroxyprogesterone Acetate/therapeutic use', '*Menopause/drug effects', 'Neoplasms/drug therapy', 'Paroxetine/pharmacology', 'Venlafaxine Hydrochloride/pharmacology/therapeutic use', 'Venous Thromboembolism/drug therapy/etiology', 'Sweating', '*Female Urogenital Diseases/etiology', '*Autonomic Nervous System Diseases/etiology']",https://pubmed.ncbi.nlm.nih.gov/36749328/
1508,venlafaxine,31368838,Venlafaxine pharmacogenetics: a comprehensive review.,"['Suwala J', 'Machowska M', 'Wiela-Hojenska A']","['Antidepressive Agents/adverse effects/*therapeutic use', 'Cytochrome P-450 CYP2D6/*genetics', 'Depressive Disorder, Major/*drug therapy/genetics', 'Genotype', 'Humans', 'Pharmacogenetics', 'Polymorphism, Genetic', 'Venlafaxine Hydrochloride/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31368838/
1509,venlafaxine,31178367,"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.","['Furukawa TA', 'Cipriani A', 'Cowen PJ', 'Leucht S', 'Egger M', 'Salanti G']","['Depressive Disorder, Major/*drug therapy', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Humans', 'Mirtazapine/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Serotonin Agents/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/*therapeutic use', 'Venlafaxine Hydrochloride/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31178367/
1510,venlafaxine,30016772,Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.,"['Fava GA', 'Benasi G', 'Lucente M', 'Offidani E', 'Cosci F', 'Guidi J']","['Adrenergic Uptake Inhibitors/*adverse effects/therapeutic use', 'Desvenlafaxine Succinate/adverse effects/therapeutic use', 'Duloxetine Hydrochloride/adverse effects/therapeutic use', 'Humans', 'Mood Disorders/drug therapy', '*Randomized Controlled Trials as Topic', 'Substance Withdrawal Syndrome/*diagnosis', 'Venlafaxine Hydrochloride/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30016772/
1511,venlafaxine,36920821,Posttraumatic Stress Disorder: Evaluation and Treatment.,"['Sartor Z', 'Kelley L', 'Laschober R']","['Humans', '*Stress Disorders, Post-Traumatic/diagnosis/therapy/psychology', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Sertraline/therapeutic use', 'Fluoxetine/therapeutic use', 'Venlafaxine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36920821/
1512,venlafaxine,24964257,Clinical drug-drug interactions: focus on venlafaxine.,"['Magalhaes P', 'Alves G', 'LLerena A', 'Falcao A']","['Antidepressive Agents, Second-Generation/pharmacokinetics/pharmacology/*therapeutic use', 'Depressive Disorder/*drug therapy', 'Drug Interactions', 'Humans', 'Serotonin and Noradrenaline Reuptake Inhibitors/pharmacokinetics/pharmacology/*therapeutic use', 'Venlafaxine Hydrochloride/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24964257/
1513,venlafaxine,27929271,Hormone Therapy and Other Treatments for Symptoms of Menopause.,"['Hill DA', 'Crider M', 'Hill SR']","['Acupuncture Therapy', 'Administration, Intravaginal', 'Amines/therapeutic use', 'Antidepressive Agents/therapeutic use', 'Atrophy', 'Cyclohexanecarboxylic Acids/therapeutic use', 'Dietary Supplements', 'Drug Therapy, Combination', 'Dyspareunia/*therapy', 'Estrogen Replacement Therapy/*methods', 'Estrogens/therapeutic use', 'Exercise Therapy', 'Female', 'Gabapentin', 'Hot Flashes/*therapy', 'Humans', 'Hypnosis', 'Indoles/therapeutic use', '*Menopause', 'Paroxetine/therapeutic use', 'Progestins/therapeutic use', 'Selective Estrogen Receptor Modulators/therapeutic use', 'Tamoxifen/analogs & derivatives/therapeutic use', 'Vagina', 'Vaginal Diseases/*therapy', 'Vasomotor System', 'Venlafaxine Hydrochloride/therapeutic use', 'gamma-Aminobutyric Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27929271/
1514,venlafaxine,28293734,[Chemotherapy-induced peripheral neuropathy and neuropathic pain].,"['Schuler U', 'Heller S']","['Antineoplastic Agents/*adverse effects', 'Cryotherapy', 'Duloxetine Hydrochloride/therapeutic use', 'Humans', 'Neuralgia/*chemically induced/prevention & control/therapy', 'Peripheral Nervous System Diseases/*chemically induced/prevention & control/therapy', 'Physical Therapy Modalities', 'Randomized Controlled Trials as Topic', 'Venlafaxine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28293734/
1515,venlafaxine,12013367,Venlafaxine-associated vaginal bleeding.,"['Linnebur SA', 'Saseen JJ', 'Pace WD']","['Adult', 'Antidepressive Agents, Second-Generation/*adverse effects/therapeutic use', 'Cyclohexanols/*adverse effects/therapeutic use', 'Depressive Disorder/complications/drug therapy', 'Female', 'Hemorrhage/*chemically induced', 'Humans', 'Menstruation/drug effects', 'Vaginal Diseases/*chemically induced', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/12013367/
1516,venlafaxine,31290965,"Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).","['Fedgchin M', 'Trivedi M', 'Daly EJ', 'Melkote R', 'Lane R', 'Lim P', 'Vitagliano D', 'Blier P', 'Fava M', 'Liebowitz M', 'Ravindran A', 'Gaillard R', 'Ameele HVD', 'Preskorn S', 'Manji H', 'Hough D', 'Drevets WC', 'Singh JB']","['Administration, Intranasal', 'Administration, Oral', 'Adolescent', 'Adult', 'Antidepressive Agents/administration & dosage/*adverse effects/*therapeutic use', 'Citalopram/therapeutic use', 'Delayed-Action Preparations/therapeutic use', 'Depressive Disorder, Treatment-Resistant/*drug therapy', 'Double-Blind Method', 'Drug Therapy, Combination/adverse effects', 'Duloxetine Hydrochloride/therapeutic use', 'Female', 'Humans', 'Ketamine/administration & dosage/*adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Sertraline/therapeutic use', 'Treatment Outcome', 'Venlafaxine Hydrochloride/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31290965/
1517,venlafaxine,35630043,Impact of Venlafaxine on Platelet Count and Activity-Case Report and Narrative Review.,"['Smolarczyk-Kosowska J', 'Kosowski M', 'Kunert L', 'Filipczyk K', 'Wojciechowski M', 'Piegza M', 'Gorczyca P', 'Okopien B', 'Pudlo R']","['*Cyclohexanols/pharmacology', 'Humans', 'Platelet Count', '*Serotonin', 'Selective Serotonin Reuptake Inhibitors/adverse effects', 'Venlafaxine Hydrochloride/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35630043/
1518,venlafaxine,27289172,Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.,"['Cipriani A', 'Zhou X', 'Del Giovane C', 'Hetrick SE', 'Qin B', 'Whittington C', 'Coghill D', 'Zhang Y', 'Hazell P', 'Leucht S', 'Cuijpers P', 'Pu J', 'Cohen D', 'Ravindran AV', 'Liu Y', 'Michael KD', 'Yang L', 'Liu L', 'Xie P']","['Adolescent', 'Amitriptyline/administration & dosage/adverse effects', 'Antidepressive Agents/*administration & dosage/*adverse effects', 'Bayes Theorem', 'Child', 'Citalopram/administration & dosage/adverse effects', 'Clomipramine/administration & dosage/adverse effects', 'Confounding Factors, Epidemiologic', 'Depressive Disorder, Major/*drug therapy', 'Desipramine/administration & dosage/adverse effects', 'Double-Blind Method', 'Drug Administration Schedule', 'Duloxetine Hydrochloride/administration & dosage/adverse effects', 'Evidence-Based Medicine', 'Fluoxetine/administration & dosage/adverse effects', 'Humans', 'Imipramine/administration & dosage/adverse effects', 'Mianserin/administration & dosage/adverse effects/analogs & derivatives', 'Mirtazapine', 'Nortriptyline/administration & dosage/adverse effects', 'Paroxetine/administration & dosage/adverse effects', 'Piperazines', 'Randomized Controlled Trials as Topic', 'Research Design', 'Sertraline/administration & dosage/adverse effects', 'Treatment Outcome', 'Triazoles/administration & dosage/adverse effects', 'Venlafaxine Hydrochloride/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27289172/
1519,venlafaxine,29509823,Clinical Inquiries: Does exercise relieve vasomotor menopausal symptoms?,"['Lyon C', 'Mullen R', 'Deffenbacher B', 'Reed A', 'Nashelsky J']","['Aged', 'Antidepressive Agents, Second-Generation/therapeutic use', 'Citalopram/therapeutic use', 'Estrogen Replacement Therapy', '*Exercise Therapy', 'Fatty Acids, Omega-3/therapeutic use', 'Female', 'Hot Flashes/*prevention & control', 'Humans', '*Menopause', 'Middle Aged', '*Sweating', 'Venlafaxine Hydrochloride/therapeutic use', 'Yoga']",https://pubmed.ncbi.nlm.nih.gov/29509823/
1520,venlafaxine,14700452,Improving antidepressant adherence.,['Nemeroff CB'],"['Antidepressive Agents/administration & dosage/adverse effects/*therapeutic use', 'Bupropion/administration & dosage/adverse effects/*therapeutic use', 'Cyclohexanols/administration & dosage/adverse effects/*therapeutic use', 'Delayed-Action Preparations', 'Depressive Disorder/*drug therapy', '*Health Promotion', 'Humans', 'Paroxetine/administration & dosage/adverse effects/*therapeutic use', '*Patient Compliance', 'Randomized Controlled Trials as Topic', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/14700452/
1521,venlafaxine,31637686,Mania induced by tramadol-venlafaxine combination.,"['Hefzi N', 'Grekin J', 'Ahmed A']","['Analgesics, Opioid', '*Bipolar Disorder/chemically induced', '*Depressive Disorder, Major/drug therapy', 'Humans', 'Male', 'Middle Aged', 'Selective Serotonin Reuptake Inhibitors/adverse effects', '*Tramadol/adverse effects/therapeutic use', '*Venlafaxine Hydrochloride/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31637686/
1522,venlafaxine,32345407,Evidence-based prescribing for post-traumatic stress disorder.,"['Bisson JI', 'Baker A', 'Dekker W', 'Hoskins MD']","['*Evidence-Based Medicine', 'Fluoxetine/therapeutic use', 'Humans', 'Paroxetine/therapeutic use', 'Sertraline/therapeutic use', 'Stress Disorders, Post-Traumatic/*drug therapy', 'Venlafaxine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32345407/
1523,venlafaxine,37748003,Status Cataplecticus Induced by an Abrupt Duloxetine Withdrawal-A Case Report.,"['Cierny M', 'Feemster J', 'Hamid M', 'Battistini HA']","['Female', 'Humans', 'Aged', 'Duloxetine Hydrochloride/adverse effects', '*Cataplexy/drug therapy', '*Narcolepsy/drug therapy', 'Antidepressive Agents/adverse effects', 'Venlafaxine Hydrochloride/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37748003/
1524,venlafaxine,23045839,Warfarin: pharmacological profile and drug interactions with antidepressants.,"['Teles JS', 'Fukuda EY', 'Feder D']","['Administration, Oral', 'Anticoagulants/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Antidepressive Agents/*pharmacology', 'Biotransformation/drug effects', 'Cyclohexanols/pharmacology', 'Cytochrome P-450 Enzyme System/metabolism', 'Drug Interactions', 'Duloxetine Hydrochloride', 'Fluoxetine/pharmacology', 'Hemorrhage/chemically induced', 'Humans', 'Paroxetine/pharmacology', 'Thiophenes/pharmacology', 'Thrombophilia/drug therapy', 'Venlafaxine Hydrochloride', 'Vitamin K/antagonists & inhibitors', 'Warfarin/adverse effects/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23045839/
1525,venlafaxine,26355986,Multiple Subungual Pyogenic Granulomas Following Levothyroxine Treatment.,"['Keles MK', 'Yosma E', 'Aydogdu IO', 'Simsek T', 'Park TH']","['Antidepressive Agents, Second-Generation/therapeutic use', 'Female', 'Follow-Up Studies', 'Granuloma, Pyogenic/*chemically induced', 'Hormone Replacement Therapy/adverse effects', 'Humans', 'Hypothyroidism/drug therapy', 'Middle Aged', 'Nail Diseases/*chemically induced', 'Recurrence', 'Thyroxine/*adverse effects', 'Venlafaxine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26355986/
1526,venlafaxine,30946169,Attrition in treatment-resistant depression: predictors and clinical impact.,"['Olgiati P', 'Serretti A', 'Souery D', 'Kasper S', 'Kraus C', 'Montgomery S', 'Zohar J', 'Mendlewicz J']","['Adult', 'Antidepressive Agents, Second-Generation/*therapeutic use', 'Citalopram/therapeutic use', 'Depressive Disorder, Treatment-Resistant/*drug therapy/*epidemiology', 'Female', 'Humans', 'Male', 'Middle Aged', 'Patient Dropouts/*statistics & numerical data', 'Venlafaxine Hydrochloride/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30946169/
1527,norfloxacin,31584459,Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management.,"['Rao SSC', 'Bhagatwala J']","['Age Factors', 'Anti-Bacterial Agents/*therapeutic use', 'Bacteria/drug effects/isolation & purification', 'Blind Loop Syndrome/*diagnosis/epidemiology/etiology/therapy', 'Breath Tests', 'Clinical Trials as Topic', 'Colectomy/adverse effects', 'Female', 'Food, Formulated', 'Gastrointestinal Microbiome/*drug effects', 'Humans', 'Intestinal Mucosa/drug effects/*microbiology', 'Intestine, Small/drug effects/*microbiology', 'Male', 'Metronidazole/therapeutic use', 'Microbiological Techniques', 'Norfloxacin/therapeutic use', 'Prevalence', 'Probiotics/administration & dosage', 'Proton Pump Inhibitors/adverse effects', 'Rifaximin/therapeutic use', 'Risk Factors', 'Sex Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31584459/
1528,norfloxacin,8386356,Overview of the fluoroquinolone antibiotics.,['Just PM'],"['*Anti-Infective Agents/adverse effects/pharmacology', 'Bacterial Infections/drug therapy', 'Ciprofloxacin/pharmacology', 'Drug Interactions', 'Drug Resistance, Microbial', 'Enoxacin/pharmacology', '*Fluoroquinolones', 'Gram-Negative Aerobic Bacteria/drug effects', 'Gram-Positive Bacteria/drug effects', 'Humans', 'Norfloxacin/pharmacology', 'Ofloxacin/pharmacology', 'Quinolones/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8386356/
1529,norfloxacin,7922402,Quinolone therapy in intensive care unit settings.,['Beam TR Jr'],"['Administration, Oral', 'Aged', 'Ciprofloxacin/pharmacokinetics/supply & distribution/*therapeutic use', 'Clinical Protocols', 'Clinical Trials as Topic', 'Cross Infection/*drug therapy/microbiology', 'Drug Interactions', 'Drug Resistance, Microbial', 'Gram-Negative Bacterial Infections/*drug therapy/microbiology', 'Humans', 'Infusions, Intravenous', '*Intensive Care Units', 'Male', 'Microbial Sensitivity Tests', 'Norfloxacin/pharmacokinetics/supply & distribution/*therapeutic use', 'Ofloxacin/pharmacokinetics/supply & distribution/*therapeutic use', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/7922402/
1530,norfloxacin,3312850,Symposium on antimicrobial agents. The quinolones.,"['Walker RC', 'Wright AJ']","['Adolescent', 'Adult', '*Anti-Bacterial Agents', 'Bacterial Infections/drug therapy', 'Ciprofloxacin/adverse effects/pharmacology', 'Drug Resistance, Microbial', 'Enoxacin', 'Female', 'Humans', 'Nalidixic Acid/adverse effects', 'Naphthyridines/adverse effects/pharmacology', 'Norfloxacin/adverse effects/pharmacology', 'Ofloxacin', '*Oxazines/adverse effects/pharmacology', '*Quinolines']",https://pubmed.ncbi.nlm.nih.gov/3312850/
1531,norfloxacin,2124212,Quinolone pharmacokinetics and metabolism.,"['Lode H', 'Hoffken G', 'Boeckk M', 'Deppermann N', 'Borner K', 'Koeppe P']","['Administration, Oral', 'Anti-Infective Agents/administration & dosage/*pharmacokinetics', 'Biological Availability', 'Biotransformation', 'Ciprofloxacin/administration & dosage/analogs & derivatives/pharmacokinetics', 'Enoxacin/administration & dosage/pharmacokinetics', 'Fleroxacin', 'Half-Life', 'Humans', 'Metabolic Clearance Rate', 'Norfloxacin/administration & dosage/pharmacokinetics', 'Ofloxacin/administration & dosage/pharmacokinetics', 'Pefloxacin/administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/2124212/
1532,norfloxacin,1919653,Otitis externa malignum.,['Sabbour MS'],"['Aged', 'Aged, 80 and over', 'Anti-Infective Agents/therapeutic use', 'Diabetes Complications', 'Female', 'Humans', 'Male', 'Norfloxacin/*therapeutic use', 'Otitis Externa/*drug therapy/microbiology', 'Pseudomonas Infections/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1919653/
1533,norfloxacin,12052667,Clinical toxicological aspects of fluoroquinolones.,['Stahlmann R'],"['Anti-Infective Agents/*adverse effects/therapeutic use', 'Bacterial Infections/*drug therapy', 'Cardiovascular Diseases/chemically induced', 'Central Nervous System Diseases/chemically induced', 'Ciprofloxacin/adverse effects/therapeutic use', 'Connective Tissue Diseases/chemically induced', 'Diarrhea/chemically induced', 'Dizziness/chemically induced', 'Gastrointestinal Diseases/*chemically induced', 'Headache/chemically induced', 'Humans', 'Nausea/chemically induced', 'Norfloxacin/adverse effects/therapeutic use', 'Ofloxacin/adverse effects/therapeutic use', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/12052667/
1534,norfloxacin,3283041,A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microflora.,"['Edlund C', 'Nord CE']","['Ciprofloxacin/pharmacology', 'Enoxacin', 'Humans', 'Intestines/drug effects/*microbiology', 'Naphthyridines/pharmacology', 'Norfloxacin/analogs & derivatives/pharmacology', 'Ofloxacin', 'Oropharynx/drug effects/*microbiology', 'Oxazines/pharmacology', 'Pefloxacin', 'Quinolines/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/3283041/
1535,norfloxacin,2191864,Review of norfloxacin in lower urinary tract infections.,"['Miano L', 'Goldoni S', 'Tubaro A', 'Paradiso Galatioto G', 'Gandolfi P']","['Clinical Trials as Topic', 'Drug Administration Schedule', 'Female', 'Humans', 'Male', 'Norfloxacin/administration & dosage/adverse effects/*therapeutic use', 'Urinary Tract Infections/*drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/2191864/
1536,norfloxacin,3056259,"Double-blind, randomized comparison of 24 weeks of norfloxacin and 12 weeks of norfloxacin followed by 12 weeks of placebo in the therapy of complicated urinary tract infection.","['Sheehan GJ', 'Harding GK', 'Haase DA', 'Thomson MJ', 'Urias B', 'Kennedy JK', 'Hoban DJ', 'Ronald AR']","['Bacteriuria/drug therapy', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Administration Schedule', 'Humans', 'Norfloxacin/administration & dosage/adverse effects/*therapeutic use', 'Prospective Studies', 'Random Allocation', 'Urinary Tract Infections/complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3056259/
1537,norfloxacin,30969469,The Natural Product Elegaphenone Potentiates Antibiotic Effects against Pseudomonas aeruginosa.,"['Zhao W', 'Cross AR', 'Crowe-McAuliffe C', 'Weigert-Munoz A', 'Csatary EE', 'Solinski AE', 'Krysiak J', 'Goldberg JB', 'Wilson DN', 'Medina E', 'Wuest WM', 'Sieber SA']","['Anti-Bacterial Agents/chemical synthesis/chemistry/*pharmacology', 'Benzophenones/chemical synthesis/chemistry/*pharmacology', 'Biological Products/chemical synthesis/chemistry/*pharmacology', 'Cells, Cultured', 'Dose-Response Relationship, Drug', 'Humans', 'Macrophages/drug effects/microbiology', 'Microbial Sensitivity Tests', 'Molecular Structure', 'Norfloxacin/antagonists & inhibitors/chemistry/pharmacology', 'Pseudomonas aeruginosa/cytology/*drug effects', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/30969469/
1538,norfloxacin,3553053,Review of the 4-quinolones.,"['Eggleston M', 'Park SY']","['Anti-Bacterial Agents/metabolism/*pharmacology/therapeutic use', 'Bacteria/*drug effects', 'Bacterial Infections/*drug therapy', 'Ciprofloxacin/metabolism/pharmacology/therapeutic use', 'Drug Interactions', 'Drug Resistance, Microbial', 'Enoxacin', 'Humans', 'Kinetics', 'Naphthyridines/metabolism/pharmacology/therapeutic use', 'Norfloxacin/metabolism/pharmacology/therapeutic use', 'Ofloxacin', 'Oxazines/metabolism/pharmacology/therapeutic use', 'Quinolines/metabolism/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3553053/
1539,norfloxacin,1805646,The fluoroquinolones.,"['Brody T', 'Pensak ML']","['Bacterial Infections/*drug therapy', 'Ciprofloxacin/administration & dosage/pharmacology/*therapeutic use', 'Humans', 'Norfloxacin/administration & dosage/pharmacology/*therapeutic use', 'Otitis Externa/*drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/1805646/
1540,norfloxacin,2760258,Effect of quinolone antimicrobials on theophylline pharmacokinetics.,"['Prince RA', 'Casabar E', 'Adair CG', 'Wexler DB', 'Lettieri J', 'Kasik JE']","['Adult', 'Ciprofloxacin/blood/*pharmacology', 'Half-Life', 'Humans', 'Male', 'Metabolic Clearance Rate', 'Nalidixic Acid/blood/*pharmacology', 'Norfloxacin/blood/*pharmacology', 'Random Allocation', 'Theophylline/administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/2760258/
1541,norfloxacin,2324482,Clostridium difficile-associated diarrhea after norfloxacin.,"['Ehrenpreis ED', 'Lievens MW', 'Craig RM']","['Aged', 'Clostridium Infections/*chemically induced/complications', 'Diarrhea/*chemically induced/complications', 'Gastroenteritis/drug therapy', 'Humans', 'Male', 'Norfloxacin/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2324482/
1542,norfloxacin,2225261,[Intraocular penetration of topical norfloxacin in humans. Preliminary study].,"['Bron A', 'Pechinot M', 'Chirpaz L', 'Razakarivony H', 'Kamcierkzak A', 'Adenis JP']","['Aged', 'Aged, 80 and over', 'Cataract Extraction', 'Clinical Trials as Topic', 'Female', 'Humans', 'Male', 'Middle Aged', 'Norfloxacin/administration & dosage/*pharmacokinetics', 'Ophthalmic Solutions']",https://pubmed.ncbi.nlm.nih.gov/2225261/
1543,norfloxacin,1488882,"Gentamicin, norfloxacin and lysozyme concentration in human tears: in vivo and in vitro study.","['Bron AM', 'Bonnin C', 'Garcher C', 'Lallemand A']","['Adolescent', 'Adult', 'Cornea/drug effects', 'Gentamicins/*pharmacology', 'Humans', 'In Vitro Techniques', 'Male', 'Muramidase/drug effects/*metabolism', 'Norfloxacin/*pharmacology', 'Ophthalmic Solutions', 'Tears/drug effects/*enzymology']",https://pubmed.ncbi.nlm.nih.gov/1488882/
1544,norfloxacin,9406312,Allergic nephropathy associated with norfloxacin and ciprofloxacin therapy. Report of two cases and review of the literature.,"['Hadimeri H', 'Almroth G', 'Cederbrant K', 'Enestrom S', 'Hultman P', 'Lindell A']","['Aged', 'Anti-Infective Agents/*adverse effects/therapeutic use', 'Biopsy', 'Ciprofloxacin/*adverse effects/therapeutic use', 'Drug Hypersensitivity/diagnosis/epidemiology/*etiology', 'Female', 'Humans', 'Kidney/pathology', 'Nephritis, Interstitial/*chemically induced/diagnosis/epidemiology', 'Norfloxacin/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9406312/
1545,norfloxacin,3286512,Pharmacokinetics of ciprofloxacin.,"['Bergan T', 'Dalhoff A', 'Rohwedder R']","['Anti-Infective Agents/pharmacokinetics', 'Biological Availability', 'Ciprofloxacin/*pharmacokinetics', 'Humans', 'Norfloxacin/pharmacokinetics', 'Ofloxacin', 'Oxazines/pharmacokinetics', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/3286512/
1546,quetiapine,37149344,Pharmacotherapy for Treatment-Resistant Depression: Antidepressants and Atypical Antipsychotics.,"['Vas C', 'Jain A', 'Trivedi M', 'Jha MK', 'Mathew SJ']","['Humans', '*Antipsychotic Agents/adverse effects', '*Depressive Disorder, Major/drug therapy', 'Depression/drug therapy', 'Antidepressive Agents/adverse effects', 'Quetiapine Fumarate/therapeutic use', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/37149344/
1547,quetiapine,37792613,Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.,"['Reif A', 'Bitter I', 'Buyze J', 'Cebulla K', 'Frey R', 'Fu DJ', 'Ito T', 'Kambarov Y', 'Llorca PM', 'Oliveira-Maia AJ', 'Messer T', 'Mulhern-Haughey S', 'Rive B', 'von Holt C', 'Young AH', 'Godinov Y']","['Humans', '*Antidepressive Agents/administration & dosage/adverse effects/therapeutic use', 'Delayed-Action Preparations', 'Depression/drug therapy', 'Drug Therapy, Combination', 'Nasal Sprays', '*Quetiapine Fumarate/administration & dosage/adverse effects/therapeutic use', 'Recurrence', '*Selective Serotonin Reuptake Inhibitors/administration & dosage/adverse effects/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/administration & dosage/adverse effects/therapeutic use', 'Single-Blind Method', 'Treatment Outcome', '*Ketamine/administration & dosage/adverse effects/therapeutic use', '*Depressive Disorder, Treatment-Resistant/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37792613/
1548,quetiapine,36427216,Weak legs.,"['Timmons P', 'Williamson A', 'Gibbs V', 'Torgersen A']","['Female', 'Humans', 'Middle Aged', '*Leg', '*Paresis', 'Muscle Weakness/etiology', 'Clopidogrel', 'Quetiapine Fumarate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36427216/
1549,quetiapine,39234895,[Not Available].,"['Norup S', 'Rosenquist SB', 'Knudsen TR', 'Thorgaard MV']","['Humans', '*Quetiapine Fumarate/adverse effects', '*Urinary Retention/chemically induced', 'Female', '*Antipsychotic Agents/adverse effects/administration & dosage', 'Young Adult', 'Dibenzothiazepines/adverse effects/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/39234895/
1550,quetiapine,33941603,Quetiapine for primary insomnia: Consider the risks.,"['Modesto-Lowe V', 'Harabasz AK', 'Walker SA']","['*Antipsychotic Agents/adverse effects', 'Humans', 'Quetiapine Fumarate/adverse effects', '*Sleep Initiation and Maintenance Disorders/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/33941603/
1551,quetiapine,36705012,Interventions for generalized anxiety disorder.,['Byrne GJ'],"['Humans', 'Quetiapine Fumarate/therapeutic use', '*COVID-19', 'Anxiety Disorders/drug therapy', 'Antidepressive Agents/therapeutic use', '*Cognitive Behavioral Therapy']",https://pubmed.ncbi.nlm.nih.gov/36705012/
1552,quetiapine,32513237,"Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium.","['Erstad BL', 'Barletta JF']","['Analgesia/methods/*standards/statistics & numerical data', 'Analgesics, Non-Narcotic/administration & dosage/therapeutic use', 'Analgesics, Opioid/administration & dosage/therapeutic use', 'Benzodiazepines/administration & dosage/therapeutic use', 'Critical Illness/therapy', 'Deep Sedation/methods/*standards/statistics & numerical data', 'Delirium/*etiology', 'Dexmedetomidine/administration & dosage/therapeutic use', '*Dose-Response Relationship, Drug', 'Etomidate/administration & dosage/therapeutic use', 'Haloperidol/administration & dosage/therapeutic use', 'Humans', 'Ketamine/administration & dosage/therapeutic use', 'Obesity/drug therapy/*physiopathology', 'Pain Management/methods', 'Quetiapine Fumarate/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32513237/
1553,quetiapine,33059460,Quetiapine withdrawal: A systematic review.,"['Monahan K', 'Cuzens-Sutton J', 'Siskind D', 'Kisely S']","['Anxiety Disorders', 'Humans', 'Psychomotor Agitation', '*Psychotic Disorders', 'Quetiapine Fumarate/adverse effects', '*Substance Withdrawal Syndrome/etiology']",https://pubmed.ncbi.nlm.nih.gov/33059460/
1554,quetiapine,36463762,Effects of quetiapine on sleep: A systematic review and meta-analysis of clinical trials.,"['Lin CY', 'Chiang CH', 'Tseng MM', 'Tam KW', 'Loh EW']","['Humans', 'Aged', 'Quetiapine Fumarate/adverse effects', '*Depressive Disorder, Major/drug therapy', '*Antipsychotic Agents/adverse effects', 'Anxiety Disorders/drug therapy', 'Sleep']",https://pubmed.ncbi.nlm.nih.gov/36463762/
1555,quetiapine,28975049,Oculogyric Crises.,"['Solberg M', 'Koht J']","['Antipsychotic Agents/*adverse effects/therapeutic use', 'Dibenzocycloheptenes', 'Dystonic Disorders/*chemically induced', 'Heterocyclic Compounds, 4 or More Rings/adverse effects/therapeutic use', 'Humans', 'Male', 'Mental Disorders/drug therapy', 'Ocular Motility Disorders/*chemically induced', 'Quetiapine Fumarate/adverse effects/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28975049/
1556,quetiapine,32036034,Quetiapine-Induced Central Hypothyroidism.,"['Zenno A', 'Leschek E']","['Humans', '*Hypothyroidism/chemically induced', 'Quetiapine Fumarate/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32036034/
1557,quetiapine,38897219,Discontinuation Rate of Lurasidone and Quetiapine Extended Release in Bipolar Depression.,"['Kishi T', 'Sakuma K', 'Hamanaka S', 'Nishii Y', 'Iwata N']","['Humans', '*Quetiapine Fumarate/adverse effects/therapeutic use', '*Lurasidone Hydrochloride/adverse effects/therapeutic use', '*Bipolar Disorder/drug therapy', 'Male', 'Female', '*Antipsychotic Agents/adverse effects/therapeutic use/administration & dosage', '*Delayed-Action Preparations', 'Retrospective Studies', 'Middle Aged', 'Adult', 'Proportional Hazards Models', 'Cohort Studies']",https://pubmed.ncbi.nlm.nih.gov/38897219/
1558,quetiapine,29372938,Second-Generation Antipsychotic-Induced Hypoglycemia.,"['Fujita T', 'Mizoguchi Y', 'Kunitake Y', 'Tateishi H', 'Inaba T', 'Kato TA', 'Monji A']","['Antidepressive Agents/adverse effects/therapeutic use', 'Antipsychotic Agents/*adverse effects/therapeutic use', 'Bipolar Disorder/blood/complications/diagnosis/drug therapy', 'Depressive Disorder, Major/blood/complications/diagnosis/drug therapy', 'Diagnostic Errors', 'Female', 'Humans', 'Hypoglycemia/blood/diagnosis/*etiology', 'Middle Aged', 'Quetiapine Fumarate/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29372938/
1559,quetiapine,33975574,Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis.,"['Kadakia A', 'Dembek C', 'Heller V', 'Singh R', 'Uyei J', 'Hagi K', 'Nosaka T', 'Loebel A']","['Adult', '*Antipsychotic Agents/adverse effects', 'Bayes Theorem', '*Bipolar Disorder/drug therapy', 'Depression', 'Humans', 'Network Meta-Analysis', 'Quetiapine Fumarate/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33975574/
1560,quetiapine,29788886,Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction.,"['Pakri Mohamed RM', 'Kumar J', 'Ahmad SU', 'Mohamed IN']","['Alcohol Deterrents/adverse effects/*therapeutic use', 'Alcoholism/*drug therapy', 'Animals', 'Aripiprazole/adverse effects/therapeutic use', 'Baclofen/adverse effects/therapeutic use', 'Cyclopentanes/adverse effects/therapeutic use', 'Gabapentin/adverse effects/therapeutic use', 'Humans', 'Naltrexone/adverse effects/analogs & derivatives/therapeutic use', 'Quetiapine Fumarate/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29788886/
1561,quetiapine,26635371,Quetiapine-induced cervical dystonia.,"['Tso G', 'Kolur U']","['Antipsychotic Agents/*adverse effects', 'Female', 'Humans', 'Middle Aged', 'Psychotic Disorders/*drug therapy', 'Quetiapine Fumarate/*adverse effects', 'Torticollis/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/26635371/
1562,quetiapine,9855315,"Quetiapine, an atypical antipsychotic.","['Goren JL', 'Levin GM']","['Antipsychotic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Dibenzothiazepines/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Quetiapine Fumarate', 'Schizophrenia/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9855315/
1563,quetiapine,15729090,Quetiapine-induced myoclonus.,"['Velayudhan L', 'Kirchner V']","['Antipsychotic Agents/administration & dosage/*adverse effects/therapeutic use', 'Dibenzothiazepines/administration & dosage/*adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', 'Electrocardiography', 'Humans', 'Male', 'Middle Aged', 'Myoclonus/*chemically induced/physiopathology', 'Quetiapine Fumarate', 'Schizophrenia, Paranoid/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15729090/
1564,quetiapine,36513918,Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update.,"['Rogowska M', 'Thornton M', 'Creese B', 'Velayudhan L', 'Aarsland D', 'Ballard C', 'Tsamakis K', 'Stewart R', 'Mueller C']","['Humans', 'Aged', '*Antipsychotic Agents/adverse effects', 'Olanzapine/therapeutic use', 'Risperidone/adverse effects', '*Psychotic Disorders/drug therapy', 'Quetiapine Fumarate/therapeutic use', '*Dementia/drug therapy/psychology', 'Benzodiazepines/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/36513918/
1565,quetiapine,28806160,Delirium in hospitalized patients: Risks and benefits of antipsychotics.,"['Thom RP', 'Mock CK', 'Teslyar P']","['Antipsychotic Agents/adverse effects/*therapeutic use', 'Aripiprazole/adverse effects/therapeutic use', 'Benzodiazepines/adverse effects/therapeutic use', 'Delirium/*drug therapy', 'Haloperidol/adverse effects/therapeutic use', 'Hospitalization', 'Humans', 'Olanzapine', 'Quetiapine Fumarate/adverse effects/therapeutic use', 'Risperidone/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28806160/
1566,Ranitidina,6312110,Ranitidine.,['Strum WB'],"['Aged', 'Animals', 'Chemical Phenomena', 'Chemistry', 'Cimetidine/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Duodenal Ulcer/drug therapy', 'Humans', 'Male', 'Mice', 'Ranitidine/adverse effects/metabolism/*therapeutic use', 'Rats', 'Stomach Ulcer/drug therapy', 'Zollinger-Ellison Syndrome/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6312110/
1567,Ranitidina,6317325,Ranitidine hydrochloride.,"['Gaginella TS', 'Bauman JH']","['Animals', 'Carcinogens', 'Chemical Phenomena', 'Chemistry', 'Drug Interactions', 'Duodenal Ulcer/drug therapy', 'Humans', 'Kinetics', 'Mutagens', '*Ranitidine/adverse effects/metabolism/pharmacology/therapeutic use', 'Zollinger-Ellison Syndrome/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6317325/
1568,Ranitidina,1958166,Ranitidine and depression.,['Stocky A'],"['Aged', 'Depressive Disorder/*chemically induced/diagnosis/*psychology', 'Esophagitis, Peptic/*drug therapy/*psychology', 'Female', 'Humans', 'Life Change Events', 'Ranitidine/administration & dosage/*adverse effects', 'Recurrence', 'Risk Factors', 'Sick Role', 'Stomach Ulcer/*drug therapy/*psychology', 'Substance Withdrawal Syndrome/*diagnosis/*psychology']",https://pubmed.ncbi.nlm.nih.gov/1958166/
1569,Ranitidina,33155242,How often we diagnose allergy to ranitidine?,"['Bocsan IC', 'Sabin O', 'Matei D', 'Muntean A', 'Buzoianu AD']","['Drug Hypersensitivity/*diagnosis/drug therapy', 'Histamine H2 Antagonists/administration & dosage/*adverse effects', 'Humans', 'Ranitidine/administration & dosage/*adverse effects', 'Rhinitis, Allergic/*diagnosis/drug therapy', 'Skin Tests']",https://pubmed.ncbi.nlm.nih.gov/33155242/
1570,Ranitidina,2874464,Actions of cimetidine and ranitidine at some cholinergic sites: implications in toxicology and anesthesia.,"['Gwee MC', 'Cheah LS']","['*Anesthesia', 'Animals', 'Antihypertensive Agents/adverse effects', 'Bradycardia/chemically induced', 'Cholinesterase Inhibitors/pharmacology', 'Cimetidine/*adverse effects/pharmacology/therapeutic use', 'Confusion/chemically induced', 'Cytochrome P-450 Enzyme System/pharmacology', 'Diarrhea/chemically induced', 'Drug Interactions', 'Erectile Dysfunction/chemically induced', 'Ganglionic Blockers/pharmacology', 'Hemodynamics/drug effects', 'Humans', 'Male', 'Mixed Function Oxygenases/antagonists & inhibitors', 'Neuromuscular Blocking Agents/pharmacology', 'Peptic Ulcer/drug therapy', 'Ranitidine/*adverse effects/pharmacology/therapeutic use', 'Receptors, Cholinergic/*drug effects/physiology', 'Receptors, Histamine H2/drug effects', 'Zollinger-Ellison Syndrome/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2874464/
1571,Ranitidina,4076334,Ranitidine-associated hallucinations.,"['Price W', 'Coli L', 'Brandstetter RD', 'Gotz VP']","['Aged', 'Duodenal Ulcer/drug therapy', 'Female', 'Hallucinations/*chemically induced', 'Humans', 'Ranitidine/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/4076334/
1572,Ranitidina,7751419,Clinical aspects of cardiovascular effects of H2-receptor antagonists.,"['Hinrichsen H', 'Halabi A', 'Kirch W']","['Animals', 'Atrioventricular Node/drug effects', 'Blood Pressure/drug effects', 'Bradycardia/chemically induced', 'Cardiovascular System/*drug effects', 'Cimetidine/adverse effects/pharmacology', 'Electrocardiography/drug effects', 'Heart Rate/drug effects', 'Hemodynamics/drug effects', 'Histamine H2 Antagonists/chemistry/*pharmacology', 'Humans', 'Ranitidine/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/7751419/
1573,Ranitidina,9440055,Ranitidine bismuth citrate plus clarithromycin for the eradication of H. pylori.,"['Dixon JS', 'Pipkin GA', 'Mills JG', 'Wood JR']","['Anti-Bacterial Agents/adverse effects/*therapeutic use', 'Bismuth/adverse effects/*therapeutic use', 'Clarithromycin/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Drug Synergism', 'Drug Therapy, Combination', 'Helicobacter Infections/*drug therapy', '*Helicobacter pylori', 'Histamine H2 Antagonists/adverse effects/*therapeutic use', 'Humans', 'Ranitidine/adverse effects/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9440055/
1574,Ranitidina,10930892,Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies.,"['Van Oijen AH', 'Verbeek AL', 'Jansen JB', 'De Boer WA']","['Amoxicillin/administration & dosage/therapeutic use', 'Anti-Bacterial Agents/administration & dosage/therapeutic use', 'Anti-Ulcer Agents/administration & dosage/*therapeutic use', 'Bismuth/administration & dosage/*therapeutic use', 'Clarithromycin/administration & dosage/therapeutic use', 'Drug Resistance, Microbial', 'Drug Therapy, Combination', 'Helicobacter Infections/*drug therapy', 'Helicobacter pylori/*drug effects', 'Humans', 'Nitroimidazoles/administration & dosage/therapeutic use', 'Penicillins/administration & dosage/therapeutic use', '*Proton Pump Inhibitors', 'Ranitidine/administration & dosage/*analogs & derivatives/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10930892/
1575,Ranitidina,2718500,Ranitidine-induced chest pain.,"['Shimp LA', 'Smith MA', 'Wahr DW']","['Chest Pain/*chemically induced', 'Duodenal Ulcer/drug therapy', 'Female', 'Humans', 'Middle Aged', 'Ranitidine/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2718500/
1576,Ranitidina,7510614,Safety profile of ranitidine. A review.,['Wormsley KG'],"['Diarrhea/chemically induced', 'Drug Interactions', 'Gastric Mucosa/drug effects', 'Headache/chemically induced', 'Humans', 'Peptic Ulcer/*drug therapy', 'Ranitidine/*adverse effects/pharmacokinetics', 'Recurrence', 'Safety']",https://pubmed.ncbi.nlm.nih.gov/7510614/
1577,Ranitidina,8854394,Pharmacokinetics of oral ranitidine in Mexicans.,"['Castaneda-Hernandez G', 'Flores-Murrieta FJ', 'Granados-Soto V', 'Herrera-Abarca A', 'Perez-Urizar J', 'Herrera JE', 'Hong E']","['Administration, Oral', 'Adult', 'Chromatography, High Pressure Liquid', 'Ethnicity', 'Half-Life', 'Humans', 'Male', 'Mexico', 'Ranitidine/administration & dosage/blood/*pharmacokinetics', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/8854394/
1578,Ranitidina,26992900,Oral intake of ranitidine increases urinary excretion of N-nitrosodimethylamine.,"['Zeng T', 'Mitch WA']","['Administration, Oral', 'Adult', 'Carcinogens/pharmacokinetics', 'Dimethylnitrosamine/*urine', 'Female', 'Humans', 'Hydrogen-Ion Concentration', 'Male', 'Middle Aged', 'Nitrosamines/pharmacokinetics/urine', 'Ranitidine/*administration & dosage/*pharmacokinetics', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/26992900/
1579,Ranitidina,12604553,ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate.,"['Pletz MW', 'Preechachatchaval V', 'Bulitta J', 'Allewelt M', 'Burkhardt O', 'Lode H']","['Adult', 'Anti-Ulcer Agents/adverse effects/*pharmacology', 'Area Under Curve', 'Biological Assay', 'Chromatography, Liquid', 'Cross-Over Studies', 'Drug Interactions', 'Erythromycin/adverse effects/*analogs & derivatives/*pharmacokinetics/*pharmacology', 'Female', 'Humans', '*Ketolides', 'Male', 'Mass Spectrometry', 'Microbial Sensitivity Tests', 'Ranitidine/adverse effects/*pharmacokinetics/*pharmacology', 'Sucralfate/adverse effects/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/12604553/
1580,Ranitidina,3717435,Depression associated with ranitidine.,"['Billings RF', 'Stein MB']","['Adult', 'Aged', 'Depressive Disorder/*chemically induced', 'Female', 'Humans', 'Male', 'Peptic Ulcer/drug therapy/prevention & control', 'Ranitidine/*adverse effects/therapeutic use', 'Substance-Related Disorders/etiology']",https://pubmed.ncbi.nlm.nih.gov/3717435/
1581,Ranitidina,33762718,The added value of H(2) antagonists in premedication regimens during paclitaxel treatment.,"['Cox JM', 'van Doorn L', 'Malmberg R', 'Oomen-de Hoop E', 'Bosch TM', 'van den Bemt PMLA', 'Boere IA', 'Jager A', 'Mathijssen RHJ', 'van Leeuwen RWF']","['Adult', 'Aged', 'Aged, 80 and over', 'Chemoprevention/adverse effects/methods', 'Clemastine/administration & dosage', 'Dexamethasone/administration & dosage', 'Drug Hypersensitivity/epidemiology/pathology/*prevention & control', 'Drug Therapy, Combination', 'Equivalence Trials as Topic', 'Female', 'Histamine H2 Antagonists/administration & dosage/therapeutic use', 'Humans', 'Infusions, Intravenous', 'Male', 'Medical Futility', 'Middle Aged', 'Neoplasms/*drug therapy/epidemiology/pathology', 'Netherlands/epidemiology', 'Paclitaxel/administration & dosage/*adverse effects', 'Premedication/adverse effects/*methods', 'Ranitidine/administration & dosage/*therapeutic use', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33762718/
1582,Ranitidina,1483989,Ranitidine--rifampicin interaction.,"['Purohit SD', 'Johri SC', 'Gupta PR', 'Mehta YR', 'Bhatnagar M']","['Adult', 'Alanine Transaminase/blood', 'Bilirubin/blood', 'Drug Interactions', 'Female', 'Gastric Acidity Determination', 'Gastrointestinal Motility/drug effects', 'Humans', 'Male', 'Middle Aged', 'Ranitidine/administration & dosage/*therapeutic use', 'Rifampin/pharmacokinetics/*therapeutic use', 'Tuberculosis, Pulmonary/*drug therapy/metabolism/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/1483989/
1583,Ranitidina,19694603,Hypersensitivity reaction to ranitidine: description of a case and review of the literature.,"['Foti C', 'Cassano N', 'Panebianco R', 'Calogiuri GF', 'Vena GA']","['Anaphylaxis/*chemically induced', 'Anesthesia, Intravenous', '*Drug Hypersensitivity', 'Female', 'Histamine H2 Antagonists/administration & dosage/*adverse effects', 'Humans', 'Middle Aged', 'Peptic Ulcer/drug therapy', 'Ranitidine/administration & dosage/*adverse effects', 'Receptors, Histamine H2']",https://pubmed.ncbi.nlm.nih.gov/19694603/
1584,Ranitidina,1687002,Histamine and histamine type-2 receptor antagonists in psoriasis. Mechanisms and speculations.,['Nielsen HJ'],"['Cyclosporine/adverse effects/pharmacology/therapeutic use', 'Histamine/physiology', 'Histamine Antagonists/*pharmacology', 'Histamine H2 Antagonists/*pharmacology', 'Humans', 'Methotrexate/adverse effects/pharmacology/therapeutic use', 'Psoriasis/*drug therapy/physiopathology', 'Ranitidine/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1687002/
1585,Ranitidina,33855953,The Effects of Ranitidine Treatment on the Risk of Necrotizing Enterocolitis in Preterm Infants: A Case-Control Study.,"['Zvizdic Z', 'Milisic E', 'Jonuzi A', 'Terzic S', 'Zvizdic D', 'Vranic S']","['Anti-Ulcer Agents/*administration & dosage/*adverse effects', 'Case-Control Studies', 'Critical Illness', 'Cross Infection/complications', 'Enterocolitis, Necrotizing/*chemically induced', 'Female', 'Humans', 'Infant, Newborn', 'Infant, Newborn, Diseases', 'Male', 'Peptic Ulcer/*prevention & control', 'Ranitidine/*administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33855953/
1586,Fulvestrant,37256976,Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.,"['Turner NC', 'Oliveira M', 'Howell SJ', 'Dalenc F', 'Cortes J', 'Gomez Moreno HL', 'Hu X', 'Jhaveri K', 'Krivorotko P', 'Loibl S', 'Morales Murillo S', 'Okera M', 'Park YH', 'Sohn J', 'Toi M', 'Tokunaga E', 'Yousef S', 'Zhukova L', 'de Bruin EC', 'Grinsted L', 'Schiavon G', 'Foxley A', 'Rugo HS']","['Female', 'Humans', 'Male', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', '*Aromatase Inhibitors/adverse effects/therapeutic use', '*Breast Neoplasms/drug therapy/pathology', 'Double-Blind Method', 'Fulvestrant/adverse effects/therapeutic use', 'Neoplasm Recurrence, Local/drug therapy', 'Proto-Oncogene Proteins c-akt', 'Receptor, ErbB-2']",https://pubmed.ncbi.nlm.nih.gov/37256976/
1587,Fulvestrant,31091374,"Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.","['Andre F', 'Ciruelos E', 'Rubovszky G', 'Campone M', 'Loibl S', 'Rugo HS', 'Iwata H', 'Conte P', 'Mayer IA', 'Kaufman B', 'Yamashita T', 'Lu YS', 'Inoue K', 'Takahashi M', 'Papai Z', 'Longin AS', 'Mills D', 'Wilke C', 'Hirawat S', 'Juric D']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Agents, Hormonal/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy/genetics', 'Class I Phosphatidylinositol 3-Kinases/*genetics', 'Diarrhea/chemically induced', 'Female', 'Fulvestrant/adverse effects/*therapeutic use', 'Humans', 'Middle Aged', 'Mutation', 'Progression-Free Survival', 'Receptor, ErbB-2', 'Receptors, Estrogen', 'Receptors, Progesterone', 'Thiazoles/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31091374/
1588,Fulvestrant,31318440,ESR1 mutations in breast cancer.,"['Dustin D', 'Gu G', 'Fuqua SAW']","['Antineoplastic Agents, Hormonal/therapeutic use', 'Breast Neoplasms/drug therapy/*genetics/pathology', 'Drug Resistance, Neoplasm/drug effects/genetics', 'Estrogen Receptor alpha/*genetics', 'Female', 'Fulvestrant/therapeutic use', 'Gene Expression Profiling/*methods', 'Humans', 'Liquid Biopsy', '*Mutation', 'Protein Kinase Inhibitors/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31318440/
1589,Fulvestrant,32669709,Fasting-mimicking diet and hormone therapy induce breast cancer regression.,"['Caffa I', 'Spagnolo V', 'Vernieri C', 'Valdemarin F', 'Becherini P', 'Wei M', 'Brandhorst S', 'Zucal C', 'Driehuis E', 'Ferrando L', 'Piacente F', 'Tagliafico A', 'Cilli M', 'Mastracci L', 'Vellone VG', 'Piazza S', 'Cremonini AL', 'Gradaschi R', 'Mantero C', 'Passalacqua M', 'Ballestrero A', 'Zoppoli G', 'Cea M', 'Arrighi A', 'Odetti P', 'Monacelli F', 'Salvadori G', 'Cortellino S', 'Clevers H', 'De Braud F', 'Sukkar SG', 'Provenzani A', 'Longo VD', 'Nencioni A']","['Animals', 'Biological Factors/blood', 'Breast Neoplasms/*diet therapy/*drug therapy/pathology', 'Diet Therapy/*methods', 'Diet, Healthy/methods', 'Disease Models, Animal', 'Disease Progression', 'Drug Resistance, Neoplasm/drug effects', 'Early Growth Response Protein 1/metabolism', 'Fasting/*physiology', 'Female', 'Fulvestrant/administration & dosage/*therapeutic use', 'Humans', 'Insulin/blood', 'Insulin-Like Growth Factor I/metabolism', 'Leptin/blood', 'MCF-7 Cells', 'Mice, Inbred NOD', 'Mice, SCID', 'PTEN Phosphohydrolase/metabolism', 'Piperazines/administration & dosage/therapeutic use', 'Pyridines/administration & dosage/therapeutic use', 'Receptors, Estrogen', 'Receptors, Progesterone', 'Tamoxifen/adverse effects/therapeutic use', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/32669709/
1590,Fulvestrant,29860922,"Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.","['Slamon DJ', 'Neven P', 'Chia S', 'Fasching PA', 'De Laurentiis M', 'Im SA', 'Petrakova K', 'Bianchi GV', 'Esteva FJ', 'Martin M', 'Nusch A', 'Sonke GS', 'De la Cruz-Merino L', 'Beck JT', 'Pivot X', 'Vidam G', 'Wang Y', 'Rodriguez Lorenc K', 'Miller M', 'Taran T', 'Jerusalem G']","['Adult', 'Aged', 'Aged, 80 and over', 'Aminopyridines/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Breast Neoplasms/*drug therapy/mortality', 'Double-Blind Method', 'Female', 'Fulvestrant/*administration & dosage/adverse effects', 'Humans', 'Kaplan-Meier Estimate', 'Middle Aged', 'Progression-Free Survival', 'Purines/*administration & dosage/adverse effects', 'Receptor, ErbB-2/biosynthesis', 'Receptors, Estrogen/biosynthesis', 'Receptors, Progesterone/biosynthesis']",https://pubmed.ncbi.nlm.nih.gov/29860922/
1591,Fulvestrant,39873916,Inavolisib: First Approval.,['Blair HA'],"['Humans', '*Breast Neoplasms/drug therapy', '*Pyridines/pharmacology/therapeutic use/administration & dosage', '*Piperazines/pharmacology/therapeutic use/administration & dosage', '*Drug Approval', '*Class I Phosphatidylinositol 3-Kinases/metabolism/genetics/antagonists & inhibitors', 'Female', 'Fulvestrant/pharmacology/therapeutic use', 'Receptor, ErbB-2/metabolism/antagonists & inhibitors', 'Antineoplastic Combined Chemotherapy Protocols/pharmacology/therapeutic use', 'Drug Resistance, Neoplasm/drug effects', 'United States', 'Phosphoinositide-3 Kinase Inhibitors/pharmacology/therapeutic use', 'Mutation']",https://pubmed.ncbi.nlm.nih.gov/39873916/
1592,Fulvestrant,38402929,Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer.,"['Guglielmi G', 'Del Re M', 'Gol LS', 'Bengala C', 'Danesi R', 'Fogli S']","['Female', 'Humans', '*Breast Neoplasms/pathology', 'Fulvestrant', 'Selective Estrogen Receptor Modulators/pharmacology/therapeutic use', 'Breast/pathology', 'Estrogen Receptor alpha/metabolism', '*Mouth Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38402929/
1593,Fulvestrant,10874568,Pure anti-oestrogens.,"['Hermenegildo C', 'Cano A']","['Animals', 'Breast Neoplasms/drug therapy', 'Estradiol/adverse effects/*analogs & derivatives/therapeutic use', '*Estrogen Antagonists/chemistry/pharmacology/therapeutic use', 'Female', 'Fulvestrant', 'Humans', 'Molecular Structure']",https://pubmed.ncbi.nlm.nih.gov/10874568/
1594,Fulvestrant,31353221,Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility.,"['Guan J', 'Zhou W', 'Hafner M', 'Blake RA', 'Chalouni C', 'Chen IP', 'De Bruyn T', 'Giltnane JM', 'Hartman SJ', 'Heidersbach A', 'Houtman R', 'Ingalla E', 'Kategaya L', 'Kleinheinz T', 'Li J', 'Martin SE', 'Modrusan Z', 'Nannini M', 'Oeh J', 'Ubhayakar S', 'Wang X', 'Wertz IE', 'Young A', 'Yu M', 'Sampath D', 'Hager JH', 'Friedman LS', 'Daemen A', 'Metcalfe C']","['Animals', 'Breast Neoplasms/drug therapy/*metabolism/pathology', 'Cell Proliferation/drug effects', 'Cinnamates/pharmacology', 'Drug Resistance, Neoplasm', 'Estrogen Receptor Antagonists/*pharmacology/therapeutic use', 'Female', 'Fulvestrant/*pharmacology/therapeutic use', 'HEK293 Cells', 'Heterografts', 'Humans', 'Indazoles/pharmacology', 'Ligands', 'MCF-7 Cells', 'Mice', 'Mice, Inbred NOD', 'Mice, Nude', 'Mice, SCID', 'Polymorphism, Single Nucleotide', 'Proteolysis/drug effects', 'Receptors, Estrogen/*antagonists & inhibitors/*metabolism', 'Signal Transduction/drug effects', 'Transcription, Genetic/drug effects']",https://pubmed.ncbi.nlm.nih.gov/31353221/
1595,Fulvestrant,31563959,"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.","['Sledge GW Jr', 'Toi M', 'Neven P', 'Sohn J', 'Inoue K', 'Pivot X', 'Burdaeva O', 'Okera M', 'Masuda N', 'Kaufman PA', 'Koh H', 'Grischke EM', 'Conte P', 'Lu Y', 'Barriga S', 'Hurt K', 'Frenzel M', 'Johnston S', 'Llombart-Cussac A']","['Aminopyridines/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Benzimidazoles', '*Breast Neoplasms/pathology', 'Female', 'Fulvestrant', 'Humans', 'Middle Aged', 'Receptor, ErbB-2', '*Triple Negative Breast Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31563959/
1596,Fulvestrant,34102253,"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.","['Slamon DJ', 'Neven P', 'Chia S', 'Jerusalem G', 'De Laurentiis M', 'Im S', 'Petrakova K', 'Valeria Bianchi G', 'Martin M', 'Nusch A', 'Sonke GS', 'De la Cruz-Merino L', 'Beck JT', 'Ji Y', 'Wang C', 'Deore U', 'Chakravartty A', 'Zarate JP', 'Taran T', 'Fasching PA']","['Adolescent', 'Aminopyridines', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', '*Breast Neoplasms/drug therapy', 'Double-Blind Method', 'Female', 'Fulvestrant', 'Humans', 'Postmenopause', 'Purines', 'Receptor, ErbB-2', 'Receptors, Estrogen', 'Receptors, Progesterone']",https://pubmed.ncbi.nlm.nih.gov/34102253/
1597,Fulvestrant,11829719,Fulvestrant.,"['Cheung KL', 'Robertson JF']","['Animals', 'Antineoplastic Agents, Hormonal/adverse effects/pharmacology', 'Breast Neoplasms/drug therapy', 'Contraindications', 'Dose-Response Relationship, Drug', 'Drug Interactions', '*Estradiol/adverse effects/*analogs & derivatives/pharmacology', '*Estrogen Receptor Modulators/adverse effects/pharmacology', 'Female', 'Fulvestrant', 'Humans', 'Randomized Controlled Trials as Topic', 'Tamoxifen/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11829719/
1598,Fulvestrant,31256368,Alpelisib: First Global Approval.,['Markham A'],"['Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy/metabolism', 'Class I Phosphatidylinositol 3-Kinases/*antagonists & inhibitors/genetics', 'Drug Approval', 'Female', 'Fulvestrant/administration & dosage', 'Humans', 'Male', 'Mutation', 'Protein Kinase Inhibitors/*administration & dosage', 'Receptor, ErbB-2/metabolism', 'Thiazoles/*administration & dosage', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/31256368/
1599,Fulvestrant,31426673,EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.,"['Bardia A', 'Aftimos P', 'Bihani T', 'Anderson-Villaluz AT', 'Jung J', 'Conlan MG', 'Kaklamani VG']","['Female', 'Humans', 'Middle Aged', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use', '*Breast Neoplasms/drug therapy/metabolism/pathology', '*Estrogen Receptor alpha/metabolism', 'Follow-Up Studies', 'Fulvestrant/administration & dosage', 'International Agencies', 'Prognosis', 'Prospective Studies', 'Survival Rate', 'Tetrahydronaphthalenes/administration & dosage', 'Randomized Controlled Trials as Topic', 'Multicenter Studies as Topic']",https://pubmed.ncbi.nlm.nih.gov/31426673/
1600,Fulvestrant,34617955,"Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.","['Llombart-Cussac A', 'Perez-Garcia JM', 'Bellet M', 'Dalenc F', 'Gil-Gil M', 'Ruiz-Borrego M', 'Gavila J', 'Sampayo-Cordero M', 'Aguirre E', 'Schmid P', 'Marme F', 'Di Cosimo S', 'Gligorov J', 'Schneeweiss A', 'Albanell J', 'Zamora P', 'Wheatley D', 'Martinez-de Duenas E', 'Amillano K', 'Malfettone A', 'Cortes J']","['Antineoplastic Combined Chemotherapy Protocols/adverse effects', '*Breast Neoplasms/pathology', 'Female', 'Fulvestrant', 'Humans', 'Letrozole/therapeutic use', 'Middle Aged', 'Piperazines', 'Pyridines', 'Receptor, ErbB-2']",https://pubmed.ncbi.nlm.nih.gov/34617955/
1601,Fulvestrant,36321996,Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma.,"['Rugo HS', 'Raskina K', 'Schrock AB', 'Madison RW', 'Graf RP', 'Sokol ES', 'Sivakumar S', 'Lee JK', 'Fisher V', 'Oxnard GR', 'Tukachinsky H']","['Humans', 'Female', 'Fulvestrant/adverse effects', '*Receptor, ErbB-2/genetics/therapeutic use', '*Breast Neoplasms/drug therapy/genetics/pathology', 'Mutation', 'Class I Phosphatidylinositol 3-Kinases/genetics', 'Biology']",https://pubmed.ncbi.nlm.nih.gov/36321996/
1602,Fulvestrant,30345905,Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.,"['Turner NC', 'Slamon DJ', 'Ro J', 'Bondarenko I', 'Im SA', 'Masuda N', 'Colleoni M', 'DeMichele A', 'Loi S', 'Verma S', 'Iwata H', 'Harbeck N', 'Loibl S', 'Andre F', 'Puyana Theall K', 'Huang X', 'Giorgetti C', 'Huang Bartlett C', 'Cristofanilli M']","['Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy/mortality', 'Double-Blind Method', 'ErbB Receptors/analysis', 'Estradiol/administration & dosage/adverse effects/*analogs & derivatives', 'Female', 'Fulvestrant', 'Humans', 'Middle Aged', 'Piperazines/*administration & dosage/adverse effects', 'Protein Kinase Inhibitors/administration & dosage/adverse effects', 'Pyridines/*administration & dosage/adverse effects', 'Receptors, Steroid/analysis', 'Survival Analysis']",https://pubmed.ncbi.nlm.nih.gov/30345905/
1603,Fulvestrant,31826360,Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.,"['Slamon DJ', 'Neven P', 'Chia S', 'Fasching PA', 'De Laurentiis M', 'Im SA', 'Petrakova K', 'Bianchi GV', 'Esteva FJ', 'Martin M', 'Nusch A', 'Sonke GS', 'De la Cruz-Merino L', 'Beck JT', 'Pivot X', 'Sondhi M', 'Wang Y', 'Chakravartty A', 'Rodriguez-Lorenc K', 'Taran T', 'Jerusalem G']","['Aged', 'Aminopyridines/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy/mortality', 'Drug Administration Schedule', 'Female', 'Fulvestrant/*administration & dosage/adverse effects', 'Humans', 'Kaplan-Meier Estimate', 'Middle Aged', 'Postmenopause', 'Progression-Free Survival', 'Purines/*administration & dosage/adverse effects', 'Receptor, ErbB-2', 'Receptors, Estrogen', 'Receptors, Progesterone']",https://pubmed.ncbi.nlm.nih.gov/31826360/
1604,Fulvestrant,32275492,Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer.,['Barghout SH'],"['Animals', 'Antineoplastic Agents/*pharmacology/therapeutic use', '*Drug Discovery', 'Fulvestrant/pharmacology/therapeutic use', 'Humans', 'Molecular Targeted Therapy', 'Neoplasms/*drug therapy/metabolism', 'Proteasome Endopeptidase Complex/metabolism', 'Proteolysis/*drug effects', 'Thalidomide/pharmacology/therapeutic use', 'Ubiquitination/drug effects']",https://pubmed.ncbi.nlm.nih.gov/32275492/
1605,Fulvestrant,27326977,Endocrine therapy for hormone treatment-naive advanced breast cancer.,"['Martin M', 'Lopez-Tarruella S', 'Gilarranz YJ']","['Anastrozole', 'Androstadienes/administration & dosage', 'Antineoplastic Agents, Hormonal/*administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Bevacizumab/administration & dosage', 'Breast Neoplasms/*drug therapy/*pathology', 'Clinical Trials, Phase II as Topic', 'Clinical Trials, Phase III as Topic', 'Estradiol/administration & dosage/analogs & derivatives', 'Female', 'Fulvestrant', 'Humans', 'Letrozole', 'Nitriles/administration & dosage', 'Piperazines/administration & dosage', 'Pyridines/administration & dosage', 'Randomized Controlled Trials as Topic', 'Tamoxifen/administration & dosage', 'Triazoles/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27326977/
1606,hydroxyzine,36843057,Efficacy and safety of hydroxyzine for sleep in adults: Systematic review.,"['Burgazli CR', 'Rana KB', 'Brown JN', 'Tillman F 3rd']","['Humans', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Hypnotics and Sedatives/pharmacology', 'Hydroxyzine/adverse effects', 'Prospective Studies', 'Sleep']",https://pubmed.ncbi.nlm.nih.gov/36843057/
1607,hydroxyzine,25397904,H1-antihistamines for chronic spontaneous urticaria.,"['Sharma M', 'Bennett C', 'Cohen SN', 'Carter B']","['Cetirizine/therapeutic use', 'Cyproheptadine/analogs & derivatives/therapeutic use', 'Histamine H1 Antagonists/adverse effects/*therapeutic use', 'Humans', 'Hydroxyzine/therapeutic use', 'Loratadine/analogs & derivatives/therapeutic use', 'Randomized Controlled Trials as Topic', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/25397904/
1608,hydroxyzine,38980829,Managing Pruritus in Advanced Chronic Disease.,"['Kaya E', 'McDonald G', 'Gallagher R']","['Humans', '*Pruritus/drug therapy/etiology', 'Chronic Disease', 'Hydroxyzine/therapeutic use/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38980829/
1609,hydroxyzine,6627988,Follicular dermographism.,"['Shelley WB', 'Shelley ED']","['Adolescent', 'Adult', 'Female', 'Humans', 'Hydroxyzine/therapeutic use', 'Male', 'Middle Aged', 'Physical Stimulation', 'Pruritus/etiology', 'Urticaria/drug therapy/*etiology']",https://pubmed.ncbi.nlm.nih.gov/6627988/
1610,hydroxyzine,1979802,Recent advances in H1-receptor antagonist treatment.,['Simons FE'],"['Astemizole', 'Benzhydryl Compounds/*pharmacokinetics', 'Benzimidazoles/*pharmacokinetics', 'Cetirizine', 'Cyproheptadine/*analogs & derivatives/pharmacokinetics', 'Histamine H1 Antagonists/*pharmacokinetics', 'Humans', 'Hydroxyzine/*analogs & derivatives/pharmacokinetics', 'Loratadine', 'Receptors, Histamine H1/drug effects', 'Rhinitis, Allergic, Perennial/drug therapy', 'Terfenadine', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1979802/
1611,hydroxyzine,35976065,Topical cetirizine for treating androgenetic alopecia: A systematic review.,"['Chen X', 'Xiang H', 'Yang M']","['Humans', 'Administration, Topical', '*Alopecia/drug therapy', '*Cetirizine/administration & dosage/adverse effects', 'Hair', 'Minoxidil/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/35976065/
1612,hydroxyzine,1686525,Cetirizine: more than an antihistamine?,"['Bernheim J', 'Arendt C', 'de Vos C']","['Allergens/immunology', 'Animals', 'Asthma/drug therapy/immunology/physiopathology', 'Cetirizine', 'Exercise', 'Histamine Antagonists/*pharmacology', 'Histamine H1 Antagonists/pharmacology', 'Humans', 'Hydroxyzine/*analogs & derivatives/pharmacology/therapeutic use', 'Hypersensitivity/physiopathology', 'Muscle Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/1686525/
1613,hydroxyzine,36613097,"The Effects of Pharmacological Treatment of Nightmares: A Systematic Literature Review and Meta-Analysis of Placebo-Controlled, Randomized Clinical Trials.","['Skeie-Larsen M', 'Stave R', 'Gronli J', 'Bjorvatn B', 'Wilhelmsen-Langeland A', 'Zandi A', 'Pallesen S']","['Humans', '*Dreams', 'Randomized Controlled Trials as Topic', 'Prazosin/therapeutic use/pharmacology', 'Adrenergic alpha-1 Receptor Antagonists/therapeutic use', '*Stress Disorders, Post-Traumatic', 'Hydroxyzine/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36613097/
1614,hydroxyzine,11034010,Cetirizine-induce cholestasis.,"['Fong DG', 'Angulo P', 'Burgart LJ', 'Lindor KD']","['Adult', 'Cetirizine/*adverse effects/therapeutic use', 'Cholestasis, Intrahepatic/*chemically induced/diagnosis/pathology', 'Histamine H1 Antagonists/*adverse effects/therapeutic use', 'Humans', 'Liver/pathology', 'Male', 'Rhinitis, Allergic, Perennial/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11034010/
1615,hydroxyzine,9852800,Oral sedation.,['Dionne R'],"['Administration, Oral', 'Algorithms', 'Anesthesia, Dental/*methods', 'Anti-Anxiety Agents/*administration & dosage', 'Chloral Hydrate/adverse effects', 'Conscious Sedation/*methods', 'Dental Anxiety/*prevention & control', 'Diazepam/administration & dosage', 'Histamine H1 Antagonists/administration & dosage', 'Humans', 'Hydroxyzine/administration & dosage', 'Hypnotics and Sedatives/adverse effects', 'Midazolam/administration & dosage', 'Mutagens', 'Premedication', 'Triazolam/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/9852800/
1616,hydroxyzine,11414551,Pharmacotherapy of generalized anxiety disorder.,['Davidson JR'],"['Anti-Anxiety Agents/therapeutic use', 'Antidepressive Agents/administration & dosage/*therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Anxiety Disorders/*drug therapy/epidemiology/psychology', 'Benzodiazepines', 'Buspirone/therapeutic use', 'Comorbidity', 'Depressive Disorder/drug therapy/epidemiology', 'Heart Rate/drug effects', 'Humans', 'Hydroxyzine/therapeutic use', 'Serotonin Receptor Agonists/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/11414551/
1617,hydroxyzine,1979793,H1-receptor antagonist treatment of seasonal allergic rhinitis.,['Kaiser HB'],"['Astemizole', 'Benzhydryl Compounds/pharmacokinetics/therapeutic use', 'Benzimidazoles/pharmacokinetics/therapeutic use', 'Cetirizine', 'Chlorpheniramine/pharmacokinetics/therapeutic use', 'Clemastine/pharmacokinetics/therapeutic use', 'Cyproheptadine/analogs & derivatives/pharmacokinetics/therapeutic use', 'Histamine H1 Antagonists/pharmacokinetics/*therapeutic use', 'Humans', 'Hydroxyzine/analogs & derivatives/pharmacokinetics/therapeutic use', 'Ketotifen/pharmacokinetics/therapeutic use', 'Loratadine', 'Rhinitis, Allergic, Seasonal/*drug therapy', 'Terfenadine']",https://pubmed.ncbi.nlm.nih.gov/1979793/
1618,hydroxyzine,11772135,Cetirizine/pseudoephedrine.,"['Wellington K', 'Jarvis B']","['Administration, Oral', 'Adrenergic Agents/adverse effects/pharmacokinetics/*pharmacology', 'Anxiety/chemically induced', 'Asthenia/chemically induced', 'Biological Availability', 'Cetirizine/adverse effects/pharmacokinetics/*pharmacology', 'Chemistry, Pharmaceutical', 'Drug Administration Schedule', 'Ephedrine/adverse effects/pharmacokinetics/*pharmacology', 'Headache/chemically induced', 'Histamine H1 Antagonists/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Nasal Cavity', 'Pruritus/drug therapy', 'Randomized Controlled Trials as Topic', 'Rhinitis, Allergic, Seasonal/*drug therapy/pathology', 'Sleep Initiation and Maintenance Disorders/chemically induced', 'Tablets', 'Treatment Outcome', 'Xerostomia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/11772135/
1619,hydroxyzine,10582736,Therapeutic index of H1-antihistamines: example of cetirizine.,['Rihoux JP'],"['Cetirizine/adverse effects/metabolism/*therapeutic use', 'Histamine H1 Antagonists/adverse effects/metabolism/*therapeutic use', 'Humans', 'Hypersensitivity, Immediate/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/10582736/
1620,hydroxyzine,34818169,Urticaria and edema in a 2-year-old boy.,"['Cook JS', 'Angles A', 'Morley E']","['Amoxicillin/*adverse effects', 'Anti-Bacterial Agents/adverse effects', 'Anti-Inflammatory Agents/therapeutic use', 'Cetirizine/therapeutic use', 'Child, Preschool', 'Diagnosis, Differential', 'Drug Eruptions/*diagnosis/*drug therapy', 'Edema', 'Histamine H1 Antagonists/therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/therapeutic use', 'Humans', 'Hydroxyzine/therapeutic use', 'Male', 'Otitis Media/*drug therapy', 'Triamcinolone/therapeutic use', 'Urticaria/*diagnosis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34818169/
1621,hydroxyzine,2871956,Repeat chemonucleolysis.,['Sutton JC Jr'],"['Adolescent', 'Adult', 'Anaphylaxis/etiology/*prevention & control', 'Chymopapain/adverse effects/*therapeutic use', 'Cimetidine/*therapeutic use', 'Female', 'Follow-Up Studies', 'Histamine H1 Antagonists/therapeutic use', 'Histamine H2 Antagonists/therapeutic use', 'Humans', 'Hydroxyzine/*therapeutic use', 'Intervertebral Disc Displacement/*drug therapy', 'Lumbar Vertebrae', 'Male', 'Middle Aged', '*Premedication', 'Recurrence', 'Risk', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2871956/
1622,hydroxyzine,9146011,Hydroxyzine therapy for interstitial cystitis.,"['Theoharides TC', 'Sant GR']","['Cystitis, Interstitial/*drug therapy', 'Histamine H1 Antagonists/*therapeutic use', 'Humans', 'Hydroxyzine/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9146011/
1623,hydroxyzine,22030083,Generalised anxiety disorder.,"['Gale CK', 'Millichamp J']","['Anxiety Disorders/drug therapy', 'Benzodiazepines/therapeutic use', '*Buspirone/therapeutic use', 'Humans', '*Hydroxyzine/therapeutic use', 'Psychiatric Status Rating Scales', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Sertraline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22030083/
1624,hydroxyzine,8833171,Aquagenic urticaria.,['Medeiros M Jr'],"['Adult', 'Cetirizine/adverse effects/therapeutic use', 'Diagnosis, Differential', 'Histamine H1 Antagonists/adverse effects/therapeutic use', 'Humans', 'Hydroxyzine/therapeutic use', 'Male', 'Urticaria/*diagnosis/drug therapy/*etiology', 'Water/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/8833171/
1625,hydroxyzine,2188436,Potentiation of pain relief with hydroxyzine: a therapeutic myth?,['Glazier HS'],"['Drug Synergism', 'Humans', 'Hydroxyzine/adverse effects/*therapeutic use', 'Narcotics/adverse effects/*therapeutic use', 'Pain/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2188436/
1626,methadone,19074706,Methadone exposure during lactation.,"['Glatstein MM', 'Garcia-Bournissen F', 'Finkelstein Y', 'Koren G']","['Analgesics, Opioid/administration & dosage/adverse effects/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Lactation/*drug effects', 'Maternal Exposure/adverse effects', 'Methadone/administration & dosage/*adverse effects/pharmacokinetics', 'Milk, Human/chemistry/drug effects', 'Opioid-Related Disorders/*drug therapy/metabolism', 'Pregnancy', 'Pregnancy Complications/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/19074706/
1627,methadone,1960766,Methadone and edema.,"[""O'Conor LM"", 'Woody G', 'Yeh HS', 'Manny I', 'Dhopesh V']","['Adult', 'Dose-Response Relationship, Drug', 'Edema/*chemically induced', 'Heroin Dependence/*rehabilitation', 'Humans', 'Male', 'Methadone/*adverse effects/therapeutic use', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/1960766/
1628,methadone,17182514,Equianalgesic dosing of opioids.,"['Berdine HJ', 'Nesbit SA']","['*Analgesics, Opioid', 'Dose-Response Relationship, Drug', 'Fentanyl/administration & dosage/*pharmacokinetics/therapeutic use', 'Humans', 'Hydromorphone/administration & dosage/*pharmacokinetics/therapeutic use', 'Methadone/administration & dosage/*pharmacokinetics/therapeutic use', 'Pain/*drug therapy', 'Therapeutic Equivalency']",https://pubmed.ncbi.nlm.nih.gov/17182514/
1629,methadone,4599599,Methadone.,['Sim SK'],"['Acetates/therapeutic use', 'Administration, Oral', 'Adolescent', 'American Medical Association', 'Canada', 'Chemical Phenomena', 'Chemistry', 'Drug and Narcotic Control', 'Female', 'Heroin Dependence/*drug therapy/rehabilitation', 'Humans', 'Methadone/administration & dosage/metabolism/pharmacology/*therapeutic use', 'Pregnancy', 'Pregnancy Complications', 'Private Practice', 'Structure-Activity Relationship', 'Substance Withdrawal Syndrome/drug therapy', 'Substance-Related Disorders', 'United States']",https://pubmed.ncbi.nlm.nih.gov/4599599/
1630,methadone,15909785,Methadone for cancer pain: what have we learned from clinical studies?,['Soares LG'],"['Analgesics, Opioid/administration & dosage/adverse effects/*therapeutic use', 'Dose-Response Relationship, Drug', 'Humans', 'Methadone/administration & dosage/adverse effects/*therapeutic use', 'Morphine/therapeutic use', 'Neoplasms/*complications', 'Pain/*drug therapy/etiology', 'Pain Measurement', 'Palliative Care/*methods', 'World Health Organization']",https://pubmed.ncbi.nlm.nih.gov/15909785/
1631,methadone,28956544,Serotonin syndrome due to co-administration of linezolid and methadone.,"['Mastroianni A', 'Ravaglia G']","['Adult', 'Anti-HIV Agents/therapeutic use', 'Drug Synergism', 'Drug Therapy, Combination', 'HIV Infections/complications', 'Humans', 'Linezolid/administration & dosage/*adverse effects/pharmacokinetics/therapeutic use', 'Male', 'Methadone/administration & dosage/*adverse effects/pharmacokinetics/therapeutic use', 'Methicillin-Resistant Staphylococcus aureus/isolation & purification', 'Monoamine Oxidase Inhibitors/adverse effects/pharmacokinetics', 'Opiate Substitution Treatment', 'Serotonin Syndrome/*etiology', 'Selective Serotonin Reuptake Inhibitors/adverse effects/pharmacokinetics', 'Staphylococcal Infections/drug therapy/microbiology', 'Substance Abuse, Intravenous/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/28956544/
1632,methadone,16859402,Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence.,"['Maas B', 'Kerr T', 'Fairbairn N', 'Montaner J', 'Wood E']","['Animals', 'Anti-HIV Agents/*adverse effects/*pharmacokinetics', 'Buprenorphine/adverse effects/pharmacokinetics/therapeutic use', 'Drug Interactions', 'Humans', 'Methadone/adverse effects/pharmacokinetics/therapeutic use', 'Methadyl Acetate/adverse effects/pharmacokinetics/therapeutic use', 'Narcotic Antagonists/*adverse effects/*pharmacokinetics/therapeutic use', 'Narcotics/adverse effects/pharmacokinetics/therapeutic use', 'Opioid-Related Disorders/*rehabilitation']",https://pubmed.ncbi.nlm.nih.gov/16859402/
1633,methadone,9547764,Opioid dependence during pregnancy. Effects and management.,"['Kaltenbach K', 'Berghella V', 'Finnegan L']","['Delivery, Obstetric', 'Female', 'Humans', 'Infant, Newborn', 'Methadone/pharmacology/therapeutic use', 'Narcotics/adverse effects', 'Neonatal Abstinence Syndrome/physiopathology/prevention & control', '*Opioid-Related Disorders/complications/drug therapy', 'Postnatal Care', 'Pregnancy', '*Pregnancy Complications/chemically induced/drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/9547764/
1634,methadone,7931860,Methadone treatment during pregnancy.,"['Jarvis MA', 'Schnoll SH']","['Female', 'Humans', 'Methadone/adverse effects/*therapeutic use', 'Opioid-Related Disorders/*complications/*rehabilitation', 'Pregnancy', 'Pregnancy Complications/*therapy', 'Pregnancy Outcome']",https://pubmed.ncbi.nlm.nih.gov/7931860/
1635,methadone,11911622,Treatment of neonatal abstinence syndrome with breast milk containing methadone.,['Ballard JL'],"['*Breast Feeding', 'Drug Administration Schedule', 'Female', 'Humans', 'Infant, Newborn', 'Labor, Obstetric/drug effects', 'Methadone/*administration & dosage/pharmacokinetics', '*Milk, Human', 'Morphine/therapeutic use', 'Neonatal Abstinence Syndrome/*rehabilitation', 'Opioid-Related Disorders/*rehabilitation', 'Pregnancy', 'Pregnancy Complications/*rehabilitation', 'Prenatal Care']",https://pubmed.ncbi.nlm.nih.gov/11911622/
1636,methadone,9034479,The dangers of dextropropoxyphene.,['Dore GM'],"['Adult', 'Analgesics, Opioid/administration & dosage/*adverse effects', 'Combined Modality Therapy', 'Dextropropoxyphene/*adverse effects', 'Drug Overdose', 'Female', 'Humans', 'Methadone/*therapeutic use', 'Psychotherapy', 'Substance-Related Disorders/*rehabilitation']",https://pubmed.ncbi.nlm.nih.gov/9034479/
1637,methadone,7224382,Phenytoin-induced methadone withdrawal.,"['Tong TG', 'Pond SM', 'Kreek MJ', 'Jaffery NF', 'Benowitz NL']","['Adult', 'Drug Administration Schedule', 'Drug Interactions', 'Humans', 'Male', 'Methadone/administration & dosage/*adverse effects', 'Phenytoin/*adverse effects', 'Pyrrolidines/urine', 'Substance Withdrawal Syndrome/*chemically induced/metabolism']",https://pubmed.ncbi.nlm.nih.gov/7224382/
1638,methadone,2846900,Implications of methadone maintenance for theories of narcotic addiction.,['Dole VP'],"['Drug Administration Schedule', 'Humans', 'Methadone/administration & dosage/pharmacokinetics/pharmacology/*therapeutic use', 'Narcotic Antagonists/pharmacology', 'Narcotics/administration & dosage/pharmacology', 'Opioid-Related Disorders/metabolism/physiopathology/*rehabilitation', 'Receptors, Opioid/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2846900/
1639,methadone,12378067,Intrathecal therapy for chronic pain.,['Miles J'],"['Administration, Oral', 'Analgesics/*administration & dosage/therapeutic use', 'Analgesics, Non-Narcotic/administration & dosage/therapeutic use', 'Analgesics, Opioid/administration & dosage/therapeutic use', 'Chronic Disease', 'Humans', 'Infusion Pumps, Implantable', 'Infusions, Parenteral', 'Injections, Spinal', 'Ketamine/administration & dosage/pharmacology/therapeutic use', 'Methadone/administration & dosage/pharmacology/therapeutic use', 'Morphine/administration & dosage/therapeutic use', 'Narcotics/administration & dosage/therapeutic use', 'Neoplasms/complications', 'Pain/*drug therapy/etiology', 'Patient Selection', 'Receptors, N-Methyl-D-Aspartate/drug effects']",https://pubmed.ncbi.nlm.nih.gov/12378067/
1640,methadone,24956254,Pharmacogenomics of methadone maintenance treatment.,"['Somogyi AA', 'Barratt DT', 'Ali RL', 'Coller JK']","['Dose-Response Relationship, Drug', 'Humans', 'Methadone/*administration & dosage/adverse effects', 'Opiate Substitution Treatment/*methods', '*Pharmacogenetics', 'Polymorphism, Single Nucleotide', 'Receptors, Opioid, mu/*genetics']",https://pubmed.ncbi.nlm.nih.gov/24956254/
1641,methadone,8160253,Probable metabolic interaction between methadone and fluvoxamine in addict patients.,"['Bertschy G', 'Baumann P', 'Eap CB', 'Baettig D']","['Adult', 'Depressive Disorder/drug therapy/psychology', 'Drug Interactions', 'Female', 'Fluvoxamine/adverse effects/*pharmacokinetics/therapeutic use', 'Humans', 'Male', 'Methadone/adverse effects/*pharmacokinetics/therapeutic use', 'Opioid-Related Disorders/drug therapy/*metabolism/psychology']",https://pubmed.ncbi.nlm.nih.gov/8160253/
1642,methadone,24519114,[No opiates against cannabis hyperemesis syndrome].,"['Bonnet U', 'Stratmann U', 'Isbruch K']","['Adult', 'Antiemetics/adverse effects/therapeutic use', 'Dronabinol/*adverse effects', 'Drug Administration Schedule', 'Drug Resistance', 'Drug Therapy, Combination', 'Germany', 'Humans', 'Infusions, Intravenous', 'Male', 'Marijuana Abuse/*complications/rehabilitation', 'Methadone/*administration & dosage/*adverse effects', 'Morphine/*administration & dosage/*adverse effects', 'Opioid-Related Disorders/etiology/*rehabilitation', 'Substance Abuse Treatment Centers', 'Substance Withdrawal Syndrome/etiology/*rehabilitation', 'Vomiting/*chemically induced/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24519114/
1643,methadone,26461073,Cardiac Effects of Opioid Therapy.,"['Chen A', 'Ashburn MA']","['Analgesics, Opioid/adverse effects/*therapeutic use', 'Chronic Pain/*drug therapy', 'Heart/*drug effects', 'Humans', 'Methadone/adverse effects/therapeutic use', 'Risk']",https://pubmed.ncbi.nlm.nih.gov/26461073/
1644,methadone,25487851,Role of Methadone in Induction and/or Exacerbation of Cluster Headache in Patients Treated for Opioid Addiction.,"['Diot C', 'Eiden C', 'Leglise Y', 'Donnadieu-Rigole H', 'Peyriere H']","['Adult', 'Cluster Headache/*chemically induced', 'Dose-Response Relationship, Drug', 'Heroin Dependence/*drug therapy', 'Humans', 'Male', 'Methadone/administration & dosage/*adverse effects', 'Opiate Substitution Treatment/adverse effects/methods']",https://pubmed.ncbi.nlm.nih.gov/25487851/
1645,methadone,31178032,[Improve the benefit/risk balance of methadone by respecting its pharmacological specificities].,"['Frauger E', 'Fouilhe Sam-Lai N', 'Mallaret M', 'Micallef J']","['Analgesics, Opioid/*administration & dosage/adverse effects/pharmacology', 'Drug Overdose', 'France', 'Humans', 'Methadone/*administration & dosage/adverse effects/pharmacology', 'Opiate Substitution Treatment/adverse effects/*methods', 'Opioid-Related Disorders/rehabilitation', 'Pharmacovigilance']",https://pubmed.ncbi.nlm.nih.gov/31178032/
1646,BISOPROLOL,38587241,Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.,"['Yndigegn T', 'Lindahl B', 'Mars K', 'Alfredsson J', 'Benatar J', 'Brandin L', 'Erlinge D', 'Hallen O', 'Held C', 'Hjalmarsson P', 'Johansson P', 'Karlstrom P', 'Kellerth T', 'Marandi T', 'Ravn-Fischer A', 'Sundstrom J', 'Ostlund O', 'Hofmann R', 'Jernberg T']","['Humans', '*Adrenergic beta-Antagonists/adverse effects/therapeutic use', '*Bisoprolol/adverse effects/therapeutic use', 'Heart Failure/etiology', '*Myocardial Infarction/complications/diagnostic imaging/mortality/therapy', 'Stroke Volume', 'Treatment Outcome', 'Ventricular Function, Left', '*Metoprolol/adverse effects/therapeutic use', 'Secondary Prevention']",https://pubmed.ncbi.nlm.nih.gov/38587241/
1647,BISOPROLOL,35093388,Beta-blockers for the treatment of arrhythmias: Bisoprolol - a systematic review.,"['Muresan L', 'Cismaru G', 'Muresan C', 'Rosu R', 'Gusetu G', 'Puiu M', 'Mada RO', 'Martins RP']","['Adrenergic beta-Antagonists/therapeutic use', '*Atrial Fibrillation/drug therapy', '*Bisoprolol/therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/35093388/
1648,BISOPROLOL,38762800,Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial.,"['Devereux G', 'Cotton S', 'Nath M', 'McMeekin N', 'Campbell K', 'Chaudhuri R', 'Choudhury G', 'De Soyza A', 'Fielding S', 'Gompertz S', 'Haughney J', 'Lee AJ', 'MacLennan G', 'Morice A', 'Norrie J', 'Price D', 'Short P', 'Vestbo J', 'Walker P', 'Wedzicha J', 'Wilson A', 'Wu O', 'Lipworth BJ']","['Aged', 'Female', 'Humans', 'Male', 'Middle Aged', 'Adrenal Cortex Hormones/therapeutic use/adverse effects', 'Adrenergic beta-1 Receptor Antagonists/therapeutic use/adverse effects', 'Anti-Bacterial Agents/therapeutic use/adverse effects', '*Bisoprolol/therapeutic use/adverse effects', '*Disease Progression', 'Double-Blind Method', 'Forced Expiratory Volume', '*Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy', 'Patient Reported Outcome Measures']",https://pubmed.ncbi.nlm.nih.gov/38762800/
1649,BISOPROLOL,34106365,Therapeutic Properties of Highly Selective beta-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.,"['AlHabeeb W', 'Mrabeti S', 'Abdelsalam AAI']","['Adrenergic beta-Antagonists/therapeutic use', 'Benzopyrans/adverse effects', 'Bisoprolol/pharmacology/therapeutic use', '*Cardiovascular Diseases/diagnosis/drug therapy', 'Ethanolamines/pharmacology/therapeutic use', '*Heart Failure/diagnosis/drug therapy', 'Humans', '*Hypertension/diagnosis/drug therapy', '*Myocardial Ischemia/drug therapy', 'Nebivolol/adverse effects', 'Stroke Volume', 'Vasodilator Agents/therapeutic use', 'Ventricular Function, Left']",https://pubmed.ncbi.nlm.nih.gov/34106365/
1650,BISOPROLOL,33351042,Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.,"['Kotecha D', 'Bunting KV', 'Gill SK', 'Mehta S', 'Stanbury M', 'Jones JC', 'Haynes S', 'Calvert MJ', 'Deeks JJ', 'Steeds RP', 'Strauss VY', 'Rahimi K', 'Camm AJ', 'Griffith M', 'Lip GYH', 'Townend JN', 'Kirchhof P']","['Adrenergic beta-1 Receptor Antagonists/therapeutic use', 'Aged', 'Aged, 80 and over', 'Anti-Arrhythmia Agents/adverse effects/pharmacology/*therapeutic use', 'Atrial Fibrillation/complications/*drug therapy/physiopathology', 'Bisoprolol/adverse effects/pharmacology/*therapeutic use', 'Digoxin/adverse effects/pharmacology/*therapeutic use', 'Female', 'Heart Failure/complications/drug therapy', 'Heart Rate/*drug effects', 'Humans', 'Male', 'Middle Aged', '*Quality of Life', 'Single-Blind Method', 'Stroke Volume']",https://pubmed.ncbi.nlm.nih.gov/33351042/
1651,BISOPROLOL,35422024,Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).,"['Cotton S', 'Devereux G', 'Abbas H', 'Briggs A', 'Campbell K', 'Chaudhuri R', 'Choudhury G', 'Dawson D', 'De Soyza A', 'Fielding S', 'Gompertz S', 'Haughney J', 'Lang CC', 'Lee AJ', 'MacLennan G', 'MacNee W', 'McCormack K', 'McMeekin N', 'Mills NL', 'Morice A', 'Norrie J', 'Petrie MC', 'Price D', 'Short P', 'Vestbo J', 'Walker P', 'Wedzicha J', 'Wilson A', 'Lipworth BJ']","['Adrenal Cortex Hormones', 'Adrenergic beta-Antagonists/therapeutic use', 'Adult', 'Anti-Bacterial Agents/adverse effects', 'Bisoprolol/adverse effects', 'Disease Progression', '*Heart Failure/drug therapy', 'Humans', '*Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/35422024/
1652,BISOPROLOL,34058112,"In older patients with permanent AF and HF, digoxin and bisoprolol did not differ for QoL at 6 mo.","['Karimzad K', 'Deswal A']","['Aged', 'Anti-Arrhythmia Agents/therapeutic use', '*Atrial Fibrillation/complications/drug therapy', 'Bisoprolol/pharmacology/therapeutic use', 'Digoxin/therapeutic use', 'Heart Rate/drug effects', 'Humans', '*Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/34058112/
1653,BISOPROLOL,28520326,[Bipressil(R) : first single-pill combination of bisoprolol and perindopril arginine].,"['Gach O', 'Falque B', 'Canivet A', 'Krzesinski F', 'Krzesinski JM', 'Lancellotti P']","['Antihypertensive Agents/*pharmacology', 'Bisoprolol/*pharmacology', 'Drug Combinations', 'Humans', 'Perindopril/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/28520326/
1654,BISOPROLOL,12846268,Use of beta-blockers in congestive heart failure.,"['Sallach JA', 'Goldstein S']","['Adrenergic beta-Antagonists/administration & dosage/*therapeutic use', 'Bisoprolol/administration & dosage/therapeutic use', 'Carbazoles/administration & dosage/therapeutic use', 'Carvedilol', 'Dose-Response Relationship, Drug', 'Forecasting', 'Heart Failure/*drug therapy', 'Humans', 'Metoprolol/administration & dosage/therapeutic use', 'Propanolamines/administration & dosage/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/12846268/
1655,BISOPROLOL,22405663,beta-blockers in stage B: a precursor of heart failure.,"['Sarraf M', 'Francis GS']","['Adrenergic beta-Antagonists/pharmacology/*therapeutic use', 'Animals', 'Benzazepines/pharmacology/therapeutic use', 'Bisoprolol/pharmacology/therapeutic use', 'Carbazoles/pharmacology/therapeutic use', 'Cardiovascular System/physiopathology', 'Carvedilol', 'Disease Progression', 'Heart Failure/*drug therapy', 'Heart Ventricles/drug effects', 'Humans', 'Ivabradine', 'Propanolamines/pharmacology/therapeutic use', 'Sympathetic Nervous System/physiopathology', 'Ventricular Dysfunction, Left/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/22405663/
1656,BISOPROLOL,33654234,"Certain beta blockers (e.g., bisoprolol) may be reevaluated in hypertension guidelines for patients with left ventricular hypertrophy to diminish the ventricular arrhythmic risk.","['Koracevic G', 'Stojanovic M', 'Lovic D', 'Zdravkovic M', 'Sakac D']","['*Bisoprolol/therapeutic use', 'Humans', '*Hypertension/complications/drug therapy', 'Hypertrophy, Left Ventricular/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/33654234/
1657,BISOPROLOL,11527133,Antiarrhythmic properties of beta-blockers.,"['Haverkamp W', 'Hindricks G', 'Gulker H']","['Adrenergic beta-Antagonists/*therapeutic use', 'Animals', 'Anti-Arrhythmia Agents/*therapeutic use', 'Bisoprolol/therapeutic use', 'Humans', 'Metoprolol/therapeutic use', 'Myocardial Infarction/*drug therapy', 'Tachycardia, Supraventricular/*drug therapy', 'Ventricular Fibrillation/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11527133/
1658,BISOPROLOL,27653022,Management of Hypertension With a Fixed-Dose (Single-Pill) Combination of Bisoprolol and Amlodipine.,"['Gottwald-Hostalek U', 'Sun N', 'Barho C', 'Hildemann S']","['Amlodipine/*administration & dosage/therapeutic use', 'Antihypertensive Agents/*administration & dosage/therapeutic use', 'Bisoprolol/*administration & dosage/therapeutic use', 'Clinical Trials as Topic', 'Drug Combinations', 'Humans', 'Hypertension/*drug therapy', 'Patient Compliance', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27653022/
1659,BISOPROLOL,11130231,The importance of beta blockers in the treatment of heart failure.,['Chavey WE 2nd'],"['Adrenergic beta-Antagonists/administration & dosage/*therapeutic use', 'Bisoprolol/therapeutic use', 'Carbazoles/therapeutic use', 'Carvedilol', 'Contraindications', 'Drug Administration Schedule', 'Female', 'Heart Failure/*drug therapy/*mortality/physiopathology', 'Humans', 'Male', 'Metoprolol/therapeutic use', 'Patient Selection', 'Propanolamines/therapeutic use', 'Randomized Controlled Trials as Topic', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/11130231/
1660,BISOPROLOL,11527141,Comparison of beta-blockade and ACE inhibitors in the treatment of hypertension.,"['Prichard BN', 'Saul PA']","['Adrenergic beta-Antagonists/pharmacology/*therapeutic use', 'Angiotensin-Converting Enzyme Inhibitors/pharmacology/*therapeutic use', 'Animals', 'Bisoprolol/pharmacology/therapeutic use', 'Blood Pressure/drug effects/physiology', 'Enalapril/pharmacology/therapeutic use', 'Exercise/physiology', 'Heart Rate/drug effects/physiology', 'Humans', 'Hypertension/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11527141/
1661,BISOPROLOL,22763935,[The choked heart].,"['Furrer F', 'Giambarba C']","['Adrenergic beta-Antagonists/administration & dosage/*adverse effects', 'Aged', 'Atrial Fibrillation/diagnosis/drug therapy', 'Bisoprolol/administration & dosage/*adverse effects', 'Calcium Channel Blockers/administration & dosage/*adverse effects', 'Cardiac Output, Low/diagnosis/drug therapy', 'Diagnosis, Differential', 'Diltiazem/administration & dosage/*adverse effects', 'Disease Progression', 'Dose-Response Relationship, Drug', 'Drug Interactions', '*Emergencies', 'Female', 'Humans', 'Shock, Cardiogenic/*chemically induced', 'Verapamil/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/22763935/
1662,BISOPROLOL,19667603,Beta-blockers in heart failure: how far have we progressed?,['Adams KF'],"['Adrenergic beta-Antagonists/*therapeutic use', 'Antihypertensive Agents/therapeutic use', 'Bisoprolol/therapeutic use', 'Carbazoles/therapeutic use', 'Carvedilol', 'Contraindications', 'Heart Failure/*drug therapy/etiology/mortality', 'Humans', 'Metoprolol/therapeutic use', 'Propanolamines/therapeutic use', 'Sympathetic Nervous System/drug effects', 'Ventricular Dysfunction, Left/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19667603/
1663,BISOPROLOL,38597063,Safety and tolerability of beta-blockers: importance of cardioselectivity.,"['Marti HP', 'Pavia Lopez AA', 'Schwartzmann P']","['Male', 'Humans', '*Bisoprolol/adverse effects', 'Adrenergic beta-Antagonists/adverse effects', '*Pulmonary Disease, Chronic Obstructive/drug therapy', 'Adrenergic beta-1 Receptor Antagonists/adverse effects', 'Receptors, Adrenergic/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38597063/
1664,BISOPROLOL,34469767,"Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial.","['Chow CK', 'Atkins ER', 'Hillis GS', 'Nelson MR', 'Reid CM', 'Schlaich MP', 'Hay P', 'Rogers K', 'Billot L', 'Burke M', 'Chalmers J', 'Neal B', 'Patel A', 'Usherwood T', 'Webster R', 'Rodgers A']","['Amlodipine/*administration & dosage', 'Antihypertensive Agents/*administration & dosage', 'Australia', 'Bisoprolol/*administration & dosage', 'Blood Pressure/*drug effects', 'Double-Blind Method', '*Drug Therapy, Combination', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Indapamide/*administration & dosage', 'Irbesartan/*administration & dosage', 'Male', 'Middle Aged', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34469767/
1665,Minovlar,145268,Effect of oral contraceptives on sebum excretion rate.,"['Pye RJ', 'Meyrick G', 'Pye MJ', 'Burton JL']","['Acne Vulgaris/metabolism', 'Adolescent', 'Adult', 'Contraceptives, Oral/*pharmacology', 'Contraceptives, Oral, Hormonal/*pharmacology', 'Ethinyl Estradiol/pharmacology', 'Female', 'Humans', 'Progesterone Congeners/pharmacology', 'Sebum/*metabolism', 'Secretory Rate/drug effects']",https://pubmed.ncbi.nlm.nih.gov/145268/
1666,Minovlar,832008,Effect of oral contraceptives on plasma testosterone concentration.,"['Browning MC', 'Anderson J']","['Contraceptives, Oral/*pharmacology', 'Contraceptives, Oral, Combined/pharmacology', 'Contraceptives, Oral, Synthetic/*pharmacology', 'Female', 'Humans', 'Testosterone/*blood']",https://pubmed.ncbi.nlm.nih.gov/832008/
1667,Minovlar,3486291,"Adverse reactions in ten years' general practice, computer analysed.",['Johnson RA'],"['Ampicillin/adverse effects', 'Computers', 'Contraceptives, Oral/adverse effects', 'Contraceptives, Oral, Combined/adverse effects', 'Drug Combinations/adverse effects', '*Drug-Related Side Effects and Adverse Reactions', '*Family Practice', 'Humans', 'Oxytetracycline/adverse effects', 'Sulfamethoxazole/adverse effects', 'Trimethoprim/adverse effects', 'Trimethoprim, Sulfamethoxazole Drug Combination']",https://pubmed.ncbi.nlm.nih.gov/3486291/
1668,Minovlar,2941052,Anti-androgen treatment in women with acne: a controlled trial.,"['Miller JA', 'Wojnarowska FT', 'Dowd PM', 'Ashton RE', ""O'Brien TJ"", 'Griffiths WA', 'Jacobs HS']","['Acne Vulgaris/*drug therapy', 'Adolescent', 'Adult', 'Androgen Antagonists/*therapeutic use', 'Clinical Trials as Topic', 'Cyproterone/*analogs & derivatives/therapeutic use', 'Cyproterone Acetate', 'Double-Blind Method', 'Drug Combinations/therapeutic use', 'Drug Therapy, Combination', 'Ethinyl Estradiol/therapeutic use', 'Female', 'Humans', 'Norethindrone/analogs & derivatives/therapeutic use', 'Norethindrone Acetate', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/2941052/
1669,Minovlar,7189454,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.,"['Back DJ', 'Breckenridge AM', 'Crawford FE', 'Hall JM', 'MacIver M', 'Orme ML', 'Rowe PH', 'Smith E', 'Watts MJ']","['Adolescent', 'Adult', 'Ethambutol/therapeutic use', 'Ethinyl Estradiol/*blood/pharmacology', 'Female', 'Humans', 'Isoniazid/therapeutic use', 'Kinetics', 'Norethindrone/analogs & derivatives/blood/pharmacology', 'Norethindrone Acetate', 'Rifampin/*pharmacology/therapeutic use', 'Sex Hormone-Binding Globulin', 'Tuberculosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7189454/
1670,Minovlar,7197136,Sex hormone binding globulin: effect of synthetic steroids on the assay and effect of oral contraceptives.,"['Bowles SM', 'Mills RJ']","['Contraceptives, Oral/*pharmacology', 'Contraceptives, Oral, Combined/*pharmacology', 'Contraceptives, Oral, Synthetic/*pharmacology', 'Dihydrotestosterone/pharmacology', 'Estradiol Congeners/pharmacology', 'Female', 'Gonadal Steroid Hormones/metabolism', 'Humans', 'Hydrocortisone/pharmacology', 'Progesterone/pharmacology', 'Progesterone Congeners/pharmacology', 'Sex Hormone-Binding Globulin/analysis/*metabolism', 'Testosterone/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/7197136/
1671,Minovlar,6809025,The effects of ampicillin on oral contraceptive steroids in women.,"['Back DJ', 'Breckenridge AM', 'MacIver M', 'Orme M', 'Rowe PH', 'Staiger C', 'Thomas E', 'Tjia J']","['Adult', 'Ampicillin/blood/*pharmacology', 'Contraceptives, Oral/*blood', 'Contraceptives, Oral, Hormonal/*blood', 'Drug Interactions', 'Ethinyl Estradiol/blood', 'Female', 'Follicle Stimulating Hormone/blood', 'Humans', 'Levonorgestrel', 'Norethindrone/blood', 'Norgestrel/blood', 'Progesterone/blood', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6809025/
1672,Minovlar,482190,Paradoxical embolism associated with oral contraceptives: an underdiagnosed lesion?,['de Swiet J'],"['Adult', 'Contraceptives, Oral/*adverse effects', 'Female', 'Humans', 'Intracranial Embolism and Thrombosis/*chemically induced', 'Pulmonary Heart Disease/chemically induced', 'Thrombophlebitis/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/482190/
1673,Minovlar,2204850,Vascular complications in women using the low steroid content combined oral contraceptive pills: case reports and review of the literature.,['Frohlich EP'],"['Adult', 'Cardiovascular Diseases/*chemically induced/epidemiology', 'Causality', 'Contraceptives, Oral, Combined/*adverse effects/classification/supply & distribution', 'Female', 'Humans', 'Incidence']",https://pubmed.ncbi.nlm.nih.gov/2204850/
1674,Minovlar,6841023,Thyroid function in oral contraception: is there cyclic variation?,"['Tuttlebee JW', 'Marsden JT']","['Adolescent', 'Adult', 'Contraceptives, Oral/*pharmacology', 'Female', 'Humans', '*Menstruation', 'Middle Aged', 'Reagent Kits, Diagnostic', '*Thyroid Function Tests', 'Thyroid Gland/*drug effects/physiology', 'Thyroxine/blood/metabolism', 'Triiodothyronine/blood/metabolism']",https://pubmed.ncbi.nlm.nih.gov/6841023/
1675,Minovlar,12264750,Drug interactions with oral contraceptive steroids.,"['Back DJ', 'Breckenridge AM', 'Orme ML']","['*Contraception', 'Contraceptive Agents', '*Contraceptive Agents, Female', '*Contraceptives, Oral', 'Family Planning Services', '*Reproductive Control Agents']",https://pubmed.ncbi.nlm.nih.gov/12264750/
1676,Minovlar,3219852,A multicentre comparative study of serum lipids and lipoproteins in four groups of oral combined contraceptive users and a control group of IUD users. World Health Organization. Task Force on Oral Contraceptives.,"['Boonsiri B', 'Kolkijkovinda S', 'Chutivongse S', 'Crona N', 'Medberg M', 'Gundersen G', 'Samsioe G', 'Garza-Flores J', 'Valles de Bourges V', 'Juarez-Ayala J', 'et al.']","['Adolescent', 'Adult', 'Cholesterol, HDL/blood', 'Cholesterol, LDL/blood', 'Contraceptives, Oral, Combined/*pharmacology', 'Dose-Response Relationship, Drug', 'Estrogens/pharmacology', 'Female', 'Humans', '*Intrauterine Devices', 'Lipids/*blood', 'Lipoproteins/*blood', 'Norethindrone/analogs & derivatives/pharmacology', 'Norethindrone Acetate', 'Progestins/pharmacology', 'Prospective Studies', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/3219852/
1677,Minovlar,6517215,[Drug interactions with oral contraceptive steroids].,['Chernev T'],"['Anti-Bacterial Agents/pharmacology', 'Anticonvulsants/pharmacology', 'Ascorbic Acid/pharmacology', 'Contraceptives, Oral/*pharmacology', 'Contraceptives, Oral, Hormonal/*pharmacology', 'Drug Interactions', 'Female', 'Humans', 'Kinetics', 'Rifampin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6517215/
1678,irbesartan,37467498,"Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.","['Desai AS', 'Webb DJ', 'Taubel J', 'Casey S', 'Cheng Y', 'Robbie GJ', 'Foster D', 'Huang SA', 'Rhyee S', 'Sweetser MT', 'Bakris GL']","['Humans', '*Angiotensinogen/blood/metabolism', '*Antihypertensive Agents/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Blood Pressure/drug effects/physiology', 'Blood Pressure Monitoring, Ambulatory', 'Double-Blind Method', '*Hypertension/blood/drug therapy/etiology/metabolism', 'Irbesartan/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'RNA Interference', 'Tetrazoles', 'Diet', 'Injections, Subcutaneous']",https://pubmed.ncbi.nlm.nih.gov/37467498/
1679,irbesartan,37931634,"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.","['Rovin BH', 'Barratt J', 'Heerspink HJL', 'Alpers CE', 'Bieler S', 'Chae DW', 'Diva UA', 'Floege J', 'Gesualdo L', 'Inrig JK', 'Kohan DE', 'Komers R', 'Kooienga LA', 'Lafayette R', 'Maes B', 'Malecki R', 'Mercer A', 'Noronha IL', 'Oh SW', 'Peh CA', 'Praga M', 'Preciado P', 'Radhakrishnan J', 'Rheault MN', 'Rote WE', 'Tang SCW', 'Tesar V', 'Trachtman H', 'Trimarchi H', 'Tumlin JA', 'Wong MG', 'Perkovic V']","['Female', 'Humans', 'Male', 'Angiotensin Receptor Antagonists/adverse effects', 'Double-Blind Method', '*Glomerulonephritis, IGA/drug therapy', 'Irbesartan/adverse effects', '*Kidney Failure, Chronic', 'Proteinuria/drug therapy', 'Treatment Outcome', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/37931634/
1680,irbesartan,37015244,"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.","['Heerspink HJL', 'Radhakrishnan J', 'Alpers CE', 'Barratt J', 'Bieler S', 'Diva U', 'Inrig J', 'Komers R', 'Mercer A', 'Noronha IL', 'Rheault MN', 'Rote W', 'Rovin B', 'Trachtman H', 'Trimarchi H', 'Wong MG', 'Perkovic V']","['Adult', 'Humans', 'Adolescent', 'Irbesartan/therapeutic use', '*Glomerulonephritis, IGA/drug therapy', 'Creatinine/urine', 'Proteinuria/drug therapy', 'Double-Blind Method', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37015244/
1681,irbesartan,37921461,Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.,"['Rheault MN', 'Alpers CE', 'Barratt J', 'Bieler S', 'Canetta P', 'Chae DW', 'Coppock G', 'Diva U', 'Gesualdo L', 'Heerspink HJL', 'Inrig JK', 'Kirsztajn GM', 'Kohan D', 'Komers R', 'Kooienga LA', 'Lieberman K', 'Mercer A', 'Noronha IL', 'Perkovic V', 'Radhakrishnan J', 'Rote W', 'Rovin B', 'Tesar V', 'Trimarchi H', 'Tumlin J', 'Wong MG', 'Trachtman H']","['Humans', 'Biomarkers', 'Creatinine', 'Glomerular Filtration Rate', '*Glomerulosclerosis, Focal Segmental/complications/drug therapy/physiopathology', '*Irbesartan/administration & dosage/adverse effects/therapeutic use', '*Proteinuria/drug therapy/etiology', 'Child', 'Adolescent', 'Young Adult', 'Adult', 'Middle Aged', 'Aged', 'Remission Induction']",https://pubmed.ncbi.nlm.nih.gov/37921461/
1682,irbesartan,37432701,Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.,"['Xie M', 'Tang T', 'Liang H']","['Humans', '*Antihypertensive Agents/therapeutic use', 'Losartan/pharmacology/therapeutic use', '*Hypertension/diagnosis/drug therapy', 'Telmisartan/pharmacology/therapeutic use', 'Irbesartan/pharmacology/therapeutic use', 'Angiotensin Receptor Antagonists/therapeutic use', 'Network Meta-Analysis', 'Hydrochlorothiazide/adverse effects', 'Valine/adverse effects', 'Drug Therapy, Combination', 'Angiotensin-Converting Enzyme Inhibitors/therapeutic use', 'Amlodipine/therapeutic use', 'Valsartan/therapeutic use', 'Tetrazoles/therapeutic use', 'Blood Pressure', 'Essential Hypertension/diagnosis/drug therapy/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37432701/
1683,irbesartan,10914449,Angiotensin receptor antagonists.,"['Wong W', 'Howes L']","['Angiotensin II/antagonists & inhibitors', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use', 'Antihypertensive Agents/adverse effects/pharmacology/*therapeutic use', 'Benzimidazoles/adverse effects/pharmacology/therapeutic use', 'Benzoates/adverse effects/pharmacology/therapeutic use', 'Biphenyl Compounds/adverse effects/pharmacology/therapeutic use', 'Humans', 'Hypertension/*drug therapy', 'Irbesartan', 'Losartan/adverse effects/pharmacology/therapeutic use', 'Telmisartan', 'Tetrazoles/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10914449/
1684,irbesartan,30002098,Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.,"['Haynes R', 'Judge PK', 'Staplin N', 'Herrington WG', 'Storey BC', 'Bethel A', 'Bowman L', 'Brunskill N', 'Cockwell P', 'Hill M', 'Kalra PA', 'McMurray JJV', 'Taal M', 'Wheeler DC', 'Landray MJ', 'Baigent C']","['Aged', 'Aminobutyrates/adverse effects/*therapeutic use', 'Angiotensin II Type 1 Receptor Blockers/adverse effects/*therapeutic use', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Glomerular Filtration Rate/*drug effects', 'Heart Failure/diagnosis/*drug therapy/mortality/physiopathology', 'Humans', 'Irbesartan/adverse effects/*therapeutic use', 'Kidney/*drug effects/physiopathology', 'Male', 'Middle Aged', 'Renal Insufficiency, Chronic/diagnosis/mortality/*physiopathology', 'Stroke Volume/*drug effects', 'Tetrazoles/adverse effects/*therapeutic use', 'Time Factors', 'Treatment Outcome', 'United Kingdom', 'Valsartan', 'Ventricular Function, Left/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/30002098/
1685,irbesartan,11565517,Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.,"['Lewis EJ', 'Hunsicker LG', 'Clarke WR', 'Berl T', 'Pohl MA', 'Lewis JB', 'Ritz E', 'Atkins RC', 'Rohde R', 'Raz I']","['Adult', 'Aged', 'Amlodipine/adverse effects/therapeutic use', '*Angiotensin Receptor Antagonists', 'Antihypertensive Agents/adverse effects/*therapeutic use', 'Biphenyl Compounds/adverse effects/*therapeutic use', 'Calcium Channel Blockers/therapeutic use', 'Creatinine/blood', 'Diabetes Mellitus, Type 2/*complications', 'Diabetic Nephropathies/complications/*drug therapy', 'Double-Blind Method', 'Female', 'Humans', 'Hypertension/complications/drug therapy', 'Irbesartan', 'Kidney Failure, Chronic/prevention & control', 'Male', 'Middle Aged', 'Proportional Hazards Models', 'Tetrazoles/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11565517/
1686,irbesartan,30361325,DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.,"['Trachtman H', 'Nelson P', 'Adler S', 'Campbell KN', 'Chaudhuri A', 'Derebail VK', 'Gambaro G', 'Gesualdo L', 'Gipson DS', 'Hogan J', 'Lieberman K', 'Marder B', 'Meyers KE', 'Mustafa E', 'Radhakrishnan J', 'Srivastava T', 'Stepanians M', 'Tesar V', 'Zhdanova O', 'Komers R']","['Adolescent', 'Adult', 'Aged', 'Angiotensin II Type 1 Receptor Blockers/administration & dosage/adverse effects/*therapeutic use', 'Child', 'Creatinine/urine', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Endothelin A Receptor Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Female', 'Glomerulosclerosis, Focal Segmental/*drug therapy/urine', 'Humans', 'Irbesartan/administration & dosage/adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Proteinuria/drug therapy/urine', 'Spiro Compounds/administration & dosage/adverse effects/*therapeutic use', 'Sulfonamides/administration & dosage/adverse effects/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30361325/
1687,irbesartan,11588406,"Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.","['Oparil S', 'Williams D', 'Chrysant SG', 'Marbury TC', 'Neutel J']","['Analysis of Variance', 'Antihypertensive Agents/adverse effects/*therapeutic use', 'Biphenyl Compounds/therapeutic use', 'Chi-Square Distribution', 'Double-Blind Method', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Irbesartan', 'Losartan/therapeutic use', 'Male', 'Middle Aged', 'Tetrazoles/therapeutic use', 'Valine/*analogs & derivatives/therapeutic use', 'Valsartan']",https://pubmed.ncbi.nlm.nih.gov/11588406/
1688,irbesartan,11565519,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.,"['Parving HH', 'Lehnert H', 'Brochner-Mortensen J', 'Gomis R', 'Andersen S', 'Arner P']","['Adult', 'Aged', 'Albuminuria/drug therapy/etiology', '*Angiotensin Receptor Antagonists', 'Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Biphenyl Compounds/administration & dosage/adverse effects/*therapeutic use', 'Creatinine/blood', 'Diabetes Mellitus, Type 2/*complications', 'Diabetic Nephropathies/etiology/*prevention & control', 'Disease Progression', 'Double-Blind Method', 'Female', 'Humans', 'Hypertension/complications/*drug therapy', 'Irbesartan', 'Male', 'Middle Aged', 'Proportional Hazards Models', 'Tetrazoles/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11565519/
1689,irbesartan,37143164,Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.,"['Zhou T', 'Xie Y', 'Hou X', 'Bai W', 'Li X', 'Liu Z', 'Man Q', 'Sun J', 'Fu D', 'Yan J', 'Zhang Z', 'Wang Y', 'Wang H', 'Jiang W', 'Gao S', 'Zhao T', 'Chang A', 'Wang X', 'Sun H', 'Zhang X', 'Yang S', 'Huang C', 'Hao J', 'Liu J']","['Mice', 'Animals', 'Humans', 'Gemcitabine', 'Irbesartan/therapeutic use', 'Retrospective Studies', '*Pancreatic Neoplasms/metabolism', '*Carcinoma, Pancreatic Ductal/pathology', 'Disease Models, Animal', 'Cell Line, Tumor']",https://pubmed.ncbi.nlm.nih.gov/37143164/
1690,irbesartan,26896240,Does this patient have hypertensive encephalopathy?,"['Christopoulou F', 'Rizos EC', 'Kosta P', 'Argyropoulou MI', 'Elisaf M']","['Amlodipine/administration & dosage/therapeutic use', 'Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Biphenyl Compounds/administration & dosage/adverse effects/therapeutic use', 'Brain/*diagnostic imaging', 'Carbazoles/administration & dosage/therapeutic use', 'Carvedilol', 'Computed Tomography Angiography', 'Confusion/etiology', 'Creatinine/blood', 'Electrocardiography', 'Glomerular Filtration Rate', 'Hallucinations/etiology', 'Headache/etiology', 'Heart/diagnostic imaging', 'Humans', 'Hydrochlorothiazide/administration & dosage/therapeutic use', 'Hypertension/*complications/*drug therapy', 'Hypertensive Encephalopathy/complications/*diagnosis', 'Irbesartan', 'Magnetic Resonance Imaging', 'Male', 'Middle Aged', 'Propanolamines/administration & dosage/therapeutic use', 'Renal Artery Obstruction/blood/*chemically induced', 'Spironolactone/administration & dosage/therapeutic use', 'Tetrazoles/administration & dosage/adverse effects/therapeutic use', 'Ultrasonography']",https://pubmed.ncbi.nlm.nih.gov/26896240/
1691,irbesartan,9793599,ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema.,['Pylypchuk GB'],"['Angioedema/*chemically induced', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/*adverse effects/therapeutic use', 'Antihypertensive Agents/*adverse effects/therapeutic use', 'Biphenyl Compounds/adverse effects/therapeutic use', 'Cough/*chemically induced', 'Humans', 'Irbesartan', 'Losartan/adverse effects/therapeutic use', 'Tetrazoles/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9793599/
1692,irbesartan,10392595,Angiotensin-II receptor antagonists: their place in therapy.,['Kirk JK'],"['Angiotensin II/*metabolism', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/pharmacology', 'Antihypertensive Agents/*pharmacology/therapeutic use', 'Benzimidazoles/pharmacology', 'Benzoates/pharmacology', 'Biphenyl Compounds/pharmacology', 'Clinical Trials as Topic', 'Drug Administration Schedule', 'Drug Interactions', 'Heart Failure/drug therapy', 'Humans', 'Hypertension/*drug therapy/metabolism', 'Irbesartan', 'Losartan/pharmacology', 'Renin-Angiotensin System/*drug effects', 'Telmisartan', 'Tetrazoles/pharmacology', 'Valine/analogs & derivatives/pharmacology', 'Valsartan']",https://pubmed.ncbi.nlm.nih.gov/10392595/
1693,irbesartan,14605589,The antihypertensive response to irbesartan treatment from a pharmacogenetic perspective.,['Kurland L'],"['Antihypertensive Agents/*therapeutic use', 'Biphenyl Compounds/*therapeutic use', 'Cytochrome P-450 CYP2D6/genetics', 'Humans', 'Hypertension/*drug therapy/genetics', 'Irbesartan', '*Pharmacogenetics', 'Pharmacokinetics', 'Polymorphism, Genetic', 'Renin-Angiotensin System/genetics', 'Tetrazoles/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/14605589/
1694,irbesartan,9850301,Irbesartan treatment in hypertension.,['Brown MJ'],"['Angiotensin-Converting Enzyme Inhibitors/adverse effects', 'Antihypertensive Agents/pharmacokinetics/*therapeutic use', 'Atenolol/therapeutic use', 'Biphenyl Compounds/pharmacokinetics/*therapeutic use', 'Enalapril/therapeutic use', 'Humans', 'Hypertension/complications/*drug therapy', 'Irbesartan', 'Losartan/therapeutic use', 'Renin-Angiotensin System/drug effects', 'Tetrazoles/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9850301/
1695,irbesartan,25703678,The cost-effectiveness of irbesartan for hypertension.,"['Borghi C', 'Urso R', 'Cicero AF']","['Adult', 'Aged', 'Angiotensin II Type 1 Receptor Blockers/economics/therapeutic use', 'Antihypertensive Agents/economics/*therapeutic use', 'Biphenyl Compounds/economics/*therapeutic use', 'Cost-Benefit Analysis', 'Humans', 'Hypertension/*drug therapy/economics/epidemiology', 'Irbesartan', 'Tetrazoles/economics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25703678/
1696,irbesartan,33461698,Irbesartan (a comprehensive profile).,"['Darwish IA', 'Darwish HW', 'Bakheit AH', 'Al-Kahtani HM', 'Alanazi Z']","['Angiotensin Receptor Antagonists/*pharmacology/therapeutic use', 'Antihypertensive Agents/pharmacology/therapeutic use', 'Diabetes Mellitus, Type 2', 'Diabetic Nephropathies/*drug therapy', 'Humans', '*Hypertension/drug therapy', 'Irbesartan/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33461698/
1697,irbesartan,35361657,Treating hypertension with a pill containing very low doses of four antihypertensive agents compared with standard dose irbesartan.,"['Eltayeb A', 'Khong TK']","['*Antihypertensive Agents/administration & dosage', 'Clinical Trials, Phase III as Topic', 'Drug Therapy, Combination', 'Humans', '*Hypertension/drug therapy', 'Irbesartan/administration & dosage', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/35361657/
1698,ofloxacin,31350743,[Legionella and Legionellosis].,"['Kolditz M', 'Luck C']","['*Anti-Bacterial Agents/pharmacology/therapeutic use', 'Drug Resistance, Bacterial', 'Humans', 'Legionella/*drug effects', '*Legionellosis/diagnosis/drug therapy/microbiology', 'Levofloxacin/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31350743/
1699,ofloxacin,39019103,Ciprofloxacin versus levofloxacin prophylaxis in hematopoietic stem cell transplantation: A randomized trial.,"['Farhan S', 'Mazur I', 'Hartzell S', 'Xie P', 'Neme K', 'German A', 'Mikulandric N', 'Patel K', 'Wu M', 'Kortam N', 'Yaseen A', 'Sweidan A', 'Latack K', 'Emole J', 'Peres E', 'Abidi MH', 'Ramesh M']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', '*Anti-Bacterial Agents/therapeutic use/administration & dosage', '*Antibiotic Prophylaxis/methods', 'Bacteremia/prevention & control/epidemiology', '*Ciprofloxacin/therapeutic use/administration & dosage', '*Hematopoietic Stem Cell Transplantation/adverse effects', '*Levofloxacin/therapeutic use/administration & dosage', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/39019103/
1700,ofloxacin,11249554,Levofloxacin.,['Norrby SR'],"['Animals', 'Anti-Infective Agents/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Bacteria/drug effects', 'Bacterial Infections/*drug therapy/microbiology', 'Clinical Trials as Topic', 'Humans', '*Levofloxacin', 'Ofloxacin/adverse effects/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11249554/
1701,ofloxacin,33964616,Levofloxacin in veterinary medicine: a literature review.,"['Sitovs A', 'Sartini I', 'Giorgi M']","['Animals', 'Anti-Infective Agents/*therapeutic use', 'Humans', 'Levofloxacin/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33964616/
1702,ofloxacin,19702070,Levofloxacin-induced severe thrombocytopenia.,"['Polprasert C', 'Prayongratana K']","['Aged', 'Anti-Bacterial Agents/*adverse effects', 'Hemoptysis/*chemically induced', 'Humans', '*Levofloxacin', 'Male', 'Ofloxacin/*adverse effects', 'Thrombocytopenia/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/19702070/
1703,ofloxacin,25629432,On two-sample McNemar test.,['Xiang JX'],"['Anti-Bacterial Agents/administration & dosage/therapeutic use', '*Clinical Trials as Topic/methods/statistics & numerical data', 'Computer Simulation', 'Cross-Over Studies', 'Data Interpretation, Statistical', 'Dose-Response Relationship, Drug', 'Fever/drug therapy', 'Humans', 'Levofloxacin/administration & dosage/therapeutic use', '*Matched-Pair Analysis', '*Models, Statistical', 'Research Design/*statistics & numerical data', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25629432/
1704,ofloxacin,32496110,Acute pancreatitis associated with levofloxacin.,"['Jimenez Moreno MA', 'Hontoria Bautista G', 'Pereda Garcia R']","['Acute Disease', 'Humans', '*Levofloxacin/adverse effects', '*Pancreatitis/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/32496110/
1705,ofloxacin,23176385,MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections.,"['Azoicai D', 'Antoniu SA']","['Administration, Inhalation', 'Anti-Bacterial Agents/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Chronic Disease', 'Clinical Trials as Topic', 'Drug Discovery', 'Drug Resistance, Bacterial/drug effects', 'Humans', '*Levofloxacin', 'Ofloxacin/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Pseudomonas Infections/*drug therapy/microbiology', 'Pseudomonas aeruginosa/*drug effects', 'Respiratory Tract Infections/*drug therapy/microbiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23176385/
1706,ofloxacin,20424532,[PK/PD profile and post-marketing surveillance of levofloxacin].,['Pea F'],"['Animals', 'Anti-Bacterial Agents/administration & dosage/pharmacokinetics/*pharmacology/therapeutic use', 'Area Under Curve', 'Cohort Studies', 'Drug Resistance, Multiple, Bacterial', 'Drug Therapy, Combination', 'Female', 'Gram-Negative Bacterial Infections/drug therapy', 'Humans', 'Kidney/physiopathology', '*Levofloxacin', 'Male', 'Metabolic Clearance Rate', 'Microbial Sensitivity Tests', 'Ofloxacin/administration & dosage/pharmacokinetics/*pharmacology/therapeutic use', 'Product Surveillance, Postmarketing', 'Respiratory Tract Infections/drug therapy', 'Spondylitis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20424532/
1707,ofloxacin,30713304,Levofloxacin-associated Encephalopathy with Severe Hyperventilation.,"['Sugiura M', 'Shibata K', 'Saito S', 'Nishimura Y', 'Sakura H']","['Anti-Infective Agents, Urinary/*adverse effects/*therapeutic use', 'Brain Diseases/*chemically induced', 'Cystitis/*drug therapy', 'Female', 'Humans', 'Hyperventilation/*chemically induced', 'Levofloxacin/*adverse effects/*therapeutic use', 'Middle Aged', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30713304/
1708,ofloxacin,37154772,In-Class Cross-Reactivity among Hospitalized Patients with Hypersensitivity Reactions to Fluoroquinolones.,"['Shah S', 'Clarke LG', 'Adams KK']","['Humans', 'Fluoroquinolones/adverse effects', 'Moxifloxacin/adverse effects', 'Levofloxacin/adverse effects', 'Anti-Bacterial Agents/adverse effects', 'Ciprofloxacin', '*Hypersensitivity/drug therapy', '*Quinolines/adverse effects', '*Aza Compounds', 'Ofloxacin']",https://pubmed.ncbi.nlm.nih.gov/37154772/
1709,ofloxacin,26238129,DRESS Syndrome Following Levofloxacin Exposure With Positive Patch-test.,"['Charfi O', 'Lakhoua G', 'Sahnoun R', 'Badri T', 'Daghfous R', 'El Aidli S', 'Kastalli S', 'Zaiem A']","['Acetaminophen/therapeutic use', 'Adult', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Drug Hypersensitivity Syndrome/diagnosis/*etiology', 'Drug Therapy, Combination', 'Epstein-Barr Virus Infections/drug therapy', 'Fluoroquinolones/adverse effects', 'Humans', 'Levofloxacin/administration & dosage/*adverse effects', 'Liver Function Tests', 'Male', 'Metronidazole/administration & dosage/therapeutic use', '*Patch Tests', 'Phenols/therapeutic use', 'Respiratory Tract Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26238129/
1710,ofloxacin,11130225,Anaphylactoid reaction to levofloxacin.,"['Smythe MA', 'Cappelletty DM']","['Anaphylaxis/*chemically induced', 'Anti-Infective Agents/*adverse effects/therapeutic use', 'Drug Hypersensitivity/*etiology', 'Female', 'Humans', '*Levofloxacin', 'Middle Aged', 'Ofloxacin/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11130225/
1711,ofloxacin,19534690,Efficacy of fluoroquinolones against pathogenic oral bacteria.,"['Nunez Otero V', 'Limeres Posse J', 'Carmona IT', 'Diz Dios P']","['Aza Compounds/chemistry/pharmacokinetics/pharmacology/*therapeutic use', 'Bacteria/drug effects', 'Bacterial Infections/*drug therapy', 'Ciprofloxacin/chemistry/pharmacokinetics/pharmacology/*therapeutic use', 'Fluoroquinolones/chemistry/pharmacokinetics/pharmacology/*therapeutic use', 'Humans', '*Levofloxacin', 'Mouth Diseases/*drug therapy', 'Moxifloxacin', 'Ofloxacin/chemistry/pharmacokinetics/pharmacology/*therapeutic use', '*Oral Medicine', 'Quinolines/chemistry/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19534690/
1712,ofloxacin,24550337,Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.,"['Thee S', 'Garcia-Prats AJ', 'McIlleron HM', 'Wiesner L', 'Castel S', 'Norman J', 'Draper HR', 'van der Merwe PL', 'Hesseling AC', 'Schaaf HS']","['Adolescent', 'Antitubercular Agents/*pharmacokinetics/*therapeutic use', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Infant', 'Levofloxacin/*pharmacokinetics/*therapeutic use', 'Male', 'Ofloxacin/*pharmacokinetics/*therapeutic use', 'Prospective Studies', 'Tuberculosis, Multidrug-Resistant/blood/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24550337/
1713,ofloxacin,31636067,DAV131A Protects Hamsters from Lethal Clostridioides difficile Infection Induced by Fluoroquinolones.,"['Saint-Lu N', 'Burdet C', 'Sablier-Gallis F', 'Corbel T', 'Neviere A', 'Sayah-Jeanne S', 'Pulse M', 'Weiss W', 'Ferreira S', 'Andremont A', 'Mentre F', 'de Gunzburg J']","['Administration, Oral', 'Adsorption', 'Animals', 'Anti-Bacterial Agents/adverse effects/pharmacokinetics', 'Charcoal/*administration & dosage', 'Ciprofloxacin/adverse effects/pharmacokinetics', '*Clostridioides difficile/pathogenicity', 'Clostridium Infections/*prevention & control', 'Disease Models, Animal', 'Dysbiosis/chemically induced/metabolism/prevention & control', 'Fluoroquinolones/adverse effects/pharmacokinetics', 'Gastrointestinal Microbiome/drug effects', 'Levofloxacin/adverse effects/pharmacokinetics', 'Male', 'Mesocricetus']",https://pubmed.ncbi.nlm.nih.gov/31636067/
1714,ofloxacin,38848797,Inhalable solid lipid nanoparticles of levofloxacin for potential tuberculosis treatment.,"['Paul PK', 'Nakpheng T', 'Paliwal H', 'Prem Ananth K', 'Srichana T']","['*Levofloxacin/administration & dosage/chemistry/pharmacology', '*Nanoparticles/chemistry', 'Administration, Inhalation', 'Humans', '*Dry Powder Inhalers', '*Antitubercular Agents/administration & dosage/chemistry/pharmacology/pharmacokinetics', '*Tuberculosis/drug therapy', '*Particle Size', 'Lipids/chemistry', 'Mycobacterium bovis/drug effects', 'Cell Line', 'Aerosols', 'A549 Cells', 'Animals', 'Spray Drying', 'Microbial Sensitivity Tests', 'Drug Carriers/chemistry', 'Polyethylene Glycols/chemistry', 'Anti-Bacterial Agents/administration & dosage/chemistry/pharmacology', 'Liposomes']",https://pubmed.ncbi.nlm.nih.gov/38848797/
1715,ofloxacin,27557756,Levofloxacin-induced rhabdomyolysis: a case report.,"['John F', 'Oluronbi R', 'Pitchumoni CS']","['Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Creatine Kinase/blood/metabolism', 'Humans', 'Levofloxacin/administration & dosage/*adverse effects', 'Male', 'Middle Aged', 'Muscle Fatigue', 'Respiratory Tract Infections/drug therapy', 'Rhabdomyolysis/*chemically induced', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27557756/
1716,ofloxacin,16669931,Levofloxacin in the treatment of ventilator-associated pneumonia.,"['Alvarez-Lerma F', 'Grau S', 'Alvarez-Beltran M']","['Anti-Infective Agents/pharmacokinetics/*therapeutic use', 'Cross Infection/*drug therapy/microbiology', 'Gram-Negative Bacterial Infections/drug therapy/etiology', 'Humans', '*Levofloxacin', 'Ofloxacin/pharmacokinetics/*therapeutic use', 'Pneumonia, Bacterial/*drug therapy/etiology', 'Respiration, Artificial/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16669931/
1717,itraconazole,35959805,"Phase 1/1b Studies of UCB0599, an Oral Inhibitor of alpha-Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease.","['Smit JW', 'Basile P', 'Prato MK', 'Detalle L', 'Mathy FX', 'Schmidt A', 'Lalla M', 'Germani M', 'Domange C', 'Biere AL', 'Bani M', 'Carson S', 'Genius J']","['Cross-Over Studies', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Humans', 'Itraconazole/therapeutic use', '*Parkinson Disease/drug therapy', '*alpha-Synuclein']",https://pubmed.ncbi.nlm.nih.gov/35959805/
1718,itraconazole,21668526,Anidulafungin: when and how? The clinician's view.,"['George J', 'Reboli AC']","['Anidulafungin', 'Antifungal Agents/therapeutic use', 'Aspergillosis/drug therapy/microbiology', 'Aspergillus/drug effects/pathogenicity', 'Candida/*drug effects/pathogenicity', 'Candidiasis/*drug therapy/microbiology', 'Drug Resistance, Fungal', 'Drug Synergism', 'Drug-Related Side Effects and Adverse Reactions', 'Echinocandins/administration & dosage/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Itraconazole/administration & dosage/pharmacology', 'Microbial Sensitivity Tests', 'Pyrimidines/administration & dosage/pharmacology', 'Triazoles/administration & dosage/pharmacology', 'Voriconazole']",https://pubmed.ncbi.nlm.nih.gov/21668526/
1719,itraconazole,12956199,The use of oral antifungal agents to treat onychomycosis.,"['Gupta AK', 'Ryder JE']","['Administration, Oral', 'Antifungal Agents/administration & dosage/*therapeutic use', 'Drug Interactions', 'Fluconazole/administration & dosage/adverse effects/therapeutic use', 'Griseofulvin/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Itraconazole/administration & dosage/adverse effects/therapeutic use', 'Ketoconazole/administration & dosage/adverse effects/therapeutic use', 'Naphthalenes/administration & dosage/adverse effects/therapeutic use', 'Onychomycosis/diagnosis/*drug therapy/microbiology/pathology', 'Terbinafine']",https://pubmed.ncbi.nlm.nih.gov/12956199/
1720,itraconazole,10423506,[Antifungal drugs for pediatric use].,['Nishimoto K'],"['Adult', '*Antifungal Agents/administration & dosage/adverse effects', 'Child', 'Fluconazole/administration & dosage/adverse effects', 'Humans', 'Infant', 'Infant, Newborn', 'Itraconazole/administration & dosage/adverse effects', 'Naphthalenes/administration & dosage/adverse effects', 'Terbinafine']",https://pubmed.ncbi.nlm.nih.gov/10423506/
1721,itraconazole,21265011,Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem - new dilemma.,"['Pana ZD', 'Roilides E']","['*Antifungal Agents/pharmacokinetics/therapeutic use/urine', '*Antineoplastic Agents, Phytogenic/adverse effects/pharmacokinetics/therapeutic use', 'Cytochrome P-450 Enzyme System/metabolism', 'Drug Interactions', 'Hematologic Neoplasms/*drug therapy', 'Humans', '*Itraconazole/adverse effects/pharmacokinetics/therapeutic use', 'Risk Factors', '*Vincristine/adverse effects/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21265011/
1722,itraconazole,30851353,Intracellular availability of poorly soluble drugs from lipid nanocapsules.,"['Bohley M', 'Haunberger A', 'Goepferich AM']","['Cell Line', 'Cell Proliferation/drug effects', 'Cyclosporine/administration & dosage/chemistry/*pharmacokinetics', 'Drug Combinations', 'Drug Compounding/methods', '*Drug Liberation', 'Endothelial Cells', 'Humans', 'Hydrophobic and Hydrophilic Interactions', 'Itraconazole/administration & dosage/chemistry/*pharmacokinetics', 'Lipids/chemistry', 'Nanocapsules/*chemistry', 'Particle Size', 'Solubility', 'Vascular Endothelial Growth Factor Receptor-2/metabolism']",https://pubmed.ncbi.nlm.nih.gov/30851353/
1723,itraconazole,11408991,Intravenous itraconazole.,"['Slain D', 'Rogers PD', 'Cleary JD', 'Chapman SW']","['Antifungal Agents/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Aspergillosis/drug therapy', 'Blastomycosis/drug therapy', 'Clinical Trials as Topic', 'Cyclodextrins/chemistry', 'Humans', 'Infusions, Intravenous', 'Itraconazole/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/11408991/
1724,itraconazole,20463252,Traditional and emerging antifungal therapies.,"['Arnold TM', 'Dotson E', 'Sarosi GA', 'Hage CA']","['Amphotericin B/administration & dosage/adverse effects', 'Anidulafungin', 'Antifungal Agents/administration & dosage/adverse effects/classification/*pharmacology/*therapeutic use', 'Caspofungin', 'Drug Therapy, Combination', 'Echinocandins/administration & dosage/pharmacology', 'Fluconazole/therapeutic use', 'Humans', 'Itraconazole/therapeutic use', 'Lipopeptides/administration & dosage', 'Micafungin', 'Pyrimidines/adverse effects', 'Triazoles/adverse effects/pharmacokinetics/therapeutic use', 'Voriconazole']",https://pubmed.ncbi.nlm.nih.gov/20463252/
1725,itraconazole,10073735,The therapeutic monitoring of antimicrobial agents.,"['Begg EJ', 'Barclay ML', 'Kirkpatrick CJ']","['Aminoglycosides/pharmacology/therapeutic use', 'Anti-Infective Agents/pharmacology/*therapeutic use', 'Antifungal Agents/pharmacology/*therapeutic use', 'Drug Monitoring/*methods', 'Flucytosine/pharmacology/therapeutic use', 'Humans', 'Itraconazole/pharmacology/therapeutic use', 'Teicoplanin/pharmacology/therapeutic use', 'Vancomycin/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10073735/
1726,itraconazole,11218451,Antimycotic agents in oral candidosis: an overview: 2. Treatment of oral candidosis.,"['Ellepola AN', 'Samaranayake LP']","['Amphotericin B/administration & dosage/therapeutic use', 'Antifungal Agents/administration & dosage/adverse effects/classification/*therapeutic use', 'Candida/drug effects/growth & development/pathogenicity', 'Candidiasis, Oral/*drug therapy', 'Clotrimazole/administration & dosage/therapeutic use', 'Drug Interactions', 'Drug Resistance, Microbial', 'Fluconazole/administration & dosage/therapeutic use', 'Humans', 'Itraconazole/administration & dosage/therapeutic use', 'Ketoconazole/administration & dosage/therapeutic use', 'Miconazole/administration & dosage/therapeutic use', 'Nystatin/administration & dosage/therapeutic use', 'Virulence/drug effects']",https://pubmed.ncbi.nlm.nih.gov/11218451/
1727,itraconazole,8286253,Folliculitis in Down's syndrome.,"['Kavanagh GM', 'Leeming JP', 'Marshman GM', 'Reynolds NJ', 'Burton JL']","['Administration, Oral', 'Adult', 'Down Syndrome/*complications/pathology', 'Female', 'Folliculitis/drug therapy/*microbiology/pathology', 'Humans', 'Itraconazole/administration & dosage/therapeutic use', '*Malassezia', 'Male', 'Recurrence', 'Skin/pathology']",https://pubmed.ncbi.nlm.nih.gov/8286253/
1728,itraconazole,32572738,PKPD and cardiac single cell modeling of a DDI study with a CYP3A4 substrate and itraconazole to quantify the effects on QT interval duration.,"['Jaminion F', 'Bentley D', 'Wang K', 'Wandel C', 'Derks M', 'Diack C']","['Adult', 'Cross-Over Studies', 'Cytochrome P-450 CYP3A/*metabolism', 'Cytochrome P-450 CYP3A Inhibitors/administration & dosage/*pharmacokinetics', 'Drug Interactions', 'Electrocardiography/drug effects', 'Female', 'GABA-A Receptor Antagonists/administration & dosage/*pharmacokinetics', 'Healthy Volunteers', 'Heart Rate/drug effects', 'Humans', 'Itraconazole/administration & dosage/*pharmacokinetics', 'Long QT Syndrome/chemically induced/*diagnosis', 'Male', 'Middle Aged', 'Models, Biological', 'Single-Cell Analysis', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32572738/
1729,itraconazole,12745853,Itraconazole versus terbinafine in the management of onychomycosis: an overview.,"['Jain S', 'Sehgal VN']","['Antifungal Agents/administration & dosage/adverse effects/*therapeutic use', 'Drug Administration Schedule', 'Humans', 'Itraconazole/administration & dosage/adverse effects/*therapeutic use', 'Naphthalenes/administration & dosage/adverse effects/*therapeutic use', 'Onychomycosis/*drug therapy', 'Terbinafine']",https://pubmed.ncbi.nlm.nih.gov/12745853/
1730,itraconazole,19681707,Toxicodynamics of itraconazole: implications for therapeutic drug monitoring.,"['Lestner JM', 'Roberts SA', 'Moore CB', 'Howard SJ', 'Denning DW', 'Hope WW']","['Antifungal Agents/*adverse effects/blood/pharmacokinetics/therapeutic use', 'Aspergillosis, Allergic Bronchopulmonary/drug therapy', 'Dose-Response Relationship, Drug', '*Drug Monitoring', 'Gastrointestinal Diseases/*chemically induced', 'Humans', 'Immunocompromised Host', 'Itraconazole/*adverse effects/blood/pharmacokinetics/therapeutic use', 'Logistic Models', 'Organ Transplantation', 'Pulmonary Aspergillosis/drug therapy', 'ROC Curve', 'Treatment Outcome', 'Water-Electrolyte Balance/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/19681707/
1731,itraconazole,38451440,Nanocrystals and nanosuspensions: an exploration from classic formulations to advanced drug delivery systems.,"['Rossier B', 'Jordan O', 'Allemann E', 'Rodriguez-Nogales C']","['*Nanoparticles/chemistry', 'Humans', '*Drug Delivery Systems', '*Suspensions', 'Animals', 'Itraconazole/chemistry/administration & dosage/pharmacokinetics', 'Drug Compounding']",https://pubmed.ncbi.nlm.nih.gov/38451440/
1732,itraconazole,11353659,Sputum itraconazole concentrations in cystic fibrosis patients.,"['Sermet-Gaudelus I', 'Lesne-Hulin A', 'Lenoir G', 'Singlas E', 'Berche P', 'Hennequin C']","['Adolescent', 'Aspergillosis, Allergic Bronchopulmonary/complications/*drug therapy', 'Aspergillus fumigatus/drug effects', 'Child', 'Child, Preschool', 'Cystic Fibrosis/*complications/*metabolism', 'Humans', 'Itraconazole/blood/metabolism/*therapeutic use', 'Microbial Sensitivity Tests', 'Sputum/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/11353659/
1733,itraconazole,27022874,Development of intranasal nanovehicles of itraconazole and their immunological activities for the therapy of rhinovirus infection.,"['Lee JJ', 'Shim A', 'Jeong JY', 'Lee SY', 'Ko HJ', 'Cho HJ']","['Administration, Intranasal', 'Animals', 'Antifungal Agents/administration & dosage/pharmacokinetics/pharmacology', 'Benzyl Alcohol/chemistry', 'Chemistry, Pharmaceutical/*methods', 'Drug Carriers/chemistry', 'Drug Delivery Systems/methods', 'Drug Liberation', 'Emulsions/chemistry', 'Female', 'Glycerol/analogs & derivatives/chemistry', 'Host-Pathogen Interactions/drug effects/immunology', 'Humans', 'Itraconazole/chemistry/immunology/*pharmacology', 'Mice, Inbred BALB C', 'Microscopy, Electron, Transmission', 'Nanoparticles/*chemistry/ultrastructure', 'Particle Size', 'Picornaviridae Infections/*drug therapy/immunology/virology', 'Polyethylene Glycols/chemistry', 'Rhinovirus/*drug effects/immunology/physiology', 'Stearic Acids/chemistry', 'Water/chemistry']",https://pubmed.ncbi.nlm.nih.gov/27022874/
1734,itraconazole,7599910,Comparative pharmacokinetics of fluconazole and of itraconazole in Japanese and in German subjects.,"['Yeates RA', 'Zimmermann T', 'Laufen H', 'Albrecht M', 'Wildfeuer A']","['Administration, Oral', 'Adolescent', 'Adult', 'Cross-Over Studies', 'Diet', 'Female', 'Fluconazole/administration & dosage/blood/*pharmacokinetics', 'Germany', 'Humans', 'Itraconazole/administration & dosage/blood/*pharmacokinetics', 'Japan', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/7599910/
1735,itraconazole,24747234,Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies.,"['Ke AB', 'Zamek-Gliszczynski MJ', 'Higgins JW', 'Hall SD']","['Clarithromycin/administration & dosage/*pharmacology', 'Cytochrome P-450 CYP3A', '*Cytochrome P-450 CYP3A Inhibitors', 'Databases, Factual', 'Drug Design', 'Drug Interactions', 'Enzyme Inhibitors/administration & dosage/adverse effects/pharmacology', 'Europe', 'Humans', 'Itraconazole/administration & dosage/*pharmacology', 'Ketoconazole/administration & dosage/adverse effects/*pharmacology', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/24747234/
1736,itraconazole,31570348,Antifungals in a case of basidiobolomycosis: role and limitations.,"['Saeed A', 'Assiri AM', 'Bukhari IA', 'Assiri R']","['Abdominal Pain/*microbiology', 'Administration, Intravenous', 'Antifungal Agents/administration & dosage/*adverse effects', 'Child', 'Crohn Disease/microbiology/*physiopathology', 'Disease Progression', 'Humans', 'Itraconazole/administration & dosage/*adverse effects', 'Male', 'Treatment Outcome', 'Voriconazole/administration & dosage/*adverse effects', 'Zygomycosis/drug therapy/*microbiology/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/31570348/
1737,Ezetimibe,39084839,Therapy for Hyperlipidemia.,"['Wright J', 'Subramanian S']","['Humans', '*Hyperlipidemias/drug therapy', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hypolipidemic Agents/therapeutic use', 'Ezetimibe/therapeutic use', 'Anticholesteremic Agents/therapeutic use', 'PCSK9 Inhibitors']",https://pubmed.ncbi.nlm.nih.gov/39084839/
1738,Ezetimibe,28073228,[Statin intolerance].,['Tonstad S'],"['Biological Products/administration & dosage/therapeutic use', 'Ezetimibe/administration & dosage/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/*adverse effects', 'Hypolipidemic Agents/administration & dosage/therapeutic use', 'Muscular Diseases/*chemically induced/diagnosis/drug therapy', 'PCSK9 Inhibitors', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/28073228/
1739,Ezetimibe,32648167,Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia.,['Lamb YN'],"['Anticholesteremic Agents/*therapeutic use', 'Cholesterol, LDL/metabolism', 'Drug Therapy, Combination/methods', 'Ezetimibe/*therapeutic use', 'Humans', 'Hypercholesterolemia/*drug therapy/metabolism', 'Rosuvastatin Calcium/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32648167/
1740,Ezetimibe,35863366,"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.","['Kim BK', 'Hong SJ', 'Lee YJ', 'Hong SJ', 'Yun KH', 'Hong BK', 'Heo JH', 'Rha SW', 'Cho YH', 'Lee SJ', 'Ahn CM', 'Kim JS', 'Ko YG', 'Choi D', 'Jang Y', 'Hong MK']","['*Anticholesteremic Agents/adverse effects', '*Atherosclerosis/drug therapy', '*Cardiovascular Diseases/drug therapy', 'Cholesterol, LDL', 'Drug Therapy, Combination', 'Ezetimibe/adverse effects', 'Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects', 'Rosuvastatin Calcium', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/35863366/
1741,Ezetimibe,26324293,[Statin intolerance].,"['Graversen CB', 'Larsen ML', 'Schmidt EB']","['Anticholesteremic Agents/therapeutic use', 'Cardiovascular Diseases/drug therapy', 'Ezetimibe/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/therapeutic use', 'Muscular Diseases/*chemically induced/drug therapy', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/26324293/
1742,Ezetimibe,37486464,Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.,"['Michaeli DT', 'Michaeli JC', 'Albers S', 'Boch T', 'Michaeli T']","['Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects', 'Proprotein Convertase 9', '*Anticholesteremic Agents/adverse effects', 'Secondary Prevention/methods', 'Hypolipidemic Agents/pharmacology/therapeutic use', 'Ezetimibe/therapeutic use', '*Cardiovascular Diseases/prevention & control/chemically induced', '*Hypertriglyceridemia/drug therapy', 'Pharmaceutical Preparations', 'Angiopoietin-Like Protein 3']",https://pubmed.ncbi.nlm.nih.gov/37486464/
1743,Ezetimibe,29777433,Are PCSK9 Inhibitors Cost Effective?,"['Korman MJ', 'Retterstol K', 'Kristiansen IS', 'Wisloff T']","['Anticholesteremic Agents/*economics/therapeutic use', 'Cost-Benefit Analysis/*statistics & numerical data', 'Drug Therapy, Combination/economics', 'Enzyme Inhibitors/*economics/therapeutic use', 'Ezetimibe/economics/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/economics/therapeutic use', 'Hypercholesterolemia/drug therapy/*economics', 'PCSK9 Inhibitors', 'Quality-Adjusted Life Years']",https://pubmed.ncbi.nlm.nih.gov/29777433/
1744,Ezetimibe,36342163,Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.,"[""O'Donoghue ML"", 'Rosenson RS', 'Gencer B', 'Lopez JAG', 'Lepor NE', 'Baum SJ', 'Stout E', 'Gaudet D', 'Knusel B', 'Kuder JF', 'Ran X', 'Murphy SA', 'Wang H', 'Wu Y', 'Kassahun H', 'Sabatine MS']","['Humans', '*Anticholesteremic Agents/administration & dosage/adverse effects/pharmacology/therapeutic use', '*Atherosclerosis/drug therapy', 'Cardiovascular Diseases/drug therapy', 'Double-Blind Method', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', '*Hypercholesterolemia/drug therapy', '*Lipoprotein(a)/analysis/antagonists & inhibitors', '*RNA, Small Interfering/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Liver/drug effects/metabolism', 'PCSK9 Inhibitors/therapeutic use', 'Ezetimibe/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36342163/
1745,Ezetimibe,35262430,Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis.,"['Burnett H', 'Fahrbach K', 'Cichewicz A', 'Jindal R', 'Tarpey J', 'Durand A', 'Di Domenico M', 'Reichelt A', 'Viljoen A']","['*Anticholesteremic Agents/adverse effects/therapeutic use', 'Bayes Theorem', '*Cardiovascular Diseases/etiology/prevention & control', 'Cholesterol', 'Cholesterol, LDL', 'Ezetimibe/therapeutic use', 'Heart Disease Risk Factors', 'Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects', '*Hypercholesterolemia/complications/drug therapy', '*Hyperlipidemias/drug therapy', 'Network Meta-Analysis', 'Risk Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/35262430/
1746,Ezetimibe,35533049,Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis.,"['Tummala R', 'Gupta M', 'Devanabanda AR', 'Bandyopadhyay D', 'Aronow WS', 'Ray KK', 'Mamas M', 'Ghosh RK']","['*Atherosclerosis/drug therapy', 'Cholesterol, LDL', 'Dicarboxylic Acids', 'Ezetimibe/therapeutic use', 'Fatty Acids', 'Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', '*Hyperlipidemias/chemically induced/drug therapy', 'Hypolipidemic Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35533049/
1747,Ezetimibe,35832642,Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights.,"['Chilbert MR', 'VanDuyn D', 'Salah S', 'Clark CM', 'Ma Q']","['*Anticholesteremic Agents', 'Cholesterol', 'Cholesterol, LDL', 'Drug Therapy, Combination', '*Dyslipidemias/drug therapy', 'Ezetimibe/therapeutic use', 'Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors', 'Rosuvastatin Calcium/therapeutic use', 'Simvastatin', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/35832642/
1748,Ezetimibe,27864787,Glycaemic Effects of Non-statin Lipid-Lowering Therapies.,"['Collins PD', 'Sattar N']","['Anticholesteremic Agents/therapeutic use', 'Blood Glucose/*metabolism', 'Cardiovascular Diseases/prevention & control', 'Diabetes Mellitus, Type 2/complications/*drug therapy/physiopathology', 'Diabetic Angiopathies/blood/*drug therapy/physiopathology', 'Ezetimibe/therapeutic use', 'Fibric Acids/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/therapeutic use', 'Hypercholesterolemia/blood/*drug therapy/physiopathology', 'Hypolipidemic Agents/*adverse effects/*therapeutic use', 'Lipid Metabolism/drug effects', 'Meta-Analysis as Topic', 'Niacin/therapeutic use', 'PCSK9 Inhibitors', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27864787/
1749,Ezetimibe,37770770,"Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial.","['Su Q', 'Liu Y', 'Zhang G', 'Xu L', 'Wang M', 'Mei S', 'Garon G', 'Wu Y', 'Lv Q', 'Ma C']","['Humans', '*Anticholesteremic Agents/administration & dosage/therapeutic use', 'Cholesterol, LDL', 'Double-Blind Method', 'East Asian People', '*Ezetimibe/administration & dosage/therapeutic use', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors', '*Hypercholesterolemia/drug therapy', '*Rosuvastatin Calcium/administration & dosage/therapeutic use', 'Treatment Outcome', 'Drug Combinations']",https://pubmed.ncbi.nlm.nih.gov/37770770/
1750,Ezetimibe,35918009,Lipid Lowering Therapy: An Era Beyond Statins.,"['Abdul-Rahman T', 'Bukhari SMA', 'Herrera EC', 'Awuah WA', 'Lawrence J', 'de Andrade H', 'Patel N', 'Shah R', 'Shaikh R', 'Capriles CAA', 'Ulusan S', 'Ahmad S', 'Corriero AC', 'Mares AC', 'Goel A', 'Hajra A', 'Bandyopadhyay D', 'Gupta R']","['Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects', '*Anticholesteremic Agents/adverse effects', 'Cholesterol, LDL/therapeutic use', '*Cardiovascular Diseases/etiology/prevention & control', 'Ezetimibe/pharmacology/therapeutic use', '*Dyslipidemias/drug therapy', 'Cholesterol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35918009/
1751,Ezetimibe,31357887,Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.,"['Ballantyne CM', 'Laufs U', 'Ray KK', 'Leiter LA', 'Bays HE', 'Goldberg AC', 'Stroes ES', 'MacDougall D', 'Zhao X', 'Catapano AL']","['Aged', 'Anticholesteremic Agents/*administration & dosage/adverse effects', 'Biomarkers/blood', 'Cardiovascular Diseases/blood/diagnosis/*prevention & control', 'Cholesterol, LDL/*blood', 'Dicarboxylic Acids/*administration & dosage/adverse effects', 'Double-Blind Method', 'Down-Regulation', 'Drug Combinations', 'Ezetimibe/*administration & dosage/adverse effects', 'Fatty Acids/*administration & dosage/adverse effects', 'Female', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hypercholesterolemia/blood/diagnosis/*drug therapy', 'Male', 'Middle Aged', 'Time Factors', 'Treatment Outcome', 'United States']",https://pubmed.ncbi.nlm.nih.gov/31357887/
1752,Ezetimibe,37495276,Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention.,"['Lee SJ', 'Joo JH', 'Park S', 'Kim C', 'Choi DW', 'Hong SJ', 'Ahn CM', 'Kim JS', 'Kim BK', 'Ko YG', 'Choi D', 'Jang Y', 'Nam CM', 'Hong MK']","['Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Rosuvastatin Calcium', '*Anticholesteremic Agents/therapeutic use', '*Drug-Eluting Stents', 'Treatment Outcome', 'Drug Therapy, Combination', 'Ezetimibe/therapeutic use', '*Myocardial Infarction/drug therapy', 'Lipids', '*Percutaneous Coronary Intervention']",https://pubmed.ncbi.nlm.nih.gov/37495276/
1753,Ezetimibe,36813611,Current and future options in cholesterol lowering treatments.,['Elis A'],"['Humans', 'Cholesterol, LDL', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Cholesterol', 'Ezetimibe/therapeutic use', 'Drug Therapy, Combination', '*Anticholesteremic Agents/therapeutic use/adverse effects', 'Proprotein Convertase 9/genetics']",https://pubmed.ncbi.nlm.nih.gov/36813611/
1754,Ezetimibe,31758270,Management of Lipid Abnormalities in Patients with Diabetes.,"['Sillars A', 'Sattar N']","['Diabetes Mellitus, Type 1/complications', 'Diabetes Mellitus, Type 2/*complications', 'Dyslipidemias/*drug therapy/etiology', 'Ezetimibe/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/*therapeutic use', 'Hypolipidemic Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31758270/
1755,Ezetimibe,27005745,Statin-related myotoxicity.,"['Fernandes V', 'Santos MJ', 'Perez A']","['Clinical Trials as Topic', 'Comorbidity', 'Creatine Kinase/blood', 'Cytochrome P-450 CYP3A/physiology', 'Dietary Supplements', 'Disease Management', 'Disease Susceptibility', 'Drug Interactions', 'Drug Substitution', 'Exercise', 'Ezetimibe/therapeutic use', 'Female', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/pharmacology', 'Incidence', 'Male', 'Meta-Analysis as Topic', 'Muscular Diseases/*chemically induced/epidemiology/genetics/physiopathology', 'Rhabdomyolysis/chemically induced/epidemiology/physiopathology', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/27005745/
1756,Ezetimibe,35063734,Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorption.,"['Zhang R', 'Liu W', 'Zeng J', 'Meng J', 'Jiang H', 'Wang J', 'Xing D']","['*Anticholesteremic Agents/pharmacology', 'Biological Transport', 'Cholesterol/pharmacology', 'Ezetimibe/pharmacology/therapeutic use', 'Humans', '*Hypercholesterolemia', 'Intestinal Absorption', 'Membrane Transport Proteins/metabolism']",https://pubmed.ncbi.nlm.nih.gov/35063734/
1757,sumatriptan,16995362,[Medication-overuse headache].,"['Rabe K', 'Katsarava Z']","['Acute Disease', 'Analgesics/administration & dosage/*adverse effects', 'Analgesics, Non-Narcotic/administration & dosage/adverse effects', 'Chronic Disease', 'Ergotamine/administration & dosage/adverse effects', 'Female', 'Headache/*chemically induced/diagnosis/drug therapy', 'Headache Disorders, Secondary/*diagnosis/prevention & control', 'Humans', 'Male', 'Migraine Disorders/*chemically induced/drug therapy', 'Prognosis', 'Recurrence', 'Serotonin Receptor Agonists/administration & dosage/therapeutic use', 'Sumatriptan/administration & dosage/therapeutic use', 'Tension-Type Headache/chemically induced/drug therapy', 'Time Factors', 'Vasoconstrictor Agents/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16995362/
1758,sumatriptan,27807736,[Analgesic drugs during pregnancy].,"['Hultzsch S', 'Schaefer C']","['Abnormalities, Drug-Induced/etiology', 'Acetaminophen/adverse effects/therapeutic use', 'Acute Pain/*drug therapy', 'Analgesics/*adverse effects/*therapeutic use', 'Analgesics, Opioid/adverse effects/therapeutic use', 'Anticonvulsants/adverse effects/therapeutic use', 'Chronic Pain/*drug therapy', 'Female', 'Gestational Age', 'Humans', 'Ibuprofen/adverse effects/therapeutic use', 'Infant, Newborn', 'Long-Term Care', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Risk Factors', 'Sumatriptan/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27807736/
1759,sumatriptan,20430313,Meeting acute migraine treatment needs through novel treatment formulations.,['Silberstein SD'],"['Analgesics, Non-Narcotic/*administration & dosage/therapeutic use', 'Diclofenac/*administration & dosage/therapeutic use', 'Dihydroergotamine/*administration & dosage/therapeutic use', 'Drug Administration Routes', 'Drug Delivery Systems', 'Drug Prescriptions', 'Humans', 'Migraine Disorders/*drug therapy/metabolism', 'Sumatriptan/*administration & dosage/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20430313/
1760,sumatriptan,15853561,Sumatriptan: a decade of use and experience in the treatment of migraine.,"['Sheftell FD', 'Bigal ME', 'Tepper SJ', 'Rapoport AM']","['Clinical Trials as Topic/*trends', 'Humans', 'Migraine Disorders/*drug therapy/metabolism', 'Sumatriptan/chemistry/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15853561/
1761,sumatriptan,12534326,Tolerability of the triptans: clinical implications.,"['Nappi G', 'Sandrini G', 'Sances G']","['Brain/drug effects', 'Cardiovascular System/drug effects', 'Drug Interactions', 'Female', 'Fetus/drug effects', 'Humans', 'Migraine Disorders/*drug therapy', 'Pregnancy', 'Receptor, Serotonin, 5-HT1B', 'Receptor, Serotonin, 5-HT1D', 'Receptors, Serotonin/drug effects', 'Serotonin Receptor Agonists/*adverse effects', 'Sumatriptan/*adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/12534326/
1762,sumatriptan,26255952,The pharmacokinetics and clinical efficacy of AVP-825: a potential advancement for acute treatment of migraine.,['Cady R'],"['Administration, Intranasal', 'Drugs, Investigational', 'Humans', 'Migraine Disorders/*drug therapy', 'Randomized Controlled Trials as Topic', 'Serotonin Receptor Agonists/*administration & dosage/adverse effects', 'Sumatriptan/*administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26255952/
1763,sumatriptan,15549517,Acute drug treatment of migraine attack.,"['Narbone MC', 'Abbate M', 'Gangemi S']","['Acute Disease', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use', 'Antiemetics/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Contraindications', 'Ergot Alkaloids/adverse effects/therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Serotonin Receptor Agonists/adverse effects/therapeutic use', 'Sumatriptan/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15549517/
1764,sumatriptan,17955173,Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment.,['Tfelt-Hansen P'],"['Administration, Oral', 'Biological Availability', 'Humans', 'Infusions, Parenteral', 'Injections, Subcutaneous', 'Migraine Disorders/*drug therapy/physiopathology', 'Piperidines/*administration & dosage/blood/pharmacokinetics', 'Serotonin Receptor Agonists/*administration & dosage/blood/pharmacokinetics', 'Sumatriptan/*administration & dosage/blood/pharmacokinetics', 'Time Factors', 'Treatment Outcome', 'Tryptamines/*administration & dosage/blood/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/17955173/
1765,sumatriptan,18778579,Cutaneous allodynia and migraine: another view.,['Dahlof C'],"['Humans', 'Hyperalgesia/*drug therapy/*physiopathology', 'Migraine Disorders/*drug therapy/*physiopathology', 'Serotonin Receptor Agonists/pharmacokinetics/*therapeutic use', 'Sumatriptan/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18778579/
1766,sumatriptan,22444161,"Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment.","['Dahlof C', 'Maassen Van Den Brink A']","['Animals', 'Dihydroergotamine/chemistry/pharmacokinetics/*therapeutic use', 'Ergotamine/chemistry/pharmacokinetics/*therapeutic use', 'Humans', 'Methysergide/chemistry/pharmacokinetics/*therapeutic use', 'Migraine Disorders/*drug therapy/metabolism', 'Sumatriptan/chemistry/pharmacokinetics/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22444161/
1767,sumatriptan,25219631,Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches.,"['Lecchi M', ""D'Alonzo L"", 'Negro A', 'Martelletti P']","['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacokinetics/*therapeutic use', 'Aspirin/administration & dosage/pharmacokinetics/*therapeutic use', 'Dose-Response Relationship, Drug', 'Headache/*drug therapy', 'Humans', 'Migraine Disorders/drug therapy', 'Practice Guidelines as Topic', 'Sumatriptan/administration & dosage/therapeutic use', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/25219631/
1768,sumatriptan,11668885,Efficacy of sumatriptan in the treatment of migraine: a review of the literature.,['McAlhany A'],"['Adult', 'Child', 'Clinical Trials as Topic', 'Humans', 'Migraine Disorders/*drug therapy/nursing', 'Sumatriptan/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/11668885/
1769,sumatriptan,12474651,[The problems of migraine headache treatment].,"['Vilionskis A', 'Vaitkus A']","['Aged', 'Analgesics/administration & dosage/therapeutic use', 'Analgesics, Non-Narcotic/administration & dosage/therapeutic use', 'Aspirin/administration & dosage/therapeutic use', 'Dihydroergotamine/administration & dosage/therapeutic use', 'Female', 'Humans', 'Male', 'Methysergide/administration & dosage/therapeutic use', 'Migraine Disorders/chemically induced/diagnosis/*drug therapy/etiology/prevention & control', 'Oxazolidinones/administration & dosage/therapeutic use', 'Serotonin Antagonists/administration & dosage/therapeutic use', 'Serotonin Receptor Agonists/administration & dosage/therapeutic use', 'Stress, Psychological/complications', 'Sumatriptan/administration & dosage/therapeutic use', 'Time Factors', 'Tryptamines', 'Vasoconstrictor Agents/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12474651/
1770,sumatriptan,20464603,New acute treatments for headache.,['Rapoport AM'],"['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use', 'Botulinum Toxins, Type A/therapeutic use', 'Clinical Trials as Topic', 'Diclofenac/administration & dosage/therapeutic use', 'Dipeptides/*therapeutic use', 'Drug Administration Routes', 'Headache Disorders/*drug therapy', 'Humans', 'Piperazines', 'Quinazolines/*therapeutic use', 'Serotonin Receptor Agonists/therapeutic use', 'Sumatriptan/*administration & dosage/therapeutic use', 'Treatment Outcome', 'Vasoconstrictor Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20464603/
1771,sumatriptan,12463280,Eletriptan: pharmacological differences and clinical results.,['Giffin N'],"['Humans', 'Indoles/*pharmacology/therapeutic use', 'Migraine Disorders/*drug therapy', 'Pyrrolidines/*pharmacology/therapeutic use', 'Serotonin Receptor Agonists/*pharmacology/therapeutic use', 'Sumatriptan/*pharmacology/therapeutic use', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/12463280/
1772,sumatriptan,12463281,Almotriptan: pharmacological differences and clinical results.,['Pascual J'],"['Administration, Oral', 'Humans', 'Indoles/*pharmacology/therapeutic use', 'Migraine Disorders/*drug therapy', 'Recurrence', 'Serotonin Receptor Agonists/*pharmacology/therapeutic use', 'Sumatriptan/*pharmacology/therapeutic use', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/12463281/
1773,sumatriptan,31425447,PARACENTRAL ACUTE MIDDLE MACULOPATHY FOLLOWING ORAL INTAKE OF SUMATRIPTAN.,"['Zonnevylle KE', 'Jacob J', 'Luyten S', 'Stanescu-Segall D']","['Acute Disease', 'Administration, Oral', 'Humans', '*Macular Degeneration/chemically induced/diagnostic imaging', '*Retinal Diseases/chemically induced/diagnostic imaging', '*Sumatriptan/administration & dosage/adverse effects', 'Tomography, Optical Coherence']",https://pubmed.ncbi.nlm.nih.gov/31425447/
1774,sumatriptan,32843411,Vasospasm induced myocardial ischaemia secondary to sumatriptan use.,"['Okonkwo K', 'Ojha U']","['Coronary Angiography', '*Coronary Vasospasm/chemically induced/diagnosis', 'Electrocardiography', 'Humans', 'Male', 'Middle Aged', 'Migraine Disorders/drug therapy', '*Myocardial Ischemia/chemically induced/diagnosis', 'Sumatriptan/*adverse effects/therapeutic use', 'Vasoconstrictor Agents/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32843411/
1775,sumatriptan,21469920,"Sumatriptan needle-free subcutaneous (Sumavel((R)) DosePro) approved for the acute treatment of migraine, with or without aura, and cluster headaches.",['Freitag FG'],"['Cluster Headache/*drug therapy/physiopathology', 'Drug Administration Routes', 'Drug Delivery Systems', 'Female', 'Humans', 'Injections, Subcutaneous', 'Male', 'Migraine Disorders/*drug therapy/physiopathology', 'Serotonin 5-HT1 Receptor Agonists/*administration & dosage/adverse effects/*therapeutic use', 'Sumatriptan/*administration & dosage/adverse effects/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21469920/
1776,pyridostigmine,25977271,Myasthenia gravis: Association of British Neurologists' management guidelines.,"['Sussman J', 'Farrugia ME', 'Maddison P', 'Hill M', 'Leite MI', 'Hilton-Jones D']","['Cholinesterase Inhibitors/therapeutic use', '*Disease Management', 'Humans', 'Myasthenia Gravis/*diagnosis/*therapy', 'Neurology/*methods/*standards', 'Pyridostigmine Bromide/therapeutic use', 'United Kingdom']",https://pubmed.ncbi.nlm.nih.gov/25977271/
1777,pyridostigmine,37132128,Pyridostigmine in chronic intestinal pseudo-obstruction - a systematic review.,"['Wilkie BD', 'Noori J', 'Johnston M', 'Woods R', 'Keck JO', 'Behrenbruch C']","['Adult', 'Humans', '*Pyridostigmine Bromide/therapeutic use/pharmacology', 'Gastrointestinal Motility', '*Intestinal Pseudo-Obstruction/drug therapy/diagnosis', 'Cholinesterase Inhibitors/therapeutic use/pharmacology', 'Chronic Disease']",https://pubmed.ncbi.nlm.nih.gov/37132128/
1778,pyridostigmine,30783322,Management of myasthenia gravis during pregnancy.,"['Bansal R', 'Goyal MK', 'Modi M']","['Azathioprine/administration & dosage/adverse effects/therapeutic use', 'Cholinesterase Inhibitors/administration & dosage/adverse effects/therapeutic use', '*Disease Management', 'Female', 'Humans', 'Immunosuppressive Agents/administration & dosage/adverse effects/therapeutic use', 'Myasthenia Gravis/*drug therapy', 'Practice Guidelines as Topic', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Pregnancy Outcome', 'Prenatal Care', 'Pyridostigmine Bromide/administration & dosage/adverse effects/therapeutic use', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/30783322/
1779,pyridostigmine,12745006,Double trouble.,['Bhatti MT'],"['Aged', 'Cholinesterase Inhibitors/therapeutic use', 'Diagnostic Techniques, Ophthalmological', 'Diplopia/drug therapy/*etiology', 'Female', 'Humans', 'Myasthenia Gravis/*complications/diagnosis', 'Oculomotor Muscles/drug effects/*pathology', 'Paresis', 'Pyridostigmine Bromide/therapeutic use', 'Strabismus/*etiology/surgery']",https://pubmed.ncbi.nlm.nih.gov/12745006/
1780,pyridostigmine,36184373,The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study.,"['Remijn-Nelissen L', 'Verschuuren JJGM', 'Tannemaat MR']","['Humans', '*Pyridostigmine Bromide/adverse effects', 'Cross-Sectional Studies', '*Myasthenia Gravis/drug therapy/chemically induced', 'Muscle Weakness/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/36184373/
1781,pyridostigmine,925839,Childhood myasthenia gravis.,"['Berkovitz S', 'Belkin M', 'Tenenbaum A']","['Adult', 'Blepharoptosis/*etiology', 'Child', 'Child, Preschool', 'Deglutition Disorders/etiology', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Male', 'Myasthenia Gravis/*complications/diagnosis/drug therapy', 'Ophthalmoplegia/*etiology', 'Pregnancy', 'Pyridostigmine Bromide/therapeutic use', 'Respiratory Insufficiency/etiology']",https://pubmed.ncbi.nlm.nih.gov/925839/
1782,pyridostigmine,8380423,Autoimmune myasthenia gravis.,"['Lopate G', 'Pestronk A']","['Adult', 'Age Factors', 'Antibody Formation/immunology', '*Autoimmune Diseases/diagnosis/immunology/therapy', 'Cyclosporine/adverse effects/therapeutic use', 'Diagnosis, Differential', 'Humans', 'Immunoglobulins, Intravenous/adverse effects/therapeutic use', 'Infant, Newborn', 'Male', '*Myasthenia Gravis/diagnosis/immunology/therapy', 'Neuromuscular Junction', 'Plasmapheresis', 'Prednisone/adverse effects/therapeutic use', 'Pyridostigmine Bromide/adverse effects/therapeutic use', 'Receptors, Cholinergic/immunology', 'Synaptic Transmission', 'Thymectomy', 'Thymus Gland/immunology/surgery']",https://pubmed.ncbi.nlm.nih.gov/8380423/
1783,pyridostigmine,3999598,[Ocular myasthenia].,['Huber A'],"['Azathioprine/therapeutic use', 'Blepharoptosis/diagnosis/*drug therapy/therapy', 'Cholinesterase Inhibitors/administration & dosage/therapeutic use', 'Cortisone/therapeutic use', 'Cyclophosphamide/therapeutic use', 'Electromyography', 'Humans', 'Myasthenia Gravis/diagnosis/*drug therapy/therapy', 'Ophthalmoplegia/diagnosis/*drug therapy/therapy', 'Prednisone/therapeutic use', 'Pyridostigmine Bromide/administration & dosage/therapeutic use', 'Thymectomy']",https://pubmed.ncbi.nlm.nih.gov/3999598/
1784,pyridostigmine,32215460,Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials.,"['Lorenzoni PJ', 'Kay CSK', 'Ducci RD', 'Fustes OJH', 'Werneck LC', 'Scola RH']","['Cholinesterase Inhibitors/*therapeutic use', 'Humans', 'Myasthenia Gravis/*drug therapy', 'Pyridostigmine Bromide/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32215460/
1785,pyridostigmine,30133608,Gluten and Neuroimmunology. Rare association with Myasthenia Gravis and Literature Review.,"['Oliveira F', 'Schoeps V', 'Sanvito W', 'Valerio B']","['Adult', 'Ataxia/diagnosis/*etiology', 'Cerebellar Diseases/diagnostic imaging/etiology', 'Cholinesterase Inhibitors/therapeutic use', 'Female', 'Food Hypersensitivity/*complications/diagnosis', 'Glutens/*adverse effects/*immunology', 'Humans', 'Magnetic Resonance Imaging', 'Myasthenia Gravis/diagnosis/*etiology', 'Neuroimmunomodulation', 'Pyridostigmine Bromide/therapeutic use', 'Vitamin B 12 Deficiency/complications']",https://pubmed.ncbi.nlm.nih.gov/30133608/
1786,pyridostigmine,33423527,Supine Parasympathetic Withdrawal and Upright Sympathetic Activation Underly Abnormalities of the Baroreflex in Postural Tachycardia Syndrome: Effects of Pyridostigmine and Digoxin.,"['Stewart JM', 'Warsy IA', 'Visintainer P', 'Terilli C', 'Medow MS']","['Adult', 'Baroreflex/drug effects/physiology', 'Blood Pressure/drug effects/physiology', 'Cardiotonic Agents/administration & dosage', 'Cholinesterase Inhibitors/administration & dosage', 'Digoxin/*administration & dosage', 'Dizziness/physiopathology', 'Female', 'Heart Rate/drug effects/physiology', 'Humans', 'Hypovolemia/etiology/physiopathology', 'Outcome Assessment, Health Care', 'Patient Positioning/methods', '*Postural Orthostatic Tachycardia Syndrome/diagnosis/physiopathology', 'Pyridostigmine Bromide/*administration & dosage', 'Sympathetic Nervous System/drug effects/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/33423527/
1787,pyridostigmine,10782353,The diagnostic value of stapedius reflex and stapedius reflex exhaustion in myasthenia gravis.,"['Toth L', 'Lampe I', 'Dioszeghy P', 'Repassy G']","['Acoustic Impedance Tests', 'Adult', 'Cholinesterase Inhibitors/therapeutic use', 'Female', 'Humans', 'Male', 'Muscle Contraction/drug effects/physiology', 'Muscle Fatigue/drug effects/physiology', 'Myasthenia Gravis/drug therapy/*physiopathology', 'Pyridostigmine Bromide/therapeutic use', 'Reflex, Acoustic/drug effects/*physiology', 'Signal Processing, Computer-Assisted', 'Stapedius/drug effects/*physiopathology']",https://pubmed.ncbi.nlm.nih.gov/10782353/
1788,pyridostigmine,28583776,[Neonatal hyperthyroidism: A sometimes challenging diagnosis].,"['Couturier C', 'Cneude F', 'Spiteri A', 'Nugues F', 'Debillon T']","['Cholinesterase Inhibitors/therapeutic use', 'Goiter/*diagnosis/*surgery', 'Humans', 'Hyperthyroidism/*etiology/therapy', 'Infant, Newborn', 'Male', 'Myasthenia Gravis, Neonatal/*diagnosis/therapy', 'Pyridostigmine Bromide/therapeutic use', 'Respiratory Distress Syndrome, Newborn/etiology', 'Thyroidectomy']",https://pubmed.ncbi.nlm.nih.gov/28583776/
1789,pyridostigmine,17538742,Post-varicella myasthenia gravis.,"['Saha A', 'Batra P', 'Vilhekar KY', 'Chaturvedi P']","['Chickenpox/*complications', 'Child, Preschool', 'Cholinesterase Inhibitors/*therapeutic use', 'Humans', 'Male', 'Myasthenia Gravis/drug therapy/*virology', 'Neostigmine/*therapeutic use', 'Pyridostigmine Bromide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17538742/
1790,pyridostigmine,27922505,Registry Participation in Neuromuscular Disease.,['Shenoy AM'],"['Aged', 'Cholinesterase Inhibitors/therapeutic use', 'Female', 'Humans', 'Myasthenia Gravis/*diagnosis/*drug therapy', 'Neuromuscular Diseases/diagnosis/drug therapy', 'Pyridostigmine Bromide/therapeutic use', '*Registries']",https://pubmed.ncbi.nlm.nih.gov/27922505/
1791,pyridostigmine,945494,The pharmacokinetics of pyridostigmine.,"['Cohan SL', 'Pohlmann JL', 'Mikszewski J', ""O'Doherty DS""]","['Administration, Oral', 'Chemical Phenomena', 'Chemistry', 'Dose-Response Relationship, Drug', 'Myasthenia Gravis/drug therapy', 'Pyridostigmine Bromide/administration & dosage/*blood/therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/945494/
1792,pyridostigmine,34020991,Myasthenia gravis and prostatic neoplasia: a rare association.,"['Pereira MS', 'Escarigo MC', 'Correia Azevedo P', 'Delerue F']","['Aged, 80 and over', '*Blepharoptosis', 'Diplopia', 'Humans', 'Male', '*Myasthenia Gravis/complications/diagnosis/drug therapy', '*Prostatic Neoplasms/complications/drug therapy', 'Pyridostigmine Bromide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34020991/
1793,pyridostigmine,30536954,Neuromuscular transmission defects in myopathies: Rare but worth searching for.,"['Elahi B', 'Laughlin RS', 'Litchy WJ', 'Milone M', 'Liewluck T']","['Cholinesterase Inhibitors/therapeutic use', 'Cohort Studies', 'Electrodiagnosis', 'Electromyography', 'Female', 'Genetic Diseases, X-Linked/drug therapy/physiopathology', 'Humans', 'Hydroxychloroquine/adverse effects', 'Immunotherapy/methods', 'Lysosomal Storage Diseases/drug therapy/physiopathology', 'Male', 'Motor Neurons', 'Muscle, Skeletal/*innervation/*physiopathology', 'Muscular Diseases/drug therapy/*physiopathology', 'Myopathies, Structural, Congenital/drug therapy/physiopathology', 'Pyridostigmine Bromide/therapeutic use', '*Synaptic Transmission']",https://pubmed.ncbi.nlm.nih.gov/30536954/
1794,pyridostigmine,18769095,Early onset myasthenia gravis with atypical features.,"['Agarwal P', 'Chapagain U', 'Deewan KR', 'Rana PV']","['Adolescent', 'Cholinesterase Inhibitors/*therapeutic use', 'Humans', 'Male', 'Myasthenia Gravis/complications/*diagnosis/*drug therapy', 'Ophthalmoplegia/etiology', 'Pyridostigmine Bromide/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18769095/
1795,pyridostigmine,2664236,Progress in medical defense against nerve agents.,"['Dunn MA', 'Sidell FR']","['Animals', 'Atropine/administration & dosage/*therapeutic use', '*Chemical Warfare Agents', 'Cholinesterase Inhibitors/adverse effects', 'Humans', 'Nervous System/*drug effects', 'Oximes/administration & dosage/*pharmacology', 'Poisoning/drug therapy', 'Pyridostigmine Bromide/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2664236/
1796,VERAPAMIL,16596036,Antihypertensive pharmacobezoar.,"['Prisant LM', 'Spaulding VC']","['Antihypertensive Agents/*administration & dosage/*adverse effects', 'Bezoars/*etiology', 'Calcium Channel Blockers/administration & dosage', 'Drug Delivery Systems/*adverse effects', 'Gastrointestinal Diseases/*etiology', 'Humans', 'Isradipine/administration & dosage/adverse effects', 'Nifedipine/administration & dosage', 'Postoperative Complications/etiology', 'Tablets', 'Verapamil/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16596036/
1797,VERAPAMIL,6340050,Verapamil: an effective calcium blocking agent for pediatric patients.,"['Porter CJ', 'Garson A Jr', 'Gillette PC']","['Administration, Oral', 'Adult', 'Aged', 'Animals', 'Arrhythmias, Cardiac/drug therapy', '*Calcium Channel Blockers', 'Cardiomyopathy, Hypertrophic/drug therapy', 'Child, Preschool', 'Drug Interactions', 'Electrophysiology', 'Female', 'Heart Conduction System/drug effects', 'Hemodynamics/drug effects', 'Humans', 'Infant', 'Infant, Newborn', 'Infusions, Parenteral', 'Male', 'Middle Aged', 'Myocardial Contraction/drug effects', 'Pregnancy', 'Tachycardia/drug therapy', 'Verapamil/administration & dosage/adverse effects/metabolism/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6340050/
1798,VERAPAMIL,6764159,Calcium-channel blocking agents.,"['Leonard RG', 'Talbert RL']","['Adolescent', 'Benzazepines/*pharmacology', 'Calcium/physiology', 'Calcium Channel Blockers/*pharmacology', 'Child', 'Child, Preschool', 'Clinical Trials as Topic', 'Diltiazem/adverse effects/metabolism/*pharmacology/therapeutic use', 'Double-Blind Method', 'Heart/*drug effects', 'Heart Diseases/*drug therapy', 'Humans', 'Hypertension/drug therapy', 'Infant', 'Myocardial Contraction/drug effects', 'Nifedipine/adverse effects/metabolism/*pharmacology/therapeutic use', 'Pyridines/*pharmacology', 'Verapamil/adverse effects/metabolism/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6764159/
1799,VERAPAMIL,9265278,[Calcium channel blockers in heart failure].,"['Hole T', 'Dickstein K', 'Gundersen T', 'Kjekshus J', 'Myhre ES', 'Ronnevik PK', 'Westheim AS']","['Calcium Channel Blockers/administration & dosage/*adverse effects', 'Dihydropyridines/administration & dosage/adverse effects', 'Diltiazem/administration & dosage/adverse effects', 'Heart Failure/*drug therapy/etiology/physiopathology', 'Humans', 'Ventricular Dysfunction, Left/complications/drug therapy/physiopathology', 'Verapamil/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/9265278/
1800,VERAPAMIL,8524707,"Verapamil-induced ""primary"" polydipsia.","['Schwartz ID', 'Scagliotti D']","['Administration, Oral', 'Drinking/*drug effects', 'Humans', 'Infant', 'Male', 'Polyuria/chemically induced', 'Tachycardia, Supraventricular/*drug therapy', 'Thirst/drug effects', 'Verapamil/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8524707/
1801,VERAPAMIL,1862052,Supraventricular tachycardia. Changes in management.,['Caruso AC'],"['Adenosine/administration & dosage/adverse effects/therapeutic use', 'Diagnosis, Differential', 'Education, Medical, Continuing', 'Electrocardiography', 'Electrocoagulation', 'Humans', 'Injections, Intravenous', 'Tachycardia, Supraventricular/classification/*diagnosis/therapy', 'Verapamil/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1862052/
1802,VERAPAMIL,6319840,Verapamil: full spectrum calcium channel blocking agent: an overview.,"['Guerrero JR', 'Martin SS']","['Calcium/*metabolism', 'Heart/drug effects', 'Heart Diseases/drug therapy', 'Hemodynamics/drug effects', 'Humans', 'Ion Channels/*drug effects', 'Kinetics', 'Muscles/metabolism', 'Myocardium/metabolism', 'Verapamil/adverse effects/metabolism/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6319840/
1803,VERAPAMIL,25331694,Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model.,"['Gupta S', 'Tyagi S', 'Bishai WR']","['Animals', 'Antitubercular Agents/administration & dosage/pharmacology/*therapeutic use', 'Calcium Channel Blockers/administration & dosage/pharmacology/*therapeutic use', 'Diarylquinolines/administration & dosage/pharmacology/*therapeutic use', 'Disease Models, Animal', 'Drug Synergism', 'Drug Therapy, Combination', 'Female', 'Lung/microbiology', 'Mice', 'Mice, Inbred BALB C', 'Mycobacterium tuberculosis/*drug effects', 'Tuberculosis, Pulmonary/*drug therapy/microbiology', 'Verapamil/administration & dosage/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25331694/
1804,VERAPAMIL,6695685,Accelerated junctional rhythms during oral verapamil therapy.,"['Schwartz JB', 'Jeang M', 'Raizner AE', 'Griffin JC', 'Wyndham CR']","['Administration, Oral', 'Arrhythmias, Cardiac/*chemically induced/diagnosis', 'Electrocardiography', 'Female', 'Heart Block/chemically induced', 'Humans', 'Male', 'Middle Aged', 'Pain/physiopathology', 'Tachycardia/drug therapy', 'Thorax', 'Verapamil/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/6695685/
1805,VERAPAMIL,7004158,The clinical use of intravenous verapamil.,['Schamroth L'],"['Angina Pectoris, Variant/drug therapy', 'Arrhythmias, Cardiac/drug therapy', 'Atrial Fibrillation/drug therapy', 'Atrial Flutter/drug therapy', 'Atrioventricular Node/drug effects', 'Electrophysiology', 'Humans', 'Hypertension/drug therapy', 'Tachycardia/drug therapy', 'Vasodilation', 'Verapamil/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7004158/
1806,VERAPAMIL,31814590,Acute calcium channel blocker withdrawal-induced cardiac arrest.,"['Peeters LEJ', 'den Uil CA', 'Feyz L', 'van den Bemt PMLA', 'Daemen J', 'Versmissen J']","['Angina Pectoris/drug therapy', 'Calcium Channel Blockers/*administration & dosage/*adverse effects', 'Coronary Vasospasm/drug therapy', 'Diagnosis, Differential', 'Female', 'Heart Arrest, Induced/*methods', 'Humans', 'Middle Aged', 'Substance Withdrawal Syndrome/*drug therapy', 'Treatment Outcome', 'Verapamil/*administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/31814590/
1807,VERAPAMIL,16244356,Modified release verapamil induced cardiogenic shock.,"['Nanda U', 'Ashish A', 'Why HJ']","['Anti-Arrhythmia Agents/administration & dosage/*adverse effects', 'Atrial Fibrillation/*drug therapy', 'Delayed-Action Preparations', 'Humans', 'Male', 'Middle Aged', 'Shock, Cardiogenic/*chemically induced', 'Verapamil/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16244356/
1808,VERAPAMIL,26901756,Hyaluronic acid modified mesoporous carbon nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells.,"['Wan L', 'Jiao J', 'Cui Y', 'Guo J', 'Han N', 'Di D', 'Chang D', 'Wang P', 'Jiang T', 'Wang S']","['Animals', 'Cell Survival/drug effects', 'Colorectal Neoplasms/*drug therapy', 'Doxorubicin/*administration & dosage/chemistry/pharmacology', 'Drug Delivery Systems', 'HCT116 Cells', 'Humans', 'Hyaluronan Receptors/*metabolism', 'Hyaluronic Acid/*chemical synthesis', 'Mice', 'Mice, Nude', 'Nanoparticles/*administration & dosage/chemistry', 'Porosity', 'Verapamil/*administration & dosage/chemistry/pharmacology', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/26901756/
1809,VERAPAMIL,6807854,Long-term effect of verapamil in hypertrophic cardiomyopathy.,"['Hasin Y', 'Lewis BS', 'Lewis N', 'Weiss AT', 'Gotsman MS']","['Adult', 'Aged', 'Cardiomyopathy, Hypertrophic/diagnosis/*drug therapy', 'Dose-Response Relationship, Drug', 'Echocardiography', 'Electrocardiography', 'Female', 'Heart Murmurs', 'Heart Rate/drug effects', 'Heart Ventricles/physiopathology', 'Humans', 'Long-Term Care', 'Male', 'Middle Aged', 'Verapamil/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6807854/
1810,VERAPAMIL,1417461,Bioavailability study of two different verapamil formulations.,"['Horne C', 'Stenzhorn G', 'Blume H', 'Knauf H', 'Mutschler E']","['Adult', 'Biological Availability', 'Delayed-Action Preparations', 'Humans', 'Male', 'Tablets', 'Verapamil/administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/1417461/
1811,VERAPAMIL,2009180,Doxorubicin in combination with verapamil in advanced colorectal cancer. A phase II trial.,"['Dalmark M', 'Pals H', 'Johnsen AH']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Colorectal Neoplasms/*drug therapy', 'Doxorubicin/administration & dosage/adverse effects', 'Female', 'Humans', 'Male', 'Middle Aged', 'Verapamil/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2009180/
1812,VERAPAMIL,3065507,Verapamil SR and propranolol LA: a comparison of efficacy and side effects in the treatment of mild to moderate hypertension.,"['Bochsler JA', 'Simmons RL', 'Ward PJ', 'Chester PC', 'Latham AN']","['Adult', 'Aged', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Delayed-Action Preparations', 'Double-Blind Method', 'Female', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Propranolol/*administration & dosage/adverse effects/therapeutic use', 'Random Allocation', 'Verapamil/*administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3065507/
1813,VERAPAMIL,6362951,Clinical pharmacokinetics of verapamil.,"['Hamann SR', 'Blouin RA', 'McAllister RG Jr']","['Adult', 'Aged', 'Digoxin/metabolism', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Humans', 'Intestinal Absorption', 'Kinetics', 'Liver Diseases/metabolism', 'Middle Aged', 'Propranolol/pharmacology', 'Protein Binding', 'Verapamil/administration & dosage/*metabolism/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6362951/
1814,VERAPAMIL,2708046,Prophylactic treatment of cluster headache with verapamil.,"['Gabai IJ', 'Spierings EL']","['Adolescent', 'Adult', 'Aged', 'Cluster Headache/*drug therapy', 'Female', 'Humans', 'Male', 'Middle Aged', 'Vascular Headaches/*drug therapy', 'Verapamil/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2708046/
1815,VERAPAMIL,29962336,Coronary No-Reflow Phenomenon in Clinical Practice.,"['Scarpone M', 'Cenko E', 'Manfrini O']","['Adenosine/administration & dosage/*pharmacology', 'Coronary Vessels/*drug effects/metabolism', 'Humans', 'Microcirculation/*drug effects', 'Nitroprusside/administration & dosage/*pharmacology', 'No-Reflow Phenomenon/*drug therapy/metabolism', 'Verapamil/administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/29962336/
1816,fexofenadine,38470381,Allergic Rhinitis: A Review.,"['Bernstein JA', 'Bernstein JS', 'Makol R', 'Ward S']","['Humans', 'Budesonide/administration & dosage/therapeutic use', 'Cetirizine/therapeutic use', 'Fluticasone/administration & dosage/therapeutic use', 'Histamine H1 Antagonists/administration & dosage/therapeutic use', 'Immunoglobulin E/immunology', 'Mometasone Furoate/administration & dosage/therapeutic use', 'Olopatadine Hydrochloride/administration & dosage/therapeutic use', 'Pruritus/etiology', '*Rhinitis, Allergic/complications/diagnosis/immunology/therapy', 'Rhinorrhea/etiology', 'Sneezing', 'Triamcinolone/administration & dosage/therapeutic use', '*Glucocorticoids/administration & dosage/therapeutic use', 'Rhinitis/drug therapy', '*Histamine Antagonists/administration & dosage/therapeutic use', 'Administration, Intranasal']",https://pubmed.ncbi.nlm.nih.gov/38470381/
1817,fexofenadine,30626077,Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties.,"['Kawauchi H', 'Yanai K', 'Wang DY', 'Itahashi K', 'Okubo K']","['Animals', 'Brain/drug effects/pathology', 'Histamine Antagonists/chemistry/pharmacology/*therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/chemistry/pharmacology/*therapeutic use', 'Humans', 'Receptors, Histamine/metabolism', 'Rhinitis, Allergic/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30626077/
1818,fexofenadine,18336052,"Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.","['Devillier P', 'Roche N', 'Faisy C']","['Cetirizine/adverse effects/pharmacokinetics/*pharmacology', 'Drug Interactions', 'Histamine H1 Antagonists, Non-Sedating/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Loratadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Rhinitis, Allergic, Perennial/drug therapy', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Terfenadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18336052/
1819,fexofenadine,9951950,Second-generation antihistamines: a comparative review.,"['Slater JW', 'Zechnich AD', 'Haxby DG']","['Asthma/drug therapy', 'Dermatitis, Atopic/drug therapy', 'Drug Interactions', '*Histamine H1 Antagonists/pharmacokinetics/pharmacology/therapeutic use', 'Humans', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9951950/
1820,fexofenadine,33030434,Efficacy and Safety of Up-dosing Antihistamines in Chronic Spontaneous Urticaria: A Systematic Review of the Literature.,"['Iriarte Sotes P', 'Armisen M', 'Usero-Barcena T', 'Rodriguez Fernandez A', 'Otero Rivas MM', 'Gonzalez MT', 'Meijide Calderon A', 'Veleiro B']","['Administration, Oral', 'Animals', 'Anti-Allergic Agents/*therapeutic use', 'Chronic Urticaria/*drug therapy', 'Clinical Trials as Topic', 'Drug Dosage Calculations', 'Drug-Related Side Effects and Adverse Reactions', 'Histamine H1 Antagonists, Non-Sedating/*therapeutic use', 'Humans', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33030434/
1821,fexofenadine,9274181,Is my antihistamine safe?,['Ashworth L'],"['Adverse Drug Reaction Reporting Systems', 'Histamine Antagonists/*adverse effects', 'Histamine H1 Antagonists/*adverse effects', 'Humans', 'Patient Selection', 'Terfenadine/*adverse effects/*analogs & derivatives', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/9274181/
1822,fexofenadine,12371532,Urticaria to cetirizine.,"['Tella R', 'Gaig P', 'Bartra J', 'Garcia-Ortega P']","['Adult', 'Cetirizine/*adverse effects', 'Drug Hypersensitivity/etiology', 'Female', 'Histamine H1 Antagonists, Non-Sedating/*adverse effects', 'Humans', 'Urticaria/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/12371532/
1823,fexofenadine,17680969,Formaldehyde-induced urticarial vasculitis.,"['Pellizzari M', 'Marshman G']","['Adult', 'Drug Therapy, Combination', 'Formaldehyde/*adverse effects', 'Glucocorticoids/therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/therapeutic use', 'Humans', 'Male', 'Occupational Exposure/adverse effects', 'Prednisolone/therapeutic use', 'Serum Sickness/chemically induced', 'Students, Medical', 'Terfenadine/analogs & derivatives/therapeutic use', 'Urticaria/*chemically induced/drug therapy', 'Vasculitis, Leukocytoclastic, Cutaneous/*chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17680969/
1824,fexofenadine,21370726,Urticaria due to antihistamines.,"['Sanchez Morillas L', 'Rojas Perez-Ezquerra P', 'Reano Martos M', 'Sanz ML', 'Laguna Martinez JJ']","['Administration, Oral', 'Butyrophenones/administration & dosage/*adverse effects', 'Diagnosis, Differential', 'Drug Hypersensitivity/diagnosis/*etiology', 'Female', 'Histamine H1 Antagonists/administration & dosage/*adverse effects', 'Histamine H1 Antagonists, Non-Sedating/administration & dosage/adverse effects', 'Humans', 'Middle Aged', 'Piperidines/administration & dosage/*adverse effects', 'Terfenadine/administration & dosage/adverse effects/*analogs & derivatives', 'Urticaria/diagnosis/*etiology']",https://pubmed.ncbi.nlm.nih.gov/21370726/
1825,fexofenadine,17112309,Grapefruit juice and drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugs.,['Bressler R'],"['Aged', 'Beverages/*adverse effects', 'Citrus paradisi/*adverse effects/metabolism', 'Cytochrome P-450 CYP3A', 'Cytochrome P-450 Enzyme System/drug effects/metabolism', 'Drug-Related Side Effects and Adverse Reactions/etiology', '*Food-Drug Interactions', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/17112309/
1826,fexofenadine,28066101,"Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial.","['Mahatme MS', 'Dakhale GN', 'Tadke K', 'Hiware SK', 'Dudhgaonkar SD', 'Wankhede S']","['Acetates/*administration & dosage/adverse effects/economics', 'Anti-Allergic Agents/administration & dosage/adverse effects/economics', 'Anti-Asthmatic Agents/administration & dosage/adverse effects/economics', 'Cetirizine/*administration & dosage/adverse effects/economics', 'Cost-Benefit Analysis/*methods', 'Cyclopropanes', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Humans', 'Male', 'Prospective Studies', 'Quinolines/*administration & dosage/adverse effects/economics', 'Rhinitis, Allergic/*diagnosis/*drug therapy/economics', 'Sulfides', 'Terfenadine/administration & dosage/adverse effects/*analogs & derivatives/economics', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28066101/
1827,fexofenadine,9506246,Fexofenadine.,"['Markham A', 'Wagstaff AJ']","['Animals', 'Histamine Antagonists/pharmacokinetics/*therapeutic use', 'Humans', 'Rhinitis, Allergic, Seasonal/*drug therapy', 'Terfenadine/*analogs & derivatives/pharmacokinetics/therapeutic use', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9506246/
1828,fexofenadine,11964751,Are antihistamines useful in managing asthma?,['Wilson AM'],"['Acetates/agonists/metabolism', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use', 'Asthma/*drug therapy/prevention & control', 'Bronchospirometry/methods', 'Cetirizine/pharmacology', 'Cyclopropanes', 'Drug Therapy, Combination', 'Histamine H1 Antagonists/metabolism/pharmacology/*therapeutic use', 'Humans', 'Loratadine/agonists/analogs & derivatives/*metabolism/pharmacology', 'Mannitol/administration & dosage/*metabolism', 'Quinolines/agonists/metabolism', 'Rhinitis/metabolism', 'Sulfides', 'Terfenadine/*analogs & derivatives/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/11964751/
1829,fexofenadine,20480793,Second-generation antihistamines for the treatment of chronic idiopathic urticaria.,['Belsito DV'],"['Brain/metabolism', 'Chronic Disease', 'Histamine H1 Antagonists/adverse effects/*therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/*therapeutic use', 'Humans', 'Quality of Life', 'Receptors, Histamine H1/drug effects/metabolism', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20480793/
1830,fexofenadine,21345359,Novel strategies for microdose studies using non-radiolabeled compounds.,"['Maeda K', 'Sugiyama Y']","['Chromatography, Liquid/methods', 'Clinical Trials, Phase I as Topic/*methods', 'Dose-Response Relationship, Drug', '*Drug Design', 'Drug Interactions', 'Humans', 'Pharmaceutical Preparations/*administration & dosage/metabolism', 'Pharmacokinetics', 'Tandem Mass Spectrometry/methods']",https://pubmed.ncbi.nlm.nih.gov/21345359/
1831,fexofenadine,12113226,H1-antihistamines in children.,['Simons FE'],"['Asthma/drug therapy', 'Child', 'Conjunctivitis, Allergic/drug therapy', 'Dermatitis, Atopic/drug therapy', 'Heart/drug effects', 'Histamine H1 Antagonists/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Otitis Media/drug therapy', 'Respiratory Tract Infections/drug therapy', 'Rhinitis, Allergic, Perennial/drug therapy', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/12113226/
1832,fexofenadine,16209158,Review of H1 antihistamines in the treatment of chronic idiopathic urticaria.,['Monroe E'],"['Anti-Inflammatory Agents/therapeutic use', 'Chronic Disease', 'Histamine H1 Antagonists/adverse effects/*therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/therapeutic use', 'Humans', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16209158/
1833,fexofenadine,25592003,Comparison of the efficacy of olopatadine and fexofenadine in chronic idiopathic urticaria patients: a crossover study.,"['Tanizaki H', 'Yamamoto Y', 'Nakamizo S', 'Otsuka A', 'Miyachi Y', 'Kabashima K']","['Adult', 'Anti-Allergic Agents/*therapeutic use', 'Chronic Disease', 'Cross-Over Studies', 'Dibenzoxepins/*therapeutic use', 'Female', 'Histamine H1 Antagonists, Non-Sedating/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Olopatadine Hydrochloride', 'Terfenadine/*analogs & derivatives/therapeutic use', 'Treatment Outcome', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/25592003/
1834,fexofenadine,22267446,Fluorodeoxyglucose-induced allergic reaction: a case report.,"['Codreanu I', 'Dasanu CA', 'Weinstein GS', 'Divgi C']","['Anti-Allergic Agents/therapeutic use', 'Anti-Inflammatory Agents/therapeutic use', 'Carcinoma, Squamous Cell/*diagnostic imaging/therapy', 'Diphenhydramine/therapeutic use', 'Drug Hypersensitivity/drug therapy/*prevention & control', 'Fluorodeoxyglucose F18/*adverse effects', 'Head and Neck Neoplasms/*diagnostic imaging/therapy', 'Humans', 'Hypopharyngeal Neoplasms/*diagnostic imaging/therapy', 'Male', 'Middle Aged', 'Multimodal Imaging', 'Positron-Emission Tomography', 'Prednisone/therapeutic use', 'Pyriform Sinus/*diagnostic imaging', 'Radiopharmaceuticals/*adverse effects', 'Secondary Prevention', 'Squamous Cell Carcinoma of Head and Neck', 'Terfenadine/analogs & derivatives/therapeutic use', 'Tomography, X-Ray Computed', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22267446/
1835,fexofenadine,27197662,The Pharmacokinetic Exposure to Fexofenadine is Volume-Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice.,"['Luo J', 'Imai H', 'Ohyama T', 'Hashimoto S', 'Hasunuma T', 'Inoue Y', 'Kotegawa T', 'Ohashi K', 'Uemura N']","['Administration, Oral', '*Beverages', 'Female', '*Healthy Volunteers', 'Humans', 'Male', '*Malus', 'Terfenadine/administration & dosage/*analogs & derivatives/blood/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/27197662/
1836,cetirizine,34474941,Unintentional cetirizine overdose causing anticholinergic syndrome.,"['Renko A', 'Cortese T', 'Karagiannis P', 'Salzman M']","['Anti-Allergic Agents/administration & dosage/*poisoning', 'Anticholinergic Syndrome/*etiology', 'Cetirizine/administration & dosage/*poisoning', 'Child', 'Drug Overdose/complications', 'Humans', 'Male']",https://pubmed.ncbi.nlm.nih.gov/34474941/
1837,cetirizine,18336052,"Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.","['Devillier P', 'Roche N', 'Faisy C']","['Cetirizine/adverse effects/pharmacokinetics/*pharmacology', 'Drug Interactions', 'Histamine H1 Antagonists, Non-Sedating/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Loratadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Rhinitis, Allergic, Perennial/drug therapy', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Terfenadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18336052/
1838,cetirizine,12371532,Urticaria to cetirizine.,"['Tella R', 'Gaig P', 'Bartra J', 'Garcia-Ortega P']","['Adult', 'Cetirizine/*adverse effects', 'Drug Hypersensitivity/etiology', 'Female', 'Histamine H1 Antagonists, Non-Sedating/*adverse effects', 'Humans', 'Urticaria/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/12371532/
1839,cetirizine,33909554,"Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study.","['Hossein Mostafa D', 'Samadi A', 'Niknam S', 'Nasrollahi SA', 'Guishard A', 'Firooz A']","['Administration, Topical', 'Adult', 'Alopecia/*drug therapy', 'Cetirizine/*therapeutic use', 'Histamine Antagonists/*therapeutic use', 'Humans', 'Male', 'Minoxidil/adverse effects/*therapeutic use', 'Single-Blind Method', 'Solutions', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33909554/
1840,cetirizine,17017922,Levocetirizine: an update.,['Walsh GM'],"['Anti-Inflammatory Agents/pharmacology/therapeutic use', 'Cetirizine/*pharmacology/therapeutic use', 'Histamine H1 Antagonists/pharmacology/therapeutic use', 'Humans', 'Piperazines/*pharmacology/therapeutic use', 'Rhinitis/drug therapy', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17017922/
1841,cetirizine,25750443,Urticaria pigmentosa-like disease in a dog.,"['Pariser MS', 'Gram DW']","['Animals', 'Anti-Allergic Agents/administration & dosage/therapeutic use', 'Anti-Ulcer Agents/administration & dosage/therapeutic use', 'Cetirizine/administration & dosage/therapeutic use', 'Diphenhydramine/administration & dosage/therapeutic use', 'Dog Diseases/diagnosis/*pathology', 'Dogs', 'Famotidine/administration & dosage/therapeutic use', 'Male', 'Urticaria Pigmentosa/diagnosis/drug therapy/pathology/*veterinary']",https://pubmed.ncbi.nlm.nih.gov/25750443/
1842,cetirizine,32558665,The allergic eye: recommendations about pharmacotherapy and recent therapeutic agents.,"['Kimchi N', 'Bielory L']","['Administration, Ophthalmic', 'Anti-Allergic Agents/*administration & dosage', 'Cetirizine/therapeutic use', 'Conjunctivitis, Allergic/*drug therapy/immunology', 'Drug Delivery Systems/methods/standards', 'Drug Repositioning', 'Histamine Antagonists/*administration & dosage', 'Humans', 'Immunotherapy/*methods/standards', 'Ophthalmic Solutions/*administration & dosage', 'Practice Guidelines as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32558665/
1843,cetirizine,9188955,Antihistamines in the treatment of asthma.,"['Malick A', 'Grant JA']","['Asthma/*drug therapy/immunology', 'Cetirizine/therapeutic use', 'Clinical Trials as Topic', 'Histamine/immunology', 'Histamine H1 Antagonists/*therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/9188955/
1844,cetirizine,11772135,Cetirizine/pseudoephedrine.,"['Wellington K', 'Jarvis B']","['Administration, Oral', 'Adrenergic Agents/adverse effects/pharmacokinetics/*pharmacology', 'Anxiety/chemically induced', 'Asthenia/chemically induced', 'Biological Availability', 'Cetirizine/adverse effects/pharmacokinetics/*pharmacology', 'Chemistry, Pharmaceutical', 'Drug Administration Schedule', 'Ephedrine/adverse effects/pharmacokinetics/*pharmacology', 'Headache/chemically induced', 'Histamine H1 Antagonists/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Nasal Cavity', 'Pruritus/drug therapy', 'Randomized Controlled Trials as Topic', 'Rhinitis, Allergic, Seasonal/*drug therapy/pathology', 'Sleep Initiation and Maintenance Disorders/chemically induced', 'Tablets', 'Treatment Outcome', 'Xerostomia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/11772135/
1845,cetirizine,19076532,Pharmacotherapy of allergic rhinitis: a pharmaco-economic approach.,"['Simoens S', 'Laekeman G']","['Cetirizine/economics/therapeutic use', 'Costs and Cost Analysis', 'Economics, Pharmaceutical', 'Humans', 'Rhinitis, Allergic, Perennial/*drug therapy/*economics']",https://pubmed.ncbi.nlm.nih.gov/19076532/
1846,cetirizine,29182459,Recurrent pityriasis rosea: A case report.,"['Li A', 'Li P', 'Li Y', 'Li W']","['Adult', 'Cetirizine/therapeutic use', 'Humans', 'Influenza A Virus, H1N1 Subtype/immunology', 'Influenza Vaccines/*adverse effects/immunology', 'Influenza, Human/immunology', 'Male', 'Pityriasis Rosea/*chemically induced/drug therapy/*immunology', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/29182459/
1847,cetirizine,10582736,Therapeutic index of H1-antihistamines: example of cetirizine.,['Rihoux JP'],"['Cetirizine/adverse effects/metabolism/*therapeutic use', 'Histamine H1 Antagonists/adverse effects/metabolism/*therapeutic use', 'Humans', 'Hypersensitivity, Immediate/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/10582736/
1848,cetirizine,36571611,"Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study.","['Bassiouny EA', 'El-Samanoudy SI', 'Abbassi MM', 'Nada HR', 'Farid SF']","['Female', 'Humans', '*Minoxidil', 'Cetirizine/pharmacology/therapeutic use', 'Administration, Topical', 'Alopecia/drug therapy', 'Hair', '*Drug-Related Side Effects and Adverse Reactions']",https://pubmed.ncbi.nlm.nih.gov/36571611/
1849,cetirizine,34818169,Urticaria and edema in a 2-year-old boy.,"['Cook JS', 'Angles A', 'Morley E']","['Amoxicillin/*adverse effects', 'Anti-Bacterial Agents/adverse effects', 'Anti-Inflammatory Agents/therapeutic use', 'Cetirizine/therapeutic use', 'Child, Preschool', 'Diagnosis, Differential', 'Drug Eruptions/*diagnosis/*drug therapy', 'Edema', 'Histamine H1 Antagonists/therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/therapeutic use', 'Humans', 'Hydroxyzine/therapeutic use', 'Male', 'Otitis Media/*drug therapy', 'Triamcinolone/therapeutic use', 'Urticaria/*diagnosis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34818169/
1850,cetirizine,22334929,[The approaches to diagnostics and therapy of allergic rhinitis].,['Zaitseva OV'],"['Administration, Oral', 'Adrenal Cortex Hormones/therapeutic use', '*Cetirizine/administration & dosage/adverse effects', 'Combined Modality Therapy', '*Histamine H1 Antagonists, Non-Sedating/administration & dosage/adverse effects', 'Humans', 'Immunotherapy', 'Rhinitis, Allergic, Perennial/classification/*diagnosis/*drug therapy', 'Rhinitis, Allergic, Seasonal/classification/*diagnosis/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22334929/
1851,cetirizine,29953057,[Allergic rhinitis: the modern aspects of therapy].,"['Yanov YK', 'Ryazantsev SV', 'Artyushkin SA', 'Fanta IV', 'Pavlova SS']","['*Cetirizine/administration & dosage/adverse effects', 'Histamine H1 Antagonists, Non-Sedating/administration & dosage/adverse effects', 'Humans', 'Immunologic Tests/methods', '*Nasal Obstruction/physiopathology/therapy', 'Patient Care Management/methods', '*Rhinitis, Allergic/classification/epidemiology/immunology/therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29953057/
1852,cetirizine,8833171,Aquagenic urticaria.,['Medeiros M Jr'],"['Adult', 'Cetirizine/adverse effects/therapeutic use', 'Diagnosis, Differential', 'Histamine H1 Antagonists/adverse effects/therapeutic use', 'Humans', 'Hydroxyzine/therapeutic use', 'Male', 'Urticaria/*diagnosis/drug therapy/*etiology', 'Water/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/8833171/
1853,cetirizine,30811151,Vesiculobullous Darier Disease Symptomatically Responsive to Cetirizine.,"['Wang JF', 'Lederhandler MH', 'Brinster N', 'Soter NA']","['Anti-Allergic Agents/pharmacology/*therapeutic use', 'Cetirizine/pharmacology/*therapeutic use', 'Darier Disease/complications/diagnosis/*drug therapy', 'Dose-Response Relationship, Drug', 'Eosinophils/drug effects', 'Female', 'Humans', 'Middle Aged', 'Skin Diseases, Vesiculobullous/complications/diagnosis/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30811151/
1854,cetirizine,28081586,A case of levocetirizine-induced liver injury.,"['Jung MC', 'Kim JK', 'Cho JY', 'Song JW', 'Lee B', 'Park JW', 'Seo J', 'Kim SE']","['Cetirizine/*adverse effects/therapeutic use', 'Chemical and Drug Induced Liver Injury/*diagnosis/pathology', 'Histamine H1 Antagonists, Non-Sedating/*adverse effects/therapeutic use', 'Humans', 'Hypersensitivity/drug therapy', 'Jaundice/etiology', 'Liver/pathology', 'Male', 'Middle Aged', 'Pruritus/etiology']",https://pubmed.ncbi.nlm.nih.gov/28081586/
1855,cetirizine,37928871,Efficacy of levocetirizine in isolated rat tracheal smooth muscle.,"['Chou YL', 'Wang YT', 'Cheng LH', 'Liu SC', 'Wang HW']","['Rats', 'Humans', 'Animals', 'Methacholine Chloride/pharmacology', '*Menthol/pharmacology', '*Cetirizine/pharmacology/therapeutic use', 'Muscle, Smooth/physiology', 'Muscle Contraction', 'Trachea/physiology']",https://pubmed.ncbi.nlm.nih.gov/37928871/
1856,clonazepam,18625105,Burning mouth syndrome.,"['Speciali JG', 'Stuginski-Barbosa J']","['Administration, Oral', 'Burning Mouth Syndrome/*diagnosis/epidemiology/*therapy', 'Clonazepam/administration & dosage', 'Dopamine Agonists/administration & dosage', 'Female', 'Humans', 'Male', 'Mouth Mucosa/drug effects/pathology', 'Postmenopause/drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/18625105/
1857,clonazepam,561907,Spinal myoclonus.,"['Hoehn MM', 'Cherington M']","['Clonazepam/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Myoclonus/drug therapy/*etiology', 'Spinal Cord Diseases/*complications', 'Tetrabenazine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/561907/
1858,clonazepam,4082246,Phenytoin/clonazepam interaction.,"['Saavedra IN', 'Aguilera LI', 'Faure E', 'Galdames DG']","['Adult', 'Benzodiazepinones/*pharmacology', 'Clonazepam/administration & dosage/blood/*pharmacology/therapeutic use', 'Drug Interactions', 'Drug Therapy, Combination', 'Epilepsy/blood/drug therapy', 'Humans', 'Male', 'Phenytoin/administration & dosage/*blood/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/4082246/
1859,clonazepam,35971024,"Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability.","['Kienitz R', 'Kay L', 'Beuchat I', 'Gelhard S', 'von Brauchitsch S', 'Mann C', 'Lucaciu A', 'Schafer JH', 'Siebenbrodt K', 'Zollner JP', 'Schubert-Bast S', 'Rosenow F', 'Strzelczyk A', 'Willems LM']","['Anticonvulsants/adverse effects', '*Benzodiazepines/adverse effects', 'Clonazepam/therapeutic use', 'Diazepam/therapeutic use', 'Humans', 'Lorazepam/therapeutic use', 'Midazolam', 'Seizures/drug therapy', '*Status Epilepticus/drug therapy', 'gamma-Aminobutyric Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35971024/
1860,clonazepam,20473065,Tapering clonazepam in patients with panic disorder after at least 3 years of treatment.,"['Nardi AE', 'Freire RC', 'Valenca AM', 'Amrein R', 'de Cerqueira AC', 'Lopes FL', 'Nascimento I', 'Mezzasalma MA', 'Veras AB', 'Sardinha A', 'de Carvalho MR', 'da Costa RT', 'Levitan MN', 'de-Melo-Neto VL', 'Soares-Filho GL', 'Versiani M']","['Adolescent', 'Adult', 'Aged', 'Clonazepam/*administration & dosage/adverse effects', 'Female', 'Follow-Up Studies', 'Humans', 'Male', 'Middle Aged', 'Panic Disorder/*drug therapy/*psychology', 'Prospective Studies', 'Psychiatric Status Rating Scales/standards', 'Substance Withdrawal Syndrome/etiology/*prevention & control/*psychology', 'Time Factors', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/20473065/
1861,clonazepam,1408017,Drugs used in the management of trigeminal neuralgia.,"['Zakrzewska JM', 'Patsalos PN']","['Anticonvulsants/*administration & dosage/*pharmacokinetics', 'Baclofen/*administration & dosage', 'Carbamazepine/administration & dosage/analogs & derivatives/pharmacokinetics', 'Clonazepam/administration & dosage/pharmacokinetics', 'Humans', 'Oxcarbazepine', 'Phenytoin/administration & dosage/pharmacokinetics', 'Trigeminal Neuralgia/*drug therapy', 'Valproic Acid/administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/1408017/
1862,clonazepam,1422166,Anticonvulsants in the treatment of bipolar disorder.,"['Keck PE Jr', 'McElroy SL', 'Nemeroff CB']","['Anticonvulsants/adverse effects/*therapeutic use', 'Bipolar Disorder/*drug therapy/psychology', 'Carbamazepine/adverse effects/therapeutic use', 'Clonazepam/adverse effects/therapeutic use', 'Drug Therapy, Combination', 'Electroconvulsive Therapy', 'Humans', 'Psychiatric Status Rating Scales', 'Recurrence', 'Valproic Acid/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1422166/
1863,clonazepam,14700107,Clonazepam associated retinopathy.,"['Gatzonis S', 'Karadimas P', 'Gatzonis S', 'Bouzas EA']","['Adult', 'Anticonvulsants/administration & dosage/*adverse effects', 'Clonazepam/administration & dosage/*adverse effects', 'Female', 'Fluorescein Angiography', 'Fundus Oculi', 'Humans', 'Retinal Diseases/*chemically induced/diagnosis/therapy', 'Vision Disorders/chemically induced/diagnosis/therapy', 'Visual Acuity']",https://pubmed.ncbi.nlm.nih.gov/14700107/
1864,clonazepam,1469409,"""Isolated"" postinfectious myoclonus.","['Bhatia K', 'Thompson PD', 'Marsden CD']","['Adolescent', 'Clonazepam/therapeutic use', 'Evoked Potentials, Somatosensory', 'Female', 'Humans', 'Infections/*complications', 'Myoclonus/diagnosis/drug therapy/*etiology', 'Prognosis', 'Valproic Acid/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1469409/
1865,clonazepam,1486834,Antiepileptic drugs and their psychotropic effects.,['Fenwick PB'],"['Affect/drug effects', 'Anticonvulsants/*pharmacology/therapeutic use', 'Brain/drug effects/growth & development', 'Carbamazepine/therapeutic use', 'Clonazepam/therapeutic use', 'Epilepsy/drug therapy', 'Humans', 'Mental Disorders/drug therapy', '*Psychotropic Drugs', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1486834/
1866,clonazepam,121641,The pharmacological treatment of epilepsy.,['Aucamp AK'],"['Anticonvulsants/adverse effects/*therapeutic use', 'Carbamazepine/therapeutic use', 'Child, Preschool', 'Clonazepam/therapeutic use', 'Drug Therapy, Combination', 'Epilepsies, Myoclonic/drug therapy', 'Epilepsy/classification/*drug therapy/pathology', 'Epilepsy, Absence/drug therapy', 'Epilepsy, Temporal Lobe/drug therapy', 'Ethosuximide/therapeutic use', 'Female', 'Humans', 'Infant', 'Phenobarbital/therapeutic use', 'Phenytoin/therapeutic use', 'Pregnancy', 'Primidone/therapeutic use', 'Spasms, Infantile/drug therapy', 'Status Epilepticus/drug therapy', 'Thyroid Gland/drug effects']",https://pubmed.ncbi.nlm.nih.gov/121641/
1867,clonazepam,34536833,Ultrasound-assisted electromembrane extraction of clonazepam from plasma and determination using capillary electrophoresis.,"['Seyfinejad B', 'Ozkan SA', 'Jouyban A']","['Clonazepam/*blood/chemistry/isolation & purification/pharmacokinetics', 'Electrophoresis, Capillary/*methods', 'Humans', 'Limit of Detection', 'Linear Models', 'Reproducibility of Results', 'Research Design', 'Sonication']",https://pubmed.ncbi.nlm.nih.gov/34536833/
1868,clonazepam,1360697,The treatment of the restless leg syndrome with or without periodic leg movements in sleep.,"['Montplaisir J', 'Lapierre O', 'Warnes H', 'Pelletier G']","['Anti-Anxiety Agents/adverse effects/therapeutic use', 'Clonazepam/adverse effects/therapeutic use', 'Dextropropoxyphene/adverse effects/therapeutic use', 'Dopamine Agents/adverse effects/therapeutic use', 'Humans', 'Levodopa/adverse effects/therapeutic use', 'Narcotics/adverse effects/therapeutic use', 'Polysomnography', 'Restless Legs Syndrome/*drug therapy/physiopathology', 'Sleep Stages/drug effects/physiology', 'Sleep Wake Disorders/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/1360697/
1869,clonazepam,2889724,Clonazepam: new uses and potential problems.,"['Cohen LS', 'Rosenbaum JF']","['Adult', 'Antipsychotic Agents/therapeutic use', 'Clonazepam/adverse effects/*therapeutic use', 'Depressive Disorder/chemically induced', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Psychotic Disorders/drug therapy', 'Sexual Dysfunctions, Psychological/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/2889724/
1870,clonazepam,21418666,Burning mouth syndrome.,"['Buchanan JA', 'Zakrzewska JM']","['Antidepressive Agents/therapeutic use', 'Benzodiazepines/therapeutic use', '*Burning Mouth Syndrome/drug therapy', '*Clonazepam/therapeutic use', 'Cognitive Behavioral Therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/21418666/
1871,clonazepam,27449005,Pramipexole in the treatment of REM sleep behaviour disorder: A critical review.,"['Tan SM', 'Wan YM']","['Benzothiazoles/pharmacology/*therapeutic use', 'Clonazepam/pharmacology/therapeutic use', 'Dopamine Agonists/pharmacology/*therapeutic use', 'Humans', 'Observational Studies as Topic/methods', 'Polysomnography/drug effects', 'Pramipexole', 'REM Sleep Behavior Disorder/diagnosis/*drug therapy/physiopathology', 'Sleep, REM/drug effects/physiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27449005/
1872,clonazepam,19450321,Burning mouth syndrome.,"['Buchanan J', 'Zakrzewska J']","['Antidepressive Agents/therapeutic use', 'Benzodiazepines/therapeutic use', '*Burning Mouth Syndrome/drug therapy', '*Clonazepam/therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/19450321/
1873,clonazepam,37287278,Post-hypoxic myoclonus; what we know and gaps in knowledge.,['Ahmed HS'],"['Humans', '*Myoclonus/diagnosis/drug therapy/etiology', 'Hypoxia/complications/therapy', 'Clonazepam/therapeutic use', '*Cardiopulmonary Resuscitation/adverse effects', 'Valproic Acid/therapeutic use', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/37287278/
1874,clonazepam,28138205,Opium Withdrawal Delirium: Two Case Reports.,"['Sharma RC', 'Kumar R', 'Sharma DD', 'Kanwar P']","['Adult', 'Analgesics, Opioid/therapeutic use', 'Anticonvulsants/therapeutic use', 'Clonazepam/therapeutic use', 'Delirium/*etiology', 'Humans', 'Male', 'Middle Aged', 'Opioid-Related Disorders/*complications', 'Opium/*adverse effects', 'Opium Dependence/drug therapy', 'Substance Withdrawal Syndrome/*complications/drug therapy/etiology', 'Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28138205/
1875,clonazepam,3102417,Antiepileptic drugs in adolescents.,['Shinnar S'],"['Adaptation, Psychological', 'Adolescent', 'Adult', 'Anticonvulsants/administration & dosage/adverse effects/*therapeutic use', 'Carbamazepine/therapeutic use', 'Child', 'Clonazepam/therapeutic use', 'Drug Interactions', 'Epilepsy/*drug therapy', 'Ethosuximide/therapeutic use', 'Female', 'Humans', 'Phenobarbital/therapeutic use', 'Phenytoin/therapeutic use', 'Pregnancy/drug effects', 'Primidone/therapeutic use', 'Sports', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3102417/
1876,carisoprodol,15276195,Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.,"['Chou R', 'Peterson K', 'Helfand M']","['Clinical Trials as Topic', 'Comorbidity', 'Evidence-Based Medicine/methods', 'Humans', 'Motor Neuron Disease/classification/*drug therapy/*epidemiology', 'Muscle Spasticity/classification/*drug therapy/*epidemiology', 'Musculoskeletal Diseases/classification/drug therapy/epidemiology', 'Neuromuscular Agents/*therapeutic use', 'Peripheral Nervous System Diseases/classification/*drug therapy/*epidemiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15276195/
1877,carisoprodol,35754070,Pharmacotherapy for Spine-Related Pain in Older Adults.,"['Fu JL', 'Perloff MD']","['Acetaminophen/therapeutic use', 'Aged', 'Analgesics, Opioid/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', '*Neuralgia/drug therapy', 'Pregabalin/adverse effects', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35754070/
1878,carisoprodol,8322081,Carisoprodol (Soma): a new and cautious perspective on an old agent.,"['Littrell RA', 'Hayes LR', 'Stillner V']","['Carisoprodol/*adverse effects/pharmacokinetics', 'Drug and Narcotic Control', 'Humans', 'Muscle Relaxants, Central/therapeutic use', 'Substance-Related Disorders/*etiology']",https://pubmed.ncbi.nlm.nih.gov/8322081/
1879,carisoprodol,22939305,Pharmacogenomics and the future of toxicology testing.,"['Agrawal YP', 'Rennert H']","['Autopsy', 'Databases, Genetic', 'Drug Labeling', 'Humans', 'Pharmaceutical Preparations/analysis/metabolism', 'Pharmacogenetics/*methods', 'Toxicity Tests/*methods']",https://pubmed.ncbi.nlm.nih.gov/22939305/
1880,carisoprodol,2671968,Is this really a muscle cramp?,['Eaton JM'],"['Carisoprodol/therapeutic use', 'Electromyography', 'Humans', '*Muscle Cramp/diagnosis/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/2671968/
1881,carisoprodol,15542749,Recent trends of drug abuse and drug-associated deaths in Korea.,"['Chung H', 'Park M', 'Hahn E', 'Choi H', 'Choi H', 'Lim M']","['Drug Overdose', 'Humans', '*Illicit Drugs', 'Korea/epidemiology', 'Poison Control Centers/statistics & numerical data/trends', 'Substance-Related Disorders/*mortality']",https://pubmed.ncbi.nlm.nih.gov/15542749/
1882,carisoprodol,6999895,Centrally acting oral skeletal muscle relaxants.,['Elenbaas JK'],"['Analgesics/therapeutic use', 'Drug Combinations', 'Drug Evaluation', 'Humans', 'Hypnotics and Sedatives/therapeutic use', 'Kinetics', 'Muscle Relaxants, Central/metabolism/pharmacology/*therapeutic use', 'Placebos']",https://pubmed.ncbi.nlm.nih.gov/6999895/
1883,carisoprodol,27550152,The Pharmacology and Toxicology of the 'Holy Trinity'.,"['Horsfall JT', 'Sprague JE']","['Analgesics, Opioid/administration & dosage/*adverse effects', 'Animals', 'Benzodiazepines/administration & dosage/*adverse effects', 'Carisoprodol/administration & dosage/*adverse effects', 'Contraindications', 'Dopamine/metabolism', 'Drug Dosage Calculations', 'Drug Synergism', 'Drug Therapy, Combination', 'Euphoria/*drug effects', 'GABA Modulators/administration & dosage/*adverse effects', 'Humans', 'Neuromuscular Agents/administration & dosage/*adverse effects', 'Nucleus Accumbens/*drug effects/metabolism/physiopathology', 'Opioid-Related Disorders/metabolism/physiopathology/psychology', 'Practice Guidelines as Topic', 'Respiration/drug effects', 'Respiratory Insufficiency/*chemically induced/metabolism/physiopathology', 'Risk Assessment', 'Signal Transduction/drug effects', 'gamma-Aminobutyric Acid/metabolism']",https://pubmed.ncbi.nlm.nih.gov/27550152/
1884,carisoprodol,25018153,Somadril and edgework in South Sulawesi.,"['Hardon AP', 'Ihsan A']","['Carisoprodol/*administration & dosage', 'Developing Countries', 'Female', 'Humans', 'Indonesia', 'Male', 'Muscle Relaxants, Central/*administration & dosage', 'Self Medication', '*Sex Workers', 'Sexual Behavior/*psychology', 'Substance-Related Disorders/*psychology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25018153/
1885,carisoprodol,8635759,Acute overdose of zolpidem.,"['Winek CL', 'Wahba WW', 'Janssen JK', 'Rozin L', 'Rafizadeh V']","['Aged', 'Drug Overdose', 'Fatal Outcome', 'Female', 'Humans', 'Hypnotics and Sedatives/blood/*poisoning', 'Pyridines/blood/*poisoning', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/8635759/
1886,carisoprodol,22687764,Postmortem drug concentration intervals for the non-intoxicated state - A review.,['Linnet K'],"['Dose-Response Relationship, Drug', 'Drug Stability', 'Drug Tolerance', '*Forensic Toxicology', 'Humans', 'Pharmaceutical Preparations/*blood', 'Pharmacokinetics', 'Postmortem Changes', 'Reference Values']",https://pubmed.ncbi.nlm.nih.gov/22687764/
1887,carisoprodol,1985650,Carbidopa-levodopa overdose.,['Sporer KA'],"['Acetaminophen/poisoning', 'Carbidopa/*poisoning', 'Carisoprodol/poisoning', 'Female', 'Humans', 'Hydrocodone/poisoning', 'Ibuprofen/poisoning', 'Levodopa/*poisoning', 'Middle Aged', 'Poisoning/diagnosis/therapy']",https://pubmed.ncbi.nlm.nih.gov/1985650/
1888,carisoprodol,2327059,Skeletal muscle relaxant ingestion.,"['Lebby TI', 'Dugger K', 'Lipscomb JW', 'Leikin JB']","['Adolescent', 'Adult', 'Child', 'Child, Preschool', 'Drug Overdose', 'Humans', 'Infant', 'Infant, Newborn', 'Middle Aged', 'Muscle Relaxants, Central/*adverse effects', 'Muscles/*drug effects', '*Poison Control Centers', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/2327059/
1889,carisoprodol,4894737,Codeine and its alternates for pain and cough relief. 2. Alternates for pain relief.,"['Eddy NB', 'Friebel H', 'Hahn KJ', 'Halbach H']","['Amides/therapeutic use', 'Analgesics/therapeutic use', 'Animals', 'Antitussive Agents/therapeutic use', 'Azepines/therapeutic use', 'Carisoprodol/therapeutic use', 'Cats', 'Chickens', 'Codeine/*therapeutic use', 'Cough/*drug therapy', 'Cyclazocine/therapeutic use', 'Dextropropoxyphene/therapeutic use', 'Diphenylacetic Acids/therapeutic use', 'Dogs', 'Ducks', 'Guinea Pigs', 'Humans', 'Indenes/therapeutic use', 'Indoles/therapeutic use', 'Isoquinolines/therapeutic use', 'Mice', 'Morphinans/therapeutic use', 'Nalorphine/therapeutic use', 'Narcotic Antagonists/therapeutic use', 'Pain/*drug therapy', 'Pentazocine/therapeutic use', 'Phenethylamines/therapeutic use', 'Pyrrolidines/therapeutic use', 'Rats', 'Substance-Related Disorders', 'Thalidomide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/4894737/
1890,carisoprodol,29457627,Combination pharmacotherapy for the treatment of fibromyalgia in adults.,"['Thorpe J', 'Shum B', 'Moore RA', 'Wiffen PJ', 'Gilron I']","['5-Hydroxytryptophan/therapeutic use', 'Acetaminophen/therapeutic use', 'Adult', 'Amitriptyline/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Antidepressive Agents/therapeutic use', 'Benzodiazepines/therapeutic use', 'Carisoprodol/therapeutic use', 'Drug Therapy, Combination/methods', 'Duloxetine Hydrochloride/therapeutic use', 'Fibromyalgia/*drug therapy', 'Fluoxetine/therapeutic use', 'Humans', 'Magnesium/therapeutic use', 'Malates/therapeutic use', 'Melatonin/therapeutic use', 'Monoamine Oxidase Inhibitors/therapeutic use', 'Muscle Relaxants, Central/therapeutic use', 'Pregabalin/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/29457627/
1891,carisoprodol,1097611,Carisoprodol in the treatment of myofascial pain-dysfunction syndrome.,"['Gallardo F', 'Molgo J', 'Miyazaki C', 'Rossi E']","['Adolescent', 'Adult', 'Aged', 'Carisoprodol/*therapeutic use', 'Clinical Trials as Topic', '*Facial Muscles', 'Female', 'Humans', 'Male', '*Masticatory Muscles', 'Middle Aged', 'Muscular Diseases/*drug therapy', 'Pain/*drug therapy', 'Placebos/therapeutic use', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/1097611/
1892,carisoprodol,9439144,Carisoprodol: a drug of continuing abuse.,"['Reeves RR', 'Pinkofsky HB', 'Carter OS']","['Adult', 'Carisoprodol/*adverse effects', 'Drug Prescriptions', 'Drug and Narcotic Control', 'Female', 'Humans', 'Male', 'Muscle Relaxants, Central/*adverse effects', 'Substance Withdrawal Syndrome/*etiology', 'Substance-Related Disorders/*etiology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/9439144/
1893,carisoprodol,21062909,Carisoprodol legal status and patterns of abuse.,['Fass JA'],"['Carisoprodol/*adverse effects', 'Drug and Narcotic Control/*legislation & jurisprudence', 'Humans', 'Muscle Relaxants, Central/*adverse effects', 'Norway/epidemiology', 'Substance-Related Disorders/*epidemiology', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/21062909/
1894,carisoprodol,20828952,Pharmacogenetics and forensic toxicology.,"['Musshoff F', 'Stamer UM', 'Madea B']","['Analgesics, Opioid/pharmacokinetics', 'Anticonvulsants/pharmacokinetics', 'Antidepressive Agents/pharmacokinetics', 'Benzodiazepines/pharmacokinetics', 'Biomarkers/analysis', 'Carisoprodol/pharmacokinetics', 'Cytochrome P-450 Enzyme System/genetics', 'Ethnicity/genetics', '*Forensic Toxicology', 'Genetic Variation', 'Humans', 'Membrane Transport Proteins/genetics', 'Molecular Targeted Therapy', 'Muscle Relaxants, Central/pharmacokinetics', 'N-Methyl-3,4-methylenedioxyamphetamine/pharmacokinetics', '*Pharmacogenetics', 'Postmortem Changes']",https://pubmed.ncbi.nlm.nih.gov/20828952/
1895,zolpidem,35843245,Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.,"['De Crescenzo F', ""D'Alo GL"", 'Ostinelli EG', 'Ciabattini M', 'Di Franco V', 'Watanabe N', 'Kurtulmus A', 'Tomlinson A', 'Mitrova Z', 'Foti F', 'Del Giovane C', 'Quested DJ', 'Cowen PJ', 'Barbui C', 'Amato L', 'Efthimiou O', 'Cipriani A']","['Adult', 'Benzodiazepines/therapeutic use', 'Doxepin/therapeutic use', 'Eszopiclone/therapeutic use', 'Humans', 'Melatonin/therapeutic use', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Zolpidem/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35843245/
1896,zolpidem,32044373,On the pathophysiology and treatment of akinetic mutism.,"['Arnts H', 'van Erp WS', 'Lavrijsen JCM', 'van Gaal S', 'Groenewegen HJ', 'van den Munckhof P']","['Adrenergic Uptake Inhibitors/*therapeutic use', '*Akinetic Mutism/drug therapy/pathology/physiopathology', 'Animals', 'Dopamine Agonists/*therapeutic use', 'Dopamine Uptake Inhibitors/*therapeutic use', '*Dopaminergic Neurons/drug effects/pathology/physiology', 'GABA-A Receptor Agonists/*therapeutic use', '*Gray Matter/drug effects/pathology/physiopathology', 'Humans', '*Motivation/drug effects/physiology', 'Zolpidem/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32044373/
1897,zolpidem,19584967,Novel zolpidem formulations.,['Owen RT'],"['Administration, Oral', 'Administration, Sublingual', 'Aerosols', 'Delayed-Action Preparations', 'Dosage Forms', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*pharmacokinetics/*pharmacology', 'Pyridines/administration & dosage/*pharmacokinetics/*pharmacology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/19584967/
1898,zolpidem,31880796,Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.,"['Rosenberg R', 'Murphy P', 'Zammit G', 'Mayleben D', 'Kumar D', 'Dhadda S', 'Filippov G', 'LoPresti A', 'Moline M']","['Aged', 'Delayed-Action Preparations', 'Double-Blind Method', 'Female', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Male', 'Middle Aged', 'Polysomnography', 'Pyridines/*therapeutic use', 'Pyrimidines/*therapeutic use', 'Sleep Aids, Pharmaceutical/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Zolpidem/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31880796/
1899,zolpidem,31953863,"Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder.","['Dauvilliers Y', 'Zammit G', 'Fietze I', 'Mayleben D', 'Seboek Kinter D', 'Pain S', 'Hedner J']","['Adult', 'Benzimidazoles/*administration & dosage/adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Humans', 'Imidazoles', 'Middle Aged', 'Orexin Receptor Antagonists/adverse effects/therapeutic use', 'Pyrrolidines/*administration & dosage/adverse effects/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Treatment Outcome', 'Triazoles/*administration & dosage/adverse effects/therapeutic use', 'Zolpidem/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31953863/
1900,zolpidem,38630476,Treatment Failure and Long-Term Prescription Risk for Guideline-Recommended Hypnotics in Japan.,"['Takeshima M', 'Yoshizawa K', 'Ogasawara M', 'Kudo M', 'Itoh Y', 'Ayabe N', 'Mishima K']","['Adult', 'Female', 'Humans', 'Male', 'Middle Aged', 'Cohort Studies', 'Eszopiclone', 'Hypnotics and Sedatives/adverse effects', '*Indenes', 'Japan', 'Retrospective Studies', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Treatment Failure', '*Triazolam', 'Zolpidem/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38630476/
1901,zolpidem,18221242,Zolpidem therapy for movement disorders.,['Abe K'],"['Animals', 'GABA Agonists/*therapeutic use', 'Humans', 'Movement Disorders/*drug therapy', 'Pyridines/*therapeutic use', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/18221242/
1902,zolpidem,38153735,Effect of Psychological and Medication Therapies for Insomnia on Daytime Functions: A Randomized Clinical Trial.,"['Morin CM', 'Chen SJ', 'Ivers H', 'Beaulieu-Bonneau S', 'Krystal AD', 'Guay B', 'Belanger L', 'Cartwright A', 'Simmons B', 'Lamy M', 'Busby M', 'Edinger JD']","['Adult', 'Female', 'Humans', 'Middle Aged', 'Behavior Therapy', 'Fatigue', '*Sleep Initiation and Maintenance Disorders/drug therapy', '*Trazodone', 'Zolpidem/therapeutic use', 'Male']",https://pubmed.ncbi.nlm.nih.gov/38153735/
1903,zolpidem,37993186,Pharmacology in Treatment of Patients with Disorders of Consciousness.,['Marino MH'],"['Humans', '*Consciousness/physiology', 'Zolpidem/therapeutic use', 'Consciousness Disorders/drug therapy', '*Brain Injuries', 'Amantadine/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37993186/
1904,zolpidem,8853211,Polysomnographic effects of hypnotic drugs. A review.,"['Parrino L', 'Terzano MG']","['Adult', 'Anti-Anxiety Agents/pharmacology/*therapeutic use', 'Azabicyclo Compounds', 'Benzodiazepines', 'Humans', 'Hypnotics and Sedatives/pharmacology/*therapeutic use', 'Middle Aged', 'Piperazines/pharmacology/therapeutic use', 'Polysomnography/*drug effects', 'Pyridines/pharmacology/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/8853211/
1905,zolpidem,27974380,Incorporation of Zolpidem into Hair and Its Distribution after a Single Administration.,"['Shima N', 'Sasaki K', 'Kamata T', 'Matsuta S', 'Wada M', 'Kakehashi H', 'Nakano S', 'Kamata H', 'Nishioka H', 'Sato T', 'Tsuchihashi H', 'Miki A', 'Katagi M']","['Adult', 'Biological Transport', 'Chromatography, Liquid', 'Drug Monitoring/*methods', 'Female', 'Hair/*chemistry', 'Healthy Volunteers', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*pharmacokinetics', 'Limit of Detection', 'Male', 'Pyridines/administration & dosage/*pharmacokinetics', 'Reproducibility of Results', 'Substance Abuse Detection/*methods', 'Tandem Mass Spectrometry', 'Time Factors', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/27974380/
1906,zolpidem,15651908,Zolpidem: a review of its use in the management of insomnia.,"['Swainston Harrison T', 'Keating GM']","['Age Factors', 'Clinical Trials as Topic/methods', 'Drug Administration Schedule', 'Drug Evaluation/methods', 'GABA Agonists/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Hypnotics and Sedatives/adverse effects/pharmacokinetics/*therapeutic use', 'Pyridines/adverse effects/pharmacokinetics/*therapeutic use', 'Sleep/drug effects', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Substance Withdrawal Syndrome/etiology', 'Treatment Outcome', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/15651908/
1907,zolpidem,34818157,Successful accelerated taper for sleeping aid.,"['Franck L', 'Prescott D', 'Smith S']","['Drug Administration Schedule', 'Humans', 'Male', 'Middle Aged', 'Sleep Aids, Pharmaceutical/*administration & dosage', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Treatment Outcome', 'Zolpidem/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/34818157/
1908,zolpidem,22424586,Zolpidem for insomnia.,"['Greenblatt DJ', 'Roth T']","['Animals', 'Humans', 'Hypnotics and Sedatives/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Pyridines/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/22424586/
1909,zolpidem,15352681,Zolpidem for postanoxic spasticity.,"['Shadan FF', 'Poceta JS', 'Kline LE']","['Adult', 'GABA Agonists/*therapeutic use', 'Heart Arrest/complications', 'Humans', 'Male', 'Muscle Spasticity/*drug therapy/etiology', 'Pyridines/*therapeutic use', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/15352681/
1910,zolpidem,11062863,The effect of zolpidem and zopiclone on memory.,"['Isawa S', 'Suzuki M', 'Uchiumi M', 'Murasaki M']","['Adult', 'Azabicyclo Compounds', 'Humans', 'Hypnotics and Sedatives/*pharmacology', 'Male', 'Memory/*drug effects', 'Memory, Short-Term/drug effects', 'Mental Recall/drug effects', 'Piperazines/*pharmacology', 'Pyridines/*pharmacology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/11062863/
1911,zolpidem,16696581,Zolpidem extended-release.,"['Moen MD', 'Plosker GL']","['Adolescent', 'Adult', 'Delayed-Action Preparations/*administration & dosage/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Administration Schedule', 'Drug Evaluation', 'Female', 'Humans', 'Hypnotics and Sedatives/*administration & dosage/pharmacokinetics', 'Male', 'Middle Aged', 'Polysomnography', 'Practice Guidelines as Topic', 'Pyridines/*administration & dosage/pharmacokinetics', 'Sleep/drug effects', 'Sleep Initiation and Maintenance Disorders/*drug therapy/metabolism', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/16696581/
1912,zolpidem,19644424,Catatonia recognition and treatment.,"['Cottencin O', 'Danel T', 'Goudemand M', 'Thomas P', 'Consoli SM']","['Catatonia/*diagnosis/*drug therapy', 'Female', 'Humans', 'Middle Aged', 'Psychiatric Status Rating Scales', 'Pyridines/administration & dosage/therapeutic use', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/19644424/
1913,zolpidem,28262178,Zolpidem's use for insomnia.,"['Monti JM', 'Spence DW', 'Buttoo K', 'Pandi-Perumal SR']","['Humans', 'Hypnotics and Sedatives/administration & dosage/pharmacokinetics/*pharmacology', 'Pyridines/administration & dosage/adverse effects/pharmacokinetics/*pharmacology', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/28262178/
1914,zolpidem,30870203,A Pilot Crossover Trial of Sleep Medications for Sleep-disturbed Methadone Maintenance Patients.,"['Stein MD', 'Kurth ME', 'Anderson BJ', 'Blevins CE']","['Actigraphy', 'Adult', 'Cross-Over Studies', 'Double-Blind Method', 'Female', 'GABA-A Receptor Agonists/therapeutic use', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Male', 'Methadone/*therapeutic use', 'Middle Aged', 'Mirtazapine/*therapeutic use', '*Opiate Substitution Treatment', 'Pilot Projects', 'Serotonin Antagonists/therapeutic use', 'Sleep/*drug effects', 'Sleep Aids, Pharmaceutical/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Sleep Latency/drug effects', 'Zolpidem/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30870203/
1915,metoclopramide,1387327,Antiemetic agents.,['Bleiberg H'],"['Antiemetics/administration & dosage/economics/*therapeutic use', 'Antineoplastic Agents/adverse effects', 'Cisplatin/adverse effects', 'Dexamethasone/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Imidazoles/administration & dosage/therapeutic use', 'Metoclopramide/administration & dosage/therapeutic use', 'Nausea/chemically induced/drug therapy', 'Ondansetron', 'Serotonin Antagonists', 'Treatment Outcome', 'Vomiting/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1387327/
1916,metoclopramide,38311315,The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69).,"['Nelson-Piercy C', 'Dean C', 'Shehmar M', 'Gadsby R', ""O'Hara M"", 'Hodson K', 'Nana M']","['Humans', 'Female', 'Pregnancy', '*Hyperemesis Gravidarum/therapy/diagnosis', '*Antiemetics/therapeutic use/administration & dosage', '*Ondansetron/therapeutic use/administration & dosage', 'Morning Sickness/therapy', 'Nausea/etiology/therapy', 'Pyridoxine/therapeutic use/administration & dosage', 'Metoclopramide/therapeutic use/administration & dosage', 'Severity of Illness Index', 'Pregnancy Complications/drug therapy/therapy']",https://pubmed.ncbi.nlm.nih.gov/38311315/
1917,metoclopramide,3515136,Metoclopramide--a review.,"['Desmond PV', 'Watson KJ']","['Anxiety/chemically induced', 'Digestive System/drug effects', 'Dopamine Antagonists', 'Drug Interactions', 'Female', 'Gastric Emptying/drug effects', 'Gastroesophageal Reflux/drug therapy', 'Humans', 'Hyperemesis Gravidarum/drug therapy', 'Metoclopramide/adverse effects/pharmacology/*therapeutic use', 'Migraine Disorders/drug therapy', 'Muscle, Smooth/drug effects', 'Nausea/drug therapy', 'Neurons/drug effects', 'Pregnancy', 'Sleep Stages/drug effects', 'Vomiting/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3515136/
1918,metoclopramide,10473023,Intranasal metoclopramide.,"['Ormrod D', 'Goa KL']","['Administration, Intranasal', 'Antiemetics/administration & dosage/adverse effects/*pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Humans', 'Metoclopramide/administration & dosage/adverse effects/*pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10473023/
1919,metoclopramide,19906028,Translating 5-HT receptor pharmacology.,['Sanger GJ'],"['Aged', 'Animals', 'Benzofurans/adverse effects/pharmacology/*therapeutic use', 'Dopamine Antagonists/pharmacology/therapeutic use', 'Gastrointestinal Diseases/*drug therapy/physiopathology', 'Gastrointestinal Motility/*drug effects', 'Humans', 'Metoclopramide/pharmacology/therapeutic use', 'Receptors, G-Protein-Coupled/drug effects', 'Receptors, Serotonin, 5-HT4/*drug effects', 'Serotonin 5-HT4 Receptor Agonists', 'Serotonin Receptor Agonists/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19906028/
1920,metoclopramide,25350407,[Pharmaceutical treatment of lactation deficiency lacks evidence].,"['Axelsson PB', 'Bjerrum F', 'Lokkegaard EC']","['*Breast Feeding', 'Domperidone/therapeutic use', 'Dopamine Antagonists/adverse effects/therapeutic use', 'Evidence-Based Medicine', 'Female', 'Humans', 'Lactation/*drug effects/physiology', 'Lactation Disorders/*drug therapy', 'Metoclopramide/adverse effects/therapeutic use', 'Oxytocics/therapeutic use', 'Oxytocin/therapeutic use', 'Pregnancy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25350407/
1921,metoclopramide,3898991,[Indications for primperan in pediatrics].,['Coignet J'],"['Anesthesia', 'Child, Preschool', 'Digestive System/diagnostic imaging', 'Gastric Emptying/drug effects', 'Gastroesophageal Reflux/drug therapy', 'Gastrointestinal Diseases/*drug therapy', 'Gastroscopy', 'Humans', 'Infant', 'Metoclopramide/pharmacology/*therapeutic use', 'Pneumonia, Aspiration/prevention & control', 'Radiography']",https://pubmed.ncbi.nlm.nih.gov/3898991/
1922,metoclopramide,234288,Some aspects of medical management of gastrointestinal disease. I.,['Badley BW'],"['Diarrhea/chemically induced', 'Disaccharides/*therapeutic use', 'Endoscopy', 'Esophagitis/drug therapy', 'Gastric Juice/metabolism', 'Gastric Mucosa/drug effects', 'Gastrointestinal Diseases/*drug therapy', 'Gastrointestinal Motility/drug effects', 'Hepatic Encephalopathy/*drug therapy', 'Histamine H1 Antagonists/therapeutic use', 'Humans', 'Hypokalemia/chemically induced', 'Intubation, Gastrointestinal', 'Lactulose/adverse effects/*therapeutic use', 'Metoclopramide/adverse effects/*therapeutic use', 'Peptic Ulcer/drug therapy', 'Secretory Rate/drug effects', 'Vomiting/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/234288/
1923,metoclopramide,28424994,Modulation of gastrointestinal motility beyond metoclopramide and domperidone : Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders.,"['Madisch A', 'Vinson BR', 'Abdel-Aziz H', 'Kelber O', 'Nieber K', 'Kraft K', 'Storr M']","['Domperidone/adverse effects/*therapeutic use', 'Gastrointestinal Diseases/*drug therapy', 'Gastrointestinal Motility/*drug effects', 'Humans', 'Irritable Bowel Syndrome/drug therapy', 'Metoclopramide/adverse effects/*therapeutic use', '*Phytotherapy', 'Plant Extracts/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/28424994/
1924,metoclopramide,1448341,[Prokinetic drugs].,['Hellstrom P'],"['Cisapride', 'Gastrointestinal Agents/*pharmacology', 'Gastrointestinal Diseases/drug therapy', 'Gastrointestinal Motility/*drug effects', 'Humans', 'Metoclopramide/pharmacokinetics/pharmacology/therapeutic use', 'Myoelectric Complex, Migrating/drug effects', 'Piperidines/pharmacokinetics/pharmacology/therapeutic use', 'Serotonin Antagonists/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/1448341/
1925,metoclopramide,1183218,Metoclopramide in hiccup.,['Madanagopolan N'],"['Administration, Oral', 'Hiccup/*drug therapy', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Metoclopramide/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1183218/
1926,metoclopramide,8879888,Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis.,['Perez EA'],"['Administration, Oral', 'Antineoplastic Agents/adverse effects', 'Dexamethasone/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Granisetron/*administration & dosage/therapeutic use', 'Humans', 'Injections, Intravenous', 'Metoclopramide/administration & dosage/therapeutic use', 'Nausea/chemically induced/prevention & control', 'Ondansetron/therapeutic use', 'Serotonin Antagonists/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8879888/
1927,metoclopramide,6421373,Tardive dyskinesia associated with metoclopramide.,"['Wiholm BE', 'Mortimer O', 'Boethius G', 'Haggstrom JE']","['Age Factors', 'Aged', 'Drug Administration Schedule', 'Dyskinesia, Drug-Induced/epidemiology/*etiology', 'Female', 'Humans', 'Metoclopramide/administration & dosage/*adverse effects', 'Sex Factors', 'Sweden']",https://pubmed.ncbi.nlm.nih.gov/6421373/
1928,metoclopramide,8931828,Use of prokinetic agents in special populations.,['Horn JR'],"['Age Factors', 'Cisapride', 'Drug Interactions', 'Gastroesophageal Reflux/*drug therapy', 'Gastrointestinal Agents/*therapeutic use', 'Gastrointestinal Motility/*drug effects', 'Gastroparesis/drug therapy', 'Humans', 'Metoclopramide/adverse effects/therapeutic use', 'Piperidines/therapeutic use', 'Serotonin Antagonists/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8931828/
1929,metoclopramide,1814735,The effect of food and metoclopramide on the pharmacokinetics and side effects of bromocriptine.,"['Kopitar Z', 'Vrhovac B', 'Povsic L', 'Plavsic F', 'Francetic I', 'Urbancic J']","['Administration, Oral', 'Adult', 'Biological Availability', 'Bromocriptine/administration & dosage/adverse effects/blood/*pharmacokinetics', '*Food', 'Humans', 'Male', 'Metoclopramide/*pharmacology', 'Radioimmunoassay']",https://pubmed.ncbi.nlm.nih.gov/1814735/
1930,metoclopramide,7288971,Metoclopramide treatment of tardive dyskinesia.,"['Karp JM', 'Perkel MS', 'Hersh T', 'McKinney AS']","['Administration, Oral', 'Aged', 'Dyskinesia, Drug-Induced/*drug therapy', 'Female', 'Humans', 'Male', 'Metoclopramide/administration & dosage/adverse effects/*therapeutic use', 'Middle Aged', 'Sleep Stages/drug effects']",https://pubmed.ncbi.nlm.nih.gov/7288971/
1931,metoclopramide,8032699,Cost-effectiveness analysis of antiemetic treatment.,"['Bleiberg H', 'Autier P', 'Michaux D']","['Antiemetics/adverse effects/*economics/*therapeutic use', 'Cost-Benefit Analysis', 'Costs and Cost Analysis', 'Dexamethasone/administration & dosage/adverse effects/economics/therapeutic use', 'Europe', 'European Union', 'Humans', 'Lorazepam/administration & dosage/adverse effects/economics/therapeutic use', 'Metoclopramide/administration & dosage/adverse effects/economics/therapeutic use', 'Ondansetron/administration & dosage/adverse effects/economics/therapeutic use', 'Randomized Controlled Trials as Topic', 'Salvage Therapy', 'Serotonin Antagonists/adverse effects/economics/therapeutic use', 'Vomiting/economics/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/8032699/
1932,metoclopramide,8527494,"Progress in identifying clinical relevance of inhibition, stimulation and measurements of poly ADP-ribosylation.","['Pero RW', 'Olsson A', 'Sheng Y', 'Hua J', 'Moller C', 'Kjellen E', 'Killander D', 'Marmor M']","['Animals', 'Antineoplastic Agents/toxicity', 'Carcinoma, Squamous Cell/drug therapy/radiotherapy', 'Clinical Trials, Phase I as Topic', 'Clinical Trials, Phase II as Topic', 'DNA/drug effects/radiation effects', '*DNA Damage', '*DNA Repair', 'Humans', 'Leukocytes, Mononuclear/enzymology', 'Lung Neoplasms/drug therapy/radiotherapy', 'Metoclopramide/adverse effects/*pharmacology/*therapeutic use', 'Mutagens/toxicity', '*Oxidative Stress', 'Poly Adenosine Diphosphate Ribose/analysis/*metabolism', 'Poly(ADP-ribose) Polymerase Inhibitors', 'Poly(ADP-ribose) Polymerases/analysis/*metabolism', 'Radiation-Sensitizing Agents/adverse effects/pharmacology/*therapeutic use', 'Zinc Fingers']",https://pubmed.ncbi.nlm.nih.gov/8527494/
1933,metoclopramide,31314613,Metoclopramide for the treatment of diabetic gastroparesis.,"['Shakhatreh M', 'Jehangir A', 'Malik Z', 'Parkman HP']","['Diabetes Complications/*complications', 'Dopamine D2 Receptor Antagonists/adverse effects/pharmacology/*therapeutic use', 'Gastric Emptying/*drug effects', 'Gastroparesis/*drug therapy/etiology', 'Humans', 'Metoclopramide/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome', 'Upper Gastrointestinal Tract/*drug effects/innervation']",https://pubmed.ncbi.nlm.nih.gov/31314613/
1934,metoclopramide,31050085,"Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited.","['Al-Saffar A', 'Lennernas H', 'Hellstrom PM']","['Antiemetics/adverse effects/*pharmacology', 'Dopamine D2 Receptor Antagonists/adverse effects/*pharmacology', 'Gastroparesis/*drug therapy', 'Humans', 'Metoclopramide/adverse effects/chemistry/*pharmacology', 'Risk Factors', 'Tardive Dyskinesia/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/31050085/
1935,simvastatin,17044581,Statin-induced rhabdomyolysis.,"['Schreiber DH', 'Anderson TR']","['Aged', 'Cyclosporine/pharmacology', 'Cytochrome P-450 Enzyme System/drug effects', 'Drug Interactions', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/pharmacology', 'Immunosuppressive Agents/pharmacology', 'Male', 'Rhabdomyolysis/*chemically induced/diagnosis/therapy', 'Simvastatin/*adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/17044581/
1936,simvastatin,12860216,"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).","['Jones PH', 'Davidson MH', 'Stein EA', 'Bays HE', 'McKenney JM', 'Miller E', 'Cain VA', 'Blasetto JW']","['Adult', 'Aged', 'Aged, 80 and over', 'Atorvastatin', 'Cholesterol, LDL/blood/*drug effects', 'Dose-Response Relationship, Drug', 'Female', 'Fluorobenzenes/*administration & dosage/adverse effects/*therapeutic use', 'Heptanoic Acids/*administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage/adverse effects/*therapeutic use', 'Hypercholesterolemia/blood/*drug therapy', 'Male', 'Middle Aged', 'Pravastatin/*administration & dosage/adverse effects/*therapeutic use', '*Pyrimidines', 'Pyrroles/*administration & dosage/adverse effects/*therapeutic use', 'Rosuvastatin Calcium', 'Simvastatin/*administration & dosage/adverse effects/*therapeutic use', '*Sulfonamides', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/12860216/
1937,simvastatin,34627266,Simvastatin induced ferroptosis for triple-negative breast cancer therapy.,"['Yao X', 'Xie R', 'Cao Y', 'Tang J', 'Men Y', 'Peng H', 'Yang W']","['Animals', 'Cell Line, Tumor', 'Delayed-Action Preparations', 'Drug Carriers/chemistry/pharmacokinetics', 'Female', 'Ferroptosis/*drug effects', 'Humans', 'MCF-7 Cells', 'Magnetite Nanoparticles/chemistry', 'Mice, Nude', 'Signal Transduction/drug effects', '*Simvastatin/chemistry/pharmacokinetics/pharmacology', 'Triple Negative Breast Neoplasms/*metabolism', 'Mice']",https://pubmed.ncbi.nlm.nih.gov/34627266/
1938,simvastatin,11401190,Simvastatin-associated memory loss.,"['Orsi A', 'Sherman O', 'Woldeselassie Z']","['Anticholesteremic Agents/*adverse effects', 'Humans', 'Hypercholesterolemia/*drug therapy', 'Male', 'Memory Disorders/*chemically induced', 'Middle Aged', 'Pravastatin/pharmacology/therapeutic use', 'Recovery of Function/drug effects', 'Simvastatin/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11401190/
1939,simvastatin,21171671,Niacin extended release (ER)/simvastatin (Simcor(R)): a guide to its use in lipid regulation.,['Lyseng-Williamson KA'],"['Clinical Trials as Topic', 'Delayed-Action Preparations/adverse effects/*therapeutic use', 'Drug Combinations', 'Dyslipidemias/*drug therapy', 'Humans', 'Hypolipidemic Agents/administration & dosage/adverse effects/*therapeutic use', 'Lipids/blood', 'Niacin/administration & dosage/adverse effects/*therapeutic use', 'Simvastatin/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21171671/
1940,simvastatin,21736529,Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.,"['Filippatos TD', 'Elisaf MS']","['Adult', 'Cardiovascular Diseases/epidemiology', 'Diabetes Complications/blood/drug therapy/metabolism', 'Drug Combinations', 'Drug Monitoring', 'Dyslipidemias/blood/*drug therapy/metabolism', 'Fenofibrate/*administration & dosage/adverse effects/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage/adverse effects/therapeutic use', 'Hypertriglyceridemia/blood/drug therapy/metabolism', 'Hypolipidemic Agents/*administration & dosage/adverse effects/therapeutic use', 'Lipoproteins/blood', 'Risk Factors', 'Simvastatin/*administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21736529/
1941,simvastatin,11575710,Ezetimibe (Schering-Plough).,['Meng CQ'],"['Animals', 'Anticholesteremic Agents/administration & dosage/*pharmacology/therapeutic use', 'Arteriosclerosis/drug therapy', 'Azetidines/administration & dosage/chemistry/*pharmacology/therapeutic use', 'Bile/metabolism', 'Cholesterol/metabolism', 'Cholesterol, LDL/biosynthesis', 'Clinical Trials, Phase II as Topic', 'Down-Regulation', 'Drug Combinations', 'Drug Evaluation, Preclinical', 'Drug Therapy, Combination', '*Drugs, Investigational', 'Ezetimibe', 'Forecasting', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/therapeutic use', 'Hypercholesterolemia/drug therapy', 'Intestinal Absorption/drug effects', 'Intestinal Mucosa/metabolism', 'Intestines/drug effects', 'Molecular Structure', 'Simvastatin/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11575710/
1942,simvastatin,25387217,"Clinical pharmacology of albiglutide, a GLP-1 receptor agonist.","['Young MA', 'Wald JA', 'Matthews JE', 'Scott R', 'Hodge RJ', 'Zhi H', 'Reinhardt RR']","['Absorption, Physiological', 'Blood Glucose/drug effects', 'Drug Interactions', 'Drug Therapy, Combination', 'Glucagon-Like Peptide 1/administration & dosage/*analogs & derivatives/pharmacokinetics/pharmacology', 'Glucagon-Like Peptide-1 Receptor', 'Half-Life', 'Heart Rate/drug effects', 'Humans', 'Incretins/administration & dosage/pharmacokinetics/*pharmacology', 'Kidney/drug effects', 'Liver/drug effects', 'Receptors, Glucagon/*agonists', 'Simvastatin/therapeutic use', 'Warfarin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/25387217/
1943,simvastatin,32754265,Calcium Supplement by Tetracycline guided amorphous Calcium Carbonate potentiates Osteoblast promotion for Synergetic Osteoporosis Therapy.,"['Wang J', 'Tao S', 'Jin X', 'Song Y', 'Zhou W', 'Lou H', 'Zhao R', 'Wang C', 'Hu F', 'Yuan H']","['Animals', 'Calcium Carbonate/*administration & dosage/chemistry/pharmacology', 'Cell Differentiation', 'Cell Line', 'Disease Models, Animal', 'Drug Delivery Systems', 'Drug Synergism', 'Female', 'Humans', 'Mice', 'Osteoblasts/*cytology/drug effects/metabolism', 'Osteoporosis/*drug therapy/metabolism', 'Rats', 'Simvastatin/*administration & dosage/chemistry/pharmacology', 'Tetracycline/*administration & dosage/chemistry/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/32754265/
1944,simvastatin,16918265,Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.,"['Robinson JG', 'Davidson MH']","['Anticholesteremic Agents/administration & dosage/*therapeutic use', 'Atorvastatin', 'Azetidines/administration & dosage/metabolism/pharmacology/*therapeutic use', 'C-Reactive Protein/analysis/drug effects', 'Cardiovascular Diseases/blood/prevention & control', 'Drug Therapy, Combination', 'Ezetimibe', 'Heptanoic Acids/administration & dosage/pharmacology/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/*therapeutic use', 'Hypercholesterolemia/blood/drug therapy', 'Intestinal Absorption/drug effects/physiology', 'Lipoproteins, LDL/blood/*drug effects', 'Phytosterols/blood', 'Pravastatin/administration & dosage/pharmacology/therapeutic use', 'Pyrroles/administration & dosage/pharmacology/therapeutic use', 'Simvastatin/administration & dosage/metabolism/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16918265/
1945,simvastatin,18973399,Niacin extended-release/simvastatin.,"['Sanford M', 'Curran MP']","['Animals', 'Clinical Trials as Topic', 'Drug Combinations', 'Flushing', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Hypercholesterolemia/*drug therapy', 'Niacin/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Simvastatin/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Vitamins/administration & dosage/adverse effects/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18973399/
1946,simvastatin,32819403,Simvastatin induces adverse effects on proliferation and mineralization of human primary osteoblasts.,"['Sabandal MMI', 'Schafer E', 'Aed J', 'Jung S', 'Kleinheinz J', 'Sielker S']","['Adult', '*Anticholesteremic Agents/adverse effects', 'Cell Differentiation', 'Cell Proliferation', 'Female', 'Humans', 'Male', '*Osteoblasts/drug effects', '*Osteogenesis/drug effects', '*Simvastatin/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32819403/
1947,simvastatin,15592632,Simvastatin improved arterial compliance in high-risk patients.,"['Saliashvili G', 'Davis WW', 'Harris MT', 'Le NA', 'Brown WV']","['Adult', 'Arteries/*physiopathology', 'Compliance/drug effects', 'Female', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology/*therapeutic use', 'Male', 'Middle Aged', 'Plethysmography', 'Simvastatin/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15592632/
1948,simvastatin,28972463,Inhaled simvastatin nanoparticles for inflammatory lung disease.,"['Tulbah AS', 'Pisano E', 'Scalia S', 'Young PM', 'Traini D', 'Ong HX']","['Administration, Inhalation', 'Anti-Inflammatory Agents/administration & dosage/chemistry/*pharmacology', 'Biological Transport', 'Chemistry, Pharmaceutical/methods', 'Chronic Disease', 'Drug Carriers/chemistry', 'Drug Liberation', 'Epithelial Cells', 'Humans', 'Inflammation/drug therapy', 'Lactic Acid/*chemistry', 'Lung Diseases/*drug therapy', 'Mucus/drug effects/metabolism', 'Nanoparticles/*chemistry', 'Particle Size', 'Polyglycolic Acid/*chemistry', 'Polylactic Acid-Polyglycolic Acid Copolymer', 'Simvastatin/administration & dosage/chemistry/*pharmacology', 'Surface Properties']",https://pubmed.ncbi.nlm.nih.gov/28972463/
1949,simvastatin,18481486,Rhabdomyolysis induced by simvastatin-fluconazole combination.,"['Hazin R', 'Abuzetun JY', 'Suker M', 'Porter J']","['Acute Kidney Injury', 'Aged', 'Antifungal Agents/administration & dosage/*adverse effects', 'Biomarkers', 'Creatine Kinase/blood', 'Drug Interactions', 'Drug Therapy, Combination', 'Fluconazole/administration & dosage/*adverse effects', 'Humans', 'Hypolipidemic Agents/administration & dosage/*adverse effects', 'Male', 'Myoglobinuria', 'Rhabdomyolysis/*chemically induced/diagnosis/therapy', 'Simvastatin/administration & dosage/*adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18481486/
1950,simvastatin,25466697,Myopathy during treatment with the antianginal drug ranolazine.,"['Kassardjian CD', 'Tian X', 'Vladutiu G', 'Wong LJ', 'Milone M']","['Acetanilides/administration & dosage/*adverse effects', 'Angina Pectoris/*drug therapy', 'Anticholesteremic Agents/administration & dosage/*adverse effects', 'Biopsy', 'Dose-Response Relationship, Drug', 'Enzyme Inhibitors/administration & dosage/*adverse effects', 'Female', 'Humans', 'Middle Aged', 'Muscular Diseases/blood/*chemically induced/pathology', 'Piperazines/administration & dosage/*adverse effects', 'Ranolazine', 'Simvastatin/administration & dosage/*adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25466697/
1951,simvastatin,19968571,Ezetimibe/simvastatin.,"['Montecucco F', 'Quercioli A', 'Mach F']","['Animals', 'Anticholesteremic Agents/*adverse effects/therapeutic use', 'Azetidines/*adverse effects/therapeutic use', 'Drug Combinations', 'Ezetimibe', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/therapeutic use', 'Hypercholesterolemia/blood/drug therapy', 'Simvastatin/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19968571/
1952,simvastatin,15571475,Simvastatin: a review.,"['Pedersen TR', 'Tobert JA']","['Clinical Trials as Topic', 'Female', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/pharmacokinetics/*therapeutic use', 'Hypercholesterolemia/*drug therapy/metabolism', 'Simvastatin/adverse effects/pharmacokinetics/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15571475/
1953,simvastatin,25804051,[Hypolipidemic and pleiotropic effects of a combination of simvastatin and ezetimibe in patients with different types of hyperlipidemia].,"['Sumarokov AB', 'Kukharchuk VV']","['Anticholesteremic Agents/administration & dosage/adverse effects/*pharmacology', 'Azetidines/administration & dosage/adverse effects/*pharmacology', '*Drug Synergism', 'Ezetimibe', 'Humans', 'Hyperlipidemias/*drug therapy', '*Randomized Controlled Trials as Topic', 'Simvastatin/administration & dosage/adverse effects/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/25804051/
1954,simvastatin,25041770,Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin.,"['Page SR', 'Yee KC']","['Aged, 80 and over', 'Clarithromycin/administration & dosage/*adverse effects', 'Cytochrome P-450 CYP3A Inhibitors/administration & dosage/adverse effects', 'Drug Interactions/physiology', 'Female', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/adverse effects', 'Rhabdomyolysis/*chemically induced/*diagnosis', 'Simvastatin/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/25041770/
1955,pemoline,17686346,Treating fatigue.,"['Lapierre Y', 'Hum S']","['Amantadine/*therapeutic use', 'Central Nervous System Stimulants/*therapeutic use', 'Comorbidity', 'Diagnosis, Differential', 'Dopamine Agents/*therapeutic use', 'Evidence-Based Medicine', 'Fatigue/drug therapy/etiology/*therapy', 'Humans', 'Multiple Sclerosis/*physiopathology', 'Patient Care Team', 'Pemoline/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17686346/
1956,pemoline,37194538,[Psychostimulants: An Overview].,"['Fukumoto S', 'Imanari E', 'Tomari S', 'Higashi T', 'Kosaka H']","['Humans', '*Central Nervous System Stimulants/therapeutic use', 'Lisdexamfetamine Dimesylate/therapeutic use', '*Attention Deficit Disorder with Hyperactivity/drug therapy', '*Methylphenidate/therapeutic use', 'Modafinil/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37194538/
1957,pemoline,21268950,Cancer-related fatigue.,"['De Waele S', 'Van Belle S']","['Fatigue/diagnosis/*etiology/*therapy', 'Humans', 'Neoplasms/*complications']",https://pubmed.ncbi.nlm.nih.gov/21268950/
1958,pemoline,9602211,Pemoline hepatotoxicity in children.,"['Marotta PJ', 'Roberts EA']","['Adolescent', 'Alkaline Phosphatase/metabolism', 'Attention Deficit Disorder with Hyperactivity/drug therapy', 'Central Nervous System Stimulants/*adverse effects', 'Chemical and Drug Induced Liver Injury/*enzymology', 'Child', 'Female', 'Humans', 'Male', 'Pemoline/*adverse effects', 'Transaminases/metabolism']",https://pubmed.ncbi.nlm.nih.gov/9602211/
1959,pemoline,11898532,Fatigue in multiple sclerosis.,"['Krupp LB', 'Christodoulou C']","['Amantadine/therapeutic use', 'Autoimmune Diseases/*complications', 'Benzhydryl Compounds/therapeutic use', 'Brain/diagnostic imaging/metabolism', 'Case Management', 'Central Nervous System Stimulants/therapeutic use', 'Combined Modality Therapy', 'Cross-Over Studies', 'Depression/etiology', 'Double-Blind Method', 'Fatigue/diagnostic imaging/*etiology/physiopathology/therapy', 'Hot Temperature/adverse effects', 'Humans', 'Hypothalamus/drug effects/physiopathology', 'Methylphenidate/therapeutic use', 'Modafinil', 'Multiple Sclerosis/*complications/psychology', 'Patient Care Team', 'Pemoline/therapeutic use', 'Physical Therapy Modalities', 'Pilot Projects', 'Randomized Controlled Trials as Topic', 'Self-Assessment', 'Severity of Illness Index', 'Tomography, Emission-Computed']",https://pubmed.ncbi.nlm.nih.gov/11898532/
1960,pemoline,9044395,Pemoline-associated hepatic failure: a critical analysis of the literature.,"['Shevell M', 'Schreiber R']","['Adverse Drug Reaction Reporting Systems', 'Attention Deficit Disorder with Hyperactivity/*drug therapy', 'Central Nervous System Stimulants/administration & dosage/*adverse effects', 'Child', 'Humans', 'Liver Failure/*chemically induced', 'Pemoline/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/9044395/
1961,pemoline,2210262,Pemoline-associated hepatic injury.,"['Nehra A', 'Mullick F', 'Ishak KG', 'Zimmerman HJ']","['Adolescent', 'Adult', '*Chemical and Drug Induced Liver Injury', 'Child', 'Child, Preschool', 'Humans', 'Liver Diseases/enzymology', 'Male', 'Middle Aged', 'Pemoline/administration & dosage/*adverse effects', 'Transaminases/blood']",https://pubmed.ncbi.nlm.nih.gov/2210262/
1962,pemoline,8856815,Use of stimulants in the medically ill.,"['Masand PS', 'Tesar GE']","['Central Nervous System Stimulants/adverse effects/*therapeutic use', 'Chronic Disease/*psychology', 'Contraindications', 'Depressive Disorder/*drug therapy/psychology', 'Dose-Response Relationship, Drug', 'Humans', 'Neurocognitive Disorders/*drug therapy/psychology', '*Patient Care Team', '*Sick Role', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/8856815/
1963,pemoline,6993557,Diet and hyperactivity.,"['Dickerson JW', 'Pepler F']","['Adolescent', 'Aging', 'Amphetamines/therapeutic use', 'Child', 'Child Behavior Disorders/etiology', 'Child, Preschool', 'Diet/*adverse effects', 'Dietary Carbohydrates/adverse effects', 'Environmental Pollutants/adverse effects', 'Female', 'Flavoring Agents/adverse effects', 'Food Additives/adverse effects', 'Food Coloring Agents/adverse effects', 'Food Hypersensitivity/complications', 'Humans', 'Hyperkinesis/diagnosis/diet therapy/*etiology/*therapy', 'Infant', 'Male', 'Methylphenidate/therapeutic use', 'Pemoline/therapeutic use', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/6993557/
1964,pemoline,12562059,Management of ADHD in adults.,"['Adler LA', 'Chua HC']","['Adolescent', 'Adult', 'Age Factors', 'Amphetamines/therapeutic use', 'Antidepressive Agents/therapeutic use', 'Antihypertensive Agents/therapeutic use', 'Attention Deficit Disorder with Hyperactivity/*diagnosis/*drug therapy', 'Brain/diagnostic imaging', 'Central Nervous System Stimulants/therapeutic use', 'Child', 'Cholinergic Agents/therapeutic use', 'Clinical Trials as Topic', 'Dihydroxyphenylalanine/*analogs & derivatives', 'Humans', 'Methylphenidate/therapeutic use', 'Pemoline/therapeutic use', 'Tomography, Emission-Computed', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12562059/
1965,pemoline,9680052,Psychopharmacology of ADHD: children and adolescents.,"['Findling RL', 'Dogin JW']","['Adolescent', 'Age Factors', 'Amphetamines/therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Attention Deficit Disorder with Hyperactivity/*drug therapy', 'Bupropion/therapeutic use', 'Central Nervous System Stimulants/*therapeutic use', 'Child', 'Cyclohexanols/therapeutic use', 'Dextroamphetamine/therapeutic use', 'Drug Administration Schedule', 'Fluoxetine/therapeutic use', 'Humans', 'Methylphenidate/therapeutic use', 'Monoamine Oxidase Inhibitors/therapeutic use', 'Pemoline/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/9680052/
1966,pemoline,9680048,Attention-deficit/hyperactivity disorder: a life-span perspective.,['Biederman J'],"['Adolescent', 'Adult', 'Age Factors', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Attention Deficit Disorder with Hyperactivity/*diagnosis/*drug therapy/epidemiology', 'Bupropion/therapeutic use', 'Child', 'Comorbidity', 'Dextroamphetamine/therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Mental Disorders/epidemiology', 'Methylphenidate/therapeutic use', 'Pemoline/therapeutic use', 'Sex Factors']",https://pubmed.ncbi.nlm.nih.gov/9680048/
1967,pemoline,10412704,['Fatigue' in multiple sclerosis].,"['Zimmermann C', 'Hohlfeld R']","['Amantadine/therapeutic use', 'Aminopyridines/therapeutic use', 'Disease Progression', 'Fatigue/*drug therapy/*etiology', 'Female', 'Humans', 'Male', 'Multiple Sclerosis/*complications/drug therapy', 'Pemoline/adverse effects/therapeutic use', 'Potassium Channel Blockers', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/10412704/
1968,pemoline,28870581,Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis.,"['Yang TT', 'Wang L', 'Deng XY', 'Yu G']","['4-Aminopyridine/therapeutic use', 'Amantadine/therapeutic use', 'Central Nervous System Stimulants/therapeutic use', 'Dopamine Agents/therapeutic use', 'Drug Therapy/*methods', 'Fatigue/*drug therapy/*etiology', 'Humans', 'Multiple Sclerosis/*complications', 'Pemoline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28870581/
1969,pemoline,2881528,The use of psychostimulants in general psychiatry. A reconsideration.,"['Chiarello RJ', 'Cole JO']","['Adult', 'Amphetamine/therapeutic use', 'Central Nervous System Stimulants/*therapeutic use', 'Clinical Trials as Topic', 'Depressive Disorder/drug therapy', 'Humans', 'Mental Disorders/*drug therapy', 'Methylphenidate/therapeutic use', 'Pemoline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2881528/
1970,pemoline,15893683,Multiple sclerosis-related fatigue.,"['MacAllister WS', 'Krupp LB']","['Antidepressive Agents/therapeutic use', 'Central Nervous System Stimulants/therapeutic use', 'Cryotherapy', 'Dopamine Agents/therapeutic use', 'Exercise Therapy', 'Fatigue/*physiopathology/psychology/therapy', 'Humans', 'Multiple Sclerosis/*physiopathology', 'Patient Care Planning', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/15893683/
1971,pemoline,4021028,Pemoline abuse.,"['Polchert SE', 'Morse RM']","['Adult', 'Hallucinations/chemically induced', 'Humans', 'Male', 'Paranoid Disorders/*chemically induced', 'Pemoline/*adverse effects', 'Psychoses, Substance-Induced/*etiology', 'Substance-Related Disorders/*complications/psychology']",https://pubmed.ncbi.nlm.nih.gov/4021028/
1972,pemoline,2417773,Pharmacologic treatment of psychiatric and neurodevelopmental disorders in children and adolescents (Part 1).,['McDaniel KD'],"['Adolescent', 'Aggression/drug effects', 'Antidepressive Agents/therapeutic use', 'Antipsychotic Agents/therapeutic use', 'Anxiety, Separation/drug therapy', 'Attention Deficit Disorder with Hyperactivity/drug therapy', 'Child', 'Child Behavior Disorders/diagnosis/drug therapy', 'Developmental Disabilities/*drug therapy', 'Diazepam/administration & dosage', 'Histamine H1 Antagonists/administration & dosage', 'Humans', 'Imipramine/administration & dosage', 'Lithium/therapeutic use', 'Mental Disorders/*drug therapy', 'Methylphenidate/therapeutic use', 'Pemoline/therapeutic use', 'Sleep Initiation and Maintenance Disorders/drug therapy', 'Sleep Wake Disorders/drug therapy', 'Thioridazine/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/2417773/
1973,pemoline,1875157,Effects of stimulant medication on learning in children with ADHD.,"['Swanson JM', 'Cantwell D', 'Lerner M', 'McBurnett K', 'Hanna G']","['Achievement', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/psychology', 'Child', 'Dextroamphetamine/*therapeutic use', 'Humans', 'Learning Disabilities/*drug therapy/psychology', 'Methylphenidate/*therapeutic use', 'Pemoline/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1875157/
1974,pemoline,8909146,Narcolepsy.,['Ware JC'],"['Amphetamines/therapeutic use', 'Cataplexy', 'Central Nervous System Stimulants/therapeutic use', 'Diagnosis, Differential', 'Humans', 'Methylphenidate/therapeutic use', 'Narcolepsy/diagnosis/*etiology/psychology', 'Pemoline/therapeutic use', 'Personality Disorders/etiology']",https://pubmed.ncbi.nlm.nih.gov/8909146/
1975,zopiclone,35843245,Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.,"['De Crescenzo F', ""D'Alo GL"", 'Ostinelli EG', 'Ciabattini M', 'Di Franco V', 'Watanabe N', 'Kurtulmus A', 'Tomlinson A', 'Mitrova Z', 'Foti F', 'Del Giovane C', 'Quested DJ', 'Cowen PJ', 'Barbui C', 'Amato L', 'Efthimiou O', 'Cipriani A']","['Adult', 'Benzodiazepines/therapeutic use', 'Doxepin/therapeutic use', 'Eszopiclone/therapeutic use', 'Humans', 'Melatonin/therapeutic use', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Zolpidem/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35843245/
1976,zopiclone,18035234,Pharmacotherapy for insomnia.,"['Tariq SH', 'Pulisetty S']","['Antidepressive Agents/therapeutic use', 'Azabicyclo Compounds/therapeutic use', 'Central Nervous System Depressants/therapeutic use', 'Eszopiclone', 'GABA Agonists/therapeutic use', '*GABA-A Receptor Antagonists', 'Humans', 'Indenes/therapeutic use', 'Melatonin/therapeutic use', 'Phytotherapy', 'Piperazines/therapeutic use', 'Pyridines/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Valerian', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/18035234/
1977,zopiclone,24614774,Hypnotic hiccups.,"['Vorona RD', 'Szklo-Coxe M', 'Ware JC']","['Azabicyclo Compounds/*adverse effects', 'Eszopiclone', 'Female', 'Hiccup/*chemically induced', 'Humans', 'Hypnotics and Sedatives/*adverse effects', 'Middle Aged', 'Piperazines/*adverse effects', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24614774/
1978,zopiclone,21786646,[Sleep and stress].,['Strygin KN'],"['Adaptation, Psychological/drug effects/physiology', 'Animals', 'Azabicyclo Compounds/therapeutic use', '*Circadian Rhythm', 'Humans', 'Piperazines/therapeutic use', 'Polysomnography', 'Sleep/drug effects/*physiology', 'Sleep Initiation and Maintenance Disorders/drug therapy/*etiology/physiopathology', '*Stress, Physiological', '*Stress, Psychological']",https://pubmed.ncbi.nlm.nih.gov/21786646/
1979,zopiclone,11816843,(S)-Zopiclone Sepracor.,['Georgiev V'],"['Animals', 'Azabicyclo Compounds', 'Clinical Trials, Phase I as Topic', 'Clinical Trials, Phase II as Topic', 'Clinical Trials, Phase III as Topic', 'Humans', 'Hypnotics and Sedatives/adverse effects/pharmacology/*therapeutic use', 'Piperazines/adverse effects/pharmacology/*therapeutic use', 'Sleep Wake Disorders/*drug therapy/psychology', 'Stereoisomerism', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/11816843/
1980,zopiclone,27751669,Review of Safety and Efficacy of Sleep Medicines in Older Adults.,"['Schroeck JL', 'Ford J', 'Conway EL', 'Kurtzhalts KE', 'Gee ME', 'Vollmer KA', 'Mergenhagen KA']","['Aged', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Middle Aged', 'Randomized Controlled Trials as Topic', 'Sleep/*drug effects', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27751669/
1981,zopiclone,38551874,[Pharmacotherapies for insomnia].,"['Vecchierini MF', 'Leger D']","['Adult', 'Humans', 'Middle Aged', '*Sleep Initiation and Maintenance Disorders/drug therapy', '*Melatonin/therapeutic use/adverse effects', 'Hypnotics and Sedatives/therapeutic use', 'Benzodiazepines/therapeutic use', 'Sleep', 'Antidepressive Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38551874/
1982,zopiclone,15883924,Insomnia.,['Holzinger E'],"['Azabicyclo Compounds', 'Clinical Trials as Topic', 'Humans', 'Hypnotics and Sedatives/chemistry/economics/therapeutic use', 'Molecular Structure', 'Piperazines/chemistry/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/diagnosis/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/15883924/
1983,zopiclone,32858054,"Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences.","['Himmerich H', 'Kan C', 'Au K', 'Treasure J']","['Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use', 'Avitaminosis', 'Clinical Decision-Making/methods', 'Drug Monitoring/methods', 'Feeding and Eating Disorders/*drug therapy/*epidemiology/physiopathology/psychology', 'Humans', 'Malnutrition/*drug therapy/*epidemiology', 'Mental Disorders/drug therapy/epidemiology', 'Patient Care Planning', 'Pharmacogenomic Testing/methods', 'Sleep Wake Disorders/drug therapy/epidemiology', 'Trace Elements/deficiency', 'Water-Electrolyte Balance/physiology']",https://pubmed.ncbi.nlm.nih.gov/32858054/
1984,zopiclone,21573250,Eszopiclone: an update on its use in insomnia.,['Owen RT'],"['Adult', 'Aged', 'Animals', 'Azabicyclo Compounds/adverse effects/chemistry/economics/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Cognition/drug effects', 'Drug Approval', 'Eszopiclone', 'Humans', 'Hypnotics and Sedatives/adverse effects/chemistry/pharmacology/*therapeutic use', 'Japan', 'Memory/drug effects', 'Middle Aged', 'Piperazines/adverse effects/chemistry/economics/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Sleep Apnea, Obstructive/drug therapy', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21573250/
1985,zopiclone,30303519,Eszopiclone for insomnia.,"['Rosner S', 'Englbrecht C', 'Wehrle R', 'Hajak G', 'Soyka M']","['Adult', 'Aged', 'Aged, 80 and over', 'Eszopiclone/*therapeutic use', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Middle Aged', 'Randomized Controlled Trials as Topic', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30303519/
1986,zopiclone,38630476,Treatment Failure and Long-Term Prescription Risk for Guideline-Recommended Hypnotics in Japan.,"['Takeshima M', 'Yoshizawa K', 'Ogasawara M', 'Kudo M', 'Itoh Y', 'Ayabe N', 'Mishima K']","['Adult', 'Female', 'Humans', 'Male', 'Middle Aged', 'Cohort Studies', 'Eszopiclone', 'Hypnotics and Sedatives/adverse effects', '*Indenes', 'Japan', 'Retrospective Studies', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Treatment Failure', '*Triazolam', 'Zolpidem/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38630476/
1987,zopiclone,8853211,Polysomnographic effects of hypnotic drugs. A review.,"['Parrino L', 'Terzano MG']","['Adult', 'Anti-Anxiety Agents/pharmacology/*therapeutic use', 'Azabicyclo Compounds', 'Benzodiazepines', 'Humans', 'Hypnotics and Sedatives/pharmacology/*therapeutic use', 'Middle Aged', 'Piperazines/pharmacology/therapeutic use', 'Polysomnography/*drug effects', 'Pyridines/pharmacology/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/8853211/
1988,zopiclone,18044182,Eszopiclone for late-life insomnia.,"['McCrae CS', 'Ross A', 'Stripling A', 'Dautovich ND']","['Adult', 'Age of Onset', 'Aged', 'Aged, 80 and over', 'Azabicyclo Compounds/adverse effects/economics/*therapeutic use', 'Chronic Disease', 'Cognitive Behavioral Therapy', 'Drug Costs', 'Drug Interactions', 'Drug Tolerance', 'Eszopiclone', 'Humans', 'Hypnotics and Sedatives/adverse effects/economics/*therapeutic use', 'Middle Aged', 'Piperazines/adverse effects/economics/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy/epidemiology', 'Substance-Related Disorders/etiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18044182/
1989,zopiclone,28391425,"Safety, Tolerability and Efficacy of Drugs for Treating Behavioural Insomnia in Children with Attention-Deficit/Hyperactivity Disorder: A Systematic Review with Methodological Quality Assessment.","['Anand S', 'Tong H', 'Besag FMC', 'Chan EW', 'Cortese S', 'Wong ICK']","['Attention Deficit Disorder with Hyperactivity/complications/*drug therapy/physiopathology', 'Child', 'Clonidine/therapeutic use', 'Eszopiclone/therapeutic use', 'Glutamates/therapeutic use', 'Guanfacine/therapeutic use', 'Humans', 'Melatonin/therapeutic use', 'Observational Studies as Topic', 'Pyridines/therapeutic use', 'Randomized Controlled Trials as Topic', 'Sleep Initiation and Maintenance Disorders/complications/*drug therapy/physiopathology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/28391425/
1990,zopiclone,25115782,Severe agitation in depression precipitated by dasatinib.,"['Sami MB', 'Yousaf F', 'Fialho A']","['Azabicyclo Compounds/administration & dosage', 'Dasatinib', 'Depression/*complications/diagnosis/drug therapy', 'Diagnosis, Differential', 'Dose-Response Relationship, Drug', 'Humans', 'Hypnotics and Sedatives/administration & dosage', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy', 'Magnetic Resonance Imaging', 'Male', 'Middle Aged', 'Piperazines/administration & dosage', 'Protein-Tyrosine Kinases/antagonists & inhibitors', 'Psychomotor Agitation/diagnosis/drug therapy/*etiology', 'Pyrimidines/*adverse effects/therapeutic use', 'Thiazoles/*adverse effects/therapeutic use', 'Tomography, X-Ray Computed']",https://pubmed.ncbi.nlm.nih.gov/25115782/
1991,zopiclone,16750956,"Insomnia in the elderly: cause, approach, and treatment.","['Kamel NS', 'Gammack JK']","['Acetamides/therapeutic use', 'Aged', '*Aging', 'Antidepressive Agents/therapeutic use', 'Azabicyclo Compounds', 'Behavior Therapy', 'Benzodiazepines/therapeutic use', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Nonprescription Drugs/therapeutic use', 'Piperazines/therapeutic use', 'Pyridines/therapeutic use', 'Pyrimidines/therapeutic use', 'Receptor, Melatonin, MT1/agonists', 'Receptor, Melatonin, MT2/agonists', 'Sleep/*drug effects', 'Sleep Initiation and Maintenance Disorders/drug therapy/*etiology/physiopathology/*therapy', 'Sleep, REM/drug effects', 'Thiophenes/therapeutic use', 'Trazodone/therapeutic use', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/16750956/
1992,zopiclone,18800955,Which medications are safe and effective for improving sleep at high altitude?,['Luks AM'],"['Acetamides/therapeutic use', 'Acetazolamide/therapeutic use', 'Altitude Sickness/*physiopathology', 'Anti-Anxiety Agents/*therapeutic use', 'Azabicyclo Compounds/therapeutic use', 'Benzodiazepines/therapeutic use', 'Diphenhydramine/therapeutic use', 'Eszopiclone', 'GABA Agonists/*therapeutic use', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', '*Mountaineering', 'Piperazines/therapeutic use', 'Pyridines/therapeutic use', 'Pyrimidines/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Sleep Stages/drug effects', 'Temazepam/therapeutic use', 'Wakefulness/drug effects', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/18800955/
1993,zopiclone,16703122,Ramelteon: profile of a new sleep-promoting medication.,['Owen RT'],"['Animals', 'Drug Interactions', 'Humans', 'Hypnotics and Sedatives/adverse effects/pharmacokinetics/*therapeutic use', 'Indenes/adverse effects/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Receptor, Melatonin, MT1/agonists/metabolism', 'Receptor, Melatonin, MT2/agonists/metabolism', 'Sleep', 'Sleep Initiation and Maintenance Disorders/*drug therapy/metabolism', 'Suprachiasmatic Nucleus/drug effects/metabolism']",https://pubmed.ncbi.nlm.nih.gov/16703122/
1994,zopiclone,18693067,Hypnotic use for insomnia management in chronic obstructive pulmonary disease.,['Roth T'],"['Humans', 'Hypnotics and Sedatives/*administration & dosage/*adverse effects', 'Pulmonary Disease, Chronic Obstructive/*complications', 'Sleep Initiation and Maintenance Disorders/*complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18693067/
1995,gabapentin,39163072,Gabapentin-induced Multifocal Myoclonus.,"['Priya L', 'Alamanda VA', 'Javali M', 'Acharya P', 'Rangaiah P', 'Nagabushana D']","['Humans', '*Gabapentin/adverse effects', 'Male', '*Myoclonus/chemically induced', '*Analgesics/adverse effects', 'Neuralgia/drug therapy', 'Aged', 'gamma-Aminobutyric Acid/adverse effects', 'Amines/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/39163072/
1996,gabapentin,29023146,Is there a role for combined use of gabapentin and pregabalin in pain control? Too good to be true?,"['Senderovich H', 'Jeyapragasan G']","['Analgesics/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Gabapentin/*administration & dosage', 'Humans', 'Neuralgia/*drug therapy', 'Pregabalin/*administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29023146/
1997,gabapentin,37493871,"Therapeutic Strategies for Postherpetic Neuralgia: Mechanisms, Treatments, and Perspectives.","['Tang J', 'Zhang Y', 'Liu C', 'Zeng A', 'Song L']","['Humans', 'Aged', '*Neuralgia, Postherpetic/therapy', 'Gabapentin/therapeutic use', 'Pregabalin/therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Lidocaine', 'Analgesics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37493871/
1998,gabapentin,33215352,Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update.,"['Evoy KE', 'Sadrameli S', 'Contreras J', 'Covvey JR', 'Peckham AM', 'Morrison MD']","['Animals', 'Drug Overdose', 'Gabapentin/*adverse effects', 'Humans', 'Pregabalin/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33215352/
1999,gabapentin,37208596,The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis.,"['Lampl C', 'MaassenVanDenBrink A', 'Deligianni CI', 'Gil-Gouveia R', 'Jassal T', 'Sanchez-Del-Rio M', 'Reuter U', 'Uluduz D', 'Versijpt J', 'Zeraatkar D', 'Sacco S']","['Adult', 'Humans', 'Topiramate/adverse effects', '*Valproic Acid/therapeutic use', 'Gabapentin/therapeutic use', 'Calcitonin Gene-Related Peptide/therapeutic use', 'Network Meta-Analysis', 'Amitriptyline/therapeutic use', 'Antibodies, Monoclonal/therapeutic use', '*Migraine Disorders/drug therapy/prevention & control/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37208596/
2000,gabapentin,36195376,Effectiveness of mirror therapy in phantom limb pain: a literature review.,"['Campo-Prieto P', 'Rodriguez-Fuentes G']","['Amitriptyline', 'Antidepressive Agents, Tricyclic', 'Gabapentin/therapeutic use', 'Humans', 'Mirror Movement Therapy', '*Phantom Limb/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36195376/
2001,gabapentin,37138086,Glioblastoma remodelling of human neural circuits decreases survival.,"['Krishna S', 'Choudhury A', 'Keough MB', 'Seo K', 'Ni L', 'Kakaizada S', 'Lee A', 'Aabedi A', 'Popova G', 'Lipkin B', 'Cao C', 'Nava Gonzales C', 'Sudharshan R', 'Egladyous A', 'Almeida N', 'Zhang Y', 'Molinaro AM', 'Venkatesh HS', 'Daniel AGS', 'Shamardani K', 'Hyer J', 'Chang EF', 'Findlay A', 'Phillips JJ', 'Nagarajan S', 'Raleigh DR', 'Brang D', 'Monje M', 'Hervey-Jumper SL']","['Humans', 'Brain/drug effects/metabolism/pathology', '*Brain Neoplasms/drug therapy/metabolism/pathology', '*Glioblastoma/drug therapy/metabolism/pathology', '*Neural Pathways', 'Thrombospondin 1/antagonists & inhibitors', 'Gabapentin/pharmacology/therapeutic use', 'Disease Progression', 'Cognition', 'Survival Rate', 'Wakefulness', 'Biopsy', 'Cell Proliferation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/37138086/
2002,gabapentin,35716275,Evidence-Based Treatment of Painful Diabetic Neuropathy: a Systematic Review.,"[""D'Souza RS"", 'Barman R', 'Joseph A', 'Abd-Elsayed A']","['*Diabetes Mellitus', '*Diabetic Neuropathies/therapy', 'Gabapentin/therapeutic use', 'Humans', '*Insulins/therapeutic use', 'Pregabalin/therapeutic use', '*Spinal Cord Stimulation']",https://pubmed.ncbi.nlm.nih.gov/35716275/
2003,gabapentin,31036121,Myocardial Ischemia Presenting with Hiccups.,['Yuan SM'],"['Baclofen/*therapeutic use', 'Electrocardiography', 'GABA-B Receptor Agonists/*therapeutic use', 'Gabapentin/*therapeutic use', 'Hiccup/diagnosis/*drug therapy/etiology/*physiopathology', 'Humans', 'Myocardial Infarction/*complications', 'Myocardial Ischemia/*complications', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31036121/
2004,gabapentin,34637958,A systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain.,"['Gimenez-Campos MS', 'Pimenta-Fermisson-Ramos P', 'Diaz-Cambronero JI', 'Carbonell-Sanchis R', 'Lopez-Briz E', 'Ruiz-Garcia V']","['Adolescent', 'Adult', 'Analgesics/adverse effects', 'Gabapentin/adverse effects', 'Humans', '*Low Back Pain', 'Pregabalin/adverse effects', '*Sciatica/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34637958/
2005,gabapentin,35754070,Pharmacotherapy for Spine-Related Pain in Older Adults.,"['Fu JL', 'Perloff MD']","['Acetaminophen/therapeutic use', 'Aged', 'Analgesics, Opioid/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', '*Neuralgia/drug therapy', 'Pregabalin/adverse effects', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35754070/
2006,gabapentin,29788886,Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction.,"['Pakri Mohamed RM', 'Kumar J', 'Ahmad SU', 'Mohamed IN']","['Alcohol Deterrents/adverse effects/*therapeutic use', 'Alcoholism/*drug therapy', 'Animals', 'Aripiprazole/adverse effects/therapeutic use', 'Baclofen/adverse effects/therapeutic use', 'Cyclopentanes/adverse effects/therapeutic use', 'Gabapentin/adverse effects/therapeutic use', 'Humans', 'Naltrexone/adverse effects/analogs & derivatives/therapeutic use', 'Quetiapine Fumarate/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29788886/
2007,gabapentin,31473025,[HTA and non-hormonal menopause treatment].,['Boivin JM'],"['Acupuncture Therapy', 'Clonidine/adverse effects/therapeutic use', 'Complementary Therapies', 'Female', 'Gabapentin/adverse effects/therapeutic use', 'Hot Flashes/drug therapy', 'Humans', 'Hypertension/*etiology', '*Menopause/drug effects', 'Panax', 'Phytoestrogens/adverse effects/*therapeutic use', 'Pregabalin/adverse effects/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/adverse effects/*therapeutic use', 'Vasomotor System/drug effects']",https://pubmed.ncbi.nlm.nih.gov/31473025/
2008,gabapentin,36890758,[Medical Treatment of Chronic Pain].,['Nodera H'],"['Humans', 'Analgesics/therapeutic use/adverse effects', '*Chronic Pain/drug therapy/chemically induced', 'Pregabalin/therapeutic use', 'Gabapentin/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use', '*Diabetic Neuropathies/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36890758/
2009,gabapentin,38574212,Diabetic Peripheral Neuropathy: Prevention and Treatment.,"['Bragg S', 'Marrison ST', 'Haley S']","['Humans', '*Diabetic Neuropathies/diagnosis/prevention & control', 'Duloxetine Hydrochloride/therapeutic use', 'Capsaicin/therapeutic use', 'Gabapentin/therapeutic use', 'Pregabalin/therapeutic use', 'Pain/drug therapy', '*Diabetes Mellitus/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38574212/
2010,gabapentin,34232226,[Hepatotoxicity probably associated with gabapentin].,"['Contreras-Mota M', 'Rosales-Cortes V']","['Amines/adverse effects', 'Analgesics', '*Chemical and Drug Induced Liver Injury/diagnosis/etiology', '*Cyclohexanecarboxylic Acids/adverse effects', 'Gabapentin/adverse effects', 'Humans', 'Male', 'Middle Aged', 'gamma-Aminobutyric Acid/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/34232226/
2011,gabapentin,39978848,Treatment of Vasomotor Symptoms.,"['Atwell K', 'White M', 'Kuphal G', 'Williams M', 'Schrager S']","['Humans', '*Hot Flashes/drug therapy', 'Female', '*Menopause/physiology', 'Vasomotor System/drug effects/physiopathology', 'Quality of Life', 'Estrogen Replacement Therapy/methods', 'Complementary Therapies/methods', 'Gabapentin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39978848/
2012,gabapentin,30326006,Effect of Gabapentin vs Pregabalin on Pain Intensity in Adults With Chronic Sciatica: A Randomized Clinical Trial.,"['Robertson K', 'Marshman LAG', 'Plummer D', 'Downs E']","['Adult', 'Aged', 'Analgesics/administration & dosage/adverse effects/*pharmacology', 'Chronic Pain/*drug therapy', 'Cross-Over Studies', 'Double-Blind Method', 'Female', 'Gabapentin/administration & dosage/adverse effects/*pharmacology', 'Humans', 'Male', 'Middle Aged', 'Outcome Assessment, Health Care', 'Pregabalin/administration & dosage/adverse effects/*pharmacology', 'Sciatica/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30326006/
2013,gabapentin,39088823,Mirogabalin: a novel gabapentinoid or another false dawn?,"['Craig TJ', 'Farquhar-Smith P']","['Humans', '*Neuralgia/drug therapy', '*Analgesics/therapeutic use', '*Bridged Bicyclo Compounds/therapeutic use/pharmacology', 'Gabapentin/therapeutic use', 'Calcium Channels/drug effects', 'gamma-Aminobutyric Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39088823/
2014,gabapentin,30383545,"Psychology of Chronic Pelvic Pain: Prevalence, Neurobiological Vulnerabilities, and Treatment.","['Till SR', 'As-Sanie S', 'Schrepf A']","['Antidepressive Agents, Tricyclic/pharmacology', 'Anxiety/*complications', 'Catastrophization/*complications', 'Chronic Pain/complications/drug therapy/*psychology/therapy', 'Cognitive Behavioral Therapy', 'Depression/*complications', 'Female', 'Gabapentin/pharmacology/therapeutic use', 'Humans', 'Off-Label Use', 'Pelvic Pain/complications/drug therapy/*psychology/therapy', 'Prevalence', 'Serotonin and Noradrenaline Reuptake Inhibitors/pharmacology/therapeutic use', 'Twin Studies as Topic']",https://pubmed.ncbi.nlm.nih.gov/30383545/
2015,propofol,20816571,Propofol.,"['Lundstrom S', 'Twycross R', 'Mihalyo M', 'Wilcock A']","['Anesthetics, Intravenous/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Death', 'Delirium/drug therapy/psychology', 'Drug Interactions', 'Humans', 'Propofol/administration & dosage/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20816571/
2016,propofol,30019172,Clinical Pharmacokinetics and Pharmacodynamics of Propofol.,"['Sahinovic MM', 'Struys MMRF', 'Absalom AR']","['Adult', 'Anesthetics, Intravenous/*administration & dosage/pharmacokinetics/pharmacology', 'Animals', 'Child', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Humans', 'Hypnotics and Sedatives/*administration & dosage/pharmacokinetics/pharmacology', 'Models, Biological', 'Obesity/complications', 'Propofol/*administration & dosage/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30019172/
2017,propofol,30732981,Clinical Practice Guideline for Emergency Department Procedural Sedation With Propofol: 2018 Update.,"['Miller KA', 'Andolfatto G', 'Miner JR', 'Burton JH', 'Krauss BS']","['Anesthetics, Intravenous/*administration & dosage/adverse effects', 'Drug Dosage Calculations', 'Drug Therapy, Combination', 'Emergency Service, Hospital', 'Evidence-Based Medicine', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Male', 'Practice Guidelines as Topic', 'Propofol/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/30732981/
2018,propofol,28566410,Postoperative drug-induced priapism.,"['Corten BJGA', 'Aarts F', 'Harms AS', 'Vogelaar J']","['Anesthetics, Intravenous/*adverse effects', 'Colonic Neoplasms/surgery', 'Diagnosis, Differential', 'Humans', 'Hypnotics and Sedatives/*adverse effects', 'Male', 'Middle Aged', 'Postoperative Complications/chemically induced/diagnosis', 'Priapism/chemically induced/*diagnosis', 'Propofol/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/28566410/
2019,propofol,26290263,Propofol: a review of its role in pediatric anesthesia and sedation.,"['Chidambaran V', 'Costandi A', ""D'Mello A""]","['Anesthetics, Intravenous/*administration & dosage/adverse effects/pharmacokinetics/pharmacology', 'Child', 'Humans', 'Hypnotics and Sedatives/*administration & dosage/adverse effects/pharmacokinetics/pharmacology', 'Propofol/*administration & dosage/adverse effects/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/26290263/
2020,propofol,29661412,Pharmacokinetic-pharmacodynamic model for propofol for broad application in anaesthesia and sedation.,"['Eleveld DJ', 'Colin P', 'Absalom AR', 'Struys MMRF']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Anesthesia/*methods', 'Anesthetics, Intravenous/administration & dosage/pharmacokinetics/*pharmacology', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Infant', 'Infusions, Intravenous', 'Male', 'Middle Aged', '*Models, Biological', 'Propofol/administration & dosage/pharmacokinetics/*pharmacology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29661412/
2021,propofol,30501158,Propofol: Review of Potential Risks During Administration.,['Adler AC'],"['Anesthetics, Intravenous/*administration & dosage/adverse effects', '*Conscious Sedation', 'Drug Administration Schedule', 'Humans', 'Hypnotics and Sedatives/*administration & dosage/adverse effects', 'Injection Site Reaction/nursing/*prevention & control', 'Nurse Anesthetists', 'Postoperative Complications/nursing/prevention & control', 'Propofol/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/30501158/
2022,propofol,33317804,Prospective clinical validation of the Eleveld propofol pharmacokinetic-pharmacodynamic model in general anaesthesia.,"['Vellinga R', 'Hannivoort LN', 'Introna M', 'Touw DJ', 'Absalom AR', 'Eleveld DJ', 'Struys MMRF']","['Adolescent', 'Adult', 'Age Factors', 'Aged', '*Anesthesia, General', 'Anesthetics, Intravenous/administration & dosage/blood/*pharmacokinetics', 'Body Weight', 'Child', 'Child, Preschool', 'Consciousness/*drug effects', 'Female', 'Humans', 'Infusions, Intravenous', 'Male', 'Middle Aged', '*Models, Biological', 'Obesity', 'Propofol/administration & dosage/blood/*pharmacokinetics', 'Prospective Studies', 'Reproducibility of Results', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33317804/
2023,propofol,28526162,Pharmacologic Considerations of Anesthetic Agents in Pediatric Patients: A Comprehensive Review.,"['Kaye AD', 'Fox CJ', 'Padnos IW', 'Ehrhardt KP Jr', 'Diaz JH', 'Cornett EM', 'Chandler D', 'Sen S', 'Patil S']","['Age Factors', 'Analgesics, Opioid/pharmacokinetics/pharmacology', 'Anesthesiologists', 'Anesthetics, Intravenous/administration & dosage/adverse effects', 'Anesthetics, Local/pharmacokinetics/*pharmacology', 'Child', 'Drug Dosage Calculations', 'Humans', 'Neuromuscular Blocking Agents/pharmacokinetics/pharmacology', 'Propofol/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/28526162/
2024,propofol,20205488,Fospropofol.,"['Garnock-Jones KP', 'Scott LJ']","['Anesthetics, Intravenous/administration & dosage/adverse effects/pharmacology/therapeutic use', '*Bronchoscopy', '*Colonoscopy', 'Humans', 'Propofol/administration & dosage/adverse effects/*analogs & derivatives/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20205488/
2025,propofol,29847365,Challenges of bringing a new sedative to market!,['Sear JW'],"['Anesthesia/adverse effects/*methods', 'Benzodiazepines/administration & dosage/adverse effects', 'Clinical Trials as Topic', 'Conscious Sedation/adverse effects/*methods', 'Drug Recalls', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*adverse effects', 'Pregnanediones/administration & dosage/adverse effects', 'Propofol/administration & dosage/adverse effects/analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/29847365/
2026,propofol,15675608,GPI-15715 Guilford.,['Krasowski MD'],"['*Anesthetics, Intravenous/adverse effects/pharmacology/therapeutic use', 'Animals', 'Clinical Trials as Topic', 'Humans', '*Prodrugs/adverse effects/pharmacology/therapeutic use', '*Propofol/adverse effects/*analogs & derivatives/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15675608/
2027,propofol,15365226,Propofol-induced alpha rhythm.,"['Feshchenko VA', 'Veselis RA', 'Reinsel RA']","['Adult', 'Alpha Rhythm/*drug effects', 'Anesthetics, Intravenous/administration & dosage/pharmacokinetics/*pharmacology', 'Dose-Response Relationship, Drug', 'Frontal Lobe/drug effects/physiology', 'Humans', 'Infusions, Intravenous', 'Propofol/administration & dosage/pharmacokinetics/*pharmacology', 'Thiopental/administration & dosage/pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/15365226/
2028,propofol,18225970,Propofol-related infusion syndrome in intensive care patients.,"['Corbett SM', 'Montoya ID', 'Moore FA']","['Adolescent', 'Adult', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*adverse effects', 'Infant', 'Infusions, Intravenous', '*Intensive Care Units', 'Male', 'Middle Aged', 'Propofol/administration & dosage/*adverse effects', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/18225970/
2029,propofol,9415349,Propofol for sedation in the intensive care unit: essentials for the clinician.,['Marinella MA'],"['Adult', 'Aged', 'Apnea/chemically induced', 'Bradycardia/chemically induced', '*Critical Care', 'Drug Administration Schedule', 'Half-Life', 'Humans', 'Hypnosis, Anesthetic', '*Hypnotics and Sedatives/administration & dosage/adverse effects/pharmacology', 'Hypotension/chemically induced', 'Metabolic Clearance Rate', 'Pain/chemically induced', '*Propofol/administration & dosage/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/9415349/
2030,propofol,28506099,Propofol-Based Palliative Sedation to Treat Antipsychotic-Resistant Agitated Delirium.,"['Covarrubias-Gomez A', 'Lopez Collada-Estrada M']","['Antipsychotic Agents', 'Delirium/*complications/*drug therapy', '*Drug Resistance/drug effects', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Infusions, Intravenous', 'Male', 'Middle Aged', 'Palliative Care/*methods', 'Propofol/administration & dosage/*therapeutic use', 'Psychomotor Agitation/*complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/28506099/
2031,propofol,28066096,Pain on propofol injection: Causes and remedies.,['Desousa KA'],"['Anesthetics, Intravenous/*administration & dosage/*adverse effects/chemistry', 'Drug Compounding', 'Humans', 'Injections, Intravenous/adverse effects', 'Pain/chemically induced/*etiology/*prevention & control', 'Propofol/*administration & dosage/*adverse effects/chemistry']",https://pubmed.ncbi.nlm.nih.gov/28066096/
2032,propofol,30898682,Sex effects on behavioral markers of emergence from propofol and isoflurane anesthesia in rats.,"['Mansouri MT', 'Fidler JA', 'Meng QC', 'Eckenhoff RG', 'Garcia PS']","['*Anesthesia', 'Anesthetics, General/administration & dosage/pharmacokinetics/*pharmacology', 'Animals', 'Behavior, Animal/*drug effects', 'Female', 'Humans', 'Injections, Intraperitoneal', 'Isoflurane/administration & dosage/pharmacokinetics/*pharmacology', 'Male', 'Movement/*drug effects', 'Propofol/administration & dosage/pharmacokinetics/*pharmacology', 'Rats', 'Rats, Sprague-Dawley', '*Sex Characteristics']",https://pubmed.ncbi.nlm.nih.gov/30898682/
2033,propofol,11983797,Efficacy and safety of venlafaxine-ECT combination in treatment-resistant depression.,"['Gonzalez-Pinto A', 'Gutierrez M', 'Gonzalez N', 'Elizagarate E', 'Perez de Heredia JL', 'Mico JA']","['Aged', 'Anesthetics, Intravenous/pharmacology/therapeutic use', 'Antidepressive Agents, Second-Generation/*therapeutic use', 'Cyclohexanols/administration & dosage/adverse effects/*therapeutic use', 'Depressive Disorder, Major/drug therapy/*therapy', 'Drug Administration Schedule', 'Electroconvulsive Therapy/*methods', 'Female', 'Heart Arrest/chemically induced/drug therapy/epidemiology', 'Heart Rate/drug effects', 'Humans', 'Male', 'Middle Aged', 'Propofol/pharmacology/therapeutic use', 'Retrospective Studies', 'Sodium Channels/drug effects', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/11983797/
2034,propofol,7621219,Successful treatment of amoxapine-induced refractory status epilepticus with propofol (diprivan).,"['Merigian KS', 'Browning RG', 'Leeper KV']","['Adult', 'Amoxapine/*adverse effects', 'Drug Overdose', 'Female', 'Humans', 'Infusions, Intravenous', 'Propofol/administration & dosage/*therapeutic use', 'Status Epilepticus/*chemically induced/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7621219/
2035,metronidazole,3280909,Metronidazole.,['Scully BE'],"['Bacteria, Anaerobic', 'Bacterial Infections/*drug therapy', 'Humans', '*Metronidazole/adverse effects/therapeutic use', 'Protozoan Infections/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3280909/
2036,metronidazole,29077920,"Metronidazole: an update on metabolism, structure-cytotoxicity and resistance mechanisms.","['Dingsdag SA', 'Hunter N']","['Animals', 'Anti-Infective Agents/adverse effects/chemistry/metabolism/*pharmacology', '*Drug Resistance, Bacterial', 'Humans', 'Metronidazole/adverse effects/chemistry/metabolism/*pharmacology', 'Mice']",https://pubmed.ncbi.nlm.nih.gov/29077920/
2037,metronidazole,24267604,Clostridium difficile infection in the elderly.,"['Keller JM', 'Surawicz CM']","['Aged', '*Anti-Bacterial Agents/administration & dosage/adverse effects', '*Clostridioides difficile/drug effects/isolation & purification/pathogenicity', '*Clostridium Infections/epidemiology/etiology/physiopathology/therapy', 'Cross Infection', 'Diarrhea/physiopathology', 'Disease Management', 'Humans', '*Metronidazole/administration & dosage/adverse effects', 'Outcome Assessment, Health Care', 'Prevalence', 'Risk Factors', 'Severity of Illness Index', '*Vancomycin/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/24267604/
2038,metronidazole,26962078,"Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.","['Mazuski JE', 'Gasink LB', 'Armstrong J', 'Broadhurst H', 'Stone GG', 'Rank D', 'Llorens L', 'Newell P', 'Pachl J']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', '*Anti-Bacterial Agents/administration & dosage/adverse effects/therapeutic use', '*Azabicyclo Compounds/administration & dosage/adverse effects/therapeutic use', '*Ceftazidime/administration & dosage/adverse effects/therapeutic use', 'Drug Combinations', 'Female', 'Humans', 'Intraabdominal Infections/*drug therapy/epidemiology', 'Male', 'Meropenem', '*Metronidazole/administration & dosage/adverse effects/therapeutic use', 'Middle Aged', '*Thienamycins/administration & dosage/adverse effects/therapeutic use', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/26962078/
2039,metronidazole,2568163,Inflammatory bowel disease.,['Van Rosendaal GM'],"['Administration, Oral', 'Adrenal Cortex Hormones/adverse effects/therapeutic use', 'Aminosalicylic Acids/administration & dosage/adverse effects/therapeutic use', 'Delayed-Action Preparations', 'Drug Evaluation', 'Forecasting', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Inflammatory Bowel Diseases/*drug therapy/therapy', 'Mesalamine', 'Metronidazole/adverse effects/therapeutic use', 'Sulfasalazine/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2568163/
2040,metronidazole,58258,Treatment of rosacea by metronidazole.,"['Pye RJ', 'Burton JL']","['Administration, Oral', 'Adult', 'Aged', 'Clinical Trials as Topic', 'Drug Evaluation', 'Humans', 'Metronidazole/administration & dosage/*therapeutic use', 'Middle Aged', 'Placebos', 'Rosacea/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/58258/
2041,metronidazole,20510762,Innovative use of topical metronidazole.,['Zip CM'],"['Acute Generalized Exanthematous Pustulosis/drug therapy', 'Administration, Cutaneous', 'Adult', 'Anti-Infective Agents/administration & dosage/adverse effects/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*therapeutic use', 'Child', 'Dermatitis, Perioral/drug therapy', 'Dermatitis, Seborrheic/drug therapy', 'Double-Blind Method', 'Drug Eruptions/diagnosis/etiology', 'ErbB Receptors/antagonists & inhibitors', 'Female', 'Humans', 'Male', 'Metronidazole/administration & dosage/adverse effects/*therapeutic use', 'Multicenter Studies as Topic', 'Off-Label Use', 'Randomized Controlled Trials as Topic', 'Rosacea/*drug therapy', '*Therapies, Investigational', 'Wounds and Injuries/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20510762/
2042,metronidazole,7791427,Clindamycin and metronidazole.,"['Falagas ME', 'Gorbach SL']","['Animals', 'Bacterial Infections/*drug therapy', 'Clindamycin/adverse effects/chemistry/*therapeutic use', 'Drug Resistance, Microbial', 'Humans', 'Metronidazole/adverse effects/metabolism/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7791427/
2043,metronidazole,9509270,Clostridium difficile infection.,"['Kelly CP', 'LaMont JT']","['Administration, Oral', 'Anti-Bacterial Agents/administration & dosage/adverse effects/economics/therapeutic use', 'Bacterial Toxins/analysis/metabolism', '*Clostridioides difficile/metabolism', 'Colon/microbiology', 'Diarrhea/microbiology', 'Drug Costs', 'Drug Resistance, Microbial', 'Enterocolitis, Pseudomembranous/drug therapy/*microbiology', 'Exotoxins/analysis/metabolism', 'Feces/chemistry', 'Hospitalization', 'Humans', 'Intestinal Mucosa/microbiology', 'Metronidazole/administration & dosage/economics/therapeutic use', 'Recurrence', 'Time Factors', 'Vancomycin/administration & dosage/economics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9509270/
2044,metronidazole,12052431,Is metronidazole carcinogenic?,"['Bendesky A', 'Menendez D', 'Ostrosky-Wegman P']","['Animals', 'Anti-Infective Agents/adverse effects/chemistry/metabolism/pharmacokinetics', 'Carcinogenicity Tests', '*Carcinogens/metabolism', 'DNA Damage', 'Humans', 'Metronidazole/*adverse effects/chemistry/metabolism/pharmacokinetics', 'Molecular Structure', 'Mutagenicity Tests', 'Mutagens/metabolism']",https://pubmed.ncbi.nlm.nih.gov/12052431/
2045,metronidazole,26238129,DRESS Syndrome Following Levofloxacin Exposure With Positive Patch-test.,"['Charfi O', 'Lakhoua G', 'Sahnoun R', 'Badri T', 'Daghfous R', 'El Aidli S', 'Kastalli S', 'Zaiem A']","['Acetaminophen/therapeutic use', 'Adult', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Drug Hypersensitivity Syndrome/diagnosis/*etiology', 'Drug Therapy, Combination', 'Epstein-Barr Virus Infections/drug therapy', 'Fluoroquinolones/adverse effects', 'Humans', 'Levofloxacin/administration & dosage/*adverse effects', 'Liver Function Tests', 'Male', 'Metronidazole/administration & dosage/therapeutic use', '*Patch Tests', 'Phenols/therapeutic use', 'Respiratory Tract Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26238129/
2046,metronidazole,8426284,The role of metronidazole in the treatment of periodontal diseases.,['Greenstein G'],"['Animals', 'Bacteria, Anaerobic/drug effects', 'Carcinogenicity Tests', 'Drug Interactions', 'Humans', 'Metronidazole/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Molecular Structure', 'Mutagenicity Tests', 'Periodontal Diseases/*drug therapy', 'Periodontitis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/8426284/
2047,metronidazole,29327947,Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment.,"['Nyirjesy P', 'Schwebke JR']","['Administration, Oral', 'Adolescent', 'Adult', 'Anti-Bacterial Agents/administration & dosage/chemistry/pharmacokinetics/*therapeutic use', 'Controlled Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Gram-Negative Bacteria/drug effects', 'Gram-Positive Bacteria/drug effects', 'Humans', 'Metronidazole/administration & dosage/*analogs & derivatives/chemistry/pharmacokinetics/therapeutic use', 'Middle Aged', 'Multicenter Studies as Topic', 'Trichomonas Vaginitis/drug therapy', 'Trichomonas vaginalis/drug effects', 'United States', 'Vaginosis, Bacterial/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29327947/
2048,metronidazole,7067925,Single dose treatment of trichomoniasis.,"['Gabriel G', 'Robertson E', 'Thin RN']","['Female', 'Humans', 'Metronidazole/*administration & dosage/therapeutic use', 'Nitroimidazoles/*administration & dosage', 'Tinidazole/*administration & dosage/therapeutic use', 'Trichomonas Vaginitis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7067925/
2049,metronidazole,28279442,Low efficacy of metronidazole in the eradication of Blastocystis hominis in symptomatic patients: Case series and systematic literature review.,"['Batista L', 'Perez Jove J', 'Rosinach M', 'Gonzalo V', 'Sainz E', 'Loras C', 'Forne M', 'Esteve M', 'Fernandez-Banares F']","['Aged', 'Antiprotozoal Agents/pharmacology/*therapeutic use', 'Blastocystis Infections/*drug therapy/parasitology', 'Blastocystis hominis/*drug effects/isolation & purification', 'Diarrhea/*drug therapy/parasitology', 'Drug Resistance', 'Drug Substitution', 'Dyspepsia/drug therapy/parasitology', 'Feces/parasitology', 'Female', 'Humans', 'Male', 'Metronidazole/pharmacology/*therapeutic use', 'Middle Aged', 'Retrospective Studies', 'Sampling Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28279442/
2050,metronidazole,3053871,The use of metronidazole (Flagyl) in Crohn's disease.,['Babb RR'],"['Clinical Trials as Topic', 'Crohn Disease/*drug therapy', 'Humans', 'Metronidazole/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3053871/
2051,metronidazole,22407994,Meeting the challenge of recurrent Clostridium difficile infection.,['Johnson S'],"['Aged, 80 and over', 'Anti-Bacterial Agents/administration & dosage/adverse effects/*therapeutic use', 'Clostridioides difficile/isolation & purification/pathogenicity', 'Enterocolitis, Pseudomembranous/diagnosis/*drug therapy/prevention & control', 'Female', 'Fluid Therapy', 'Humans', 'Hygiene/education/standards', 'Metronidazole/administration & dosage/adverse effects/*therapeutic use', 'Risk Factors', 'Secondary Prevention', 'Severity of Illness Index', 'Vancomycin/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22407994/
2052,metronidazole,7436193,Metronidazole.,['Finegold SM'],"['Animals', 'Dysentery, Amebic/*drug therapy', 'Female', 'Giardiasis/drug therapy', 'Humans', 'Liver Abscess, Amebic/*drug therapy', 'Metronidazole/administration & dosage/adverse effects/*therapeutic use', 'Mice', 'Mutation', 'Neoplasms, Experimental/chemically induced', 'Rats', 'Trichomonas Infections/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7436193/
2053,metronidazole,28758800,Dosing antibiotics in neonates: review of the pharmacokinetic data.,"['Rivera-Chaparro ND', 'Cohen-Wolkowiez M', 'Greenberg RG']","['Adult', 'Aminoglycosides/administration & dosage/adverse effects/pharmacokinetics', 'Anti-Bacterial Agents/*administration & dosage/adverse effects/*pharmacokinetics', 'Birth Weight/drug effects', 'Body Size/drug effects', 'Cephalosporins/administration & dosage', 'Child', 'Clindamycin/administration & dosage/adverse effects/pharmacokinetics', 'Glycopeptides/administration & dosage/adverse effects/pharmacokinetics', 'Humans', 'Infant', 'Infant, Newborn/*physiology', 'Medication Reconciliation', 'Meropenem', 'Metronidazole/administration & dosage/adverse effects/pharmacokinetics', 'Penicillanic Acid/administration & dosage/analogs & derivatives', 'Piperacillin/administration & dosage', 'Piperacillin, Tazobactam Drug Combination', 'Thienamycins/administration & dosage/adverse effects/pharmacokinetics', 'beta-Lactams/administration & dosage/adverse effects/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/28758800/
2054,metronidazole,8193418,Metronidazole hypersensitivity.,"['Knowles S', 'Choudhury T', 'Shear NH']","['Adult', 'Biological Availability', 'Candidiasis, Vulvovaginal/*drug therapy', '*Drug Hypersensitivity', 'Drug Therapy, Combination', 'Female', 'Humans', 'Metronidazole/*adverse effects/pharmacokinetics', 'Nystatin/therapeutic use', 'Recurrence', 'Vaginosis, Bacterial/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/8193418/
2055,felodipine,1693718,Vascular selectivity of felodipine: clinical experience.,"['Thomas P', 'Sheridan DJ']","['Animals', 'Felodipine/pharmacology/*therapeutic use', 'Heart/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Muscle, Smooth, Vascular/*drug effects', 'Organ Specificity', 'Vascular Resistance/drug effects']",https://pubmed.ncbi.nlm.nih.gov/1693718/
2056,felodipine,9420451,How grapefruit juice potentiates drug bioavailability.,['Feldman EB'],"['Area Under Curve', '*Beverages', 'Biological Availability', 'Calcium Channel Blockers/blood/*pharmacokinetics', '*Citrus', 'Down-Regulation', 'Drug Synergism', 'Felodipine/blood/*pharmacokinetics', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/9420451/
2057,felodipine,18666368,Effect of grapefruit juice in relation to human pharmacokinetic study.,"['Uno T', 'Yasui-Furukori N']","['*Beverages', 'Biological Availability', 'Calcium Channel Blockers/pharmacokinetics', '*Citrus paradisi', 'Cytochrome P-450 CYP3A/physiology', 'Felodipine/pharmacokinetics', '*Food-Drug Interactions', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/18666368/
2058,felodipine,9723817,Grapefruit juice-drug interactions.,"['Bailey DG', 'Malcolm J', 'Arnold O', 'Spence JD']","['Administration, Oral', '*Beverages', 'Biological Availability', 'Calcium Channel Blockers/pharmacokinetics', '*Citrus', 'Cytochrome P-450 CYP3A', 'Cytochrome P-450 Enzyme System/metabolism', 'Felodipine/pharmacokinetics', '*Food-Drug Interactions', 'Humans', 'Intestine, Small/metabolism', 'Mixed Function Oxygenases/metabolism', '*Pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/9723817/
2059,felodipine,2280237,"Antihypertensive drugs and glucose metabolism: comparison between a diuretic, a beta-blocker and felodipine, a new calcium antagonist in subjects with arterial hypertension and diabetes.","['Lundgren H', 'Bengtsson C', 'Lapidus L', 'Bengtsson L']","['Aged', 'Blood Glucose/*drug effects', 'Diabetes Mellitus/*chemically induced', 'Double-Blind Method', 'Felodipine/adverse effects/*therapeutic use', 'Female', 'Glucose Tolerance Test', 'Humans', 'Hydrochlorothiazide/adverse effects/*therapeutic use', 'Hypertension/*drug therapy', 'Male', 'Metoprolol/adverse effects/*therapeutic use', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/2280237/
2060,felodipine,8112371,A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices.,"['Bainbridge AD', 'Herlihy O', 'Meredith PA', 'Elliott HL']","['Aged', 'Amlodipine/*pharmacokinetics/pharmacology', 'Blood Pressure/*drug effects', 'Delayed-Action Preparations', 'Felodipine/*pharmacokinetics/pharmacology', 'Female', 'Heart Rate/*drug effects', 'Humans', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/8112371/
2061,felodipine,9812220,Rational use of calcium-channel antagonists in Raynaud's phenomenon.,"['Sturgill MG', 'Seibold JR']","['Amlodipine/pharmacokinetics/pharmacology/therapeutic use', 'Calcium Channel Blockers/pharmacokinetics/pharmacology/*therapeutic use', 'Diltiazem/pharmacokinetics/pharmacology/therapeutic use', 'Felodipine/pharmacokinetics/pharmacology/therapeutic use', 'Humans', 'Isradipine/pharmacokinetics/pharmacology/therapeutic use', 'Nicardipine/pharmacokinetics/pharmacology/therapeutic use', 'Nifedipine/pharmacokinetics/pharmacology/therapeutic use', 'Raynaud Disease/*drug therapy/epidemiology/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/9812220/
2062,felodipine,7523062,Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.,['Cohn JN'],"['Clinical Trials as Topic', 'Drug Therapy, Combination', 'Enalapril/*therapeutic use', 'Exercise', 'Felodipine/*therapeutic use', 'Heart Failure/*drug therapy/mortality', 'Humans', 'Hydralazine/*therapeutic use', 'Isosorbide Dinitrate/*therapeutic use', 'Norepinephrine/blood', 'Oxygen Consumption', 'Prognosis', 'Stroke Volume/drug effects', 'Survival Analysis']",https://pubmed.ncbi.nlm.nih.gov/7523062/
2063,felodipine,8720766,"Antihypertensive drugs and glucose metabolism: a comparison between a diuretic and felodipine, a new calcium antagonist, when added to a beta-blocker in non-diabetic hypertensive women.","['Bengtsson C', 'Lapidus L']","['Adrenergic beta-Antagonists/administration & dosage/therapeutic use', 'Aged', 'Calcium Channel Blockers/administration & dosage/*therapeutic use', 'Cross-Over Studies', 'Diuretics', 'Drug Therapy, Combination', 'Felodipine/administration & dosage/*therapeutic use', 'Female', 'Glucose/*metabolism', 'Glucose Tolerance Test', 'Humans', 'Hydrochlorothiazide/administration & dosage/*therapeutic use', 'Hypertension/*drug therapy', 'Insulin/blood', 'Middle Aged', 'Sodium Chloride Symporter Inhibitors/administration & dosage/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/8720766/
2064,felodipine,1671113,Interaction of citrus juices with felodipine and nifedipine.,"['Bailey DG', 'Spence JD', 'Munoz C', 'Arnold JM']","['Biological Availability', 'Blood Pressure/drug effects', 'Citrus/*metabolism', 'Drug Interactions', 'Evaluation Studies as Topic', 'Felodipine/administration & dosage/blood/*pharmacokinetics', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Nifedipine/administration & dosage/blood/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/1671113/
2065,felodipine,25973793,"Pharmacology, Efficacy and Safety of Felodipine with a Focus on Hypertension and Angina Pectoris.","['Navadiya K', 'Tiwari S']","['Angina Pectoris/diagnosis/*drug therapy/physiopathology', 'Animals', 'Antihypertensive Agents/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Calcium Channel Blockers/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Felodipine/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Hypertension/diagnosis/*drug therapy/physiopathology', 'Treatment Outcome', 'Vasodilator Agents/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25973793/
2066,felodipine,9675532,Felodipine-induced gingival hyperplasia.,"['Young PC', 'Turiansky GW', 'Sau P', 'Liebman MD', 'Benson PM']","['Aged', 'Calcium Channel Blockers/*adverse effects', 'Felodipine/*adverse effects', 'Female', 'Gingival Hyperplasia/*chemically induced', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/9675532/
2067,felodipine,1424224,"Efficacy and safety of felodipine, a new dihydropyridine calcium channel blocker, in elderly hypertensive patients.",['DeQuattro V'],"['Aging/*physiology', 'Felodipine/adverse effects/pharmacokinetics/*therapeutic use', 'Hemodynamics/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/1424224/
2068,felodipine,3327674,Aspects on the benefit-risk balance of felodipine in hypertension.,"['Elmfeldt D', 'Westerling S']","['Antihypertensive Agents/adverse effects/*therapeutic use', 'Felodipine', 'Humans', 'Hypertension/complications/*drug therapy', 'Nitrendipine/adverse effects/*analogs & derivatives/therapeutic use', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/3327674/
2069,felodipine,21515290,The effect of metoprolol alone and combined metoprolol-felodipin on the digital microcirculation of patients with primary Raynaud's syndrome.,"['Csiki Z', 'Garai I', 'Shemirani AH', 'Papp G', 'Zsori KS', 'Andras C', 'Zeher M']","['Adult', 'Drug Therapy, Combination/methods', 'Felodipine/pharmacology/*therapeutic use', 'Female', 'Fingers/*blood supply', 'Humans', 'Hyperemia/physiopathology', 'Hypertension/complications/physiopathology', 'Laser-Doppler Flowmetry', 'Metoprolol/pharmacology/*therapeutic use', 'Microcirculation/*drug effects/physiology', 'Middle Aged', 'Raynaud Disease/complications/*drug therapy/physiopathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21515290/
2070,felodipine,2404502,Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets.,"['Blychert E', 'Wingstrand K', 'Edgar B', 'Lidman K']","['Adult', 'Biological Availability', 'Blood Pressure/drug effects', 'Delayed-Action Preparations', 'Double-Blind Method', 'Felodipine/administration & dosage/pharmacokinetics/*pharmacology', 'Heart Rate/drug effects', 'Hemodynamics/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Randomized Controlled Trials as Topic', 'Solubility', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/2404502/
2071,felodipine,3069435,"Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.","['Saltiel E', 'Ellrodt AG', 'Monk JP', 'Langley MS']","['Felodipine', 'Humans', 'Hypertension/*drug therapy', 'Metabolic Clearance Rate', 'Nitrendipine/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3069435/
2072,felodipine,1693711,Long-term treatment of hypertension with felodipine.,['Flygt G'],"['Blood Pressure/drug effects', 'Double-Blind Method', 'Drug Therapy, Combination', 'Felodipine/administration & dosage/adverse effects/*therapeutic use', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/1693711/
2073,felodipine,7574861,A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension.,"['Moncica I', 'Oh PI', 'ul Qamar I', 'Scolnik D', 'Arbus GS', 'Hebert D', 'Balfe JW', 'Koren G']","['Adolescent', 'Antihypertensive Agents/*therapeutic use', 'Child', 'Cross-Over Studies', 'Delayed-Action Preparations', 'Drug Administration Schedule', 'Felodipine/*therapeutic use', 'Humans', 'Hypertension, Renal/*drug therapy', 'Nifedipine/*therapeutic use', 'Patient Compliance']",https://pubmed.ncbi.nlm.nih.gov/7574861/
2074,felodipine,2676559,The clinical effect of felodipine and nifedipine in Raynaud's phenomenon.,"['Schmidt JF', 'Valentin N', 'Nielsen SL']","['Adolescent', 'Adult', 'Child', 'Child, Preschool', 'Double-Blind Method', 'Felodipine/adverse effects/*therapeutic use', 'Female', 'Humans', 'Infant', 'Male', 'Nifedipine/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Raynaud Disease/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2676559/
2075,metoprolol,38619832,Serious Bleeding in Patients With Atrial Fibrillation Using Diltiazem With Apixaban or Rivaroxaban.,"['Ray WA', 'Chung CP', 'Stein CM', 'Smalley W', 'Zimmerman E', 'Dupont WD', 'Hung AM', 'Daugherty JR', 'Dickson A', 'Murray KT']","['Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Male', '*Atrial Fibrillation/drug therapy/complications', '*Diltiazem/adverse effects/therapeutic use', 'Drug Therapy, Combination', 'Embolism/prevention & control', '*Factor Xa Inhibitors/adverse effects/therapeutic use', '*Hemorrhage/chemically induced', 'Hospitalization/statistics & numerical data', 'Medicare', 'Metoprolol/adverse effects/therapeutic use/administration & dosage', 'Pyrazoles/adverse effects/therapeutic use', 'Pyridones/adverse effects/therapeutic use/administration & dosage', 'Retrospective Studies', '*Rivaroxaban/adverse effects/therapeutic use', 'United States']",https://pubmed.ncbi.nlm.nih.gov/38619832/
2076,metoprolol,35764772,Clinical Pharmacokinetics of Metoprolol: A Systematic Review.,"['Zamir A', 'Hussain I', 'Ur Rehman A', 'Ashraf W', 'Imran I', 'Saeed H', 'Majeed A', 'Alqahtani F', 'Rasool MF']","['Administration, Oral', 'Area Under Curve', 'Female', 'Food-Drug Interactions', 'Humans', '*Liver', '*Metoprolol/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/35764772/
2077,metoprolol,34781150,Intravenous diltiazem versus metoprolol for atrial fibrillation with rapid ventricular rate: A meta-analysis.,"['Lan Q', 'Wu F', 'Han B', 'Ma L', 'Han J', 'Yao Y']","['Administration, Intravenous', 'Atrial Fibrillation/*drug therapy', 'Blood Pressure/drug effects', 'Diltiazem/administration & dosage/*therapeutic use', 'Heart Rate/*drug effects', 'Humans', 'Metoprolol/administration & dosage/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/34781150/
2078,metoprolol,2668307,"Metoprolol-controlled release, zero order kinetics.",['Kendall MJ'],"['Delayed-Action Preparations', 'Humans', 'Metoprolol/administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/2668307/
2079,metoprolol,18479744,Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.,"['Devereaux PJ', 'Yang H', 'Yusuf S', 'Guyatt G', 'Leslie K', 'Villar JC', 'Xavier D', 'Chrolavicius S', 'Greenspan L', 'Pogue J', 'Pais P', 'Liu L', 'Xu S', 'Malaga G', 'Avezum A', 'Chan M', 'Montori VM', 'Jacka M', 'Choi P']","['Adrenergic beta-Antagonists/adverse effects/pharmacology/*therapeutic use', 'Aged', 'Blood Pressure/drug effects', 'Cardiovascular Diseases/mortality/*prevention & control', 'Delayed-Action Preparations', 'Female', 'Humans', 'Intraoperative Complications/*prevention & control', 'Male', 'Metoprolol/adverse effects/*analogs & derivatives/pharmacology/therapeutic use', 'Middle Aged', 'Perioperative Care/*methods', 'Preoperative Care/*methods', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/18479744/
2080,metoprolol,2871805,Use of beta adrenoceptor blockade during and after acute myocardial infarction.,['Sleight P'],"['Adrenergic beta-Antagonists/*therapeutic use', 'Arrhythmias, Cardiac/drug therapy', 'Atenolol/administration & dosage/therapeutic use', 'Cardiotonic Agents/therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Fibrinolytic Agents/administration & dosage', 'Heart Rupture/prevention & control', 'Humans', 'Injections, Intravenous', 'Male', 'Metoprolol/administration & dosage/therapeutic use', 'Myocardial Infarction/*drug therapy/mortality/prevention & control', 'Random Allocation', 'Retrospective Studies', 'Risk', 'Streptokinase/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/2871805/
2081,metoprolol,2723107,Obesity and beta-blockers: influence of body fat on their kinetics and cardiovascular effects.,"['Galletti F', 'Fasano ML', 'Ferrara LA', 'Groppi A', 'Montagna M', 'Mancini M']","['Adipose Tissue/*metabolism', 'Atenolol/blood/*pharmacokinetics/therapeutic use', 'Blood Pressure/drug effects', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*complications/drug therapy/metabolism', 'Kinetics', 'Male', 'Metoprolol/blood/*pharmacokinetics/therapeutic use', 'Middle Aged', 'Obesity/complications/*metabolism', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/2723107/
2082,metoprolol,21547667,Pulsatile multiparticulate drug delivery system for metoprolol succinate.,"['Jagdale SC', 'Chede SM', 'Gulwady R', 'Kuchekar BS', 'Lokhande PD', 'Shah TP', 'Chabukswar AR']","['Adrenergic beta-Antagonists/*administration & dosage/therapeutic use', 'Cardiovascular Diseases/drug therapy', 'Chemistry, Pharmaceutical', 'Delayed-Action Preparations', 'Drug Carriers/*chemistry', 'Drug Chronotherapy', 'Drug Compounding/methods', 'Drug Stability', 'Humans', 'Metoprolol/administration & dosage/*analogs & derivatives/therapeutic use', 'Solubility']",https://pubmed.ncbi.nlm.nih.gov/21547667/
2083,metoprolol,7059440,Comparison of the pharmacodynamic and pharmacokinetic profiles of single and multiple doses of a commercial slow-release metoprolol formulation with a new Oros delivery system.,"['Kendall MJ', 'Jack DB', 'Woods KL', 'Laugher SJ', 'Quarterman CP', 'John VA']","['Adult', 'Blood Pressure/drug effects', 'Delayed-Action Preparations', 'Double-Blind Method', 'Heart Rate/drug effects', 'Hemodynamics/*drug effects', 'Humans', 'Kinetics', 'Male', 'Metoprolol/*administration & dosage/metabolism/pharmacology', 'Physical Exertion', 'Propanolamines/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/7059440/
2084,metoprolol,2715675,Aqueous humor concentration of metoprolol after oral administration.,"['Calissendorff B', 'Savvaides I']","['Administration, Oral', 'Adult', 'Aged', 'Aged, 80 and over', 'Aqueous Humor/*metabolism', 'Female', 'Half-Life', 'Humans', 'Male', 'Metoprolol/administration & dosage/*pharmacokinetics', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/2715675/
2085,metoprolol,409024,Metoprolol and the peripheral platelet count.,"['Kutti J', 'Bergstrom AL', 'Lundborg P']","['Administration, Oral', 'Adolescent', 'Adult', 'Blood Cell Count', 'Blood Platelets/*drug effects', 'Female', 'Humans', 'Male', 'Metoprolol/administration & dosage/*pharmacology', 'Middle Aged', 'Propanolamines/*pharmacology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/409024/
2086,metoprolol,12784773,"Tolerability of beta-blockers in heart failure: reassurance needed, reassurance provided.",['Krum H'],"['Adrenergic beta-Antagonists/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Heart Failure/*drug therapy', 'Humans', 'Metoprolol/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12784773/
2087,metoprolol,2280237,"Antihypertensive drugs and glucose metabolism: comparison between a diuretic, a beta-blocker and felodipine, a new calcium antagonist in subjects with arterial hypertension and diabetes.","['Lundgren H', 'Bengtsson C', 'Lapidus L', 'Bengtsson L']","['Aged', 'Blood Glucose/*drug effects', 'Diabetes Mellitus/*chemically induced', 'Double-Blind Method', 'Felodipine/adverse effects/*therapeutic use', 'Female', 'Glucose Tolerance Test', 'Humans', 'Hydrochlorothiazide/adverse effects/*therapeutic use', 'Hypertension/*drug therapy', 'Male', 'Metoprolol/adverse effects/*therapeutic use', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/2280237/
2088,metoprolol,3829948,[Can beta-receptor blockers trigger coronary spasm?].,"['Cieslinski G', 'Hopf R', 'Kober G', 'Kaltenbach M']","['Cardiac Catheterization', 'Coronary Vasospasm/*chemically induced/diagnosis', 'Exercise Test', 'Female', 'Humans', 'Hypertension/drug therapy', 'Male', 'Metoprolol/*adverse effects/therapeutic use', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/3829948/
2089,metoprolol,32420783,"The comparison of side effects of methyldopa, amlodipine, and metoprolol in pregnant women with chronic hypertension.","['Ghafarzadeh M', 'Shakarami A', 'Yari F', 'Namdari P']","['Adult', 'Amlodipine/administration & dosage/*adverse effects', 'Antihypertensive Agents/administration & dosage/*adverse effects', 'Blood Pressure/drug effects', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Incidence', 'Methyldopa/administration & dosage/*adverse effects', 'Metoprolol/administration & dosage/*adverse effects', 'Obstetric Labor, Premature/chemically induced/*epidemiology', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/*drug therapy', 'Prevalence', 'Retrospective Studies', 'Risk']",https://pubmed.ncbi.nlm.nih.gov/32420783/
2090,metoprolol,6961757,Peripheral vasospasm during beta-receptor blockade - a comparison between metoprolol and pindolol.,"['Eliasson K', 'Lins LE', 'Sundqvist K']","['Adult', 'Angina Pectoris/drug therapy', 'Forearm/blood supply', 'Humans', 'Male', 'Metoprolol/*adverse effects/therapeutic use', 'Middle Aged', 'Pindolol/*adverse effects/therapeutic use', 'Propanolamines/*adverse effects', 'Raynaud Disease/*chemically induced', 'Regional Blood Flow/drug effects', 'Skin Temperature/drug effects']",https://pubmed.ncbi.nlm.nih.gov/6961757/
2091,metoprolol,7038656,Once-daily metoprolol for hypertension.,"['Ward MJ', 'Roland JM', 'Banks DC']","['Antihypertensive Agents', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Administration Schedule', 'Humans', 'Hypertension/*drug therapy', 'Metoprolol/administration & dosage/*therapeutic use', 'Patient Compliance', 'Propanolamines/*therapeutic use', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/7038656/
2092,metoprolol,18174771,"Treatment with metoprolol succinate, a selective beta adrenergic blocker, lowers blood pressure without altering insulin sensitivity in diabetic patients.","['Falkner B', 'Kushner H']","['Adrenergic beta-Antagonists/administration & dosage/*pharmacology/therapeutic use', 'Adult', 'Aged', 'Blood Pressure/*drug effects', 'Diabetes Mellitus, Type 2/*physiopathology', 'Diabetic Angiopathies/drug therapy', 'Female', 'Glucose Clamp Technique', 'Humans', 'Hypertension/drug therapy', 'Insulin/metabolism', '*Insulin Resistance', 'Male', 'Metoprolol/administration & dosage/*analogs & derivatives/pharmacology/therapeutic use', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/18174771/
2093,metoprolol,6973256,Intravenous metoprolol for the treatment of acute supraventricular tachyarrhythmias.,"['Stroobandt R', 'Kesteloot H']","['Aged', 'Atrial Fibrillation/drug therapy', 'Atrial Flutter/drug therapy', 'Female', 'Humans', 'Injections, Intravenous', 'Male', 'Metoprolol/*administration & dosage/adverse effects', 'Middle Aged', 'Propanolamines/*administration & dosage', 'Tachycardia/*drug therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6973256/
2094,metoprolol,453778,Metoprolol in the treatment of supraventricular tachyarrhythmias.,"['Moller B', 'Ringqvist C']","['Adult', 'Aged', 'Atrial Fibrillation/*drug therapy', 'Atrial Flutter/*drug therapy', 'Blood Pressure/drug effects', 'Drug Evaluation', 'Female', 'Heart Rate/drug effects', 'Humans', 'Injections, Intravenous', 'Male', 'Metoprolol/administration & dosage/adverse effects/*therapeutic use', 'Middle Aged', 'Myocardial Contraction/drug effects', 'Propanolamines/*therapeutic use', 'Tachycardia, Paroxysmal/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/453778/
2095,ketoprofen,27103611,Topical NSAIDs for chronic musculoskeletal pain in adults.,"['Derry S', 'Conaghan P', 'Da Silva JA', 'Wiffen PJ', 'Moore RA']","['Administration, Topical', 'Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects', 'Chronic Pain/*drug therapy', 'Diclofenac/*administration & dosage/adverse effects', 'Humans', 'Ketoprofen/*administration & dosage/adverse effects', 'Musculoskeletal Pain/*drug therapy', 'Numbers Needed To Treat', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/27103611/
2096,ketoprofen,11317922,[Allergies to ketoprofen gels].,['Milpied-Homsi B'],"['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects', 'Dermatitis, Allergic Contact/diagnosis/*etiology', 'Dermatitis, Photoallergic/diagnosis/etiology', 'Drug Eruptions/diagnosis/*etiology', 'Female', 'Follow-Up Studies', 'Gels/adverse effects', 'Humans', 'Ketoprofen/administration & dosage/*adverse effects', 'Male', 'Photosensitivity Disorders/*complications/diagnosis/prevention & control', 'Skin Tests', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/11317922/
2097,ketoprofen,28474616,Ketoprofen-induced photoallergic dermatitis.,"['Loh TY', 'Cohen PR']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Dermatitis, Photoallergic/etiology/*pathology', 'Exanthema/chemically induced/drug therapy/pathology', 'Humans', 'Ketoprofen/*adverse effects/therapeutic use', 'Photosensitivity Disorders/chemically induced/*pathology', 'Sunscreening Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28474616/
2098,ketoprofen,19832694,Ketoprofen allergic reactions.,"['Cantisani C', 'Grieco T', 'Faina V', 'Mattozzi C', 'Bohnenberger H', 'Silvestri E', 'Calvieri S']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Cross Reactions/immunology', 'Dermatitis, Photoallergic/etiology/*immunology', 'Drug Delivery Systems', 'Drug Hypersensitivity/etiology/*immunology', 'Humans', 'Ketoprofen/*adverse effects/chemistry/therapeutic use', 'Musculoskeletal Diseases/*drug therapy', 'Patents as Topic']",https://pubmed.ncbi.nlm.nih.gov/19832694/
2099,ketoprofen,38813682,Efficacy and safety of simple analgesics for acute treatment of episodic tension-type headache in adults: a network meta-analysis.,"['Xie R', 'Li J', 'Jing Y', 'Tian J', 'Li H', 'Cai Y', 'Wang Y', 'Chen W', 'Xu F']","['Humans', '*Tension-Type Headache/drug therapy', '*Analgesics/adverse effects/therapeutic use/administration & dosage', 'Adult', '*Network Meta-Analysis', '*Ibuprofen/adverse effects/administration & dosage/therapeutic use', 'Acetaminophen/therapeutic use/adverse effects/administration & dosage', 'Bayes Theorem', 'Treatment Outcome', 'Diclofenac/adverse effects/therapeutic use/administration & dosage', 'Randomized Controlled Trials as Topic', 'Naproxen/therapeutic use/adverse effects/administration & dosage', 'Ketoprofen/adverse effects/therapeutic use/administration & dosage/analogs & derivatives', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use/administration & dosage', 'Female', 'Male']",https://pubmed.ncbi.nlm.nih.gov/38813682/
2100,ketoprofen,16274258,Topical ketoprofen patch.,['Mazieres B'],"['Administration, Cutaneous', '*Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Humans', '*Ketoprofen/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Pain/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16274258/
2101,ketoprofen,7002065,Clotrimazole in rheumatoid arthritis.,"['Wojtulewski JA', 'Gow PJ', 'Walter J', 'Grahame R', 'Gibson T', 'Panayi GS', 'Mason J']","['Arthritis, Rheumatoid/*drug therapy', 'Clinical Trials as Topic', 'Clotrimazole/adverse effects/*therapeutic use', 'Double-Blind Method', 'Humans', 'Imidazoles/*therapeutic use', 'Ketoprofen/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7002065/
2102,ketoprofen,7938218,Photochemical and photobiological properties of ketoprofen associated with the benzophenone chromophore.,"['Bosca F', 'Miranda MA', 'Carganico G', 'Mauleon D']","['Dermatitis, Phototoxic/etiology', 'Humans', 'In Vitro Techniques', 'Ketoprofen/adverse effects/chemistry/*radiation effects', 'Lipid Peroxidation/drug effects/radiation effects', 'Molecular Structure', 'Photochemistry']",https://pubmed.ncbi.nlm.nih.gov/7938218/
2103,ketoprofen,7506182,Tolerability of nimesulide and ketoprofen in paediatric patients with traumatic or surgical fractures.,"['Facchini R', 'Selva G', 'Peretti G']","['Adolescent', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Child', 'Female', 'Fractures, Bone/*drug therapy', 'Humans', 'Ketoprofen/adverse effects/*therapeutic use', 'Male', 'Pain/*drug therapy', 'Sulfonamides/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7506182/
2104,ketoprofen,796946,A clinical study of ketoprofen suppositories.,"['Fournie A', 'Ayrolles C']","['*Anti-Inflammatory Agents', 'Arthritis, Rheumatoid/*drug therapy', 'Benzophenones/*administration & dosage', 'Clinical Trials as Topic', 'Humans', 'Ketoprofen/*administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/796946/
2105,ketoprofen,39809346,Investigation of the suitability of confocal Raman spectroscopy for the demonstration of bioequivalence of topical products.,"['Gaiser A', 'Lunter D']","['*Therapeutic Equivalency', '*Spectrum Analysis, Raman/methods', 'Animals', 'Swine', '*Skin Absorption', '*Skin/metabolism', '*Ketoprofen/pharmacokinetics/administration & dosage/chemistry', 'Humans', 'Administration, Cutaneous', 'Male']",https://pubmed.ncbi.nlm.nih.gov/39809346/
2106,ketoprofen,33932737,Future prospects of ketoprofen in improving the safety of the gastric mucosa.,"['Kuczynska J', 'Nieradko-Iwanicka B']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage', 'Gastric Mucosa/*drug effects', 'Humans', 'Ketoprofen/*administration & dosage', 'Stomach Ulcer/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/33932737/
2107,ketoprofen,23711416,Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis.,"['Sarzi-Puttini P', 'Atzeni F', 'Lanata L', 'Bagnasco M']","['Administration, Oral', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*therapeutic use', 'Diclofenac/administration & dosage/adverse effects/*therapeutic use', 'Female', 'Humans', 'Ibuprofen/administration & dosage/adverse effects/*therapeutic use', 'Ketoprofen/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Pain/diagnosis/*drug therapy', 'Pain Measurement', 'Patient Selection', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23711416/
2108,ketoprofen,24359044,Paracetamol vs dexketoprofen for perineal pain relief after episiotomy or perineal tear.,"['Akil A', 'Api O', 'Bektas Y', 'Yilmaz AO', 'Yalti S', 'Unal O']","['Acetaminophen/*therapeutic use', 'Adult', 'Analgesics, Non-Narcotic/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Double-Blind Method', 'Episiotomy/adverse effects', 'Female', 'Humans', 'Infusions, Intravenous', 'Ketoprofen/*analogs & derivatives/therapeutic use', 'Pain/*drug therapy/etiology', 'Perineum/injuries', 'Pregnancy', 'Tromethamine/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24359044/
2109,ketoprofen,25567464,Ataxia caused by a single dose of dexketoprofen trometamol.,"['Avci S', 'Genc S', 'Aydin M', 'Buyukcam F', 'Ozkan S']","['Administration, Oral', 'Adult', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects', 'Ataxia/*chemically induced', 'Dose-Response Relationship, Drug', 'Female', 'Follow-Up Studies', 'Humans', 'Ketoprofen/administration & dosage/adverse effects/*analogs & derivatives', 'Tromethamine/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/25567464/
2110,ketoprofen,126848,A comparative trial of azapropazone and ketoprofen in the treatment of acute backache.,"['Hingorani K', 'Templeton JS']","['Acute Disease', 'Adult', 'Aged', 'Apazone/adverse effects/*therapeutic use', 'Back Pain/*drug therapy', 'Benzophenones/*therapeutic use', 'Female', 'Humans', 'Ketoprofen/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Triazines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/126848/
2111,ketoprofen,25412595,Esophagitis due to dexketoprofen trometamol: a rare case report.,"['Olmez S', 'Donmez S', 'Aslan M', 'Karadas S', 'Yavuz A']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Chest Pain/chemically induced', 'Deglutition Disorders/chemically induced', 'Diagnosis, Differential', 'Esophagitis/*chemically induced/diagnosis', 'Esophagoscopy', 'Heartburn/chemically induced', 'Humans', 'Ketoprofen/adverse effects/*analogs & derivatives/therapeutic use', 'Male', 'Risk Factors', 'Tromethamine/*adverse effects/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25412595/
2112,ketoprofen,773499,Four new anti-inflammatory drugs: responses and variations.,"['Huskisson EC', 'Woolf DL', 'Balme HW', 'Scott J', 'Franklin S']","['Anti-Inflammatory Agents/adverse effects/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Clinical Trials as Topic', 'Fenoprofen/adverse effects/therapeutic use', 'Gastrointestinal Diseases/chemically induced', 'Humans', 'Ibuprofen/adverse effects/therapeutic use', 'Ketoprofen/adverse effects/therapeutic use', 'Naproxen/adverse effects/therapeutic use', 'Pain']",https://pubmed.ncbi.nlm.nih.gov/773499/
2113,ketoprofen,30876777,Intradermal mesotherapy versus systemic therapy in the treatment of musculoskeletal pain: A prospective randomized study.,['Kocak AO'],"['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/therapeutic use', 'Emergency Service, Hospital', 'Female', 'Follow-Up Studies', 'Humans', 'Injections, Intravenous', 'Ketoprofen/administration & dosage/*analogs & derivatives/therapeutic use', 'Male', '*Mesotherapy', 'Middle Aged', 'Musculoskeletal Pain/*drug therapy', 'Piroxicam/administration & dosage/*analogs & derivatives/therapeutic use', 'Prospective Studies', 'Treatment Outcome', 'Tromethamine/*administration & dosage/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30876777/
2114,ketoprofen,21052564,Pain and ketoprofen: what is its role in clinical practice?,"['Sarzi-Puttini P', 'Atzeni F', 'Lanata L', 'Bagnasco M', 'Colombo M', 'Fischer F', ""D'Imporzano M""]","['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Calcinosis/prevention & control', 'Cardiovascular Diseases/chemically induced/epidemiology', 'Chronic Disease', 'Clinical Trials as Topic', 'Drug Administration Routes', 'Gout/drug therapy', 'Humans', 'Hyperalgesia/drug therapy/physiopathology', 'Ketoprofen/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Osteoarthritis/drug therapy', 'Pain/classification/*drug therapy/epidemiology/physiopathology', 'Pain Perception/drug effects/physiology', 'Pain, Postoperative/drug therapy', 'Postoperative Complications/prevention & control', 'Soft Tissue Injuries/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21052564/
2115,lansoprazole,36228734,Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.,"['Laine L', 'DeVault K', 'Katz P', 'Mitev S', 'Lowe J', 'Hunt B', 'Spechler S']","['Adult', 'Humans', 'Lansoprazole/therapeutic use', 'Pyrroles/adverse effects', 'Sulfonamides/therapeutic use', '*Esophagitis', 'Proton Pump Inhibitors/therapeutic use', '*Peptic Ulcer', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36228734/
2116,lansoprazole,35679950,Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.,"['Chey WD', 'Megraud F', 'Laine L', 'Lopez LJ', 'Hunt BJ', 'Howden CW']","['Adult', 'Amoxicillin/adverse effects', 'Anti-Bacterial Agents/adverse effects', 'Clarithromycin/adverse effects', 'Drug Therapy, Combination', '*Helicobacter Infections/diagnosis/drug therapy', '*Helicobacter pylori', 'Humans', 'Lansoprazole/adverse effects', 'Proton Pump Inhibitors/adverse effects', 'Pyrroles', 'Sulfonamides', 'Treatment Outcome', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/35679950/
2117,lansoprazole,36142643,Proton Pump Inhibitors and Bone Health: An Update Narrative Review.,"['Lespessailles E', 'Toumi H']","['2-Pyridinylmethylsulfinylbenzimidazoles', 'Adenosine Triphosphatases', 'Antacids', 'Bone Density', 'Dexlansoprazole', 'Esomeprazole', 'Humans', 'Lansoprazole', 'Omeprazole/pharmacology', '*Osteoporotic Fractures/drug therapy', 'Pantoprazole', '*Proton Pump Inhibitors/adverse effects', 'Rabeprazole', 'United States']",https://pubmed.ncbi.nlm.nih.gov/36142643/
2118,lansoprazole,19708852,Dexlansoprazole MR.,"['Aslam N', 'Wright R']","['2-Pyridinylmethylsulfinylbenzimidazoles/adverse effects/*pharmacokinetics', 'Acute Disease', 'Anti-Ulcer Agents/adverse effects/*pharmacokinetics', 'Delayed-Action Preparations/metabolism/pharmacokinetics', 'Dexlansoprazole', 'Esophagitis, Peptic/drug therapy', 'Gastroesophageal Reflux/drug therapy', 'Humans', 'Lansoprazole', '*Proton Pump Inhibitors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/19708852/
2119,lansoprazole,37849071,Clinical pharmacokinetics of nebivolol: a systematic review.,"['Hanif N', 'Zamir A', 'Imran I', 'Saeed H', 'Majeed A', 'Rehman AU', 'Ashraf W', 'Alqahtani F', 'Rasool MF']","['Male', 'Humans', 'Nebivolol/pharmacokinetics/therapeutic use', '*Hypertension/drug therapy', 'Fluvoxamine/therapeutic use', 'Lansoprazole/therapeutic use', 'Drug Interactions']",https://pubmed.ncbi.nlm.nih.gov/37849071/
2120,lansoprazole,37883084,"Ceftriaxone and the Risk of Ventricular Arrhythmia, Cardiac Arrest, and Death Among Patients Receiving Lansoprazole.","['Bai AD', 'Wilkinson A', 'Almufleh A', 'Rai M', 'Razak F', 'Verma AA', 'Srivastava S']","['Adult', 'Humans', 'Male', 'Aged', 'Female', 'Lansoprazole/therapeutic use', '*Ceftriaxone/adverse effects', 'Cohort Studies', 'Retrospective Studies', 'Arrhythmias, Cardiac/chemically induced/epidemiology', '*Heart Arrest/chemically induced/epidemiology', 'Proton Pump Inhibitors/adverse effects', 'Inpatients', 'Ontario/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/37883084/
2121,lansoprazole,27782887,"Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastric pH in extensive metabolizer patients with gastroesophageal reflux disease.","['Celebi A', 'Aydin D', 'Kocaman O', 'Konduk BT', 'Senturk O', 'Hulagu S']","['2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/pharmacology', 'Adult', 'Cross-Over Studies', 'Cytochrome P-450 CYP2C19/*metabolism', 'Double-Blind Method', 'Esomeprazole/administration & dosage/pharmacology', 'Female', 'Gastric Acid/*chemistry', 'Gastroesophageal Reflux/*drug therapy/genetics', 'Genotype', 'Humans', 'Hydrogen-Ion Concentration/*drug effects', 'Lansoprazole/administration & dosage/pharmacology', 'Male', 'Middle Aged', 'Pantoprazole', 'Proton Pump Inhibitors/administration & dosage/*pharmacology', 'Rabeprazole/administration & dosage/pharmacology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27782887/
2122,lansoprazole,24414180,Lansoprazole-induced hypomagnesaemia.,"['Krupa LZ', 'Fellows IW']","['Aged', 'Female', 'Humans', 'Hypocalcemia/chemically induced', 'Lansoprazole/*adverse effects', 'Magnesium/*therapeutic use', 'Magnesium Deficiency/*chemically induced/complications', 'Proton Pump Inhibitors/*adverse effects', 'Tachycardia, Supraventricular/etiology', 'Withholding Treatment']",https://pubmed.ncbi.nlm.nih.gov/24414180/
2123,lansoprazole,38897240,Concomitant use of lansoprazole and ceftriaxone is associated with an increased risk of ventricular arrhythmias and cardiac arrest in a large Japanese hospital database.,"['Mitsuboshi S', 'Imai S', 'Kizaki H', 'Hori S']","['Humans', '*Lansoprazole/adverse effects/administration & dosage', '*Ceftriaxone/adverse effects/administration & dosage', '*Heart Arrest/chemically induced/epidemiology', 'Male', 'Japan/epidemiology', 'Female', 'Aged', 'Middle Aged', '*Proton Pump Inhibitors/adverse effects/administration & dosage', '*Arrhythmias, Cardiac/chemically induced/epidemiology', 'Anti-Bacterial Agents/adverse effects/administration & dosage', 'Databases, Factual', 'Aged, 80 and over', 'Adult', 'Retrospective Studies', 'Incidence', 'Administration, Oral', 'Risk Factors', 'Drug Therapy, Combination/adverse effects', 'East Asian People']",https://pubmed.ncbi.nlm.nih.gov/38897240/
2124,lansoprazole,21366513,Dexlansoprazole MR: a review.,"['Hershcovici T', 'Jha LK', 'Fass R']","['2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/adverse effects/*therapeutic use', 'Delayed-Action Preparations', 'Dexlansoprazole', 'Esophagitis/*drug therapy/physiopathology', 'Gastroesophageal Reflux/drug therapy/physiopathology', 'Humans', 'Lansoprazole', 'Mucous Membrane/pathology', 'Proton Pump Inhibitors/administration & dosage/adverse effects/*therapeutic use', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/21366513/
2125,lansoprazole,32701188,"Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.","['Cho YK', 'Choi MG', 'Choi SC', 'Lee KM', 'Kim TO', 'Park SH', 'Moon JS', 'Lim YJ', 'Kang DH', 'Cheon GJ', 'Baik GH', 'Kim KO', 'Cho KB', 'Jang JS', 'Park JJ', 'Son BK', 'Jung HK', 'Kim BW', 'Kim SK', 'Lee ST', 'Cha JM', 'Kim AR', 'Kim EJ', 'Park HW', 'Song GS']","['Adult', 'Aged', 'Anti-Ulcer Agents/administration & dosage/adverse effects', 'Benzene Derivatives/*administration & dosage/adverse effects', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Administration Schedule', 'Female', 'Humans', 'Imidazoles/*administration & dosage/adverse effects', 'Lansoprazole/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Potassium/metabolism', 'Proton Pump Inhibitors/administration & dosage/adverse effects', 'Republic of Korea', 'Stomach Ulcer/*drug therapy', 'Treatment Outcome', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/32701188/
2126,lansoprazole,37127558,Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis.,"['Haruma K', 'Kinoshita Y', 'Yao T', 'Kushima R', 'Akiyama J', 'Aoyama N', 'Kanoo T', 'Miyata K', 'Kusumoto N', 'Uemura N']","['Humans', 'Proton Pump Inhibitors/therapeutic use', 'Hyperplasia', '*Esophagitis', 'Lansoprazole/adverse effects', '*Peptic Ulcer', 'Treatment Outcome', '2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use', '*Anti-Ulcer Agents/therapeutic use', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/37127558/
2127,lansoprazole,35294415,Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects.,"['Laine L', 'Sharma P', 'Mulford DJ', 'Hunt B', 'Leifke E', 'Smith N', 'Howden CW']","['Adult', 'Humans', 'Hydrogen-Ion Concentration', 'Lansoprazole/pharmacology', '*Potassium', '*Proton Pump Inhibitors/pharmacology', 'Pyrroles/pharmacology', 'Sulfonamides']",https://pubmed.ncbi.nlm.nih.gov/35294415/
2128,lansoprazole,31409606,"Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.","['Xiao Y', 'Zhang S', 'Dai N', 'Fei G', 'Goh KL', 'Chun HJ', 'Sheu BS', 'Chong CF', 'Funao N', 'Zhou W', 'Chen M']","['Adult', 'Aged', 'Double-Blind Method', 'Drug Administration Schedule', 'Esophagitis, Peptic/*drug therapy', 'Female', 'Humans', 'Lansoprazole/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Proton Pump Inhibitors/administration & dosage/adverse effects/*therapeutic use', 'Pyrroles/administration & dosage/adverse effects/*therapeutic use', 'Severity of Illness Index', 'Sulfonamides/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome', 'Wound Healing']",https://pubmed.ncbi.nlm.nih.gov/31409606/
2129,lansoprazole,38777170,Comparison of Los Angeles Grades of Erosive Esophagitis Scored by Local Investigators vs Central Adjudicators in a Clinical Trial.,"['Spechler SJ', 'Laine L', 'DeVault KR', 'Nabulsi A', 'Hunt B', 'Katz P']","['Adult', 'Female', 'Humans', 'Male', 'Middle Aged', '*Esophagitis/pathology/diagnosis/drug therapy', 'Lansoprazole/therapeutic use', 'Pyrroles/therapeutic use', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/38777170/
2130,lansoprazole,20687622,Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.,"['Croxtall JD', 'Scott LJ']","['2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/pharmacology/*therapeutic use', 'Anti-Ulcer Agents/administration & dosage/pharmacology/*therapeutic use', 'Delayed-Action Preparations', 'Dexlansoprazole', 'Esophagitis/*drug therapy', 'Gastroesophageal Reflux/*drug therapy', 'Humans', 'Lansoprazole', 'Proton Pump Inhibitors/administration & dosage/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20687622/
2131,lansoprazole,26420698,Upper gastrointestinal bleed associated with cholinesterase inhibitor use.,"['Kok KS', 'Loke Y', 'Southgate J']","['Aged, 80 and over', 'Alzheimer Disease', 'Cholinesterase Inhibitors/administration & dosage/*adverse effects', 'Donepezil', 'Duodenal Ulcer/*diagnosis/*drug therapy', 'Endoscopy/methods', 'Gastrointestinal Hemorrhage/chemically induced', 'Humans', 'Indans/administration & dosage/*adverse effects', 'Lansoprazole/*administration & dosage', 'Male', 'Piperidines/administration & dosage/*adverse effects', 'Proton Pump Inhibitors/*administration & dosage', 'Syncope/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/26420698/
2132,lansoprazole,38654422,Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial.,"['Xiao Y', 'Qian J', 'Zhang S', 'Dai N', 'Chun HJ', 'Chiu C', 'Chong CF', 'Funao N', 'Sakurai Y', 'Eisner JD', 'Xie L', 'Chen M']","['Adult', 'East Asian People', '*Proton Pump Inhibitors/therapeutic use', 'Female', 'Humans', 'Aged', 'Middle Aged', 'Male', '*Sulfonamides/therapeutic use', 'Esophagitis, Peptic/drug therapy', 'Asian People', 'China', 'Esophagitis/drug therapy', 'Republic of Korea', 'Malaysia', '*Pyrroles/therapeutic use', '*Lansoprazole/therapeutic use', 'Southeast Asian People', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/38654422/
2133,lansoprazole,26559637,"Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.","['Ashida K', 'Sakurai Y', 'Hori T', 'Kudou K', 'Nishimura A', 'Hiramatsu N', 'Umegaki E', 'Iwakiri K']","['Adult', 'Aged', 'Cytochrome P-450 CYP2C19/metabolism', 'Double-Blind Method', 'Esophagitis/*drug therapy', 'Female', 'Humans', 'Lansoprazole/*therapeutic use', 'Male', 'Middle Aged', 'Proton Pump Inhibitors/*therapeutic use', 'Pyrroles/*therapeutic use', 'Recurrence', 'Sulfonamides/*therapeutic use', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/26559637/
2134,lansoprazole,8490081,Safety of lansoprazole.,['Colin-Jones DG'],"['2-Pyridinylmethylsulfinylbenzimidazoles', 'Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Anti-Ulcer Agents/*adverse effects', 'Clinical Trials as Topic', 'Humans', 'Lansoprazole', 'Middle Aged', 'Omeprazole/adverse effects/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/8490081/
2135,Tobracin,3317953,Tobramycin in ophthalmology.,"['Wilhelmus KR', 'Gilbert ML', 'Osato MS']","['Blepharitis/drug therapy', 'Cellulitis/drug therapy', 'Conjunctivitis/drug therapy', 'Ear Diseases/chemically induced', 'Endophthalmitis/drug therapy', 'Humans', 'Keratitis/drug therapy', 'Kidney Diseases/chemically induced', 'Neuromuscular Junction/drug effects', 'Ophthalmology/*methods', 'Orbital Diseases/drug therapy', 'Tobramycin/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3317953/
2136,Tobracin,20030477,Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.,"['Prescott WA Jr', 'Nagel JL']","['Adolescent', 'Adult', 'Aged', 'Aminoglycosides/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Anti-Bacterial Agents/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Child', 'Clinical Trials as Topic', 'Cystic Fibrosis/*complications', 'Drug Administration Schedule', 'Drug Monitoring', 'Humans', 'Middle Aged', 'Respiratory Tract Infections/complications/*drug therapy', 'Tobramycin/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/20030477/
2137,Tobracin,20814306,Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity.,"['Prayle A', 'Smyth AR']","['Acute Kidney Injury/chemically induced', 'Aminoglycosides/*adverse effects/*therapeutic use', 'Cystic Fibrosis/*drug therapy', 'Dose-Response Relationship, Drug', 'Gentamicins/adverse effects/therapeutic use', 'Humans', 'Tobramycin/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20814306/
2138,Tobracin,37026770,Acute Kidney Injury because of Implanted Tobramycin Pellets: A Case Report.,"['Windfeld-Mathiasen J', 'Horwitz H', 'Schwartz F']","['Male', 'Humans', 'Middle Aged', '*Tobramycin/adverse effects/pharmacokinetics', 'Anti-Bacterial Agents/adverse effects', '*Acute Kidney Injury/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37026770/
2139,Tobracin,7715376,Management of chronic sinusitis in cystic fibrosis.,"['Davidson TM', 'Murphy C', 'Mitchell M', 'Smith C', 'Light M']","['Adolescent', 'Adult', 'Child', 'Child, Preschool', 'Chronic Disease', 'Clinical Protocols', 'Combined Modality Therapy', 'Cystic Fibrosis/*complications', 'Endoscopy', 'Humans', 'Lung Transplantation/adverse effects', 'Maxillary Sinus/surgery', 'Nasal Polyps/surgery', 'Nasal Septum/surgery', 'Pneumonia, Bacterial/prevention & control', 'Preoperative Care', 'Pseudomonas Infections/prevention & control', 'Respiratory Tract Infections/prevention & control', 'Rhinitis/*drug therapy/*surgery', 'Sinusitis/*drug therapy/*surgery', 'Sodium Chloride', 'Therapeutic Irrigation', 'Tobramycin/administration & dosage/therapeutic use', 'Turbinates/surgery']",https://pubmed.ncbi.nlm.nih.gov/7715376/
2140,Tobracin,3285809,Moxalactam vs tobramycin-clindamycin. A randomized trial in secondary peritonitis.,"['Stellato TA', 'Danziger LH', 'Hau T', 'Gauderer MW', 'Ferron JL', 'Gordon N']","['Abscess/drug therapy/surgery', 'Adolescent', 'Adult', 'Bacteroides Infections/drug therapy', 'Clindamycin/administration & dosage/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Combined Modality Therapy', 'Drug Therapy, Combination', 'Escherichia coli Infections/etiology', 'Humans', 'Hypoprothrombinemias/chemically induced', 'Infant, Newborn', 'Middle Aged', 'Moxalactam/adverse effects/blood/*therapeutic use', 'Peritonitis/blood/*drug therapy/surgery', '*Premedication', 'Prospective Studies', 'Random Allocation', 'Sepsis/drug therapy', 'Streptococcal Infections/drug therapy', 'Surgical Wound Infection/etiology', 'Tobramycin/administration & dosage/adverse effects/blood/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3285809/
2141,Tobracin,12571406,Aminoglycoside-induced reversible tubular dysfunction.,"['Alexandridis G', 'Liberopoulos E', 'Elisaf M']","['Aged', 'Alkalosis/chemically induced', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Drug Administration Schedule', 'Female', 'Gentamicins/administration & dosage/*adverse effects', 'Humans', 'Hypokalemia/chemically induced/metabolism', 'Kidney Diseases/*chemically induced/physiopathology', 'Kidney Tubules, Proximal/*physiopathology', 'Magnesium/blood/metabolism', 'Magnesium Deficiency/chemically induced/metabolism', 'Male', 'Potassium Chloride/therapeutic use', 'Tobramycin/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/12571406/
2142,Tobracin,22186073,[Efficacy and future of the aerosoltherapy in the treatment of cystic fibrosis patients infected by Pseudomonas aeruginosa].,"['Rognon A', 'Curti C', 'Montana M', 'Terme T', 'Rathelot P', 'Vanelle P']","['Administration, Inhalation', 'Aerosols', 'Amikacin/administration & dosage/adverse effects/therapeutic use', 'Anti-Infective Agents/*administration & dosage/adverse effects/*therapeutic use', 'Ciprofloxacin/administration & dosage/therapeutic use', 'Colistin/administration & dosage/adverse effects/therapeutic use', 'Cystic Fibrosis/*complications', 'Drug Therapy, Combination', 'Fluoroquinolones/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Pseudomonas Infections/*drug therapy/*etiology/microbiology', 'Pseudomonas aeruginosa/drug effects', 'Tobramycin/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22186073/
2143,Tobracin,38286409,Necessity of Tobramycin trough Levels in Once Daily Iv-Treatment in Patients with Cystic Fibrosis.,"['Schlegtendal A', 'Rettberg S', 'Maier C', 'Brinkmann F', 'Koerner-Rettberg C']","['Humans', 'Anti-Bacterial Agents/administration & dosage', '*Cystic Fibrosis/complications', 'Infusions, Intravenous', '*Pseudomonas Infections/drug therapy', '*Tobramycin/administration & dosage/blood']",https://pubmed.ncbi.nlm.nih.gov/38286409/
2144,Tobracin,21289326,Eradication of Pseudomonas aeruginosa in an adult patient with cystic fibrosis.,"['Hayes D Jr', 'Feola DJ', 'Murphy BS', 'Kuhn RJ', 'Davis GA']","['Adult', 'Anti-Infective Agents/administration & dosage/*therapeutic use', 'Cefepime', 'Cephalosporins/administration & dosage/*therapeutic use', 'Cystic Fibrosis/complications/*drug therapy', 'Drug Therapy, Combination', 'Female', 'Humans', 'Infusions, Intravenous', 'Pseudomonas Infections/complications/*drug therapy', 'Pseudomonas aeruginosa/*drug effects', 'Tobramycin/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21289326/
2145,Tobracin,21367484,[Cornea imagery and keratitis caused by processionary caterpillar hairs].,"['Fournier I', 'Saleh M', 'Beynat J', 'Creuzot-Garcher C', 'Bourcier T', 'Speeg-Schatz C']","['Adolescent', 'Animals', 'Blepharospasm/etiology', 'Combined Modality Therapy', 'Conjunctival Diseases/etiology', 'Cornea/*pathology', 'Corneal Injuries', 'Dexamethasone/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Emergencies', 'Eye Foreign Bodies/*diagnosis/pathology/surgery', 'Histamine Antagonists/administration & dosage/therapeutic use', 'Humans', 'Keratitis/diagnosis/drug therapy/*etiology/pathology/surgery', 'Larva', 'Lubricants/administration & dosage/therapeutic use', 'Male', '*Microscopy, Confocal', 'Moths/*growth & development', 'Ophthalmic Solutions/administration & dosage/therapeutic use', 'Particulate Matter/*adverse effects', '*Sensilla', 'Tobramycin/administration & dosage/therapeutic use', '*Tomography, Optical Coherence']",https://pubmed.ncbi.nlm.nih.gov/21367484/
2146,Tobracin,16889285,Fixed exanthema from systemic tobramycin.,"['Garcia-Rubio I', 'Martinez-Cocera C', 'Robledo Echarren T', 'Vazquez Cortes S']","['Aged', 'Aminoglycosides/administration & dosage/adverse effects/immunology', 'Anti-Bacterial Agents/administration & dosage/*adverse effects/immunology', 'Cross Reactions', 'Drug Hypersensitivity/etiology/immunology', 'Exanthema/*etiology/immunology', 'Female', 'Humans', 'Immunologic Tests', 'Neomycin/administration & dosage/adverse effects/immunology', 'Ophthalmic Solutions', 'Skin Tests', 'Tobramycin/administration & dosage/*adverse effects/immunology']",https://pubmed.ncbi.nlm.nih.gov/16889285/
2147,Tobracin,28634121,Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis.,"['Wang X', 'Koehne-Voss S', 'Anumolu SS', 'Yu J']","['Administration, Inhalation', 'Adolescent', 'Adult', 'Anti-Bacterial Agents/administration & dosage/blood/*pharmacokinetics', 'Biological Availability', 'Child', 'Child, Preschool', 'Computer Simulation', 'Cystic Fibrosis/*complications/drug therapy', 'Female', 'Humans', 'Infant', 'Male', 'Models, Biological', 'Pseudomonas Infections/*complications/*drug therapy', 'Pseudomonas aeruginosa/*drug effects', 'Tobramycin/administration & dosage/blood/*pharmacokinetics', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28634121/
2148,Tobracin,23046902,Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis.,"['Uluer AZ', 'Waltz DA', 'Kalish LA', 'Adams S', 'Gerard C', 'Ericson DA']","['Administration, Inhalation', 'Amiloride/*administration & dosage', 'Anti-Bacterial Agents/*therapeutic use', 'Burkholderia Infections/*drug therapy', 'Chronic Disease', 'Drug Synergism', 'Drug Therapy, Combination', 'Endpoint Determination', 'Humans', 'Tobramycin/*administration & dosage', 'Treatment Failure']",https://pubmed.ncbi.nlm.nih.gov/23046902/
2149,Tobracin,32713806,Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin.,"['Garinis A', 'Gleser M', 'Johns A', 'Larsen E', 'Vachhani J']","['Administration, Intravenous', 'Adolescent', 'Adult', 'Aminoglycosides/administration & dosage/*adverse effects', 'Audiometry, Pure-Tone', 'Cystic Fibrosis/*complications', 'Female', 'Hearing Loss/*chemically induced', 'Humans', 'Male', 'Middle Aged', '*Ototoxicity', 'Prospective Studies', 'Tobramycin/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32713806/
2150,Tobracin,30910434,Vestibulotoxicity in a patient without renal failure after inhaled tobramycin.,"['Kaufman AC', 'Eliades SJ']","['Administration, Inhalation', 'Aged', 'Anti-Bacterial Agents/*administration & dosage/adverse effects/*toxicity', 'Humans', 'Male', 'Pneumonia, Bacterial/drug therapy/microbiology', 'Pseudomonas Infections', 'Pseudomonas aeruginosa', 'Renal Insufficiency', 'Tobramycin/*administration & dosage/adverse effects/*toxicity', 'Treatment Outcome', 'Vestibular Diseases/*chemically induced/diagnosis/rehabilitation', 'Vestibular Function Tests']",https://pubmed.ncbi.nlm.nih.gov/30910434/
2151,Tobracin,39405956,Redox-responsive degradation of antimicrobials with programmable drug release for enhanced antibacterial activity.,"['Zhang Y', 'Yang X', 'Zhao Y', 'Chen F', 'Shi T', 'Wu Z', 'Chen X', 'Zhang M', 'Chen L']","['*Anti-Bacterial Agents/pharmacology/chemistry', '*Oxidation-Reduction', '*Drug Liberation', '*Silver/chemistry/pharmacology', '*Microbial Sensitivity Tests', '*Tobramycin/pharmacology/chemistry/administration & dosage', 'Metal Nanoparticles/chemistry', 'Animals', 'Mice', 'Staphylococcus aureus/drug effects', 'Drug Delivery Systems', 'Particle Size', 'Humans', 'Escherichia coli/drug effects', 'Surface Properties']",https://pubmed.ncbi.nlm.nih.gov/39405956/
2152,Tobracin,19651542,Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.,"['Hubert D', 'Leroy S', 'Nove-Josserand R', 'Murris-Espin M', 'Mely L', 'Dominique S', 'Delaisi B', 'Kho P', 'Kovarik JM']","['Administration, Inhalation', 'Adult', 'Anti-Bacterial Agents/administration & dosage/*pharmacokinetics', 'Cross-Over Studies', 'Cystic Fibrosis/*complications', 'Female', 'Humans', 'Lung/microbiology', 'Lung Diseases', 'Male', 'Nebulizers and Vaporizers', 'Pseudomonas Infections/complications/*drug therapy/microbiology', 'Pseudomonas aeruginosa/*isolation & purification', 'Tobramycin/administration & dosage/*pharmacokinetics', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/19651542/
2153,Tobracin,3402229,Prospective comparison of traditional and pharmacokinetic aminoglycoside dosing methods.,"['Franson TR', 'Quebbeman EJ', 'Whipple J', 'Thomson R', 'Bubrick J', 'Rosenberger SL', 'Ausman RK']","['Gentamicins/*administration & dosage/blood/pharmacokinetics', 'Humans', 'Pharmacy Service, Hospital', 'Prospective Studies', 'Referral and Consultation', 'Tobramycin/*administration & dosage/blood/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/3402229/
2154,Tobracin,1926903,In vivo inactivation of tobramycin by piperacillin.,"['Uber WE', 'Brundage RC', 'White RL', 'Brundage DM', 'Bromley HR']","['Drug Interactions', 'Female', 'Half-Life', 'Humans', 'Kidney Failure, Chronic/complications/*metabolism', 'Male', 'Middle Aged', 'Piperacillin/*adverse effects/pharmacokinetics/therapeutic use', 'Pseudomonas Infections/drug therapy/microbiology', 'Tobramycin/*antagonists & inhibitors/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1926903/
2155,Colesevelam,21342078,Statin-induced myopathy: a review and update.,"['Abd TT', 'Jacobson TA']","['Animals', 'Drug Interactions', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/pharmacology/therapeutic use', 'Muscles/drug effects', 'Muscular Diseases/*chemically induced', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/21342078/
2156,Colesevelam,29671894,Select medications that unexpectedly lower HbA1c levels.,"['Tillman F', 'Kim J']","['Blood Glucose/drug effects', 'Bromocriptine/therapeutic use', 'Colesevelam Hydrochloride/therapeutic use', 'Diabetes Mellitus, Type 2/*drug therapy/metabolism', 'Glycated Hemoglobin/*metabolism', 'Humans', 'Hypoglycemic Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29671894/
2157,Colesevelam,28153426,Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review.,"['Skelin M', 'Lucijanic T', 'Amidzic Klaric D', 'Resic A', 'Bakula M', 'Liberati-Cizmek AM', 'Gharib H', 'Rahelic D']","['Gastrointestinal Diseases/*physiopathology', 'Humans', '*Intestinal Absorption', 'Proton Pump Inhibitors/pharmacology', 'Thyrotropin/blood', 'Thyroxine/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/28153426/
2158,Colesevelam,24410472,Advances in understanding of bile acid diarrhea.,['Camilleri M'],"['Antidiarrheals/therapeutic use', 'Bile Acids and Salts/*metabolism', 'Diarrhea/drug therapy/*metabolism/*physiopathology', 'Fibroblast Growth Factors/metabolism', 'Humans', 'Ileum/metabolism', 'Receptors, Cytoplasmic and Nuclear/agonists']",https://pubmed.ncbi.nlm.nih.gov/24410472/
2159,Colesevelam,32400758,Colesevelam in the management of type 2 diabetes.,"['Kalra S', 'Priya G', 'Aggarwal S']","['Anticholesteremic Agents/pharmacology', 'Colesevelam Hydrochloride/*pharmacology', '*Diabetes Mellitus, Type 2/drug therapy/metabolism', 'Dyslipidemias/*drug therapy/metabolism', 'Humans', 'Pharmacovigilance']",https://pubmed.ncbi.nlm.nih.gov/32400758/
2160,Colesevelam,23317402,Colesevelam: a new and improved bile acid sequestrant?,"['Tziomalos K', 'Karagiannis A', 'Mikhailidis DP', 'Athyros VG']","['Allylamine/adverse effects/*analogs & derivatives/pharmacology/therapeutic use', 'Anticholesteremic Agents/*therapeutic use', 'Bile Acids and Salts/*metabolism', 'C-Reactive Protein/analysis', 'Cholesterol, LDL/blood', 'Clinical Trials as Topic', 'Colesevelam Hydrochloride', 'Diabetes Mellitus, Type 2/drug therapy', 'Drug Interactions', 'Drug Therapy, Combination', 'Glycated Hemoglobin/analysis', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage', 'Hypercholesterolemia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/23317402/
2161,Colesevelam,21739227,Use and indications of cholestyramine and bile acid sequestrants.,"['Scaldaferri F', 'Pizzoferrato M', 'Ponziani FR', 'Gasbarrini G', 'Gasbarrini A']","['Anticholesteremic Agents/*therapeutic use', 'Bile/metabolism', 'Cholestasis/complications/*drug therapy', 'Cholestyramine Resin/*therapeutic use', 'Humans', 'Hypercholesterolemia/complications/drug therapy', 'Sequestering Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21739227/
2162,Colesevelam,27578074,Itch Management: Treatments under Development.,"['Pereira MP', 'Stander S']","['Acrylamides/therapeutic use', 'Analgesics, Opioid/*therapeutic use', 'Antibodies, Monoclonal, Humanized/therapeutic use', 'Antipruritics/*therapeutic use', 'Carrier Proteins/antagonists & inhibitors', 'Cholestasis/complications', 'Colesevelam Hydrochloride', 'Humans', 'Lymphoma, T-Cell, Cutaneous/complications/drug therapy', 'Membrane Glycoproteins/antagonists & inhibitors', 'Nerve Growth Factor/antagonists & inhibitors', 'Neurokinin-1 Receptor Antagonists/*therapeutic use', 'Prurigo/complications/drug therapy', 'Pruritus/*drug therapy/etiology', 'Pyridines/therapeutic use', 'Receptors, Interleukin/antagonists & inhibitors', 'Receptors, Opioid, kappa/agonists', 'Sequestering Agents/*therapeutic use', 'TRPV Cation Channels/antagonists & inhibitors', 'Uremia/complications']",https://pubmed.ncbi.nlm.nih.gov/27578074/
2163,Colesevelam,14728043,Colesevelam.,"['Melian EB', 'Plosker GL']","['Allylamine/adverse effects/*analogs & derivatives/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Colesevelam Hydrochloride', 'Drug Therapy, Combination', 'Humans', 'Hypercholesterolemia/*drug therapy', 'Hypolipidemic Agents/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/14728043/
2164,Colesevelam,16568248,Lipid-lowering drugs.,['Pahan K'],"['Alzheimer Disease/drug therapy', '*Clofibric Acid/therapeutic use', 'Diabetes Mellitus/drug therapy', 'Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hyperlipidemias/*drug therapy', 'Hypolipidemic Agents/*therapeutic use', 'Lipids/biosynthesis', 'Neoplasms/drug therapy', 'Osteoporosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16568248/
2165,Colesevelam,20415686,Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.,"['Fonseca VA', 'Handelsman Y', 'Staels B']","['Adult', 'Allylamine/administration & dosage/*analogs & derivatives/pharmacology', 'Anticholesteremic Agents/*administration & dosage/pharmacology', 'Blood Glucose/*drug effects/metabolism', 'Cardiovascular Diseases/*prevention & control', 'Colesevelam Hydrochloride', 'Diabetes Mellitus, Type 2/*drug therapy/metabolism', 'Diabetic Angiopathies/*prevention & control', 'Female', 'Glycated Hemoglobin/drug effects/metabolism', 'Humans', 'Lipids/*blood', 'Male']",https://pubmed.ncbi.nlm.nih.gov/20415686/
2166,Colesevelam,25041567,Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential.,"['Bronden A', 'Hansen M', 'Sonne DP', 'Rohde U', 'Vilsboll T', 'Knop FK']","['Allylamine/*analogs & derivatives/pharmacokinetics/pharmacology', 'Anticholesteremic Agents/pharmacokinetics/pharmacology', 'Cholesterol, LDL/blood/drug effects', 'Colesevelam Hydrochloride', 'Diabetes Mellitus, Type 2/blood/*drug therapy', 'Glycated Hemoglobin/*drug effects/metabolism', 'Humans', 'Hypercholesterolemia/blood/*drug therapy', 'Hypoglycemic Agents/pharmacokinetics/*pharmacology', 'Polyamines/pharmacokinetics/*pharmacology', 'Sevelamer', 'Treatment Outcome', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/25041567/
2167,Colesevelam,25640999,Risk identification and possible countermeasures for muscle adverse effects during statin therapy.,"['Magni P', 'Macchi C', 'Morlotti B', 'Sirtori CR', 'Ruscica M']","['Age Factors', 'Aged', 'Aged, 80 and over', 'Anticholesteremic Agents/*therapeutic use', 'Colesevelam Hydrochloride/therapeutic use', 'Creatine Kinase/blood', 'Drug Interactions', 'Drug Therapy, Combination', 'Dyslipidemias/*drug therapy/epidemiology', 'Ezetimibe/therapeutic use', 'Fatty Acids, Monounsaturated/adverse effects', 'Female', 'Fluvastatin', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects', 'Indoles/adverse effects', 'Male', 'Muscular Diseases/chemically induced/metabolism', 'Myalgia/blood/*chemically induced', 'Rhabdomyolysis/blood/*chemically induced', 'Risk Assessment', 'Risk Factors', 'Rosuvastatin Calcium/adverse effects', 'Sex Factors', 'Vitamin D Deficiency/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/25640999/
2168,Colesevelam,11383377,New therapies on the horizon.,['Brown WV'],"['Allylamine/analogs & derivatives/metabolism/therapeutic use', 'Anticholesteremic Agents/metabolism/*therapeutic use', 'Bile Acids and Salts/metabolism', 'Biological Transport', 'Cholesterol/metabolism', 'Cholestyramine Resin/metabolism/therapeutic use', 'Colesevelam Hydrochloride', 'Esterification', 'Fluorobenzenes/metabolism/therapeutic use', 'Humans', 'Intestinal Absorption', 'Lipoproteins, LDL/*blood', '*Pyrimidines', 'Rosuvastatin Calcium', '*Sulfonamides', 'United States']",https://pubmed.ncbi.nlm.nih.gov/11383377/
2169,Colesevelam,30336707,Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes.,"['Nerild HH', 'Christensen MB', 'Knop FK', 'Bronden A']","['Animals', 'Anticholesteremic Agents/administration & dosage/adverse effects/pharmacology', 'Blood Glucose/*drug effects', 'Clinical Trials, Phase III as Topic', 'Colesevelam Hydrochloride/*administration & dosage/adverse effects/pharmacology', 'Diabetes Mellitus, Type 2/*drug therapy/physiopathology', 'Drug Therapy, Combination', 'Glycated Hemoglobin/metabolism', 'Humans', 'Hypoglycemic Agents/administration & dosage/adverse effects/pharmacology', 'Patient Selection']",https://pubmed.ncbi.nlm.nih.gov/30336707/
2170,Colesevelam,12040732,Colesevelam hydrochloride.,['Steinmetz KL'],"['*Allylamine/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Cholestyramine Resin/therapeutic use', 'Colesevelam Hydrochloride', 'Colestipol/therapeutic use', 'Drug Administration Schedule', 'Drug Interactions', 'Drug Therapy, Combination', 'Humans', 'Hypercholesterolemia/*drug therapy', '*Hypolipidemic Agents/pharmacokinetics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12040732/
2171,Colesevelam,19682080,Combined therapy in the treatment of dyslipidemia.,['Reiner Z'],"['Animals', 'Drug Therapy, Combination', 'Dyslipidemias/*drug therapy/physiopathology', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/adverse effects/*therapeutic use', 'Hypolipidemic Agents/administration & dosage/adverse effects/*therapeutic use', 'Practice Guidelines as Topic', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/19682080/
2172,Colesevelam,20819059,Combination of fenofibrate with non-statin drug regimens.,"['Agouridis AP', 'Filippatos TD', 'Derdemezis CS', 'Mikhailidis DP', 'Elisaf MS']","['Animals', 'Drug Therapy, Combination', 'Fenofibrate/administration & dosage/*pharmacology/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/therapeutic use', 'Hyperlipidemias/*drug therapy/physiopathology', 'Hypolipidemic Agents/administration & dosage/*pharmacology/therapeutic use', 'Lipid Metabolism/drug effects', 'Metabolic Syndrome/drug therapy/etiology/physiopathology', 'Obesity/complications']",https://pubmed.ncbi.nlm.nih.gov/20819059/
2173,Colesevelam,22142158,Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus?,"['Handelsman Y', 'Fonseca V', 'Rosenstock J']","['Animals', 'Anticholesteremic Agents/administration & dosage', 'Cardiovascular Diseases/blood/drug therapy', 'Cholesterol, HDL/blood', 'Cholesterol, LDL/blood', 'Clinical Trials as Topic/methods', 'Diabetes Mellitus, Type 2/*blood/*drug therapy', 'Drug Therapy, Combination', '*Goals', 'Humans', 'Hypolipidemic Agents/administration & dosage', 'Lipid Metabolism/*drug effects/physiology', 'Lipoproteins, LDL/blood', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22142158/
2174,Colesevelam,33471721,Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary.,"['Handelsman Y', 'Jellinger PS', 'Guerin CK', 'Bloomgarden ZT', 'Brinton EA', 'Budoff MJ', 'Davidson MH', 'Einhorn D', 'Fazio S', 'Fonseca VA', 'Garber AJ', 'Grunberger G', 'Krauss RM', 'Mechanick JI', 'Rosenblit PD', 'Smith DA', 'Wyne KL']","['Algorithms', '*Anticholesteremic Agents', '*Cardiovascular Diseases/epidemiology/prevention & control', 'Consensus', '*Dyslipidemias/drug therapy/epidemiology', 'Endocrinologists', 'Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Risk Factors', 'United States']",https://pubmed.ncbi.nlm.nih.gov/33471721/
2175,oxazepam,15584332,Benzodiazepine dependence.,"['Khong E', 'Sim MG', 'Hulse G']","['Anti-Anxiety Agents/*adverse effects', 'Anxiety Disorders/complications/therapy', 'Benzodiazepines/*adverse effects', 'Clinical Protocols', 'Drug Tolerance', 'Family Practice/methods', 'Female', 'Humans', 'Middle Aged', 'Oxazepam/therapeutic use', 'Relaxation Therapy', 'Sleep Initiation and Maintenance Disorders/etiology/therapy', 'Substance Withdrawal Syndrome/*therapy', 'Substance-Related Disorders/*diagnosis/*therapy']",https://pubmed.ncbi.nlm.nih.gov/15584332/
2176,oxazepam,28101764,Diazepam in the Treatment of Moderate to Severe Alcohol Withdrawal.,['Weintraub SJ'],"['Alcohol Withdrawal Delirium/*drug therapy', 'Alcohol Withdrawal Seizures/*drug therapy', 'Benzodiazepines/administration & dosage/adverse effects/pharmacokinetics', 'Diazepam/*administration & dosage/adverse effects/pharmacokinetics', 'Half-Life', 'Humans', 'Hypnotics and Sedatives/administration & dosage/adverse effects/pharmacokinetics', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/28101764/
2177,oxazepam,35194860,Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis.,"['Bahji A', 'Bach P', 'Danilewitz M', 'Crockford D', 'El-Guebaly N', 'Devoe DJ', 'Saitz R']","['Adult', '*Alcohol Withdrawal Delirium/drug therapy', '*Alcoholism/drug therapy', 'Benzodiazepines/therapeutic use', 'Carbamazepine/adverse effects', 'Diazepam/therapeutic use', 'Female', 'Humans', 'Male', 'Network Meta-Analysis', 'Seizures/chemically induced', '*Substance Withdrawal Syndrome/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/35194860/
2178,oxazepam,33319916,Melatonin for preoperative and postoperative anxiety in adults.,"['Madsen BK', 'Zetner D', 'Moller AM', 'Rosenberg J']","['Adult', 'Aged', 'Aged, 80 and over', 'Alprazolam/therapeutic use', 'Anti-Anxiety Agents/adverse effects/*therapeutic use', 'Anxiety/*drug therapy', 'Bias', 'Clonidine/therapeutic use', 'Drug Administration Schedule', 'Humans', 'Melatonin/adverse effects/*therapeutic use', 'Midazolam/therapeutic use', 'Middle Aged', 'Oxazepam/therapeutic use', 'Postoperative Care', 'Postoperative Complications/drug therapy/psychology', 'Preoperative Care', 'Publication Bias', 'Randomized Controlled Trials as Topic', 'Surgical Procedures, Operative/*psychology']",https://pubmed.ncbi.nlm.nih.gov/33319916/
2179,oxazepam,35703059,[Acute benzodiazepine withdrawal delirium].,"['Makinen VN', 'Hansen KB', 'Knudsen ST']","['*Alcohol Withdrawal Delirium/drug therapy', 'Benzodiazepines/adverse effects', '*Delirium/chemically induced/drug therapy', 'Diazepam/adverse effects', 'Humans', 'Male', 'Middle Aged', 'Oxazepam/therapeutic use', '*Substance Withdrawal Syndrome/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/35703059/
2180,oxazepam,37380897,Beyond benzodiazepines: a meta-analysis and narrative synthesis of the efficacy and safety of alternative options for alcohol withdrawal syndrome management.,"['Fluyau D', 'Kailasam VK', 'Pierre CG']","['Humans', '*Alcoholism/drug therapy', 'Benzodiazepines/adverse effects', 'Ethanol/adverse effects', 'Lorazepam/adverse effects', '*Substance Withdrawal Syndrome/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37380897/
2181,oxazepam,8692185,Genetic toxicology of four commonly used benzodiazepines: a review.,"['Giri AK', 'Banerjee S']","['Animals', 'Benzodiazepines/*toxicity', 'Chlordiazepoxide/toxicity', '*DNA Damage', 'Diazepam/toxicity', 'Humans', 'Mutagenicity Tests/*methods', 'Mutagens/*toxicity', 'Nitrazepam/toxicity', 'Oxazepam/toxicity']",https://pubmed.ncbi.nlm.nih.gov/8692185/
2182,oxazepam,10507746,Outpatient detoxification of the addicted or alcoholic patient.,"['Prater CD', 'Miller KE', 'Zylstra RG']","['Alcohol Withdrawal Delirium/diagnosis/*drug therapy', 'Alcoholic Intoxication/diagnosis/*drug therapy', '*Ambulatory Care', 'Anti-Anxiety Agents/therapeutic use', 'Chlordiazepoxide/therapeutic use', 'Diagnosis, Differential', 'Drug Administration Schedule', 'Drug Interactions', 'Humans', 'Hypnotics and Sedatives/therapeutic use', 'Lorazepam/therapeutic use', 'Oxazepam/therapeutic use', 'Patient Education as Topic', 'Phenobarbital/therapeutic use', 'Severity of Illness Index', 'Substance-Related Disorders/diagnosis/*drug therapy', 'Surveys and Questionnaires', 'Teaching Materials']",https://pubmed.ncbi.nlm.nih.gov/10507746/
2183,oxazepam,6114793,Benzodiazepine withdrawal.,['Lapierre YD'],"['Anti-Anxiety Agents/administration & dosage/*adverse effects', 'Anxiety/etiology', 'Diazepam/adverse effects', 'Drug Tolerance', 'Humans', 'Lorazepam/adverse effects', 'Oxazepam/adverse effects', 'Sleep Initiation and Maintenance Disorders/etiology', 'Substance Withdrawal Syndrome/*diagnosis', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6114793/
2184,oxazepam,329424,Selection among benzodiazepines for alcohol withdrawal.,"['Keeler MH', 'Miller WC']","['Administration, Oral', 'Benzodiazepines/administration & dosage/pharmacology/*therapeutic use', 'Central Nervous System/drug effects', 'Chlordiazepoxide/administration & dosage/pharmacology/therapeutic use', 'Clorazepate Dipotassium/administration & dosage/pharmacology/therapeutic use', 'Depression, Chemical', 'Diazepam/administration & dosage/pharmacology/therapeutic use', 'Drug Synergism', '*Ethanol', 'Half-Life', 'Humans', 'Oxazepam/administration & dosage/pharmacology/therapeutic use', 'Seizures/drug therapy', 'Substance Withdrawal Syndrome/*drug therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/329424/
2185,oxazepam,6124415,"Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations.",['Kanto JH'],"['Anti-Anxiety Agents/adverse effects/*metabolism', 'Chlordiazepoxide/metabolism', 'Clorazepate Dipotassium/metabolism', 'Diazepam/metabolism', 'Female', 'Flunitrazepam/metabolism', 'Humans', 'Infant, Newborn', '*Labor, Obstetric', '*Lactation', 'Lorazepam/metabolism', 'Maternal-Fetal Exchange', 'Nitrazepam/metabolism', 'Oxazepam/metabolism', '*Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/6124415/
2186,oxazepam,1354722,Oral benzodiazepines and conscious sedation: a review.,['Loeffler PM'],"['Administration, Oral', 'Alprazolam/administration & dosage', 'Ambulatory Surgical Procedures', 'Anti-Anxiety Agents/*administration & dosage/pharmacology', 'Conscious Sedation/*methods', 'Diazepam/administration & dosage', 'Flurazepam/administration & dosage', 'Humans', 'Lorazepam/administration & dosage', 'Midazolam/administration & dosage', 'Oxazepam/administration & dosage', 'Premedication', 'Receptors, GABA-A/physiology', 'Temazepam/administration & dosage', 'Triazolam/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/1354722/
2187,oxazepam,11679026,Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam.,"['Akhondzadeh S', 'Naghavi HR', 'Vazirian M', 'Shayeganpour A', 'Rashidi H', 'Khani M']","['Adult', 'Anti-Anxiety Agents/*therapeutic use', 'Anxiety Disorders/*drug therapy', 'Ataxia/chemically induced', 'Dizziness/chemically induced', 'Double-Blind Method', 'Female', 'Humans', 'Hypersensitivity/etiology', 'Male', 'Oxazepam/therapeutic use', '*Passiflora', '*Phytotherapy', 'Plant Extracts/adverse effects/*therapeutic use', 'Task Performance and Analysis']",https://pubmed.ncbi.nlm.nih.gov/11679026/
2188,oxazepam,6131488,Benzodiazepine withdrawal effects.,"['Pecknold JC', 'McClure DJ', 'Fleuri D', 'Chang H']","['Anti-Anxiety Agents/*adverse effects/therapeutic use', 'Anxiety Disorders/drug therapy', '*Benzodiazepines', 'Benzodiazepinones/*adverse effects/therapeutic use', 'Drug Administration Schedule', 'Humans', 'Oxazepam/*adverse effects/therapeutic use', 'Substance Withdrawal Syndrome/*etiology']",https://pubmed.ncbi.nlm.nih.gov/6131488/
2189,oxazepam,6133535,The use of benzodiazepines in clinical practice.,"['Shader RI', 'Greenblatt DJ']","['Anti-Anxiety Agents/*metabolism', 'Chlordiazepoxide/metabolism', 'Clorazepate Dipotassium/metabolism', 'Diazepam/adverse effects/metabolism', 'Humans', 'Kinetics', 'Lorazepam/metabolism', 'Metabolic Clearance Rate', 'Oxazepam/metabolism', 'Prazepam/metabolism', 'Substance Withdrawal Syndrome']",https://pubmed.ncbi.nlm.nih.gov/6133535/
2190,oxazepam,4717418,Benzodiazepines and tricyclic antidepressant plasma levels.,"['Silverman G', 'Braithwaite RA']","['Amitriptyline/*blood', 'Benzazepines/*pharmacology', 'Chlordiazepoxide/administration & dosage/pharmacology', 'Diazepam/administration & dosage/pharmacology', 'Drug Combinations', 'Drug Interactions', 'Female', 'Humans', 'Male', 'Nitrazepam/administration & dosage/pharmacology', 'Nortriptyline/*blood', 'Oxazepam/administration & dosage/pharmacology', 'Tranquilizing Agents/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/4717418/
2191,oxazepam,6138067,Efficacy and safety of midazolam and oxazepam in insomniacs.,"['Lupolover R', 'Ballmer U', 'Helcl J', 'Escher J', 'Pavletic B']","['Anti-Anxiety Agents/adverse effects/*therapeutic use', 'Benzodiazepines/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Midazolam', 'Middle Aged', 'Oxazepam/adverse effects/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6138067/
2192,oxazepam,17302,Clinical implications of benzodiazepine pharmacokinetics.,"['Shader RI', 'Greenblatt DJ']","['Administration, Oral', 'Adult', 'Age Factors', 'Aged', 'Alcoholism/metabolism', 'Anti-Anxiety Agents/administration & dosage/*metabolism', 'Chlordiazepoxide/metabolism', 'Clorazepate Dipotassium/metabolism', 'Diazepam/metabolism', 'Drug Interactions', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Intestinal Absorption', 'Liver/metabolism', 'Lorazepam/metabolism', 'Medazepam/metabolism', 'Oxazepam/metabolism']",https://pubmed.ncbi.nlm.nih.gov/17302/
2193,oxazepam,32581020,Reduction of Drug-Drug Interaction Risk; CDC Guidelines Influence on Opiate Benzodiazepine Prescribing.,"['Pesce A', 'Thomas R', 'Krock K', 'Tran K', 'Ackerman G', 'Nickley J']","['Benzodiazepines/adverse effects/therapeutic use', 'Centers for Disease Control and Prevention, U.S.', 'Drug Interactions/physiology', 'Drug Therapy, Combination/adverse effects/*trends', 'Guideline Adherence/statistics & numerical data/*trends', 'Humans', 'Hydrocodone/adverse effects', 'Morphine/adverse effects', 'Opiate Alkaloids/adverse effects/therapeutic use', 'Opioid-Related Disorders/*metabolism', 'Oxycodone/adverse effects', 'Pain/drug therapy', 'Pharmaceutical Preparations', 'United States']",https://pubmed.ncbi.nlm.nih.gov/32581020/
2194,oxazepam,24484984,The combination of metyrapone and oxazepam for the treatment of cocaine and other drug addictions.,"['Goeders NE', 'Guerin GF', 'Schmoutz CD']","['Animals', 'Anti-Anxiety Agents/administration & dosage', 'Cocaine-Related Disorders/*drug therapy/psychology', 'Humans', 'Metyrapone/*administration & dosage', 'Oxazepam/*administration & dosage', 'Stress, Psychological/*drug therapy/psychology', 'Substance-Related Disorders/drug therapy/psychology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24484984/
2195,cyclobenzaprine,27377815,EULAR revised recommendations for the management of fibromyalgia.,"['Macfarlane GJ', 'Kronisch C', 'Dean LE', 'Atzeni F', 'Hauser W', 'Fluss E', 'Choy E', 'Kosek E', 'Amris K', 'Branco J', 'Dincer F', 'Leino-Arjas P', 'Longley K', 'McCarthy GM', 'Makri S', 'Perrot S', 'Sarzi-Puttini P', 'Taylor A', 'Jones GT']","['*Activities of Daily Living', 'Acupuncture Therapy', 'Amitriptyline/analogs & derivatives/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Anticonvulsants/therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Biofeedback, Psychology', 'Capsaicin/therapeutic use', 'Cognitive Behavioral Therapy', 'Europe', 'Evidence-Based Medicine', 'Exercise Therapy', 'Fatigue/physiopathology/*therapy', 'Fibromyalgia/physiopathology/*therapy', 'Human Growth Hormone/therapeutic use', 'Humans', 'Hydrotherapy', 'Hypnosis', 'Manipulation, Chiropractic', 'Massage', 'Mind-Body Therapies', 'Mindfulness', 'Monoamine Oxidase Inhibitors/therapeutic use', 'Pain/physiopathology', '*Practice Guidelines as Topic', 'S-Adenosylmethionine/therapeutic use', 'Sensory System Agents/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Sleep', 'Societies, Medical', 'Sodium Oxybate/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27377815/
2196,cyclobenzaprine,18711953,Choosing a skeletal muscle relaxant.,"['See S', 'Ginzburg R']","['Back Pain/drug therapy', 'Fibromyalgia/drug therapy', 'Humans', 'Neck Pain/drug therapy', 'Neuromuscular Agents/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18711953/
2197,cyclobenzaprine,18225966,Skeletal muscle relaxants.,"['See S', 'Ginzburg R']","['Drug Interactions', 'Humans', 'Muscle Relaxants, Central/adverse effects/classification/*therapeutic use', 'Musculoskeletal Diseases/drug therapy', 'Nervous System Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18225966/
2198,cyclobenzaprine,26868680,"Maladaptive plasticity in tinnitus--triggers, mechanisms and treatment.","['Shore SE', 'Roberts LE', 'Langguth B']","['Animals', 'Auditory Cortex/pathology/physiopathology', 'Auditory Pathways/pathology/*physiopathology', 'Cochlear Nucleus/pathology/physiopathology', 'Humans', 'Neuronal Plasticity/*physiology', 'Noise/adverse effects', 'Tinnitus/*diagnosis/*physiopathology/therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26868680/
2199,cyclobenzaprine,15276195,Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.,"['Chou R', 'Peterson K', 'Helfand M']","['Clinical Trials as Topic', 'Comorbidity', 'Evidence-Based Medicine/methods', 'Humans', 'Motor Neuron Disease/classification/*drug therapy/*epidemiology', 'Muscle Spasticity/classification/*drug therapy/*epidemiology', 'Musculoskeletal Diseases/classification/drug therapy/epidemiology', 'Neuromuscular Agents/*therapeutic use', 'Peripheral Nervous System Diseases/classification/*drug therapy/*epidemiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15276195/
2200,cyclobenzaprine,38355316,"""Fibromyalgia - are there any new approaches?"".","['Martinez JE', 'Guimaraes I']","['*Fibromyalgia/therapy/drug therapy', 'Humans', '*Cognitive Behavioral Therapy', 'Exercise Therapy', 'Pain Management/methods', 'Analgesics/therapeutic use', 'Patient Education as Topic', 'Combined Modality Therapy']",https://pubmed.ncbi.nlm.nih.gov/38355316/
2201,cyclobenzaprine,2644679,Treatment of fibromyalgia syndrome.,['Goldenberg DL'],"['Amitriptyline/analogs & derivatives/therapeutic use', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Fibromyalgia/*drug therapy/therapy', 'Humans', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/2644679/
2202,cyclobenzaprine,35754070,Pharmacotherapy for Spine-Related Pain in Older Adults.,"['Fu JL', 'Perloff MD']","['Acetaminophen/therapeutic use', 'Aged', 'Analgesics, Opioid/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', '*Neuralgia/drug therapy', 'Pregabalin/adverse effects', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35754070/
2203,cyclobenzaprine,39298168,Long-Term Use of Muscle Relaxant Medications for Chronic Pain: A Systematic Review.,"['Oldfield BJ', 'Gleeson B', 'Morford KL', 'Adams Z', 'Funaro MC', 'Becker WC', 'Merlin JS']","['Humans', '*Chronic Pain/drug therapy', 'Muscle Relaxants, Central/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39298168/
2204,cyclobenzaprine,38621248,Rheumatology: What You May Have Missed in 2023.,"['Jalali K', 'Mandl LA']","['Humans', '*Glucocorticoids/therapeutic use/adverse effects/administration & dosage', 'Osteoporosis/drug therapy', 'Arthritis, Rheumatoid/drug therapy', 'Antirheumatic Agents/therapeutic use/adverse effects', 'Methotrexate/therapeutic use/adverse effects', 'Rheumatology/standards', 'Rheumatic Diseases/drug therapy/complications', 'Biosimilar Pharmaceuticals/therapeutic use/adverse effects', 'Polymyalgia Rheumatica/drug therapy', 'Fibromyalgia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38621248/
2205,cyclobenzaprine,27649348,Compounded Topical Analgesics for Chronic Pain.,"['Cline AE', 'Turrentine JE']","['Administration, Cutaneous', 'Amines/administration & dosage', 'Amitriptyline/administration & dosage/analogs & derivatives', 'Analgesics/*administration & dosage', 'Anesthetics, Local/administration & dosage', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage', 'Baclofen/administration & dosage', 'Capsaicin/administration & dosage', 'Chronic Pain/*drug therapy', 'Clonidine/administration & dosage', 'Cyclohexanecarboxylic Acids/administration & dosage', 'Drug Combinations', 'Drug Compounding', 'Gabapentin', 'Humans', 'Ketamine/administration & dosage', 'Lidocaine/administration & dosage', 'Muscle Relaxants, Central/administration & dosage', 'gamma-Aminobutyric Acid/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27649348/
2206,cyclobenzaprine,6620442,Cyclobenzaprine overdosage.,"['Linden CH', 'Mitchiner JC', 'Lindzon RD', 'Rumack BH']","['Adolescent', 'Adult', 'Amitriptyline/*analogs & derivatives/poisoning', 'Female', 'Humans', 'Male', 'Physostigmine/*therapeutic use', 'Suicide, Attempted']",https://pubmed.ncbi.nlm.nih.gov/6620442/
2207,cyclobenzaprine,37165930,"Efficacy and Safety of Sublingual Cyclobenzaprine for the Treatment of Fibromyalgia: Results From a Randomized, Double-Blind, Placebo-Controlled Trial.","['Lederman S', 'Arnold LM', 'Vaughn B', 'Kelley M', 'Sullivan GM']","['Humans', 'Double-Blind Method', '*Fibromyalgia/diagnosis/drug therapy/complications', 'Pain/complications', 'Pain Measurement', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37165930/
2208,cyclobenzaprine,19590258,Torticollis under cyclobenzaprine.,"['Reuss R', 'Reuter I', 'Jauss M', 'Fischer F', 'Muller SC', 'Stolz E']","['Amitriptyline/adverse effects/*analogs & derivatives/therapeutic use', 'Biperiden/therapeutic use', 'Humans', 'Male', 'Muscarinic Antagonists/therapeutic use', 'Muscle Relaxants, Central/*adverse effects/therapeutic use', 'Myoclonus/chemically induced/drug therapy', 'Torticollis/*chemically induced/drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/19590258/
2209,cyclobenzaprine,3078905,Cyclobenzaprine in the treatment of acute muscle spasm: review of a decade of clinical experience.,"['Katz WA', 'Dube J']","['Amitriptyline/*analogs & derivatives/therapeutic use', 'Humans', 'Muscle Relaxants, Central/*therapeutic use', 'Spasm/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3078905/
2210,cyclobenzaprine,31017819,Transfer of Cyclobenzaprine into Human Milk and Subsequent Infant Exposure.,"['Burra B', 'Datta P', 'Rewers-Felkins K', 'Baker T', 'Hale TW']","['Adult', 'Amitriptyline/adverse effects/*analogs & derivatives/pharmacokinetics', '*Breast Feeding', 'Diagnosis, Differential', 'Female', 'Humans', 'Infant, Newborn', 'Mass Spectrometry', 'Milk, Human/*chemistry/metabolism', 'Muscle Relaxants, Central/*adverse effects/pharmacokinetics', 'Pain/*drug therapy', 'Pregnancy', '*Prenatal Care']",https://pubmed.ncbi.nlm.nih.gov/31017819/
2211,cyclobenzaprine,1861061,Post-triathalon delirium.,"['Stephen JM', 'Ghezzi KT', 'Bailey K', 'Shesser R']","['Adult', '*Akathisia, Drug-Induced', 'Amitriptyline/*analogs & derivatives/poisoning', 'Delirium/*chemically induced/diagnosis/drug therapy', 'Humans', 'Male', 'Muscle Relaxants, Central/*poisoning', 'Physostigmine/therapeutic use', 'Psychomotor Agitation/drug therapy', 'Sports']",https://pubmed.ncbi.nlm.nih.gov/1861061/
2212,cyclobenzaprine,27474822,PURLs: More isn't better with acute low back pain treatment.,"['Frazer K', 'Stevermer JJ']","['Acetaminophen/*therapeutic use', 'Amitriptyline/*analogs & derivatives/therapeutic use', 'Drug Combinations', 'Female', 'Humans', 'Low Back Pain/*drug therapy', 'Male', 'Muscle Relaxants, Central/*therapeutic use', 'Naproxen/*therapeutic use', 'Oxycodone/*therapeutic use', 'Pain Measurement', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27474822/
2213,cyclobenzaprine,8187451,Fibromyalgia associated with female urethral syndrome.,['Paira SO'],"['Adult', 'Aged', 'Blood Sedimentation', 'Female', 'Fibromyalgia/*complications', 'Humans', 'Middle Aged', 'Retrospective Studies', 'Syndrome', 'Urethral Diseases/*complications/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/8187451/
2214,lorazepam,15762814,The effects of benzodiazepines on cognition.,['Stewart SA'],"['Activities of Daily Living/psychology', 'Anti-Anxiety Agents/adverse effects/pharmacology/therapeutic use', 'Anxiety Disorders/drug therapy', 'Benzodiazepines/*adverse effects/*pharmacology/therapeutic use', 'Cognition/*drug effects', 'Cognition Disorders/*chemically induced/epidemiology/psychology', 'Female', 'Humans', 'Long-Term Care/statistics & numerical data', 'Lorazepam/adverse effects/pharmacology/therapeutic use', 'Middle Aged', 'Patient Education as Topic', 'Substance Withdrawal Syndrome/psychology']",https://pubmed.ncbi.nlm.nih.gov/15762814/
2215,lorazepam,24741200,Lorazepam-induced diplopia.,"['Lucca JM', 'Ramesh M', 'Parthasarathi G', 'Ram D']","['Adult', 'Anti-Anxiety Agents/administration & dosage/*adverse effects/therapeutic use', 'Diplopia/*chemically induced/diagnosis', 'Humans', 'Lorazepam/administration & dosage/*adverse effects/therapeutic use', 'Male', 'Obsessive-Compulsive Disorder/drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24741200/
2216,lorazepam,11949276,Lorazepam.,['Noerr B'],"['Anti-Anxiety Agents/*administration & dosage/adverse effects', 'Anxiety/drug therapy/*prevention & control', 'Asphyxia Neonatorum/drug therapy/nursing', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Infant, Newborn', 'Intensive Care Units, Neonatal', 'Lorazepam/*administration & dosage/adverse effects', 'Male', 'Neonatal Nursing/methods', 'Risk Assessment', 'Seizures/drug therapy/nursing', 'Sensitivity and Specificity']",https://pubmed.ncbi.nlm.nih.gov/11949276/
2217,lorazepam,21360232,Delirium and sedation in the ICU.,['Frontera JA'],"['Conscious Sedation/*adverse effects', 'Delirium/*chemically induced/diagnosis/mortality', 'Dexmedetomidine/administration & dosage/adverse effects', 'Diagnosis, Differential', 'Hospital Mortality', 'Humans', 'Hypnotics and Sedatives/administration & dosage/adverse effects', '*Intensive Care Units', 'Lorazepam/administration & dosage/adverse effects', 'Midazolam/administration & dosage/adverse effects', 'Neurologic Examination/drug effects', 'Prognosis', 'Risk Factors', 'Survival Rate']",https://pubmed.ncbi.nlm.nih.gov/21360232/
2218,lorazepam,32340820,Efficacy of ketamine for initial control of acute agitation in the emergency department: A randomized study.,"['Lin J', 'Figuerado Y', 'Montgomery A', 'Lee J', 'Cannis M', 'Norton VC', 'Calvo R', 'Sikand H']","['Adult', 'Aged', 'Aged, 80 and over', 'Anesthetics, Dissociative/administration & dosage/*therapeutic use', 'Anti-Anxiety Agents/administration & dosage/therapeutic use', 'Antipsychotic Agents/administration & dosage/therapeutic use', '*Emergency Service, Hospital', 'Female', 'Haloperidol/administration & dosage/therapeutic use', 'Humans', 'Ketamine/administration & dosage/*therapeutic use', 'Lorazepam/administration & dosage/therapeutic use', 'Male', 'Middle Aged', 'Pilot Projects', 'Prospective Studies', 'Psychomotor Agitation/*drug therapy', 'United States']",https://pubmed.ncbi.nlm.nih.gov/32340820/
2219,lorazepam,3605432,Lorazepam for psychogenic catatonia.,"['Salam SA', 'Pillai AK', 'Beresford TP']","['Adult', 'Aged', 'Catatonia/*drug therapy/psychology', 'Humans', 'Injections, Intramuscular', 'Lorazepam/administration & dosage/*therapeutic use', 'Male', 'Middle Aged', 'Psychophysiologic Disorders/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/3605432/
2220,lorazepam,39936259,"[Acute psychosis after ""puff bar"" use].","['Tehrani FM', 'Badawey J']","['Humans', 'Male', 'Adolescent', '*Psychoses, Substance-Induced/etiology/diagnosis', 'Antipsychotic Agents/adverse effects/therapeutic use', 'Electrocardiography', 'Acute Disease', 'Cannabinoids/adverse effects', 'Long QT Syndrome/chemically induced', 'Lorazepam/therapeutic use/adverse effects/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/39936259/
2221,lorazepam,30810723,Association of Delirium Response and Safety of Pharmacological Interventions for the Management and Prevention of Delirium: A Network Meta-analysis.,"['Wu YC', 'Tseng PT', 'Tu YK', 'Hsu CY', 'Liang CS', 'Yeh TC', 'Chen TY', 'Chu CS', 'Matsuoka YJ', 'Stubbs B', 'Carvalho AF', 'Wada S', 'Lin PY', 'Chen YW', 'Su KP']","['Antipsychotic Agents/administration & dosage/*therapeutic use', 'Delirium/drug therapy/*prevention & control', 'Drug Therapy, Combination', 'Haloperidol/administration & dosage/therapeutic use', 'Humans', 'Indenes/administration & dosage/therapeutic use', 'Lorazepam/administration & dosage/therapeutic use', 'Network Meta-Analysis', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30810723/
2222,lorazepam,18073360,Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial.,"['Pandharipande PP', 'Pun BT', 'Herr DL', 'Maze M', 'Girard TD', 'Miller RR', 'Shintani AK', 'Thompson JL', 'Jackson JC', 'Deppen SA', 'Stiles RA', 'Dittus RS', 'Bernard GR', 'Ely EW']","['Aged', 'Coma/*chemically induced/diagnosis', '*Conscious Sedation/economics', 'Delirium/*chemically induced/diagnosis', 'Dexmedetomidine/*administration & dosage/adverse effects/economics', 'Double-Blind Method', 'Female', 'Humans', 'Hypnotics and Sedatives/*administration & dosage/adverse effects/economics', 'Intensive Care Units/economics', 'Lorazepam/*administration & dosage/adverse effects/economics', 'Male', 'Middle Aged', 'Neuropsychological Tests', '*Respiration, Artificial/economics']",https://pubmed.ncbi.nlm.nih.gov/18073360/
2223,lorazepam,28975307,Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.,"['Hui D', 'Frisbee-Hume S', 'Wilson A', 'Dibaj SS', 'Nguyen T', 'De La Cruz M', 'Walker P', 'Zhukovsky DS', 'Delgado-Guay M', 'Vidal M', 'Epner D', 'Reddy A', 'Tanco K', 'Williams J', 'Hall S', 'Liu D', 'Hess K', 'Amin S', 'Breitbart W', 'Bruera E']","['Adult', 'Aged', 'Aged, 80 and over', 'Anti-Anxiety Agents/*administration & dosage/adverse effects', 'Antipsychotic Agents/*administration & dosage/adverse effects', 'Delirium/*drug therapy/etiology', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Haloperidol/*administration & dosage/adverse effects', 'Hospitalization', 'Humans', 'Lorazepam/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Neoplasms/*complications/psychology/therapy', '*Palliative Care']",https://pubmed.ncbi.nlm.nih.gov/28975307/
2224,lorazepam,20138190,Atypical behavioural effects of lorazepam: clues to the design of novel therapies?,"['Giersch A', 'Boucart M', 'Elliott M', 'Vidailhet P']","['Attention/drug effects', 'Benzodiazepines/pharmacokinetics/*pharmacology/*therapeutic use', 'Cognition/*drug effects', 'Drug Discovery/*methods', 'Humans', 'Lorazepam/pharmacokinetics/*pharmacology/*therapeutic use', 'Memory/drug effects', 'Mental Disorders/*drug therapy', 'Receptors, GABA-A/drug effects', 'Visual Perception/drug effects']",https://pubmed.ncbi.nlm.nih.gov/20138190/
2225,lorazepam,2905805,"Lormetazepam, memory and information processing: a review.","['Bhatti JZ', 'Alford CA', 'Hindmarch I']","['Anti-Anxiety Agents/*pharmacology', '*Benzodiazepines', 'Humans', 'Lorazepam/*analogs & derivatives/pharmacology', 'Memory/*drug effects', 'Mental Processes/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/2905805/
2226,lorazepam,22721935,Homicide by methane gas.,"['De-Giorgio F', 'Grassi VM', 'Vetrugno G', 'Rossi R', 'Fucci N', ""d'Aloja E"", 'Pascali VL']","['Female', 'Forensic Pathology', '*Gases', '*Homicide', 'Humans', 'Hypnotics and Sedatives/administration & dosage/adverse effects', 'Lorazepam/administration & dosage/adverse effects', 'Lung/pathology', 'Male', 'Methane/*poisoning', 'Middle Aged', 'Myocardium/pathology', 'Suicide, Attempted']",https://pubmed.ncbi.nlm.nih.gov/22721935/
2227,lorazepam,13599,Intramuscular premedication with lorazepam.,['Mundeleer P'],"['Adult', 'Age Factors', 'Aged', 'Amnesia/chemically induced', 'Anti-Anxiety Agents/*administration & dosage', 'Female', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Lorazepam/*administration & dosage/adverse effects', 'Male', 'Middle Aged', '*Preanesthetic Medication']",https://pubmed.ncbi.nlm.nih.gov/13599/
2228,lorazepam,25030,Pain and clinical thrombophlebitis following intravenous diazepam and lorazepam.,"['Graham CW', 'Pagano RR', 'Conner JT']","['Adolescent', 'Adult', 'Aged', 'Anti-Anxiety Agents/*adverse effects', 'Clinical Trials as Topic', 'Diazepam/administration & dosage/*adverse effects', 'Double-Blind Method', 'Female', 'Humans', 'Injections, Intravenous', 'Lorazepam/administration & dosage/*adverse effects', 'Male', 'Middle Aged', 'Pain/*chemically induced', 'Thrombophlebitis/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/25030/
2229,lorazepam,30762,Clinical pharmacokinetics of lorazepam: a review.,"['Kyriakopoulos AA', 'Greenblatt DJ', 'Shader RI']","['Administration, Oral', 'Age Factors', 'Anti-Anxiety Agents/*metabolism', 'Chromatography, Gas', 'Dose-Response Relationship, Drug', 'Glucuronates/metabolism', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Kidney Failure, Chronic/metabolism', 'Kinetics', 'Lorazepam/administration & dosage/blood/*metabolism/urine', 'Metabolic Clearance Rate', 'Protein Binding']",https://pubmed.ncbi.nlm.nih.gov/30762/
2230,lorazepam,16179702,Status epilepticus: an evidence based guide.,['Walker M'],"['Anticonvulsants/adverse effects/*therapeutic use', 'Chronic Disease', 'Critical Care', 'Drug Administration Routes', 'Emergency Treatment', 'Evidence-Based Medicine', 'Humans', 'Lorazepam/administration & dosage/adverse effects', 'Midazolam/*administration & dosage/adverse effects', 'Phenobarbital/administration & dosage/adverse effects', 'Phenytoin/administration & dosage', 'Prognosis', 'Randomized Controlled Trials as Topic', 'Referral and Consultation', '*Status Epilepticus/diagnosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16179702/
2231,lorazepam,8032699,Cost-effectiveness analysis of antiemetic treatment.,"['Bleiberg H', 'Autier P', 'Michaux D']","['Antiemetics/adverse effects/*economics/*therapeutic use', 'Cost-Benefit Analysis', 'Costs and Cost Analysis', 'Dexamethasone/administration & dosage/adverse effects/economics/therapeutic use', 'Europe', 'European Union', 'Humans', 'Lorazepam/administration & dosage/adverse effects/economics/therapeutic use', 'Metoclopramide/administration & dosage/adverse effects/economics/therapeutic use', 'Ondansetron/administration & dosage/adverse effects/economics/therapeutic use', 'Randomized Controlled Trials as Topic', 'Salvage Therapy', 'Serotonin Antagonists/adverse effects/economics/therapeutic use', 'Vomiting/economics/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/8032699/
2232,lorazepam,1806620,Agitation in the demented elderly: a role for benzodiazepines?,"['Ancill RJ', 'Carlyle WW', 'Liang RA', 'Holliday SG']","['Aged', 'Alprazolam/adverse effects/*therapeutic use', 'Dementia/*drug therapy/psychology', 'Double-Blind Method', 'Female', 'Humans', 'Lorazepam/adverse effects/*therapeutic use', 'Male', 'Motor Activity/drug effects', 'Psychomotor Agitation/*drug therapy/psychology', 'Substance Withdrawal Syndrome/etiology']",https://pubmed.ncbi.nlm.nih.gov/1806620/
2233,lorazepam,11697755,"Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration.","['Wermeling DP', 'Miller JL', 'Archer SM', 'Manaligod JM', 'Rudy AC']","['Administration, Intranasal', 'Adult', 'Anti-Anxiety Agents/administration & dosage/blood/*pharmacokinetics', 'Area Under Curve', 'Biological Availability', 'Cross-Over Studies', 'Female', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Lorazepam/administration & dosage/blood/*pharmacokinetics', 'Male', 'Metabolic Clearance Rate']",https://pubmed.ncbi.nlm.nih.gov/11697755/
2234,ticlopidine,17107286,Prasugrel.,"['Tantry US', 'Bliden KP', 'Gurbel PA']","['Adenosine Diphosphate/antagonists & inhibitors/pharmacology', 'Animals', 'Aspirin/administration & dosage/therapeutic use', 'Clinical Trials, Phase I as Topic', 'Clinical Trials, Phase III as Topic', 'Clopidogrel', 'Collagen/antagonists & inhibitors/pharmacology', 'Coronary Disease/drug therapy', 'Drug Evaluation, Preclinical', 'Drug Resistance', 'Drug Synergism', 'Drug Therapy, Combination', '*Drugs, Investigational/administration & dosage/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Humans', '*Piperazines/administration & dosage/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Platelet Activation/drug effects', 'Platelet Aggregation/drug effects', '*Platelet Aggregation Inhibitors/administration & dosage/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Prasugrel Hydrochloride', 'Prodrugs/pharmacokinetics/therapeutic use', '*Purinergic P2 Receptor Antagonists', 'Pyridines/administration & dosage/therapeutic use', 'Rats', 'Receptors, Purinergic P2Y12', '*Thiophenes/administration & dosage/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Ticlopidine/analogs & derivatives/chemistry/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17107286/
2235,ticlopidine,17109936,Clopidogrel resistance?,"['Gurbel PA', 'Tantry US']","['Aspirin/therapeutic use', 'Cardiovascular Diseases/blood/drug therapy', 'Clopidogrel', '*Drug Resistance', 'Drug Therapy, Combination', 'Humans', 'Membrane Proteins/antagonists & inhibitors', 'Models, Biological', 'Platelet Aggregation/drug effects', 'Platelet Aggregation Inhibitors/adverse effects/metabolism/*therapeutic use', 'Purinergic P2 Receptor Antagonists', 'Receptors, Purinergic P2Y12', 'Ticlopidine/adverse effects/*analogs & derivatives/metabolism/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17109936/
2236,ticlopidine,22012820,[Clopidogrel and stroke].,"['Rodriguez-Yanez M', 'Arias-Rivas S', 'Fernandez-Ferro J', 'Leira R', 'Castillo J', 'Blanco M']","['Acute Disease', 'Aspirin/administration & dosage', 'Atrial Fibrillation/drug therapy', 'Clopidogrel', 'Drug Therapy, Combination', 'Humans', 'Inflammation/drug therapy', 'Platelet Aggregation Inhibitors/*therapeutic use', 'Practice Guidelines as Topic', 'Stroke/etiology/*prevention & control', 'Ticlopidine/administration & dosage/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22012820/
2237,ticlopidine,11504573,Complications of oral antiplatelet medications.,"['Van De Graaff E', 'Steinhubl SR']","['Administration, Oral', 'Aspirin/adverse effects', 'Clinical Trials as Topic', 'Clopidogrel', 'Dipyridamole/adverse effects', 'Humans', 'Platelet Aggregation Inhibitors/administration & dosage/*adverse effects', 'Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors', 'Ticlopidine/adverse effects/analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/11504573/
2238,ticlopidine,9360060,Clopidogrel.,"['Coukell AJ', 'Markham A']","['Animals', 'Clopidogrel', 'Coronary Artery Disease/*drug therapy', 'Humans', 'Platelet Aggregation Inhibitors/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Ticlopidine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9360060/
2239,ticlopidine,23735447,New anticoagulant and antiplatelet agents: a primer for the gastroenterologist.,"['Baron TH', 'Kamath PS', 'McBane RD']","['Anticoagulants/*administration & dosage/adverse effects/pharmacokinetics', 'Benzimidazoles/administration & dosage', 'Blood Coagulation Factors/therapeutic use', 'Cholangiopancreatography, Endoscopic Retrograde', 'Clopidogrel', 'Dabigatran', 'Drug Interactions', 'Fondaparinux', 'Gastrointestinal Hemorrhage/chemically induced', 'Humans', 'Piperazines/pharmacology/therapeutic use', 'Platelet Aggregation Inhibitors/*administration & dosage/adverse effects/pharmacokinetics', 'Polysaccharides/administration & dosage', 'Prasugrel Hydrochloride', 'Proton Pump Inhibitors/pharmacology/therapeutic use', 'Purinergic P2Y Receptor Antagonists/pharmacology/therapeutic use', 'Thiophenes/pharmacology/therapeutic use', 'Ticlopidine/analogs & derivatives/pharmacology/therapeutic use', 'beta-Alanine/administration & dosage/analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/23735447/
2240,ticlopidine,22135129,Clopidogrel (plavix).,"['Comin J', 'Kallmes D']","['Clopidogrel', 'Dose-Response Relationship, Drug', 'Hemorrhage/*chemically induced/*prevention & control', 'Humans', 'Platelet Aggregation Inhibitors/administration & dosage', 'Stroke/*prevention & control', 'Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/22135129/
2241,ticlopidine,21293086,"Pharmacokinetics, drug metabolism, and safety of prasugrel and clopidogrel.",['Achar S'],"['Area Under Curve', 'Clopidogrel', 'Drug Interactions', 'Half-Life', 'Humans', 'Metabolic Clearance Rate', 'Piperazines/*adverse effects/*pharmacokinetics/therapeutic use', 'Platelet Aggregation Inhibitors/*adverse effects/*pharmacokinetics/therapeutic use', 'Prasugrel Hydrochloride', 'Thiophenes/*adverse effects/*pharmacokinetics/therapeutic use', 'Ticlopidine/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21293086/
2242,ticlopidine,18537762,Clopidogrel in secondary ischemic stroke prevention.,"['Belvis R', 'Pagonabarraga J', 'Santamaria A', 'Kulisevsky J']","['Aspirin/therapeutic use', 'Brain Ischemia/complications/*drug therapy/pathology', 'Clinical Trials as Topic', 'Clopidogrel', 'Drug Therapy, Combination', 'Evidence-Based Medicine', 'Humans', 'Patient Selection', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/*therapeutic use', 'Practice Guidelines as Topic', 'Risk Assessment', 'Risk Factors', 'Secondary Prevention', 'Stroke/*drug therapy/etiology/pathology', 'Thrombolytic Therapy', 'Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18537762/
2243,ticlopidine,26520003,On-treatment platelet reactivity: State of the art and perspectives.,"['Marcucci R', 'Grifoni E', 'Giusti B']","['Acute Coronary Syndrome/blood/*drug therapy/enzymology', 'Adenosine/administration & dosage/adverse effects/analogs & derivatives/pharmacokinetics/therapeutic use', 'Age Factors', 'Blood Platelets/*drug effects', 'Clopidogrel', 'Cytochrome P-450 CYP2C19/genetics', 'Drug Interactions', 'Hemorrhage/prevention & control', 'Humans', 'Platelet Aggregation/*drug effects', 'Platelet Aggregation Inhibitors/administration & dosage/*adverse effects/pharmacokinetics/therapeutic use', 'Polymorphism, Genetic', 'Prasugrel Hydrochloride/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Sex Factors', 'Stents', 'Thrombosis/prevention & control', 'Ticagrelor', 'Ticlopidine/administration & dosage/adverse effects/analogs & derivatives/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26520003/
2244,ticlopidine,28224612,Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study.,"['Agergaard K', 'Mau-Sorensen M', 'Stage TB', 'Jorgensen TL', 'Hassel RE', 'Steffensen KD', 'Pedersen JW', 'Milo M', 'Poulsen SH', 'Pottegard A', 'Hallas J', 'Brosen K', 'Bergmann TK']","['Aged', 'Aspirin/administration & dosage', 'Clopidogrel', 'Cytochrome P-450 CYP2C8/*metabolism', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Female', 'Humans', 'Liver/metabolism', 'Male', 'Middle Aged', 'Paclitaxel/*administration & dosage/adverse effects/pharmacokinetics', 'Peripheral Nervous System Diseases/*chemically induced/epidemiology', 'Pharmacoepidemiology', 'Platelet Aggregation Inhibitors/*administration & dosage/adverse effects/pharmacokinetics', 'Retrospective Studies', 'Severity of Illness Index', 'Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/28224612/
2245,ticlopidine,26589471,Clopidogrel Response Variability: Review of the Literature and Practical Considerations.,"['Oliphant CS', 'Trevarrow BJ', 'Dobesh PP']","['Clopidogrel', 'Hemorrhage/chemically induced/prevention & control', 'Humans', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/therapeutic use', '*Platelet Function Tests/standards', 'Thrombosis/drug therapy/prevention & control', 'Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Treatment Failure']",https://pubmed.ncbi.nlm.nih.gov/26589471/
2246,ticlopidine,20345494,Proton pump inhibitors and clopidogrel.,"['Gaglia MA Jr', 'Waksman R']","['Aryl Hydrocarbon Hydroxylases/genetics/metabolism', 'Biotransformation', 'Clopidogrel', 'Cytochrome P-450 CYP2C19', 'Drug Interactions', 'Evidence-Based Medicine', 'Gastrointestinal Hemorrhage/chemically induced/*prevention & control', 'Humans', 'Platelet Aggregation/*drug effects', 'Platelet Aggregation Inhibitors/adverse effects/pharmacokinetics/*therapeutic use', 'Proton Pump Inhibitors/adverse effects/pharmacokinetics/*therapeutic use', 'Risk Assessment', 'Ticlopidine/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20345494/
2247,ticlopidine,21546883,"The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.","['Price MJ', 'Tantry US', 'Gurbel PA']","['Aryl Hydrocarbon Hydroxylases/*genetics/metabolism', 'Aspirin/therapeutic use', 'Clopidogrel', 'Cytochrome P-450 CYP2C19', 'Drug Therapy, Combination', 'Genotype', 'Humans', 'Pharmacogenetics', 'Phenotype', 'Platelet Aggregation/*drug effects', 'Platelet Aggregation Inhibitors/adverse effects/pharmacokinetics/*therapeutic use', '*Polymorphism, Genetic', 'Precision Medicine', 'Purinergic P2Y Receptor Antagonists/adverse effects/pharmacokinetics/*therapeutic use', 'Ticlopidine/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21546883/
2248,ticlopidine,23539388,Endoscopic procedures in patients under clopidogrel/dual antiplatelet therapy: to do or not to do?,"['Abdel Samie A', 'Theilmann L']","['Clopidogrel', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Endoscopy, Gastrointestinal/*adverse effects', 'Gastrointestinal Hemorrhage/*etiology', 'Humans', 'Intestinal Polyps/surgery', 'Platelet Aggregation Inhibitors/administration & dosage/*adverse effects', 'Practice Guidelines as Topic', 'Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/23539388/
2249,ticlopidine,25782570,Clopidogrel-Associated Neutropenia: Case Report and Review of the Literature.,"['Wu CW', 'Wu YJ', 'Wu CC']","['Aged', 'Aged, 80 and over', 'Clopidogrel', 'Female', 'Granulocyte Colony-Stimulating Factor/therapeutic use', 'Humans', 'Male', 'Neutropenia/*chemically induced/drug therapy', 'Platelet Aggregation Inhibitors/administration & dosage/*adverse effects', 'Purinergic P2Y Receptor Antagonists/administration & dosage/adverse effects', 'Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/25782570/
2250,ticlopidine,28528236,[Management of the bleeding risk associated with antiplatelet agents].,"['Martin AC', 'Houssany-Pissot S', 'Zlotnik D', 'Taylor G', 'Godier A']","['Adenosine/administration & dosage/adverse effects/analogs & derivatives', 'Aspirin/administration & dosage/adverse effects', 'Clopidogrel', 'Drug-Related Side Effects and Adverse Reactions/prevention & control/*therapy', 'Hemorrhage/*chemically induced/*therapy', 'Humans', 'Platelet Aggregation Inhibitors/adverse effects/*therapeutic use', 'Risk Factors', 'Ticagrelor', 'Ticlopidine/administration & dosage/adverse effects/analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/28528236/
2251,ticlopidine,27055051,The pharmacodynamics of antiplatelet compounds in thrombosis treatment.,"['Jayakumar T', 'Yang CH', 'Geraldine P', 'Yen TL', 'Sheu JR']","['Acute Coronary Syndrome/drug therapy', 'Animals', 'Aspirin/administration & dosage/adverse effects/therapeutic use', 'Blood Platelets/drug effects/metabolism', 'Clopidogrel', '*Drug Design', 'Drug Therapy, Combination', 'Humans', 'Platelet Aggregation Inhibitors/*administration & dosage/adverse effects/therapeutic use', 'Practice Guidelines as Topic', 'Thrombosis/*drug therapy', 'Ticlopidine/administration & dosage/adverse effects/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27055051/
2252,ticlopidine,22027718,Antiplatelet therapy in the era of percutaneous coronary intervention with drug-eluting balloons.,"['Bonaventura K', 'Sonntag S', 'Kleber FX']","['Angioplasty, Balloon, Coronary/adverse effects/*instrumentation', 'Aspirin/adverse effects/*therapeutic use', 'Cardiovascular Agents/*administration & dosage', 'Clopidogrel', '*Coated Materials, Biocompatible', 'Coronary Artery Disease/*therapy', 'Coronary Restenosis/etiology/prevention & control', 'Drug Delivery Systems/*instrumentation', 'Drug Therapy, Combination', 'Equipment Design', 'Evidence-Based Medicine', 'Humans', 'Patient Selection', 'Platelet Aggregation Inhibitors/adverse effects/*therapeutic use', 'Practice Guidelines as Topic', 'Risk Assessment', 'Risk Factors', 'Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22027718/
2253,Lenalidomide,38084760,"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.","['Sonneveld P', 'Dimopoulos MA', 'Boccadoro M', 'Quach H', 'Ho PJ', 'Beksac M', 'Hulin C', 'Antonioli E', 'Leleu X', 'Mangiacavalli S', 'Perrot A', 'Cavo M', 'Belotti A', 'Broijl A', 'Gay F', 'Mina R', 'Nijhof IS', 'van de Donk NWCJ', 'Katodritou E', 'Schjesvold F', 'Sureda Balari A', 'Rosinol L', 'Delforge M', 'Roeloffzen W', 'Silzle T', 'Vangsted A', 'Einsele H', 'Spencer A', 'Hajek R', 'Jurczyszyn A', 'Lonergan S', 'Ahmadi T', 'Liu Y', 'Wang J', 'Vieyra D', 'van Brummelen EMJ', 'Vanquickelberghe V', 'Sitthi-Amorn A', 'de Boer CJ', 'Carson R', 'Rodriguez-Otero P', 'Blade J', 'Moreau P']","['Humans', 'Antibodies, Monoclonal/administration & dosage/adverse effects', '*Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Bortezomib/administration & dosage/adverse effects', 'Dexamethasone/administration & dosage/adverse effects', 'Disease Progression', 'Lenalidomide/administration & dosage/adverse effects', '*Multiple Myeloma/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38084760/
2254,Lenalidomide,32325490,"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.","['Voorhees PM', 'Kaufman JL', 'Laubach J', 'Sborov DW', 'Reeves B', 'Rodriguez C', 'Chari A', 'Silbermann R', 'Costa LJ', 'Anderson LD Jr', 'Nathwani N', 'Shah N', 'Efebera YA', 'Holstein SA', 'Costello C', 'Jakubowiak A', 'Wildes TM', 'Orlowski RZ', 'Shain KH', 'Cowan AJ', 'Murphy S', 'Lutska Y', 'Pei H', 'Ukropec J', 'Vermeulen J', 'de Boer C', 'Hoehn D', 'Lin TS', 'Richardson PG']","['Adult', 'Aged', 'Antibodies, Monoclonal/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Bortezomib/*administration & dosage/adverse effects', 'Combined Modality Therapy', 'Dexamethasone/*administration & dosage', 'Female', '*Hematopoietic Stem Cell Transplantation', 'Humans', 'Lenalidomide/*administration & dosage/adverse effects', 'Maintenance Chemotherapy/methods', 'Male', 'Middle Aged', 'Multiple Myeloma/drug therapy/mortality/pathology/*therapy', 'Patient Selection', 'Transplantation, Autologous']",https://pubmed.ncbi.nlm.nih.gov/32325490/
2255,Lenalidomide,37738563,Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.,"['Qualls DA', 'Lambert N', 'Caimi PF', 'Merrill M', 'Pullarkat P', 'Godby RC', 'Bond DA', 'Wehmeyer GT', 'Romancik J', 'Amoozgar B', 'Leslie L', 'Nastoupil LJ', 'Crombie JL', 'Abramson JS', 'Khurana A', 'Nowakowski GS', 'Maddocks K', 'Rutherford SC', 'Kahl B', 'Okwali M', 'Buege MJ', 'Seshan V', 'Batlevi CL', 'Salles G']","['Humans', 'Lenalidomide/therapeutic use', 'Treatment Outcome', 'Retrospective Studies', '*Lymphoma, Large B-Cell, Diffuse/drug therapy', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37738563/
2256,Lenalidomide,31141632,Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.,"['Facon T', 'Kumar S', 'Plesner T', 'Orlowski RZ', 'Moreau P', 'Bahlis N', 'Basu S', 'Nahi H', 'Hulin C', 'Quach H', 'Goldschmidt H', ""O'Dwyer M"", 'Perrot A', 'Venner CP', 'Weisel K', 'Mace JR', 'Raje N', 'Attal M', 'Tiab M', 'Macro M', 'Frenzel L', 'Leleu X', 'Ahmadi T', 'Chiu C', 'Wang J', 'Van Rampelbergh R', 'Uhlar CM', 'Kobos R', 'Qi M', 'Usmani SZ']","['Aged', 'Aged, 80 and over', 'Antibodies, Monoclonal/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Dexamethasone/*administration & dosage/adverse effects', 'Female', 'Humans', 'Lenalidomide/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Multiple Myeloma/*drug therapy', 'Neutropenia/chemically induced', 'Progression-Free Survival']",https://pubmed.ncbi.nlm.nih.gov/31141632/
2257,Lenalidomide,38832972,"Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.","['Facon T', 'Dimopoulos MA', 'Leleu XP', 'Beksac M', 'Pour L', 'Hajek R', 'Liu Z', 'Minarik J', 'Moreau P', 'Romejko-Jarosinska J', 'Spicka I', 'Vorobyev VI', 'Besemer B', 'Ishida T', 'Janowski W', 'Kalayoglu-Besisik S', 'Parmar G', 'Robak P', 'Zamagni E', 'Goldschmidt H', 'Martin TG', 'Manier S', 'Mohty M', 'Oprea C', 'Bregeault MF', 'Mace S', 'Berthou C', 'Bregman D', 'Klippel Z', 'Orlowski RZ']","['Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Male', 'Middle Aged', 'Antibodies, Monoclonal, Humanized/therapeutic use/adverse effects/administration & dosage', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', '*Bortezomib/administration & dosage/adverse effects/therapeutic use', '*Dexamethasone/administration & dosage/adverse effects/therapeutic use', 'Kaplan-Meier Estimate', '*Lenalidomide/administration & dosage/adverse effects/therapeutic use', '*Multiple Myeloma/drug therapy/mortality', 'Neoplasm, Residual', 'Progression-Free Survival']",https://pubmed.ncbi.nlm.nih.gov/38832972/
2258,Lenalidomide,26927826,[Lenalidomide nephrotoxicity].,"['Kheder El-Fekih R', 'Izzedine H']","['Graft vs Host Disease/chemically induced/immunology', 'Humans', 'Immunologic Factors/administration & dosage/*adverse effects/pharmacokinetics', 'Kidney/*drug effects/pathology', 'Kidney Tubules/drug effects/pathology', 'Lenalidomide', 'Necrosis/chemically induced', 'Nephritis, Interstitial/chemically induced', 'Prevalence', '*Renal Insufficiency/epidemiology/metabolism', 'Thalidomide/administration & dosage/adverse effects/*analogs & derivatives/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/26927826/
2259,Lenalidomide,30897038,AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.,"['Leonard JP', 'Trneny M', 'Izutsu K', 'Fowler NH', 'Hong X', 'Zhu J', 'Zhang H', 'Offner F', 'Scheliga A', 'Nowakowski GS', 'Pinto A', 'Re F', 'Fogliatto LM', 'Scheinberg P', 'Flinn IW', 'Moreira C', 'Cabecadas J', 'Liu D', 'Kalambakas S', 'Fustier P', 'Wu C', 'Gribben JG']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Female', 'Humans', 'Lenalidomide/administration & dosage/adverse effects', 'Lymphoma, B-Cell, Marginal Zone/*drug therapy', 'Lymphoma, Follicular/*drug therapy', 'Male', 'Middle Aged', 'Neoplasm Recurrence, Local/drug therapy', 'Placebos', 'Rituximab/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30897038/
2260,Lenalidomide,32511983,"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.","['Salles G', 'Duell J', 'Gonzalez Barca E', 'Tournilhac O', 'Jurczak W', 'Liberati AM', 'Nagy Z', 'Obr A', 'Gaidano G', 'Andre M', 'Kalakonda N', 'Dreyling M', 'Weirather J', 'Dirnberger-Hertweck M', 'Ambarkhane S', 'Fingerle-Rowson G', 'Maddocks K']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Antibodies, Monoclonal, Humanized/administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Drug Resistance, Neoplasm/*drug effects', 'Female', 'Follow-Up Studies', 'Humans', 'Lenalidomide/administration & dosage', 'Lymphoma, Large B-Cell, Diffuse/*drug therapy/pathology', 'Male', 'Middle Aged', 'Neoplasm Recurrence, Local/*drug therapy/pathology', 'Prospective Studies', '*Salvage Therapy', 'Survival Rate', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32511983/
2261,Lenalidomide,35660812,"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.","['Richardson PG', 'Jacobus SJ', 'Weller EA', 'Hassoun H', 'Lonial S', 'Raje NS', 'Medvedova E', 'McCarthy PL', 'Libby EN', 'Voorhees PM', 'Orlowski RZ', 'Anderson LD Jr', 'Zonder JA', 'Milner CP', 'Gasparetto C', 'Agha ME', 'Khan AM', 'Hurd DD', 'Gowin K', 'Kamble RT', 'Jagannath S', 'Nathwani N', 'Alsina M', 'Cornell RF', 'Hashmi H', 'Campagnaro EL', 'Andreescu AC', 'Gentile T', 'Liedtke M', 'Godby KN', 'Cohen AD', 'Openshaw TH', 'Pasquini MC', 'Giralt SA', 'Kaufman JL', 'Yee AJ', 'Scott E', 'Torka P', 'Foley A', 'Fulciniti M', 'Hebert K', 'Samur MK', 'Masone K', 'Maglio ME', 'Zeytoonjian AA', 'Nadeem O', 'Schlossman RL', 'Laubach JP', 'Paba-Prada C', 'Ghobrial IM', 'Perrot A', 'Moreau P', 'Avet-Loiseau H', 'Attal M', 'Anderson KC', 'Munshi NC']","['Adult', 'Antineoplastic Agents/adverse effects/therapeutic use', '*Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Bortezomib/administration & dosage/adverse effects', 'Dexamethasone/administration & dosage/adverse effects', 'Disease Progression', 'Disease-Free Survival', 'Humans', 'Lenalidomide/administration & dosage/adverse effects', '*Maintenance Chemotherapy/methods', 'Melphalan/administration & dosage', '*Multiple Myeloma/diagnosis/drug therapy/surgery', '*Stem Cell Transplantation', 'Transplantation, Autologous']",https://pubmed.ncbi.nlm.nih.gov/35660812/
2262,Lenalidomide,32586576,Immunomodulatory Agents in Follicular Lymphoma.,"['Ysebaert L', 'Morschhauser F']","['Antineoplastic Agents/pharmacology/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Biomarkers, Tumor', 'Humans', 'Immune Checkpoint Inhibitors/pharmacology/therapeutic use', 'Immunologic Factors/pharmacology/*therapeutic use', 'Immunological Synapses/drug effects', 'Immunomodulation/*drug effects', 'Lenalidomide/pharmacology/therapeutic use', 'Lymphoma, Follicular/diagnosis/*drug therapy/etiology/mortality', 'Molecular Targeted Therapy', 'Treatment Outcome', 'Tumor Microenvironment/drug effects/immunology']",https://pubmed.ncbi.nlm.nih.gov/32586576/
2263,Lenalidomide,37753960,"Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.","['Leypoldt LB', 'Tichy D', 'Besemer B', 'Hanel M', 'Raab MS', 'Mann C', 'Munder M', 'Reinhardt HC', 'Nogai A', 'Gorner M', 'Ko YD', 'de Wit M', 'Salwender H', 'Scheid C', 'Graeven U', 'Peceny R', 'Staib P', 'Dieing A', 'Einsele H', 'Jauch A', 'Hundemer M', 'Zago M', 'Pozek E', 'Benner A', 'Bokemeyer C', 'Goldschmidt H', 'Weisel KC']","['Humans', 'Middle Aged', '*Multiple Myeloma/therapy', 'Lenalidomide/therapeutic use/pharmacology', 'Prospective Studies', 'Dexamethasone/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37753960/
2264,Lenalidomide,38899693,Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.,"['Melani C', 'Lakhotia R', 'Pittaluga S', 'Phelan JD', 'Huang DW', 'Wright G', 'Simard J', 'Muppidi J', 'Thomas CJ', 'Ceribelli M', 'Tosto FA', 'Yang Y', 'Xu W', 'Davies-Hill T', 'Pack SD', 'Peer CJ', 'Arisa O', 'Mena E', 'Lindenberg L', 'Bergvall E', 'Portell CA', 'Farah RJ', 'Lee ST', 'Pradhan A', 'Morrison C', 'Tadese A', 'Juanitez AM', 'Lu C', 'Jacob A', 'Simmons H', 'Figg WD', 'Steinberg SM', 'Jaffe ES', 'Roschewski M', 'Staudt LM', 'Wilson WH']","['Adult', 'Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Male', 'Middle Aged', 'Adenine/analogs & derivatives/adverse effects/therapeutic use/administration & dosage', '*Antibodies, Monoclonal, Humanized/adverse effects/therapeutic use/administration & dosage', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Bridged Bicyclo Compounds, Heterocyclic/adverse effects/therapeutic use/administration & dosage', '*Lenalidomide/adverse effects/administration & dosage/therapeutic use', '*Lymphoma, Large B-Cell, Diffuse/drug therapy/mortality', 'Molecular Targeted Therapy', '*Piperidines/adverse effects/therapeutic use/administration & dosage', 'Prednisone/adverse effects/administration & dosage/therapeutic use', 'Progression-Free Survival', 'Pyrazoles/adverse effects/therapeutic use/administration & dosage', 'Pyrimidines/adverse effects/therapeutic use/administration & dosage', 'Recurrence', 'Sulfonamides/adverse effects/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38899693/
2265,Lenalidomide,32976949,Mechanisms of lenalidomide sensitivity and resistance.,"['Martinez-Hoyer S', 'Karsan A']","['Adaptor Proteins, Signal Transducing/antagonists & inhibitors', 'Anemia, Macrocytic/drug therapy/physiopathology', 'Angiogenesis Inhibitors/pharmacology/therapeutic use', 'Antineoplastic Agents/*pharmacology/therapeutic use', 'Autophagy/drug effects', 'Cell Differentiation/drug effects', 'Chromosome Deletion', 'Chromosomes, Human, Pair 5', 'Cytokines/metabolism', 'Disease Progression', 'Drug Resistance, Neoplasm/physiology', 'Gene Expression Regulation, Neoplastic/drug effects', 'Humans', 'Ikaros Transcription Factor/antagonists & inhibitors', 'Immunologic Factors/*pharmacology/therapeutic use', 'Lenalidomide/*pharmacology/therapeutic use', 'Megakaryocytes/drug effects', 'Multiple Myeloma/drug therapy/physiopathology', 'Neoplasm Proteins/antagonists & inhibitors', 'Neovascularization, Pathologic/drug therapy/physiopathology', 'Phosphoprotein Phosphatases/antagonists & inhibitors', 'Ubiquitin-Protein Ligases/antagonists & inhibitors/physiology']",https://pubmed.ncbi.nlm.nih.gov/32976949/
2266,Lenalidomide,32430504,Genetics of progression from MDS to secondary leukemia.,"['Menssen AJ', 'Walter MJ']","['Cell Count', 'Clonal Evolution', 'DNA Methylation/drug effects', 'DNA Mutational Analysis', 'Disease Progression', 'Epigenesis, Genetic', 'Hematopoietic Stem Cells/pathology', 'Humans', 'Lenalidomide/pharmacology/therapeutic use', 'Leukemia, Myeloid, Acute/etiology/*genetics/prevention & control', 'Mutation', 'Myelodysplastic Syndromes/drug therapy/*genetics/pathology', 'Myelopoiesis', 'Neoplastic Stem Cells/pathology', 'Prognosis', 'Tumor Burden', 'Exome Sequencing', 'Whole Genome Sequencing']",https://pubmed.ncbi.nlm.nih.gov/32430504/
2267,Lenalidomide,37506339,"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.","['Rosinol L', 'Oriol A', 'Rios R', 'Blanchard MJ', 'Jarque I', 'Bargay J', 'Hernandez MT', 'Cabanas V', 'Carrillo-Cruz E', 'Sureda A', 'Martinez-Lopez J', 'Krsnik I', 'Gonzalez ME', 'Casado LF', 'Marti JM', 'Encinas C', 'de Arriba F', 'Palomera L', 'Sampol A', 'Gonzalez-Montes Y', 'Cabezudo E', 'Paiva B', 'Puig N', 'Cedena MT', 'de la Cruz J', 'Mateos MV', 'San Miguel J', 'Lahuerta JJ', 'Blade J']","['Humans', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Dexamethasone/therapeutic use', 'Lenalidomide/therapeutic use', '*Multiple Myeloma/therapy']",https://pubmed.ncbi.nlm.nih.gov/37506339/
2268,Lenalidomide,37500385,[Treatment of lower risk myelodysplastic syndromes].,['Park S'],"['Humans', '*Myelodysplastic Syndromes/complications/drug therapy', 'Lenalidomide/therapeutic use', '*Anemia/drug therapy/complications', '*Hematinics/therapeutic use', 'Risk', '*Thrombocytopenia/complications']",https://pubmed.ncbi.nlm.nih.gov/37500385/
2269,Lenalidomide,38977707,Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.,"['Chari A', 'Kaufman JL', 'Laubach J', 'Sborov DW', 'Reeves B', 'Rodriguez C', 'Silbermann R', 'Costa LJ', 'Anderson LD Jr', 'Nathwani N', 'Shah N', 'Bumma N', 'Holstein SA', 'Costello C', 'Jakubowiak A', 'Wildes TM', 'Orlowski RZ', 'Shain KH', 'Cowan AJ', 'Pei H', 'Cortoos A', 'Patel S', 'Lin TS', 'Voorhees PM', 'Usmani SZ', 'Richardson PG']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', '*Antibodies, Monoclonal/therapeutic use/administration & dosage', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Bortezomib/therapeutic use/administration & dosage', 'Dexamethasone/administration & dosage/therapeutic use', 'Lenalidomide/therapeutic use/administration & dosage', '*Multiple Myeloma/drug therapy/mortality/therapy/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/38977707/
2270,Lenalidomide,31652094,Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.,"['Lonial S', 'Jacobus S', 'Fonseca R', 'Weiss M', 'Kumar S', 'Orlowski RZ', 'Kaufman JL', 'Yacoub AM', 'Buadi FK', ""O'Brien T"", 'Matous JV', 'Anderson DM', 'Emmons RV', 'Mahindra A', 'Wagner LI', 'Dhodapkar MV', 'Rajkumar SV']","['Adult', 'Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Lenalidomide/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Quality of Life', 'Smoldering Multiple Myeloma/*drug therapy/mortality']",https://pubmed.ncbi.nlm.nih.gov/31652094/
2271,Lenalidomide,35717005,Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients.,"['Rafae A', 'Ehsan H', 'Wahab A', 'Khan SI', 'Khan I', 'Ashraf S', 'Ali S', 'Khalid F', 'Neupane K', 'Valent J', 'Khouri J', 'Samaras C', 'Mazzoni S', 'Anwer F']","['Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Bortezomib', 'Dexamethasone', '*Hematopoietic Stem Cell Transplantation/adverse effects', 'Humans', 'Lenalidomide/therapeutic use', '*Multiple Myeloma/diagnosis/drug therapy', 'Transplantation, Autologous']",https://pubmed.ncbi.nlm.nih.gov/35717005/
2272,Lenalidomide,33763699,"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.","['Facon T', 'Venner CP', 'Bahlis NJ', 'Offner F', 'White DJ', 'Karlin L', 'Benboubker L', 'Rigaudeau S', 'Rodon P', 'Voog E', 'Yoon SS', 'Suzuki K', 'Shibayama H', 'Zhang X', 'Twumasi-Ankrah P', 'Yung G', 'Rifkin RM', 'Moreau P', 'Lonial S', 'Kumar SK', 'Richardson PG', 'Rajkumar SV']","['Administration, Oral', 'Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects', 'Boron Compounds/administration & dosage/adverse effects', 'Dexamethasone/administration & dosage/adverse effects', 'Disease-Free Survival', 'Double-Blind Method', 'Female', 'Follow-Up Studies', 'Glycine/administration & dosage/adverse effects/analogs & derivatives', 'Humans', 'Lenalidomide/administration & dosage/adverse effects', 'Male', 'Middle Aged', '*Multiple Myeloma/diagnosis/drug therapy/mortality', 'Survival Rate']",https://pubmed.ncbi.nlm.nih.gov/33763699/
2273,alprazolam,28777203,"A Review of Alprazolam Use, Misuse, and Withdrawal.","['Ait-Daoud N', 'Hamby AS', 'Sharma S', 'Blevins D']","['Alprazolam/*adverse effects/therapeutic use', 'Anxiety Disorders/drug therapy', 'Benzodiazepines/*adverse effects/therapeutic use', 'Female', 'Humans', 'Panic Disorder/drug therapy', 'Pregnancy', '*Prescription Drug Misuse', 'Substance Withdrawal Syndrome/*therapy']",https://pubmed.ncbi.nlm.nih.gov/28777203/
2274,alprazolam,2185302,Oxazepam: update 1989.,['Ayd FJ Jr'],"['Aged', 'Alcoholism/drug therapy', 'Alprazolam/adverse effects/pharmacology/therapeutic use', 'Female', 'Humans', '*Oxazepam/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Seizures/chemically induced', 'Substance Withdrawal Syndrome', 'Substance-Related Disorders']",https://pubmed.ncbi.nlm.nih.gov/2185302/
2275,alprazolam,1980694,Efficacy of benzodiazepines in panic disorder and agoraphobia.,['Ballenger JC'],"['Agoraphobia/*drug therapy/psychology', 'Alprazolam/therapeutic use', 'Anti-Anxiety Agents/*therapeutic use', 'Anxiety Disorders/*drug therapy/psychology', 'Arousal/drug effects', 'Humans', 'Panic/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/1980694/
2276,alprazolam,16858890,Hypersensitivity to paroxetine.,"['Mera MT', 'Perez BV', 'Fernandez RO', 'Iglesias JF']","['Alprazolam/administration & dosage/therapeutic use', 'Depressive Disorder/drug therapy', 'Drug Eruptions/diagnosis/*etiology', 'Exanthema/*chemically induced/diagnosis', 'Female', 'Humans', 'Middle Aged', 'Paroxetine/*adverse effects/therapeutic use', 'Patch Tests', 'Selective Serotonin Reuptake Inhibitors/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16858890/
2277,alprazolam,3536383,A review of alprazolam withdrawal.,"['Browne JL', 'Hauge KJ']","['Alprazolam/*adverse effects', 'Humans', 'Substance Withdrawal Syndrome/*etiology']",https://pubmed.ncbi.nlm.nih.gov/3536383/
2278,alprazolam,1684083,Snorting benzodiazepines.,"['Sheehan MF', 'Sheehan DV', 'Torres A', 'Coppola A', 'Francis E']","['Administration, Intranasal', 'Adult', 'Alprazolam/administration & dosage', '*Anti-Anxiety Agents/administration & dosage/adverse effects', 'Arousal/drug effects', 'Bipolar Disorder/psychology', 'Diazepam/administration & dosage', 'Female', 'Humans', 'Male', 'Personality Disorders/psychology', 'Substance Withdrawal Syndrome/diagnosis/psychology', 'Substance-Related Disorders/*psychology']",https://pubmed.ncbi.nlm.nih.gov/1684083/
2279,alprazolam,8262887,Medication discontinuation in panic disorder.,"['Ballenger JC', 'Pecknold J', 'Rickels K', 'Sellers EM']","['Alprazolam/*administration & dosage/therapeutic use', 'Benzodiazepines/*administration & dosage/therapeutic use', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Humans', 'Panic Disorder/*drug therapy/psychology', 'Patient Compliance', 'Patient Education as Topic', 'Recurrence', 'Substance Withdrawal Syndrome/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/8262887/
2280,alprazolam,22275853,Experimental panic provocation in healthy man-a translational role in anti-panic drug development?,['Kellner M'],"['Alprazolam/*administration & dosage', 'Anti-Anxiety Agents/administration & dosage', 'Clinical Trials as Topic/trends', 'Drug Design', 'Humans', 'Panic Disorder/*chemically induced/*drug therapy', 'Tetragastrin/*adverse effects', 'Translational Research, Biomedical/*trends']",https://pubmed.ncbi.nlm.nih.gov/22275853/
2281,alprazolam,2823537,Pharmacology of the benzodiazepines; with special emphasis on alprazolam.,['Soderpalm B'],"['Alprazolam/pharmacology', 'Animals', 'Anxiety Disorders/drug therapy', 'Benzodiazepines/pharmacokinetics/*pharmacology', 'Drug Tolerance', 'Humans', 'Rats', 'Receptors, GABA-A/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2823537/
2282,alprazolam,2187582,Problems in the treatment of premenstrual syndrome.,"['Robinson GE', 'Garfinkel PE']","['Alprazolam/therapeutic use', 'Combined Modality Therapy', 'Female', 'Humans', 'Premenstrual Syndrome/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/2187582/
2283,alprazolam,16296788,Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery.,"['Alberti I', 'Grenier A', 'Kraus H', 'Carrara DN']","['*Administration, Cutaneous', 'Alprazolam/administration & dosage/therapeutic use', 'Animals', 'Anti-Anxiety Agents/administration & dosage/therapeutic use', '*Drug Delivery Systems', 'Estradiol/administration & dosage/therapeutic use', 'Female', '*Gels', 'Humans', 'Hypogonadism/drug therapy', 'Male', 'Mandelic Acids/administration & dosage/therapeutic use', 'Norethindrone/administration & dosage/therapeutic use', 'Parasympatholytics/administration & dosage/therapeutic use', 'Progesterone Congeners/administration & dosage/therapeutic use', 'Testosterone/administration & dosage/therapeutic use', 'Urinary Bladder, Neurogenic/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16296788/
2284,alprazolam,6135693,Pharmacokinetics of alprazolam.,"['Abernethy DR', 'Greenblatt DJ', 'Divoll M', 'Shader RI']","['Age Factors', 'Alprazolam', 'Anti-Anxiety Agents/*metabolism', 'Benzodiazepines/*metabolism', 'Biotransformation/drug effects', 'Body Weight', 'Cimetidine/pharmacology', 'Female', 'Humans', 'Kinetics', 'Male', 'Sex Factors']",https://pubmed.ncbi.nlm.nih.gov/6135693/
2285,alprazolam,2890266,Brain neurotransmission in panic disorder.,['Eriksson E'],"['Alprazolam/pharmacology', 'Antidepressive Agents/pharmacology', 'Anxiety Disorders/drug therapy/*physiopathology', 'Brain Chemistry', 'Fear/*physiology', 'Humans', 'Neurotransmitter Agents/*physiology', 'Panic/drug effects/*physiology']",https://pubmed.ncbi.nlm.nih.gov/2890266/
2286,alprazolam,9617514,Alprazolam withdrawal delirium: a case report.,"['Zalsman G', 'Hermesh H', 'Munitz H']","['Aged', 'Alprazolam/*adverse effects', 'Anti-Anxiety Agents/*adverse effects', 'Delirium/*chemically induced', 'Humans', 'Male', 'Substance Withdrawal Syndrome/*complications']",https://pubmed.ncbi.nlm.nih.gov/9617514/
2287,alprazolam,23070072,Oral alprazolam acutely increases nucleus accumbens perfusion.,"['Wolf DH', 'Pinkham AE', 'Satterthwaite TD', 'Ruparel K', 'Elliott MA', 'Valdez J', 'Smith MA', 'Detre JA', 'Gur RC', 'Gur RE']","['Administration, Oral', 'Alprazolam/*administration & dosage', 'Anti-Anxiety Agents/*administration & dosage', 'Anxiety/drug therapy', 'Benzodiazepines/therapeutic use', 'Cerebrovascular Circulation/drug effects', 'Cross-Sectional Studies', 'Double-Blind Method', 'Female', 'Humans', 'Magnetic Resonance Imaging', 'Male', 'Nucleus Accumbens/diagnostic imaging/*drug effects', 'Positron-Emission Tomography']",https://pubmed.ncbi.nlm.nih.gov/23070072/
2288,alprazolam,37040158,"Alprazolam: Good for Some, Not Good for All!","['Mamtani H', 'Chaturvedi SK']","['Humans', 'Alprazolam/adverse effects', 'Benzodiazepines/adverse effects', '*Panic Disorder/drug therapy', 'Anxiety Disorders/drug therapy', 'Antisocial Personality Disorder/chemically induced/drug therapy', '*Anti-Anxiety Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37040158/
2289,alprazolam,27369688,[Duloxetine-Induced Hypertension: A Case Report].,"['Mermi O', 'Atmaca M']","['Alprazolam/administration & dosage', 'Anti-Anxiety Agents/administration & dosage', 'Depressive Disorder/*drug therapy', 'Diagnosis, Differential', 'Drug Therapy, Combination', 'Duloxetine Hydrochloride/*administration & dosage/adverse effects', 'Female', 'Humans', 'Hypertension/chemically induced/*diagnosis', 'Middle Aged', 'Selective Serotonin Reuptake Inhibitors/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27369688/
2290,alprazolam,7932278,Hypercapneic ventilatory response in patients with panic disorder before and after alprazolam treatment and in pre- and postmenstrual women.,"['Fishman SM', 'Carr DB', 'Beckett A', 'Rosenbaum JF']","['Adult', 'Alprazolam/*therapeutic use', 'Arousal/drug effects/physiology', '*Carbon Dioxide/blood', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Humans', 'Menstrual Cycle/drug effects/*physiology', 'Panic Disorder/diagnosis/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/7932278/
2291,alprazolam,3655003,Alprazolam: effects on sleep and withdrawal phenomena.,"['Kales A', 'Bixler EO', 'Vela-Bueno A', 'Soldatos CR', 'Manfredi RL']","['Adult', 'Alprazolam/adverse effects/*therapeutic use', 'Electroencephalography', 'Humans', 'Middle Aged', 'Sleep Stages/drug effects', 'Sleep Wake Disorders/*drug therapy', 'Substance Withdrawal Syndrome/*psychology']",https://pubmed.ncbi.nlm.nih.gov/3655003/
2292,alprazolam,1806620,Agitation in the demented elderly: a role for benzodiazepines?,"['Ancill RJ', 'Carlyle WW', 'Liang RA', 'Holliday SG']","['Aged', 'Alprazolam/adverse effects/*therapeutic use', 'Dementia/*drug therapy/psychology', 'Double-Blind Method', 'Female', 'Humans', 'Lorazepam/adverse effects/*therapeutic use', 'Male', 'Motor Activity/drug effects', 'Psychomotor Agitation/*drug therapy/psychology', 'Substance Withdrawal Syndrome/etiology']",https://pubmed.ncbi.nlm.nih.gov/1806620/
2293,formoterol,36639054,The ICS/Formoterol Reliever Therapy Regimen in Asthma: A Review.,"['Beasley R', 'Bruce P', 'Houghton C', 'Hatter L']","['Adult', 'Adolescent', 'Humans', 'Formoterol Fumarate/therapeutic use', 'Budesonide/therapeutic use', 'Bronchodilator Agents/therapeutic use', '*Anti-Asthmatic Agents/therapeutic use', '*Asthma/drug therapy', 'Adrenal Cortex Hormones/therapeutic use', 'Drug Therapy, Combination', 'Administration, Inhalation', 'Ethanolamines/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36639054/
2294,formoterol,34666208,A Practical Guide to Implementing SMART in Asthma Management.,"['Reddel HK', 'Bateman ED', 'Schatz M', 'Krishnan JA', 'Cloutier MM']","['Administration, Inhalation', 'Adolescent', 'Adult', '*Asthma/drug therapy', 'Bronchodilator Agents/therapeutic use', '*Budesonide/therapeutic use', 'Child', 'Drug Combinations', 'Ethanolamines/therapeutic use', 'Formoterol Fumarate/therapeutic use', 'Humans', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34666208/
2295,formoterol,34342835,Budesonide/Glycopyrronium/Formoterol: A Review in COPD.,['Heo YA'],"['Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists/*therapeutic use', 'Bronchodilator Agents/therapeutic use', 'Budesonide/*therapeutic use', 'Drug Combinations', 'Formoterol Fumarate/*therapeutic use', 'Glucocorticoids/*therapeutic use', 'Glycopyrrolate/*therapeutic use', 'Humans', 'Metered Dose Inhalers', 'Muscarinic Antagonists/*therapeutic use', 'Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/34342835/
2296,formoterol,29768149,Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma.,"[""O'Byrne PM"", 'FitzGerald JM', 'Bateman ED', 'Barnes PJ', 'Zhong N', 'Keen C', 'Jorup C', 'Lamarca R', 'Ivanov S', 'Reddel HK']","['Administration, Inhalation', 'Adolescent', 'Adult', 'Aged', 'Asthma/*drug therapy', 'Bronchodilator Agents/*administration & dosage/adverse effects', 'Budesonide/*administration & dosage/adverse effects', 'Child', 'Double-Blind Method', 'Drug Administration Schedule', 'Drug Combinations', 'Female', 'Forced Expiratory Volume', 'Formoterol Fumarate/*administration & dosage/adverse effects', 'Glucocorticoids/administration & dosage', 'Humans', 'Maintenance Chemotherapy', 'Male', 'Medication Adherence', 'Middle Aged', 'Surveys and Questionnaires', 'Terbutaline/*administration & dosage/adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29768149/
2297,formoterol,35569035,Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.,"['Papi A', 'Chipps BE', 'Beasley R', 'Panettieri RA Jr', 'Israel E', 'Cooper M', 'Dunsire L', 'Jeynes-Ellis A', 'Johnsson E', 'Rees R', 'Cappelletti C', 'Albers FC']","['Administration, Inhalation', 'Adolescent', 'Adult', '*Albuterol/administration & dosage/adverse effects/therapeutic use', '*Asthma/drug therapy', '*Budesonide/administration & dosage/adverse effects/therapeutic use', 'Child', 'Child, Preschool', 'Double-Blind Method', 'Drug Combinations', 'Ethanolamines/therapeutic use', 'Formoterol Fumarate/therapeutic use', 'Glucocorticoids/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Maintenance Chemotherapy', 'Nebulizers and Vaporizers', 'Symptom Flare Up', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/35569035/
2298,formoterol,31112386,Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.,"['Beasley R', 'Holliday M', 'Reddel HK', 'Braithwaite I', 'Ebmeier S', 'Hancox RJ', 'Harrison T', 'Houghton C', 'Oldfield K', 'Papi A', 'Pavord ID', 'Williams M', 'Weatherall M']","['Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists/administration & dosage/adverse effects', 'Adult', 'Aged', 'Albuterol/*administration & dosage/adverse effects', 'Asthma/*drug therapy', 'Bronchodilator Agents/*administration & dosage/adverse effects', 'Budesonide/*administration & dosage/adverse effects', 'Drug Therapy, Combination', 'Female', 'Formoterol Fumarate/*administration & dosage/adverse effects', 'Humans', 'Male', 'Metered Dose Inhalers', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/31112386/
2299,formoterol,30232048,"Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.","['Ferguson GT', 'Rabe KF', 'Martinez FJ', 'Fabbri LM', 'Wang C', 'Ichinose M', 'Bourne E', 'Ballal S', 'Darken P', 'DeAngelis K', 'Aurivillius M', 'Dorinsky P', 'Reisner C']","['Administration, Inhalation', 'Adult', 'Aged', 'Aged, 80 and over', 'Budesonide/*administration & dosage', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Forced Expiratory Volume/drug effects', 'Formoterol Fumarate/*administration & dosage', 'Glycopyrrolate/*administration & dosage', 'Humans', 'Male', 'Metered Dose Inhalers', 'Middle Aged', 'Pulmonary Disease, Chronic Obstructive/*drug therapy', 'Respiratory Function Tests', 'Respiratory System Agents/*administration & dosage', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30232048/
2300,formoterol,35023469,[Asthma treatment in general practice].,"['Behrendt V', 'Hilberg O', 'Bakker V', 'Ulrik CS', 'Bjerring N', 'Lokke A']","['Administration, Inhalation', 'Adrenal Cortex Hormones/therapeutic use', 'Adult', '*Anti-Asthmatic Agents/adverse effects', '*Asthma/drug therapy', 'Drug Therapy, Combination', 'Ethanolamines/therapeutic use', 'Formoterol Fumarate/therapeutic use', '*General Practice', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/35023469/
2301,formoterol,35230437,Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis.,"['Beasley R', 'Harrison T', 'Peterson S', 'Gustafson P', 'Hamblin A', 'Bengtsson T', 'Fageras M']","['Administration, Inhalation', 'Adolescent', 'Adrenal Cortex Hormones/therapeutic use', 'Adult', '*Anti-Asthmatic Agents/therapeutic use', '*Asthma/drug therapy', 'Budesonide/therapeutic use', 'Budesonide, Formoterol Fumarate Drug Combination/therapeutic use', 'Drug Combinations', 'Female', 'Formoterol Fumarate/therapeutic use', 'Humans', 'Male', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/35230437/
2302,formoterol,39421468,Update on Asthma Management Guidelines.,"['Dubin S', 'Patak P', 'Jung D']","['Humans', '*Asthma/drug therapy', 'Administration, Inhalation', '*Anti-Asthmatic Agents/therapeutic use/administration & dosage', '*Adrenal Cortex Hormones/therapeutic use/administration & dosage', 'Practice Guidelines as Topic', 'Adult', 'Adolescent', 'Adrenergic beta-Agonists/therapeutic use/administration & dosage', 'Formoterol Fumarate/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39421468/
2303,formoterol,29768147,As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma.,"['Bateman ED', 'Reddel HK', ""O'Byrne PM"", 'Barnes PJ', 'Zhong N', 'Keen C', 'Jorup C', 'Lamarca R', 'Siwek-Posluszna A', 'FitzGerald JM']","['Administration, Inhalation', 'Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Asthma/*drug therapy', 'Bronchodilator Agents/*administration & dosage/adverse effects', 'Budesonide/*administration & dosage/adverse effects', 'Child', 'Double-Blind Method', 'Drug Administration Schedule', 'Drug Combinations', 'Female', 'Forced Expiratory Volume', 'Formoterol Fumarate/*administration & dosage/adverse effects', 'Glucocorticoids/administration & dosage', 'Humans', 'Maintenance Chemotherapy', 'Male', 'Medication Adherence', 'Middle Aged', 'Proportional Hazards Models', 'Severity of Illness Index', 'Surveys and Questionnaires', 'Terbutaline/*administration & dosage/adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29768147/
2304,formoterol,38227870,Acute Asthma Exacerbations: Management Strategies.,"['Dabbs W', 'Bradley MH', 'Chamberlin SM']","['Child', 'Humans', '*Anti-Asthmatic Agents/therapeutic use', 'Administration, Inhalation', '*Asthma/diagnosis/drug therapy', 'Formoterol Fumarate/therapeutic use', 'Adrenal Cortex Hormones/therapeutic use', 'Oxygen/therapeutic use', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/38227870/
2305,formoterol,38237858,The Role of ICS-Containing Rescue Therapy Versus SABA Alone in Asthma Management Today.,"['Krings JG', 'Beasley R']","['Adult', 'Adolescent', 'Humans', '*Anti-Asthmatic Agents/therapeutic use', '*Asthma/drug therapy/epidemiology', 'Bronchodilator Agents/therapeutic use', 'Adrenal Cortex Hormones/therapeutic use', 'Formoterol Fumarate/therapeutic use', 'Albuterol/therapeutic use', 'Administration, Inhalation', 'Budesonide/therapeutic use', 'Ethanolamines/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38237858/
2306,formoterol,33929661,Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.,"['Bourdin A', 'Molinari N', 'Ferguson GT', 'Singh B', 'Siddiqui MK', 'Holmgren U', 'Ouwens M', 'Jenkins M', 'De Nigris E']","['Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists/therapeutic use', 'Bayes Theorem', 'Bronchodilator Agents/adverse effects', 'Budesonide/adverse effects', 'Drug Combinations', 'Formoterol Fumarate/therapeutic use', 'Fumarates/therapeutic use', '*Glycopyrrolate/adverse effects', 'Humans', 'Muscarinic Antagonists/therapeutic use', 'Network Meta-Analysis', '*Pulmonary Disease, Chronic Obstructive/drug therapy', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/33929661/
2307,formoterol,36725331,Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD.,"['Muiser S', 'Imkamp K', 'Seigers D', 'Halbersma NJ', 'Vonk JM', 'Luijk BHD', 'Braunstahl GJ', 'van den Berg JW', 'Kroesen BJ', 'Kocks JWH', 'Heijink IH', 'Reddel HK', 'Kerstjens HAM', 'van den Berge M']","['Humans', '*Bronchodilator Agents/therapeutic use', 'Ethanolamines/adverse effects', 'Drug Combinations', 'Androstadienes/adverse effects', 'Treatment Outcome', 'Fluticasone-Salmeterol Drug Combination/therapeutic use', 'Budesonide/adverse effects', 'Formoterol Fumarate/therapeutic use', '*Pulmonary Disease, Chronic Obstructive/drug therapy', 'Budesonide, Formoterol Fumarate Drug Combination/therapeutic use', 'Adrenal Cortex Hormones/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36725331/
2308,formoterol,35735152,[Novelties in the Treatment of Asthma].,"['Leuppi JD', 'Bridevaux PO', 'Charbonnier F', 'Clarenbach C', 'Duchna HW', 'Gianella P', 'Jochmann A', 'Kern L', 'Meyer F', 'Pavlov N', 'Rothe T', 'Steurer-Stey C', 'Von Garnier C']","['Administration, Inhalation', 'Adrenal Cortex Hormones/therapeutic use', '*Anti-Asthmatic Agents/therapeutic use', '*Asthma/drug therapy', 'Formoterol Fumarate/therapeutic use', 'Humans', '*Pulmonary Disease, Chronic Obstructive/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/35735152/
2309,formoterol,39465893,Inhaled Reliever Therapies for Asthma: A Systematic Review and Meta-Analysis.,"['Rayner DG', 'Ferri DM', 'Guyatt GH', ""O'Byrne PM"", 'Brignardello-Petersen R', 'Foroutan F', 'Chipps B', 'Sumino K', 'Perry TT', 'Nyenhuis S', 'Oppenheimer J', 'Israel E', 'Hoyte F', 'Rivera-Spoljaric K', 'McCabe E', 'Rangel S', 'Shade LE', 'Press VG', 'Hall L', 'Sue-Wah-Sing D', 'Melendez A', 'Orr H', 'Winders T', 'Gardner DD', 'Przywara K', 'Rank MA', 'Bacharier LB', 'Mosnaim G', 'Chu DK']","['*Asthma/drug therapy', 'Humans', 'Administration, Inhalation', '*Formoterol Fumarate/administration & dosage', '*Adrenal Cortex Hormones/administration & dosage/therapeutic use', '*Randomized Controlled Trials as Topic', '*Drug Therapy, Combination', 'Anti-Asthmatic Agents/administration & dosage/adverse effects/therapeutic use', 'Quality of Life', 'Adrenergic beta-Agonists/administration & dosage/therapeutic use', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/39465893/
2310,formoterol,27340255,High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma.,"['Corradi M', 'Spinola M', 'Petruzzelli S', 'Kuna P']","['Administration, Inhalation', 'Adrenal Cortex Hormones/administration & dosage', 'Anti-Asthmatic Agents/administration & dosage/adverse effects', 'Asthma/*drug therapy/physiopathology', 'Beclomethasone/*administration & dosage/adverse effects', 'Bronchodilator Agents/administration & dosage', 'Dose-Response Relationship, Drug', 'Drug Combinations', 'Formoterol Fumarate/*administration & dosage/adverse effects', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/27340255/
2311,formoterol,26938578,Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma.,"['Crisafulli E', 'Zanini A', 'Pisi G', 'Pignatti P', 'Poli G', 'Scuri M', 'Chetta A']","['Administration, Inhalation', 'Anti-Asthmatic Agents/administration & dosage/*therapeutic use', 'Asthma/*drug therapy', 'Beclomethasone/administration & dosage/*therapeutic use', 'Drug Combinations', 'Dry Powder Inhalers', 'Formoterol Fumarate/administration & dosage/*therapeutic use', 'Humans', 'Metered Dose Inhalers', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26938578/
2312,clonidine,12126186,Clonidine toxicity revisited.,['Seger DL'],"['Adolescent', '*Adrenergic alpha-Agonists/pharmacokinetics/poisoning', 'Adult', '*Clonidine/antagonists & inhibitors/pharmacokinetics/poisoning', 'Drug Overdose', 'Female', 'Humans', 'Hypertension/chemically induced', 'Infant', 'Male', 'Middle Aged', 'Naloxone/adverse effects/*therapeutic use', 'Narcotic Antagonists/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12126186/
2313,clonidine,2869681,Alpha-adrenergic receptors and blood pressure control.,['Reid JL'],"['Adrenergic alpha-Agonists/adverse effects/*pharmacology', 'Adrenergic alpha-Antagonists/*pharmacology', 'Animals', 'Blood Pressure/*drug effects', 'Clonidine/adverse effects/pharmacology/therapeutic use', 'Drug Evaluation', 'Guanfacine', 'Guanidines/adverse effects/pharmacology/therapeutic use', 'Half-Life', 'Heart Rate/drug effects', 'Humans', 'Hypertension/drug therapy', 'Phenylacetates/adverse effects/pharmacology/therapeutic use', 'Prazosin/therapeutic use', 'Receptors, Adrenergic, alpha/*drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/2869681/
2314,clonidine,2668350,Clinical pharmacology of centrally acting antihypertensive agents.,['Weber MA'],"['Antihypertensive Agents/administration & dosage/pharmacokinetics/*therapeutic use', 'Blood Pressure/drug effects', 'Clonidine/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Dose-Response Relationship, Drug', 'Guanfacine', 'Guanidines/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Methyldopa/administration & dosage/therapeutic use', 'Phenylacetates/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/2668350/
2315,clonidine,7046065,Clonidine hydrochloride.,['Houston MC'],"['Antihypertensive Agents', 'Clonidine/adverse effects/metabolism/*pharmacology/therapeutic use', 'Diuretics/pharmacology', 'Drug Interactions', 'Drug Therapy, Combination', 'Hemodynamics/drug effects', 'Humans', 'Kinetics', 'Methyldopa/pharmacology', 'Prazosin/pharmacology', 'Propranolol/pharmacology', 'Renin-Angiotensin System/drug effects', 'Vasodilator Agents/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/7046065/
2316,clonidine,28833346,"Repurposing Valproate, Enteral Clonidine, and Phenobarbital for Comfort in Adult ICU Patients: A Literature Review with Practical Considerations.","['Gagnon DJ', 'Fontaine GV', 'Riker RR', 'Fraser GL']","['Administration, Oral', 'Administration, Sublingual', 'Adult', 'Clonidine/administration & dosage/*therapeutic use', 'Critical Illness', '*Drug Repositioning', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*therapeutic use', '*Intensive Care Units', 'Patient Comfort', 'Phenobarbital/administration & dosage/*therapeutic use', 'Valproic Acid/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28833346/
2317,clonidine,24195803,Oral clonidine in the management of acquired opioid dependency.,['Beaulieu MJ'],"['Administration, Oral', 'Adult', 'Analgesics/administration & dosage/*therapeutic use', 'Analgesics, Opioid/*adverse effects', 'Child', 'Clonidine/administration & dosage/*therapeutic use', 'Female', 'Humans', 'Infant, Newborn', 'Neonatal Abstinence Syndrome/*drug therapy', 'Opioid-Related Disorders/*drug therapy', 'Pregnancy', 'Prenatal Exposure Delayed Effects/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24195803/
2318,clonidine,10180510,Selectivity of site of action and systemic effects of topical alpha agonists.,"['Robin AL', 'Burnstein Y']","['Administration, Topical', 'Adrenergic alpha-Agonists/administration & dosage/adverse effects/*pharmacology', 'Animals', 'Brimonidine Tartrate', 'Clonidine/administration & dosage/adverse effects/analogs & derivatives/pharmacology', 'Glaucoma, Open-Angle/*drug therapy/physiopathology', 'Humans', 'Intraocular Pressure/drug effects', 'Ophthalmic Solutions', 'Optic Nerve/drug effects', 'Quinoxalines/administration & dosage/adverse effects/pharmacology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10180510/
2319,clonidine,490793,Abrupt discontinuation of clonidine therapy.,"['Ram CV', 'Engelman K']","['Adult', 'Blood Pressure/*drug effects', 'Clonidine/administration & dosage/*adverse effects/therapeutic use', 'Female', 'Humans', 'Hypertension/drug therapy', 'Male', 'Middle Aged', 'Substance Withdrawal Syndrome/*etiology/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/490793/
2320,clonidine,6641092,Alinidine in angina.,"['Meinertz T', 'Kasper W', 'Meier R', 'Wiegand U', 'Bechtold H', 'Forster I', 'Pop T', 'Jahnchen E']","['Adult', 'Angina Pectoris/*drug therapy', 'Blood Pressure/drug effects', 'Clonidine/*analogs & derivatives/pharmacology/therapeutic use', 'Double-Blind Method', 'Drug Evaluation', 'Electrocardiography', 'Exercise Test', 'Heart Rate/drug effects', 'Humans', 'Male', 'Middle Aged', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/6641092/
2321,clonidine,9471796,[The use of sirdalud in painful muscle tonic syndromes].,['Damulin IV'],"['Clonidine/administration & dosage/adverse effects/*analogs & derivatives', 'Humans', 'Muscle Relaxants, Central/*administration & dosage/adverse effects', 'Muscle Spasticity/drug therapy', 'Muscle Tonus/*drug effects', 'Muscular Diseases/*drug therapy', 'Pain/*drug therapy', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/9471796/
2322,clonidine,17233517,The pharmacological management of spasticity.,"['Saulino M', 'Jacobs BW']","['Baclofen/adverse effects/pharmacology/*therapeutic use', 'Clonidine/adverse effects/*analogs & derivatives/pharmacology/therapeutic use', 'Dantrolene/adverse effects/pharmacology/*therapeutic use', 'Humans', 'Muscle Relaxants, Central/adverse effects/pharmacology/*therapeutic use', 'Muscle Spasticity/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17233517/
2323,clonidine,3966758,Treatment of diabetic diarrhea with clonidine.,"['Fedorak RN', 'Field M', 'Chang EB']","['Chronic Disease', 'Clonidine/adverse effects/*therapeutic use', 'Diabetes Mellitus, Type 1/*complications', 'Diarrhea/*drug therapy/etiology', 'Feces/drug effects', 'Humans', 'Substance Withdrawal Syndrome/etiology']",https://pubmed.ncbi.nlm.nih.gov/3966758/
2324,clonidine,9327348,Clinical experience with apraclonidine 0.5%.,"['Gross RL', 'Pinyero A', 'Orengo-Nania S']","['Adolescent', 'Adrenergic alpha-Agonists/*therapeutic use', 'Adult', 'Aged', 'Aged, 80 and over', 'Child', 'Chronic Disease', 'Clonidine/administration & dosage/*analogs & derivatives/immunology/therapeutic use', 'Drug Hypersensitivity/immunology', 'Eye/immunology', 'Female', 'Glaucoma/*drug therapy/physiopathology', 'Humans', 'Intraocular Pressure/drug effects', 'Male', 'Middle Aged', 'Osmolar Concentration', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/9327348/
2325,clonidine,21353141,"A case of delirium, motor disturbances, and autonomic dysfunction due to baclofen and tizanidine withdrawal: a review of the literature.","['Karol DE', 'Muzyk AJ', ""Preud'homme XA""]","['Akathisia, Drug-Induced/*etiology', 'Anticonvulsants/administration & dosage/*adverse effects', 'Autonomic Nervous System Diseases/*chemically induced', 'Baclofen/administration & dosage/*adverse effects', 'Clonidine/administration & dosage/adverse effects/*analogs & derivatives', 'Delirium/*chemically induced', 'Humans', 'Male', 'Middle Aged', 'Substance Withdrawal Syndrome/etiology']",https://pubmed.ncbi.nlm.nih.gov/21353141/
2326,clonidine,11723871,Intrathecal clonidine for controlling spastic hypertonia.,"['Remy-Neris O', 'Denys P', 'Bussel B']","['Adrenergic alpha-Agonists/administration & dosage/*pharmacology/therapeutic use', 'Animals', 'Clonidine/administration & dosage/*pharmacology/therapeutic use', 'Humans', 'Injections, Spinal', 'Muscle Spasticity/*drug therapy/etiology', 'Reflex, Stretch/drug effects', 'Spinal Cord Injuries/complications']",https://pubmed.ncbi.nlm.nih.gov/11723871/
2327,clonidine,27779775,Clonidine for Sedation and Analgesia and Withdrawal in Critically Ill Infants and Children.,"['Capino AC', 'Miller JL', 'Johnson PN']","['Adrenergic alpha-2 Receptor Agonists/*administration & dosage/adverse effects', 'Analgesics/administration & dosage/adverse effects', 'Child', 'Clonidine/*administration & dosage/adverse effects', 'Critical Illness', 'Dose-Response Relationship, Drug', 'Humans', 'Hypnotics and Sedatives/administration & dosage/adverse effects', 'Infant', 'Substance Withdrawal Syndrome/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27779775/
2328,clonidine,7561715,Clonidine-induced bradycardia.,"['Golusinski LL Jr', 'Blount BW']","['Antihypertensive Agents/*adverse effects/pharmacology/therapeutic use', 'Bradycardia/*chemically induced', 'Clonidine/*adverse effects/pharmacology/therapeutic use', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/7561715/
2329,clonidine,6822133,Pharmacokinetics and pharmacodynamics of clonidine in varying states of renal function.,"['Lowenthal DT', 'Affrime MB', 'Meyer A', 'Kim KE', 'Falkner B', 'Sharif K']","['Adult', 'Clonidine/administration & dosage/*metabolism/therapeutic use', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Kidney Failure, Chronic/*metabolism', 'Kinetics', 'Male', 'Middle Aged', 'Renal Dialysis']",https://pubmed.ncbi.nlm.nih.gov/6822133/
2330,clonidine,8270972,Transdermal clonidine for ameliorating tamoxifen-induced hot flashes.,"['Goldberg RM', 'Loprinzi CL', ""O'Fallon JR"", 'Veeder MH', 'Miser AW', 'Mailliard JA', 'Michalak JC', 'Dose AM', 'Rowland KM Jr', 'Burnham NL']","['Administration, Cutaneous', 'Breast Neoplasms/drug therapy', 'Climacteric/*drug effects/physiology', 'Clonidine/administration & dosage/adverse effects/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Middle Aged', 'Prospective Studies', 'Tamoxifen/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/8270972/
2331,clonidine,1347973,Reformulation and drop size of apraclonidine hydrochloride.,"['Vocci MJ', 'Robin AL', 'Wahl JC', 'Mayer P', 'Graves A', 'York B', 'Enger C', 'Sutton J']","['Adrenergic alpha-Agonists/*administration & dosage/adverse effects', 'Adult', 'Clonidine/administration & dosage/adverse effects/*analogs & derivatives', 'Double-Blind Method', 'Female', 'Formularies as Topic', 'Humans', 'Hypromellose Derivatives', 'Intraocular Pressure/*drug effects', 'Lysophosphatidylcholines/administration & dosage/adverse effects', 'Male', 'Methylcellulose/administration & dosage/adverse effects/analogs & derivatives', 'Middle Aged', 'Placebos', 'Prospective Studies', 'Vision Disorders/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/1347973/
2332,metformin,25456737,Metformin: from mechanisms of action to therapies.,"['Foretz M', 'Guigas B', 'Bertrand L', 'Pollak M', 'Viollet B']","['AMP-Activated Protein Kinases/metabolism', 'Animals', 'Diabetes Mellitus, Type 2/drug therapy/metabolism', 'Energy Metabolism/drug effects', 'Humans', 'Hypoglycemic Agents/*therapeutic use', 'Metformin/*therapeutic use', 'Oxidative Phosphorylation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/25456737/
2333,metformin,24393785,Metformin--mode of action and clinical implications for diabetes and cancer.,"['Pernicova I', 'Korbonits M']","['AMP-Activated Protein Kinases/metabolism', 'Diabetes Mellitus, Type 2/*drug therapy/metabolism', 'Energy Metabolism/drug effects', 'Glucagon/metabolism', 'Gluconeogenesis/drug effects', 'Humans', 'Liver/*drug effects/metabolism', 'Metformin/*pharmacology/therapeutic use', 'Signal Transduction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/24393785/
2334,metformin,37397787,Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes.,"['Dutta S', 'Shah RB', 'Singhal S', 'Dutta SB', 'Bansal S', 'Sinha S', 'Haque M']","['Female', 'Humans', '*Metformin/pharmacology/therapeutic use', '*Diabetes Mellitus, Type 2/drug therapy', 'Hypoglycemic Agents/pharmacology/therapeutic use', '*Neoplasms/drug therapy', 'Glucose/metabolism', 'AMP-Activated Protein Kinases/metabolism']",https://pubmed.ncbi.nlm.nih.gov/37397787/
2335,metformin,37786390,Early Metformin in Gestational Diabetes: A Randomized Clinical Trial.,"['Dunne F', 'Newman C', 'Alvarez-Iglesias A', 'Ferguson J', 'Smyth A', 'Browne M', ""O'Shea P"", 'Devane D', 'Gillespie P', 'Bogdanet D', 'Kgosidialwa O', 'Egan A', 'Finn Y', 'Gaffney G', 'Khattak A', ""O'Keeffe D"", 'Liew A', ""O'Donnell M""]","['Adult', 'Female', 'Humans', 'Infant, Newborn', 'Pregnancy', 'Birth Weight', '*Diabetes, Gestational/drug therapy', 'Hypoglycemic Agents/administration & dosage/adverse effects/therapeutic use', 'Insulin/administration & dosage/therapeutic use', '*Metformin/administration & dosage/adverse effects/therapeutic use', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/37786390/
2336,metformin,28258677,Metformin - its potential anti-cancer and anti-aging effects.,"['Podhorecka M', 'Ibanez B', 'Dmoszynska A']","['Animals', 'Antineoplastic Agents/pharmacokinetics', 'Cell Death/drug effects', 'Glucose/metabolism', 'Humans', 'Hypoglycemic Agents/*pharmacology', 'Metformin/*pharmacology', 'Neoplasms/*drug therapy', 'Signal Transduction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/28258677/
2337,metformin,35640743,Metformin: Is it a drug for all reasons and diseases?,"['Triggle CR', 'Mohammed I', 'Bshesh K', 'Marei I', 'Ye K', 'Ding H', 'MacDonald R', 'Hollenberg MD', 'Hill MA']","['Animals', '*Diabetes Mellitus, Type 2/drug therapy', 'Female', 'Humans', 'Hypoglycemic Agents/pharmacology/therapeutic use', 'Insulin/metabolism', 'Mammals/metabolism', '*Metformin/pharmacology/therapeutic use', 'Reproducibility of Results', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/35640743/
2338,metformin,32994049,Metformin and Systemic Metabolism.,['He L'],"['Animals', 'Glucose/metabolism', 'Glycolysis/drug effects', 'Humans', 'Hyperglycemia/*drug therapy/metabolism', 'Intestinal Mucosa/drug effects/metabolism', 'Intestines/drug effects/microbiology', 'Lipid Metabolism/drug effects', 'Liver/drug effects/metabolism', 'Metabolism/drug effects', 'Metformin/administration & dosage/pharmacokinetics/*pharmacology', 'Microbiota/drug effects']",https://pubmed.ncbi.nlm.nih.gov/32994049/
2339,metformin,21241070,Clinical pharmacokinetics of metformin.,"['Graham GG', 'Punt J', 'Arora M', 'Day RO', 'Doogue MP', 'Duong JK', 'Furlong TJ', 'Greenfield JR', 'Greenup LC', 'Kirkpatrick CM', 'Ray JE', 'Timmins P', 'Williams KM']","['Administration, Oral', 'Biological Availability', 'Blood Glucose/*analysis', 'Diabetes Mellitus, Type 2/*drug therapy/metabolism', 'Half-Life', 'Humans', 'Hypoglycemic Agents/administration & dosage/*pharmacokinetics/therapeutic use', 'Injections, Intravenous', 'Metformin/administration & dosage/*pharmacokinetics/therapeutic use', 'Organic Cation Transport Proteins/*genetics/metabolism', 'Polymorphism, Single Nucleotide', 'Renal Insufficiency/metabolism']",https://pubmed.ncbi.nlm.nih.gov/21241070/
2340,metformin,33689478,The intersection of metformin and inflammation.,"['Bharath LP', 'Nikolajczyk BS']","['Animals', 'Anti-Inflammatory Agents/*therapeutic use', 'Autophagy-Related Proteins/metabolism', 'Humans', 'Inflammation/*drug therapy/metabolism/pathology', 'Inflammation Mediators/metabolism', 'Metformin/*therapeutic use', 'Mitochondria/*drug effects/metabolism/pathology', 'Mitophagy/*drug effects', 'Signal Transduction']",https://pubmed.ncbi.nlm.nih.gov/33689478/
2341,metformin,26059289,Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention.,"['Hostalek U', 'Gwilt M', 'Hildemann S']","['Diabetes Mellitus, Type 2/*prevention & control', 'Humans', 'Hypoglycemic Agents/pharmacology/therapeutic use', 'Metformin/adverse effects/pharmacology/*therapeutic use', 'Prediabetic State/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26059289/
2342,metformin,37344841,Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing.,"['Hua Y', 'Zheng Y', 'Yao Y', 'Jia R', 'Ge S', 'Zhuang A']","['Humans', '*Metformin/pharmacology/therapeutic use', 'Blood Glucose', 'Drug Repositioning', '*Neoplasms/drug therapy/pathology', '*Insulins/therapeutic use', 'Hypoglycemic Agents/pharmacology/therapeutic use', '*Diabetes Mellitus, Type 2/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37344841/
2343,metformin,33524789,The effects of metformin on autophagy.,"['Lu G', 'Wu Z', 'Shang J', 'Xie Z', 'Chen C', 'Zhang C']","['Animals', 'Autophagy/*drug effects', 'Autophagy-Related Proteins/*metabolism', 'Humans', 'Hypoglycemic Agents/adverse effects/*therapeutic use', 'Metformin/adverse effects/*therapeutic use', 'Signal Transduction']",https://pubmed.ncbi.nlm.nih.gov/33524789/
2344,metformin,9428832,"Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.","['Garber AJ', 'Duncan TG', 'Goodman AM', 'Mills DJ', 'Rohlf JL']","['Adult', 'Aged', 'Analysis of Variance', 'Blood Glucose/metabolism', 'Diabetes Mellitus, Type 2/blood/*drug therapy', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Glycated Hemoglobin/metabolism', 'Humans', 'Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Metformin/administration & dosage/adverse effects/*therapeutic use', 'Middle Aged', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9428832/
2345,metformin,35124206,"Mitochondria as an important target of metformin: The mechanism of action, toxic and side effects, and new therapeutic applications.","['Feng J', 'Wang X', 'Ye X', 'Ares I', 'Lopez-Torres B', 'Martinez M', 'Martinez-Larranaga MR', 'Wang X', 'Anadon A', 'Martinez MA']","['Humans', 'Hypoglycemic Agents/adverse effects', '*Metformin/pharmacology/therapeutic use', 'Mitochondria']",https://pubmed.ncbi.nlm.nih.gov/35124206/
2346,metformin,17728845,Pioglitazone and metformin.,"['Hill NR', 'Matthews DR']","['Animals', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Combinations', 'Humans', '*Hypoglycemic Agents/administration & dosage/adverse effects/pharmacology/therapeutic use', '*Metformin/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Pioglitazone', 'Therapeutic Equivalency', '*Thiazolidinediones/administration & dosage/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17728845/
2347,metformin,17139584,[Oral antidiabetic therapy].,"['Schneider S', 'Pazdzierny G', 'Klein HH']","['Administration, Oral', 'Cardiovascular Diseases/*prevention & control', 'Clinical Trials as Topic', 'Diabetes Mellitus, Type 2/complications/diet therapy/*drug therapy', 'Drug Therapy, Combination', 'Humans', 'Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use', 'Metformin/administration & dosage/adverse effects/*therapeutic use', 'Sulfonylurea Compounds/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17139584/
2348,metformin,26651913,[Metformin and the obstetric patient].,"['Pedersen KD', 'Bulow NS', 'Aaboe K', 'Galsgaard J', 'Odgaard HS', 'Mathiesen ER', 'Lauenborg J']","['Breast Feeding', 'Diabetes, Gestational/*drug therapy', 'Female', 'Humans', '*Hypoglycemic Agents/adverse effects/pharmacology/therapeutic use', '*Metformin/adverse effects/pharmacology/therapeutic use', 'Polycystic Ovary Syndrome/*drug therapy', 'Pregnancy', 'Pregnancy Trimester, Second', 'Pregnancy Trimester, Third', 'Prenatal Exposure Delayed Effects']",https://pubmed.ncbi.nlm.nih.gov/26651913/
2349,metformin,29291990,A reappraisal on metformin.,"['Adak T', 'Samadi A', 'Unal AZ', 'Sabuncuoglu S']","['Animals', 'Diabetes Mellitus, Type 2/drug therapy', 'Drug Interactions', 'Humans', 'Hypoglycemic Agents/pharmacokinetics/*pharmacology/therapeutic use', 'Metformin/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29291990/
2350,metformin,12093242,Metformin: an update.,"['Kirpichnikov D', 'McFarlane SI', 'Sowers JR']","['Animals', 'Cardiovascular Diseases/mortality/prevention & control', 'Diabetes Mellitus, Type 2/*complications', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hyperglycemia/complications/*drug therapy', 'Hypoglycemic Agents/adverse effects/*pharmacology/therapeutic use', 'Metformin/adverse effects/*pharmacology/therapeutic use', 'Polycystic Ovary Syndrome/drug therapy', 'Vascular Resistance/drug effects']",https://pubmed.ncbi.nlm.nih.gov/12093242/
2351,metformin,23410645,Use of noninsulin antidiabetic medications in hospitalized patients.,['Kopecky C'],"['Benzamides/pharmacology/therapeutic use', 'Biguanides/pharmacology/therapeutic use', 'Bromocriptine/administration & dosage/therapeutic use', 'Diabetes Mellitus/*drug therapy/nursing', 'Dipeptidyl-Peptidase IV Inhibitors/administration & dosage/therapeutic use', 'Glycoside Hydrolase Inhibitors', '*Hospitalization', 'Humans', 'Hypoglycemia/chemically induced', 'Hypoglycemic Agents/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Incretins/administration & dosage/therapeutic use', 'Islet Amyloid Polypeptide/agonists', 'Metformin/pharmacology/therapeutic use', 'Sulfonylurea Compounds/administration & dosage/metabolism/therapeutic use', 'Thiazolidinediones/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23410645/
2352,celecoxib,36053397,Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.,"['Ziesenitz VC', 'Welzel T', 'van Dyk M', 'Saur P', 'Gorenflo M', 'van den Anker JN']","['Adolescent', 'Infant', 'Child', 'Humans', 'Meloxicam', 'Naproxen/therapeutic use', 'Celecoxib/adverse effects', 'Ibuprofen', '*Ketoprofen', 'Diclofenac', 'Ketorolac', '*Flurbiprofen', 'Niflumic Acid', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Aspirin/adverse effects', 'Anti-Inflammatory Agents', 'Chronic Disease', 'Pain/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36053397/
2353,celecoxib,30073924,Celecoxib in Cancer Therapy and Prevention - Review.,"['Toloczko-Iwaniuk N', 'Dziemianczyk-Pakiela D', 'Nowaszewska BK', 'Celinska-Janowicz K', 'Miltyk W']","['Animals', 'Apoptosis/drug effects', 'Celecoxib/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Cyclooxygenase 2 Inhibitors/pharmacology/*therapeutic use', 'Female', 'Humans', 'Male', 'Neoplasms/*drug therapy/epidemiology/prevention & control', 'Precancerous Conditions/*drug therapy/enzymology', 'Treatment Outcome', 'Tumor Microenvironment/drug effects']",https://pubmed.ncbi.nlm.nih.gov/30073924/
2354,celecoxib,36106817,Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.,"['Salomon-Zimri S', 'Pushett A', 'Russek-Blum N', 'Van Eijk RPA', 'Birman N', 'Abramovich B', 'Eitan E', 'Elgrart K', 'Beaulieu D', 'Ennist DL', 'Berry JD', 'Paganoni S', 'Shefner JM', 'Drory VE']","['Humans', '*Amyotrophic Lateral Sclerosis/diagnosis/drug therapy', 'Biomarkers', 'Celecoxib/therapeutic use', '*COVID-19', 'Disease Progression', 'DNA-Binding Proteins', 'Double-Blind Method', '*Neurodegenerative Diseases', 'Ciprofloxacin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36106817/
2355,celecoxib,35655045,Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.,"['Pandy JGP', 'Franco PIG', 'Li RK']","['Humans', '*Hand-Foot Syndrome/etiology/prevention & control/drug therapy', 'Capecitabine/adverse effects', 'Sorafenib/therapeutic use', 'Pyridoxine/therapeutic use', 'Celecoxib/therapeutic use', 'Randomized Controlled Trials as Topic', '*Neoplasms/drug therapy/complications']",https://pubmed.ncbi.nlm.nih.gov/35655045/
2356,celecoxib,34376069,Gastrointestinal and cardiovascular adverse events associated with NSAIDs.,"['Domper Arnal MJ', 'Hijos-Mallada G', 'Lanas A']","['Aged', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Celecoxib/adverse effects', '*Cyclooxygenase 2 Inhibitors/adverse effects', '*Gastrointestinal Diseases/drug therapy', 'Humans', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/34376069/
2357,celecoxib,35277974,Etoricoxib and celecoxib sensitive indomethacin-responsive headache disorders.,"['Farag M', 'Bahra A']","['Anti-Inflammatory Agents, Non-Steroidal/pharmacology', 'Celecoxib/adverse effects', 'Etoricoxib/therapeutic use', 'Headache/chemically induced/drug therapy', '*Headache Disorders/drug therapy', 'Humans', '*Indomethacin/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35277974/
2358,celecoxib,30240679,Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis.,"['Smith SM', 'Cooper-DeHoff RM']","['Amlodipine/administration & dosage/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use', 'Antihypertensive Agents/administration & dosage/therapeutic use', 'Celecoxib/administration & dosage/*therapeutic use', 'Humans', 'Hypertension/*drug therapy', 'Osteoarthritis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30240679/
2359,celecoxib,32296574,COX-2 as a potential biomarker and therapeutic target in melanoma.,"['Tudor DV', 'Baldea I', 'Lupu M', 'Kacso T', 'Kutasi E', 'Hopartean A', 'Stretea R', 'Gabriela Filip A']","['Animals', 'Antineoplastic Combined Chemotherapy Protocols/pharmacology/therapeutic use', 'Biomarkers, Tumor/*analysis/metabolism', 'Celecoxib/pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Cyclooxygenase 2/*analysis/metabolism', 'Cyclooxygenase 2 Inhibitors/pharmacology/therapeutic use', 'Disease Models, Animal', 'Disease Progression', 'Humans', 'Melanoma/drug therapy/immunology/*mortality/pathology', 'Molecular Targeted Therapy/methods', 'Prognosis', 'Progression-Free Survival', 'Signal Transduction/drug effects/immunology', 'Skin/immunology/pathology', 'Skin Neoplasms/drug therapy/immunology/*mortality/pathology', 'Tumor Escape/drug effects', 'Tumor Microenvironment/drug effects/immunology']",https://pubmed.ncbi.nlm.nih.gov/32296574/
2360,celecoxib,36890655,Modulation effects of different treatments on periaqueductal gray resting state functional connectivity in knee osteoarthritis knee pain patients.,"['Zhou J', 'Zeng F', 'Cheng S', 'Dong X', 'Jiang N', 'Zhang X', 'Tang C', 'He W', 'Chen Y', 'Sun N', 'Zhou Y', 'Li X', 'Hu S', 'Sun R', 'Wintermark M', 'Yang W', 'Liang F', 'Li Z']","['Humans', '*Osteoarthritis, Knee/diagnostic imaging/drug therapy', 'Periaqueductal Gray/diagnostic imaging', 'Celecoxib/pharmacology/therapeutic use', 'Capsules', 'Pain/complications', '*Acupuncture Therapy', 'Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use', 'Magnetic Resonance Imaging']",https://pubmed.ncbi.nlm.nih.gov/36890655/
2361,celecoxib,33783231,Repurposing celecoxib analogues as leads for antibiotics.,"['Yang B', 'Mei Y', 'Li Q', 'Zhang M', 'Tang H', 'Liu T', 'Feng F', 'Fu Q', 'Jiang Y', 'Ye Q']","['Acinetobacter baumannii/*drug effects/growth & development', 'Animals', 'Anti-Bacterial Agents/chemical synthesis/chemistry/*pharmacology', 'Celecoxib/chemical synthesis/chemistry/*pharmacology', 'Cell Survival/drug effects', 'Female', 'Hep G2 Cells', 'Humans', 'Mice', 'Mice, Inbred ICR', 'Microbial Sensitivity Tests', 'Molecular Structure', 'Staphylococcus aureus/*drug effects/growth & development']",https://pubmed.ncbi.nlm.nih.gov/33783231/
2362,celecoxib,33821899,Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.,"['Meyerhardt JA', 'Shi Q', 'Fuchs CS', 'Meyer J', 'Niedzwiecki D', 'Zemla T', 'Kumthekar P', 'Guthrie KA', 'Couture F', 'Kuebler P', 'Bendell JC', 'Kumar P', 'Lewis D', 'Tan B', 'Bertagnolli M', 'Grothey A', 'Hochster HS', 'Goldberg RM', 'Venook A', 'Blanke C', ""O'Reilly EM"", 'Shields AF']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Celecoxib/adverse effects/*therapeutic use', '*Chemotherapy, Adjuvant', 'Colonic Neoplasms/*drug therapy/surgery', 'Cyclooxygenase 2 Inhibitors/adverse effects/*therapeutic use', 'Disease-Free Survival', 'Female', 'Humans', 'Male', 'Middle Aged', 'Neoplasm Recurrence, Local/epidemiology/prevention & control', 'Neoplasm Staging', 'Patient Compliance', 'Proportional Hazards Models', 'Secondary Prevention', 'Survival Rate', 'Treatment Failure', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33821899/
2363,celecoxib,26520197,[Gastrointestinal bleeding].,['Lanas A'],"['Anemia/etiology/therapy', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Anticoagulants/adverse effects/therapeutic use', 'Aspirin/adverse effects/therapeutic use', 'Blood Transfusion', 'Celecoxib/therapeutic use', 'Drug Therapy, Combination', 'Endoscopy, Gastrointestinal', '*Gastrointestinal Hemorrhage/etiology/therapy', 'Hemorrhagic Disorders/chemically induced', 'Hemostatic Techniques', 'Humans', 'Ligation', 'Platelet Aggregation Inhibitors/adverse effects/therapeutic use', 'Proton Pump Inhibitors/therapeutic use', 'Randomized Controlled Trials as Topic', 'Recurrence', 'Thrombophilia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26520197/
2364,celecoxib,32615181,MicroRNAs in the anticancer effects of celecoxib: A systematic review.,"['Mishan MA', 'Khazeei Tabari MA', 'Zargari M', 'Bagheri A']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Antineoplastic Agents/*therapeutic use', 'Celecoxib/*therapeutic use', 'Humans', '*MicroRNAs', 'Neoplasms/*drug therapy/genetics']",https://pubmed.ncbi.nlm.nih.gov/32615181/
2365,celecoxib,37749237,Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis.,"['Liu H', 'Deng R', 'Zhu CW', 'Han HK', 'Zong GF', 'Ren L', 'Cheng P', 'Wei ZH', 'Zhao Y', 'Yu SY', 'Lu Y']","['Humans', 'Animals', 'Mice', 'B7-H1 Antigen/metabolism', 'Cyclooxygenase 2/metabolism', 'Rosmarinic Acid', 'Celecoxib/pharmacology/therapeutic use', 'Cyclooxygenase 2 Inhibitors/pharmacology/therapeutic use', 'Immune Checkpoint Inhibitors/therapeutic use', 'Programmed Cell Death 1 Receptor/metabolism', 'Cell Line, Tumor', '*Colonic Neoplasms/drug therapy/metabolism', '*Lung Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37749237/
2366,celecoxib,37739445,Angioedema without urticaria after recent initiation of celecoxib.,"['Jasti VV', 'Anderson J', 'Abdujelil I']","['Humans', 'Celecoxib/adverse effects', '*Urticaria/chemically induced', '*Angioedema/chemically induced', 'Skin', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37739445/
2367,celecoxib,27524864,Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials.,"['Marini S', 'De Berardis D', 'Vellante F', 'Santacroce R', 'Orsolini L', 'Valchera A', 'Girinelli G', 'Carano A', 'Fornaro M', 'Gambi F', 'Martinotti G', 'Di Giannantonio M']","['Antipsychotic Agents/*therapeutic use', 'Celecoxib/*therapeutic use', 'Humans', 'Randomized Controlled Trials as Topic', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27524864/
2368,celecoxib,14519044,Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity.,"['West PM', 'Fernandez C']","['Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use', 'Aspirin/administration & dosage/*adverse effects', 'Asthma/*chemically induced/drug therapy/*prevention & control', 'Celecoxib', 'Cyclooxygenase 2', 'Drug Hypersensitivity/complications/*etiology', 'Humans', 'Isoenzymes/*antagonists & inhibitors', 'Lactones/administration & dosage/pharmacokinetics/therapeutic use', 'Membrane Proteins', 'Meta-Analysis as Topic', 'Prostaglandin-Endoperoxide Synthases', 'Pyrazoles', 'Sulfonamides/administration & dosage/pharmacokinetics/therapeutic use', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/14519044/
2369,celecoxib,36964012,Quality of recovery after pericapsular nerve group (PENG) block for primary total hip arthroplasty under spinal anaesthesia: a randomised controlled observer-blinded trial.,"['Kukreja P', 'Uppal V', 'Kofskey AM', 'Feinstein J', 'Northern T', 'Davis C', 'Morgan CJ', 'Kalagara H']","['Humans', '*Anesthesia, Spinal/methods', 'Anesthetics, Local/therapeutic use', 'Analgesics, Opioid/therapeutic use', 'Acetaminophen/therapeutic use', 'Femoral Nerve', '*Arthroplasty, Replacement, Hip/adverse effects', 'Celecoxib/therapeutic use', 'Pain, Postoperative/prevention & control/etiology']",https://pubmed.ncbi.nlm.nih.gov/36964012/
2370,celecoxib,25589511,"Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib.","['Hochberg MC', 'Martel-Pelletier J', 'Monfort J', 'Moller I', 'Castillo JR', 'Arden N', 'Berenbaum F', 'Blanco FJ', 'Conaghan PG', 'Domenech G', 'Henrotin Y', 'Pap T', 'Richette P', 'Sawitzke A', 'du Souich P', 'Pelletier JP']","['Aged', 'Celecoxib/*therapeutic use', 'Chondroitin Sulfates/adverse effects/*therapeutic use', 'Cyclooxygenase 2 Inhibitors/*therapeutic use', 'Double-Blind Method', 'Drug Combinations', 'Edema/*etiology', 'Female', 'Glucosamine/adverse effects/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Musculoskeletal Pain/drug therapy/etiology', 'Osteoarthritis, Knee/complications/*drug therapy/physiopathology', 'Pain Measurement', 'Quality of Life', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25589511/
2371,celecoxib,28530031,Celecoxib for osteoarthritis.,"['Puljak L', 'Marin A', 'Vrdoljak D', 'Markotic F', 'Utrobicic A', 'Tugwell P']","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Celecoxib/adverse effects/*therapeutic use', 'Diclofenac/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Naproxen/therapeutic use', 'Osteoarthritis, Hip/*drug therapy', 'Osteoarthritis, Knee/*drug therapy', 'Pain Measurement/methods', 'Placebos/adverse effects/therapeutic use', 'Quality of Life', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/28530031/
2372,ketorolac,27042717,[Muscle-skeletal pain].,"['Vygonskaya MV', 'Filatova EG']","['Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use', 'Chronic Pain', 'Combined Modality Therapy', 'Humans', 'Ketorolac/adverse effects/therapeutic use', 'Low Back Pain/*physiopathology/*therapy', 'Musculoskeletal Pain/*physiopathology/*therapy']",https://pubmed.ncbi.nlm.nih.gov/27042717/
2373,ketorolac,37097781,What is the analgesic ceiling dose of ketorolac for treating acute pain in the ED?,"['Jaglal R', 'Nemec EC 2nd']","['Humans', '*Ketorolac/therapeutic use', '*Acute Pain/drug therapy', 'Analgesics/adverse effects', 'Pain Management', 'Pain, Postoperative/drug therapy', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/37097781/
2374,ketorolac,28526155,"Ketorolac, Oxymorphone, Tapentadol, and Tramadol: A Comprehensive Review.","['Vadivelu N', 'Chang D', 'Helander EM', 'Bordelon GJ', 'Kai A', 'Kaye AD', 'Hsu D', 'Bang D', 'Julka I']","['Analgesics, Opioid/adverse effects/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Humans', 'Ketorolac/adverse effects/*therapeutic use', 'Oxymorphone/adverse effects/*therapeutic use', 'Pain/*drug therapy', 'Pain Measurement', 'Phenols/adverse effects/*therapeutic use', 'Tapentadol', 'Tramadol/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28526155/
2375,ketorolac,27993418,Comparison of Intravenous Ketorolac at Three Single-Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial.,"['Motov S', 'Yasavolian M', 'Likourezos A', 'Pushkar I', 'Hossain R', 'Drapkin J', 'Cohen V', 'Filk N', 'Smith A', 'Huang F', 'Rockoff B', 'Homel P', 'Fromm C']","['Acute Pain/*drug therapy/physiopathology', 'Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/pharmacology/*therapeutic use', 'Dose-Response Relationship, Drug', 'Double-Blind Method', '*Emergency Service, Hospital', 'Female', 'Humans', 'Injections, Intravenous', 'Ketorolac/*administration & dosage/pharmacology/*therapeutic use', 'Male', 'Pain Measurement', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27993418/
2376,ketorolac,29247538,Narrative review shows that the short-term use of ketorolac is safe and effective in the management of moderate-to-severe pain in children.,"['Marzuillo P', 'Calligaris L', 'Amoroso S', 'Barbi E']","['Age Factors', 'Anti-Inflammatory Agents, Non-Steroidal/*pharmacology', 'Child', 'Child, Preschool', 'Humans', 'Infant', 'Ketorolac/*pharmacology', 'Pain/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/29247538/
2377,ketorolac,35274178,The Efficacy of Local Anesthesia for Postoperative Pain Control in Breast Augmentation Surgery: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.,"['Chen IC', 'Kang YN', 'Wang HJ', 'Chiu WK', 'Chen C']","['Analgesics/therapeutic use', '*Anesthesia, Local/methods', 'Anesthetics, Local', 'Bupivacaine/therapeutic use', 'Female', 'Humans', 'Ketorolac/therapeutic use', '*Mammaplasty/adverse effects/methods', 'Narcotics/therapeutic use', 'Network Meta-Analysis', 'Pain, Postoperative/drug therapy/prevention & control', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/35274178/
2378,ketorolac,27931700,Pediatric Tonsillectomy and Ketorolac.,"['Phillips-Reed LD', 'Austin PN', 'Rodriguez RE']","['Adolescent', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Child', 'Child, Preschool', 'Hemorrhage/chemically induced', 'Humans', 'Infant', 'Ketorolac/*adverse effects', '*Tonsillectomy']",https://pubmed.ncbi.nlm.nih.gov/27931700/
2379,ketorolac,11027904,Pain responses in methadone-maintained opioid abusers.,"['Compton P', 'Charuvastra VC', 'Kintaudi K', 'Ling W']","['Adult', 'Cold Temperature/adverse effects', 'Drug Interactions/*physiology', 'Female', 'Humans', 'Hydromorphone/administration & dosage/adverse effects', 'Ketorolac/administration & dosage/adverse effects', 'Male', 'Methadone/*adverse effects', 'Middle Aged', 'Opioid-Related Disorders/drug therapy/*physiopathology', 'Pain/*drug therapy/physiopathology', 'Pain Measurement/statistics & numerical data', 'Pain Threshold/drug effects/physiology', 'Pressure/adverse effects', 'Reaction Time/drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/11027904/
2380,ketorolac,37088148,A possible role for ketorolac in the management of increased biliary drain output.,"['Yu AT', 'Khajoueinejad N', 'Gross A', 'Golas BJ', 'Cohen NA']","['Humans', 'Ketorolac/therapeutic use', '*Cholestasis/etiology', 'Treatment Outcome', '*Jaundice', '*Adenocarcinoma/complications', 'Drainage']",https://pubmed.ncbi.nlm.nih.gov/37088148/
2381,ketorolac,29426743,Bridging multimodal pain management provides 48-hour pain control in patients undergoing total shoulder replacement.,"['Boddu C', 'Genza A', 'McCann PD']","['Acetaminophen/therapeutic use', 'Adult', 'Aged', 'Aged, 80 and over', 'Analgesics, Non-Narcotic/therapeutic use', 'Analgesics, Opioid/administration & dosage', 'Anesthetics, Local/*administration & dosage', 'Anti-Inflammatory Agents/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal', 'Arthroplasty, Replacement, Shoulder/*adverse effects', 'Bupivacaine/*administration & dosage', 'Cryotherapy', 'Dexamethasone/therapeutic use', 'Female', 'Humans', 'Ketorolac/therapeutic use', 'Length of Stay', 'Liposomes', 'Male', 'Middle Aged', 'Narcotics/therapeutic use', 'Nerve Block', 'Pain Management/*methods', 'Pain Measurement', 'Pain, Postoperative/etiology/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/29426743/
2382,ketorolac,15195936,Multimodal acute pain management.,['Skinner HB'],"['Analgesia, Epidural', 'Analgesia, Patient-Controlled', 'Analgesics, Opioid', '*Anesthesia, Conduction', 'Anesthesia, Spinal', 'Anesthetics, Local', 'Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use', '*Arthroplasty', 'Arthroplasty, Replacement, Hip', 'Arthroplasty, Replacement, Knee', 'Bupivacaine', 'Drug Therapy, Combination', 'Humans', 'Ketorolac/pharmacology/therapeutic use', 'Nerve Block', 'Pain Measurement', 'Pain, Postoperative/physiopathology/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/15195936/
2383,ketorolac,17464604,"Reduced hospital stay and narcotic consumption, and improved mobilization with local and intraarticular infiltration after hip arthroplasty: a randomized clinical trial of an intraarticular technique versus epidural infusion in 80 patients.","['Andersen KV', 'Pfeiffer-Jensen M', 'Haraldsted V', 'Soballe K']","['Aged', 'Amides/*administration & dosage/adverse effects', 'Analgesia/*methods', 'Analgesia, Epidural/*methods', 'Analgesics, Opioid/*administration & dosage/adverse effects', 'Anesthetics, Local/*administration & dosage/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects', 'Arthroplasty, Replacement, Hip/*adverse effects', 'Drug Therapy, Combination', 'Female', 'Humans', 'Injections, Intra-Articular', 'Ketorolac/*administration & dosage/adverse effects', '*Length of Stay', 'Male', 'Middle Aged', 'Pain Measurement', 'Pain, Postoperative/*drug therapy', 'Recovery of Function', 'Ropivacaine', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17464604/
2384,ketorolac,14516415,Effect of oral ketorolac and gender on human cold pressor pain tolerance.,"['Compton P', 'Charuvastra VC', 'Ling W']","['Administration, Oral', 'Adult', 'Analysis of Variance', 'Cold Temperature/*adverse effects', 'Cross-Over Studies', 'Double-Blind Method', 'Female', 'Humans', 'Ketorolac/*administration & dosage', 'Male', 'Middle Aged', 'Pain/*drug therapy/physiopathology', 'Pain Threshold/*drug effects/physiology', '*Sex Characteristics']",https://pubmed.ncbi.nlm.nih.gov/14516415/
2385,ketorolac,29771750,Injectable Nonsteroidal Anti-Inflammatory Drugs in Sport.,['Matava MJ'],"['Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', '*Athletes', 'Athletic Injuries/*drug therapy', 'Humans', 'Inflammation/*drug therapy', 'Injections', 'Ketorolac/administration & dosage/adverse effects/therapeutic use', 'Pain', '*Pain Management', 'Soft Tissue Injuries/drug therapy', 'Sports']",https://pubmed.ncbi.nlm.nih.gov/29771750/
2386,ketorolac,37733089,Opioid-free percutaneous nephrolithotomy: an initial experience.,"['Khargi R', 'Yaghoubian AJ', 'Blake RM', 'Ricapito A', 'Connors C', 'Gallante B', 'Khusid JA', 'Atallah W', 'Gupta M']","['Humans', '*Analgesics, Opioid/therapeutic use', 'Ketorolac/therapeutic use', '*Nephrolithotomy, Percutaneous/adverse effects', 'Retrospective Studies', 'Prospective Studies', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Pain, Postoperative/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37733089/
2387,ketorolac,19641054,An evaluation of perioperative pregabalin for prevention and attenuation of postoperative shoulder pain after laparoscopic cholecystectomy.,"['Chang SH', 'Lee HW', 'Kim HK', 'Kim SH', 'Kim DK']","['Adult', 'Analgesics/*administration & dosage/adverse effects', '*Cholecystectomy, Laparoscopic', 'Double-Blind Method', 'Drug Administration Schedule', 'Humans', 'Ketorolac/administration & dosage', 'Pain Measurement', 'Pain, Postoperative/*prevention & control', 'Pregabalin', 'Prospective Studies', 'Severity of Illness Index', 'Shoulder Pain/*prevention & control', 'Sleep/drug effects', 'Time Factors', 'gamma-Aminobutyric Acid/administration & dosage/adverse effects/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/19641054/
2388,ketorolac,22391075,Aspirin-sensitive asthma and upper airway diseases.,"['Chang JE', 'Chin W', 'Simon R']","['Administration, Intranasal', 'Administration, Oral', 'Animals', 'Asthma, Aspirin-Induced/*diagnosis/immunology/*therapy', '*Desensitization, Immunologic', 'Drug Dosage Calculations', 'Humans', 'Immunization', 'Ketorolac/administration & dosage/adverse effects', 'Respiratory Tract Diseases/*diagnosis/immunology/*therapy']",https://pubmed.ncbi.nlm.nih.gov/22391075/
2389,ketorolac,28238723,Non-steroidal Anti-inflammatory Drugs Are Caspase Inhibitors.,"['Smith CE', 'Soti S', 'Jones TA', 'Nakagawa A', 'Xue D', 'Yin H']","['Anti-Inflammatory Agents, Non-Steroidal/*chemistry/metabolism/pharmacology', 'Caspase Inhibitors/*chemistry/metabolism/pharmacology', 'Caspases/chemistry/*metabolism', 'Caspases, Initiator/chemistry/metabolism', 'Cell Line', 'Cell Survival/drug effects', 'High-Throughput Screening Assays', 'Humans', 'Ibuprofen/chemistry/metabolism/pharmacology', 'Inhibitory Concentration 50', 'Ketorolac/chemistry/metabolism/pharmacology', 'Naproxen/chemistry/metabolism/pharmacology', 'Small Molecule Libraries/chemistry/metabolism/pharmacology', 'Substrate Specificity']",https://pubmed.ncbi.nlm.nih.gov/28238723/
2390,ketorolac,32877323,Injectable Ketorolac and Corticosteroid Use in Athletes: A Systematic Review.,"['Jelsema TR', 'Tam AC', 'Moeller JL']","['Adrenal Cortex Hormones/*administration & dosage/adverse effects/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects/therapeutic use', 'Athletic Injuries/*drug therapy', 'Humans', 'Injections, Intramuscular', 'Ketorolac/*administration & dosage/adverse effects/therapeutic use', 'Musculoskeletal System/injuries', 'Myalgia/drug therapy', 'Return to Sport', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/32877323/
2391,ketorolac,24564610,Characterization and treatment of postsurgical dental implant pain employing intranasal ketorolac.,"['Bockow R', 'Korostoff J', 'Pinto A', 'Hutcheson M', 'Secreto SA', 'Bodner L', 'Hersh EV']","['Acetaminophen/therapeutic use', 'Administration, Intranasal', 'Adult', 'Analgesia, Patient-Controlled/methods', 'Analgesics, Non-Narcotic/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects', 'Cohort Studies', '*Dental Implantation, Endosseous', 'Dental Implants', 'Female', 'Humans', 'Ketorolac/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Nasal Mucosa/drug effects', 'Operative Time', 'Pain Measurement', 'Pain, Postoperative/*drug therapy', 'Pilot Projects', 'Rhinitis/chemically induced', 'Time Factors', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24564610/
2392,ADAPALENE,33751778,"Perioral dermatitis: Diagnosis, proposed etiologies, and management.","['Searle T', 'Ali FR', 'Al-Niaimi F']","['Anti-Bacterial Agents/therapeutic use', '*Dermatitis, Perioral/diagnosis/drug therapy/etiology', '*Dermatologic Agents/therapeutic use', 'Humans', 'Isotretinoin', 'Metronidazole/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33751778/
2393,ADAPALENE,34812859,Management of Acne Vulgaris: A Review.,"['Eichenfield DZ', 'Sprague J', 'Eichenfield LF']","['Acne Vulgaris/*drug therapy/pathology/therapy', 'Administration, Cutaneous', 'Administration, Oral', 'Adolescent', 'Adult', 'Anti-Bacterial Agents/administration & dosage/adverse effects/*therapeutic use', 'Benzoyl Peroxide/administration & dosage', 'Child', 'Contraceptives, Oral, Combined/therapeutic use', 'Dermatologic Agents/*administration & dosage/adverse effects', 'Drug Therapy, Combination', 'Humans', 'Retinoids/*administration & dosage', 'Salicylic Acid/administration & dosage', 'Spironolactone/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34812859/
2394,ADAPALENE,38300170,Guidelines of care for the management of acne vulgaris.,"['Reynolds RV', 'Yeung H', 'Cheng CE', 'Cook-Bolden F', 'Desai SR', 'Druby KM', 'Freeman EE', 'Keri JE', 'Stein Gold LF', 'Tan JKL', 'Tollefson MM', 'Weiss JS', 'Wu PA', 'Zaenglein AL', 'Han JM', 'Barbieri JS']","['Humans', '*Acne Vulgaris/drug therapy', 'Administration, Cutaneous', 'Administration, Oral', 'Adrenal Cortex Hormones/administration & dosage/therapeutic use', '*Anti-Bacterial Agents/administration & dosage/therapeutic use', '*Benzoyl Peroxide/administration & dosage/therapeutic use', 'Contraceptives, Oral, Combined/administration & dosage/therapeutic use', 'Cortodoxone/analogs & derivatives', '*Dermatologic Agents/administration & dosage/therapeutic use', '*Dicarboxylic Acids/administration & dosage/therapeutic use', '*Doxycycline/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Evidence-Based Medicine/standards', 'Injections, Intralesional', '*Isotretinoin/administration & dosage/therapeutic use', 'Minocycline/administration & dosage/therapeutic use', 'Propionates', 'Retinoids/administration & dosage/therapeutic use', '*Salicylic Acid/administration & dosage/therapeutic use', '*Spironolactone/administration & dosage/therapeutic use', 'Tetracyclines/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38300170/
2395,ADAPALENE,38154809,Managing acne vulgaris: an update.,"['Santer M', 'Burden-Teh E', 'Ravenscroft J']","['Humans', 'Female', '*Isotretinoin', '*Acne Vulgaris/drug therapy', 'Benzoyl Peroxide', 'Anti-Bacterial Agents/adverse effects', 'Adapalene']",https://pubmed.ncbi.nlm.nih.gov/38154809/
2396,ADAPALENE,36301760,Novel and emerging treatment options for acne vulgaris.,"['Auffret N', 'Claudel JP', 'Leccia MT', 'Ballanger F', 'Dreno B']","['Humans', 'Anti-Bacterial Agents/adverse effects', '*Acne Vulgaris/drug therapy', 'Benzoyl Peroxide/adverse effects', 'Adapalene', 'Propionibacterium acnes', '*Dermatologic Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/36301760/
2397,ADAPALENE,36220974,Use of Retinoids in Topical Antiaging Treatments: A Focused Review of Clinical Evidence for Conventional and Nanoformulations.,"['Milosheska D', 'Roskar R']","['Humans', 'Retinoids/therapeutic use', '*Dermatologic Agents/therapeutic use', '*Cosmeceuticals/therapeutic use', 'Adapalene', 'Tretinoin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36220974/
2398,ADAPALENE,30674002,Topical Retinoids in Acne Vulgaris: A Systematic Review.,"['Kolli SS', 'Pecone D', 'Pona A', 'Cline A', 'Feldman SR']","['Acne Vulgaris/diagnosis/*drug therapy', 'Administration, Cutaneous', 'Administration, Oral', 'Anti-Bacterial Agents/*administration & dosage', 'Benzoyl Peroxide/*administration & dosage/adverse effects', 'Clinical Trials as Topic', 'Dermatologic Agents/*administration & dosage/adverse effects', 'Drug Therapy, Combination', 'Humans', 'Retinoids/*administration & dosage/adverse effects', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30674002/
2399,ADAPALENE,38428412,Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells.,"['Colucci M', 'Zumerle S', 'Bressan S', 'Gianfanti F', 'Troiani M', 'Valdata A', ""D'Ambrosio M"", 'Pasquini E', 'Varesi A', 'Cogo F', 'Mosole S', 'Dongilli C', 'Desbats MA', 'Contu L', 'Revankdar A', 'Chen J', 'Kalathur M', 'Perciato ML', 'Basilotta R', 'Endre L', 'Schauer S', 'Othman A', 'Guccini I', 'Saponaro M', 'Maraccani L', 'Bancaro N', 'Lai P', 'Liu L', 'Pernigoni N', 'Mele F', 'Merler S', 'Trotman LC', 'Guarda G', 'Cali B', 'Montopoli M', 'Alimonti A']","['Male', 'Humans', 'Animals', 'Mice', '*Cellular Senescence', '*Prostatic Neoplasms/drug therapy', 'Receptors, Retinoic Acid', 'Killer Cells, Natural', 'Adapalene']",https://pubmed.ncbi.nlm.nih.gov/38428412/
2400,ADAPALENE,38428411,Unleashing a safe and potent pro-senescence anti-tumor strategy.,"['Chen S', 'Sun B', 'Dong Z']","['Humans', 'Cell Line, Tumor', 'Docetaxel/pharmacology', 'Adapalene', '*Cellular Senescence']",https://pubmed.ncbi.nlm.nih.gov/38428411/
2401,ADAPALENE,32356369,"Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne.","['Liu H', 'Yu H', 'Xia J', 'Liu L', 'Liu GJ', 'Sang H', 'Peinemann F']","['Acne Vulgaris/*drug therapy', 'Adapalene/adverse effects/therapeutic use', 'Adolescent', 'Adult', 'Anti-Bacterial Agents/therapeutic use', 'Benzoyl Peroxide/therapeutic use', 'Bias', 'Child', 'Clindamycin/adverse effects/therapeutic use', 'Dermatologic Agents/adverse effects/*therapeutic use', 'Dicarboxylic Acids/adverse effects/therapeutic use', 'Erythromycin/adverse effects/therapeutic use', 'Female', 'Glycolates/therapeutic use', 'Humans', 'Keratolytic Agents/therapeutic use', 'Male', 'Mandelic Acids/therapeutic use', 'Niacinamide/adverse effects/therapeutic use', 'Patient Dropouts/statistics & numerical data', 'Pyruvic Acid/adverse effects/therapeutic use', 'Quality of Life', 'Salicylic Acid/therapeutic use', 'Sulfur/therapeutic use', 'Tretinoin/therapeutic use', 'Young Adult', 'Zinc/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32356369/
2402,ADAPALENE,37683070,Topical Treatments for Photoaged Skin.,"['Sadick N', 'Pannu S', 'Abidi Z', 'Arruda S']","['Humans', '*Keratinocytes', 'Melanocytes', 'Retinoids/adverse effects', '*Skin', 'Tretinoin/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37683070/
2403,ADAPALENE,37843943,Over-the-Counter Medications in Pregnancy.,"['Powers EA', 'Tewell R', 'Bayard M']","['Pregnancy', 'Female', 'Humans', 'Histamine Antagonists', 'Vomiting', 'Nausea', '*Rhinitis, Allergic', 'Administration, Intranasal', '*Pregnancy Complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37843943/
2404,ADAPALENE,18046911,Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety.,"['Mukherjee S', 'Date A', 'Patravale V', 'Korting HC', 'Roeder A', 'Weindl G']","['Adapalene', 'Dermatologic Agents/pharmacology/therapeutic use', 'Dermis/drug effects', 'Epidermis/drug effects', 'Humans', 'Naphthalenes/pharmacology/therapeutic use', 'Nicotinic Acids/pharmacology/therapeutic use', 'Retinaldehyde/pharmacology/therapeutic use', 'Retinoids/adverse effects/*pharmacology/*therapeutic use', 'Skin Aging/*drug effects', 'Treatment Outcome', 'Tretinoin/pharmacology/therapeutic use', 'Vitamin A Deficiency/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18046911/
2405,ADAPALENE,32175593,Topical benzoyl peroxide for acne.,"['Yang Z', 'Zhang Y', 'Lazic Mosler E', 'Hu J', 'Li H', 'Zhang Y', 'Liu J', 'Zhang Q']","['Acne Vulgaris/complications/*drug therapy', 'Adolescent', 'Adult', 'Benzoyl Peroxide/*therapeutic use', 'Cicatrix/etiology/prevention & control', 'Dermatologic Agents/*therapeutic use', 'Female', 'Humans', 'Male', 'Randomized Controlled Trials as Topic', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32175593/
2406,ADAPALENE,38118404,Single-cell transcriptomics identifies adipose tissue CD271(+) progenitors for enhanced angiogenesis in limb ischemia.,"['Inoue O', 'Goten C', 'Hashimuko D', 'Yamaguchi K', 'Takeda Y', 'Nomura A', 'Ootsuji H', 'Takashima S', 'Iino K', 'Takemura H', 'Halurkar M', 'Lim HW', 'Hwa V', 'Sanchez-Gurmaches J', 'Usui S', 'Takamura M']","['Humans', 'Adapalene', '*Angiogenesis', '*Gene Expression Profiling', 'Adipose Tissue', 'Ischemia/genetics']",https://pubmed.ncbi.nlm.nih.gov/38118404/
2407,ADAPALENE,14738100,Axillary granular parakeratosis.,"['English JC 3rd', 'Derdeyn AS', 'Wilson WM', 'Patterson JW']","['Adapalene', 'Adult', 'Axilla', 'Dermatologic Agents/*therapeutic use', 'Female', 'Humans', 'Naphthalenes/*therapeutic use', 'Parakeratosis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/14738100/
2408,ADAPALENE,34841914,Therapeutic Options for the Treatment of Darier's Disease: A Comprehensive Review of the Literature.,"['Hanna N', 'Lam M', 'Fleming P', 'Lynde CW']","['Acitretin/therapeutic use', 'Adapalene', '*Darier Disease/drug therapy', 'Humans', 'Isotretinoin/therapeutic use', 'Sunscreening Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34841914/
2409,ADAPALENE,17824582,Utilizing combination therapy for ethnic skin.,['Taylor SC'],"['Acne Vulgaris/complications/*drug therapy/*ethnology', 'Adapalene', 'Black or African American', 'Anti-Bacterial Agents/pharmacology/therapeutic use', 'Asian People', 'Benzoyl Peroxide/pharmacology/therapeutic use', 'Clindamycin/pharmacology/therapeutic use', 'Dermatologic Agents/pharmacology/therapeutic use', 'Dimethylpolysiloxanes/pharmacology', 'Drug Combinations', 'Drug Therapy, Combination', 'Glycerol/pharmacology', 'Hispanic or Latino', 'Humans', 'Hyperpigmentation/*drug therapy/ethnology/etiology/*prevention & control', 'Keratolytic Agents/pharmacology/therapeutic use', 'Naphthalenes/pharmacology/therapeutic use', 'Randomized Controlled Trials as Topic', 'Skin Pigmentation/*drug effects', 'Tretinoin/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17824582/
2410,ADAPALENE,37276158,Ceramide-Containing Adjunctive Skin Care for Skin Barrier Restoration During Acne Vulgaris Treatment.,"['Draelos ZD', 'Baalbaki N', 'Colon G', 'Dreno B']","['Humans', '*Dermatologic Agents', 'Drug Combinations', 'Benzoyl Peroxide', '*Acne Vulgaris/drug therapy/pathology', 'Adapalene', 'Erythema/chemically induced/drug therapy', 'Skin Care', 'Double-Blind Method', 'Inflammation/drug therapy', 'Treatment Outcome', 'Gels/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37276158/
2411,ADAPALENE,32729430,Current Insights for the Management of Acne in the Modern Era.,"['Singh N', 'Singh A', 'Pandey K', 'Nimisha']","['Acne Vulgaris/*drug therapy/epidemiology/*etiology', 'Administration, Topical', 'Anti-Infective Agents/pharmacology/therapeutic use', 'Cosmetics/administration & dosage/pharmacology', 'Dermatologic Agents/administration & dosage/*pharmacology/therapeutic use', 'Drug Delivery Systems/*methods', 'Humans', 'Patents as Topic', 'Plant Extracts/administration & dosage/pharmacology', 'Plants, Medicinal', 'Tetracyclines/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/32729430/
2412,Mycolog,28438376,Current Trends in the Use of Two Combination Antifungal/Corticosteroid Creams.,"['Wheat CM', 'Bickley RJ', 'Hsueh YH', 'Cohen BA']","['Adolescent', 'Anti-Inflammatory Agents/*therapeutic use', 'Antifungal Agents/*therapeutic use', 'Betamethasone/*therapeutic use', 'Child', 'Child, Preschool', 'Clotrimazole/*therapeutic use', 'Dermatomycoses/*drug therapy', 'Drug Combinations', 'Glucocorticoids/*therapeutic use', 'Gramicidin/*therapeutic use', 'Humans', 'Infant', 'Infant, Newborn', 'Neomycin/*therapeutic use', 'Nystatin/*therapeutic use', ""Practice Patterns, Physicians'"", 'Triamcinolone Acetonide/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28438376/
2413,Mycolog,2137392,Allergic contact dermatitis to ethylenediamine. A continuing problem.,['Hogan DJ'],"['Cross Reactions/drug effects', 'Dermatitis, Contact/*etiology', 'Dermatitis, Occupational/chemically induced', 'Emollients/adverse effects', 'Ethylenediamines/*adverse effects', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/2137392/
2414,Mycolog,93117,Allergic contact dermatitis to the perfume in Mycolog cream.,['Larsen WG'],"['Dermatitis, Atopic/*chemically induced', 'Dermatitis, Contact/*etiology', 'Dermatologic Agents/*adverse effects', 'Drug Combinations', 'Ethylenediamines/*adverse effects', 'Gramicidin/*adverse effects', 'Humans', 'Neomycin/*adverse effects', 'Nystatin/*adverse effects', 'Patch Tests', 'Perfume/*adverse effects', 'Triamcinolone Acetonide/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/93117/
2415,Mycolog,131515,Generalized exfoliative dermatitis from ethylenediamine.,"['Petrozzi JW', 'Shore RN']","['Aminophylline/adverse effects/therapeutic use', 'Dermatitis, Contact/*etiology', 'Dermatitis, Exfoliative/*chemically induced', '*Drug Hypersensitivity', 'Drug Interactions', 'Ethylenediamines/*adverse effects', 'Humans', 'Male', 'Middle Aged', 'Respiratory Insufficiency/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/131515/
2416,Mycolog,6186704,Sensitivity to alpha-amylcinnamic aldehyde and alpha-amylcinnamic alcohol.,"['Guin JD', 'Haffley P']","['Alcohols/*adverse effects/analysis', 'Aldehydes/*adverse effects/analysis', 'Dermatitis, Contact/diagnosis/*etiology', 'Drug Combinations/adverse effects', 'Female', 'Gramicidin/adverse effects', 'Humans', 'Male', 'Neomycin/adverse effects', 'Nystatin/adverse effects', 'Patch Tests', 'Perfume/*adverse effects/analysis', 'Triamcinolone Acetonide/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/6186704/
2417,Mycolog,2452718,"The significance of ethylenediamine hydrochloride dermatitis caused by a ""generic"" nystatin-triamcinolone II cream.",['Fisher AA'],"['Adult', 'Candidiasis/drug therapy', 'Dermatitis, Contact/*etiology', 'Drug Combinations/administration & dosage/adverse effects', 'Ethylenediamines/*adverse effects', 'Excipients/*adverse effects', 'Gramicidin/administration & dosage/*adverse effects', 'Humans', 'Male', 'Neomycin/administration & dosage/*adverse effects', 'Nystatin/administration & dosage/*adverse effects', 'Patch Tests', 'Therapeutic Equivalency', 'Triamcinolone Acetonide/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2452718/
2418,Mycolog,66117,Ethylenediamine sensitivity from exposure to epoxy resin hardeners and Mycolog cream.,['Van Hecke E'],"['Adult', 'Aged', 'Dermatitis, Contact/*etiology', 'Dermatitis, Occupational/*chemically induced', 'Drug Combinations', 'Drug Eruptions/*etiology', 'Epoxy Resins/*adverse effects', 'Ethylenediamines/*adverse effects', 'Gramicidin/adverse effects', 'Humans', 'Male', 'Neomycin/adverse effects', 'Nystatin/adverse effects', 'Ointments', 'Triamcinolone Acetonide/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/66117/
2419,Mycolog,157103,"Allergic contact hypersensitivity to nickel, neomycin, ethylenediamine, and benzocaine. Relationships between age, sex, history of exposure, and reactivity to standard patch tests and use tests in a general population.","['Prystowsky SD', 'Allen AM', 'Smith RW', 'Nonomura JH', 'Odom RB', 'Akers WA']","['Adult', 'Age Factors', 'Benzocaine/*adverse effects', 'Dermatitis, Contact/*diagnosis/epidemiology/etiology', 'Drug Eruptions/*diagnosis/epidemiology', 'Ethylenediamines/*adverse effects', 'Female', 'Humans', 'Male', 'Neomycin/*adverse effects', 'Nickel/*adverse effects', '*Patch Tests', 'Sex Factors', '*Skin Tests']",https://pubmed.ncbi.nlm.nih.gov/157103/
2420,Mycolog,717411,Successful treatment of acrodermatitis enteropathica with zinc sulfate.,['Steiner GA'],"['Acrodermatitis/*drug therapy', 'Diagnosis, Differential', 'Female', 'Gastrointestinal Diseases/*drug therapy', 'Humans', 'Infant', 'Syndrome', 'Zinc/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/717411/
2421,diazepam,28101764,Diazepam in the Treatment of Moderate to Severe Alcohol Withdrawal.,['Weintraub SJ'],"['Alcohol Withdrawal Delirium/*drug therapy', 'Alcohol Withdrawal Seizures/*drug therapy', 'Benzodiazepines/administration & dosage/adverse effects/pharmacokinetics', 'Diazepam/*administration & dosage/adverse effects/pharmacokinetics', 'Half-Life', 'Humans', 'Hypnotics and Sedatives/administration & dosage/adverse effects/pharmacokinetics', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/28101764/
2422,diazepam,24552479,Classics in chemical neuroscience: diazepam (valium).,"['Calcaterra NE', 'Barrow JC']","['Anxiety Disorders/*drug therapy', 'Diazepam/*administration & dosage/*adverse effects', 'Dose-Response Relationship, Drug', 'Drug Design', 'Drug Overdose/*etiology/prevention & control', 'Humans', 'Respiration Disorders/*chemically induced/prevention & control', 'Seizures/*chemically induced/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/24552479/
2423,diazepam,1505149,"Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time.","['Friedman H', 'Greenblatt DJ', 'Peters GR', 'Metzler CM', 'Charlton MD', 'Harmatz JS', 'Antal EJ', 'Sanborn EC', 'Francom SF']","['Administration, Oral', 'Adult', 'Conscious Sedation', 'Diazepam/blood/*pharmacokinetics/pharmacology', 'Dose-Response Relationship, Drug', 'Electroencephalography/drug effects', 'Female', 'Humans', 'Male', 'Motor Activity/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/1505149/
2424,diazepam,11963349,Diazepam use during pregnancy: a review of the literature.,"['Iqbal MM', 'Sobhan T', 'Aftab SR', 'Mahmud SZ']","['Animals', 'Anti-Anxiety Agents/administration & dosage/*adverse effects', 'Anxiety/*drug therapy', 'Diazepam/administration & dosage/*adverse effects', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Infant, Newborn, Diseases/*chemically induced', 'Lactation/*drug effects', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Rats', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/11963349/
2425,diazepam,2292778,Diazepam (Valium): its dependency liability.,['Murray JB'],"['Arousal/drug effects', '*Diazepam/adverse effects/pharmacokinetics', 'Drug Tolerance', 'Humans', 'Substance Withdrawal Syndrome/psychology', 'Substance-Related Disorders/*psychology']",https://pubmed.ncbi.nlm.nih.gov/2292778/
2426,diazepam,7990791,Eclampsia.,"['Kaplan PW', 'Repke JT']","['Diagnosis, Differential', 'Diazepam/administration & dosage/adverse effects/pharmacokinetics', 'Eclampsia/diagnosis/*etiology/therapy', 'Female', 'Humans', 'Infant, Newborn', 'Magnesium Sulfate/administration & dosage/adverse effects/pharmacokinetics', 'Neurologic Examination/drug effects', 'Phenytoin/administration & dosage/adverse effects/pharmacokinetics', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/7990791/
2427,diazepam,6120393,Diazepam and the risk of breast cancer.,"['Kaufman DW', 'Shapiro S', 'Slone D', 'Rosenberg L', 'Helmrich SP', 'Miettinen OS', 'Stolley PD', 'Levy M', 'Schottenfeld D']","['Adult', 'Animals', 'Breast Neoplasms/*chemically induced', 'Clinical Trials as Topic', 'Diazepam/administration & dosage/*adverse effects', 'Female', 'Humans', 'Menopause', 'Middle Aged', 'Rats', 'Risk', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6120393/
2428,diazepam,27731571,Local Anesthetics Systemic Toxicity.,"['Jayanthi R', 'Nasser K', 'Monica K']","['Administration, Intravenous', 'Adult', 'Anesthetics, Local/administration & dosage/*adverse effects', 'Diazepam/administration & dosage/therapeutic use', 'Female', 'Humans', 'Lidocaine/administration & dosage/*adverse effects', 'Male', 'Middle Aged', 'Seizures/*chemically induced/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27731571/
2429,diazepam,19519511,The plastic phenomenon underlying the associative processes in the addictive properties of diazepam and other psychoactive drugs.,"['Ramirez OA', 'Perez MF']","['Animals', 'Behavior, Addictive/*chemically induced', 'Brain/drug effects/physiopathology', 'Diazepam/administration & dosage/*adverse effects/chemistry', 'Drug Tolerance', 'Humans', 'Psychotropic Drugs/administration & dosage/*adverse effects/chemistry', 'Substance-Related Disorders/etiology']",https://pubmed.ncbi.nlm.nih.gov/19519511/
2430,diazepam,2677941,"Lytic/""DPT"" cocktail: time for rational and safe alternatives.","['Snodgrass WR', 'Dodge WF']","['Child', 'Child, Preschool', 'Chlorpromazine/administration & dosage/adverse effects', 'Diazepam/administration & dosage/pharmacology', 'Drug Combinations/*adverse effects', 'Humans', 'Infant', 'Meperidine/administration & dosage/adverse effects', 'Midazolam/administration & dosage/pharmacology', 'Morphine/administration & dosage/pharmacology', 'Preanesthetic Medication/*adverse effects', 'Promethazine/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2677941/
2431,diazepam,2185438,The pharmacokinetics of agents used to treat status epilepticus.,['Browne TR'],"['Anticonvulsants/*pharmacokinetics/therapeutic use', 'Diazepam/administration & dosage/blood/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Humans', 'Injections, Intramuscular', 'Lipid Metabolism', 'Phenobarbital/administration & dosage/pharmacokinetics', 'Phenytoin/administration & dosage/blood/pharmacokinetics', 'Solubility', 'Status Epilepticus/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2185438/
2432,diazepam,25538342,A case of etizolam dependence.,"['Gupta S', 'Garg B']","['Adult', 'Anti-Anxiety Agents/*adverse effects/therapeutic use', 'Anxiety Disorders/drug therapy', 'Diazepam/adverse effects/*analogs & derivatives/therapeutic use', 'Humans', 'Male', 'Substance-Related Disorders/*etiology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25538342/
2433,diazepam,1547766,Intrarectal diazepam in epileptic adults.,"['Remy C', 'Jourdil N', 'Villemain D', 'Favel P', 'Genton P']","['Administration, Rectal', 'Adult', 'Diazepam/*administration & dosage/pharmacokinetics/therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Electroencephalography', 'Epilepsies, Partial/drug therapy/physiopathology', 'Epilepsy/*drug therapy/physiopathology', 'Female', 'Humans', 'Male', 'Status Epilepticus/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/1547766/
2434,diazepam,9448787,Use of inhalational and intravenous sedation in dentistry.,['Rodrigo MR'],"['Accidents', '*Anesthesia, Dental', '*Anesthesia, Inhalation', '*Anesthesia, Intravenous', 'Anesthesia, Local', 'Anesthetics, Inhalation/administration & dosage', 'Anesthetics, Intravenous/administration & dosage', 'Anti-Anxiety Agents/administration & dosage/adverse effects/antagonists & inhibitors', 'Antidotes/therapeutic use', 'Cause of Death', 'Computers', '*Conscious Sedation', 'Dental Care', 'Diazepam/administration & dosage/adverse effects/antagonists & inhibitors', 'Drug Overdose', 'Emergencies', 'Flumazenil/therapeutic use', 'GABA Modulators/therapeutic use', 'Humans', 'Hypnotics and Sedatives/administration & dosage', 'Iatrogenic Disease', 'Infusion Pumps', 'Isoflurane/administration & dosage', 'Midazolam/administration & dosage', 'Nitrous Oxide/administration & dosage', 'Oxygen/administration & dosage', 'Practice Guidelines as Topic', 'Propofol/administration & dosage', 'United Kingdom']",https://pubmed.ncbi.nlm.nih.gov/9448787/
2435,diazepam,25030,Pain and clinical thrombophlebitis following intravenous diazepam and lorazepam.,"['Graham CW', 'Pagano RR', 'Conner JT']","['Adolescent', 'Adult', 'Aged', 'Anti-Anxiety Agents/*adverse effects', 'Clinical Trials as Topic', 'Diazepam/administration & dosage/*adverse effects', 'Double-Blind Method', 'Female', 'Humans', 'Injections, Intravenous', 'Lorazepam/administration & dosage/*adverse effects', 'Male', 'Middle Aged', 'Pain/*chemically induced', 'Thrombophlebitis/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/25030/
2436,diazepam,9097367,New drug therapy for acute seizure management.,"['Morton LD', 'Rizkallah E', 'Pellock JM']","['Acute Disease', 'Anticonvulsants/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Child', 'Diazepam/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Epilepsy/*drug therapy', 'Humans', 'Phenytoin/adverse effects/analogs & derivatives/pharmacokinetics/therapeutic use', 'Prodrugs/adverse effects/pharmacokinetics/therapeutic use', 'Seizures/*drug therapy', 'Valproic Acid/administration & dosage/adverse effects/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9097367/
2437,diazepam,1454506,Influence of diazepam on prospective time estimation.,"['Unrug-Neervoort A', 'Kaiser J', 'Coenen A']","['Adult', 'Attention/drug effects', 'Diazepam/adverse effects/*pharmacology', 'Double-Blind Method', 'Humans', 'Placebos', 'Psychomotor Performance/*drug effects', 'Random Allocation', 'Time Perception/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/1454506/
2438,diazepam,329424,Selection among benzodiazepines for alcohol withdrawal.,"['Keeler MH', 'Miller WC']","['Administration, Oral', 'Benzodiazepines/administration & dosage/pharmacology/*therapeutic use', 'Central Nervous System/drug effects', 'Chlordiazepoxide/administration & dosage/pharmacology/therapeutic use', 'Clorazepate Dipotassium/administration & dosage/pharmacology/therapeutic use', 'Depression, Chemical', 'Diazepam/administration & dosage/pharmacology/therapeutic use', 'Drug Synergism', '*Ethanol', 'Half-Life', 'Humans', 'Oxazepam/administration & dosage/pharmacology/therapeutic use', 'Seizures/drug therapy', 'Substance Withdrawal Syndrome/*drug therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/329424/
2439,diazepam,1068178,Human cardiorespiratory and analgesic effects of intravenous diazepam and local anesthesia.,"['Allen GD', 'Everett GB', 'Butler LA']","['*Analgesics', '*Anesthesia, Dental', '*Anesthesia, Local', 'Cardiac Output/drug effects', 'Diazepam/administration & dosage/*pharmacology', 'Female', 'Heart/*drug effects', 'Heart Rate/drug effects', 'Humans', 'Injections, Intravenous', 'Lidocaine', 'Male', 'Mandibular Nerve', 'Nerve Block', 'Respiration/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/1068178/
2440,diazepam,34954745,Oxazepam Detected in Urine 79 Days After Withdrawal of Diazepam: A Case Report.,"['Serkland TT', 'Dale GH', 'Kaldestad IC', 'Berg JA', 'Methlie CB']","['Adult', 'Benzodiazepines/adverse effects', 'Diazepam/adverse effects/pharmacokinetics', 'Female', 'Humans', 'Oxazepam/adverse effects', '*Substance Withdrawal Syndrome/diagnosis/etiology', '*Substance-Related Disorders/complications']",https://pubmed.ncbi.nlm.nih.gov/34954745/
2441,isradipine,28641520,Try to Remember: Interplay between Memory and Substance Use Disorder.,"['Mohamed RMP', 'Kumar J', 'Yap E', 'Mohamed IN', 'Sidi H', 'Adam RL', 'Das S']","['Cues', 'Heterocyclic Compounds, 4 or More Rings/pharmacology/therapeutic use', 'Humans', 'Isradipine/pharmacology/therapeutic use', 'Memory, Long-Term/*drug effects', 'Molecular Targeted Therapy', 'Neuronal Plasticity/drug effects', 'Substance-Related Disorders/drug therapy/*psychology']",https://pubmed.ncbi.nlm.nih.gov/28641520/
2442,isradipine,16596036,Antihypertensive pharmacobezoar.,"['Prisant LM', 'Spaulding VC']","['Antihypertensive Agents/*administration & dosage/*adverse effects', 'Bezoars/*etiology', 'Calcium Channel Blockers/administration & dosage', 'Drug Delivery Systems/*adverse effects', 'Gastrointestinal Diseases/*etiology', 'Humans', 'Isradipine/administration & dosage/adverse effects', 'Nifedipine/administration & dosage', 'Postoperative Complications/etiology', 'Tablets', 'Verapamil/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16596036/
2443,isradipine,36595455,Applications of isradipine in human addiction studies: A systematic literature review.,"['Natal S', 'Young CC', 'Kaur K', 'Gebhardt ES', 'Perrone A', 'Morikawa H', 'Tirado C', 'Smits JAJ']","['Adult', 'Humans', 'Isradipine/pharmacology/therapeutic use', 'Calcium Channel Blockers/pharmacology/therapeutic use', '*Cocaine', '*Methamphetamine', '*Substance-Related Disorders/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36595455/
2444,isradipine,1830320,Isradipine.,['Schachter M'],"['Angina Pectoris/drug therapy', 'Animals', 'Antihypertensive Agents/pharmacokinetics/*therapeutic use', 'Arteriosclerosis/prevention & control', 'Calcium Channel Blockers/pharmacokinetics/*therapeutic use', 'Humans', 'Hypertension/drug therapy', 'Isradipine', 'Pyridines/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1830320/
2445,isradipine,8097608,Role of isradipine and other antihypertensive agents in the treatment of peri- and postoperative hypertension.,['Marty J'],"['Adrenergic alpha-Antagonists/therapeutic use', 'Adrenergic beta-Antagonists/therapeutic use', 'Calcium Channel Blockers/therapeutic use', 'Humans', 'Hypertension/*prevention & control', 'Intraoperative Complications/*prevention & control', 'Isradipine/*therapeutic use', 'Postoperative Complications/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/8097608/
2446,isradipine,8743037,Antiatherosclerotic effects of antihypertensive drugs: recent evidence and ongoing trials.,['Zanchetti A'],"['Aged', 'Angiotensin-Converting Enzyme Inhibitors/pharmacology', 'Antihypertensive Agents/*pharmacology', 'Arteriosclerosis/*prevention & control', 'Calcium Channel Blockers/pharmacology', 'Carotid Arteries/diagnostic imaging/drug effects', 'Carotid Artery Diseases/diagnostic imaging/etiology/prevention & control', 'Clinical Trials as Topic', 'Dihydropyridines/pharmacology', 'Humans', 'Hypertension/complications/diagnostic imaging/drug therapy', 'Isradipine/pharmacology', 'Ultrasonography', 'Verapamil/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8743037/
2447,isradipine,30758052,Calcium antagonists for acute ischemic stroke.,"['Zhang J', 'Liu J', 'Li D', 'Zhang C', 'Liu M']","['Acute Disease', 'Adult', 'Aged', 'Aged, 80 and over', 'Brain Ischemia/*drug therapy/mortality', 'Calcium/metabolism', 'Calcium Channel Blockers/administration & dosage/adverse effects/*therapeutic use', 'Female', 'Flunarizine/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Isradipine/administration & dosage/adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Nimodipine/administration & dosage/adverse effects/therapeutic use', 'Randomized Controlled Trials as Topic', 'Stroke/*drug therapy', 'Vasodilator Agents/administration & dosage/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30758052/
2448,isradipine,9812220,Rational use of calcium-channel antagonists in Raynaud's phenomenon.,"['Sturgill MG', 'Seibold JR']","['Amlodipine/pharmacokinetics/pharmacology/therapeutic use', 'Calcium Channel Blockers/pharmacokinetics/pharmacology/*therapeutic use', 'Diltiazem/pharmacokinetics/pharmacology/therapeutic use', 'Felodipine/pharmacokinetics/pharmacology/therapeutic use', 'Humans', 'Isradipine/pharmacokinetics/pharmacology/therapeutic use', 'Nicardipine/pharmacokinetics/pharmacology/therapeutic use', 'Nifedipine/pharmacokinetics/pharmacology/therapeutic use', 'Raynaud Disease/*drug therapy/epidemiology/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/9812220/
2449,isradipine,1376831,Antiatherosclerotic actions of isradipine.,"['Sinzinger H', 'Fitscha P']","['Arteriosclerosis/*drug therapy', 'Calcium Channel Blockers/*therapeutic use', 'Dihydropyridines/*therapeutic use', 'Humans', 'Isradipine', 'Lipid Metabolism']",https://pubmed.ncbi.nlm.nih.gov/1376831/
2450,isradipine,9790159,Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness.,"['Pazzaglia PJ', 'Post RM', 'Ketter TA', 'Callahan AM', 'Marangell LB', 'Frye MA', 'George MS', 'Kimbrell TA', 'Leverich GS', 'Cora-Locatelli G', 'Luckenbaugh D']","['Adult', 'Antimanic Agents/*administration & dosage/adverse effects', 'Bipolar Disorder/diagnosis/*drug therapy/psychology', 'Calcium Channel Blockers/*administration & dosage/adverse effects', 'Carbamazepine/*administration & dosage/adverse effects', 'Depressive Disorder/diagnosis/*drug therapy/psychology', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Isradipine/administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Nimodipine/*administration & dosage/adverse effects', 'Psychiatric Status Rating Scales', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9790159/
2451,isradipine,9600578,Isradipine prevents global and regional cocaine-induced changes in brain blood flow: a preliminary study.,"['Johnson B', 'Barron B', 'Fang B', 'Lamki L', 'Wagner L', 'Wells L', 'Kenny P', 'Overton D', 'Dhother S', 'Abramson D', 'Chen R', 'Kramer L']","['Adult', 'Brain/blood supply/diagnostic imaging/*drug effects', 'Calcium Channel Blockers/*pharmacology', 'Cerebral Arteries/diagnostic imaging/*drug effects', 'Cocaine/antagonists & inhibitors/*pharmacology', 'Female', 'Humans', 'Isradipine/*pharmacology', 'Male', 'Narcotics/*pharmacology', 'Regional Blood Flow', 'Substance-Related Disorders/diagnostic imaging', 'Tomography, Emission-Computed, Single-Photon']",https://pubmed.ncbi.nlm.nih.gov/9600578/
2452,isradipine,8827760,Hypertensive crisis in children.,['Groshong T'],"['Antihypertensive Agents/*therapeutic use', 'Emergencies', 'Enalapril/therapeutic use', 'Humans', 'Hypertension/diagnosis/*drug therapy/etiology/physiopathology', 'Isradipine/therapeutic use', 'Labetalol/therapeutic use', 'Nicardipine/therapeutic use', 'Nitroprusside/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8827760/
2453,isradipine,33460320,Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease.,"['Venuto CS', 'Yang L', 'Javidnia M', 'Oakes D', 'James Surmeier D', 'Simuni T']","['Aged', 'Calcium Channel Blockers/administration & dosage/blood/*pharmacokinetics', '*Disease Progression', 'Double-Blind Method', 'Female', 'Humans', 'Isradipine/administration & dosage/blood/*pharmacokinetics', 'Male', 'Middle Aged', '*Outcome Assessment, Health Care', 'Parkinson Disease/*drug therapy/physiopathology', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/33460320/
2454,isradipine,8480505,Isradipine and the coronary circulation.,"['Feneck RO', 'Underwood SM', 'Walesby RK']","['Animals', 'Coronary Circulation/*drug effects/physiology', 'Hemodynamics/*drug effects/physiology', 'Humans', 'Isradipine/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8480505/
2455,isradipine,8647348,Effects of calcium on the migration and recruitment of macrophages and macrophage-derived foam cells.,"['Shi H', 'Severs NJ', 'Robenek H']","['Animals', 'Arteriosclerosis/etiology', 'Calcinosis/etiology', 'Calcium/*pharmacology', 'Cell Movement/drug effects', 'Chemotaxis', 'Foam Cells/*drug effects/physiology', 'Humans', 'Isradipine/pharmacology', 'Lipoproteins/pharmacology', 'Macrophages/*drug effects/physiology', 'Male', 'Mice']",https://pubmed.ncbi.nlm.nih.gov/8647348/
2456,isradipine,37640098,Quinpirole inhibits levodopa-induced dyskinesias at structural and behavioral levels: Efficacy negated by co-administration of isradipine.,"['Collier TJ', 'Begg L', 'Stancati JA', 'Mercado NM', 'Sellnow RC', 'Sandoval IM', 'Sortwell CE', 'Steece-Collier K']","['Animals', '*Levodopa/toxicity/adverse effects', '*Isradipine/pharmacology/therapeutic use', '*Dyskinesia, Drug-Induced/prevention & control/drug therapy', 'Rats', '*Quinpirole/pharmacology', 'Male', '*Calcium Channel Blockers/pharmacology', '*Rats, Sprague-Dawley', 'Antiparkinson Agents', 'Calcium Channels, L-Type/metabolism/drug effects', 'Dopamine Agonists/pharmacology', 'Dendritic Spines/drug effects/pathology', 'Corpus Striatum/drug effects/metabolism/pathology', 'Parkinsonian Disorders/drug therapy/chemically induced/metabolism/pathology/prevention & control', 'Calcium Channels']",https://pubmed.ncbi.nlm.nih.gov/37640098/
2457,isradipine,8397999,Antihypertensive medication-taking. Investigation of a simple regimen.,"['Guerrero D', 'Rudd P', 'Bryant-Kosling C', 'Middleton B', 'Middleton BF [corrected to Middleton B]']","['Adult', 'Clinical Protocols', 'Double-Blind Method', 'Drug Evaluation', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Isradipine/administration & dosage/*therapeutic use', 'Male', '*Patient Compliance', 'Research Design']",https://pubmed.ncbi.nlm.nih.gov/8397999/
2458,isradipine,34353274,Formulation and Evaluation of Isradipine Nanosuspension and Exploring its Role as a Potential Anticancer Drug by Computational Approach.,"['Mohapatra PK', 'Srivastava R', 'Varshney KK', 'Babu SH']","['*Antineoplastic Agents/pharmacology', 'Aspartic Acid', 'Biological Availability', 'Humans', 'Isradipine/chemistry', 'Metalloproteases', '*Nanoparticles/chemistry', 'Particle Size', 'Peptide Hydrolases', 'Polymers', 'Solubility', 'Suspensions']",https://pubmed.ncbi.nlm.nih.gov/34353274/
2459,isradipine,7789292,Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension.,"['Brogden RN', 'Sorkin EM']","['Cardiac Surgical Procedures', 'Clinical Trials as Topic', 'Drug Interactions', 'Drug Therapy, Combination', 'Female', 'Hemodynamics/*drug effects', 'Humans', 'Hypertension/*drug therapy/etiology', 'Isradipine/administration & dosage/adverse effects/*pharmacokinetics/*therapeutic use', 'Postoperative Complications/drug therapy', 'Pregnancy', 'Renal Circulation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/7789292/
2460,candesartan,10914449,Angiotensin receptor antagonists.,"['Wong W', 'Howes L']","['Angiotensin II/antagonists & inhibitors', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use', 'Antihypertensive Agents/adverse effects/pharmacology/*therapeutic use', 'Benzimidazoles/adverse effects/pharmacology/therapeutic use', 'Benzoates/adverse effects/pharmacology/therapeutic use', 'Biphenyl Compounds/adverse effects/pharmacology/therapeutic use', 'Humans', 'Hypertension/*drug therapy', 'Irbesartan', 'Losartan/adverse effects/pharmacology/therapeutic use', 'Telmisartan', 'Tetrazoles/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10914449/
2461,candesartan,38861046,Comparative efficacy and safety of six angiotensin II receptor blockers in hypertensive patients: a network meta-analysis.,"['Zhang Z', 'Yang H', 'Guo H']","['Humans', '*Angiotensin Receptor Antagonists/therapeutic use/adverse effects/administration & dosage', '*Antihypertensive Agents/therapeutic use/adverse effects', 'Blood Pressure/drug effects', '*Hypertension/drug therapy', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38861046/
2462,candesartan,15592574,Candesartan.,"['Gleiter CH', 'Jagle C', 'Gresser U', 'Morike K']","['Angiotensin Receptor Antagonists', 'Animals', 'Benzimidazoles/chemistry/*pharmacology/*therapeutic use', 'Biphenyl Compounds', 'Germany', 'Humans', 'Randomized Controlled Trials as Topic', 'Receptors, Angiotensin/therapeutic use', 'Tetrazoles/chemistry/*pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15592574/
2463,candesartan,28841231,Noncholestatic acute hepatocellular injury following candesartan administration.,"['Lammel-Lindemann JA', 'Flores-Villalba E', 'Martagon AJ', 'DeObeso-Gonzalez E', 'Puente-Gallegos F']","['Adult', 'Amlodipine/therapeutic use', 'Angiotensin II Type 1 Receptor Blockers/administration & dosage/*adverse effects', 'Antihypertensive Agents/*therapeutic use', 'Benzimidazoles/administration & dosage/*adverse effects', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Chemical and Drug Induced Liver Injury/blood/*diagnosis/etiology', 'Dose-Response Relationship, Drug', 'Humans', 'Hypertension/blood/*drug therapy', 'Liver Function Tests', 'Male', 'Tetrazoles/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/28841231/
2464,candesartan,16451099,Indapamide sustained release: a review of its use in the treatment of hypertension.,"['Robinson DM', 'Wellington K']","['Animals', 'Antihypertensive Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Clinical Trials as Topic', 'Delayed-Action Preparations', 'Diuretics/administration & dosage/adverse effects/pharmacokinetics', 'Humans', 'Hypertension/*drug therapy/metabolism', 'Indapamide/*administration & dosage/adverse effects/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/16451099/
2465,candesartan,13678870,Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.,"['Granger CB', 'McMurray JJ', 'Yusuf S', 'Held P', 'Michelson EL', 'Olofsson B', 'Ostergren J', 'Pfeffer MA', 'Swedberg K']","['Aged', 'Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/*adverse effects/therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Benzimidazoles/*therapeutic use', 'Biphenyl Compounds', 'Cardiac Output, Low/drug therapy/epidemiology', 'Comorbidity', 'Cough/chemically induced', 'Female', 'Follow-Up Studies', 'Heart Failure/*drug therapy/epidemiology', 'Humans', 'Hypotension/chemically induced', 'Kidney Diseases/chemically induced', 'Male', 'Tetrazoles/*therapeutic use', 'Treatment Outcome', 'Ventricular Dysfunction, Left/*drug therapy/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/13678870/
2466,candesartan,17020420,Candesartan for the management of heart failure: more than an alternative.,['McKelvie RS'],"['Angiotensin II Type 1 Receptor Blockers/metabolism/pharmacokinetics/*therapeutic use', 'Benzimidazoles/metabolism/pharmacokinetics/*therapeutic use', 'Biphenyl Compounds', 'Clinical Trials as Topic', 'Heart Failure/*drug therapy', 'Humans', 'Stroke Volume/drug effects', 'Tetrazoles/metabolism/pharmacokinetics/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17020420/
2467,candesartan,15969893,Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.,"['Bonner G', 'Fuchs W']","['*Angiotensin Receptor Antagonists', 'Antihypertensive Agents/pharmacokinetics/pharmacology/*therapeutic use', 'Benzimidazoles/pharmacokinetics/pharmacology/*therapeutic use', 'Biphenyl Compounds/pharmacokinetics/pharmacology/*therapeutic use', 'Blood Pressure/*drug effects', 'Female', 'Germany', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Tetrazoles/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15969893/
2468,candesartan,16230887,"Angiotensin receptor blockers in congestive heart failure: evidence, concerns, and controversies.","['Bhatia V', 'Bhatia R', 'Mathew B']","['Adrenergic beta-Antagonists/therapeutic use', 'Angiotensin II Type 1 Receptor Blockers/administration & dosage/*therapeutic use', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*therapeutic use', 'Benzimidazoles/therapeutic use', 'Biphenyl Compounds', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Drug Therapy, Combination', 'Heart Failure/*drug therapy', 'Humans', 'Losartan/therapeutic use', 'Mineralocorticoid Receptor Antagonists/therapeutic use', 'Tetrazoles/therapeutic use', 'Valine/analogs & derivatives/therapeutic use', 'Valsartan']",https://pubmed.ncbi.nlm.nih.gov/16230887/
2469,candesartan,27250611,[What are the effects of fixed-dose combination of candesartan and amlodipine].,"['Vitovec J', 'Spinar J']","['Amlodipine/*administration & dosage', 'Antihypertensive Agents/*administration & dosage', 'Benzimidazoles/*administration & dosage', 'Biphenyl Compounds', 'Drug Combinations', 'Humans', 'Hypertension/drug therapy', 'Tetrazoles/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27250611/
2470,candesartan,31732254,Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.,"['Ni S', 'Chen X', 'Yu Q', 'Xu Y', 'Hu Z', 'Zhang J', 'Zhang W', 'Li B', 'Yang X', 'Mao F', 'Huang J', 'Sun Y', 'Li J', 'Jia L']","['A549 Cells', 'Animals', 'Antineoplastic Agents/administration & dosage/chemistry/*pharmacology', 'Benzimidazoles/administration & dosage/chemistry/*pharmacology', 'Biphenyl Compounds/administration & dosage/chemistry/*pharmacology', 'Cell Proliferation/drug effects', 'Cell Survival/drug effects', 'Dose-Response Relationship, Drug', '*Drug Discovery', 'Drug Screening Assays, Antitumor', 'Female', 'Humans', 'Injections, Intraperitoneal', 'Injections, Subcutaneous', 'Mice', 'Mice, Nude', 'Molecular Structure', 'Neoplasms, Experimental/drug therapy/pathology', 'Structure-Activity Relationship', 'Tetrazoles/administration & dosage/chemistry/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/31732254/
2471,candesartan,30265168,"The Precision HYpertenSIon Care (PHYSIC) study: a double-blind, randomized, repeated cross-over study.","['Sundstrom J', 'Lind L', 'Nowrouzi S', 'Lytsy P', 'Marttala K', 'Ekman I', 'Ohagen P', 'Ostlund O']","['Adult', 'Aged', 'Amlodipine/administration & dosage', 'Antihypertensive Agents/administration & dosage', 'Benzimidazoles/administration & dosage', 'Biomarkers/metabolism', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Blood Pressure Determination', 'Cross-Over Studies', 'Double-Blind Method', 'Female', 'Humans', 'Hydrochlorothiazide/administration & dosage', 'Hypertension/epidemiology/*therapy', 'Lisinopril/administration & dosage', 'Male', 'Middle Aged', '*Precision Medicine', 'Randomized Controlled Trials as Topic', 'Research Design', 'Risk Factors', 'Tetrazoles/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/30265168/
2472,candesartan,38418298,Safety and efficacy of candesartan versus valsartan combined with amlodipine on peripheral and central blood pressure.,"['Hanna SM', 'Rabea HM', 'Abdelrahim MEA', 'Mahmoud HB']","['Humans', '*Amlodipine/adverse effects', 'Valsartan/pharmacology/therapeutic use', 'Blood Pressure', '*Hypertension/drug therapy', 'Prospective Studies', 'Valine/pharmacology/therapeutic use', 'Antihypertensive Agents/adverse effects', 'Tetrazoles/adverse effects', 'Drug Therapy, Combination', '*Benzimidazoles', '*Biphenyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/38418298/
2473,candesartan,10980901,Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure.,"['Ennezat PV', 'Berlowitz M', 'Sonnenblick EH', 'Le Jemtel TH']","['Angiotensin-Converting Enzyme Inhibitors/*administration & dosage', 'Animals', 'Antihypertensive Agents/therapeutic use', 'Benzimidazoles/therapeutic use', 'Biphenyl Compounds', 'Drug Therapy, Combination', 'Enalapril/administration & dosage/therapeutic use', 'Heart Failure/*drug therapy/physiopathology', 'Humans', 'Randomized Controlled Trials as Topic', 'Tetrazoles/therapeutic use', 'Ventricular Dysfunction, Left/drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/10980901/
2474,candesartan,29701105,A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure.,"['de Denus S', 'Dube MP', 'Fouodjio R', 'Huynh T', 'LeBlanc MH', 'Lepage S', 'Sheppard R', 'Giannetti N', 'Lavoie J', 'Mansour A', 'Provost S', 'Normand V', 'Mongrain I', 'Langlois M', ""O'Meara E"", 'Ducharme A', 'Racine N', 'Guertin MC', 'Turgeon J', 'Phillips MS', 'Rouleau JL', 'Tardif JC', 'White M']","['Aged', 'Angiotensin II Type 1 Receptor Blockers/pharmacokinetics/*therapeutic use', 'Benzimidazoles/pharmacokinetics/*therapeutic use', 'Biomarkers/blood', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Female', 'Heart Failure/blood/*drug therapy/genetics', 'Humans', 'Kidney Function Tests', 'Male', 'Natriuretic Peptide, Brain/blood', 'Peptide Fragments/blood', 'Pharmacogenetics', '*Polymorphism, Single Nucleotide', 'Prospective Studies', 'Receptor, Angiotensin, Type 1/*genetics', 'Renin-Angiotensin System/*drug effects/genetics', 'Tetrazoles/pharmacokinetics/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29701105/
2475,candesartan,17339065,Angiotensin receptor blockade in diabetic renal disease--focus on candesartan.,"['Garcia Donaire JA', 'Ruilope LM']","['Angiotensin II Type 1 Receptor Blockers/pharmacokinetics/*therapeutic use', 'Benzimidazoles/pharmacokinetics/*therapeutic use', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Diabetic Angiopathies/prevention & control', 'Diabetic Nephropathies/*drug therapy/epidemiology/*prevention & control', 'Glomerular Filtration Rate/drug effects', 'Humans', 'Hypertension/prevention & control', 'Kidney Failure, Chronic/prevention & control', 'Renal Circulation/drug effects/physiology', 'Tetrazoles/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17339065/
2476,candesartan,21421652,A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension.,"['Zhenfeng Zheng', 'Huilan Shi', 'Junya Jia', 'Dong Li', 'Shan Lin']","['Antihypertensive Agents/pharmacology/*therapeutic use', 'Benzimidazoles/adverse effects/pharmacology/*therapeutic use', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Losartan/adverse effects/pharmacology/*therapeutic use', 'Publication Bias', 'Regression Analysis', 'Tetrazoles/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21421652/
2477,candesartan,10073836,Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators.,"['Bell TP', 'DeQuattro V', 'Lasseter KC', 'Ruff D', 'Hardison JD', 'Cushing D', 'Kezer AE', 'Michelson EL']","['Antihypertensive Agents/*administration & dosage', 'Benzimidazoles/*administration & dosage', 'Biphenyl Compounds/*administration & dosage', 'Blood Pressure/drug effects', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Posture', 'Prodrugs/administration & dosage', '*Tetrazoles']",https://pubmed.ncbi.nlm.nih.gov/10073836/
2478,candesartan,19101048,"Angiotensin converting-enzyme inhibitors and candesartan have no effects on atrial fibrillation after cardiac surgery: comment on: Mehmet Ozaydin et al. ""Effect of renin-angiotensin aldosterone system blockers on postoperative atrial fibrillation"".","['Mariscalco G', 'Dominici C', 'Banach M', 'Sala A']","['Angiotensin II Type 1 Receptor Blockers/administration & dosage', 'Angiotensin-Converting Enzyme Inhibitors/*administration & dosage', 'Atrial Fibrillation/*drug therapy/etiology/metabolism', 'Benzimidazoles/*administration & dosage', 'Biphenyl Compounds', 'Cardiac Surgical Procedures/*adverse effects', 'Humans', 'Mineralocorticoid Receptor Antagonists/administration & dosage', 'Postoperative Complications/*drug therapy/etiology/metabolism', 'Prospective Studies', 'Renin-Angiotensin System/*drug effects/physiology', 'Tetrazoles/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/19101048/
2479,candesartan,27651039,Angiotensin II receptor blocker combined with eplerenone or hydrochlorothiazide for hypertensive patients with diabetes mellitus.,"['Karashima S', 'Yoneda T', 'Kometani M', 'Ohe M', 'Mori S', 'Sawamura T', 'Furukawa K', 'Yamagishi M', 'Takeda Y']","['Adult', 'Aged', 'Angiotensin Receptor Antagonists/administration & dosage', 'Antihypertensive Agents/administration & dosage', '*Benzimidazoles/administration & dosage/adverse effects', 'Biphenyl Compounds', 'Blood Pressure/*drug effects', '*Diabetes Mellitus, Type 2/complications/diagnosis/drug therapy', 'Drug Monitoring/methods', 'Drug Therapy, Combination/methods', 'Eplerenone', 'Essential Hypertension', 'Female', 'Glycated Hemoglobin/analysis', 'Humans', '*Hydrochlorothiazide/administration & dosage/adverse effects', 'Hypertension/complications/diagnosis/drug therapy', 'Male', 'Middle Aged', 'Mineralocorticoid Receptor Antagonists/administration & dosage', 'Spironolactone/administration & dosage/adverse effects/*analogs & derivatives', '*Tetrazoles/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27651039/
2480,amitriptyline,26488799,Topical amitriptyline and ketamine for the treatment of neuropathic pain.,['Mercadante S'],"['Administration, Topical', 'Amitriptyline/administration & dosage/*therapeutic use', 'Analgesics/administration & dosage/therapeutic use', 'Humans', 'Ketamine/administration & dosage/*therapeutic use', 'Neuralgia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26488799/
2481,amitriptyline,12638679,Drug-induced toxic myocarditis.,"['Ansari A', 'Maron BJ', 'Berntson DG']","['Adrenergic Uptake Inhibitors/*adverse effects/therapeutic use', 'Aged', 'Amitriptyline/*adverse effects/therapeutic use', 'Antipsychotic Agents/*adverse effects/therapeutic use', 'Female', 'Heart Failure/*diagnosis/*etiology', 'Humans', 'Myocarditis/*chemically induced/complications/*diagnosis', 'Perphenazine/*adverse effects/therapeutic use', 'Schizophrenia, Paranoid/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/12638679/
2482,amitriptyline,19590258,Torticollis under cyclobenzaprine.,"['Reuss R', 'Reuter I', 'Jauss M', 'Fischer F', 'Muller SC', 'Stolz E']","['Amitriptyline/adverse effects/*analogs & derivatives/therapeutic use', 'Biperiden/therapeutic use', 'Humans', 'Male', 'Muscarinic Antagonists/therapeutic use', 'Muscle Relaxants, Central/*adverse effects/therapeutic use', 'Myoclonus/chemically induced/drug therapy', 'Torticollis/*chemically induced/drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/19590258/
2483,amitriptyline,7044154,Trazodone in depressed outpatients.,"['Rickels K', 'Case WG']","['Adult', 'Ambulatory Care', 'Amitriptyline/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy/psychology', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Piperazines/*therapeutic use', 'Trazodone/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7044154/
2484,amitriptyline,3893842,Discrepancies between pharmacokinetic studies of amitriptyline.,"['Schulz P', 'Dick P', 'Blaschke TF', 'Hollister L']","['Amitriptyline/administration & dosage/*metabolism/therapeutic use', 'Depressive Disorder/drug therapy', 'Half-Life', 'Humans', 'Kinetics', 'Models, Biological', 'Nortriptyline/blood']",https://pubmed.ncbi.nlm.nih.gov/3893842/
2485,amitriptyline,20883117,Pharmacokinetic profile of once-daily cyclobenzaprine extended-release.,"['Darwish M', 'Hellriegel ET']","['Aged', 'Amitriptyline/administration & dosage/*analogs & derivatives/pharmacokinetics/therapeutic use', 'Animals', 'Delayed-Action Preparations', 'Drug Administration Schedule', 'Food-Drug Interactions', 'Humans', 'Muscle Relaxants, Central/administration & dosage/*pharmacokinetics/therapeutic use', 'Randomized Controlled Trials as Topic', 'Spasm/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20883117/
2486,amitriptyline,30618472,Induction of Psychosis by Cyclobenzaprine.,"['Cohen JY', 'Guilbault A']","['Adult', 'Amitriptyline/adverse effects/*analogs & derivatives', 'Antidepressive Agents, Tricyclic/*adverse effects', 'Bipolar Disorder/*drug therapy', 'Borderline Personality Disorder/*drug therapy', 'Female', 'Humans', 'Muscle Relaxants, Central/*adverse effects', 'Psychoses, Substance-Induced/*etiology', 'Tranquilizing Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30618472/
2487,amitriptyline,7203728,Pharmacokinetics of amitriptyline in the elderly.,"['Henry JF', 'Altamura C', 'Gomeni R', 'Hervy MP', 'Forette F', 'Morselli PL']","['Aged', 'Amitriptyline/adverse effects/*metabolism/pharmacology', 'Electrocardiography', 'Hemodynamics/drug effects', 'Humans', 'Kinetics', 'Nortriptyline/blood']",https://pubmed.ncbi.nlm.nih.gov/7203728/
2488,amitriptyline,2147517,Cardiovascular effects of paroxetine.,"['Kuhs H', 'Rudolf GA']","['Adult', 'Amitriptyline/adverse effects/therapeutic use', 'Antidepressive Agents/*adverse effects/therapeutic use', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Electrocardiography', 'Female', 'Heart Rate/drug effects', 'Hemodynamics/*drug effects', 'Humans', 'Male', 'Middle Aged', 'Paroxetine', 'Piperidines/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2147517/
2489,amitriptyline,19882939,[Antidepressants in migraine prophylaxis].,['Nagata E'],"['Amitriptyline/*administration & dosage/adverse effects', 'Antidepressive Agents/*administration & dosage/adverse effects', 'Clinical Trials as Topic', 'Depression/complications/drug therapy', 'Drug Administration Schedule', 'Evidence-Based Medicine', 'Humans', 'Imipramine/administration & dosage/adverse effects', 'Migraine Disorders/complications/*prevention & control', 'Practice Guidelines as Topic', '*Premedication']",https://pubmed.ncbi.nlm.nih.gov/19882939/
2490,amitriptyline,6764165,Evaluation of amoxapine.,"['Kinney JL', 'Evans RL Jr']","['Amitriptyline/therapeutic use', '*Amoxapine/administration & dosage/adverse effects/metabolism/pharmacology/therapeutic use', 'Animals', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', '*Dibenzoxazepines', 'Double-Blind Method', 'Humans', 'Imipramine/therapeutic use', 'Kinetics']",https://pubmed.ncbi.nlm.nih.gov/6764165/
2491,amitriptyline,3133714,Trazodone for deafferentation pain. Comparison with amitriptyline.,"['Ventafridda V', 'Caraceni A', 'Saita L', 'Bonezzi C', 'De Conno F', 'Guarise G', 'Ramella G', 'Silvani V', 'Tamburini M', 'Toscani F']","['Adult', 'Afferent Pathways/physiopathology', 'Aged', 'Amitriptyline/administration & dosage/*therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Humans', 'Middle Aged', 'Neuralgia/*drug therapy/etiology', 'Random Allocation', 'Trazodone/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3133714/
2492,amitriptyline,24129218,Lessons learned from hospice care.,['Martin CM'],"['Aged', 'Aged, 80 and over', 'Amitriptyline/administration & dosage/adverse effects/therapeutic use', 'Analgesics, Opioid/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', '*Drug Monitoring/methods/standards', 'Fentanyl/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', '*Health Services for the Aged/organization & administration/standards/trends', '*Hospice Care/organization & administration/standards/trends', 'Humans', 'Nausea/drug therapy', 'Pruritus/drug therapy', 'Transdermal Patch', 'Vomiting/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24129218/
2493,amitriptyline,23645641,Neuropsychiatric side effects of cyclobenzaprine.,"['Shprecher D', 'Sloan CT', 'Sederholm B']","['Amitriptyline/adverse effects/*analogs & derivatives/therapeutic use', 'Antidepressive Agents/*adverse effects/therapeutic use', 'Delirium/*chemically induced', 'Humans', 'Male', 'Middle Aged', 'Movement Disorders/*etiology', 'Muscle Relaxants, Central/*adverse effects/therapeutic use', 'Oxycodone/*adverse effects', 'Pain/drug therapy', 'Serotonin Syndrome/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/23645641/
2494,amitriptyline,2612556,Amitriptyline: linear or nonlinear kinetics in every day practice?,"['Vandel S', 'Bertschy G', 'Vandel B', 'Allers G', 'Volmat R']","['Amitriptyline/administration & dosage/blood/*pharmacokinetics', 'Biotransformation', 'Depression/*drug therapy', 'Humans', 'Linear Models', 'Nortriptyline/*blood']",https://pubmed.ncbi.nlm.nih.gov/2612556/
2495,amitriptyline,31974296,No benefit from amitriptyline for chronic low back pain?,"['Khong TK', 'Lall K']","['Amitriptyline/*administration & dosage', 'Chronic Pain/*drug therapy', 'Humans', 'Low Back Pain/*drug therapy', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31974296/
2496,amitriptyline,27113954,Very Low Dose Amitriptyline for Clozapine-Associated Sialorrhea.,"['Sinha S', 'Simlai J', 'Praharaj SK']","['Amitriptyline/*administration & dosage', 'Antidepressive Agents, Tricyclic/*administration & dosage', 'Antipsychotic Agents/*adverse effects', 'Clozapine/*adverse effects', 'Humans', 'Male', 'Schizophrenia/diagnosis/drug therapy', 'Sialorrhea/*chemically induced/diagnosis/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27113954/
2497,amitriptyline,3894196,Long-term amitriptyline in chronic depression.,"['Giller E Jr', 'Bialos D', 'Harkness L', 'Jatlow P', 'Waldo M']","['Amitriptyline/adverse effects/blood/*therapeutic use', 'Chronic Disease', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Middle Aged', 'Nortriptyline/blood', 'Recurrence', 'Substance Withdrawal Syndrome/etiology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3894196/
2498,amitriptyline,9522337,[Unmasking pheochromocytoma by amitriptyline].,['Kuhs H'],"['Adrenal Gland Neoplasms/*diagnosis/psychology', 'Amitriptyline/*administration & dosage/adverse effects', 'Antidepressive Agents/*administration & dosage/adverse effects', 'Blood Pressure/drug effects', 'Catecholamines/urine', 'Depressive Disorder/*drug therapy/psychology', 'Dose-Response Relationship, Drug', 'Female', 'Heart Rate/drug effects', 'Humans', 'Middle Aged', 'Patient Care Team', 'Pheochromocytoma/*diagnosis/psychology']",https://pubmed.ncbi.nlm.nih.gov/9522337/
2499,amitriptyline,37018325,Amitriptyline's anticholinergic adverse drug reactions-A systematic multiple-indication review and meta-analysis.,"['Brueckle MS', 'Thomas ET', 'Seide SE', 'Pilz M', 'Gonzalez-Gonzalez AI', 'Dinh TS', 'Gerlach FM', 'Harder S', 'Glasziou PP', 'Muth C']","['Adult', 'Aged', 'Humans', '*Amitriptyline/therapeutic use', '*Cholinergic Antagonists']",https://pubmed.ncbi.nlm.nih.gov/37018325/
2500,propranolol,28431779,Propranolol.,"['Al-Majed AA', 'Bakheit AHH', 'Abdel Aziz HA', 'Alajmi FM', 'AlRabiah H']","['*Adrenergic beta-Antagonists/chemistry/pharmacokinetics/pharmacology/therapeutic use', 'Drug Stability', 'Humans', 'Hypertension/drug therapy', 'Molecular Structure', '*Propranolol/chemistry/pharmacokinetics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28431779/
2501,propranolol,31136408,Can propranolol prevent progression of melanoma?,"['Kao J', 'Luu B']","['Adrenergic beta-Antagonists/*therapeutic use', 'Disease Progression', 'Humans', 'Melanoma/*drug therapy', 'Neoplasm Recurrence, Local/*prevention & control', 'Propranolol/*therapeutic use', 'Skin Neoplasms/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31136408/
2502,propranolol,22874493,[News on infantile hemangioma therapy by beta-blocker].,"['Delmotte N', 'Curti C', 'Montana M', 'Crozet M', 'Vanelle P', 'Gensollen S']","['Adrenergic beta-Antagonists/adverse effects/pharmacology/*therapeutic use', 'Child', 'Child, Preschool', 'Hemangioma/complications/*drug therapy/physiopathology', 'Humans', 'Infant', 'Propranolol/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22874493/
2503,propranolol,24305730,Treatment of infantile hemangiomas with beta-blockers: a review.,"['Shah S', 'Frieden IJ']","['Adrenergic beta-Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Drug Monitoring/methods', 'Glucocorticoids/adverse effects/therapeutic use', 'Hemangioma/*drug therapy/epidemiology/pathology', 'Humans', 'Infant', 'Prevalence', 'Propranolol/administration & dosage/adverse effects/therapeutic use', 'Skin Neoplasms/*drug therapy/epidemiology/pathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24305730/
2504,propranolol,3894197,The use of propranolol in the treatment of anxiety disorders.,"['Fonte RJ', 'Stevenson JM']","['Anxiety/drug therapy', 'Anxiety Disorders/complications/*drug therapy', 'Double-Blind Method', 'Heart Diseases/complications', 'Humans', 'Mitral Valve Prolapse/complications', 'Panic/drug effects', 'Propranolol/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3894197/
2505,propranolol,6682990,Propranolol in schizophrenia.,"['Sethi BB', 'Dube S']","['Adult', 'Humans', 'Male', 'Propranolol/adverse effects/*therapeutic use', 'Psychiatric Status Rating Scales', 'Schizophrenia/*drug therapy', 'Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/6682990/
2506,propranolol,3503570,Propranolol for the treatment of the alcoholic hangover.,"['Bogin RM', 'Nostrant TT', 'Young MJ']","['Adult', 'Alcoholic Intoxication/*complications/physiopathology', 'Double-Blind Method', 'Female', 'Heart Rate/drug effects', 'Humans', 'Male', 'Propranolol/adverse effects/*therapeutic use', 'Random Allocation', 'Tremor/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/3503570/
2507,propranolol,95728,Minoxidil in resistant hypertension.,"['Dargie HJ', 'Dollery CT', 'Daniel J']","['Blood Pressure/drug effects', 'Drug Combinations', 'Female', 'Follow-Up Studies', 'Furosemide/administration & dosage/therapeutic use', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Minoxidil/administration & dosage/adverse effects/*therapeutic use', 'Propranolol/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/95728/
2508,propranolol,7055283,Propranolol and depression.,"['Petrie WM', 'Maffucci RJ', 'Woosley RL']","['Adult', 'Arrhythmias, Cardiac/drug therapy', 'Depressive Disorder/*chemically induced', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Propranolol/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/7055283/
2509,propranolol,9352395,Inverse PK/PD: estimation and differentiation of bioavailability from effect kinetics--observations with beta-adrenoceptor antagonists.,['De Mey C'],"['Adrenergic beta-Antagonists/*pharmacokinetics/*pharmacology', 'Adult', 'Binding, Competitive', 'Biological Availability', 'Carbazoles/pharmacokinetics/pharmacology', 'Carvedilol', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Heart Rate/*drug effects', 'Humans', 'Male', 'Models, Biological', 'Propanolamines/pharmacokinetics/pharmacology', 'Propranolol/administration & dosage/pharmacokinetics/pharmacology', 'Randomized Controlled Trials as Topic', 'Tachycardia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9352395/
2510,propranolol,32662682,beta-blocker therapy for infantile hemangioma.,"['Koh SP', 'Leadbitter P', 'Smithers F', 'Tan ST']","['Adrenergic beta-Antagonists/*administration & dosage/adverse effects/pharmacology', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage/adverse effects/pharmacology', 'Animals', 'Hemangioma/*drug therapy/pathology', 'Humans', 'Infant', 'Propranolol/administration & dosage/adverse effects/pharmacology', 'Renin-Angiotensin System/drug effects', 'Skin Neoplasms/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/32662682/
2511,propranolol,937905,Treatment of recurrent symptomatic ventricular tachycardia.,"['Winkle RA', 'Alderman EL', 'Fitzgerald JW', 'Harrison DC']","['Adult', 'Aged', 'Anti-Arrhythmia Agents/*therapeutic use', 'Cardiomyopathies/complications', 'Coronary Disease/complications', 'Drug Evaluation', 'Female', 'Heart Aneurysm/complications/surgery', 'Hemochromatosis/complications', 'Humans', 'Male', 'Middle Aged', 'Mitral Valve Insufficiency/complications', 'Phenytoin/administration & dosage/adverse effects/therapeutic use', 'Procainamide/administration & dosage/adverse effects/therapeutic use', 'Propranolol/administration & dosage/adverse effects/therapeutic use', 'Quinidine/administration & dosage/adverse effects/therapeutic use', 'Recurrence', 'Tachycardia/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/937905/
2512,propranolol,1237822,Essential tremor: treatment with propranolol.,"['Tolosa ES', 'Loewenson RB']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', 'Propranolol/administration & dosage/*therapeutic use', 'Tremor/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1237822/
2513,propranolol,28265298,Safety and effectiveness of propranolol in severely burned patients: systematic review and meta-analysis.,"['Manzano-Nunez R', 'Garcia-Perdomo HA', 'Ferrada P', 'Ordonez Delgado CA', 'Gomez DA', 'Foianini JE']","['Adrenergic beta-Antagonists/adverse effects/pharmacology/therapeutic use', 'Burns/*drug therapy', 'Humans', 'Patient Safety', 'Propranolol/adverse effects/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28265298/
2514,propranolol,33776033,Propranolol Therapy in Infantile Hemangioma: It Is Not Just About the Beta.,"['Lee JC', 'Modiri O', 'England RW', 'Shawber CJ', 'Wu JK']","['Adrenergic beta-Antagonists/*therapeutic use', 'Hemangioma, Capillary/*drug therapy', 'Humans', 'Infant', 'Propranolol/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33776033/
2515,propranolol,21622997,Propranolol for infantile haemangiomas: a review.,"['Starkey E', 'Shahidullah H']","['Adrenergic beta-Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Child, Preschool', 'Drug Administration Schedule', 'Hemangioma/*drug therapy/epidemiology', 'Humans', 'Infant', 'Infant, Newborn', 'Propranolol/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21622997/
2516,propranolol,234668,A comparison of timolol and propranolol in essential hypertension.,"['Lohmoller G', 'Frohlich ED']","['Adrenergic beta-Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Evaluation', 'Follow-Up Studies', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy', 'Morpholines/therapeutic use', 'Placebos', 'Propanolamines/*therapeutic use', 'Propranolol/administration & dosage/adverse effects/*therapeutic use', 'Thiadiazoles/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/234668/
2517,propranolol,3087677,"Enprostil, in contrast to cimetidine, does not inhibit propranolol metabolism.","['Reilly CS', 'Biollaz J', 'Koshakji RP', 'Wood AJ']","['Administration, Oral', 'Adult', 'Cimetidine/*pharmacology', 'Double-Blind Method', 'Drug Interactions', 'Enprostil', 'Humans', 'Indocyanine Green/blood', 'Injections, Intravenous', 'Kinetics', 'Liver Circulation', 'Male', 'Propranolol/administration & dosage/*metabolism', 'Prostaglandins E, Synthetic/adverse effects/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/3087677/
2518,propranolol,2502256,Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis.,['Kiire CF'],"['Administration, Oral', 'Adolescent', 'Adult', 'Aged', 'Clinical Trials as Topic', 'Esophageal and Gastric Varices/etiology/*prevention & control', 'Female', 'Follow-Up Studies', 'Gastrointestinal Hemorrhage/etiology/*prevention & control', 'Humans', 'Hypertension, Portal/complications', 'Liver Cirrhosis/*complications', 'Male', 'Middle Aged', 'Propranolol/administration & dosage/*therapeutic use', 'Pulse/drug effects', 'Random Allocation', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/2502256/
2519,propranolol,333492,The influence of propranolol on the exposure in vivo of agoraphobics.,"['Hafner J', 'Milton F']","['Adult', 'Agoraphobia/*drug therapy/psychology', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Follow-Up Studies', 'Heart Rate/drug effects', 'Humans', 'Male', 'Phobic Disorders/*drug therapy', 'Propranolol/administration & dosage/*therapeutic use', 'Psychiatric Status Rating Scales', 'Social Adjustment']",https://pubmed.ncbi.nlm.nih.gov/333492/
